CompoundName	TargetGene	PubchemCID	InKey	ClinicalPhase	MOA	DiseaseArea	Indication
(R)-(-)-apomorphine	ADRA2A	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	ADRA2B	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	ADRA2C	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	CALY	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	DRD1	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	DRD2	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	DRD3	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	DRD4	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	DRD5	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	HTR1A	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	HTR1B	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	HTR1D	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	HTR2A	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	HTR2B	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	HTR2C	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-apomorphine	HTR5A	6005	VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-rolipram	PDE4A	448055	HJORMJIFDVBMOB-LBPRGKRZSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
(R)-(-)-rolipram	PDE4B	448055	HJORMJIFDVBMOB-LBPRGKRZSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
(R)-(-)-rolipram	PDE4C	448055	HJORMJIFDVBMOB-LBPRGKRZSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
(R)-(-)-rolipram	PDE4D	448055	HJORMJIFDVBMOB-LBPRGKRZSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
(R)-(-)-rolipram	PDE5A	448055	HJORMJIFDVBMOB-LBPRGKRZSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
(R)-baclofen	GABBR1	6918881	KPYSYYIEGFHWSV-QMMMGPOBSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
(R)-baclofen	GABBR2	6918881	KPYSYYIEGFHWSV-QMMMGPOBSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
(S)-(+)-rolipram	PDE4B	158758	HJORMJIFDVBMOB-GFCCVEGCSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
(S)-(+)-rolipram	PDE4D	158758	HJORMJIFDVBMOB-GFCCVEGCSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
"[sar9,met(o2)11]-substance-p"	TACR1	163829	OUPXSLGGCPUZJJ-SARDKLJWSA-N	Preclinical	tachykinin antagonist	NA	NA
A-1070722	GSK3A	49830684	VQPBIJGXSXEOCU-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
A-1070722	GSK3B	49830684	VQPBIJGXSXEOCU-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
A-1120	RBP4	25138295	"InChI=1S/C20H19F3N2O3/c21-20(22,23)16-7-3-1-5-14(16)13-9-11-25(12-10-13)19(28)24-17-8-4-2-6-15(17)18(26)27/h1-8,13H,9-12H2,(H,24,28)(H,26,27)"	Preclinical	retinoid receptor ligand	NA	NA
A-317491	P2RX3	9829395	VQGBOYBIENNKMI-LJAQVGFWSA-N	Preclinical	purinergic receptor antagonist	NA	NA
A-366	EHMT1	76285486	BKCDJTRMYWSXMC-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
A-366	EHMT2	76285486	BKCDJTRMYWSXMC-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
A-412997	DRD4	10425450	JFCDMGGMCUKHST-UHFFFAOYSA-N	Preclinical	dopamine receptor agonist	NA	NA
A-438079	P2RX7	11673921	MMPAULQSJLVKHP-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
A-582941	CHRNA7	44190553	GTMRUYCIJSNXGB-GASCZTMLSA-N	Preclinical	nicotinic receptor agonist	NA	NA
A-61603	ADRA1A	10804826	OQFCXJDXHCDLHX-NSHDSACASA-N	Preclinical	adrenergic receptor agonist	NA	NA
A-61603	ADRA1B	10804826	OQFCXJDXHCDLHX-NSHDSACASA-N	Preclinical	adrenergic receptor agonist	NA	NA
A-61603	ADRA1D	10804826	OQFCXJDXHCDLHX-NSHDSACASA-N	Preclinical	adrenergic receptor agonist	NA	NA
A-674563	AKT1	11314340	BPNUQXPIQBZCMR-IBGZPJMESA-N	Preclinical	AKT inhibitor	NA	NA
A-674563	PKIA	11314340	BPNUQXPIQBZCMR-IBGZPJMESA-N	Preclinical	AKT inhibitor	NA	NA
A-674563	PRKACA	11314340	BPNUQXPIQBZCMR-IBGZPJMESA-N	Preclinical	AKT inhibitor	NA	NA
A-784168	TRPV1	11420211	SDUAWRFBHRAFBM-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
A-803467	SCN10A	16038374	VHKBTPQDHDSBSP-UHFFFAOYSA-N	Preclinical	sodium channel blocker	NA	NA
A-804598	P2RX7	53325874	PQYCRDPLPKGSME-AWEZNQCLSA-N	Preclinical	purinergic receptor antagonist	NA	NA
A-839977	P2RX7	53325875	GMVNBKZQJFRFAR-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
A-867744	CHRNA3	23642319	ABACVOXFUHDKNZ-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
A-867744	CHRNA4	23642319	ABACVOXFUHDKNZ-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
A-867744	CHRNA7	23642319	ABACVOXFUHDKNZ-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
A-887826	SCN10A	46919335	JPJGFWKHSMUKFO-UHFFFAOYSA-N	Preclinical	sodium channel blocker	NA	NA
A-922500	DGAT1	24768261	BOZRFEQDOFSZBV-DHIUTWEWSA-N	Preclinical	diacylglycerol O acyltransferase inhibitor	NA	NA
A-939572	SCD	24905400	DPYTYQFYDLYWHZ-UHFFFAOYSA-N	Preclinical	stearoyl-CoA desaturase inhibitor	NA	NA
A-967079	TRPA1	42641861	HKROEBDHHKMNBZ-CHBKHGQFSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
A-987306	ADORA1	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	AVPR1A	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	CCR1	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	CHRM1	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	CHRM2	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	CHRM3	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	CHRM4	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	DRD3	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	HTR1A	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	HTR1B	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	HTR2A	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	HTR2B	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	HTR3A	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
A-987306	TACR2	25109291	DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	histamine receptor antagonist	NA	NA
AA-29504	GABRA1	23188887	SCOOTUMXCXKEAD-UHFFFAOYSA-N	Preclinical	GABA receptor positive allosteric modulator	NA	NA
AA-29504	GABRA4	23188887	SCOOTUMXCXKEAD-UHFFFAOYSA-N	Preclinical	GABA receptor positive allosteric modulator	NA	NA
AA-29504	GABRB3	23188887	SCOOTUMXCXKEAD-UHFFFAOYSA-N	Preclinical	GABA receptor positive allosteric modulator	NA	NA
abamectin	GABBR1	6858005	ZFUKERYTFURFGA-PVVXTEPVSA-N	Launched	benzodiazepine receptor agonist	infectious disease	gastrointestinal parasites
abamectin	GABBR2	6858005	ZFUKERYTFURFGA-PVVXTEPVSA-N	Launched	benzodiazepine receptor agonist	infectious disease	gastrointestinal parasites
abametapir	MMP9	15664	PTRATZCAGVBFIQ-UHFFFAOYSA-N	Phase 3	metalloproteinase inhibitor	NA	NA
abarelix	GNRHR	16131215	AIWRTTMUVOZGPW-HSPKUQOVSA-N	Phase 3	gonadotropin releasing factor hormone receptor antagonist	NA	NA
ABC-294640	SPHK2	NA	CAOTVXGYTWCKQE-BRNYJPRKSA-N	Phase 2	sphingosine kinase inhibitor	NA	NA
abemaciclib	CDK4	46220502	UZWDCWONPYILKI-UHFFFAOYSA-N	Launched	CDK inhibitor	oncology	breast cancer
abemaciclib	CDK6	46220502	UZWDCWONPYILKI-UHFFFAOYSA-N	Launched	CDK inhibitor	oncology	breast cancer
abiraterone	CYP11B1	132971	GZOSMCIZMLWJML-VJLLXTKPSA-N	Launched	androgen biosynthesis inhibitor	oncology	prostate cancer
abiraterone	CYP17A1	132971	GZOSMCIZMLWJML-VJLLXTKPSA-N	Launched	androgen biosynthesis inhibitor	oncology	prostate cancer
abiraterone-acetate	CYP17A1	9821849	UVIQSJCZCSLXRZ-UBUQANBQSA-N	Launched	androgen biosynthesis inhibitor	oncology	prostate cancer
ABT-239	HRH1	9818903	KFHYZKCRXNRKRC-MRXNPFEDSA-N	Phase 1	histamine receptor antagonist	NA	NA
ABT-239	HRH2	9818903	KFHYZKCRXNRKRC-MRXNPFEDSA-N	Phase 1	histamine receptor antagonist	NA	NA
ABT-239	HRH3	9818903	KFHYZKCRXNRKRC-MRXNPFEDSA-N	Phase 1	histamine receptor antagonist	NA	NA
ABT-491	PTAFR	154087	GDLNHSUSOZEAOR-UHFFFAOYSA-N	Phase 1	platelet activating factor receptor antagonist	NA	NA
ABT-639	CACNA1G	46851313	AGPIHNZOZNKRGT-CYBMUJFWSA-N	Phase 2	calcium channel blocker	NA	NA
ABT-639	CACNA1H	46851313	AGPIHNZOZNKRGT-CYBMUJFWSA-N	Phase 2	calcium channel blocker	NA	NA
ABT-639	CACNA1I	46851313	AGPIHNZOZNKRGT-CYBMUJFWSA-N	Phase 2	calcium channel blocker	NA	NA
ABT-702	ADK	1973	RQCXKDWOCUJWQZ-UHFFFAOYSA-N	Preclinical	adenosine kinase inhibitor	NA	NA
ABT-724	DRD4	5025739	FRPJGTNLZNXQEX-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
ABT-737	BCL2	11228183	"InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1"	Phase 1/Phase 2	BCL inhibitor	NA	NA
ABT-737	BCL2L1	11228183	"InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1"	Phase 1/Phase 2	BCL inhibitor	NA	NA
ABT-737	BCL2L2	11228183	"InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1"	Phase 1/Phase 2	BCL inhibitor	NA	NA
ABT-751	TUBB	3035714	URCVCIZFVQDVPM-UHFFFAOYSA-N	Phase 2	tubulin polymerization inhibitor	NA	NA
AC-186	ESR2	71245042	HSMUKSLNDJOZQG-UHFFFAOYSA-N	Preclinical	estrogen receptor agonist	NA	NA
AC-261066	RARB	11530459	HSAOETBFVAWNRP-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
AC-264613	F2RL1	25108278	RQKXQCSEZPQBNZ-QSBCOWLBSA-N	Preclinical	PAR agonist	NA	NA
AC-55541	PARP2	129362181	UCUHFWIFSHROPY-SQEMJAKJSA-N	Preclinical	PARP inhibitor	NA	NA
AC-55649	RARA	1714884	HXBKPYIEQLLNBK-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
AC-55649	RARB	1714884	HXBKPYIEQLLNBK-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
AC-710	CSF1R	54760053	JVCWPUFNLFSKFS-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
AC-710	FLT3	54760053	JVCWPUFNLFSKFS-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
AC-710	KIT	54760053	JVCWPUFNLFSKFS-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
AC-710	PDGFRA	54760053	JVCWPUFNLFSKFS-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
AC-710	PDGFRB	54760053	JVCWPUFNLFSKFS-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
AC-7954-(+/-)	UTS2R	10937426	HIVBATDUVFEJFZ-IBGZPJMESA-N	Preclinical	urotensin receptor agonist	NA	NA
acalabrutinib	BTK	71226662	WDENQIQQYWYTPO-IBGZPJMESA-N	Launched	Bruton's tyrosine kinase (BTK) inhibitor	hematologic malignancy	mantle cell lymphoma (MCL)
acalisib	PIK3CB	11618268	DOCINCLJNAXZQF-LBPRGKRZSA-N	Phase 1	PI3K inhibitor	NA	NA
acalisib	PIK3CD	11618268	DOCINCLJNAXZQF-LBPRGKRZSA-N	Phase 1	PI3K inhibitor	NA	NA
acamprosate	GABRA1	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRA2	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRA3	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRA4	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRA5	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRA6	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRB1	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRB2	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRB3	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRD	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRE	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRG1	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRG2	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRG3	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRP	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GABRQ	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRIN1	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRIN2A	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRIN2B	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRIN2C	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRIN2D	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRIN3A	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRIN3B	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acamprosate	GRM5	71158	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acarbose	AMY2A	444254	XUFXOAAUWZOOIT-SXARVLRPSA-N	Launched	glucosidase inhibitor	endocrinology	diabetes mellitus
acarbose	MGAM	444254	XUFXOAAUWZOOIT-SXARVLRPSA-N	Launched	glucosidase inhibitor	endocrinology	diabetes mellitus
ACDPP	GRM5	16759169	RNGRUHWJJPTYNR-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
acebutolol	ADRB1	657184	GOEMGAFJFRBGGG-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension|ventricular arrhythmias
acecainide	SCN5A	4342	KEECCEWTUVWFCV-UHFFFAOYSA-N	Phase 3	polarization inhibitor	NA	NA
aceclidine	CHRM1	1273944	WRJPSSPFHGNBMG-VIFPVBQESA-N	Launched	acetylcholine receptor agonist	ophthalmology	glaucoma
aceclidine	CHRM2	1273944	WRJPSSPFHGNBMG-VIFPVBQESA-N	Launched	acetylcholine receptor agonist	ophthalmology	glaucoma
aceclidine	CHRM3	1273944	WRJPSSPFHGNBMG-VIFPVBQESA-N	Launched	acetylcholine receptor agonist	ophthalmology	glaucoma
aceclidine	CHRM4	1273944	WRJPSSPFHGNBMG-VIFPVBQESA-N	Launched	acetylcholine receptor agonist	ophthalmology	glaucoma
aceclidine	CHRM5	1273944	WRJPSSPFHGNBMG-VIFPVBQESA-N	Launched	acetylcholine receptor agonist	ophthalmology	glaucoma
aceclofenac	PTGS2	71771	MNIPYSSQXLZQLJ-UHFFFAOYSA-N	Launched	prostanoid receptor antagonist	rheumatology	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia
acefylline	ADORA1	69550	HCYFGRCYSCXKNQ-UHFFFAOYSA-N	Launched	adenosine receptor agonist	pulmonary	asthma
acemetacin	PTGS1	1981	FSQKKOOTNAMONP-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis
acemetacin	PTGS2	1981	FSQKKOOTNAMONP-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis
aceneuramic-acid	CES1	445063	SQVRNKJHWKZAKO-PFQGKNLYSA-N	Phase 3		NA	NA
aceneuramic-acid	SELE	445063	SQVRNKJHWKZAKO-PFQGKNLYSA-N	Phase 3		NA	NA
aceneuramic-acid	SELP	445063	SQVRNKJHWKZAKO-PFQGKNLYSA-N	Phase 3		NA	NA
acenocoumarol	VKORC1	54683745	VABCILAOYCMVPS-HNNXBMFYSA-N	Launched	vitamin K antagonist	hematology	deep vein thrombosis (DVT)
acepromazine	ADRA1A	6077	NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
acepromazine	ADRA1B	6077	NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
acepromazine	DRD1	6077	NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
acepromazine	DRD2	6077	NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
acepromazine	HTR1A	6077	NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
acepromazine	HTR2A	6077	NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
acetazolamide	AQP1	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetazolamide	CA1	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetazolamide	CA12	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetazolamide	CA14	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetazolamide	CA2	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetazolamide	CA3	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetazolamide	CA4	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetazolamide	CA7	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetohexamide	ABCC8	1989	VGZSUPCWNCWDAN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
acetohexamide	KCNJ1	1989	VGZSUPCWNCWDAN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
acetohexamide	KCNJ10	1989	VGZSUPCWNCWDAN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
acetohexamide	KCNJ11	1989	VGZSUPCWNCWDAN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
acetohydroxamic-acid	MMP12	1990	RRUDCFGSUDOHDG-UHFFFAOYSA-N	Launched	urease inhibitor	infectious disease	urinary tract infections
acetophenazine	DRD1	17676	WNTYBHLDCKXEOT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	psychosis
acetophenazine	DRD2	17676	WNTYBHLDCKXEOT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	psychosis
acetyl-farnesyl-cysteine	PPARG	6438381	XTURYZYJYQRJDO-BNAHBJSTSA-N	Launched	methyltransferase inhibitor	dermatology	acne vulgaris (AV)
acetyl-11-keto-beta-boswellic-acid	HSD11B1	NA	HMMGKOVEOFBCAU-OQJDUFEHSA-N	Phase 2	lipoxygenase inhibitor	NA	NA
acetyl-11-keto-beta-boswellic-acid	HSD11B2	NA	HMMGKOVEOFBCAU-OQJDUFEHSA-N	Phase 2	lipoxygenase inhibitor	NA	NA
acetylcholine	ACHE	187	OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion
acetylcholine	CHRM1	187	OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion
acetylcholine	CHRM2	187	OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion
acetylcholine	CHRM3	187	OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion
acetylcholine	CHRM4	187	OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion
acetylcholine	CHRM5	187	OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion
acetylcholine	CHRNA2	187	OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion
acetylcysteine	ACY1	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	CHUK	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	GRIN1	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	GRIN2A	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	GRIN2B	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	GRIN2D	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	GRIN3A	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	GSS	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	IKBKB	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	RELA	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acetylcysteine	SLC7A11	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	mucolytic agent	gastroenterology	acetaminophen overdose|hepatic injury
acexamic-acid	GAST	2005	WDSCBUNMANHPFH-UHFFFAOYSA-N	Launched	5 alpha reductase inhibitor	dermatology	wound healing
acifran	HCAR2	76969700	DFDGRKNOFOJBAJ-LBPRGKRZSA-N	Phase 3	cholesterol inhibitor	NA	NA
acifran	HCAR3	76969700	DFDGRKNOFOJBAJ-LBPRGKRZSA-N	Phase 3	cholesterol inhibitor	NA	NA
acipimox	HCAR2	5310993	DJQOOSBJCLSSEY-UHFFFAOYSA-N	Launched	cholesterol inhibitor	endocrinology	hyperlipidemia
acitretin	RARA	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acitretin	RARB	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acitretin	RARG	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acitretin	RBP1	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acitretin	RXRA	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acitretin	RXRB	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acitretin	RXRG	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acitretin	STAT3	5284513	IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	retinoid receptor agonist	dermatology	psoriasis
acivicin	CTPS1	16758175	QAWIHIJWNYOLBE-ZAFYKAAXSA-N	Phase 2	gamma glutamyltransferase inhibitor	NA	NA
aclarubicin	TOP1	86289437	USZYSDMBJDPRIF-SVEJIMAYSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
aclarubicin	TOP2A	86289437	USZYSDMBJDPRIF-SVEJIMAYSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
aclidinium	CHRM1	11434515	ASMXXROZKSBQIH-VITNCHFBSA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)
aclidinium	CHRM2	11434515	ASMXXROZKSBQIH-VITNCHFBSA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)
aclidinium	CHRM3	11434515	ASMXXROZKSBQIH-VITNCHFBSA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)
aclidinium	CHRM4	11434515	ASMXXROZKSBQIH-VITNCHFBSA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)
aclidinium	CHRM5	11434515	ASMXXROZKSBQIH-VITNCHFBSA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)
acriflavine	HIF1A	452192	BCBIBQWDFMQRSJ-UHFFFAOYSA-O	Launched	hypoxia inducible factor inhibitor	infectious disease	fungal infection
acriflavinium	HIF1A	2016	XSIOKTWDEOJMGG-UHFFFAOYSA-O	Launched	hypoxia inducible factor inhibitor	infectious disease	fungal infection
acrivastine	HRH1	5284514	PWACSDKDOHSSQD-IUTFFREVSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis
ACT-132577	EDNRA	25099191	DKULOVKANLVDEA-UHFFFAOYSA-N	Launched	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
ACT-132577	EDNRB	25099191	DKULOVKANLVDEA-UHFFFAOYSA-N	Launched	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
ACT-462206	HCRTR1	40924317	NHPQGZOBHSVTAQ-IBGZPJMESA-N	Phase 1	orexin receptor antagonist	NA	NA
ACT-462206	HCRTR2	40924317	NHPQGZOBHSVTAQ-IBGZPJMESA-N	Phase 1	orexin receptor antagonist	NA	NA
ACTB-1003	KDR	23653175	GZPJCJKUZPUFAL-UHFFFAOYSA-N	Phase 1	FGFR inhibitor|VEGFR inhibitor	NA	NA
ACTB-1003	TEK	23653175	GZPJCJKUZPUFAL-UHFFFAOYSA-N	Phase 1	FGFR inhibitor|VEGFR inhibitor	NA	NA
ACY-1215	HDAC1	53340666	QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2	HDAC inhibitor	NA	NA
ACY-1215	HDAC2	53340666	QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2	HDAC inhibitor	NA	NA
ACY-1215	HDAC3	53340666	QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2	HDAC inhibitor	NA	NA
ACY-1215	HDAC6	53340666	QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2	HDAC inhibitor	NA	NA
ACY-1215	HDAC8	53340666	QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2	HDAC inhibitor	NA	NA
acyclovir	PNP	135398513	MKUXAQIIEYXACX-UHFFFAOYSA-N	Launched	DNA polymerase inhibitor	infectious disease	genitial herpes|shingles|chicken pox
AD-5467	AKR1B1	6933882	CLDJCRWXLDLJLO-CQSZACIVSA-N	Phase 2	aldose reductase inhibitor	NA	NA
adapalene	RARA	60164	LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
adapalene	RARB	60164	LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
adapalene	RARG	60164	LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
adapalene	RXRA	60164	LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
adapalene	RXRB	60164	LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
adapalene	RXRG	60164	LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
adaprev	AKR1B1	439284	NBSCHQHZLSJFNQ-DVKNGEFBSA-N	Phase 3	TGF beta receptor inhibitor	NA	NA
adaprev	GPI	439284	NBSCHQHZLSJFNQ-DVKNGEFBSA-N	Phase 3	TGF beta receptor inhibitor	NA	NA
adaprev	HK1	439284	NBSCHQHZLSJFNQ-DVKNGEFBSA-N	Phase 3	TGF beta receptor inhibitor	NA	NA
adaprev	M6PR	439284	NBSCHQHZLSJFNQ-DVKNGEFBSA-N	Phase 3	TGF beta receptor inhibitor	NA	NA
adaprev	PYGM	439284	NBSCHQHZLSJFNQ-DVKNGEFBSA-N	Phase 3	TGF beta receptor inhibitor	NA	NA
adaptavir	CCR5	184644	AKWRNBWMGFUAMF-ZESMOPTKSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
adarotene	RARB	9864378	QAWBIEIZDDIEMW-FPYGCLRLSA-N	Phase 1	retinoid receptor agonist	NA	NA
adarotene	RARG	9864378	QAWBIEIZDDIEMW-FPYGCLRLSA-N	Phase 1	retinoid receptor agonist	NA	NA
adatanserin	HTR1A	130918	HPFLVTSWRFCPCV-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist|serotonin receptor antagonist	NA	NA
adatanserin	HTR2A	130918	HPFLVTSWRFCPCV-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist|serotonin receptor antagonist	NA	NA
adenine	ACACB	190	GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical	protein synthesis stimulant	NA	NA
adenine	ACP1	190	GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical	protein synthesis stimulant	NA	NA
adenine	APRT	190	GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical	protein synthesis stimulant	NA	NA
adenine	MTAP	190	GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical	protein synthesis stimulant	NA	NA
adenine	PECR	190	GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical	protein synthesis stimulant	NA	NA
adenine	SRPK2	190	GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical	protein synthesis stimulant	NA	NA
adenosine	ADORA1	60961	OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine	ADORA2A	60961	OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine	ADORA2B	60961	OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine	ADORA3	60961	OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine	PI4K2A	60961	OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine	PI4K2B	60961	OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine	TRPM4	60961	OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine-phosphate	ACSL1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	ACSS1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	ACSS2	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	ADCY1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	ADK	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	CREB1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	FBP1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	HINT1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	PDE4B	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	PDE4D	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	PIM1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	PRKAA1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	PRKAB1	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	PRKAB2	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	PYGL	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-phosphate	TRPM4	6083	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABCA1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABCB1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABCB11	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABCC2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABCC8	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABCC9	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABCG1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABL1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ABL2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ACSL1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ACSS1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ACSS2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ACVR1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ACVR1B	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ACVRL1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ADCY1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ADRBK1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ADRBK2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	AFG3L2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	AKT1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ALK	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	AMHR2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	APAF1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ARAF	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ASNA1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ASNS	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ASS1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	CDK15	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	GPR17	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	ITPR1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	NAE1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	NT5C2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	P2RY1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	P2RY11	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	P2RY13	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	P2RY2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	P2RY4	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	PRKAA1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	RYR1	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	RYR2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	RYR3	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	SLC25A4	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	TNK2	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	TRPM4	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adenosine-triphosphate	TRPM7	5957	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	adenosine receptor agonist	NA	NA
adiphenine	CHRNA1	2031	JGOAIQNSOGZNBX-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	spasms
adipic-acid	SLC22A6	22494954	WNLRTRBMVRJNCN-UHFFFAOYSA-N	Preclinical	solute carrier family member inhibitor	NA	NA
adiporon	ADIPOR1	16307093	SHHUPGSHGSNPDB-UHFFFAOYSA-N	Preclinical	adiponectin receptor agonist	NA	NA
adiporon	ADIPOR2	16307093	SHHUPGSHGSNPDB-UHFFFAOYSA-N	Preclinical	adiponectin receptor agonist	NA	NA
ADL5859	OPRD1	11417954	OPIKUXLJQFYMSC-UHFFFAOYSA-N	Phase 2	opioid receptor agonist	NA	NA
adoprazine	DRD2	9887537	IUVSEUFHPNITEQ-UHFFFAOYSA-N	Phase 2	dopamine receptor antagonist|serotonin receptor agonist	NA	NA
adoprazine	HTR1A	9887537	IUVSEUFHPNITEQ-UHFFFAOYSA-N	Phase 2	dopamine receptor antagonist|serotonin receptor agonist	NA	NA
adrenalone	ADRA1A	7436	PZMVOUYYNKPMSI-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	hematology	hemorrhage
adrenosterone	HSD11B1	223997	RZRPTBIGEANTGU-IRIMSJTPSA-N	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	NA	NA
adrenosterone	HSD11B2	223997	RZRPTBIGEANTGU-IRIMSJTPSA-N	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	NA	NA
ADX-10059	GRM5	10331863	MEDCLNYIYBERKO-UHFFFAOYSA-N	Phase 2	glutamate receptor negative allosteric modulator	NA	NA
ADX-47273	GRM5	11383075	VXQCCZHCFBHTTD-HNNXBMFYSA-N	Preclinical	glutamate receptor modulator	NA	NA
AEE788	EGFR	10297043	OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
AEE788	ERBB2	10297043	OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
AEE788	ERBB4	10297043	OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
AEE788	FGFR2	10297043	OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
AEE788	FGFR3	10297043	OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
AEE788	KDR	10297043	OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
afalanine	DRD2	74839	CBQJSKKFNMDLON-JTQLQIEISA-N	Phase 3	dopamine receptor agonist	NA	NA
afatinib	EGFR	10184653	ULXXDDBFHOBEHA-CWDCEQMOSA-N	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
afatinib	ERBB2	10184653	ULXXDDBFHOBEHA-CWDCEQMOSA-N	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
afatinib	ERBB4	10184653	ULXXDDBFHOBEHA-CWDCEQMOSA-N	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
afimoxifene	ESR1	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
afimoxifene	ESR2	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
afimoxifene	ESRRG	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
afimoxifene	PLD1	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
afimoxifene	PRKCD	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
afimoxifene	PRKCE	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
afimoxifene	PRKCQ	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
afimoxifene	PRKCZ	449459	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	estrogen receptor antagonist	NA	NA
AF38469	SORT1	72706115	JWCUSQCZMQIBMR-UHFFFAOYSA-N	Preclinical	sortilin inhibitor	NA	NA
AG-1024	IGF1R	2044	ABBADGFSRBWENF-UHFFFAOYSA-N	Preclinical	insulin growth factor receptor inhibitor	NA	NA
AG-14361	PARP1	9840076	SEKJSSBJKFLZIT-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
AG-490	EGFR	5328779	TUCIOBMMDDOEMM-RIYZIHGNSA-N	Preclinical	EGFR inhibitor|JAK inhibitor	NA	NA
AG-490	JAK2	5328779	TUCIOBMMDDOEMM-RIYZIHGNSA-N	Preclinical	EGFR inhibitor|JAK inhibitor	NA	NA
AG-490	JAK3	5328779	TUCIOBMMDDOEMM-RIYZIHGNSA-N	Preclinical	EGFR inhibitor|JAK inhibitor	NA	NA
AG-555	CDK2	5328770	GSQOBTOAOGXIFL-LFIBNONCSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
AGI-5198	IDH1	97161269	FNYGWXSATBUBER-AREMUKBSSA-N	Preclinical	isocitrate dehydrogenase inhibitor	NA	NA
AGI-6780	IDH2	71299339	CCAWRGNYALGPQH-UHFFFAOYSA-N	Preclinical	isocitrate dehydrogenase inhibitor	NA	NA
AGM-1470	METAP2	14942882	MSHZHSPISPJWHW-FRDQJGBZSA-N	Phase 2	cell cycle inhibitor	NA	NA
agmatine	ADRA2C	199	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
agmatine	ASIC3	199	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
agmatine	CACNA1B	199	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
agmatine	CHRNA1	199	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
agmatine	GRIN1	199	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
agmatine	KCNJ1	199	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
agmatine	NISCH	199	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
AGN-192403	NISCH	124581813	SHXVJSFOJHMEEQ-AXTSPUMRSA-N	Preclinical	imidazoline receptor ligand	NA	NA
AGN-194310	RXRA	9867046	LHUPKWKWYWOMSK-UHFFFAOYSA-N	Phase 3	retinoid receptor antagonist	NA	NA
AGN-194310	RXRB	9867046	LHUPKWKWYWOMSK-UHFFFAOYSA-N	Phase 3	retinoid receptor antagonist	NA	NA
AGN-194310	RXRG	9867046	LHUPKWKWYWOMSK-UHFFFAOYSA-N	Phase 3	retinoid receptor antagonist	NA	NA
AGN-195183	RARA	9867758	PNAWUIKCVQSLFG-UHFFFAOYSA-N	Phase 1/Phase 2	retinoid receptor agonist	NA	NA
agomelatine	HTR2A	82148	YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched	melatonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
agomelatine	HTR2B	82148	YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched	melatonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
agomelatine	HTR2C	82148	YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched	melatonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
agomelatine	MTNR1A	82148	YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched	melatonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
agomelatine	MTNR1B	82148	YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched	melatonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
AH-7614	FFAR4	233085	OZCQEUZTOAAWDK-UHFFFAOYSA-N	Preclinical	free fatty acid receptor antagonist	NA	NA
AH11110	ADRA1B	6604792	HSVZQQYIMKLNLN-GOSISDBHSA-N	Preclinical	adrenergic receptor ligand	NA	NA
AH6809	PTGDR	119461	AQFFXPQJLZFABJ-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
AH6809	PTGER1	119461	AQFFXPQJLZFABJ-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
AH6809	PTGER2	119461	AQFFXPQJLZFABJ-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
AH6809	PTGER3	119461	AQFFXPQJLZFABJ-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
AI-10-49	CBFB	49806644	WJBSSBFGPKTMQQ-UHFFFAOYSA-N	Preclinical	core binding factor inhibitor	NA	NA
AIM-100	TNK2	11501591	XNFHHOXCDUAYSR-SFHVURJKSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
AJ76-(+)	DRD2	122334	YGHLYBIUVOLKCV-SMDDNHRTSA-N	Preclinical	dopamine receptor antagonist	NA	NA
AJ76-(+)	DRD3	122334	YGHLYBIUVOLKCV-SMDDNHRTSA-N	Preclinical	dopamine receptor antagonist	NA	NA
AJ76-(+)	DRD4	122334	YGHLYBIUVOLKCV-SMDDNHRTSA-N	Preclinical	dopamine receptor antagonist	NA	NA
AK-7	SIRT2	1328033	IYAYHZZWYNXHEQ-UHFFFAOYSA-N	Preclinical	SIRT inhibitor	NA	NA
AKBA	ALOX5	11168203	HMMGKOVEOFBCAU-BCDBGHSCSA-N	Phase 3	lipoxygenase inhibitor	NA	NA
AL-8697	MAPK14	25060093	ZVBTZTQYHOXIBC-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
alacepril	ACE	71992	FHHHOYXPRDYHEZ-COXVUDFISA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
alantolactone	STAT3	72724	PXOYOCNNSUAQNS-AGNJHWRGSA-N	Preclinical	apoptosis stimulant|STAT inhibitor	NA	NA
alaproclate	SLC6A4	23622192	FZSPJBYOKQPKCD-SECBINFHSA-N	Phase 2	serotonin receptor antagonist	NA	NA
alarelin	GNRH1	9855027	QLGKMLRGKPKGKI-QWQCQAQZSA-N	Launched	gonadotropin releasing factor hormone receptor antagonist	NA	NA
albendazole	TUBA1A	2082	HXHWSAZORRCQMX-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	cystic hydatid disease|parenchymal neurocysticercosis
albendazole	TUBB	2082	HXHWSAZORRCQMX-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	cystic hydatid disease|parenchymal neurocysticercosis
albendazole	TUBB4B	2082	HXHWSAZORRCQMX-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	cystic hydatid disease|parenchymal neurocysticercosis
albuterol	ADRB2	182176	NDAUXUAQIAJITI-GFCCVEGCSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
alcaftadine	HRH1	19371515	MWTBKTRZPHJQLH-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy	allergic conjunctivitis
alclofenac	PTGS1	30951	ARHWPKZXBHOEEE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis
alclometasone-dipropionate	CYP3A4	NA	DJHCCTTVDRAMEH-FQEREKBASA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
alclometasone-dipropionate	NR3C1	NA	DJHCCTTVDRAMEH-FQEREKBASA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
alclometasone-dipropionate	SERPINA6	NA	DJHCCTTVDRAMEH-FQEREKBASA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
alcuronium	CHRM1	NA	MUQUYTSLDVKIOF-JGNNFNAWSA-N	Launched	muscle relaxant	neurology/psychiatry	muscle relaxant
alcuronium	CHRM2	NA	MUQUYTSLDVKIOF-JGNNFNAWSA-N	Launched	muscle relaxant	neurology/psychiatry	muscle relaxant
alcuronium	CHRM3	NA	MUQUYTSLDVKIOF-JGNNFNAWSA-N	Launched	muscle relaxant	neurology/psychiatry	muscle relaxant
alcuronium	CHRM4	NA	MUQUYTSLDVKIOF-JGNNFNAWSA-N	Launched	muscle relaxant	neurology/psychiatry	muscle relaxant
alcuronium	CHRNA7	NA	MUQUYTSLDVKIOF-JGNNFNAWSA-N	Launched	muscle relaxant	neurology/psychiatry	muscle relaxant
alda-1	ALDH2	831629	NMKJFZCBCIUYHI-UHFFFAOYSA-N	Preclinical	aldehyde dehydrogenase activator	NA	NA
aldoxorubicin	TOP2A	9810709	OBMJQRLIQQTJLR-USGQOSEYSA-N	Phase 3	topoisomerase inhibitor	NA	NA
alectinib	ALK	49806720	KDGFLJKFZUIJMX-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
alectinib	MET	49806720	KDGFLJKFZUIJMX-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
alendronate	ATP6V1A	44400013	OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
alendronate	FDPS	44400013	OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
alendronate	PTPN4	44400013	OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
alendronate	PTPRE	44400013	OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
alendronate	PTPRS	44400013	OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
alexidine	PTPMT1	40488318	LFVVNPBBFUSSHL-SZPZYZBQSA-N	Preclinical	phosphatidylglycerophosphatase inhibitor	NA	NA
alfacalcidol	CYP27B1	5282181	OFHCOWSQAMBJIW-AVJTYSNKSA-N	Launched	vitamin D receptor agonist	endocrinology	vitamin D deficiency
alfacalcidol	VDR	5282181	OFHCOWSQAMBJIW-AVJTYSNKSA-N	Launched	vitamin D receptor agonist	endocrinology	vitamin D deficiency
alfuzosin	ADRA1A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	ADRA1B	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	ADRA1D	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN10A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN11A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN1A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN2A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN3A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN4A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN5A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN7A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN8A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alfuzosin	SCN9A	37888195	WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
alimemazine	HRH1	6604496	ZZHLYYDVIOPZBE-AWEZNQCLSA-N	Launched	histamine receptor agonist|histamine receptor antagonist	neurology/psychiatry|allergy|pulmonary	sedative|urticaria|itching|cough suppressant
alisertib	AURKA	24771867	"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)"	Phase 3	Aurora kinase inhibitor	NA	NA
aliskiren-hemifumarate	REN	5493444	UXOWGYHJODZGMF-QORCZRPOSA-N	Launched	renin inhibitor	cardiology	hypertension
allicin	TRPA1	51399529	JDLKFOPOAOFWQN-SECBINFHSA-N	Phase 2	cytokine production inhibitor	NA	NA
allicin	TRPV1	51399529	JDLKFOPOAOFWQN-SECBINFHSA-N	Phase 2	cytokine production inhibitor	NA	NA
allopurinol	XDH	135401907	OFCNXPDARWKPPY-UHFFFAOYSA-N	Launched	xanthine oxidase inhibitor	rheumatology|urology	gout|kidney stones
allylestrenol	ESR1	235905	ATXHVCQZZJYMCF-XUDSTZEESA-N	Launched	steroidal progestin	obstetrics/gynecology	premature labor
allylestrenol	PGR	235905	ATXHVCQZZJYMCF-XUDSTZEESA-N	Launched	steroidal progestin	obstetrics/gynecology	premature labor
allylestrenol	SLC6A9	235905	ATXHVCQZZJYMCF-XUDSTZEESA-N	Launched	steroidal progestin	obstetrics/gynecology	premature labor
allylisothiocyanate	TRPA1	5971	ZOJBYZNEUISWFT-UHFFFAOYSA-N	Preclinical	TRPV agonist	NA	NA
almitrine	ATP1A1	33887	OBDOVFRMEYHSQB-UHFFFAOYSA-N	Launched	neurotransmitter agonist	pulmonary	chronic obstructive pulmonary disease (COPD)
almorexant	HCRTR1	23727689	DKMACHNQISHMDN-RPLLCQBOSA-N	Phase 3	orexin receptor antagonist	NA	NA
almorexant	HCRTR2	23727689	DKMACHNQISHMDN-RPLLCQBOSA-N	Phase 3	orexin receptor antagonist	NA	NA
almotriptan	HTR1B	123606	WKEMJKQOLOHJLZ-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
almotriptan	HTR1D	123606	WKEMJKQOLOHJLZ-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
aloe-emodin	CASP8	10207	YDQWDHRMZQUTBA-UHFFFAOYSA-N	Preclinical	anticancer agent	NA	NA
alogliptin	DPP4	11450633	ZSBOMTDTBDDKMP-OAHLLOKOSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
alosetron	HTR3A	2099	JSWZEAMFRNKZNL-UHFFFAOYSA-N	Withdrawn	serotonin receptor antagonist	NA	NA
aloxistatin	CTSG	65663	SRVFFFJZQVENJC-IHRRRGAJSA-N	Phase 3	protease inhibitor	NA	NA
alpelisib	PIK3CA	56649450	STUWGJZDJHPWGZ-LBPRGKRZSA-N	Launched	PI3K inhibitor	oncology	breast cancer
alpelisib	PIK3CB	56649450	STUWGJZDJHPWGZ-LBPRGKRZSA-N	Launched	PI3K inhibitor	oncology	breast cancer
alpelisib	PIK3CD	56649450	STUWGJZDJHPWGZ-LBPRGKRZSA-N	Launched	PI3K inhibitor	oncology	breast cancer
alpelisib	PIK3CG	56649450	STUWGJZDJHPWGZ-LBPRGKRZSA-N	Launched	PI3K inhibitor	oncology	breast cancer
alpha-asarone	HMGCR	636822	RKFAZBXYICVSKP-AATRIKPKSA-N	Preclinical	cytochrome P450 inhibitor|HMGCR inhibitor	NA	NA
alpha-linolenic-acid	ELOVL4	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-linolenic-acid	FADS1	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-linolenic-acid	FADS2	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-linolenic-acid	FFAR1	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-linolenic-acid	FFAR4	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-linolenic-acid	PTGS2	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-linolenic-acid	SLC8A1	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-linolenic-acid	TRPV1	5280934	DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	omega 3 fatty acid stimulant	NA	NA
alpha-methylhistamine-dihydrobromide-(R)-(-)	HRH3	156615	XNQIOISZPFVUFG-RXMQYKEDSA-N	Preclinical	histamine receptor agonist	NA	NA
alpha-methylhistamine-dihydrobromide-(S)-(+)	HRH3	6603865	XNQIOISZPFVUFG-YFKPBYRVSA-N	Preclinical	histamine receptor agonist	NA	NA
alpha-methylserotonin	HTR1D	14083218	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	serotonin receptor agonist	NA	NA
alpha-methylserotonin	HTR1E	14083218	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	serotonin receptor agonist	NA	NA
alpha-methylserotonin	HTR1F	14083218	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	serotonin receptor agonist	NA	NA
alpha-methylserotonin	HTR2A	14083218	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	serotonin receptor agonist	NA	NA
alpha-methylserotonin	HTR2B	14083218	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	serotonin receptor agonist	NA	NA
alpha-methylserotonin	HTR2C	14083218	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	serotonin receptor agonist	NA	NA
alpha-methylserotonin	HTR4	14083218	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	serotonin receptor agonist	NA	NA
alpidem	GABRA1	54897	JRTIDHTUMYMPRU-UHFFFAOYSA-N	Withdrawn	benzodiazepine receptor agonist	NA	NA
alprenolol	ADRB1	203685	PAZJSJFMUHDSTF-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris
alprenolol	ADRB2	203685	PAZJSJFMUHDSTF-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris
alprostadil	CATSPER1	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	CATSPER2	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	CATSPER3	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	CATSPER4	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	PTGDR	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	PTGER1	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	PTGER2	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	PTGER4	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alprostadil	PTGIR	5280723	GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	prostanoid receptor agonist	cardiology	congenital heart defects
alrestatin	AKR1B1	2120	GCUCIFQCGJIRNT-UHFFFAOYSA-N	Preclinical	aldose reductase inhibitor	NA	NA
altanserin	HTR2A	3033677	SMYALUSCZJXWHG-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
altinicline	CHRNA4	3036156	NUPUDYKEEJNZRG-LBPRGKRZSA-N	Phase 2	nicotinic receptor agonist	NA	NA
altinicline	CHRNB2	3036156	NUPUDYKEEJNZRG-LBPRGKRZSA-N	Phase 2	nicotinic receptor agonist	NA	NA
altiratinib	KDR	54576299	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	Phase 1	MET inhibitor|VEGFR inhibitor	NA	NA
altiratinib	MET	54576299	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	Phase 1	MET inhibitor|VEGFR inhibitor	NA	NA
altiratinib	TEK	54576299	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	Phase 1	MET inhibitor|VEGFR inhibitor	NA	NA
altrenogest	PGR	10041070	VWAUPFMBXBWEQY-ANULTFPQSA-N	Launched	progestogen hormone	endocrinology	estrus
alverine	HTR1A	3678	ZPFXAOWNKLFJDN-UHFFFAOYSA-N	Launched	muscle relaxant	gastroenterology	irritable bowel syndrome|diverticular disease
alvespimycin	HSP90AA1	59996481	KUFRQPKVAWMTJO-UBNVGODQSA-N	Phase 2	HSP inhibitor	NA	NA
alvimopan	OPRD1	5488548	UPNUIXSCZBYVBB-JVFUWBCBSA-N	Launched	opioid receptor antagonist	gastroenterology	postoperative ileus
alvimopan	OPRK1	5488548	UPNUIXSCZBYVBB-JVFUWBCBSA-N	Launched	opioid receptor antagonist	gastroenterology	postoperative ileus
alvimopan	OPRM1	5488548	UPNUIXSCZBYVBB-JVFUWBCBSA-N	Launched	opioid receptor antagonist	gastroenterology	postoperative ileus
alvocidib	CDK1	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	CDK2	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	CDK4	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	CDK5	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	CDK6	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	CDK7	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	CDK8	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	CDK9	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	EGFR	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
alvocidib	PYGM	5287969	BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	CDK inhibitor	NA	NA
ALX-5407	SLC6A9	86306255	FDORQEIHOKEJNX-HSZRJFAPSA-N	Phase 1	glycine transporter inhibitor	NA	NA
AM-1241	CNR1	23583507	ZUHIXXCLLBMBDW-MRXNPFEDSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
AM-1241	CNR2	23583507	ZUHIXXCLLBMBDW-MRXNPFEDSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
AM-24	ALOX5	11862	VAPDZNUFNKUROY-UHFFFAOYSA-N	Phase 2	lipoxygenase inhibitor	NA	NA
AM-251	CNR1	2125	BUZAJRPLUGXRAB-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-251	GPR18	2125	BUZAJRPLUGXRAB-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-251	GPR55	2125	BUZAJRPLUGXRAB-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-281	CNR1	4302962	AJFFBPZYXRNAIC-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-281	CNR2	4302962	AJFFBPZYXRNAIC-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-281	GPR55	4302962	AJFFBPZYXRNAIC-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-404	CNR1	6604822	IJBZOOZRAXHERC-DOFZRALJSA-N	Preclinical	cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist	NA	NA
AM-404	CNR2	6604822	IJBZOOZRAXHERC-DOFZRALJSA-N	Preclinical	cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist	NA	NA
AM-404	FAAH	6604822	IJBZOOZRAXHERC-DOFZRALJSA-N	Preclinical	cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist	NA	NA
AM-404	TRPV1	6604822	IJBZOOZRAXHERC-DOFZRALJSA-N	Preclinical	cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist	NA	NA
AM-580	RARA	2126	SZWKGOZKRMMLAJ-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
AM-630	CNR1	4302963	JHOTYHDSLIUKCJ-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-630	CNR2	4302963	JHOTYHDSLIUKCJ-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
AM-92016	GRIN1	6604771	BQBSHJUQVIWEFM-MRXNPFEDSA-N	Preclinical	potassium channel blocker	NA	NA
amantadine	DRD2	2130	DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease
amantadine	GRIN2A	2130	DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease
amantadine	GRIN2B	2130	DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease
amantadine	GRIN2C	2130	DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease
amantadine	GRIN2D	2130	DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease
amantadine	GRIN3A	2130	DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease
ambenonium	ACHE	2131	OMHBPUNFVFNHJK-UHFFFAOYSA-P	Launched	cholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
ambrisentan	EDNRA	6918493	OUJTZYPIHDYQMC-LJQANCHMSA-N	Launched	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
ambrisentan	EDNRB	6918493	OUJTZYPIHDYQMC-LJQANCHMSA-N	Launched	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
ambroxol	CYP3A4		JBDGDEWWOUBZPM-XYPYZODXSA-N	Launched	sodium channel blocker	pulmonary	bronchitis
amcinonide	NR3C1	40469418	ILKJAFIWWBXGDU-KNPIAJNZSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
AMD-3465	CXCR4	483559	CWJJHESJXJQCJA-UHFFFAOYSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
AMD11070	CCR5	11256587	WVLHHLRVNDMIAR-IBGZPJMESA-N	Phase 3	CC chemokine receptor antagonist	NA	NA
AMD11070	CXCR4	11256587	WVLHHLRVNDMIAR-IBGZPJMESA-N	Phase 3	CC chemokine receptor antagonist	NA	NA
amezinium	ADRB2	71927	VXROHTDSRBRJLN-UHFFFAOYSA-O	Launched	adrenergic receptor agonist	cardiology	hypotension
amfenac	PTGS1	2136	SOYCMDCMZDHQFP-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
amfenac	PTGS2	2136	SOYCMDCMZDHQFP-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
amflutizole	XDH	54833	KVMCEGAWQYTFKC-UHFFFAOYSA-N	Phase 2	xanthine oxidase inhibitor	NA	NA
AMG-PERK-44	EIF2AK4	86583045	YPPSMYLMSKHYAY-UHFFFAOYSA-N	Preclinical	PERK inhibitor	NA	NA
AMG-208	MET	24864821	HEAIZQNMNCHNFD-UHFFFAOYSA-N	Phase 1	tyrosine kinase inhibitor	NA	NA
AMG-232	MDM2	58573469	DRLCSJFKKILATL-YWCVFVGNSA-N	Phase 2	MDM inhibitor	NA	NA
AMG-319	PIK3CD	68947304	KWRYMZHCQIOOEB-LBPRGKRZSA-N	Phase 2	PI3K inhibitor	NA	NA
AMG-337	MET	44181686	DWHXUGDWKAIASB-CQSZACIVSA-N	Phase 2	MET inhibitor	NA	NA
AMG-487-(+/-)	CXCR3	24957182	WQTKNBPCJKRYPA-OAQYLSRUSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
AMG-517	TRPV1	16007367	YUTIXVXZQIQWGY-UHFFFAOYSA-N	Phase 1	TRPV antagonist	NA	NA
AMG-548	MAPK11	11167112	RQVKVJIRFKVPBF-VWLOTQADSA-N	Phase 1	MAP kinase inhibitor	NA	NA
AMG-548	MAPK12	11167112	RQVKVJIRFKVPBF-VWLOTQADSA-N	Phase 1	MAP kinase inhibitor	NA	NA
AMG-548	MAPK13	11167112	RQVKVJIRFKVPBF-VWLOTQADSA-N	Phase 1	MAP kinase inhibitor	NA	NA
AMG-548	MAPK14	11167112	RQVKVJIRFKVPBF-VWLOTQADSA-N	Phase 1	MAP kinase inhibitor	NA	NA
AMG-837	FFAR1	46854655	ZOPNBMMVVZRSGH-NRFANRHFSA-N	Phase 1	free fatty acid receptor agonist	NA	NA
AMG-925	CDK4	NA	BBUVDDPUURMFOX-SAABIXHNSA-N	Phase 1	CDK inhibitor|FLT3 inhibitor	NA	NA
AMG-925	CDK6	NA	BBUVDDPUURMFOX-SAABIXHNSA-N	Phase 1	CDK inhibitor|FLT3 inhibitor	NA	NA
AMG-925	FLT3	NA	BBUVDDPUURMFOX-SAABIXHNSA-N	Phase 1	CDK inhibitor|FLT3 inhibitor	NA	NA
AMG-9810	TRPV1	680502	GZTFUVZVLYUPRG-IZZDOVSWSA-N	Preclinical	TRPV antagonist	NA	NA
AMG319	PIK3CD	133547162	KWRYMZHCQIOOEB-GFCCVEGCSA-N	Phase 2	PI3K inhibitor	NA	NA
AMG458	MET	24764449	GLBZSOQDAOLMGC-UHFFFAOYSA-N	Preclinical	MET inhibitor	NA	NA
AMG900	AURKA	24856041	IVUGFMLRJOCGAS-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
AMG900	AURKB	24856041	IVUGFMLRJOCGAS-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
AMG900	AURKC	24856041	IVUGFMLRJOCGAS-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
AMI-1	PRMT1	67254	PCGISRHGYLRXSR-UHFFFAOYSA-N	Preclinical	protein arginine N-methyltransferase inhibitor	NA	NA
amibegron	ADRB3	3035442	RDJQCOBTKKAQAH-FPOVZHCZSA-N	Phase 3	adrenergic receptor agonist	NA	NA
amiflamine	MAOA	6336525	HFQMYSHATTXRTC-SNVBAGLBSA-N	Phase 1	monoamine oxidase inhibitor	NA	NA
amiflamine	SLC6A2	6336525	HFQMYSHATTXRTC-SNVBAGLBSA-N	Phase 1	monoamine oxidase inhibitor	NA	NA
amifostine	ALPPL2	29927142	JKOQGQFVAUAYPM-UHFFFAOYSA-N	Launched	reducing agent	nephrology	renal toxicity
amifostine	ENPP1	29927142	JKOQGQFVAUAYPM-UHFFFAOYSA-N	Launched	reducing agent	nephrology	renal toxicity
amiloride	AOC1	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	ASIC1	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	ASIC2	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	ASIC3	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	PKD2	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	PKD2L1	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	PLAU	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	SCNN1A	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	SCNN1B	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	SCNN1D	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	SCNN1G	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	SLC9A1	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	TRPC7	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amiloride	TRPV2	16231	XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	hypertension|congestive heart failure
amineptine	SLC6A2	38988248	ONNOFKFOZAJDHT-UHFFFAOYSA-N	Withdrawn	dopamine receptor agonist	NA	NA
amineptine	SLC6A4	38988248	ONNOFKFOZAJDHT-UHFFFAOYSA-N	Withdrawn	dopamine receptor agonist	NA	NA
aminocaproic-acid	LPA	564	SLXKOJJOQWFEFD-UHFFFAOYSA-N	Launched	plasminogen activator inhibitor	hematology	fibrinolytic bleeding
aminocaproic-acid	PLAT	564	SLXKOJJOQWFEFD-UHFFFAOYSA-N	Launched	plasminogen activator inhibitor	hematology	fibrinolytic bleeding
aminocaproic-acid	PLG	564	SLXKOJJOQWFEFD-UHFFFAOYSA-N	Launched	plasminogen activator inhibitor	hematology	fibrinolytic bleeding
aminoglutethimide	CYP11A1	1548995	ROBVIMPUHSLWNV-ZDUSSCGKSA-N	Launched	glucocorticoid receptor antagonist	endocrinology|oncology	Cushing's syndrome|breast cancer
aminoglutethimide	CYP19A1	1548995	ROBVIMPUHSLWNV-ZDUSSCGKSA-N	Launched	glucocorticoid receptor antagonist	endocrinology|oncology	Cushing's syndrome|breast cancer
aminoguanidine	AKR1B1	2146	HAMNKKUPIHEESI-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
aminoguanidine	NOS2	2146	HAMNKKUPIHEESI-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
aminoguanidine	TIMP3	2146	HAMNKKUPIHEESI-UHFFFAOYSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
aminomethyltransferase	NOS2	7059445	BATVOUKHGLKDGQ-BYPYZUCNSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
aminopentamide	CHRM1	176163	NARHAGIVSFTMIG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	acute abdominal visceral spasm|hypertrophic gastritis (GHG)|nausea
aminophylline	ADORA1	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	ADORA2A	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	ADORA2B	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	ADORA3	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	HDAC2	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	PDE3A	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	PDE3B	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	PDE4A	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	PDE4B	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	PDE4C	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	PDE4D	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminophylline	PDE5A	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis|emphysema
aminopterin	DHFR	169371	TVZGACDUOSZQKY-LBPRGKRZSA-N	Phase 3	dihydrofolate reductase inhibitor	NA	NA
aminopterin	SLC46A1	169371	TVZGACDUOSZQKY-LBPRGKRZSA-N	Phase 3	dihydrofolate reductase inhibitor	NA	NA
aminopurvalanol-a	CDK1	6604931	RAMROQQYRRQPDL-HNNXBMFYSA-N	Preclinical	CDK inhibitor|tyrosine kinase inhibitor	NA	NA
aminopurvalanol-a	CDK2	6604931	RAMROQQYRRQPDL-HNNXBMFYSA-N	Preclinical	CDK inhibitor|tyrosine kinase inhibitor	NA	NA
aminopurvalanol-a	CDK5	6604931	RAMROQQYRRQPDL-HNNXBMFYSA-N	Preclinical	CDK inhibitor|tyrosine kinase inhibitor	NA	NA
aminosalicylate	ALOX5	4649	WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	inflammatory bowel disease|ulcerative colitis
aminosalicylate	CHUK	4649	WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	inflammatory bowel disease|ulcerative colitis
aminosalicylate	PLA2G2E	4649	WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	inflammatory bowel disease|ulcerative colitis
aminosalicylate	PTGS1	4649	WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	inflammatory bowel disease|ulcerative colitis
aminosalicylate	PTGS2	4649	WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	inflammatory bowel disease|ulcerative colitis
aminothiadiazole	ADORA3	19909	QUKGLNCXGVWCJX-UHFFFAOYSA-N	Phase 2	inosine monophosphate dehydrogenase inhibitor	NA	NA
aminothiadiazole	IMPDH1	19909	QUKGLNCXGVWCJX-UHFFFAOYSA-N	Phase 2	inosine monophosphate dehydrogenase inhibitor	NA	NA
aminothiazole	NOS2	2155	RAIPHJJURHTUIC-UHFFFAOYSA-N	Preclinical	cyclin D inhibitor	NA	NA
amiodarone	ADRB1	2157	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched	potassium channel blocker	cardiology	ventricular arrhythmias
amiodarone	CACNA1H	2157	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched	potassium channel blocker	cardiology	ventricular arrhythmias
amiodarone	CACNA2D2	2157	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched	potassium channel blocker	cardiology	ventricular arrhythmias
amiodarone	KCNA7	2157	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched	potassium channel blocker	cardiology	ventricular arrhythmias
amiodarone	KCNH2	2157	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched	potassium channel blocker	cardiology	ventricular arrhythmias
amisulpride	DRD2	5746246	NTJOBXMMWNYJFB-GFCCVEGCSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	psychosis|bipolar disorder|schizophrenia
amitifadine	SLC6A2	11658655	BSMNRYCSBFHEMQ-KCJUWKMLSA-N	Phase 3	serotonin transporter (SERT) inhibitor	NA	NA
amitifadine	SLC6A3	11658655	BSMNRYCSBFHEMQ-KCJUWKMLSA-N	Phase 3	serotonin transporter (SERT) inhibitor	NA	NA
amitifadine	SLC6A4	11658655	BSMNRYCSBFHEMQ-KCJUWKMLSA-N	Phase 3	serotonin transporter (SERT) inhibitor	NA	NA
amitraz	ADRA1A	NA	QXAITBQSYVNQDR-ZIOPAAQOSA-N	Launched	adrenergic receptor agonist	infectious disease	generalized demodicosis
amitraz	ADRA2A	NA	QXAITBQSYVNQDR-ZIOPAAQOSA-N	Launched	adrenergic receptor agonist	infectious disease	generalized demodicosis
amitriptyline	ADRA1A	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	ADRA1B	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	ADRA1D	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	ADRA2A	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	ADRB1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	ADRB2	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	ADRB3	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	CHRM1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	CHRM2	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	CHRM3	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	CHRM4	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	CHRM5	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HRH1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HRH2	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HRH4	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HTR1A	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HTR1B	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HTR1D	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HTR2A	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HTR2C	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HTR6	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	HTR7	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	KCNA1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	KCND2	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	KCND3	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	KCNQ2	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	KCNQ3	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	NTRK1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	NTRK2	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	OPRD1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	OPRK1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	OPRM1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	SIGMAR1	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	SLC6A2	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amitriptyline	SLC6A4	2160	KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amlexanox	FGF1	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlexanox	IL3	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlexanox	PDE4A	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlexanox	PDE4B	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlexanox	PDE4C	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlexanox	PDE4D	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlexanox	S100A12	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlexanox	S100A13	2161	SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
amlodipine	CACNA1C	9801597	HTIQEAQVCYTUBX-QGZVFWFLSA-N	Launched	calcium channel blocker	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)
amlodipine	CACNA1D	9801597	HTIQEAQVCYTUBX-QGZVFWFLSA-N	Launched	calcium channel blocker	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)
amlodipine	CACNA1F	9801597	HTIQEAQVCYTUBX-QGZVFWFLSA-N	Launched	calcium channel blocker	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)
amlodipine	CACNA1S	9801597	HTIQEAQVCYTUBX-QGZVFWFLSA-N	Launched	calcium channel blocker	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)
amlodipine	CACNA2D1	9801597	HTIQEAQVCYTUBX-QGZVFWFLSA-N	Launched	calcium channel blocker	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)
ammonium-glycyrrhizinate	HSD11B1	14982	LPLVUJXQOOQHMX-QWBHMCJMSA-N	Launched	thrombin inhibitor	dermatology	cosmetic
ammonium-glycyrrhizinate	HSD11B2	14982	LPLVUJXQOOQHMX-QWBHMCJMSA-N	Launched	thrombin inhibitor	dermatology	cosmetic
ammonium-glycyrrhizinate	SLCO1B1	14982	LPLVUJXQOOQHMX-QWBHMCJMSA-N	Launched	thrombin inhibitor	dermatology	cosmetic
ammonium-glycyrrhizinate	SLCO1B3	14982	LPLVUJXQOOQHMX-QWBHMCJMSA-N	Launched	thrombin inhibitor	dermatology	cosmetic
ammonium-lactate	HCAR1	10313098	RZOBLYBZQXQGFY-HSHFZTNMSA-N	Launched		dermatology	xerosis cutis|ichthyosis vulgaris
ammonium-perfluorocaprylate	PIM1	9554	SNGREZUHAYWORS-UHFFFAOYSA-N	Phase 1	Pim kinase inhibitor	NA	NA
AMN-082	GRM7	1894361	DTZDSNQYNPNCPK-UHFFFAOYSA-N	Preclinical	glutamate receptor modulator	NA	NA
amodiaquine	HNMT	3647519	OVCDSSHSILBFBN-UHFFFAOYSA-N	Launched	histamine receptor agonist	infectious disease	malaria
amonafide	TOP2A	50515	UPALIKSFLSVKIS-UHFFFAOYSA-N	Phase 3	topoisomerase inhibitor	NA	NA
amonafide	TOP2B	50515	UPALIKSFLSVKIS-UHFFFAOYSA-N	Phase 3	topoisomerase inhibitor	NA	NA
amoxapine	ADRA1A	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	ADRA1B	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	ADRA1D	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	ADRA2A	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	ADRA2B	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	ADRA2C	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	CHRM1	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	CHRM2	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	CHRM3	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	CHRM4	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	CHRM5	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	DRD1	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	DRD2	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	DRD3	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	DRD4	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	DRD5	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRA1	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRA2	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRA3	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRA4	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRA5	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRA6	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRB1	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRB2	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRB3	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRD	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRE	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRG1	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRG2	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRG3	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRP	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	GABRQ	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HRH1	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HRH4	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR1A	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR1B	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR2A	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR2B	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR2C	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR3A	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR6	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	HTR7	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	SLC6A2	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	SLC6A3	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxapine	SLC6A4	2170	QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxicillin	CYP2C19	40467057	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	Launched	penicillin binding protein inhibitor	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections
amoxicillin	SLC15A1	40467057	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	Launched	penicillin binding protein inhibitor	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections
amoxicillin	SLC15A2	40467057	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	Launched	penicillin binding protein inhibitor	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections
amoxicillin	SLC22A6	40467057	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	Launched	penicillin binding protein inhibitor	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections
AMPA-(RS)	GRIN1	7059442	UUDAMDVQRQNNHZ-RXMQYKEDSA-N	Preclinical	glutamate receptor agonist	NA	NA
AMPA-(S)	GRIA2	7000183	UUDAMDVQRQNNHZ-YFKPBYRVSA-N	Preclinical	glutamate receptor agonist	NA	NA
AMPA-(S)	GRIN1	7000183	UUDAMDVQRQNNHZ-YFKPBYRVSA-N	Preclinical	glutamate receptor agonist	NA	NA
ampalex	GRIA1	148184	ANDGGVOPIJEHOF-UHFFFAOYSA-N	Phase 2	glutamate receptor agonist	NA	NA
ampalex	GRIA2	148184	ANDGGVOPIJEHOF-UHFFFAOYSA-N	Phase 2	glutamate receptor agonist	NA	NA
ampalex	GRIA3	148184	ANDGGVOPIJEHOF-UHFFFAOYSA-N	Phase 2	glutamate receptor agonist	NA	NA
ampalex	GRIA4	148184	ANDGGVOPIJEHOF-UHFFFAOYSA-N	Phase 2	glutamate receptor agonist	NA	NA
amperozide	FAAH	73333	NNAIYOXJNVGUOM-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	psychosis
amperozide	HTR2A	73333	NNAIYOXJNVGUOM-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	psychosis
ampiroxicam	PTGS1	25273583	LSNWBKACGXCGAJ-ZDUSSCGKSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ampiroxicam	PTGS2	25273583	LSNWBKACGXCGAJ-ZDUSSCGKSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
amrinone	PDE3A	3698	RNLQIBCLLYYYFJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
amrinone	PDE3B	3698	RNLQIBCLLYYYFJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
amrinone	PDE4B	3698	RNLQIBCLLYYYFJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
amrinone	TNF	3698	RNLQIBCLLYYYFJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
amrubicin	TOP2A	3035016	VJZITPJGSQKZMX-XDPRQOKASA-N	Launched	topoisomerase inhibitor	oncology	small cell lung cancer
amrubicin	TOP2B	3035016	VJZITPJGSQKZMX-XDPRQOKASA-N	Launched	topoisomerase inhibitor	oncology	small cell lung cancer
amsacrine	KCNH2	2179	XCPGHVQEEXUHNC-UHFFFAOYSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
amsacrine	TOP2A	2179	XCPGHVQEEXUHNC-UHFFFAOYSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
amthamine	HRH2	126688	LHVRFUVVRXGZPV-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
amtolmetin-guacil	PTGS1	65655	CWJNMKKMGIAGDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
amtolmetin-guacil	PTGS2	65655	CWJNMKKMGIAGDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
amuvatinib	KIT	11282283	"InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)"	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor	NA	NA
amuvatinib	MET	11282283	"InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)"	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor	NA	NA
amygdalin	CASP3	656516	XUCIJNAGGSZNQT-JHSLDZJXSA-N	Phase 2	caspase activator	NA	NA
AM679	ALOX5AP	44627267	VYXWHVDEWWHDLH-LJAQVGFWSA-N	Preclinical	cannabinoid receptor agonist|lipoxygenase inhibitor	NA	NA
AM679	CNR1	44627267	VYXWHVDEWWHDLH-LJAQVGFWSA-N	Preclinical	cannabinoid receptor agonist|lipoxygenase inhibitor	NA	NA
AM679	CNR2	44627267	VYXWHVDEWWHDLH-LJAQVGFWSA-N	Preclinical	cannabinoid receptor agonist|lipoxygenase inhibitor	NA	NA
ANA-12	NTRK2	6977265	TUSCYCAIGRVBMD-KRWDZBQOSA-N	Preclinical	tropomyosin receptor kinase inhibitor	NA	NA
anacetrapib	CETP	11556427	MZZLGJHLQGUVPN-HAWMADMCSA-N	Phase 3	cholesteryl ester transfer protein inhibitor	NA	NA
anagliptin	DPP4	44513473	LDXYBEHACFJIEL-HNNXBMFYSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
anagrelide	PDE3A	135409400	OTBXOEAOVRKTNQ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	hematology|hematologic malignancy	thrombocythemia|myeloproliferative neoplasms
anamorelin	GHSR	9828911	VQPFSIRUEPQQPP-MXBOTTGLSA-N	Phase 3	growth hormone secretagogue receptor agonist	NA	NA
anandamide	CACNA1G	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	CACNA1H	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	CACNA1I	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	CNR1	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	CNR2	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	GLRA1	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	GPR18	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	GPR55	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	KCNA2	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	KCNK3	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	KCNK9	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	TRPM8	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anandamide	TRPV1	5281969	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
anastrozole	CYP19A1	2187	YBBLVLTVTVSKRW-UHFFFAOYSA-N	Launched	aromatase inhibitor	oncology	breast cancer
andarine	AR	9824562	YVXVTLGIDOACBJ-SFHVURJKSA-N	Phase 1	androgen receptor modulator	NA	NA
andrographolide	IL1B	5318517	BOJKULTULYSRAS-OTESTREVSA-N	Phase 2	tumor necrosis factor production inhibitor	NA	NA
andrographolide	IL6	5318517	BOJKULTULYSRAS-OTESTREVSA-N	Phase 2	tumor necrosis factor production inhibitor	NA	NA
andrographolide	NFKB1	5318517	BOJKULTULYSRAS-OTESTREVSA-N	Phase 2	tumor necrosis factor production inhibitor	NA	NA
andrographolide	NFKB2	5318517	BOJKULTULYSRAS-OTESTREVSA-N	Phase 2	tumor necrosis factor production inhibitor	NA	NA
andrographolide	TNF	5318517	BOJKULTULYSRAS-OTESTREVSA-N	Phase 2	tumor necrosis factor production inhibitor	NA	NA
anguidine	SLC5A1	91518	AUGQEEXBDZWUJY-ZLJUKNTDSA-N	Phase 2	protein synthesis inhibitor	NA	NA
aniracetam	DRD2	2196	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched	glutamate receptor agonist	NA	NA
aniracetam	GRIA1	2196	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched	glutamate receptor agonist	NA	NA
aniracetam	GRIA2	2196	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched	glutamate receptor agonist	NA	NA
aniracetam	GRIA3	2196	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched	glutamate receptor agonist	NA	NA
aniracetam	GRIA4	2196	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched	glutamate receptor agonist	NA	NA
aniracetam	HTR2A	2196	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched	glutamate receptor agonist	NA	NA
anisindione	GGCX	2197	XRCFXMGQEVUZFC-UHFFFAOYSA-N	Launched	vitamin K antagonist	hematology	deep vein thrombosis (DVT)
anisodamine	ADRA1A	NA	WTQYWNWRJNXDEG-JKJDWNRSSA-N	Phase 3	lipid peroxidase inhibitor	NA	NA
anisomycin	NHP2L1	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL10L	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL11	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL13A	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL15	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL19	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL23	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL23A	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL26L1	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL3	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL37	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RPL8	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anisomycin	RSL24D1	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	DNA synthesis inhibitor	NA	NA
anlotinib	KDR	25017411	KSMZEXLVHXZPEF-UHFFFAOYSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
anlotinib	PDGFRB	25017411	KSMZEXLVHXZPEF-UHFFFAOYSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
anpirtoline	HTR1B	65854	GGALEXMXDMUMDM-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
ANR-94	ADORA2A	11805896	QUGDTMONBLMLLD-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
antagonist-g	MAPK8	163960	CUCSSYAUKKIDJV-FAXBSAIASA-N	Phase 1	neuropeptide receptor antagonist	NA	NA
antalarmin	CRHR1	177990	IXPROWGEHNVJOY-UHFFFAOYSA-N	Preclinical	corticotropin releasing factor receptor antagonist	NA	NA
antazoline	HRH1	2200	REYFJDPCWQRWAA-UHFFFAOYSA-N	Launched	antihistamine	ophthalmology|otolaryngology	conjunctivitis|nasal congestion
anthraquinone	CDC25B	6780	RZVHIXYEVGDQDX-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
antimycin-A	CYCS	14957	UIFFUZWRFRDZJC-SBOOETFBSA-N	Preclinical	ATP synthase inhibitor	NA	NA
AP-18	TRPA1	9584673	MHTJEUOFLVQMCL-NJHPPEEMSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
apabetalone	BRD3	135564749	NETXMUIMUZJUTB-UHFFFAOYSA-N	Phase 3	apolipoprotein expression enhancer	NA	NA
apafant	PTAFR	65889	JGPJQFOROWSRRS-UHFFFAOYSA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
apatinib	CSK	11315474	WPEWQEMJFLWMLV-UHFFFAOYSA-N	Phase 3	RET tyrosine kinase inhibitor	NA	NA
apatinib	KDR	11315474	WPEWQEMJFLWMLV-UHFFFAOYSA-N	Phase 3	RET tyrosine kinase inhibitor	NA	NA
apatinib	KIT	11315474	WPEWQEMJFLWMLV-UHFFFAOYSA-N	Phase 3	RET tyrosine kinase inhibitor	NA	NA
apatinib	RET	11315474	WPEWQEMJFLWMLV-UHFFFAOYSA-N	Phase 3	RET tyrosine kinase inhibitor	NA	NA
APC-100	AR	99479	SEBPXHSZHLFWRL-UHFFFAOYSA-N	Phase 1/Phase 2	androgen receptor antagonist|anti-inflammatory agent	NA	NA
APcK-110	KIT	24786010	CAMGZGMEPKFVMF-UHFFFAOYSA-N	Preclinical	KIT inhibitor	NA	NA
APcK-110	STAT3	24786010	CAMGZGMEPKFVMF-UHFFFAOYSA-N	Preclinical	KIT inhibitor	NA	NA
APD597	GPR119	11691484	WPDCHTSXOPUOII-UHFFFAOYSA-N	Phase 1	glucose dependent insulinotropic receptor agonist	NA	NA
APD668	GPR119	11705608	XTRUQJBVQBUKSQ-UHFFFAOYSA-N	Phase 1	glucose dependent insulinotropic receptor agonist	NA	NA
API-001	SIGMAR1	44247568	DGPGXHRHNRYVDH-UHFFFAOYSA-N	Phase 2	sigma receptor antagonist	NA	NA
API-1	AKT1	24773090	SPBWHPXCWJLQRU-FITJORAGSA-N	Preclinical	AKT inhibitor	NA	NA
API-1	AKT2	24773090	SPBWHPXCWJLQRU-FITJORAGSA-N	Preclinical	AKT inhibitor	NA	NA
API-1	AKT3	24773090	SPBWHPXCWJLQRU-FITJORAGSA-N	Preclinical	AKT inhibitor	NA	NA
apigenin	AKR1B1	5280443	KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	NA	NA
apigenin	AR	5280443	KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	NA	NA
apigenin	CDK6	5280443	KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	NA	NA
apigenin	CFTR	5280443	KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	NA	NA
apigenin	CYP19A1	5280443	KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	NA	NA
apigenin	CYP1B1	5280443	KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	NA	NA
apigenin	HSD17B1	5280443	KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	NA	NA
apixaban	F10	10182969	QNZCBYKSOIHPEH-UHFFFAOYSA-N	Launched	coagulation factor inhibitor	neurology/psychiatry|hematology|cardiology	stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT)
apocynin	NOX4	2214	DFYRUELUNQRZTB-UHFFFAOYSA-N	Phase 1	NADPH oxidase inhibitor	NA	NA
apoptosis-activator-II	BCHE	1901244	KGRJPLRFGLMQMV-UHFFFAOYSA-N	Preclinical	carboxylesterase inhibitor	NA	NA
apoptosis-activator-II	CES1	1901244	KGRJPLRFGLMQMV-UHFFFAOYSA-N	Preclinical	carboxylesterase inhibitor	NA	NA
APR-246	TP53	76965201	BGBNULCRKBVAKL-SNVBAGLBSA-N	Phase 3	p53 activator	NA	NA
apraclonidine	ADRA1A	2216	IEJXVRYNEISIKR-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	glaucoma|intraocular pressure
apraclonidine	ADRA2A	2216	IEJXVRYNEISIKR-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	glaucoma|intraocular pressure
apraclonidine	ADRA2B	2216	IEJXVRYNEISIKR-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	glaucoma|intraocular pressure
apraclonidine	ADRA2C	2216	IEJXVRYNEISIKR-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	glaucoma|intraocular pressure
apratastat	ADAM17	11452716	MAVDNGWEBZTACC-HNNXBMFYSA-N	Phase 2	matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor	NA	NA
apratastat	MMP1	11452716	MAVDNGWEBZTACC-HNNXBMFYSA-N	Phase 2	matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor	NA	NA
apratastat	MMP13	11452716	MAVDNGWEBZTACC-HNNXBMFYSA-N	Phase 2	matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor	NA	NA
apratastat	MMP9	11452716	MAVDNGWEBZTACC-HNNXBMFYSA-N	Phase 2	matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor	NA	NA
apremilast	PDE4A	11561674	IMOZEMNVLZVGJZ-QGZVFWFLSA-N	Launched	phosphodiesterase inhibitor	dermatology|rheumatology	psoriasis|psoriatic arthritis
apremilast	PDE4B	11561674	IMOZEMNVLZVGJZ-QGZVFWFLSA-N	Launched	phosphodiesterase inhibitor	dermatology|rheumatology	psoriasis|psoriatic arthritis
apremilast	PDE4C	11561674	IMOZEMNVLZVGJZ-QGZVFWFLSA-N	Launched	phosphodiesterase inhibitor	dermatology|rheumatology	psoriasis|psoriatic arthritis
apremilast	PDE4D	11561674	IMOZEMNVLZVGJZ-QGZVFWFLSA-N	Launched	phosphodiesterase inhibitor	dermatology|rheumatology	psoriasis|psoriatic arthritis
aprepitant	TACR1	135413536	ATALOFNDEOCMKK-OITMNORJSA-N	Launched	tachykinin antagonist	gastroenterology	nausea|vomiting
aprindine	CALM1	2218	NZLBHDRPUJLHCE-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	cardiology	cardiac arrythmia
aprindine	SCN5A	2218	NZLBHDRPUJLHCE-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	cardiology	cardiac arrythmia
aptiganel	GRIN1	60840	BFNCJMURTMZBTE-UHFFFAOYSA-N	Phase 3	glutamate receptor antagonist	NA	NA
APTO-253	KLF4	11960271	NIRXBXIPHUTNNI-UHFFFAOYSA-N	Phase 1	krppel-like factor expression enhancer	NA	NA
APY-29	ERN1	42627755	WJNBSTLIALIIEW-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
APY0201	IL12A	56927660	RFZQYGBLRIKROZ-PCLIKHOPSA-N	Preclinical	phosphoinositide dependent kinase inhibitor	NA	NA
APY0201	IL12B	56927660	RFZQYGBLRIKROZ-PCLIKHOPSA-N	Preclinical	phosphoinositide dependent kinase inhibitor	NA	NA
APY0201	PIKFYVE	56927660	RFZQYGBLRIKROZ-PCLIKHOPSA-N	Preclinical	phosphoinositide dependent kinase inhibitor	NA	NA
AP1903	MTOR	16135625	GQLCLPLEEOUJQC-ZTQDTCGGSA-N	Phase 1/Phase 2		NA	NA
AP26113	ALK	57390074	OVDSPTSBIQCAIN-UHFFFAOYSA-N	Phase 2	ALK tyrosine kinase receptor inhibitor	NA	NA
AP26113	EGFR	57390074	OVDSPTSBIQCAIN-UHFFFAOYSA-N	Phase 2	ALK tyrosine kinase receptor inhibitor	NA	NA
AQ-RA741	CHRM2	129989	BCUGCHZRMKTPMU-UHFFFAOYSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
AR-A014418	GSK3B	448014	YAEMHJKFIIIULI-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
AR-C155858	SLC16A1	10226546	ISIVOJWVBJIOFM-ZDUSSCGKSA-N	Preclinical	monocarboxylate transporter inhibitor	NA	NA
AR-C155858	SLC16A7	10226546	ISIVOJWVBJIOFM-ZDUSSCGKSA-N	Preclinical	monocarboxylate transporter inhibitor	NA	NA
AR-12	PDPK1	10027278	YULUCECVQOCQFQ-UHFFFAOYSA-N	Phase 1	phosphoinositide dependent kinase inhibitor	NA	NA
AR-42	HDAC1	6918848	LAMIXXKAWNLXOC-INIZCTEOSA-N	Phase 1	HDAC inhibitor	NA	NA
arachidonic-acid	CLCN2	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	KCNJ4	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	KCNK10	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	KCNK18	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	KCNK2	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	PRKCZ	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	PTGS1	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	TRPC6	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arachidonic-acid	TRPM2	444899	YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	cytochrome P450 inhibitor	NA	NA
arbidol	CYP3A4	28446253	KCFYEAOKVJSACF-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor	infectious disease	influenza A virus infection
arbutin	TYR	440936	BJRNKVDFDLYUGJ-RMPHRYRLSA-N	Phase 2/Phase 3	melanin inhibitor	NA	NA
ARC-239	ADRA2A	609483	JFNKXGOEOQCXDM-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
ARC-239	ADRA2B	609483	JFNKXGOEOQCXDM-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
ARC-239	ADRA2C	609483	JFNKXGOEOQCXDM-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
arctigenin	CHUK	64981	NQWVSMVXKMHKTF-JKSUJKDBSA-N	Preclinical	MEK inhibitor	NA	NA
arctigenin	MAP2K1	64981	NQWVSMVXKMHKTF-JKSUJKDBSA-N	Preclinical	MEK inhibitor	NA	NA
arcyriaflavin-a	CCND1	5327723	KAJXOWFGKYKMMZ-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
arcyriaflavin-a	CDK4	5327723	KAJXOWFGKYKMMZ-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
ardeparin	SERPIND1	100942142	HXSDFQWQRCUQHF-IDOMHHBZSA-N	Withdrawn	thrombin inhibitor	NA	NA
arecaidine-but-2-ynyl-ester	CHRM2	4214594	LBFWTPRSXIRKMZ-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
arecaidine-propargyl-ester	CHRM1	2229	SPHRJZBOFYIKMC-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
arecaidine-propargyl-ester	CHRM2	2229	SPHRJZBOFYIKMC-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
arecaidine-propargyl-ester	CHRM3	2229	SPHRJZBOFYIKMC-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
arecaidine-propargyl-ester	CHRM4	2229	SPHRJZBOFYIKMC-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
arecoline	CHRM1	2230	HJJPJSXJAXAIPN-UHFFFAOYSA-N	Phase 1	acetylcholine receptor agonist	NA	NA
arecoline	CHRM2	2230	HJJPJSXJAXAIPN-UHFFFAOYSA-N	Phase 1	acetylcholine receptor agonist	NA	NA
arecoline	CHRM3	2230	HJJPJSXJAXAIPN-UHFFFAOYSA-N	Phase 1	acetylcholine receptor agonist	NA	NA
arecoline	CHRM4	2230	HJJPJSXJAXAIPN-UHFFFAOYSA-N	Phase 1	acetylcholine receptor agonist	NA	NA
argatroban	F2	152951	KXNPVXPOPUZYGB-XYVMCAHJSA-N	Launched	thrombin inhibitor	hematology	heparin-induced thrombocytopenia (HIT)
arglabin	FNTA	5574924	UVJYAKBJSGRTHA-CUZKYEQNSA-N	Launched	farnesyltransferase inhibitor	NA	NA
arglabin	NFKB1	5574924	UVJYAKBJSGRTHA-CUZKYEQNSA-N	Launched	farnesyltransferase inhibitor	NA	NA
aripiprazole	ADRA1A	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	ADRA1B	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	ADRA2A	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	ADRA2B	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	ADRA2C	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	CHRM1	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	CHRM2	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	CHRM3	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	CHRM4	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	CHRM5	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	DRD1	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	DRD2	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	DRD3	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	DRD4	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	DRD5	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HRH1	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR1A	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR1B	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR1D	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR1E	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR2A	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR2C	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR3A	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR6	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
aripiprazole	HTR7	60795	CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression|schizophrenia|bipolar disorder
arofylline	PDE4A	166553	GVTLDPJNRVMCAL-UHFFFAOYSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
arotinolol	ADRB3	12797283	BHIAIPWSVYSKJS-SECBINFHSA-N	Launched	adrenergic receptor antagonist	cardiology|neurology/psychiatry	hypertension|tremors
ARQ-092	AKT2	53262401	HNFMVVHMKGFCMB-UHFFFAOYSA-N	Phase 1	AKT inhibitor	NA	NA
ARQ-621	KIF11	25110841	UPJSUQWHUVLLNW-XMMPIXPASA-N	Phase 1	kinesin-like spindle protein inhibitor	NA	NA
ARRY-334543	ERBB2	42642648	UWXSAYUXVSFDBQ-CYBMUJFWSA-N	Phase 2/Phase 3	EGFR inhibitor	NA	NA
arsanilic-acid	LYZ	7389	XKNKHVGWJDPIRJ-UHFFFAOYSA-N	Phase 1		NA	NA
arsenic-trioxide	AKT1	261004	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	apoptosis stimulant	gastroenterology	diarrhea
arsenic-trioxide	CCND1	261004	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	apoptosis stimulant	gastroenterology	diarrhea
arsenic-trioxide	IKBKB	261004	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	apoptosis stimulant	gastroenterology	diarrhea
arsenic-trioxide	JUN	261004	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	apoptosis stimulant	gastroenterology	diarrhea
arsenic-trioxide	MAPK1	261004	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	apoptosis stimulant	gastroenterology	diarrhea
arsenic-trioxide	MAPK3	261004	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	apoptosis stimulant	gastroenterology	diarrhea
arsenic-trioxide	TXNRD1	261004	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	apoptosis stimulant	gastroenterology	diarrhea
artemether	ATP1A1	68911	SXYIRMFQILZOAM-HVNFFKDJSA-N	Launched	antimalarial agent	infectious disease	malaria
artemisinin	CYP2B6	68827	BLUAFEHZUWYNDE-NNWCWBAJSA-N	Launched	DNA synthesis inhibitor	infectious disease	malaria
arundic-acid	PTGS2	208925	YCYMCMYLORLIJX-SNVBAGLBSA-N	Phase 2/Phase 3	astrocyte modulating agent	NA	NA
arundic-acid	S100B	208925	YCYMCMYLORLIJX-SNVBAGLBSA-N	Phase 2/Phase 3	astrocyte modulating agent	NA	NA
ARV-825	BRD4	124870683	RWLOGRLTDKDANT-ZPGRZCPFSA-N	Preclinical	bromodomain inhibitor	NA	NA
AS-1269574	GPR119	5332859	DUKPGOOUJNUIOI-UHFFFAOYSA-N	Preclinical	glucose dependent insulinotropic receptor agonist	NA	NA
AS-1892802	ROCK1	46911016	WDTFYYZHMRBVHK-LJQANCHMSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
AS-1949490	INPP5D	44473434	RFZPGNRLOKVZJY-AWEZNQCLSA-N	Preclinical	SHIP2 phosphatase inhibitor	NA	NA
AS-2034178	FFAR1	24808572	VENOXIKBBUVHRY-UHFFFAOYSA-N	Preclinical	free fatty acid receptor agonist	NA	NA
AS-2444697	IRAK4	52913874	JANBIXNDYNRYQP-UHFFFAOYSA-N	Preclinical	interleukin inhibitor	NA	NA
AS-252424	PIK3CG	11630874	OYYVWNDMOQPMGE-SDQBBNPISA-N	Preclinical	PI3K inhibitor	NA	NA
AS-604850	PIK3CA	5287855	SRLVNYDXMUGOFI-YWEYNIOJSA-N	Preclinical	PI3K inhibitor	NA	NA
AS-604850	PIK3CG	5287855	SRLVNYDXMUGOFI-YWEYNIOJSA-N	Preclinical	PI3K inhibitor	NA	NA
AS-703026	MAP2K1	44187362	VIUAUNHCRHHYNE-JTQLQIEISA-N	Phase 2	MEK inhibitor	NA	NA
AS-703026	MAP2K2	44187362	VIUAUNHCRHHYNE-JTQLQIEISA-N	Phase 2	MEK inhibitor	NA	NA
AS-77	KCNA3	11302540	KINMYBBFQRSVLL-UHFFFAOYSA-N	Phase 1	potassium channel blocker	NA	NA
AS-77	KCNA5	11302540	KINMYBBFQRSVLL-UHFFFAOYSA-N	Phase 1	potassium channel blocker	NA	NA
AS-77	KCNN4	11302540	KINMYBBFQRSVLL-UHFFFAOYSA-N	Phase 1	potassium channel blocker	NA	NA
asaraldehyde	PTGS2	20525	IAJBQAYHSQIQRE-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
ASC-J9	AR	74891315	ZMGUKFHHNQMKJI-URFDALOKSA-N	Phase 2	androgen receptor enhancer	NA	NA
ascomycin	FKBP1A	134129697	ZDQSOHOQTUFQEM-MONOPTSESA-N	Preclinical	calcineurin inhibitor	NA	NA
ascorbic-acid	SLC23A1		KRGQEOSDQHTZMX-TXQLHFEISA-N	Launched	antioxidant	endocrinology	scurvy
ascorbic-acid	SLC23A2		KRGQEOSDQHTZMX-TXQLHFEISA-N	Launched	antioxidant	endocrinology	scurvy
asenapine	DRD2	163091	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
asenapine	HRH1	163091	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
asenapine	HTR1A	163091	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
asenapine	HTR1B	163091	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
asenapine	HTR1D	163091	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
asenapine	HTR1E	163091	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
asenapine	HTR2A	163091	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
asiatic-acid	PYGM	119034	JXSVIVRDWWRQRT-UYDOISQJSA-N	Preclinical	apoptosis stimulant	NA	NA
asimadoline	OPRK1	179340	JHLHNYVMZCADTC-LOSJGSFVSA-N	Phase 3	opioid receptor agonist	NA	NA
ASP-2535	SLC6A9	9800113	FQGLDGKVKDPVLO-UHFFFAOYSA-N	Phase 1	glycine transporter inhibitor	NA	NA
aspartame	TAS1R2	6992066	IAOZJIPTCAWIRG-QWRGUYRKSA-N	Launched		NA	NA
aspartame	TRPV1	6992066	IAOZJIPTCAWIRG-QWRGUYRKSA-N	Launched		NA	NA
aspirin	AKR1C1	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	ASIC3	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	EDNRA	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	HSPA5	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	IKBKB	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	NFKB1	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	NFKB2	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	NFKBIA	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PRKAA1	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PRKAA2	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PRKAB1	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PRKAB2	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PRKAG1	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PRKAG2	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PRKAG3	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PTGS1	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	PTGS2	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	RPS6KA3	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
aspirin	TP53	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain
ASP3026	ALK	25134326	MGGBYMDAPCCKCT-UHFFFAOYSA-N	Phase 1	ALK tyrosine kinase receptor inhibitor	NA	NA
AST-1306	EGFR	24739943	MVZGYPSXNDCANY-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
AST-1306	ERBB2	24739943	MVZGYPSXNDCANY-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
astemizole	HRH1	2247	GXDALQBWZGODGZ-UHFFFAOYSA-N	Withdrawn	histamine receptor antagonist	NA	NA
astemizole	KCNH1	2247	GXDALQBWZGODGZ-UHFFFAOYSA-N	Withdrawn	histamine receptor antagonist	NA	NA
astemizole	KCNH2	2247	GXDALQBWZGODGZ-UHFFFAOYSA-N	Withdrawn	histamine receptor antagonist	NA	NA
asymmetrical-dimethylarginine	NOS2	123831	YDGMGEXADBMOMJ-LURJTMIESA-N	Phase 1	nitric oxide synthase inhibitor	NA	NA
asymmetrical-dimethylarginine	NOS3	123831	YDGMGEXADBMOMJ-LURJTMIESA-N	Phase 1	nitric oxide synthase inhibitor	NA	NA
AT-1015	HTR2A	9805664	BSPMYKLEFGUTSI-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
AT-7519	CDK1	11338033	OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
AT-7519	CDK2	11338033	OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
AT-7519	CDK4	11338033	OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
AT-7519	CDK5	11338033	OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
AT-7519	CDK6	11338033	OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
AT-7519	CDK9	11338033	OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
AT-9283	AURKA	135398495	"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)"	Phase 2	Aurora kinase inhibitor|JAK inhibitor	NA	NA
AT-9283	AURKB	135398495	"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)"	Phase 2	Aurora kinase inhibitor|JAK inhibitor	NA	NA
AT-9283	JAK2	135398495	"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)"	Phase 2	Aurora kinase inhibitor|JAK inhibitor	NA	NA
AT-9283	JAK3	135398495	"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)"	Phase 2	Aurora kinase inhibitor|JAK inhibitor	NA	NA
AT-9283	RPS6KA6	135398495	"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)"	Phase 2	Aurora kinase inhibitor|JAK inhibitor	NA	NA
AT-9283	STK17A	135398495	"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)"	Phase 2	Aurora kinase inhibitor|JAK inhibitor	NA	NA
ataluren	DMD	11219835	OOUGLTULBSNHNF-UHFFFAOYSA-N	Launched	CFTR channel agonist|dystrophin stimulant	genetics|pulmonary	duchenne muscular dystrophy (DMD)|cystic fibrosis
ATB-346	PTGER2	76963724	YCNMAPLPQYQJFC-CYBMUJFWSA-N	Phase 2	cyclooxygenase inhibitor	NA	NA
atenolol-(+/-)	ADRB1	180559	METKIMKYRPQLGS-GFCCVEGCSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension|angina pectoris
atenolol-(+/-)	ADRB2	180559	METKIMKYRPQLGS-GFCCVEGCSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension|angina pectoris
atenolol-(+/-)	LTF	180559	METKIMKYRPQLGS-GFCCVEGCSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension|angina pectoris
atenolol-(+/-)	PLA2G2E	180559	METKIMKYRPQLGS-GFCCVEGCSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension|angina pectoris
atiprimod	JAK2	129869	SERHTTSLBVGRBY-UHFFFAOYSA-N	Phase 2	JAK inhibitor|STAT inhibitor	NA	NA
atiprimod	STAT3	129869	SERHTTSLBVGRBY-UHFFFAOYSA-N	Phase 2	JAK inhibitor|STAT inhibitor	NA	NA
atizoram	PDE4A	9861730	LITNEAPWQHVPOK-FFSVYQOJSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
atizoram	PDE4B	9861730	LITNEAPWQHVPOK-FFSVYQOJSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
atizoram	PDE4C	9861730	LITNEAPWQHVPOK-FFSVYQOJSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
atizoram	PDE4D	9861730	LITNEAPWQHVPOK-FFSVYQOJSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
ATN-161	ITGA5	9960285	MMHDBUJXLOFTLC-WOYTXXSLSA-N	Phase 2	integrin antagonist	NA	NA
ATN-161	ITGAV	9960285	MMHDBUJXLOFTLC-WOYTXXSLSA-N	Phase 2	integrin antagonist	NA	NA
ATN-161	ITGB1	9960285	MMHDBUJXLOFTLC-WOYTXXSLSA-N	Phase 2	integrin antagonist	NA	NA
ATN-161	ITGB3	9960285	MMHDBUJXLOFTLC-WOYTXXSLSA-N	Phase 2	integrin antagonist	NA	NA
atomoxetine	GRIN1	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	GRIN2A	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	GRIN2B	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	GRIN2C	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	GRIN2D	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	GRIN3A	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	GRIN3B	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	SLC6A2	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	SLC6A3	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atomoxetine	SLC6A4	54841	VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atorvastatin	AHR	60823	XUKUURHRXDUEBC-KAYWLYCHSA-N	Launched	HMGCR inhibitor	neurology/psychiatry|cardiology	stroke|heart attack
atorvastatin	DPP4	60823	XUKUURHRXDUEBC-KAYWLYCHSA-N	Launched	HMGCR inhibitor	neurology/psychiatry|cardiology	stroke|heart attack
atorvastatin	HMGCR	60823	XUKUURHRXDUEBC-KAYWLYCHSA-N	Launched	HMGCR inhibitor	neurology/psychiatry|cardiology	stroke|heart attack
atosiban	AVPR1A	NA	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N	Launched	oxytocin receptor antagonist	neurology/psychiatry|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia
atosiban	AVPR1B	NA	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N	Launched	oxytocin receptor antagonist	neurology/psychiatry|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia
atosiban	AVPR2	NA	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N	Launched	oxytocin receptor antagonist	neurology/psychiatry|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia
atosiban	OXTR	NA	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N	Launched	oxytocin receptor antagonist	neurology/psychiatry|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia
ATPA	GRIK1	11345201	PIXJURSCCVBKRF-ZCFIWIBFSA-N	Preclinical	glutamate receptor agonist	NA	NA
atrasentan	EDNRA	159594	MOTJMGVDPWRKOC-QPVYNBJUSA-N	Phase 3	endothelin receptor antagonist	NA	NA
atropine	CHRM1		RKUNBYITZUJHSG-JJXSEGSLSA-N	Launched	acetylcholine receptor antagonist	ophthalmology	cycloplegia|mydriasis|amblyopia
atropine	CHRM2		RKUNBYITZUJHSG-JJXSEGSLSA-N	Launched	acetylcholine receptor antagonist	ophthalmology	cycloplegia|mydriasis|amblyopia
atropine	CHRM3		RKUNBYITZUJHSG-JJXSEGSLSA-N	Launched	acetylcholine receptor antagonist	ophthalmology	cycloplegia|mydriasis|amblyopia
atropine-oxide	CHRM1	NA	HGWPFSBHDACWNL-JFBPSJKJSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
atropine-oxide	CHRM2	NA	HGWPFSBHDACWNL-JFBPSJKJSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
atropine-oxide	CHRM3	NA	HGWPFSBHDACWNL-JFBPSJKJSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
atropine-oxide	CHRM4	NA	HGWPFSBHDACWNL-JFBPSJKJSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
atropine-oxide	CHRM5	NA	HGWPFSBHDACWNL-JFBPSJKJSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
AT13148	AKT1	24905401	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1	protein kinase inhibitor	NA	NA
AT13148	AKT2	24905401	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1	protein kinase inhibitor	NA	NA
AT13148	AKT3	24905401	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1	protein kinase inhibitor	NA	NA
AT13148	ROCK1	24905401	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1	protein kinase inhibitor	NA	NA
AT13148	ROCK2	24905401	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1	protein kinase inhibitor	NA	NA
AT13148	SGK3	24905401	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1	protein kinase inhibitor	NA	NA
AT13387	HSP90AA1	11955716	IFRGXKKQHBVPCQ-UHFFFAOYSA-N	Phase 2	HSP inhibitor	NA	NA
AT7867	AKT2	11175137	LZMOSYUFVYJEPY-UHFFFAOYSA-N	Preclinical	AKT inhibitor	NA	NA
AT7867	GSK3B	11175137	LZMOSYUFVYJEPY-UHFFFAOYSA-N	Preclinical	AKT inhibitor	NA	NA
AT7867	PKIA	11175137	LZMOSYUFVYJEPY-UHFFFAOYSA-N	Preclinical	AKT inhibitor	NA	NA
AT7867	PRKACA	11175137	LZMOSYUFVYJEPY-UHFFFAOYSA-N	Preclinical	AKT inhibitor	NA	NA
auranofin	IKBKB	6918453	AUJRCFUBUPVWSZ-XTZHGVARSA-M	Launched	NFkB pathway inhibitor	rheumatology	rheumatoid arthritis
auranofin	PRDX5	6918453	AUJRCFUBUPVWSZ-XTZHGVARSA-M	Launched	NFkB pathway inhibitor	rheumatology	rheumatoid arthritis
auranofin	TRPA1	6918453	AUJRCFUBUPVWSZ-XTZHGVARSA-M	Launched	NFkB pathway inhibitor	rheumatology	rheumatoid arthritis
aurora-a-inhibitor-i	AURKA	44139710	AKSIZPIFQAYJGF-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
aurothioglucose	PRKCI	6916934	XHVAWZZCDCWGBK-WYRLRVFGSA-M	Launched	PKC inhibitor	rheumatology	rheumatoid arthritis
autotaxin-modulator-1	ENPP2	NA	PZASAAIJIFDWSB-PQGZPOPSSA-N	Preclinical	autotaxin inhibitor	NA	NA
AV-412	EGFR	9806229	ZAJXXUDARPGGOC-UHFFFAOYSA-N	Phase 1	protein tyrosine kinase inhibitor	NA	NA
AV-412	ERBB2	9806229	ZAJXXUDARPGGOC-UHFFFAOYSA-N	Phase 1	protein tyrosine kinase inhibitor	NA	NA
AV-608	TACR1	9917079	NXLUTEDAEFXMQR-BJKOFHAPSA-N	Phase 2	tachykinin antagonist	NA	NA
avagacestat	PSEN1	46883536	XEAOPVUAMONVLA-QGZVFWFLSA-N	Phase 2	gamma secretase inhibitor	NA	NA
avanafil	PDE5A	9869929	WEAJZXNPAWBCOA-INIZCTEOSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
avasimibe	CES1	166558	PTQXTEKSNBVPQJ-UHFFFAOYSA-N	Phase 3	ACAT inhibitor	NA	NA
avatrombopag	MPL	9852519	OFZJKCQENFPZBH-UHFFFAOYSA-N	Launched	thrombopoietin receptor agonist	hematology	thrombocytopenia
AVE-0991	MRGPRX1	9851724	QTOZBSNPDCWHPV-UHFFFAOYSA-N	Preclinical	angiotensin receptor agonist	NA	NA
AVL-292	BTK	59174488	KXBDTLQSDKGAEB-UHFFFAOYSA-N	Phase 2	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
AVL-292	YES1	59174488	KXBDTLQSDKGAEB-UHFFFAOYSA-N	Phase 2	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
AVN-944	IMPDH1	9918559	GYCPCOJTCINIFZ-OXJNMPFZSA-N	Phase 2	inosine monophosphate dehydrogenase inhibitor	NA	NA
AVN-944	IMPDH2	9918559	GYCPCOJTCINIFZ-OXJNMPFZSA-N	Phase 2	inosine monophosphate dehydrogenase inhibitor	NA	NA
axitinib	CSF1	6450551	RITAVMQDGBJQJZ-FMIVXFBMSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
axitinib	FLT1	6450551	RITAVMQDGBJQJZ-FMIVXFBMSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
axitinib	FLT4	6450551	RITAVMQDGBJQJZ-FMIVXFBMSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
axitinib	KDR	6450551	RITAVMQDGBJQJZ-FMIVXFBMSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
axitinib	PLK4	6450551	RITAVMQDGBJQJZ-FMIVXFBMSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
AZ-10417808	CASP3	135665263	VUBILPOZTRGZJK-UHFFFAOYSA-N	Preclinical	caspase inhibitor	NA	NA
AZ-10606120	P2RX7	10310632	FQMZXMVHHKXGTM-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
AZ-12080282	DHH	25253556	KMSKKYBHDQYHMC-UHFFFAOYSA-N	Preclinical	hedgehog pathway inhibitor	NA	NA
AZ-628	BRAF	11676786	ZGBGPEDJXCYQPH-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
AZ-628	RAF1	11676786	ZGBGPEDJXCYQPH-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
azacitidine	DNMT1	9444	NMUSYJAQQFHJEW-KVTDHHQDSA-N	Launched	DNA methyltransferase inhibitor	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)
azacitidine	DNMT3A	9444	NMUSYJAQQFHJEW-KVTDHHQDSA-N	Launched	DNA methyltransferase inhibitor	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)
azacyclonol	HRH1	15723	ZMISODWVFHHWNR-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
azaguanine-8	PNP	135403646	LPXQRXLUHJKZIE-UHFFFAOYSA-N	Preclinical	purine antagonist	NA	NA
azaperone	DRD2	15443	XTKDAFGWCDAMPY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
azaperone	DRD3	15443	XTKDAFGWCDAMPY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	sedative
azapropazone	PTGS2	6604340	MPHPHYZQRGLTBO-LLVKDONJSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
azasetron	HTR3A	25271863	WUKZPHOXUVCQOR-ZDUSSCGKSA-N	Launched	serotonin receptor antagonist	infectious disease	genitial herpes
azasetron	HTR3B	25271863	WUKZPHOXUVCQOR-ZDUSSCGKSA-N	Launched	serotonin receptor antagonist	infectious disease	genitial herpes
azatadine	HRH1	19861	SEBMTIQKRHYNIT-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis
azathioprine	HPRT1	2265	LMEKQMALGUDUQG-UHFFFAOYSA-N	Launched	dehydrogenase inhibitor	transplant|rheumatology	renal homotransplantation|rheumatoid arthritis
azathioprine	IMPDH1	2265	LMEKQMALGUDUQG-UHFFFAOYSA-N	Launched	dehydrogenase inhibitor	transplant|rheumatology	renal homotransplantation|rheumatoid arthritis
azathioprine	PPAT	2265	LMEKQMALGUDUQG-UHFFFAOYSA-N	Launched	dehydrogenase inhibitor	transplant|rheumatology	renal homotransplantation|rheumatoid arthritis
AZD1080	GSK3A	10065474	RDXUCTYBYOIJGA-UHFFFAOYSA-N	Phase 1	glycogen synthase kinase inhibitor	NA	NA
AZD1080	GSK3B	10065474	RDXUCTYBYOIJGA-UHFFFAOYSA-N	Phase 1	glycogen synthase kinase inhibitor	NA	NA
AZD1208	PIM1	58423153	MCUJKPPARUPFJM-UWCCDQBKSA-N	Phase 1	Pim kinase inhibitor	NA	NA
AZD1208	PIM2	58423153	MCUJKPPARUPFJM-UWCCDQBKSA-N	Phase 1	Pim kinase inhibitor	NA	NA
AZD1208	PIM3	58423153	MCUJKPPARUPFJM-UWCCDQBKSA-N	Phase 1	Pim kinase inhibitor	NA	NA
AZD1283	P2RY12	23649325	NEMHKCNXXRQYRF-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
AZD1446	CHRNA4	96568205	GTUIQNHJSXQMKW-HTQZYQBOSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
AZD1446	CHRNB2	96568205	GTUIQNHJSXQMKW-HTQZYQBOSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
AZD1480	JAK1	16659841	PDOQBOJDRPLBQU-QMMMGPOBSA-N	Phase 1	JAK inhibitor	NA	NA
AZD1480	JAK2	16659841	PDOQBOJDRPLBQU-QMMMGPOBSA-N	Phase 1	JAK inhibitor	NA	NA
AZD1480	JAK3	16659841	PDOQBOJDRPLBQU-QMMMGPOBSA-N	Phase 1	JAK inhibitor	NA	NA
AZD1981	PTGDR2	11292191	JWYIGNODXSRKGP-UHFFFAOYSA-N	Phase 2	CRTH receptor antagonist	NA	NA
AZD2014	MTOR	25262792	JUSFANSTBFGBAF-IRXDYDNUSA-N	Phase 2	mTOR inhibitor	NA	NA
AZD2858	GSK3B	10138980	FHCSBLWRGCOVPT-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
AZD3264	IKBKB	91666658	NMFIXEFNQPDISY-ZDUSSCGKSA-N	Preclinical	IKK inhibitor	NA	NA
AZD3463	ALK	56599293	GCYIGMXOIWJGBU-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor	NA	NA
AZD3463	IGF1R	56599293	GCYIGMXOIWJGBU-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor	NA	NA
AZD3514	AR	46893585	JMEYDSHPKCSIJC-UHFFFAOYSA-N	Phase 1	androgen receptor modulator	NA	NA
AZD3759	EGFR	78209992	MXDSJQHFFDGFDK-CYBMUJFWSA-N	Phase 2/Phase 3	EGFR inhibitor	NA	NA
AZD3839	BACE1	46202416	MRXBCEQZNKUUIP-DEOSSOPVSA-N	Phase 1	beta-secretase inhibitor	NA	NA
AZD3965	SLC16A1	10369242	PRNXOFBDXNTIFG-FQEVSTJZSA-N	Phase 1	monocarboxylate transporter inhibitor	NA	NA
AZD3988	DGAT1	NA	NGEBYTLALFOQKI-HDJSIYSDSA-N	Preclinical	diacylglycerol kinase inhibitor	NA	NA
AZD4282	AGXT	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	AGXT2	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	ALAS1	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	ALAS2	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	BAAT	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GARS	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GATM	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GCAT	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GCSH	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLDC	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLRA1	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLRA2	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLRA3	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLRB	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLYAT	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLYATL1	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GLYATL2	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GNMT	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GPR18	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GPRC6A	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GRIN1	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GRIN2A	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GRIN2B	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GRIN2C	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GRIN2D	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GRIN3B	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	GSS	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	PIPOX	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	SHMT1	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	SHMT2	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	SLC32A1	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	SLC36A1	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	SLC6A5	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4282	SLC6A9	750	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
AZD4547	FGFR1	51039095	"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+"	Phase 2/Phase 3	FGFR inhibitor	NA	NA
AZD4547	FGFR2	51039095	"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+"	Phase 2/Phase 3	FGFR inhibitor	NA	NA
AZD4547	FGFR3	51039095	"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+"	Phase 2/Phase 3	FGFR inhibitor	NA	NA
AZD4547	FGFR4	51039095	"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+"	Phase 2/Phase 3	FGFR inhibitor	NA	NA
AZD4547	IGF1R	51039095	"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+"	Phase 2/Phase 3	FGFR inhibitor	NA	NA
AZD4547	KDR	51039095	"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+"	Phase 2/Phase 3	FGFR inhibitor	NA	NA
AZD5069	CXCR2	56645576	QZECRCLSIGFCIO-RISCZKNCSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
AZD5363	AKT1	25227436	JDUBGYFRJFOXQC-KRWDZBQOSA-N	Phase 3	AKT inhibitor	NA	NA
AZD5363	AKT2	25227436	JDUBGYFRJFOXQC-KRWDZBQOSA-N	Phase 3	AKT inhibitor	NA	NA
AZD5363	AKT3	25227436	JDUBGYFRJFOXQC-KRWDZBQOSA-N	Phase 3	AKT inhibitor	NA	NA
AZD5438	KCNH2	16747683	"InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)"	Phase 1	CDK inhibitor	NA	NA
AZD5582	BIRC2	49847690	WLMCRYCCYXHPQF-ZVMUOSSASA-N	Preclinical	XIAP inhibitor	NA	NA
AZD5582	BIRC3	49847690	WLMCRYCCYXHPQF-ZVMUOSSASA-N	Preclinical	XIAP inhibitor	NA	NA
AZD5582	XIAP	49847690	WLMCRYCCYXHPQF-ZVMUOSSASA-N	Preclinical	XIAP inhibitor	NA	NA
AZD6482	PIK3CA	44137675	IRTDIKMSKMREGO-OAHLLOKOSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD6482	PIK3CB	44137675	IRTDIKMSKMREGO-OAHLLOKOSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD6482	PIK3CD	44137675	IRTDIKMSKMREGO-OAHLLOKOSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD6482	PIK3CG	44137675	IRTDIKMSKMREGO-OAHLLOKOSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD6738	ATR	54761305	OHUHVTCQTUDPIJ-MUWSIPGASA-N	Phase 2	ATR kinase inhibitor	NA	NA
AZD6765	GRIN1	9794203	FWUQWDCOOWEXRY-ZDUSSCGKSA-N	Phase 2	glutamate receptor antagonist	NA	NA
AZD7545	PDK1	16741245	DTDZLJHKVNTQGZ-GOSISDBHSA-N	Phase 1	pyruvate dehydrogenase kinase inhibitor	NA	NA
AZD7687	DGAT1	NA	YXFNPRHZMOGREC-SHTZXODSSA-N	Phase 1	diacylglycerol O acyltransferase inhibitor	NA	NA
AZD7762	CHEK1	11152667	IAYGCINLNONXHY-LBPRGKRZSA-N	Phase 1	CHK inhibitor	NA	NA
AZD7762	CHEK2	11152667	IAYGCINLNONXHY-LBPRGKRZSA-N	Phase 1	CHK inhibitor	NA	NA
AZD8055	MTOR	25262965	KVLFRAWTRWDEDF-IRXDYDNUSA-N	Phase 1	mTOR inhibitor	NA	NA
AZD8186	PIK3CB	52913813	LMJFJIDLEAWOQJ-CQSZACIVSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD8186	PIK3CD	52913813	LMJFJIDLEAWOQJ-CQSZACIVSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD8330	MAP3K1	16666708	RWEVIPRMPFNTLO-UHFFFAOYSA-N	Phase 1	MEK inhibitor	NA	NA
AZD8835	PIK3CA	76685059	ZGRDYKFVDCFJCZ-UHFFFAOYSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD8835	PIK3CD	76685059	ZGRDYKFVDCFJCZ-UHFFFAOYSA-N	Phase 1	PI3K inhibitor	NA	NA
AZD8931	EGFR	11488320	DFJSJLGUIXFDJP-UHFFFAOYSA-N	Phase 2	EGFR inhibitor	NA	NA
AZD8931	ERBB2	11488320	DFJSJLGUIXFDJP-UHFFFAOYSA-N	Phase 2	EGFR inhibitor	NA	NA
AZD8931	ERBB3	11488320	DFJSJLGUIXFDJP-UHFFFAOYSA-N	Phase 2	EGFR inhibitor	NA	NA
AZD9272	GRM5	9838729	RBSPCALDSNXWEP-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
AZD9496	ESR1	86287635	DFBDRVGWBHBJNR-BBNFHIFMSA-N	Phase 1	estrogen receptor agonist	NA	NA
AZD9668	ELANE	46861623	QNQZWEGMKJBHEM-UHFFFAOYSA-N	Phase 2	elastase inhibitor	NA	NA
azelaic-acid	AKR1D1	2266	BDJRBEYXGGNYIS-UHFFFAOYSA-N	Launched	tyrosinase inhibitor	dermatology	rosacea
azelaic-acid	SRD5A2	2266	BDJRBEYXGGNYIS-UHFFFAOYSA-N	Launched	tyrosinase inhibitor	dermatology	rosacea
azelaic-acid	TYR	2266	BDJRBEYXGGNYIS-UHFFFAOYSA-N	Launched	tyrosinase inhibitor	dermatology	rosacea
azelastine	HRH1	12831281	MBUVEWMHONZEQD-SFHVURJKSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
azeliragon	AGER	11180124	KJNNWYBAOPXVJY-UHFFFAOYSA-N	Phase 3	RAGE receptor antagonist	NA	NA
azelnidipine	CACNA1C	9873077	ZKFQEACEUNWPMT-MUUNZHRXSA-N	Launched	calcium channel blocker	cardiology	hypertension
azilsartan	AGTR1	135415867	KGSXMPPBFPAXLY-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
azilsartan	AGTR2	135415867	KGSXMPPBFPAXLY-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
azilsartan-medoxomil	AGTR1	135409642	QJFSABGVXDWMIW-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
azilsartan-medoxomil	AGTR2	135409642	QJFSABGVXDWMIW-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
azimilide	KCNA5	9571004	MREBEPTUUMTTIA-PCLIKHOPSA-N	Phase 3	potassium channel blocker	NA	NA
azithromycin	MLNR	71206984	MQTOSJVFKKJCRP-CBLJCGFISA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	pelvic inflammatory disease|pneumonia
AZM-475271	SRC	5330175	WPOXAFXHRJYEIC-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
azosemide	SLC12A1	2273	HMEDEBAJARCKCT-UHFFFAOYSA-N	Launched	electrolyte reabsorption inhibitor	cardiology	edema
azosemide	SLC12A2	2273	HMEDEBAJARCKCT-UHFFFAOYSA-N	Launched	electrolyte reabsorption inhibitor	cardiology	edema
AZ191	DYRK1B	72716071	ZYVXTMKTGDARKR-UHFFFAOYSA-N	Preclinical	DYRK inhibitor	NA	NA
AZ20	ATR	46244454	SCGCBAAYLFTIJU-CQSZACIVSA-N	Preclinical	ATR kinase inhibitor	NA	NA
AZ20	MTOR	46244454	SCGCBAAYLFTIJU-CQSZACIVSA-N	Preclinical	ATR kinase inhibitor	NA	NA
AZ505	SMYD2	24961094	LIBVHXXKHSODII-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
AZ5104	EGFR	71496460	IQNVEOMHJHBNHC-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
AZ960	JAK2	25099184	SUNXHXDJOIXABJ-NSHDSACASA-N	Preclinical	JAK inhibitor	NA	NA
A12B4C3	PNKP	NA	KVHGJAKTBPFFNV-KUXCXQDQSA-N	Preclinical	polynucleotide kinase/phosphatase inhibitor	NA	NA
A205804	ICAM1	9839311	QQGWEXFLMJGCAL-UHFFFAOYSA-N	Preclinical	ICAM1 expression inhibitor	NA	NA
A205804	SELE	9839311	QQGWEXFLMJGCAL-UHFFFAOYSA-N	Preclinical	ICAM1 expression inhibitor	NA	NA
A61603	ADRA1A	6604803	OQFCXJDXHCDLHX-LLVKDONJSA-N	Preclinical	adrenergic receptor agonist	NA	NA
A66	PIK3CA	42636535	HBPXWEPKNBHKAX-NSHDSACASA-N	Preclinical	PI3K inhibitor	NA	NA
A740003	P2RX7	98050091	PUHSRMSFDASMAE-DEOSSOPVSA-N	Preclinical	purinergic receptor antagonist	NA	NA
A77636	CALY	NA	QLJOSZATCBCBDR-KLONBWLYSA-N	Preclinical	dopamine receptor agonist	NA	NA
A922500	DGAT1	24768273	BOZRFEQDOFSZBV-PKTZIBPZSA-N	Preclinical	diacylglycerol O acyltransferase inhibitor	NA	NA
bacitracin	IDE	NA	CLKOFPXJLQSYAH-BBLSSJOMSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	first-aid antibiotic
baclofen	GABBR1	6923772	KPYSYYIEGFHWSV-MRVPVSSYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	multiple sclerosis|spasms
baclofen	GABBR2	6923772	KPYSYYIEGFHWSV-MRVPVSSYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	multiple sclerosis|spasms
baclofen	KCTD12	6923772	KPYSYYIEGFHWSV-MRVPVSSYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	multiple sclerosis|spasms
baclofen	KCTD16	6923772	KPYSYYIEGFHWSV-MRVPVSSYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	multiple sclerosis|spasms
baclofen	KCTD8	6923772	KPYSYYIEGFHWSV-MRVPVSSYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	multiple sclerosis|spasms
BADGE	PPARG	6994088	LCFVJGUPQDGYKZ-PMACEKPBSA-N	Preclinical	PPAR receptor antagonist	NA	NA
bafetinib	ABL1	11387605	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	Phase 2	Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor	NA	NA
bafetinib	BCR	11387605	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	Phase 2	Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor	NA	NA
bafetinib	LYN	11387605	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	Phase 2	Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor	NA	NA
BAG-956	PIK3CG	24882589	GVPAGJWVBUZHNQ-UHFFFAOYSA-N	Preclinical	phosphoinositide dependent kinase inhibitor	NA	NA
baicalein	ALOX5	NA	WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
baicalein	GLO1	NA	WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
baicalein	PREP	NA	WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
baicalein	SELL	NA	WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
baicalein	SELP	NA	WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
baicalein	TNF	NA	WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
baicalein	XDH	NA	WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
baicalin	PREP		DAIGSUHCWOZEQG-ZFORQUDYSA-N	Launched	beta glucuronidase inhibitor	neurology/psychiatry	anxiety
bakuchiol	HIF1A	5468522	LFYJSSARVMHQJB-QIXNEVBVSA-N	Phase 2	DNA polymerase inhibitor	NA	NA
balaglitazone	PPARG	76968728	IETKPTYAGKZLKY-MRXNPFEDSA-N	Phase 3	insulin sensitizer|PPAR receptor partial agonist	NA	NA
balicatib	CTSK	10201696	LLCRBOWRJOUJAE-UHFFFAOYSA-N	Phase 2	cathepsin inhibitor	NA	NA
balsalazide	ALOX5	NA	IPOKCKJONYRRHP-FMQUCBEESA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
balsalazide	PPARG	NA	IPOKCKJONYRRHP-FMQUCBEESA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
balsalazide	PTGS1	NA	IPOKCKJONYRRHP-FMQUCBEESA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
balsalazide	PTGS2	NA	IPOKCKJONYRRHP-FMQUCBEESA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
bambuterol	ADRB2	57515921	ANZXOIAKUNOVQU-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
bambuterol	BCHE	57515921	ANZXOIAKUNOVQU-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
BAM7	BAX	NA	KOCVKGYKBLJEPK-LYBHJNIJSA-N	Preclinical	BAX activator	NA	NA
BAN-ORL-24	OPRL1	10296561	MAKMQGKJURAJEN-RUZDIDTESA-N	Preclinical	nociceptin/orphanin FQ receptor antagonist	NA	NA
banoxantrone	TOP2A	9955116	YZBAXVICWUUHGG-UHFFFAOYSA-N	Phase 1/Phase 2	topoisomerase inhibitor	NA	NA
barasertib	AURKA	11497983	GBJVVSCPOBPEIT-UHFFFAOYSA-N	Phase 2/Phase 3	Aurora kinase inhibitor	NA	NA
barasertib	AURKB	11497983	GBJVVSCPOBPEIT-UHFFFAOYSA-N	Phase 2/Phase 3	Aurora kinase inhibitor	NA	NA
barasertib-HQPA	AURKB	16007391	"InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)"	Phase 2/Phase 3	Aurora kinase inhibitor	NA	NA
bardoxolone	NOS2	400010	"InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1"	Phase 1	nuclear factor erythroid derived|like (NRF2) activator	NA	NA
bardoxolone	PPARG	400010	"InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1"	Phase 1	nuclear factor erythroid derived|like (NRF2) activator	NA	NA
bardoxolone-methyl	PPARG	400769	"InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1"	Phase 3	nuclear factor erythroid derived|like (NRF2) activator	NA	NA
bardoxolone-methyl	STAT3	400769	"InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1"	Phase 3	nuclear factor erythroid derived|like (NRF2) activator	NA	NA
baricitinib	JAK1	44205240	XUZMWHLSFXCVMG-UHFFFAOYSA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
baricitinib	JAK2	44205240	XUZMWHLSFXCVMG-UHFFFAOYSA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
basimglurant	GRM5	11438771	UPZWINBEAHDTLA-UHFFFAOYSA-N	Phase 2	glutamate receptor antagonist	NA	NA
batimastat	ADAM28	5362422	XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
batimastat	ADAMTS5	5362422	XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
batimastat	MMP12	5362422	XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
batimastat	MMP16	5362422	XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
batimastat	MMP2	5362422	XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
batimastat	MMP8	5362422	XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
bavisant	HRH3	16061509	BGBVSGSIXIIREO-UHFFFAOYSA-N	Phase 2	histamine receptor antagonist	NA	NA
BAX-channel-blocker	BAX	981054	KUUJEXLRLIPQQJ-HNNXBMFYSA-N	Preclinical	cytochrome C release inhibitor	NA	NA
BAY-K-8644-(s)-(-)	CACNA1C	6603728	ZFLWDHHVRRZMEI-ZDUSSCGKSA-N	Preclinical	L-type calcium channel activator	NA	NA
BAY-11-7082	RELA	5353431	DOEWDSDBFRHVAP-KRXBUXKQSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
BAY-11-7085	NFKBIA	5353432	VHKZGNPOHPFPER-ONNFQVAWSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
BAY-41-2272	GUCY1A3	9798973	ATOAHNRJAXSBOR-UHFFFAOYSA-N	Preclinical	guanylyl cyclase activator	NA	NA
BAY-41-2272	GUCY1B3	9798973	ATOAHNRJAXSBOR-UHFFFAOYSA-N	Preclinical	guanylyl cyclase activator	NA	NA
BAY-60-6583	ADORA1	11717831	ZTYHZMAZUWOXNC-UHFFFAOYSA-N	Preclinical	adenosine receptor agonist	NA	NA
BAY-60-6583	ADORA2A	11717831	ZTYHZMAZUWOXNC-UHFFFAOYSA-N	Preclinical	adenosine receptor agonist	NA	NA
BAY-60-6583	ADORA2B	11717831	ZTYHZMAZUWOXNC-UHFFFAOYSA-N	Preclinical	adenosine receptor agonist	NA	NA
BAY-60-6583	ADORA3	11717831	ZTYHZMAZUWOXNC-UHFFFAOYSA-N	Preclinical	adenosine receptor agonist	NA	NA
BAY-60-7550	PDE2A	135564787	MYTWFJKBZGMYCS-NQIIRXRSSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
BAY-61-3606	SYK	10200390	JWQOJVOKBAAAAR-UHFFFAOYSA-N	Preclinical	SYK inhibitor	NA	NA
BAY-87-2243	HIF1A	67377767	CDJNNOJINJAXPV-UHFFFAOYSA-N	Phase 1	hypoxia inducible factor inhibitor	NA	NA
bazedoxifene	ESR1	154257	UCJGJABZCDBEDK-UHFFFAOYSA-N	Launched	selective estrogen receptor modulator (SERM)	orthopedics|endocrinology	osteoporosis|menopause
bazedoxifene	ESR2	154257	UCJGJABZCDBEDK-UHFFFAOYSA-N	Launched	selective estrogen receptor modulator (SERM)	orthopedics|endocrinology	osteoporosis|menopause
BAZ2-ICR	ZNF215	91654625	RRZVGDGTWNQAPW-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
BC-11	PLAU	60126757	KDQVMGQHPAKJAN-UHFFFAOYSA-N	Preclinical	urokinase inhibitor	NA	NA
BCTC	TRPV1	9929425	ROGUAPYLUCHQGK-UHFFFAOYSA-N	Preclinical	TRPV antagonist	NA	NA
BCX-1470	CFD	9822205	OTGQTQBPQCRNRG-UHFFFAOYSA-N	Phase 1	complement inhibitor|serine protease inhibitor	NA	NA
BD-1047	SIGMAR1	188914	MGVRNMUKTZOQOW-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
BD-1063	SIGMAR1	574780	SUIZRDJCBVPASY-UHFFFAOYSA-N	Preclinical	sigma receptor antagonist	NA	NA
BE-2254	ADRA1A	86308637	PZZOEXPDTYIBPI-MRXNPFEDSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
beclomethasone	NR3C1	NA	NBMKJKDGKREAPL-DGLOSGAVSA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
beclomethasone	SERPINA6	NA	NBMKJKDGKREAPL-DGLOSGAVSA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
beclomethasone-dipropionate	GPR97	21700	KUVIULQEHSCUHY-XYWKZLDCSA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
beclomethasone-dipropionate	NR3C1	21700	KUVIULQEHSCUHY-XYWKZLDCSA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
begacestat	PSEN1	11269353	PSXOKXJMVRSARX-SCSAIBSYSA-N	Phase 1	gamma secretase inhibitor	NA	NA
belinostat	HDAC1	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC10	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC11	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC2	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC3	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC4	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC5	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC6	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC7	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC8	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belinostat	HDAC9	6918638	"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+"	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
bemegride	GABRA1	2310	ORRZGUBHBVWWOP-UHFFFAOYSA-N	Launched	chemoreceptor agonist	critical care	poison antidote
bemesetron	HTR3A	NA	MNJNPLVXBISNSX-WDNDVIMCSA-N	Phase 3	serotonin receptor antagonist	NA	NA
bemesetron	HTR3B	NA	MNJNPLVXBISNSX-WDNDVIMCSA-N	Phase 3	serotonin receptor antagonist	NA	NA
bempedoic-acid	ACLY	10472693	HYHMLYSLQUKXKP-UHFFFAOYSA-N	Launched	AMPK inhibitor	NA	NA
benazepril	ACE	5362124	XPCFTKFZXHTYIP-PMACEKPBSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
bendazac	PTGS1	2313	BYFMCKSPFYVMOU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain
bendazac	PTGS2	2313	BYFMCKSPFYVMOU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain
bendroflumethiazide	SLC12A1	9845085	HDWIHXWEUNVBIY-CQSZACIVSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology	hypertension
bendroflumethiazide	SLC12A3	9845085	HDWIHXWEUNVBIY-CQSZACIVSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology	hypertension
benfluorex	HMGCR	6604374	CJAVTWRYCDNHSM-AWEZNQCLSA-N	Withdrawn	gluconeogenesis inhibitor	NA	NA
benfluralin	CYP1A1	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfluralin	CYP1A2	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfluralin	CYP2B6	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfluralin	CYP3A4	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfluralin	ESR1	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfluralin	MMP1	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfluralin	SULT2A1	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfluralin	UGT1A1	2319	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3		NA	NA
benfotiamine	AGER	3032771	BTNNPSLJPBRMLZ-LGMDPLHJSA-N	Launched	antioxidant	rheumatology	lumbago
benidipine	CACNA1C	656667	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N	Launched	calcium channel blocker	cardiology	hypertension
benidipine	CACNA1G	656667	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N	Launched	calcium channel blocker	cardiology	hypertension
benperidol	DRD2	16363	FEBOTPHFXYHVPL-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
benproperine	SCN5A	14456347	JTUQXGZRVLWBCR-SFHVURJKSA-N	Launched	antitussive	pulmonary	cough suppressant
benserazide	DDC	657280	BNQDCRGUHNALGH-UHFFFAOYSA-N	Launched	DOPA decarboxylase inhibitor	neurology/psychiatry	Parkinson's Disease
bentiromide	HPN	6957673	SPPTWHFVYKCNNK-FQEVSTJZSA-N	Launched		gastroenterology	pancreas diagnostic agent
benzamil	ASIC1	108107	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	sodium channel blocker	NA	NA
benzamil	PKD2L1	108107	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	sodium channel blocker	NA	NA
benzamil	SCNN1A	108107	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	sodium channel blocker	NA	NA
benzamil	SCNN1B	108107	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	sodium channel blocker	NA	NA
benzamil	SCNN1D	108107	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	sodium channel blocker	NA	NA
benzamil	SCNN1G	108107	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	sodium channel blocker	NA	NA
benzamil	SLC8A1	108107	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	sodium channel blocker	NA	NA
benzbromarone	ABCC1	2333	WHQCHUCQKNIQEC-UHFFFAOYSA-N	Launched	chloride channel blocker	rheumatology	gout
benzethonium	SCN10A	2335	SIYLLGKDQZGJHK-UHFFFAOYSA-N	Launched	sodium channel blocker	infectious disease	first-aid antiseptic
benzocaine	SCN10A	2337	BLFLLBZGZJTVJG-UHFFFAOYSA-N	Launched	sodium channel blocker	infectious disease	first-aid antiseptic
benzoic-acid	DAO	243	WPYMKLBDIGXBTP-UHFFFAOYSA-N	Launched	food preservative	infectious disease	tinea pedis
benzoic-acid	HRSP12	243	WPYMKLBDIGXBTP-UHFFFAOYSA-N	Launched	food preservative	infectious disease	tinea pedis
benzoic-acid	PRDX5	243	WPYMKLBDIGXBTP-UHFFFAOYSA-N	Launched	food preservative	infectious disease	tinea pedis
benzoic-acid	RAB9A	243	WPYMKLBDIGXBTP-UHFFFAOYSA-N	Launched	food preservative	infectious disease	tinea pedis
benzoin	CES1	640038	ISAOCJYIOMOJEB-CYBMUJFWSA-N	Preclinical		NA	NA
benzonatate	SCN5A	7699	MAFMQEKGGFWBAB-UHFFFAOYSA-N	Launched	local anesthetic	pulmonary	cough suppressant
benzoquinonium-dibromide	CHRNA1	9394	YERABYSOHUZTPQ-UHFFFAOYSA-P	Preclinical	cholinergic receptor antagonist	NA	NA
benzotript	CCKAR	2060890	QJERBBQXOMUURJ-INIZCTEOSA-N	Phase 1	CCK receptor antagonist	NA	NA
benzotript	CCKBR	2060890	QJERBBQXOMUURJ-INIZCTEOSA-N	Phase 1	CCK receptor antagonist	NA	NA
benzthiazide	CA2	132458842	MQMCZGVMQZPYQA-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	cardiology	hypertension|edema
benztropine-mesylate	CHRM1	NA	GIJXKZJWITVLHI-PMOLBWCYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	extrapyramidal symptoms (EPS)|Parkinson's Disease
benztropine-mesylate	HRH1	NA	GIJXKZJWITVLHI-PMOLBWCYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	extrapyramidal symptoms (EPS)|Parkinson's Disease
benztropine-mesylate	SLC6A3	NA	GIJXKZJWITVLHI-PMOLBWCYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	extrapyramidal symptoms (EPS)|Parkinson's Disease
benzyl-benzoate	LIPE	2345	SESFRYSPDFLNCH-UHFFFAOYSA-N	Launched	lipase inhibitor	allergy	sweet itch
bepotastine	HRH1	25273609	YWGDOWXRIALTES-NRFANRHFSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
bepridil	KCNQ4	50088	UIEATEWHFDRYRU-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	angina pectoris
berberine	LDLR	2353	YBHILYKTIRIUTE-UHFFFAOYSA-N	Launched	LDL receptor activator	NA	NA
bergenin	IL1B	66065	YWJXCIXBAKGUKZ-HJJNZUOJSA-N	Preclinical	interleukin inhibitor	NA	NA
bergenin	TNF	66065	YWJXCIXBAKGUKZ-HJJNZUOJSA-N	Preclinical	interleukin inhibitor	NA	NA
beta-amyloid-synthesis-inhibitor	APP	9882580	GYNDFOLSPPBBIK-UHFFFAOYSA-N	Preclinical	beta amyloid synthesis inhibitor	NA	NA
beta-CCB	GABRA1	128618	WGNGIELOOKACSB-UHFFFAOYSA-N	Launched	benzodiazepine receptor ligand	NA	NA
beta-CCB	GABRG2	128618	WGNGIELOOKACSB-UHFFFAOYSA-N	Launched	benzodiazepine receptor ligand	NA	NA
beta-elemene	MMP2	6918391	OPFTUNCRGUEPRZ-QLFBSQMISA-N	Launched	apoptosis stimulant	NA	NA
beta-elemene	MMP9	6918391	OPFTUNCRGUEPRZ-QLFBSQMISA-N	Launched	apoptosis stimulant	NA	NA
beta-funaltrexamine	OPRD1	5311018	PQKHESYTSKMWFP-WZJCLRDWSA-N	Preclinical	opioid receptor antagonist	NA	NA
beta-funaltrexamine	OPRK1	5311018	PQKHESYTSKMWFP-WZJCLRDWSA-N	Preclinical	opioid receptor antagonist	NA	NA
beta-funaltrexamine	OPRM1	5311018	PQKHESYTSKMWFP-WZJCLRDWSA-N	Preclinical	opioid receptor antagonist	NA	NA
beta-hydroxy-beta-methylbutyrate	MTOR	129010087	KORPMXSVHOHPMS-UHFFFAOYSA-N	Launched	protein synthesis stimulant	NA	NA
beta-hydroxybutyrate	HCAR2	441	WHBMMWSBFZVSSR-UHFFFAOYSA-N	Phase 1		NA	NA
beta-lapachone	TOP1	3885	QZPQTZZNNJUOLS-UHFFFAOYSA-N	Phase 2	topoisomerase inhibitor	NA	NA
betahistine	HRH1	2366	UUQMNUMQCIQDMZ-UHFFFAOYSA-N	Launched	histamine receptor agonist|histamine receptor antagonist	neurology/psychiatry	Meniere's disease
betahistine	HRH3	2366	UUQMNUMQCIQDMZ-UHFFFAOYSA-N	Launched	histamine receptor agonist|histamine receptor antagonist	neurology/psychiatry	Meniere's disease
betamethasone	NR3C1	9782	UREBDLICKHMUKA-DVTGEIKXSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
betamethasone-acetate	NR3C1	443967	AKUJBENLRBOFTD-QZIXMDIESA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
betamethasone-dipropionate	NR3C1	21800	CIWBQSYVNNPZIQ-XYWKZLDCSA-N	Launched	anti-inflammatory agent	dermatology	corticosteroid-responsive dermatoses
betamethasone-valerate	NR3C1	16533	SNHRLVCMMWUAJD-SUYDQAKGSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
betaxolol	ADRB1	6093355	NWIUTZDMDHAVTP-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
betaxolol	ADRB2	6093355	NWIUTZDMDHAVTP-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
betazole	HRH2	7741	JXDFEQONERDKSS-UHFFFAOYSA-N	Launched	histamine receptor agonist	gastroenterology	gastric hypersecretion diagnostic
bethanechol	CHRM1	6603779	NZUPCNDJBJXXRF-LURJTMIESA-O	Launched	acetylcholine receptor agonist	urology	urinary retention
bethanechol	CHRM2	6603779	NZUPCNDJBJXXRF-LURJTMIESA-O	Launched	acetylcholine receptor agonist	urology	urinary retention
bethanechol	CHRM3	6603779	NZUPCNDJBJXXRF-LURJTMIESA-O	Launched	acetylcholine receptor agonist	urology	urinary retention
bethanechol	CHRM4	6603779	NZUPCNDJBJXXRF-LURJTMIESA-O	Launched	acetylcholine receptor agonist	urology	urinary retention
BETP	GLP1R	97182196	NTDFYGSSDDMNHI-NDEPHWFRSA-N	Preclinical	GLP receptor positive allosteric modulator	NA	NA
betrixaban	KCNH2	10275777	XHOLNRLADUSQLD-UHFFFAOYSA-N	Launched	coagulation factor inhibitor	hematology	deep vein thrombosis (DVT)
betulinic-acid	GPBAR1	64971	QGJZLNKBHJESQX-FZFNOLFKSA-N	Phase 1/Phase 2	apoptosis stimulant|NFkB pathway inhibitor	NA	NA
bexarotene	RXRA	82146	NAVMQTYZDKMPEU-UHFFFAOYSA-N	Launched	retinoid receptor agonist	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
bexarotene	RXRB	82146	NAVMQTYZDKMPEU-UHFFFAOYSA-N	Launched	retinoid receptor agonist	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
bexarotene	RXRG	82146	NAVMQTYZDKMPEU-UHFFFAOYSA-N	Launched	retinoid receptor agonist	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
bezafibrate	PPARA	39042	IIBYAHWJQTYFKB-UHFFFAOYSA-N	Launched	PPAR receptor agonist	cardiology	cholesterol
bezafibrate	PPARD	39042	IIBYAHWJQTYFKB-UHFFFAOYSA-N	Launched	PPAR receptor agonist	cardiology	cholesterol
bezafibrate	PPARG	39042	IIBYAHWJQTYFKB-UHFFFAOYSA-N	Launched	PPAR receptor agonist	cardiology	cholesterol
BGT226	MTOR	11978790	BMMXYEBLEBULND-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
BGT226	PIK3CA	11978790	BMMXYEBLEBULND-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
BGT226	PIK3CB	11978790	BMMXYEBLEBULND-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
BGT226	PIK3CG	11978790	BMMXYEBLEBULND-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
BHQ	ATP2A1	2374	JZODKRWQWUWGCD-UHFFFAOYSA-N	Preclinical	ATPase inhibitor	NA	NA
BI-D1870	RPS6KA1	44141268	DTEKTGDVSARYDS-NSHDSACASA-N	Preclinical	ribosomal protein inhibitor	NA	NA
BI-D1870	RPS6KA2	44141268	DTEKTGDVSARYDS-NSHDSACASA-N	Preclinical	ribosomal protein inhibitor	NA	NA
BI-D1870	RPS6KA3	44141268	DTEKTGDVSARYDS-NSHDSACASA-N	Preclinical	ribosomal protein inhibitor	NA	NA
BI-D1870	RPS6KA6	44141268	DTEKTGDVSARYDS-NSHDSACASA-N	Preclinical	ribosomal protein inhibitor	NA	NA
BI-2536	BRD4	11364421	"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1"	Phase 2	PLK inhibitor	NA	NA
BI-2536	PLK1	11364421	"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1"	Phase 2	PLK inhibitor	NA	NA
BI-2536	PLK2	11364421	"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1"	Phase 2	PLK inhibitor	NA	NA
BI-2536	PLK3	11364421	"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1"	Phase 2	PLK inhibitor	NA	NA
BI-78D3	MAPK8	2747117	QFRLDZGQEZCCJZ-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
BI-847325	AURKA	NA	FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1	Aurora kinase inhibitor|MEK inhibitor	NA	NA
BI-847325	AURKB	NA	FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1	Aurora kinase inhibitor|MEK inhibitor	NA	NA
BI-847325	AURKC	NA	FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1	Aurora kinase inhibitor|MEK inhibitor	NA	NA
BI-847325	MAP2K1	NA	FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1	Aurora kinase inhibitor|MEK inhibitor	NA	NA
BI-847325	MAP2K2	NA	FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1	Aurora kinase inhibitor|MEK inhibitor	NA	NA
BIBN4096	CALCA	6918509	ITIXDWVDFFXNEG-JHOUSYSJSA-N	Phase 2	calcitonin antagonist	NA	NA
BIBN4096	CALCRL	6918509	ITIXDWVDFFXNEG-JHOUSYSJSA-N	Phase 2	calcitonin antagonist	NA	NA
BIBN4096	RAMP1	6918509	ITIXDWVDFFXNEG-JHOUSYSJSA-N	Phase 2	calcitonin antagonist	NA	NA
BIBR-1532	TERT	9927531	PGFQXGLPJUCTOI-WYMLVPIESA-N	Preclinical	telomerase inhibitor	NA	NA
BIBU-1361	EGFR	17756796	JUGSLZCFNSTKBN-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
BIBX-1382	EGFR	6918508	FTFRZXFNZVCRSK-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
BIBX-1382	ERBB2	6918508	FTFRZXFNZVCRSK-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
bicalutamide	AR	2375	LKJPYSCBVHEWIU-UHFFFAOYSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
bicuculline-(+)	GABRA1	10237	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	GABA receptor antagonist	NA	NA
bicuculline-(+)	GABRA2	10237	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	GABA receptor antagonist	NA	NA
bicuculline-(+)	GABRA3	10237	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	GABA receptor antagonist	NA	NA
bicuculline-(+)	GABRA4	10237	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	GABA receptor antagonist	NA	NA
bicuculline-(+)	GABRA5	10237	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	GABA receptor antagonist	NA	NA
bicuculline-(+)	GABRA6	10237	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	GABA receptor antagonist	NA	NA
bicuculline-(+)	KCNN1	10237	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	GABA receptor antagonist	NA	NA
bicyclol	HSPA1A	9821754	KXMTXZACPVCDMH-UHFFFAOYSA-N	Launched	NFkB pathway inhibitor	infectious disease	hepatitis B|hepatitis C
bicyclol	HSPB1	9821754	KXMTXZACPVCDMH-UHFFFAOYSA-N	Launched	NFkB pathway inhibitor	infectious disease	hepatitis B|hepatitis C
bifemelane	MAOA	2377	QSQQPMHPCBLLGX-UHFFFAOYSA-N	Launched	acetylcholine release enhancer	ophthalmology|neurology/psychiatry	glaucoma|senile dementia
bifemelane	MAOB	2377	QSQQPMHPCBLLGX-UHFFFAOYSA-N	Launched	acetylcholine release enhancer	ophthalmology|neurology/psychiatry	glaucoma|senile dementia
BIIB021	HSP90AA1	16736529	QULDDKSCVCJTPV-UHFFFAOYSA-N	Phase 2	HSP inhibitor	NA	NA
bilastine	HRH1	40467029	ACCMWZWAEFYUGZ-UHFFFAOYSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
bilobalide	GLRA1	73581	MOLPUWBMSBJXER-YDGSQGCISA-N	Preclinical	GABA receptor modulator	NA	NA
bilobalide	GLRA2	73581	MOLPUWBMSBJXER-YDGSQGCISA-N	Preclinical	GABA receptor modulator	NA	NA
bilobalide	GLRB	73581	MOLPUWBMSBJXER-YDGSQGCISA-N	Preclinical	GABA receptor modulator	NA	NA
bilobalide	HTR3A	73581	MOLPUWBMSBJXER-YDGSQGCISA-N	Preclinical	GABA receptor modulator	NA	NA
bilobalide	HTR3B	73581	MOLPUWBMSBJXER-YDGSQGCISA-N	Preclinical	GABA receptor modulator	NA	NA
bimatoprost	AKR1C3	5311027	AQOKCDNYWBIDND-FTOWTWDKSA-N	Launched	prostanoid receptor agonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
bimatoprost	PTGER1	5311027	AQOKCDNYWBIDND-FTOWTWDKSA-N	Launched	prostanoid receptor agonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
bimatoprost	PTGER3	5311027	AQOKCDNYWBIDND-FTOWTWDKSA-N	Launched	prostanoid receptor agonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
bimatoprost	PTGFR	5311027	AQOKCDNYWBIDND-FTOWTWDKSA-N	Launched	prostanoid receptor agonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
BIMU-8	HTR4	NA	AFOFVIBWSLOHFR-QDMKHBRRSA-N	Preclinical	serotonin receptor agonist	NA	NA
BINA	GRM2	86311024	KMKBEESNZAPKMP-AREMUKBSSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
bindarit	CCL2	71354	MTHORRSSURHQPZ-UHFFFAOYSA-N	Phase 2	NFkB pathway inhibitor	NA	NA
bindarit	CCL7	71354	MTHORRSSURHQPZ-UHFFFAOYSA-N	Phase 2	NFkB pathway inhibitor	NA	NA
bindarit	CCL8	71354	MTHORRSSURHQPZ-UHFFFAOYSA-N	Phase 2	NFkB pathway inhibitor	NA	NA
binimetinib	MAP2K1	10288191	ACWZRVQXLIRSDF-UHFFFAOYSA-N	Launched	MEK inhibitor	oncology	melanoma
binimetinib	MAP2K2	10288191	ACWZRVQXLIRSDF-UHFFFAOYSA-N	Launched	MEK inhibitor	oncology	melanoma
BIO-1211	ITGA4	9961766	NVVGCQABIHSJSQ-KFZSMJGVSA-N	Phase 2	integrin antagonist	NA	NA
BIO-1211	ITGB1	9961766	NVVGCQABIHSJSQ-KFZSMJGVSA-N	Phase 2	integrin antagonist	NA	NA
BIO-5192	ITGA4	10350459	MNQBPRHHZPXCKZ-ZDCRTTOTSA-N	Preclinical	integrin inhibitor	NA	NA
BIO-5192	ITGB1	10350459	MNQBPRHHZPXCKZ-ZDCRTTOTSA-N	Preclinical	integrin inhibitor	NA	NA
biotin	ACACA	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	ACACB	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	HLCS	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	MCCC1	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	MCCC2	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	PC	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	PCCA	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	PCCB	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
biotin	SLC5A6	171548	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	vitamin B	NA	NA
bipenamol	CTSC	43961	HLAFSNJRKZLMPT-UHFFFAOYSA-N	Phase 2	dipeptidyl peptidase inhibitor	NA	NA
biperiden	CHRM1	12147323	YSXKPIUOCJLQIE-UYWIDEMCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
biperiden	CHRM2	12147323	YSXKPIUOCJLQIE-UYWIDEMCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
biperiden	CHRM3	12147323	YSXKPIUOCJLQIE-UYWIDEMCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
biperiden	CHRM4	12147323	YSXKPIUOCJLQIE-UYWIDEMCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
biperiden	CHRM5	12147323	YSXKPIUOCJLQIE-UYWIDEMCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
birinapant	BIRC2	49836020	"InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1"	Phase 2	XIAP inhibitor	NA	NA
birinapant	XIAP	49836020	"InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1"	Phase 2	XIAP inhibitor	NA	NA
BIRT-377	ICAM1	9803375	FJNJHZQMQRVZEE-GOSISDBHSA-N	Preclinical	lymphocyte function-associated antigen negative modulator	NA	NA
bis(maltolato)oxovanadium(IV)	PTPN1	3035454	XUOLEICXAPEOSI-UHFFFAOYSA-L	Phase 2	tyrosine phosphatase inhibitor	NA	NA
bisindolylmaleimide-IX	AKT1	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	GSK3B	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	LCK	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	MAPK1	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	MAPK11	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	MAPK12	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	MAPK14	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	MAPK8	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	PRKCA	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	ROCK1	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	RPS6KB1	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bisindolylmaleimide-IX	SIRT1	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
bismuth-subgallate	NOS1	73415769	JAONZGLTYYUPCT-UHFFFAOYSA-K	Launched	nitric oxide synthase inhibitor	gastroenterology	internal deoderant
bisoprolol	ADRB1	6604464	VHYCDWMUTMEGQY-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
bisphenol-A	AR	6623	IISBACLAFKSPIT-UHFFFAOYSA-N	Phase 1	synthetic estrogen	NA	NA
bisphenol-A	ESR1	6623	IISBACLAFKSPIT-UHFFFAOYSA-N	Phase 1	synthetic estrogen	NA	NA
bisphenol-A	ESR2	6623	IISBACLAFKSPIT-UHFFFAOYSA-N	Phase 1	synthetic estrogen	NA	NA
bisphenol-A	ESRRG	6623	IISBACLAFKSPIT-UHFFFAOYSA-N	Phase 1	synthetic estrogen	NA	NA
bisphenol-A	PPARG	6623	IISBACLAFKSPIT-UHFFFAOYSA-N	Phase 1	synthetic estrogen	NA	NA
bithionol	ESR1	2406	"InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H"	Withdrawn	autotaxin inhibitor	NA	NA
bithionol	ESR2	2406	"InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H"	Withdrawn	autotaxin inhibitor	NA	NA
bithionol	MCL1	2406	"InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H"	Withdrawn	autotaxin inhibitor	NA	NA
bitopertin	SLC6A5	24946690	YUUGYIUSCYNSQR-LBPRGKRZSA-N	Phase 3	glycine transporter inhibitor	NA	NA
bitopertin	SLC6A9	24946690	YUUGYIUSCYNSQR-LBPRGKRZSA-N	Phase 3	glycine transporter inhibitor	NA	NA
bivalirudin	F2	73952246	OIRCOABEOLEUMC-GEJPAHFPSA-N	Launched	thrombin inhibitor	cardiology	angina pectoris
BIX-01294	EHMT1	25150857	OSXFATOLZGZLSK-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
BIX-01294	EHMT2	25150857	OSXFATOLZGZLSK-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
BIX-02188	MAP2K5		FSZPIAXLCCQFCM-FCQUAONHSA-N	Preclinical	MEK inhibitor	NA	NA
BIX-02189	MAP2K5	NA	HOMJAAIVTDVQJA-IZHYLOQSSA-N	Preclinical	MEK inhibitor	NA	NA
BIX-02189	MAPK7	NA	HOMJAAIVTDVQJA-IZHYLOQSSA-N	Preclinical	MEK inhibitor	NA	NA
blebbistatin-(+/-)	MYH14	5287792	LZAXPYOBKSJSEX-GOSISDBHSA-N	Preclinical	ATPase inhibitor	NA	NA
blebbistatin-(+/-)	MYH2	5287792	LZAXPYOBKSJSEX-GOSISDBHSA-N	Preclinical	ATPase inhibitor	NA	NA
blonanserin	DRD2	125564	XVGOZDAJGBALKS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
blonanserin	HTR2A	125564	XVGOZDAJGBALKS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
BLU9931	FGFR4	72710839	TXEBNKKOLVBTFK-UHFFFAOYSA-N	Preclinical	FGFR inhibitor	NA	NA
BML-190	CNR2	2415	BJSDNVVWJYDOLK-UHFFFAOYSA-N	Preclinical	cannabinoid receptor inverse agonist	NA	NA
BMS-CCR2-22	CCR2	24801690	IBPXYDUJQWENPM-XZOQPEGZSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
BMS-182874	EDNRA	122272	MJRGSRRZKSJHOE-UHFFFAOYSA-N	Phase 2	endothelin receptor antagonist	NA	NA
BMS-191011	KCNMA1	10474339	QKOWACXSXTXRKA-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
BMS-265246	CDK1	5329775	SCFMWQIQBVZOQR-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
BMS-265246	CDK2	5329775	SCFMWQIQBVZOQR-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
BMS-309403	FABP4	16122583	SJRVJRYZAQYCEE-UHFFFAOYSA-N	Preclinical	fatty acid binding protein inhibitor	NA	NA
BMS-345541	CHUK	9813758	PSPFQEBFYXJZEV-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BMS-345541	IKBKB	9813758	PSPFQEBFYXJZEV-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BMS-387032	CDK2	3025986	OUSFTKFNBAZUKL-UHFFFAOYSA-N	Phase 1	CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor	NA	NA
BMS-387032	CDK7	3025986	OUSFTKFNBAZUKL-UHFFFAOYSA-N	Phase 1	CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor	NA	NA
BMS-387032	CDK9	3025986	OUSFTKFNBAZUKL-UHFFFAOYSA-N	Phase 1	CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor	NA	NA
BMS-470539	MC1R	9915813	GULVVTHHUIIMRL-WUFINQPMSA-N	Preclinical	melanocortin receptor agonist	NA	NA
BMS-536924	AKT1	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	CCNE1	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	CDK2	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	CYP3A4	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	ERBB2	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	IGF1R	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	KDR	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	LCK	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	MAPK1	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	MET	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	PDGFRA	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-536924	PDGFRB	135440466	ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	IGF-1 inhibitor	NA	NA
BMS-566419	IMPDH1	9913339	XEVJUIZOZCFECP-UHFFFAOYSA-N	Preclinical	inosine monophosphate dehydrogenase inhibitor	NA	NA
BMS-566419	IMPDH2	9913339	XEVJUIZOZCFECP-UHFFFAOYSA-N	Preclinical	inosine monophosphate dehydrogenase inhibitor	NA	NA
BMS-587101	ITGAL	11635371	NXNKJLOEGWSJGI-BKMJKUGQSA-N	Phase 2	integrin antagonist	NA	NA
BMS-587101	ITGB2	11635371	NXNKJLOEGWSJGI-BKMJKUGQSA-N	Phase 2	integrin antagonist	NA	NA
BMS-599626	EGFR	10437018	LUJZZYWHBDHDQX-QFIPXVFZSA-N	Phase 1	EGFR inhibitor|protein tyrosine kinase inhibitor	NA	NA
BMS-599626	ERBB2	10437018	LUJZZYWHBDHDQX-QFIPXVFZSA-N	Phase 1	EGFR inhibitor|protein tyrosine kinase inhibitor	NA	NA
BMS-599626	ERBB4	10437018	LUJZZYWHBDHDQX-QFIPXVFZSA-N	Phase 1	EGFR inhibitor|protein tyrosine kinase inhibitor	NA	NA
BMS-649	RXRA	127019	ZZUKALQMHNSWTK-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
BMS-688521	ICAM1	11699447	LILGMDXLRPEBNH-HFZDXXHNSA-N	Preclinical	ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist	NA	NA
BMS-690514	EGFR	11349170	CSGQVNMSRKWUSH-IAGOWNOFSA-N	Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
BMS-690514	ERBB2	11349170	CSGQVNMSRKWUSH-IAGOWNOFSA-N	Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
BMS-690514	FLT3	11349170	CSGQVNMSRKWUSH-IAGOWNOFSA-N	Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
BMS-690514	KDR	11349170	CSGQVNMSRKWUSH-IAGOWNOFSA-N	Phase 2	EGFR inhibitor|VEGFR inhibitor	NA	NA
BMS-754807	AKT1	24785538	LQVXSNNAFNGRAH-QHCPKHFHSA-N	Phase 2	IGF-1 inhibitor	NA	NA
BMS-754807	IGF1R	24785538	LQVXSNNAFNGRAH-QHCPKHFHSA-N	Phase 2	IGF-1 inhibitor	NA	NA
BMS-777607	AXL	24794418	VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor	NA	NA
BMS-777607	MERTK	24794418	VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor	NA	NA
BMS-777607	MET	24794418	VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor	NA	NA
BMS-777607	MST1R	24794418	VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor	NA	NA
BMS-777607	TYRO3	24794418	VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor	NA	NA
BMS-817378	KDR	44137813	KXDZWUPUSDCGDD-UHFFFAOYSA-N	Phase 1	c-Met inhibitor|VEGFR inhibitor	NA	NA
BMS-817378	MET	44137813	KXDZWUPUSDCGDD-UHFFFAOYSA-N	Phase 1	c-Met inhibitor|VEGFR inhibitor	NA	NA
BMS-833923	SMO	57662985	KLRRGBHZCJLIEL-UHFFFAOYSA-N	Phase 2	smoothened receptor antagonist	NA	NA
BMS-863233	CDC7	135564632	JJWLXRKVUJDJKG-VIFPVBQESA-N	Phase 1/Phase 2	CDC inhibitor	NA	NA
BMS-863233	PIM1	135564632	JJWLXRKVUJDJKG-VIFPVBQESA-N	Phase 1/Phase 2	CDC inhibitor	NA	NA
BMS-986020	LPAR1	49792850	GQBRZBHEPUQRPL-LJQANCHMSA-N	Phase 2	lysophosphatidic acid receptor antagonist	NA	NA
BMY-14802	HTR1A	10020651	ZXUYYZPJUGQHLQ-KRWDZBQOSA-N	Phase 2	sigma receptor antagonist	NA	NA
BMY-45778	PTGIR	127861	DSRSEEYZGWTODH-UHFFFAOYSA-N	Preclinical	IP1 prostacyclin receptor agonist	NA	NA
BMY-7378	ADRA1A	2419	AYYCFGDXLUPJAQ-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	NA	NA
BMY-7378	ADRA1B	2419	AYYCFGDXLUPJAQ-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	NA	NA
BMY-7378	ADRA1D	2419	AYYCFGDXLUPJAQ-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	NA	NA
BMY-7378	HTR1A	2419	AYYCFGDXLUPJAQ-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	NA	NA
BNTX	OPRD1	5310988	WXOUFNFMPVMGFZ-BDQAUFNLSA-N	Preclinical	opioid receptor antagonist	NA	NA
BNTX	OPRK1	5310988	WXOUFNFMPVMGFZ-BDQAUFNLSA-N	Preclinical	opioid receptor antagonist	NA	NA
BNTX	OPRM1	5310988	WXOUFNFMPVMGFZ-BDQAUFNLSA-N	Preclinical	opioid receptor antagonist	NA	NA
boceprevir	CMA1	10324368	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
boceprevir	CTSA	10324368	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
boceprevir	CTSF	10324368	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
boceprevir	CTSK	10324368	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
boceprevir	CTSL	10324368	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
boceprevir	CTSS	10324368	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
bortezomib	PSMA1	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMA2	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMA3	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMA4	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMA5	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMA6	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMA7	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMA8	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB1	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB10	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB11	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB2	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB3	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB4	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB5	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB6	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB7	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB8	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMB9	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMD1	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	PSMD2	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bortezomib	RELA	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)
bosentan	EDNRA	104865	GJPICJJJRGTNOD-UHFFFAOYSA-N	Launched	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
bosentan	EDNRB	104865	GJPICJJJRGTNOD-UHFFFAOYSA-N	Launched	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
bosutinib	ABL1	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	BCR	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	CAMK1D	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	CAMK2G	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	CDK2	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	FRK	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	FYN	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	HCK	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	LYN	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	MAP2K1	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	MAP2K2	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	MAP3K2	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	MAP4K5	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	SRC	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	STK10	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	STK24	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	STK4	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	TNK2	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
bosutinib	TXK	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
BP-554	HTR1A	134117	VUSNBQDZGKZEDL-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
BP-897	ADRA1A	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	ADRA1D	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	ADRA2A	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	DRD1	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	DRD2	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	DRD3	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	DRD4	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	HTR1A	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BP-897	HTR2B	3038495	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
BQ-123	EDNRA	443289	VYCMAAOURFJIHD-PJNXIOHISA-N	Phase 2	endothelin receptor antagonist	NA	NA
BQ-788	EDNRB	5311032	LPAHKJMGDSJDRG-DJYQTOCQSA-N	Phase 1	endothelin receptor antagonist	NA	NA
BQU57	RALA	NA	QFUFJOJDXRWBNA-YUZLPWPTSA-N	Preclinical	Ras GTPase inhibitor	NA	NA
BQU57	RALB	NA	QFUFJOJDXRWBNA-YUZLPWPTSA-N	Preclinical	Ras GTPase inhibitor	NA	NA
BRD4770	EHMT2	72193870	UCGWYCMPZXDHNR-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
BRD7389	RPS6KA1	1080352	"InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,25H,13-14H2,(H,26,28)"	Preclinical	ribosomal protein inhibitor	NA	NA
BRD7389	RPS6KA2	1080352	"InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,25H,13-14H2,(H,26,28)"	Preclinical	ribosomal protein inhibitor	NA	NA
BRD7389	RPS6KA3	1080352	"InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,25H,13-14H2,(H,26,28)"	Preclinical	ribosomal protein inhibitor	NA	NA
BRD9876	KIF11	613000	MKILROQBJOOZKC-UHFFFAOYSA-N	Preclinical	kinesin inhibitor	NA	NA
brefeldin-A	ARF1	5287620	KQNZDYYTLMIZCT-KQPMLPITSA-N	Preclinical	protein synthesis inhibitor	NA	NA
brefeldin-A	CYTH2	5287620	KQNZDYYTLMIZCT-KQPMLPITSA-N	Preclinical	protein synthesis inhibitor	NA	NA
bremelanotide	MC1R	NA	FFHBJDQSGDNCIV-VEUPWBLKSA-N	Launched	melanocortin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
bremelanotide	MC2R	NA	FFHBJDQSGDNCIV-VEUPWBLKSA-N	Launched	melanocortin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
bremelanotide	MC3R	NA	FFHBJDQSGDNCIV-VEUPWBLKSA-N	Launched	melanocortin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
bremelanotide	MC4R	NA	FFHBJDQSGDNCIV-VEUPWBLKSA-N	Launched	melanocortin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
bremelanotide	MC5R	NA	FFHBJDQSGDNCIV-VEUPWBLKSA-N	Launched	melanocortin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
brequinar	DHODH	57030	PHEZJEYUWHETKO-UHFFFAOYSA-N	Phase 2	dihydroorotate dehydrogenase inhibitor	NA	NA
bretazenil	GABRA1	107926	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2	GABA benzodiazepine site receptor partial agonist	NA	NA
bretazenil	GABRA2	107926	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2	GABA benzodiazepine site receptor partial agonist	NA	NA
bretazenil	GABRA3	107926	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2	GABA benzodiazepine site receptor partial agonist	NA	NA
bretazenil	GABRA4	107926	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2	GABA benzodiazepine site receptor partial agonist	NA	NA
bretazenil	GABRA5	107926	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2	GABA benzodiazepine site receptor partial agonist	NA	NA
bretazenil	GABRA6	107926	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2	GABA benzodiazepine site receptor partial agonist	NA	NA
bretylium	ATP1A1	2431	AAQOQKQBGPPFNS-UHFFFAOYSA-N	Launched	norepinephrine inhibitor	cardiology	ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT)
brexpiprazole	DRD2	11978813	ZKIAIYBUSXZPLP-UHFFFAOYSA-N	Launched	dopamine receptor partial agonist	neurology/psychiatry	depression|schizophrenia
briciclib	CCND1	11248490	LXENKEWVEVKKGV-BQYQJAHWSA-N	Phase 1	cyclin D inhibitor	NA	NA
brigatinib	ALK	68165256	AILRADAXUVEEIR-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor|EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
brigatinib	EGFR	68165256	AILRADAXUVEEIR-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor|EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
brimonidine	ADRA2A	2435	XYLJNLCSTIOKRM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brimonidine	ADRA2B	2435	XYLJNLCSTIOKRM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brimonidine	ADRA2C	2435	XYLJNLCSTIOKRM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brinzolamide	CA1	68844	HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brinzolamide	CA12	68844	HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brinzolamide	CA14	68844	HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brinzolamide	CA2	68844	HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brinzolamide	CA4	68844	HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brinzolamide	CA5A	68844	HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brinzolamide	CA7	68844	HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
brivanib	CYP3A4	11234052	WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3	FGFR inhibitor|VEGFR inhibitor	NA	NA
brivanib	FGFR1	11234052	WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3	FGFR inhibitor|VEGFR inhibitor	NA	NA
brivanib	FLT1	11234052	WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3	FGFR inhibitor|VEGFR inhibitor	NA	NA
brivanib	KCNH2	11234052	WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3	FGFR inhibitor|VEGFR inhibitor	NA	NA
brivanib	KDR	11234052	WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3	FGFR inhibitor|VEGFR inhibitor	NA	NA
brivanib-alaninate	FGFR3	11154925	LTEJRLHKIYCEOX-OCCSQVGLSA-N	Phase 3	FGFR inhibitor|VEGFR inhibitor	NA	NA
BRL-15572	HTR1A	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR1B	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR1D	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR1E	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR1F	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR2A	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR2B	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR2C	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-15572	HTR6	92844253	QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	serotonin receptor antagonist	NA	NA
BRL-26314	LPL	14259155	SAOHCSVJQIAGDD-OAHLLOKOSA-N	Phase 1	cholesterol inhibitor	NA	NA
BRL-37344	ADRB1	9841972	ZGGNJJJYUVRADP-ACJLOTCBSA-N	Phase 2	adrenergic receptor agonist	NA	NA
BRL-37344	ADRB2	9841972	ZGGNJJJYUVRADP-ACJLOTCBSA-N	Phase 2	adrenergic receptor agonist	NA	NA
BRL-37344	ADRB3	9841972	ZGGNJJJYUVRADP-ACJLOTCBSA-N	Phase 2	adrenergic receptor agonist	NA	NA
BRL-44408	ADRA2A	6604824	SGOFAUSEYBZKDQ-SNVBAGLBSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
BRL-44408	ADRA2B	6604824	SGOFAUSEYBZKDQ-SNVBAGLBSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
BRL-44408	ADRA2C	6604824	SGOFAUSEYBZKDQ-SNVBAGLBSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
BRL-50481	PDE7A	2921148	IFIUFCJFLGCQPH-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
BRL-50481	PDE7B	2921148	IFIUFCJFLGCQPH-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
BRL-52537	OPRK1	14810948	GHCCBWMZKJQGLS-OAHLLOKOSA-N	Preclinical	opioid receptor agonist	NA	NA
BRL-54443	HTR1E	2438	WKNFADCGOAHBPG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
BRL-54443	HTR1F	2438	WKNFADCGOAHBPG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
brolitene	RYR1	1550874	OSCTXCOERRNGLW-VOTSOKGWSA-N	Launched	muscle relaxant	rheumatology	lumbago
bromfenac	PTGS1	60726	ZBPLOVFIXSTCRZ-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
bromfenac	PTGS2	60726	ZBPLOVFIXSTCRZ-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
bromocriptine	ADRA1A	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	ADRA1B	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	ADRA1D	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	ADRA2A	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	ADRA2B	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	ADRA2C	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	DRD1	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	DRD2	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	DRD3	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	DRD4	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	DRD5	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR1A	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR1B	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR1D	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR2A	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR2B	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR2C	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR6	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromocriptine	HTR7	31101	OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	dopamine receptor agonist	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly
bromopride	DRD2	2446	GIYAQDDTCWHPPL-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting|gastroesophageal reflux disease (GERD)
bromperidol	DRD2	2448	RKLNONIVDFXQRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
brompheniramine	HRH1	16960	ZDIGNSYAACHWNL-HNNXBMFYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology	allergic rhinitis|common cold
broxaterol	ADRB2	13626987	JBRBWHCVRGURBA-ZCFIWIBFSA-N	Phase 3	adrenergic receptor agonist	NA	NA
brucine	CHRM1	442021	RRKTZKIUPZVBMF-IBTVXLQLSA-N	Preclinical	glycine receptor antagonist	NA	NA
brucine	CHRM2	442021	RRKTZKIUPZVBMF-IBTVXLQLSA-N	Preclinical	glycine receptor antagonist	NA	NA
brucine	CHRM3	442021	RRKTZKIUPZVBMF-IBTVXLQLSA-N	Preclinical	glycine receptor antagonist	NA	NA
brucine	CHRM4	442021	RRKTZKIUPZVBMF-IBTVXLQLSA-N	Preclinical	glycine receptor antagonist	NA	NA
brucine	CHRM5	442021	RRKTZKIUPZVBMF-IBTVXLQLSA-N	Preclinical	glycine receptor antagonist	NA	NA
BS-181	CDK7	49867929	DNYBIOICMDTDAP-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
BTB06584	ATP5F1	2799764	WNDWKKPBLAKXMI-UHFFFAOYSA-N	Preclinical	ATPase inhibitor	NA	NA
BTB1	KIF18A	291461	VZDUQPHKUBZMLW-UHFFFAOYSA-N	Preclinical	mitotic kinesin inhibitor	NA	NA
BTS-54505	SLC6A2	9900576	WQSACWZKKZPCHN-CQSZACIVSA-N	Withdrawn	dopamine reuptake inhibitor	NA	NA
BTS-54505	SLC6A3	9900576	WQSACWZKKZPCHN-CQSZACIVSA-N	Withdrawn	dopamine reuptake inhibitor	NA	NA
BTS-54505	SLC6A4	9900576	WQSACWZKKZPCHN-CQSZACIVSA-N	Withdrawn	dopamine reuptake inhibitor	NA	NA
BTS-72664	GABBR1	1480409	FCEPUTGEUCVRRI-SECBINFHSA-N	Phase 1	GABA receptor antagonist	NA	NA
BTT-3033	ITGA2	49841251	NSLIQOPYDUKWTA-UHFFFAOYSA-N	Preclinical	integrin inhibitor	NA	NA
BTT-3033	ITGB1	49841251	NSLIQOPYDUKWTA-UHFFFAOYSA-N	Preclinical	integrin inhibitor	NA	NA
BU-224	MAOA	2457	OSUVWJGCKQEMHK-UHFFFAOYSA-N	Preclinical	imidazoline receptor ligand	NA	NA
BU-224	MAOB	2457	OSUVWJGCKQEMHK-UHFFFAOYSA-N	Preclinical	imidazoline receptor ligand	NA	NA
bucladesine	PRKACA	9687	CJGYSWNGNKCJSB-YVLZZHOMSA-N	Launched	adenosine receptor agonist|cAMP stimulant	dermatology	skin ulcer
buclizine	HRH1	3246096	MOYGZHXDRJNJEP-MHZLTWQESA-N	Launched	histamine receptor antagonist	neurology/psychiatry	migraine headache
budesonide	NR3C1	63006	VOVIALXJUBGFJZ-AMTWPJRWSA-N	Launched	glucocorticoid receptor agonist	gastroenterology	Crohn's disease
budipine	GRIN1	68778	QIHLUZAFSSMXHQ-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	Parkinson's Disease
bufexamac	HDAC10	2466	MXJWRABVEGLYDG-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
bufexamac	HDAC6	2466	MXJWRABVEGLYDG-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
buflomedil	ADRA1A	2467	OWYLAEYXIQKAOL-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|calcium channel blocker	cardiology	peripheral artery disease (PAD)
bumetanide	CFTR	2471	MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched	solute carrier family member inhibitor	cardiology	edema|congestive heart failure
bumetanide	GPR35	2471	MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched	solute carrier family member inhibitor	cardiology	edema|congestive heart failure
bumetanide	SLC12A1	2471	MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched	solute carrier family member inhibitor	cardiology	edema|congestive heart failure
bumetanide	SLC12A2	2471	MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched	solute carrier family member inhibitor	cardiology	edema|congestive heart failure
bumetanide	SLC12A4	2471	MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched	solute carrier family member inhibitor	cardiology	edema|congestive heart failure
bumetanide	SLC12A5	2471	MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched	solute carrier family member inhibitor	cardiology	edema|congestive heart failure
bunazosin	ADRA1A	2472	RHLJLALHBZGAFM-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	ophthalmology	glaucoma|intraocular pressure
buparlisib	PIK3CA	16654980	CWHUFRVAEUJCEF-UHFFFAOYSA-N	Phase 3	PI3K inhibitor	NA	NA
buparlisib	PIK3CG	16654980	CWHUFRVAEUJCEF-UHFFFAOYSA-N	Phase 3	PI3K inhibitor	NA	NA
buphenine	ADRB2	657392	PTGXAUBQBSGPKF-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	rheumatology	Raynaud's disease
bupicomide	ADRB1	31447	VKSPIPWLHGKJQO-UHFFFAOYSA-N	Phase 1	adrenergic receptor antagonist	NA	NA
bupivacaine	KCNA5	92253	LEBVLXFERQHONN-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	peripheral nerve block|caudal epidural block|lumbar epidural block
bupivacaine	SCN10A	92253	LEBVLXFERQHONN-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	peripheral nerve block|caudal epidural block|lumbar epidural block
bupranolol	ADRB1	66601885	HQIRNZOQPUAHHV-NSHDSACASA-N	Launched	adrenergic receptor antagonist	cardiology|ophthalmology	hypertension|glaucoma
bupranolol	ADRB2	66601885	HQIRNZOQPUAHHV-NSHDSACASA-N	Launched	adrenergic receptor antagonist	cardiology|ophthalmology	hypertension|glaucoma
bupranolol	ADRB3	66601885	HQIRNZOQPUAHHV-NSHDSACASA-N	Launched	adrenergic receptor antagonist	cardiology|ophthalmology	hypertension|glaucoma
bupropion	SLC6A2	688387	SNPPWIUOZRMYNY-SECBINFHSA-N	Launched	dopamine reuptake inhibitor	neurology/psychiatry	depression
bupropion	SLC6A3	688387	SNPPWIUOZRMYNY-SECBINFHSA-N	Launched	dopamine reuptake inhibitor	neurology/psychiatry	depression
buspirone	DRD2	2477	QWCRAEMEVRGPNT-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD)
buspirone	HTR1A	2477	QWCRAEMEVRGPNT-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD)
butabindide	TPP2	9817923	HAQIRIMIVLFYIX-ZFWWWQNUSA-N	Preclinical	tripeptidyl peptidase inhibitor	NA	NA
butaclamol	DRD1	37459	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	dopamine receptor antagonist	NA	NA
butaclamol	DRD2	37459	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	dopamine receptor antagonist	NA	NA
butaclamol	DRD3	37459	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	dopamine receptor antagonist	NA	NA
butaclamol	DRD4	37459	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	dopamine receptor antagonist	NA	NA
butaclamol	DRD5	37459	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	dopamine receptor antagonist	NA	NA
butaclamol	HTR1A	37459	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	dopamine receptor antagonist	NA	NA
butaclamol	HTR2A	37459	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	dopamine receptor antagonist	NA	NA
butalbital	CHRNA4	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	CHRNA7	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRA1	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRA2	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRA3	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRA4	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRA5	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRA6	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRB1	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRB2	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRB3	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRD	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRE	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRG1	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRG2	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRG3	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRP	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GABRQ	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GRIA2	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butalbital	GRIK2	2481	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	headache|muscle relaxant
butein	ACE	5281222	AYMYWHCQALZEGT-ORCRQEGFSA-N	Preclinical	EGFR inhibitor|SRC inhibitor	NA	NA
butenafine	SQLE	2484	ABJKWBDEJIDSJZ-UHFFFAOYSA-N	Launched	fungal squalene epoxidase inhibitor	infectious disease	tinea pedis|tinea cruris|tinea corporis
buthionine-sulfoximine	GCLM	1548918	KJQFBVYMGADDTQ-CVSPRKDYSA-N	Phase 1	glutathione transferase inhibitor	NA	NA
butylated-hydroxytoluene	CA2	31404	NLZUEZXRPGMBCV-UHFFFAOYSA-N	Phase 1	carbonic anhydrase inhibitor	NA	NA
butylphthalide	KCNK2	9990075	HJXMNVQARNZTEE-LLVKDONJSA-N	Launched	potassium channel antagonist	neurology/psychiatry	stroke
BVT-2733	HSD17B1	6918651	YDPRNGAPPNPYQQ-UHFFFAOYSA-N	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	NA	NA
BVT-948	PTPN1	6604934	LLPBUXODFQZPFH-UHFFFAOYSA-N	Preclinical	tyrosine phosphatase inhibitor	NA	NA
BVT-948	PTPN11	6604934	LLPBUXODFQZPFH-UHFFFAOYSA-N	Preclinical	tyrosine phosphatase inhibitor	NA	NA
BVT-948	PTPN2	6604934	LLPBUXODFQZPFH-UHFFFAOYSA-N	Preclinical	tyrosine phosphatase inhibitor	NA	NA
BW-A4C	ALOX5	6438354	CEUDWZXMLMKPNN-SOFGYWHQSA-N	Phase 1	lipoxygenase inhibitor	NA	NA
BW-B70C	ALOX5	88473969	UAIYNMRLUHHRMF-FYJFLYSWSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
BW-180C	OPRD1	6917707	ZHUJMSMQIPIPTF-IBURTVSXSA-N	Phase 2	opioid receptor agonist	NA	NA
BW-180C	OPRM1	6917707	ZHUJMSMQIPIPTF-IBURTVSXSA-N	Phase 2	opioid receptor agonist	NA	NA
BW-373U86	OPRD1	119029	LBLDMHBSVIVJPM-YZIHRLCOSA-N	Preclinical	opioid receptor agonist	NA	NA
BW-616U	MAOA	11722381	MLPSDBJCWIYSEA-UHFFFAOYSA-N	Preclinical	monoamine oxidase inhibitor	NA	NA
BW-723C86	HTR2A	40418385	ALFGDCNSEBJYSP-LLVKDONJSA-N	Preclinical	serotonin receptor agonist	NA	NA
BW-723C86	HTR2B	40418385	ALFGDCNSEBJYSP-LLVKDONJSA-N	Preclinical	serotonin receptor agonist	NA	NA
BW-723C86	HTR2C	40418385	ALFGDCNSEBJYSP-LLVKDONJSA-N	Preclinical	serotonin receptor agonist	NA	NA
BX-795	CDK2	10077147	VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BX-795	CHEK1	10077147	VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BX-795	GSK3B	10077147	VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BX-795	KDR	10077147	VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BX-795	PDK1	10077147	VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BX-795	PDPK1	10077147	VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
BX-912	CDK2	11754511	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical	pyruvate dehydrogenase kinase inhibitor	NA	NA
BX-912	CHEK1	11754511	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical	pyruvate dehydrogenase kinase inhibitor	NA	NA
BX-912	GSK3B	11754511	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical	pyruvate dehydrogenase kinase inhibitor	NA	NA
BX-912	KDR	11754511	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical	pyruvate dehydrogenase kinase inhibitor	NA	NA
BX-912	PDK1	11754511	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical	pyruvate dehydrogenase kinase inhibitor	NA	NA
BX-912	PDPK1	11754511	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical	pyruvate dehydrogenase kinase inhibitor	NA	NA
BYK-204165	PARP1	25113764	BTYSIDSTHDDAJW-LCYFTJDESA-N	Preclinical	PARP inhibitor	NA	NA
C-021	CCR4	25141190	WYVBISCFCHREDA-UHFFFAOYSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
C-1	PRKCA	3545	UPTYCYWTFGTCCG-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
cabazitaxel	TUBA1A	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBA1B	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBA1C	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBA3C	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBA3D	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBA3E	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBA4A	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB1	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB2A	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB2B	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB3	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB4A	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB4B	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB6	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabazitaxel	TUBB8	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	microtubule inhibitor	oncology	prostate cancer
cabergoline	ADRA1A	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	ADRA1B	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	ADRA1D	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	ADRA2A	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	ADRA2B	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	ADRA2C	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	ADRB1	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	ADRB2	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	DRD1	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	DRD2	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	DRD3	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	DRD4	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	DRD5	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	HTR1A	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	HTR1B	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	HTR1D	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	HTR2A	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	HTR2B	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	HTR2C	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabergoline	HTR7	54746	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabozantinib	KDR	25102847	"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)"	Launched	RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
cabozantinib	MET	25102847	"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)"	Launched	RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
cabozantinib	RET	25102847	"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)"	Launched	RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
CaCCinh-A01	CLCA1	747218	ACLUEOBQFRYTQS-JTQLQIEISA-N	Preclinical	calcium-activated chloride channel inhibitor	NA	NA
caffeic-acid	ALOX5	689043	QAIPRVGONGVQAS-DUXPYHPUSA-N	Preclinical	HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor	NA	NA
caffeic-acid	MIF	689043	QAIPRVGONGVQAS-DUXPYHPUSA-N	Preclinical	HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor	NA	NA
caffeic-acid-phenethyl-ester	RELA	5281787	SWUARLUWKZWEBQ-VQHVLOKHSA-N	Preclinical	HIV integrase inhibitor	NA	NA
caffeine	ADORA1	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	ADORA2A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	ADORA2B	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	ADORA3	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	ATM	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	ITPR1	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	ITPR2	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	ITPR3	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE10A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE11A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE1A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE1B	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE1C	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE2A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE3A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE3B	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE4A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE4B	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE4C	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE4D	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE5A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE6A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE6B	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE6C	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE7A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE7B	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE8A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE8B	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PDE9A	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PIK3CA	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PIK3CB	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PIK3CD	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	PRKDC	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	RYR1	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	RYR2	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
caffeine	RYR3	2519	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	fatigue|drowsiness
calcifediol	VDR	5283731	JWUBBDSIWDLEOM-DTOXIADCSA-N	Launched	vitamin D receptor agonist	endocrinology	hyperparathyroidism
calcipotriol	VDR	5288783	LWQQLNNNIPYSNX-UROSTWAQSA-N	Launched	vitamin D receptor agonist	dermatology	psoriasis
calcitriol	VDR	5280453	GMRQFYUYWCNGIN-NKMMMXOESA-N	Launched	vitamin D receptor agonist	endocrinology|orthopedics	hypocalcemia|hypoparathyroidism|osteoporosis
Calhex-231	CASR	11849514	YTFUQWWKTIWYEY-CQLNOVPUSA-N	Preclinical	calcium sensing receptor negative allosteric modulator	NA	NA
camicinal	MLNR	15984937	RZKDEGZIFSJVNA-IBGZPJMESA-N	Phase 2	motilin receptor agonist	NA	NA
CaMKII-IN-1	AKT1	50898538	LGUUETDTMQTHML-UHFFFAOYSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	NA	NA
CaMKII-IN-1	CAMK2A	50898538	LGUUETDTMQTHML-UHFFFAOYSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	NA	NA
CaMKII-IN-1	CAMK4	50898538	LGUUETDTMQTHML-UHFFFAOYSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	NA	NA
CaMKII-IN-1	MYLK	50898538	LGUUETDTMQTHML-UHFFFAOYSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	NA	NA
camostat-mesilate	PRSS1	2536	XASIMHXSUQUHLV-UHFFFAOYSA-N	Launched	protease inhibitor	gastroenterology	pancreatitis
camphor-(1R)	TRPV1	5284500	DSSYKIVIOFKYAU-GMSGAONNSA-N	Phase 1	TRPV activator	NA	NA
camptothecin	TOP1	24360	VSJKWCGYPAHWDS-FQEVSTJZSA-N	Phase 3	topoisomerase inhibitor	NA	NA
canagliflozin	SLC5A1	24812758	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
canagliflozin	SLC5A2	24812758	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
candesartan	AGTR1	2541	HTQMVQVXFRQIKW-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension|congestive heart failure
canertinib	AKT1	156414	"InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)"	Phase 3	EGFR inhibitor	NA	NA
canertinib	EGFR	156414	"InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)"	Phase 3	EGFR inhibitor	NA	NA
canertinib	ERBB2	156414	"InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)"	Phase 3	EGFR inhibitor	NA	NA
canertinib	ERBB4	156414	"InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)"	Phase 3	EGFR inhibitor	NA	NA
canrenone	NR3C2	13789	UJVLDDZCTMKXJK-WNHSNXHDSA-N	Withdrawn	mineralocorticoid receptor antagonist	NA	NA
capadenoson	ADORA1	9936489	CITWCLNVRIKQAF-UHFFFAOYSA-N	Phase 2	adenosine receptor agonist	NA	NA
capecitabine	TYMS	60953	GAGWJHPBXLXJQN-UORFTKCHSA-N	Launched	DNA synthesis inhibitor|thymidylate synthase inhibitor	oncology	breast cancer|colorectal cancer
capsaicin	CFTR	1548943	YKPUWZUDDOIDPM-SOFGYWHQSA-N	Launched	TRPV agonist	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis
capsaicin	TRPV1	1548943	YKPUWZUDDOIDPM-SOFGYWHQSA-N	Launched	TRPV agonist	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis
capsazepine	TRPV1	2733484	DRCMAZOSEIMCHM-UHFFFAOYSA-N	Preclinical	TRPV agonist	NA	NA
capsazepine	TRPV4	2733484	DRCMAZOSEIMCHM-UHFFFAOYSA-N	Preclinical	TRPV agonist	NA	NA
captopril	ACE	44093	FAKRSMQSSFJEIM-RQJHMYQMSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy
captopril	LTA4H	44093	FAKRSMQSSFJEIM-RQJHMYQMSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy
captopril	MMP2	44093	FAKRSMQSSFJEIM-RQJHMYQMSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy
captopril	MMP9	44093	FAKRSMQSSFJEIM-RQJHMYQMSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy
caracemide	RRM1	54747	JURAJLFHWXNPHG-UHFFFAOYSA-N	Phase 2	ribonucleotide reductase inhibitor	NA	NA
caramiphen	CHRM1	6472	OFAIGZWCDGNZGT-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	neurology/psychiatry	Parkinson's Disease
caramiphen	CHRM2	6472	OFAIGZWCDGNZGT-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	neurology/psychiatry	Parkinson's Disease
carazolol	ADRB1	13023331	BQXQGZPYHWWCEB-CYBMUJFWSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris|cardiac arrythmia|hypertension|myocardial infarction
carazolol	ADRB2	13023331	BQXQGZPYHWWCEB-CYBMUJFWSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris|cardiac arrythmia|hypertension|myocardial infarction
carazolol	ADRB3	13023331	BQXQGZPYHWWCEB-CYBMUJFWSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris|cardiac arrythmia|hypertension|myocardial infarction
carbachol	CHRM1	2551	VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched	cholinergic receptor agonist	ophthalmology	intraocular pressure
carbachol	CHRM2	2551	VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched	cholinergic receptor agonist	ophthalmology	intraocular pressure
carbachol	CHRM3	2551	VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched	cholinergic receptor agonist	ophthalmology	intraocular pressure
carbachol	CHRM4	2551	VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched	cholinergic receptor agonist	ophthalmology	intraocular pressure
carbachol	CHRM5	2551	VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched	cholinergic receptor agonist	ophthalmology	intraocular pressure
carbachol	CHRNA2	2551	VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched	cholinergic receptor agonist	ophthalmology	intraocular pressure
carbamazepine	SCN10A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN11A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN1A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN2A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN3A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN4A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN5A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN7A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN8A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbamazepine	SCN9A	2554	FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	carboxamide antiepileptic	neurology/psychiatry	seizures
carbendazim	TP53	25429	TWFZGCMQGLPBSX-UHFFFAOYSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	fungicide
carbendazim	TUBB	25429	TWFZGCMQGLPBSX-UHFFFAOYSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	fungicide
carbenoxolone	GJA1	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJA10	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJA3	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJA4	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJA5	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJA8	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJA9	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJB1	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJB2	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJB3	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJB4	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJB5	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJB6	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJB7	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJC1	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJC2	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJC3	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJD2	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJD3	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJD4	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	GJE1	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	HSD11B1	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	PANX1	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	PANX2	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbenoxolone	PANX3	636403	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation
carbetapentane	CHRM2	2562	CFJMRBQWBDQYMK-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	otolaryngology|pulmonary	common cold|nasal congestion|bronchitis
carbetocin	OXTR	NA	NSTRIRCPWQHTIA-CPWZVOFUSA-N	Launched	oxytocin receptor agonist	hematology	hemorrhage
carbidopa	DDC	34359	TZFNLOMSOLWIDK-JTQLQIEISA-N	Launched	aromatic L-amino acid decarboxylase inhibitor	neurology/psychiatry	Parkinson's Disease
carbimazole	TPO	31072	CFOYWRHIYXMDOT-UHFFFAOYSA-N	Launched	antithyroid agent	endocrinology	hyperthyroidism
carbinoxamine	HRH1	170336	OJFSXZCBGQGRNV-INIZCTEOSA-N	Launched	histamine receptor antagonist	allergy|ophthalmology|otolaryngology|dermatology	allergic rhinitis|conjunctivitis|vasomotor rhinitis|dermatographism
carboxyamidotriazole	CXCL8	108144	WNRZHQBJSXRYJK-UHFFFAOYSA-N	Phase 3	calcium channel blocker	NA	NA
carboxylosartan	AGTR1	108185	ZEUXAIYYDDCIRX-UHFFFAOYSA-N	Phase 1	angiotensin antagonist	NA	NA
cardionogen-1	CTNNB1	663145	SWTUPSNBTSPBIH-UHFFFAOYSA-N	Preclinical	WNT signaling inhibitor	NA	NA
carebastine	HRH1	65820	XGHOVGYJHWQGCC-UHFFFAOYSA-N	Phase 1	histamine receptor antagonist	NA	NA
carfilzomib	PSMA1	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMA2	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMA3	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMA4	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMA5	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMA6	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMA7	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMA8	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB1	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB10	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB11	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB2	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB3	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB4	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB5	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB6	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB7	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB8	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carfilzomib	PSMB9	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	proteasome inhibitor	hematologic malignancy	multiple myeloma
carglumic-acid	CPS1	121396	LCQLHJZYVOQKHU-VKHMYHEASA-N	Launched	carbamoyl phosphate synthase activator	metabolism	hyperammonemia
caricotamide	NQO2	403128	WEJRSYKFMCUCRQ-UHFFFAOYSA-N	Phase 2	NADPH quinone oxidoreductase inhibitor	NA	NA
cariporide	SLC9A1	151172	IWXNYAIICFKCTM-UHFFFAOYSA-N	Phase 3	sodium/hydrogen exchanger inhibitor	NA	NA
cariprazine	DRD2	NA	KPWSJANDNDDRMB-QAQDUYKDSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
cariprazine	DRD3	NA	KPWSJANDNDDRMB-QAQDUYKDSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
carmofur	TYMS	2577	AOCCBINRVIKJHY-UHFFFAOYSA-N	Launched	thymidylate synthase inhibitor	oncology	breast cancer|colorectal cancer
carmoterol	ADRB2	86306667	IHOXNOQMRZISPV-YJYMSZOUSA-N	Phase 2	adrenergic receptor agonist	NA	NA
carmoxirole	DRD2	86308157	AFSOIHMEOKEZJF-UHFFFAOYSA-N	Phase 2	dopamine receptor agonist	NA	NA
carmustine	GSR	59087767	IIJOAQBKDPUMEO-UHFFFAOYSA-N	Launched	DNA alkylating agent|DNA inhibitor	hematologic malignancy|oncology	non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma
caroxazone	MAOA	29083	KYCBWEZLKCTALM-UHFFFAOYSA-N	Withdrawn	monoamine oxidase inhibitor	NA	NA
caroxazone	MAOB	29083	KYCBWEZLKCTALM-UHFFFAOYSA-N	Withdrawn	monoamine oxidase inhibitor	NA	NA
carprofen	PTGS2	6997572	PUXBGTOOZJQSKH-MRVPVSSYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis
carteolol	ADRB1	49852288	LWAFSWPYPHEXKX-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
carteolol	ADRB2	49852288	LWAFSWPYPHEXKX-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
carteolol	ADRB3	49852288	LWAFSWPYPHEXKX-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	ophthalmology	intraocular pressure|glaucoma|ocular hypertension
carvedilol	ADRB1	185394	OGHNVEJMJSYVRP-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	cardiology	myocardial infarction|hypertension
carvedilol	ADRB2	185394	OGHNVEJMJSYVRP-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	cardiology	myocardial infarction|hypertension
carvedilol	ADRB3	185394	OGHNVEJMJSYVRP-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	cardiology	myocardial infarction|hypertension
carzenide	CA1	8739	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical		NA	NA
carzenide	CA12	8739	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical		NA	NA
carzenide	CA14	8739	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical		NA	NA
carzenide	CA2	8739	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical		NA	NA
carzenide	CA6	8739	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical		NA	NA
carzenide	CA9	8739	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical		NA	NA
casin	CDC42	1600664	RXIUMAOXORBRCY-IBGZPJMESA-N	Preclinical	GTPase inhibitor	NA	NA
castanospermine	GAA	54445	JDVVGAQPNNXQDW-TVNFTVLESA-N	Phase 2	glucosidase inhibitor	NA	NA
castanospermine	GBA	54445	JDVVGAQPNNXQDW-TVNFTVLESA-N	Phase 2	glucosidase inhibitor	NA	NA
cathepsin-inhibitor-1	CTSB	44224135	MZRVIHRERYCHBL-HNNXBMFYSA-N	Preclinical	cathepsin inhibitor	NA	NA
cathepsin-inhibitor-1	CTSL	44224135	MZRVIHRERYCHBL-HNNXBMFYSA-N	Preclinical	cathepsin inhibitor	NA	NA
cathepsin-inhibitor-1	CTSV	44224135	MZRVIHRERYCHBL-HNNXBMFYSA-N	Preclinical	cathepsin inhibitor	NA	NA
CAY10505	PIK3CG	1204893	UFBTYTGRUBUUIL-KPKJPENVSA-N	Preclinical	PI3K inhibitor	NA	NA
CB-03-01	AR	11750009	GPNHMOZDMYNCPO-PDUMRIMRSA-N	Phase 3	androgen receptor antagonist	NA	NA
CB-5083	VCP	73051434	RDALZZCKQFLGJP-UHFFFAOYSA-N	Phase 1	valosin-containing protein inhibitor	NA	NA
CB-839	GLS	71577426	PRAAPINBUWJLGA-UHFFFAOYSA-N	Phase 2	glutaminase inhibitor	NA	NA
CBiPES	GRM2	9864510	HDVYXILCBYGKGU-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
CBS-1114	ALOX5	6338223	ZOBKPJRHDMKXQG-UHFFFAOYSA-N	Phase 1	lipoxygenase inhibitor	NA	NA
CC-115	MTOR	58298318	GMYLVKUGJMYTFB-UHFFFAOYSA-N	Phase 2	DNA protein kinase inhibitor|mTOR inhibitor	NA	NA
CC-223	MTOR	NA	UFKLYTOEMRFKAD-SHTZXODSSA-N	Phase 2	mTOR inhibitor	NA	NA
CC-401	MAPK8	10430360	XDJCLCLBSGGNKS-UHFFFAOYSA-N	Phase 1	JNK inhibitor	NA	NA
CCG-1423	RHOC	40782280	DSMXVSGJIDFLKP-SECBINFHSA-N	Preclinical	apoptosis stimulant	NA	NA
CCG-1423	SRF	40782280	DSMXVSGJIDFLKP-SECBINFHSA-N	Preclinical	apoptosis stimulant	NA	NA
CCG-50014	RGS4	2733079	QUIIIYITNGOFEI-UHFFFAOYSA-N	Preclinical	G protein signaling inhibitor	NA	NA
CCG-50014	RGS8	2733079	QUIIIYITNGOFEI-UHFFFAOYSA-N	Preclinical	G protein signaling inhibitor	NA	NA
CCG-63802	RGS4	6057678	VFSVKVQMZDJFQX-NBVRZTHBSA-N	Preclinical	G protein signaling inhibitor	NA	NA
CCG-63808	RGS4	5948316	IPZHFKHGSYRBNT-DTQAZKPQSA-N	Preclinical	G protein signaling inhibitor	NA	NA
CCMI	CHRNA7	67042344	VMAKIACTLSBBIY-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
CCT-031374	CTNNB1	2853753	JPCYSKNELCOPKJ-UHFFFAOYSA-N	Preclinical	WNT signaling inhibitor	NA	NA
CCT018159	HSP90AA1	984170	OWPMENVYXDJDOW-UHFFFAOYSA-N	Preclinical	HSP inhibitor	NA	NA
CCT018159	HSP90AB1	984170	OWPMENVYXDJDOW-UHFFFAOYSA-N	Preclinical	HSP inhibitor	NA	NA
CCT129202	AURKA	16202152	QYKHWEFPFAGNEV-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
CCT129202	AURKB	16202152	QYKHWEFPFAGNEV-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
CCT129202	AURKC	16202152	QYKHWEFPFAGNEV-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
CCT137690	AURKA	25154041	GFLQCBTXTRCREJ-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
CCT137690	AURKB	25154041	GFLQCBTXTRCREJ-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
CCT137690	AURKC	25154041	GFLQCBTXTRCREJ-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
CC4	CHRNB2	91654624	LEXDAVFCJPDCNA-VNTMZGSJSA-N	Preclinical	nicotinic receptor agonist	NA	NA
CD-1530	RARG	9952709	VCQGNUWOMLYNNG-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
CD-437	RARG	135411	LDGIHZJOIQSHPB-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
CDK1-5-inhibitor	CDK1	438981	DWHVZCLBMTZRQM-UHFFFAOYSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
CDK1-5-inhibitor	CDK5	438981	DWHVZCLBMTZRQM-UHFFFAOYSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
CDK1-5-inhibitor	GSK3B	438981	DWHVZCLBMTZRQM-UHFFFAOYSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
CDK9-IN-6	CDK9	NA	XWQVQSXLXAXOPJ-ACRUOGEOSA-N	Preclinical	CDK inhibitor	NA	NA
CDPPB	GRM5	11245456	BKUIZWILNWHFHD-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
cebranopadol	OPRL1	NA	CSMVOZKEWSOFER-RQNOJGIXSA-N	Phase 3	opioid receptor agonist	NA	NA
cebranopadol	OPRM1	NA	CSMVOZKEWSOFER-RQNOJGIXSA-N	Phase 3	opioid receptor agonist	NA	NA
cediranib	CSF1R	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cediranib	FLT1	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cediranib	FLT3	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cediranib	FLT4	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cediranib	KDR	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cediranib	KIT	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cediranib	PDGFRA	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cediranib	PDGFRB	9933475	XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	KIT inhibitor|VEGFR inhibitor	NA	NA
cefadroxil	SLC15A1	6560167	BOEGTKLJZSQCCD-UEKVPHQBSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology	urinary tract infections|skin infections|tonsillitis|pharyngitis
cefadroxil	SLC15A2	6560167	BOEGTKLJZSQCCD-UEKVPHQBSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology	urinary tract infections|skin infections|tonsillitis|pharyngitis
cefadroxil	SLC22A6	6560167	BOEGTKLJZSQCCD-UEKVPHQBSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology	urinary tract infections|skin infections|tonsillitis|pharyngitis
cefadroxil	SLC22A8	6560167	BOEGTKLJZSQCCD-UEKVPHQBSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology	urinary tract infections|skin infections|tonsillitis|pharyngitis
cefazolin	PON1	33255	MLYYVTUWGNIJIB-BXKDBHETSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections
cefdinir	MPO	6915944	RTXOFQZKPXMALH-GHXIOONMSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology|pulmonary	pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis
cefradine	CYP3A4	40467109	RDLPVSKMFDYCOR-UEKVPHQBSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia
celecoxib	CA12	2662	RZEKVGVHFLEQIL-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|endocrinology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)
celecoxib	PDPK1	2662	RZEKVGVHFLEQIL-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|endocrinology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)
celecoxib	PTGS2	2662	RZEKVGVHFLEQIL-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|endocrinology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)
celiprolol	ADRA2A	11406333	JOATXPAWOHTVSZ-INIZCTEOSA-N	Launched	adrenergic receptor antagonist	genetics	Ehlers-Danlos syndrome (EDS)
celiprolol	ADRB1	11406333	JOATXPAWOHTVSZ-INIZCTEOSA-N	Launched	adrenergic receptor antagonist	genetics	Ehlers-Danlos syndrome (EDS)
celiprolol	ADRB2	11406333	JOATXPAWOHTVSZ-INIZCTEOSA-N	Launched	adrenergic receptor antagonist	genetics	Ehlers-Danlos syndrome (EDS)
CEP-32496	BRAF	56846693	DKNUPRMJNUQNHR-UHFFFAOYSA-N	Phase 1/Phase 2	RAF inhibitor	NA	NA
CEP-32496	RAF1	56846693	DKNUPRMJNUQNHR-UHFFFAOYSA-N	Phase 1/Phase 2	RAF inhibitor	NA	NA
CEP-33779	JAK2	57336812	RFZKSQIFOZZIAQ-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
CEP-37440	ALK	71721648	"InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)/t21-/m0/s1"	Phase 1	ALK tyrosine kinase receptor inhibitor	NA	NA
ceritinib	ALK	57379345	VERWOWGGCGHDQE-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
ceritinib	FLT3	57379345	VERWOWGGCGHDQE-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
ceritinib	IGF1R	57379345	VERWOWGGCGHDQE-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
ceritinib	INSR	57379345	VERWOWGGCGHDQE-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
ceritinib	TSSK1B	57379345	VERWOWGGCGHDQE-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
cerulenin	FASN	5282054	GVEZIHKRYBHEFX-NQQPLRFYSA-N	Launched	fatty acid synthase inhibitor	infectious disease	fungal infection
ceruletide	CCKAR	16129675	YRALAIOMGQZKOW-HYAOXDFASA-N	Preclinical	CCK receptor agonist	NA	NA
cetaben	PPARA	47263	QXWKHSSBFQDQPR-UHFFFAOYSA-N	Phase 2	ACAT inhibitor|cholesterol inhibitor	NA	NA
cetilistat	PNLIP	9952916	MVCQKIKWYUURMU-UHFFFAOYSA-N	Phase 3	triacylglycerol lipase inhibitor	NA	NA
cetirizine	HRH1	28145930	ZKLPARSLTMPFCP-NRFANRHFSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis
cetrorelix	GNRHR	25074887	SBNPWPIBESPSIF-MHWMIDJBSA-N	Launched	gonadotropin releasing factor hormone receptor antagonist	endocrinology	premature luteinizing hormone surges
cetrorelix	LHCGR	25074887	SBNPWPIBESPSIF-MHWMIDJBSA-N	Launched	gonadotropin releasing factor hormone receptor antagonist	endocrinology	premature luteinizing hormone surges
cevimeline	CHRM3	18642481	WUTYZMFRCNBCHQ-WPRPVWTQSA-N	Launched	acetylcholine receptor agonist	rheumatology	sjogren's syndrome
cevipabulin	TUBB	11488110	ZUZPCOQWSYNWLU-VIFPVBQESA-N	Phase 1	microtubule stimulant|tubulin polymerization inhibitor	NA	NA
CE3F4	RAPGEF3	73669656	ZZLQPWXVZCPUGC-LURJTMIESA-N	Preclinical	rap guanine nucleotide exchange factor inhibitor	NA	NA
CFTRinh-172	CFTR	1554210	JIMHYXZZCWVCMI-RIYZIHGNSA-N	Preclinical	chloride channel blocker	NA	NA
CF102	ADORA1	3035850	IPSYPUKKXMNCNQ-PFHKOEEOSA-N	Phase 2	adenosine receptor agonist	NA	NA
CF102	ADORA2A	3035850	IPSYPUKKXMNCNQ-PFHKOEEOSA-N	Phase 2	adenosine receptor agonist	NA	NA
CF102	ADORA2B	3035850	IPSYPUKKXMNCNQ-PFHKOEEOSA-N	Phase 2	adenosine receptor agonist	NA	NA
CF102	ADORA3	3035850	IPSYPUKKXMNCNQ-PFHKOEEOSA-N	Phase 2	adenosine receptor agonist	NA	NA
CGH2466	ADORA1	5282339	BEPGKLOHQTXUHX-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
CGH2466	ADORA2B	5282339	BEPGKLOHQTXUHX-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
CGH2466	ADORA3	5282339	BEPGKLOHQTXUHX-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
CGK-733	ATM	92509770	HLCDNLNLQNYZTK-OAQYLSRUSA-N	Preclinical	ATM kinase inhibitor|ATR kinase inhibitor	NA	NA
CGK-733	ATR	92509770	HLCDNLNLQNYZTK-OAQYLSRUSA-N	Preclinical	ATM kinase inhibitor|ATR kinase inhibitor	NA	NA
CGM097	MDM2	NA	CLRSLRWKONPSRQ-IIPSPAQQSA-N	Phase 1	MDM inhibitor	NA	NA
CGP-12177	ADRB1	76962943	UMQUQWCJKFOUGV-SECBINFHSA-N	Phase 1	adrenergic receptor agonist	NA	NA
CGP-12177	ADRB2	76962943	UMQUQWCJKFOUGV-SECBINFHSA-N	Phase 1	adrenergic receptor agonist	NA	NA
CGP-12177	ADRB3	76962943	UMQUQWCJKFOUGV-SECBINFHSA-N	Phase 1	adrenergic receptor agonist	NA	NA
CGP-13501	GABBR1	3519541	XGWATTXMMMANFJ-UHFFFAOYSA-N	Preclinical	GABA receptor modulator	NA	NA
CGP-20712A	ADRB1	91667713	VFPOVCXWKBYDNF-XFULWGLBSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
CGP-20712A	ADRB3	91667713	VFPOVCXWKBYDNF-XFULWGLBSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
CGP-37157	SLC8A1	6604821	KQEPIRKXSUIUTH-HNNXBMFYSA-N	Preclinical	mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor	NA	NA
CGP-37849	GRIN2A	6604869	BDYHNCZIGYIOGJ-XWCPEMDWSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CGP-37849	GRIN2B	6604869	BDYHNCZIGYIOGJ-XWCPEMDWSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CGP-37849	GRIN2C	6604869	BDYHNCZIGYIOGJ-XWCPEMDWSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CGP-37849	GRIN2D	6604869	BDYHNCZIGYIOGJ-XWCPEMDWSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CGP-52411	EGFR	1697	AAALVYBICLMAMA-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
CGP-53353	EGFR	6711154	RONQPWQYDRPRGG-UHFFFAOYSA-N	Preclinical	EGFR inhibitor|PKC inhibitor	NA	NA
CGP-53353	PRKCB	6711154	RONQPWQYDRPRGG-UHFFFAOYSA-N	Preclinical	EGFR inhibitor|PKC inhibitor	NA	NA
CGP-54626	GABBR1	197584	JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-54626	GABBR2	197584	JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-54626	KCTD12	197584	JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-54626	KCTD16	197584	JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-54626	KCTD8	197584	JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-55845	GABBR1	5311042	ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-55845	GABBR2	5311042	ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-55845	KCTD12	5311042	ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-55845	KCTD16	5311042	ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-55845	KCTD8	5311042	ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGP-57380	AURKB	11644425	UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
CGP-57380	LCK	11644425	UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
CGP-57380	MKNK1	11644425	UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
CGP-57380	MKNK2	11644425	UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
CGP-57380	SGK1	11644425	UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
CGP-60474	CDK1	644215	IYNDTACKOAXKBJ-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
CGP-60474	CDK2	644215	IYNDTACKOAXKBJ-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
CGP-71683	NPY5R	NA	UULIGRNKXHCLQN-WGSAOQKQSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
CGP-74514	CDK1	2794188	UTBSBSOBZHXMHI-LSDHHAIUSA-N	Preclinical	CDK inhibitor	NA	NA
CGP-7930	GABBR1	5024764	XLWJPQQFJNGUPA-UHFFFAOYSA-N	Preclinical	GABA receptor modulator	NA	NA
CGS-15943	ADORA1	2690	MSJODEOZODDVGW-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
CGS-15943	ADORA2A	2690	MSJODEOZODDVGW-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
CGS-15943	ADORA2B	2690	MSJODEOZODDVGW-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
CGS-15943	ADORA3	2690	MSJODEOZODDVGW-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
CGS-20625	GABRA1	163844	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	NA	NA
CGS-20625	GABRA2	163844	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	NA	NA
CGS-20625	GABRA3	163844	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	NA	NA
CGS-20625	GABRA4	163844	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	NA	NA
CGS-20625	GABRA5	163844	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	NA	NA
CGS-20625	GABRA6	163844	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	NA	NA
CGS-21680	ADORA1	3086599	PAOANWZGLPPROA-RQXXJAGISA-N	Preclinical	adenosine receptor agonist	NA	NA
CGS-21680	ADORA2A	3086599	PAOANWZGLPPROA-RQXXJAGISA-N	Preclinical	adenosine receptor agonist	NA	NA
CGS-21680	ADORA2B	3086599	PAOANWZGLPPROA-RQXXJAGISA-N	Preclinical	adenosine receptor agonist	NA	NA
CGS-21680	ADORA3	3086599	PAOANWZGLPPROA-RQXXJAGISA-N	Preclinical	adenosine receptor agonist	NA	NA
CGS-9896	GABRA1	108030	QCBUAKLOWCOUCR-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGS-9896	GABRB2	108030	QCBUAKLOWCOUCR-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
CGS-9896	GABRG2	108030	QCBUAKLOWCOUCR-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
CH-5183284	FGFR1	66555680	BEMNJULZEQTDJY-UHFFFAOYSA-N	Phase 2	fibroblast growth factor inhibitor	NA	NA
CH-5183284	FGFR2	66555680	BEMNJULZEQTDJY-UHFFFAOYSA-N	Phase 2	fibroblast growth factor inhibitor	NA	NA
CH-5183284	FGFR3	66555680	BEMNJULZEQTDJY-UHFFFAOYSA-N	Phase 2	fibroblast growth factor inhibitor	NA	NA
CHC	SLC16A1	5328791	"InChI=1S/C10H7NO3/c11-6-8(10(13)14)5-7-1-3-9(12)4-2-7/h1-5,12H,(H,13,14)/b8-5+"	Preclinical	monocarboxylate transporter inhibitor	NA	NA
chenodeoxycholic-acid	HSD11B1	10133	RUDATBOHQWOJDD-BSWAIDMHSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist	cardiology|gastroenterology	cerebral cholesterosis|gallstones
chenodeoxycholic-acid	NR1H4	10133	RUDATBOHQWOJDD-BSWAIDMHSA-N	Launched	11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist	cardiology|gastroenterology	cerebral cholesterosis|gallstones
CHF5074	PSEN1	9996409	LIYLTQQDABRNRX-UHFFFAOYSA-N	Phase 2	gamma secretase modulator	NA	NA
chicago-sky-blue-6b	MIF	6817703	BGULJNMSWJQIEK-UHFFFAOYSA-N	Preclinical	glutamate inhibitor|macrophage migration inhibiting factor inhibitor	NA	NA
chidamide	HDAC10	9800555	WXHHICFWKXDFOW-BJMVGYQFSA-N	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
chidamide	HDAC3	9800555	WXHHICFWKXDFOW-BJMVGYQFSA-N	Launched	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
CHIR-124	CHEK1	135399748	MOVBBVMDHIRCTG-LJQANCHMSA-N	Preclinical	CHK inhibitor	NA	NA
CHIR-98014	GSK3A	53396311	MDZCSIDIPDZWKL-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
CHIR-98014	GSK3B	53396311	MDZCSIDIPDZWKL-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
CHIR-99021	CDK1	9956119	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
CHIR-99021	GSK3A	9956119	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
CHIR-99021	GSK3B	9956119	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
CHIR-99021	MAPK1	9956119	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
chloramphenicol	CD55	5959	WIIZWVCIJKGZOK-RKDXNWHRSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease|endocrinology	meningitis|fever|cholera
chlorisondamine-diiodide	CHRNA1	6244	IXWDUZLHWJKVPX-UHFFFAOYSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
chlormadinone-acetate	PGR	9324	QMBJSIBWORFWQT-DFXBJWIESA-N	Launched	5 alpha reductase inhibitor	endocrinology	hypermenorrhea|amenorrhea|oligomenorrhea|polymenorrhea
chlormezanone	GABRA1	6604211	WEQAYVWKMWHEJO-LLVKDONJSA-N	Withdrawn	GABA receptor modulator	NA	NA
chlorogenic-acid	SLC37A4	1794427	CWVRJTMFETXNAD-JUHZACGLSA-N	Launched	antioxidant	neurology/psychiatry|pulmonary|allergy	headache|chest congestion|allergic rhinitis
chloroprocaine	ATP1A1	8612	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
chloroprocaine	CHRNA10	8612	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
chloroprocaine	GRIN3A	8612	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
chloroprocaine	HTR3A	8612	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
chloroprocaine	SCN10A	8612	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
chloroprocaine	SLC6A3	8612	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
chloropyramine	HRH1	25295	ICKFFNBDFNZJSX-UHFFFAOYSA-N	Launched	histamine receptor antagonist	cardiology|ophthalmology|allergy|pulmonary	edema|conjunctivitis|allergic rhinitis|asthma
chloroquine	MRGPRX1	444810	WHTVZRBIWZFKQO-CQSZACIVSA-N	Launched	antimalarial agent	infectious disease	malaria|amebiasis
chlorothiazide	CA1	2720	JBMKAUGHUNFTOL-UHFFFAOYSA-N	Launched	diuretic	cardiology	hypertension
chlorothiazide	CA2	2720	JBMKAUGHUNFTOL-UHFFFAOYSA-N	Launched	diuretic	cardiology	hypertension
chlorothiazide	CA4	2720	JBMKAUGHUNFTOL-UHFFFAOYSA-N	Launched	diuretic	cardiology	hypertension
chlorothiazide	SLC12A3	2720	JBMKAUGHUNFTOL-UHFFFAOYSA-N	Launched	diuretic	cardiology	hypertension
chlorotrianisene	ESR1	11289	BFPSDSIWYFKGBC-UHFFFAOYSA-N	Launched	estrogenic hormone	endocrinology|oncology	menopause|prostate cancer
chlorotrianisene	ESR2	11289	BFPSDSIWYFKGBC-UHFFFAOYSA-N	Launched	estrogenic hormone	endocrinology|oncology	menopause|prostate cancer
chloroxine	OPRK1	2722	WDFKMLRRRCGAKS-UHFFFAOYSA-N	Launched	opioid receptor antagonist	gastroenterology|infectious disease|dermatology	diarrhea|inflammatory bowel disease|giardiasis|dandruff
chlorproguanil	DHFR	9571037	ISZNZKHCRKXXAU-UHFFFAOYSA-N	Launched	dihydrofolate reductase inhibitor	infectious disease	malaria
chlorpromazine	ADRA1A	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	ADRA1B	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	ADRA1D	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	ADRA2A	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	ADRA2B	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	ADRA2C	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	CALM1	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	CHRM1	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	CHRM3	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	DRD1	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	DRD2	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	DRD3	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	DRD4	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	DRD5	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HRH1	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HRH4	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HTR1A	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HTR2A	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HTR2B	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HTR2C	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HTR6	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	HTR7	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	KCNH2	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	ORM1	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	ORM2	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	SMPD1	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpromazine	TRPC5	2726	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
chlorpropamide	ABCC8	2727	RKWGIWYCVPQPMF-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
chlorpropamide	KCNJ10	2727	RKWGIWYCVPQPMF-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
chlorprothixene	CHRM1	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	CHRM2	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	CHRM3	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	CHRM4	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	CHRM5	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	DRD1	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	DRD2	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	DRD3	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	HRH1	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	HTR2A	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	HTR2B	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorprothixene	HTR2C	667467	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
chlorpyrifos	ACHE	2730	SBPBAQFWLVIOKP-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	NA	NA
chlorthalidone	CA1	688424	JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	carbonic anhydrase inhibitor	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
chlorthalidone	CA12	688424	JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	carbonic anhydrase inhibitor	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
chlorthalidone	CA14	688424	JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	carbonic anhydrase inhibitor	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
chlorthalidone	CA2	688424	JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	carbonic anhydrase inhibitor	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
chlorthalidone	CA4	688424	JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	carbonic anhydrase inhibitor	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
chlorthalidone	CA7	688424	JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	carbonic anhydrase inhibitor	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
chlorthalidone	SLC12A1	688424	JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	carbonic anhydrase inhibitor	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
chlorzoxazone	KCNMA1	2733	TZFWDZFKRBELIQ-UHFFFAOYSA-N	Launched	bacterial 30S ribosomal subunit inhibitor	neurology/psychiatry	muscle relaxant
chlorzoxazone	KCNN4	2733	TZFWDZFKRBELIQ-UHFFFAOYSA-N	Launched	bacterial 30S ribosomal subunit inhibitor	neurology/psychiatry	muscle relaxant
cholecalciferol	VDR	5280795	QYSXJUFSXHHAJI-YRZJJWOYSA-N	Launched		endocrinology	vitamin D deficiency
cholesterol	RORA	5997	HVYWMOMLDIMFJA-DPAQBDIFSA-N	Preclinical		NA	NA
cholic-acid	ADH1C	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	CES1	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX4I1	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX5A	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX5B	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX6A2	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX6B1	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX6C	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX7A1	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX7B	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX7C	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	COX8A	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	ESRRG	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	FABP6	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	FECH	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	GPBAR1	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	MT-CO1	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	MT-CO2	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	MT-CO3	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
cholic-acid	PLA2G1B	221493	BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
choline	ACHE	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
choline	BCHE	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
choline	CHRNA2	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
choline	PCYT1A	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
choline	PCYT1B	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
choline	PHOSPHO1	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
choline	PLD1	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
choline	PLD2	305	OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	acetylcholine precursor	NA	NA
CHPG	GRM5	6604802	UNIDAFCQFPGYJJ-SSDOTTSWSA-N	Preclinical	glutamate receptor agonist	NA	NA
CHR-6494	GSG2	70679308	CZZCAOGIEGXMBZ-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
chrysin	AKR1B1	5281607	RTIXKCRFFJGDFG-UHFFFAOYSA-N	Phase 1	breast cancer resistance protein inhibitor	NA	NA
chrysin	CDK6	5281607	RTIXKCRFFJGDFG-UHFFFAOYSA-N	Phase 1	breast cancer resistance protein inhibitor	NA	NA
chrysin	CYP19A1	5281607	RTIXKCRFFJGDFG-UHFFFAOYSA-N	Phase 1	breast cancer resistance protein inhibitor	NA	NA
chrysin	CYP1B1	5281607	RTIXKCRFFJGDFG-UHFFFAOYSA-N	Phase 1	breast cancer resistance protein inhibitor	NA	NA
chrysophanic-acid	EGFR	10208	LQGUBLBATBMXHT-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
chrysophanic-acid	MTOR	10208	LQGUBLBATBMXHT-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
CH223191	AHR	NA	LKTNEXPODAWWFM-GHVJWSGMSA-N	Preclinical	aryl hydrocarbon receptor antagonist	NA	NA
CH5132799	MTOR	49784945	JEGHXKRHKHPBJD-UHFFFAOYSA-N	Phase 1	PI3K inhibitor	NA	NA
CH5132799	PIK3CA	49784945	JEGHXKRHKHPBJD-UHFFFAOYSA-N	Phase 1	PI3K inhibitor	NA	NA
CH5132799	PIK3CB	49784945	JEGHXKRHKHPBJD-UHFFFAOYSA-N	Phase 1	PI3K inhibitor	NA	NA
CH5132799	PIK3CD	49784945	JEGHXKRHKHPBJD-UHFFFAOYSA-N	Phase 1	PI3K inhibitor	NA	NA
CH5132799	PIK3CG	49784945	JEGHXKRHKHPBJD-UHFFFAOYSA-N	Phase 1	PI3K inhibitor	NA	NA
CH55	RARA	6184667	FOUVTBKPJRMLPE-FMIVXFBMSA-N	Preclinical	retinoid receptor binder	NA	NA
CH55	RARB	6184667	FOUVTBKPJRMLPE-FMIVXFBMSA-N	Preclinical	retinoid receptor binder	NA	NA
CI-966	SLC6A1	198693	CMHQDSBIBSKHFP-UHFFFAOYSA-N	Phase 1	GAT inhibitor	NA	NA
CI-976	ACAT1	122327	WAFNZAURAWBNDZ-UHFFFAOYSA-N	Phase 1	ACAT inhibitor	NA	NA
CI-976	CES1	122327	WAFNZAURAWBNDZ-UHFFFAOYSA-N	Phase 1	ACAT inhibitor	NA	NA
cianidanol	PTGS1	9064	PFTAWBLQPZVEMU-DZGCQCFKSA-N	Withdrawn	fatty acid synthase inhibitor	NA	NA
ciclesonide	NR3C1	6918155	LUKZNWIVRBCLON-GXOBDPJESA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
ciclesonide	SERPINA6	6918155	LUKZNWIVRBCLON-GXOBDPJESA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
ciclopirox	ATP1A1	2749	SCKYRAXSEDYPSA-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	infectious disease	onychomycosis
cicloprofen	PTGS1	14694110	LRXFKKPEBXIPMW-SNVBAGLBSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
cicloprofen	PTGS2	14694110	LRXFKKPEBXIPMW-SNVBAGLBSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
CID-16020046	GPR55	51436118	VGUQVYZXABOXCX-QHCPKHFHSA-N	Preclinical	G protein-coupled receptor antagonist	NA	NA
CID-2011756	PKD1	2011756	XQJWTJLJEYIUDZ-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
CID-2745687	GPR35	9581011	CYNLZIBKERMMOA-AWQFTUOYSA-N	Preclinical	G protein-coupled receptor antagonist	NA	NA
CID-5458317	MAPK3	NA	BJJVCNWHNQAAGB-HMMYKYKNSA-N	Preclinical	MAP kinase phosphatase inhibitor	NA	NA
ciglitazone	PPARG	6604850	YZFWTZACSRHJQD-OAHLLOKOSA-N	Phase 2	PPAR receptor agonist	NA	NA
cilastatin	DPEP1	6435415	DHSUYTOATWAVLW-WFVMDLQDSA-N	Launched	dehydropeptidase inhibitor	NA	NA
cilazapril	ACE	56330	HHHKFGXWKKUNCY-FHWLQOOXSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|congestive heart failure
cilengitide	ITGAV	176873	AMLYAMJWYAIXIA-VWNVYAMZSA-N	Phase 3	integrin antagonist	NA	NA
cilengitide	ITGB3	176873	AMLYAMJWYAIXIA-VWNVYAMZSA-N	Phase 3	integrin antagonist	NA	NA
cilnidipine	CACNA1B	28248392	KJEBULYHNRNJTE-HGJFNOKFSA-N	Launched	calcium channel blocker	cardiology	hypertension
cilomilast	PDE4A	NA	CFBUZOUXXHZCFB-OYOVHJISSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
cilomilast	PDE4B	NA	CFBUZOUXXHZCFB-OYOVHJISSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
cilomilast	PDE4D	NA	CFBUZOUXXHZCFB-OYOVHJISSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
cilostamide	PDE3A	2753	UIAYVIIHMORPSJ-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
cilostamide	PDE3B	2753	UIAYVIIHMORPSJ-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
cilostazol	PDE3A	2754	RRGUKTPIGVIEKM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
cilostazol	PDE3B	2754	RRGUKTPIGVIEKM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
CIM-0216	TRPM3	25331887	KSEXDSJYVSEVGF-FQEVSTJZSA-N	Preclinical	transient receptor potential channel agonist	NA	NA
cimaterol	ADRB1	10911051	BUXRLJCGHZZYNE-GFCCVEGCSA-N	Preclinical	adrenergic receptor agonist	NA	NA
cimaterol	ADRB2	10911051	BUXRLJCGHZZYNE-GFCCVEGCSA-N	Preclinical	adrenergic receptor agonist	NA	NA
cimaterol	ADRB3	10911051	BUXRLJCGHZZYNE-GFCCVEGCSA-N	Preclinical	adrenergic receptor agonist	NA	NA
cimetidine	HRH2	2756	AQIXAKUUQRKLND-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma
cimetidine	SLC29A4	2756	AQIXAKUUQRKLND-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma
cimetidine	SLC47A1	2756	AQIXAKUUQRKLND-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma
cimetidine	SLC47A2	2756	AQIXAKUUQRKLND-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma
cimetropium	CHRM1	NA	QVVOZYKELHAIPX-IGDPVYPXSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
cinacalcet	CASR	156419	"InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1"	Launched	calcium channel activator	endocrinology|nephrology|oncology	hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia
cinaciguat	GUCY1A3	9808022	WPYWMXNXEZFMAK-UHFFFAOYSA-N	Phase 2	guanylate cyclase activator	NA	NA
cinaciguat	GUCY1B3	9808022	WPYWMXNXEZFMAK-UHFFFAOYSA-N	Phase 2	guanylate cyclase activator	NA	NA
cinalukast	CYSLTR1	6436135	BZMKNPGKXJAIDV-VAWYXSNFSA-N	Phase 2	leukotriene receptor antagonist	NA	NA
cinanserin	HTR2A	5475158	RSUVYMGADVXGOU-BUHFOSPRSA-N	Preclinical	serotonin receptor antagonist	NA	NA
cinchocaine	CALM1	3025	PUFQVTATUTYEAL-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
cinchocaine	SCN10A	3025	PUFQVTATUTYEAL-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
cinchocaine	SCN5A	3025	PUFQVTATUTYEAL-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
cinchonine	CYP2D6	90454	KMPWYEUPVWOPIM-QAMTZSDWSA-N	Preclinical	P glycoprotein inhibitor	NA	NA
cinnamaldehyde	TRPA1	637511	KJPRLNWUNMBNBZ-QPJJXVBHSA-N	Preclinical	aldose reductase inhibitor|TRPV agonist	NA	NA
CINPA-1	NR1H4	969470	AYQBYSPEGRYKFA-UHFFFAOYSA-N	Preclinical	CAR antagonist	NA	NA
CINPA-1	NR1I3	969470	AYQBYSPEGRYKFA-UHFFFAOYSA-N	Preclinical	CAR antagonist	NA	NA
CINPA-1	PPARG	969470	AYQBYSPEGRYKFA-UHFFFAOYSA-N	Preclinical	CAR antagonist	NA	NA
cipemastat	ADAM17	9824350	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	metalloproteinase inhibitor	NA	NA
cipemastat	MMP1	9824350	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	metalloproteinase inhibitor	NA	NA
cipemastat	MMP13	9824350	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	metalloproteinase inhibitor	NA	NA
cipemastat	MMP2	9824350	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	metalloproteinase inhibitor	NA	NA
cipemastat	MMP3	9824350	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	metalloproteinase inhibitor	NA	NA
cipemastat	MMP8	9824350	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	metalloproteinase inhibitor	NA	NA
cipemastat	MMP9	9824350	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	metalloproteinase inhibitor	NA	NA
ciprofibrate	PPARA	9882424	KPSRODZRAIWAKH-SNVBAGLBSA-N	Launched	PPAR receptor agonist	endocrinology	hyperlipidemia
ciprofloxacin	TOP2A	4011971	MYSWGUAQZAJSOK-UHFFFAOYSA-N	Launched	bacterial DNA gyrase inhibitor	otolaryngology	otitis
ciproxifan	ADRA2A	6422124	ACQBHJXEAYTHCY-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
ciproxifan	ADRA2C	6422124	ACQBHJXEAYTHCY-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
ciproxifan	HRH3	6422124	ACQBHJXEAYTHCY-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
ciproxifan	HRH4	6422124	ACQBHJXEAYTHCY-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
ciproxifan	HTR3A	6422124	ACQBHJXEAYTHCY-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
CIQ	GRIN2C	40450008	VYMILMYEENZHAR-HSZRJFAPSA-N	Preclinical	glutamate receptor potentiator	NA	NA
CIQ	GRIN2D	40450008	VYMILMYEENZHAR-HSZRJFAPSA-N	Preclinical	glutamate receptor potentiator	NA	NA
cirazoline	ADRA1A	2765	YAORIDZYZDUZCM-UHFFFAOYSA-N	Preclinical	adrenergic receptor agonist	NA	NA
cis-aconitic-acid	ACO2	643757	GTZCVFVGUGFEME-IWQZZHSRSA-N	Preclinical		NA	NA
cis-ACPD	GRM2	231345	YFYNOWXBIBKGHB-CLZZGJSISA-N	Preclinical	glutamate receptor agonist	NA	NA
cis-ACPD	GRM3	231345	YFYNOWXBIBKGHB-CLZZGJSISA-N	Preclinical	glutamate receptor agonist	NA	NA
cis-ACPD	GRM6	231345	YFYNOWXBIBKGHB-CLZZGJSISA-N	Preclinical	glutamate receptor agonist	NA	NA
cis-ACPD	GRM7	231345	YFYNOWXBIBKGHB-CLZZGJSISA-N	Preclinical	glutamate receptor agonist	NA	NA
cis-ACPD	GRM8	231345	YFYNOWXBIBKGHB-CLZZGJSISA-N	Preclinical	glutamate receptor agonist	NA	NA
"cis-exo-camphanediol-2,3"	NOS3	21626088	AYEOSGBMQHXVER-AZQAYCESSA-N	Phase 1	nitric oxide stimulant	NA	NA
cis-urocanic-acid	HTR2A	1549103	LOIYMIARKYCTBW-UPHRSURJSA-N	Phase 2	serotonin receptor agonist	NA	NA
cisapride	HTR2A	6917698	DCSUBABJRXZOMT-IRLDBZIGSA-N	Withdrawn	serotonin receptor agonist	NA	NA
cisapride	HTR3A	6917698	DCSUBABJRXZOMT-IRLDBZIGSA-N	Withdrawn	serotonin receptor agonist	NA	NA
cisapride	HTR4	6917698	DCSUBABJRXZOMT-IRLDBZIGSA-N	Withdrawn	serotonin receptor agonist	NA	NA
cisapride	KCNH2	6917698	DCSUBABJRXZOMT-IRLDBZIGSA-N	Withdrawn	serotonin receptor agonist	NA	NA
cisatracurium	CHRNA2	62887	YXSLJKQTIDHPOT-LJCJQEJUSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry|critical care	muscle relaxant|endotracheal intubation
cisplatin	XIAP	86820626	DQLATGHUWYMOKM-UHFFFAOYSA-L	Launched	DNA alkylating agent|DNA synthesis inhibitor	oncology	testicular carcinoma|ovarian cancer|bladder cancer
citalopram	ADRA1A	146570	WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression
citalopram	CHRM1	146570	WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression
citalopram	HRH1	146570	WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression
citalopram	SLC6A2	146570	WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression
citalopram	SLC6A3	146570	WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression
citalopram	SLC6A4	146570	WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression
CITCO	NR1I3	9600409	ZQWBOKJVVYNKTL-AUEPDCJTSA-N	Preclinical	constitutive androstane receptor (CAR) agonist	NA	NA
citicoline	ACHE	13805	RZZPDXZPRHQOCG-OJAKKHQRSA-O	Launched	glutathione transferase stimulant|membrane permeability enhancer	neurology/psychiatry|ophthalmology	stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma
citicoline	SLC1A2	13805	RZZPDXZPRHQOCG-OJAKKHQRSA-O	Launched	glutathione transferase stimulant|membrane permeability enhancer	neurology/psychiatry|ophthalmology	stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma
citric-acid	AKR1B1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	ANG	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	APRT	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	BHMT	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	C8G	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	CA4	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	CPB1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	CS	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	CTDSP1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	GNMT	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	HGS	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	HS3ST3A1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	IL4I1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	ITPA	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	LSM6	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	MDH2	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	MIF	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	PDE5A	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	PKD2L1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	PLEKHA1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	RNASE1	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	RNASE3	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	SRC	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	TNFSF13B	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
citric-acid	UCK2	88113319	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	coagulation factor inhibitor	NA	NA
CJ-033466	HTR4	10429706	ISKHMDNIWXPUGR-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
CK-636	ACTR2	588963	ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	actin related protein inhibitor	NA	NA
CK-636	ACTR3	588963	ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	actin related protein inhibitor	NA	NA
CK-636	ARPC1B	588963	ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	actin related protein inhibitor	NA	NA
CK-636	ARPC2	588963	ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	actin related protein inhibitor	NA	NA
CK-636	ARPC3	588963	ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	actin related protein inhibitor	NA	NA
CK-636	ARPC4	588963	ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	actin related protein inhibitor	NA	NA
CK-636	ARPC5	588963	ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	actin related protein inhibitor	NA	NA
CKD-712	JAK2	9861304	YGCQFKVNIBDJFW-SFHVURJKSA-N	Phase 1	NFkB pathway inhibitor	NA	NA
CKD-712	STAT1	9861304	YGCQFKVNIBDJFW-SFHVURJKSA-N	Phase 1	NFkB pathway inhibitor	NA	NA
CKI-7	CSNK1G2	129236	OGKYMFFYOWUTKV-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
CL-218872	GABRA1	107950	GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
CL-218872	GABRA2	107950	GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
CL-218872	GABRA3	107950	GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
CL-218872	GABRA5	107950	GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
CL-218872	GABRB2	107950	GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
CL-218872	GABRG2	107950	GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
cladribine	ADA	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	PNP	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	POLA1	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	POLE	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	POLE2	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	POLE3	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	POLE4	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	RRM1	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	RRM2	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
cladribine	RRM2B	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
clarithromycin	CYP3A4		AGOYDEPGAOXOCK-AAFHZFQRSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	otolaryngology|pulmonary|infectious disease	pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis
clebopride	ACHE	2780	BVPWJMCABCPUQY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea
clebopride	DRD2	2780	BVPWJMCABCPUQY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea
clemastine	HRH1	26987	YNNUSGIPVFPVBX-NHCUHLMSSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis|urticaria
clenbuterol	ABCC8	688428	STJMRWALKKWQGH-SNVBAGLBSA-N	Launched	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)|asthma
clenbuterol	ADRB2	688428	STJMRWALKKWQGH-SNVBAGLBSA-N	Launched	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)|asthma
clenbuterol	KCNJ11	688428	STJMRWALKKWQGH-SNVBAGLBSA-N	Launched	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)|asthma
cleviprex	CACNA1C	22884799	KPBZROQVTHLCDU-SFHVURJKSA-N	Launched	calcium channel blocker	cardiology	hypertension
cleviprex	CACNA1D	22884799	KPBZROQVTHLCDU-SFHVURJKSA-N	Launched	calcium channel blocker	cardiology	hypertension
cleviprex	CACNA1F	22884799	KPBZROQVTHLCDU-SFHVURJKSA-N	Launched	calcium channel blocker	cardiology	hypertension
cleviprex	CACNA1S	22884799	KPBZROQVTHLCDU-SFHVURJKSA-N	Launched	calcium channel blocker	cardiology	hypertension
clidinium	CHRM1	24867263	HOOSGZJRQIVJSZ-WEQDKIBNSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis
clidinium	CHRM3	24867263	HOOSGZJRQIVJSZ-WEQDKIBNSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis
clinofibrate	LPL	NA	BMOVQUBVGICXQN-AVJYQCBHSA-N	Launched	lipase clearing factor inhibitor	endocrinology	hypertriglyceridemia
clioquinol	OPRK1	2788	QCDFBFJGMNKBDO-UHFFFAOYSA-N	Withdrawn	chelating agent	NA	NA
clobenpropit	HRH1	2790	UCAIEVHKDLMIFL-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
clobenpropit	HRH2	2790	UCAIEVHKDLMIFL-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
clobenpropit	HRH3	2790	UCAIEVHKDLMIFL-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
clobenpropit	HRH4	2790	UCAIEVHKDLMIFL-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
clobetasol-propionate	NR3C1	32798	CBGUOGMQLZIXBE-XGQKBEPLSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
clobetasol-propionate	PLA2G1B	32798	CBGUOGMQLZIXBE-XGQKBEPLSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
clobetasone-butyrate	NR3C1	71386	FBRAWBYQGRLCEK-AVVSTMBFSA-N	Launched	corticosteroid agonist	dermatology	eczema|psoriasis|dermatitis
clocortolone-pivalate	NR3C1	5282493	SXYZQZLHAIHKKY-GSTUPEFVSA-N	Launched	steroid	dermatology	corticosteroid-responsive dermatoses
clocortolone-pivalate	PLA2G1B	5282493	SXYZQZLHAIHKKY-GSTUPEFVSA-N	Launched	steroid	dermatology	corticosteroid-responsive dermatoses
clodronic-acid	SLC25A4	25419	ACSIXWWBWUQEHA-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics|endocrinology|hematologic malignancy	osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma
clodronic-acid	SLC25A5	25419	ACSIXWWBWUQEHA-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics|endocrinology|hematologic malignancy	osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma
clodronic-acid	SLC25A6	25419	ACSIXWWBWUQEHA-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics|endocrinology|hematologic malignancy	osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma
clofarabine	POLA1	119182	WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
clofarabine	POLD1	119182	WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
clofarabine	POLE	119182	WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
clofarabine	RRM1	119182	WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
clofarabine	RRM2	119182	WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
clofarabine	RRM2B	119182	WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
clofedanol	HRH1	688422	WRCHFMBCVFFYEQ-QGZVFWFLSA-N	Launched	histamine receptor antagonist	pulmonary	cough suppressant
clofibrate	LPL	2796	KNHUKKLJHYUCFP-UHFFFAOYSA-N	Launched	PPAR receptor agonist	endocrinology|cardiology	hyperlipidemia|cholesterol
clofibrate	PPARA	2796	KNHUKKLJHYUCFP-UHFFFAOYSA-N	Launched	PPAR receptor agonist	endocrinology|cardiology	hyperlipidemia|cholesterol
clofibric-acid	PPARA	2797	TXCGAZHTZHNUAI-UHFFFAOYSA-N	Launched	PPAR receptor agonist	endocrinology	hyperlipidemia
clofilium	KCNA5	2798	WPSYTTKBGAZSCX-UHFFFAOYSA-N	Phase 2	potassium channel blocker	NA	NA
clofilium	KCNH1	2798	WPSYTTKBGAZSCX-UHFFFAOYSA-N	Phase 2	potassium channel blocker	NA	NA
clomethiazole	GABRA1	10783	PCLITLDOTJTVDJ-UHFFFAOYSA-N	Launched	GABA receptor antagonist|GABA receptor modulator	neurology/psychiatry	Parkinson's Disease|sedative|muscle relaxant
clomifene	ESR1	1548955	GKIRPKYJQBWNGO-QPLCGJKRSA-N	Launched	estrogen receptor antagonist	obstetrics/gynecology	infertility
clomipramine	GSTP1	2801	GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clomipramine	HTR2A	2801	GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clomipramine	HTR2B	2801	GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clomipramine	HTR2C	2801	GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clomipramine	SLC6A2	2801	GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clomipramine	SLC6A3	2801	GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clomipramine	SLC6A4	2801	GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clonidine	ADRA1A	2803	GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)
clonidine	ADRA1B	2803	GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)
clonidine	ADRA1D	2803	GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)
clonidine	ADRA2A	2803	GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)
clonidine	ADRA2B	2803	GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)
clonidine	ADRA2C	2803	GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)
clonixin	PTGS1	28718	CLOMYZFHNHFSIQ-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	rheumatology|infectious disease	rheumatoid arthritis|soft tissue infection
clonixin	PTGS2	28718	CLOMYZFHNHFSIQ-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	rheumatology|infectious disease	rheumatoid arthritis|soft tissue infection
clopidogrel	P2RY12	60606	GKTWGGQPFAXNFI-HNNXBMFYSA-N	Launched	purinergic receptor antagonist	cardiology|neurology/psychiatry	myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS)
cloprostenol-(+/-)	PTGDR	5311053	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched	prostaglandin receptor agonist	obstetrics/gynecology	endometriosis
cloprostenol-(+/-)	PTGER1	5311053	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched	prostaglandin receptor agonist	obstetrics/gynecology	endometriosis
cloprostenol-(+/-)	PTGER3	5311053	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched	prostaglandin receptor agonist	obstetrics/gynecology	endometriosis
cloprostenol-(+/-)	PTGFR	5311053	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched	prostaglandin receptor agonist	obstetrics/gynecology	endometriosis
cloprostenol-(+/-)	TBXA2R	5311053	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched	prostaglandin receptor agonist	obstetrics/gynecology	endometriosis
cloranolol	ADRB1	76964677	XYCMOTOFHFTUIU-SNVBAGLBSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
cloranolol	ADRB2	76964677	XYCMOTOFHFTUIU-SNVBAGLBSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
cloranolol	ADRB3	76964677	XYCMOTOFHFTUIU-SNVBAGLBSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
clorgiline	MAOA	4380	BTFHLQRNAMSNLC-UHFFFAOYSA-N	Phase 2	monoamine oxidase inhibitor	NA	NA
clorotepine	ADRA1A	12765746	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	neurology/psychiatry	psychosis
clorotepine	ADRA1B	12765746	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	neurology/psychiatry	psychosis
clorotepine	ADRA1D	12765746	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	neurology/psychiatry	psychosis
clorotepine	DRD2	12765746	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	neurology/psychiatry	psychosis
clorotepine	HRH1	12765746	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	neurology/psychiatry	psychosis
clorotepine	HTR2C	12765746	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	neurology/psychiatry	psychosis
clorotepine	HTR6	12765746	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	neurology/psychiatry	psychosis
clorprenaline	ADRB1	12463921	SSMSBSWKLKKXGG-LLVKDONJSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
clorprenaline	ADRB2	12463921	SSMSBSWKLKKXGG-LLVKDONJSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
clotrimazole	CYP3A4	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis
clotrimazole	KCNN4	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis
clotrimazole	NR1I2	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis
clotrimazole	NR1I3	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis
clotrimazole	TRPM2	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis
clotrimazole	TRPM4	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis
clotrimazole	TRPM8	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis
cloxyquin	KCNK18	2817	CTQMJYWDVABFRZ-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
clozapine	ADRA1A	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	ADRA1B	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	ADRA1D	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	ADRA2A	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	ADRA2B	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	ADRA2C	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	CALY	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	CHRM1	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	CHRM2	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	CHRM3	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	CHRM4	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	CHRM5	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	DRD1	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	DRD2	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	DRD3	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	DRD4	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	DRD5	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HRH1	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HRH4	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR1A	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR1B	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR1D	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR1E	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR1F	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR2A	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR2B	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR2C	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR3A	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR5A	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR6	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
clozapine	HTR7	135398737	QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
CL316243	ADRB3	5486546	JEDJMKTVUPSHFW-ABAIWWIYSA-N	Phase 2	adrenergic receptor agonist	NA	NA
CL316243	UCP1	5486546	JEDJMKTVUPSHFW-ABAIWWIYSA-N	Phase 2	adrenergic receptor agonist	NA	NA
CL316243	UCP2	5486546	JEDJMKTVUPSHFW-ABAIWWIYSA-N	Phase 2	adrenergic receptor agonist	NA	NA
CL316243	UCP3	5486546	JEDJMKTVUPSHFW-ABAIWWIYSA-N	Phase 2	adrenergic receptor agonist	NA	NA
CMPD-1	GNRHR	11382492	ODYAQBDIXCVKAE-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
CMPD-1	MAPK14	11382492	ODYAQBDIXCVKAE-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
CNQX	GRIA1	3721046	RPXVIAFEQBNEAX-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CNQX	GRIA2	3721046	RPXVIAFEQBNEAX-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CNQX	GRIA3	3721046	RPXVIAFEQBNEAX-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CNQX	GRIA4	3721046	RPXVIAFEQBNEAX-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
CNX-2006	EGFR	56968072	BFSRTTWIPACGMI-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
CNX-774	BTK	59174579	VVLHQJDAUIPZFH-UHFFFAOYSA-N	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
CO-101244	GRIN2B	6918409	VKMFDKYCIKEDMR-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
CO-102862	SCN4A	9816959	MHUUDVZSPFRUSK-RQZCQDPDSA-N	Phase 1	sodium channel blocker	NA	NA
CO-102862	SCN9A	9816959	MHUUDVZSPFRUSK-RQZCQDPDSA-N	Phase 1	sodium channel blocker	NA	NA
cobicistat	CYP3A4	25151504	ZCIGNRJZKPOIKD-CQXVEOKZSA-N	Launched	cytochrome P450 inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
cobicistat	CYP3A43	25151504	ZCIGNRJZKPOIKD-CQXVEOKZSA-N	Launched	cytochrome P450 inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
cobicistat	CYP3A5	25151504	ZCIGNRJZKPOIKD-CQXVEOKZSA-N	Launched	cytochrome P450 inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
cobicistat	CYP3A7	25151504	ZCIGNRJZKPOIKD-CQXVEOKZSA-N	Launched	cytochrome P450 inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
cobimetinib	MAP2K1	16222096	BSMCAPRUBJMWDF-KRWDZBQOSA-N	Launched	MEK inhibitor	oncology	melanoma
coenzyme-A	ACAT2	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-A	CRAT	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-A	CS	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-A	DBI	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-A	HMGCR	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-A	KAT2A	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-A	KAT2B	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-A	KAT5	87642	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched		NA	NA
coenzyme-I	AASS	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ACADS	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ADH1A	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ADH1B	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ADH1C	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ADH4	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ADH5	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ADH7	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	AKR1B1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	AKR1C1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	AKR1C2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	AKR1C3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	AKR1C4	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH1A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH1A2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH1A3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH1B1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH3A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH3A2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH3B1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH3B2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH4A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH5A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH6A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH7A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ALDH9A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	AMT	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	BDH1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	BLVRA	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	BLVRB	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	CDO1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	CYB5R3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	CYP17A1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	CYP4A11	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	DHCR7	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	DHFR	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	DLAT	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	DLD	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	EHHADH	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	GAPDH	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	GAPDHS	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	GLUD1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	GLUD2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	GPD1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	GSR	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	H6PD	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HADH	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HADHA	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HIBADH	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HMGCR	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HMOX1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HMOX2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HPGD	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD11B1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD11B2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD17B1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD17B10	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD17B2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD17B3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD17B4	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD17B7	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD17B8	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD3B1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	HSD3B2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	IDH3A	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	IDH3B	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	IDH3G	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	IMPDH1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	IMPDH2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	LDHA	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	LDHAL6A	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	LDHAL6B	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	LDHB	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	LDHC	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MDH1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MDH2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ME1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ME2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	ME3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MSMO1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MT-ND1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MT-ND2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MT-ND3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MT-ND4	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MT-ND4L	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MT-ND5	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MT-ND6	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MTHFD1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	MTHFD2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA10	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA11	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA12	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA13	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA4	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA4L2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA5	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA6	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA7	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA8	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFA9	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFAB1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB10	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB4	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB5	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB6	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB7	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB8	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFB9	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFC1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFC2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS4	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS5	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS6	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS7	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFS8	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFV1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFV2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NDUFV3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NNT	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NQO2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	NSDHL	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	OGDH	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	PDHA1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	PDHA2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	PDHB	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	PHGDH	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	PYCR1	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	PYCR2	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	QDPR	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	RDH5	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	SORD	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	TSTA3	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	TYR	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
coenzyme-I	UGDH	439153	BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2		NA	NA
colchicine	GLRA1	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	GLRA2	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBA1A	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBA1B	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBA1C	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBA3C	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBA3D	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBA3E	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBA4A	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB1	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB2A	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB2B	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB3	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB4A	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB4B	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB6	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colchicine	TUBB8	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	microtubule inhibitor	rheumatology|endocrinology	gout|fever
colforsin	ADCY2	47936	OHCQJHSOBUTRHG-KGGHGJDLSA-N	Phase 2	adenylyl cyclase activator	NA	NA
colforsin	ADCY5	47936	OHCQJHSOBUTRHG-KGGHGJDLSA-N	Phase 2	adenylyl cyclase activator	NA	NA
compound-w	BACE1	16760376	JOSXKPZXMVHRKU-UHFFFAOYSA-N	Preclinical	beta-secretase inhibitor	NA	NA
compound-401	MTOR	10039361	BVRDQVRQVGRNHG-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor	NA	NA
compound-401	PRKDC	10039361	BVRDQVRQVGRNHG-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor	NA	NA
conivaptan	AVPR1A	151171	IKENVDNFQMCRTR-UHFFFAOYSA-N	Launched	vasopressin receptor antagonist	endocrinology	hyponatremia
conivaptan	AVPR2	151171	IKENVDNFQMCRTR-UHFFFAOYSA-N	Launched	vasopressin receptor antagonist	endocrinology	hyponatremia
copanlisib	PIK3CA	NA	PZBCKZWLPGJMAO-UHFFFAOYSA-N	Launched	PI3K inhibitor	hematologic malignancy	follicular lymphoma
copanlisib	PIK3CB	NA	PZBCKZWLPGJMAO-UHFFFAOYSA-N	Launched	PI3K inhibitor	hematologic malignancy	follicular lymphoma
copanlisib	PIK3CD	NA	PZBCKZWLPGJMAO-UHFFFAOYSA-N	Launched	PI3K inhibitor	hematologic malignancy	follicular lymphoma
copanlisib	PIK3CG	NA	PZBCKZWLPGJMAO-UHFFFAOYSA-N	Launched	PI3K inhibitor	hematologic malignancy	follicular lymphoma
copper-histidine	SLC15A3	71083	HNDVDQJCIGZPNO-RXMQYKEDSA-N	Phase 3		NA	NA
copper-histidine	SLC15A4	71083	HNDVDQJCIGZPNO-RXMQYKEDSA-N	Phase 3		NA	NA
copper-histidine	SLC38A5	71083	HNDVDQJCIGZPNO-RXMQYKEDSA-N	Phase 3		NA	NA
COR-170	CNR2	25033736	MSJISJDTJJYBFT-UHFFFAOYSA-N	Preclinical	cannabinoid receptor inverse agonist	NA	NA
corosolic-acid	HSD11B1	6918774	HFGSQOYIOKBQOW-ZSDYHTTISA-N	Phase 2	PKC inhibitor|protein tyrosine kinase inhibitor	NA	NA
corosolic-acid	PTPN1	6918774	HFGSQOYIOKBQOW-ZSDYHTTISA-N	Phase 2	PKC inhibitor|protein tyrosine kinase inhibitor	NA	NA
corticosterone	HSD11B1	5753	OMFXVFTZEKFJBZ-HJTSIMOOSA-N	Preclinical	mineralocorticoid receptor agonist	NA	NA
corticosterone	NCOA1	5753	OMFXVFTZEKFJBZ-HJTSIMOOSA-N	Preclinical	mineralocorticoid receptor agonist	NA	NA
corticosterone	NR3C2	5753	OMFXVFTZEKFJBZ-HJTSIMOOSA-N	Preclinical	mineralocorticoid receptor agonist	NA	NA
cortisone	NR3C1	222786	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	Launched	glucocorticoid receptor agonist	gastroenterology|rheumatology|dermatology	ulcerative colitis|rheumatoid arthritis|psoriasis|joint inflammation|eczema
cortisone-acetate	NR3C1	5745	ITRJWOMZKQRYTA-RFZYENFJSA-N	Launched	glucocorticoid receptor agonist	pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease	asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis
cortodoxone	AR	440707	WHBHBVVOGNECLV-OBQKJFGGSA-N	Phase 3	androgen receptor antagonist	NA	NA
cot-inhibitor-1	MAP3K8	11584834	ZWFKJFUFYPOTKL-UHFFFAOYSA-N	Preclinical	MAPK-interacting kinase inhibitor	NA	NA
cot-inhibitor-2	MAP3K8	44143370	PHNZIIMWDVXPGG-UHFFFAOYSA-N	Preclinical	MAPK-interacting kinase inhibitor	NA	NA
coumarin	CA1	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
coumarin	CA12	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
coumarin	CA14	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
coumarin	CA2	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
coumarin	CA4	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
coumarin	CA6	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
coumarin	CA9	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
coumarin	CYP2A6	323	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	vitamin K antagonist	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease
CP-316819	PYGL	10273347	WEQLRDLTRCEUHG-PKOBYXMFSA-N	Preclinical	glycogen phosphorylase inhibitor	NA	NA
CP-339818	KCNA3	NA	MMGAVKCAGQCFHS-LSDHQDQOSA-N	Preclinical	potassium channel blocker	NA	NA
CP-376395	CRHR1	9862166	VIZBSVDBNLAVAW-UHFFFAOYSA-N	Phase 1	corticotropin releasing factor receptor antagonist	NA	NA
CP-471474	MMP1	9907286	QCOQJYRPDUMCNP-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
CP-471474	MMP13	9907286	QCOQJYRPDUMCNP-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
CP-471474	MMP2	9907286	QCOQJYRPDUMCNP-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
CP-471474	MMP3	9907286	QCOQJYRPDUMCNP-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
CP-471474	MMP9	9907286	QCOQJYRPDUMCNP-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
CP-532623	CETP	10145345	TUPKOWFPVAXQFP-OFNKIYASSA-N	Phase 1	cholesteryl ester transfer protein inhibitor	NA	NA
CP-640186	ACACA	449097	LDQKDRLEMKIYMC-XMMPIXPASA-N	Preclinical	acetyl-CoA carboxylase inhibitor	NA	NA
CP-640186	ACACB	449097	LDQKDRLEMKIYMC-XMMPIXPASA-N	Preclinical	acetyl-CoA carboxylase inhibitor	NA	NA
CP-673451	KIT	10158940	DEEOXSOLTLIWMG-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
CP-673451	PDGFRA	10158940	DEEOXSOLTLIWMG-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
CP-673451	PDGFRB	10158940	DEEOXSOLTLIWMG-UHFFFAOYSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
CP-724714	ERBB2	9874913	LLVZBTWPGQVVLW-SNAWJCMRSA-N	Phase 2	EGFR inhibitor|protein tyrosine kinase inhibitor	NA	NA
CP-775146	PPARA	10410059	OISHBINQIFNIPV-JOCHJYFZSA-N	Preclinical	PPAR receptor agonist	NA	NA
CP-91149	PYGL	9843900	HINJNZFCMLSBCI-PKOBYXMFSA-N	Preclinical	glycogen phosphorylase inhibitor	NA	NA
CP-93129	HTR1A	124007	PJYVGMRFPFNZCT-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
CP-94253	HTR1B	4029677	KWQWBZIGHIOKIO-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
"CP-945,598"	CNR1	10052040	UNAZAADNBYXMIV-UHFFFAOYSA-N	Phase 3	cannabinoid receptor antagonist	NA	NA
CP-99994	TACR1	5311057	DTQNEFOKTXXQKV-HKUYNNGSSA-N	Phase 2	tachykinin antagonist	NA	NA
CPA-inhibitor	CPA1	124386386	PONANXDRJJIGPG-MRXNPFEDSA-N	Preclinical	carboxypeptidase inhibitor	NA	NA
CPA-inhibitor	CPA2	124386386	PONANXDRJJIGPG-MRXNPFEDSA-N	Preclinical	carboxypeptidase inhibitor	NA	NA
CPCCOEt	GRM1	10106002	FXCTZFMSAHZQTR-PFJVYOFESA-N	Preclinical	glutamate receptor antagonist	NA	NA
CPI-0610	BRD4	57389999	GCWIQUVXWZWCLE-INIZCTEOSA-N	Phase 2	bromodomain inhibitor	NA	NA
CPI-1189	TNF	151118	DJKNRCWSXSZACF-UHFFFAOYSA-N	Phase 2	tumor necrosis factor release inhibitor	NA	NA
CPI-169	EZH2	71712226	LHGUZCKPFXXVPV-GOSISDBHSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
CPI-203	BRD4	71291068	QECMENZMDBOLDR-AWEZNQCLSA-N	Preclinical	bromodomain inhibitor	NA	NA
CPI-360	EZH2	73442743	PFPSFENQCNMITC-MRXNPFEDSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
CPI-613	PDHA1	70881528	ZYRLHJIMTROTBO-NRFANRHFSA-N	Phase 3	pyruvate dehydrogenase inhibitor	NA	NA
CPP	GRIN1	6603754	CUVGUPIVTLGRGI-SSDOTTSWSA-N	Phase 2	glutamate receptor antagonist	NA	NA
CPP	GRIN2A	6603754	CUVGUPIVTLGRGI-SSDOTTSWSA-N	Phase 2	glutamate receptor antagonist	NA	NA
CPP	GRIN2B	6603754	CUVGUPIVTLGRGI-SSDOTTSWSA-N	Phase 2	glutamate receptor antagonist	NA	NA
CPP	GRIN2C	6603754	CUVGUPIVTLGRGI-SSDOTTSWSA-N	Phase 2	glutamate receptor antagonist	NA	NA
CPP	GRIN2D	6603754	CUVGUPIVTLGRGI-SSDOTTSWSA-N	Phase 2	glutamate receptor antagonist	NA	NA
CPSI-1306-(+/-)	MIF	52936269	GUWOSEVHCSNYFK-LLVKDONJSA-N	Preclinical	macrophage migration inhibiting factor inhibitor	NA	NA
creatine	CKB	586	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched		NA	NA
creatine	CKM	586	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched		NA	NA
creatine	CKMT1A	586	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched		NA	NA
creatine	CKMT2	586	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched		NA	NA
creatine	GAMT	586	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched		NA	NA
creatine	SLC6A8	586	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched		NA	NA
crenolanib	CSF1R	10366136	DYNHJHQFHQTFTP-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor	NA	NA
crenolanib	FLT3	10366136	DYNHJHQFHQTFTP-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor	NA	NA
crenolanib	KIT	10366136	DYNHJHQFHQTFTP-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor	NA	NA
crenolanib	PDGFRA	10366136	DYNHJHQFHQTFTP-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor	NA	NA
crenolanib	PDGFRB	10366136	DYNHJHQFHQTFTP-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor	NA	NA
cridanimod	PGR	38072	UOMKBIIXHQIERR-UHFFFAOYSA-N	Launched	progesterone receptor agonist	infectious disease	influenza A virus infection
crisaborole	PDE4A	44591583	USZAGAREISWJDP-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	dermatitis
crisaborole	PDE4B	44591583	USZAGAREISWJDP-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	dermatitis
crisaborole	PDE4C	44591583	USZAGAREISWJDP-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	dermatitis
crisaborole	PDE4D	44591583	USZAGAREISWJDP-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	dermatitis
crizotinib	ALK	11626560	KTEIFNKAUNYNJU-GFCCVEGCSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
crizotinib	MET	11626560	KTEIFNKAUNYNJU-GFCCVEGCSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
crizotinib-(S)	NUDT1	56671814	KTEIFNKAUNYNJU-LBPRGKRZSA-N	Preclinical	MTH1 inhibitor	NA	NA
cromakalim	KCNJ8	76968376	BVMDRSUIADWFLV-PNSAJKJISA-N	Phase 2		NA	NA
cromoglicic-acid	KCNMA1	2882	IMZMKUWMOSJXDT-UHFFFAOYSA-N	Launched	immunosuppressant	pulmonary|ophthalmology|allergy|gastroenterology	asthma|conjunctivitis|urticaria|ulcerative colitis
cromoglicic-acid	S100P	2882	IMZMKUWMOSJXDT-UHFFFAOYSA-N	Launched	immunosuppressant	pulmonary|ophthalmology|allergy|gastroenterology	asthma|conjunctivitis|urticaria|ulcerative colitis
cryptotanshinone	STAT3	160254	GVKKJJOMQCNPGB-JTQLQIEISA-N	Preclinical	acetylcholinesterase inhibitor|STAT inhibitor	NA	NA
CR8-(R)	CCNA2	10224714	HOCBJBNQIQQQGT-LJQANCHMSA-N	Preclinical	CDK inhibitor	NA	NA
CS-110266	SLC6A3	123692	RGSVXQJPSWZXOP-UHFFFAOYSA-N	Preclinical	dopamine receptor agonist	NA	NA
CS-917	FBP1	11289630	XJMYIJPPDSZOPN-UHFFFAOYSA-N	Phase 2	fructose biphosphate inhibitor	NA	NA
CT-7758	ITGA4	10186367	KYHVWHYLKOHLKA-FQEVSTJZSA-N	Phase 2	integrin antagonist	NA	NA
CTEP	GRM5	11646823	GOHCTCOGYKAJLZ-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
CTS-1027	MMP1	3342298	ROSNVSQTEGHUKU-UHFFFAOYSA-N	Phase 2	metalloproteinase inhibitor	NA	NA
CTS-1027	MMP13	3342298	ROSNVSQTEGHUKU-UHFFFAOYSA-N	Phase 2	metalloproteinase inhibitor	NA	NA
CTS-1027	MMP2	3342298	ROSNVSQTEGHUKU-UHFFFAOYSA-N	Phase 2	metalloproteinase inhibitor	NA	NA
CTS-1027	MMP3	3342298	ROSNVSQTEGHUKU-UHFFFAOYSA-N	Phase 2	metalloproteinase inhibitor	NA	NA
CTS-1027	MMP9	3342298	ROSNVSQTEGHUKU-UHFFFAOYSA-N	Phase 2	metalloproteinase inhibitor	NA	NA
CTS21166	BACE1	445649	NIOCOJFPGCXNKL-ZKZXETMPSA-N	Phase 1	beta-secretase inhibitor	NA	NA
CU-CPT-4a	TLR3	53242268	IAASQMCXDRISAV-CYBMUJFWSA-N	Preclinical	toll-like receptor inhibitor	NA	NA
CU-T12-9	TLR1	91826088	LITXVDAFEYLWQE-UHFFFAOYSA-N	Preclinical	toll-like receptor agonist	NA	NA
CU-T12-9	TLR2	91826088	LITXVDAFEYLWQE-UHFFFAOYSA-N	Preclinical	toll-like receptor agonist	NA	NA
CUDC-101	EGFR	24756910	PLIVFNIUGLLCEK-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
CUDC-101	ERBB2	24756910	PLIVFNIUGLLCEK-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
CUDC-427	XIAP	71600094	HSHPBORBOJIXSQ-HARLFGEKSA-N	Phase 1	apoptosis inhibitor	NA	NA
CUDC-907	HDAC2	54575456	JOWXJLIFIIOYMS-UHFFFAOYSA-N	Phase 2	PI3K inhibitor	NA	NA
CUDC-907	PIK3R1	54575456	JOWXJLIFIIOYMS-UHFFFAOYSA-N	Phase 2	PI3K inhibitor	NA	NA
CUR-61414	DHH	10392802	WPHXYKUPFJRJDK-AHWVRZQESA-N	Phase 1	smoothened receptor antagonist	NA	NA
CUR-61414	IHH	10392802	WPHXYKUPFJRJDK-AHWVRZQESA-N	Phase 1	smoothened receptor antagonist	NA	NA
CUR-61414	SMO	10392802	WPHXYKUPFJRJDK-AHWVRZQESA-N	Phase 1	smoothened receptor antagonist	NA	NA
curcumin	APP	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CA1	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CA12	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CA14	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CA2	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CA4	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CA6	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CA9	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CHRM3	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	CYP3A4	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	DNMT3B	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	EP300	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	MMP13	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	MMP9	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	NOS2	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	PTGS1	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	PTGS2	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumin	XDH	6971205	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	NA	NA
curcumol	JAK1	14240392	QRMPRVXWPCLVNI-YYFQZIEXSA-N	Phase 1	JAK inhibitor	NA	NA
curcumol	JAK2	14240392	QRMPRVXWPCLVNI-YYFQZIEXSA-N	Phase 1	JAK inhibitor	NA	NA
curcumol	JAK3	14240392	QRMPRVXWPCLVNI-YYFQZIEXSA-N	Phase 1	JAK inhibitor	NA	NA
cutamesine	SIGMAR1	9907323	UVSWWUWQVAQPJR-UHFFFAOYSA-N	Phase 2	sigma receptor agonist	NA	NA
CV-1808	ADORA2A	6917803	SCNILGOVBBRMBK-SDBHATRESA-N	Preclinical	adenosine receptor agonist	NA	NA
CVT-10216	ALDH2	23661666	YYOOFJZTRCPVFD-UHFFFAOYSA-N	Phase 1	aldehyde dehydrogenase inhibitor	NA	NA
CW-008	PRKACA	59528098	KCIMKTNQCUDTFI-UHFFFAOYSA-N	Preclinical	PKA activator	NA	NA
CX-4945	CSNK2A1	24748573	MUOKSQABCJCOPU-UHFFFAOYSA-N	Phase 1/Phase 2	casein kinase inhibitor	NA	NA
CX-4945	CSNK2A2	24748573	MUOKSQABCJCOPU-UHFFFAOYSA-N	Phase 1/Phase 2	casein kinase inhibitor	NA	NA
CX-4945	DAPK3	24748573	MUOKSQABCJCOPU-UHFFFAOYSA-N	Phase 1/Phase 2	casein kinase inhibitor	NA	NA
CX-4945	HIPK3	24748573	MUOKSQABCJCOPU-UHFFFAOYSA-N	Phase 1/Phase 2	casein kinase inhibitor	NA	NA
cyamemazine	HTR1A	14050069	SLFGIOIONGJGRT-AWEZNQCLSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	schizophrenia|anxiety
cyamemazine	HTR2A	14050069	SLFGIOIONGJGRT-AWEZNQCLSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	schizophrenia|anxiety
cyamemazine	HTR2C	14050069	SLFGIOIONGJGRT-AWEZNQCLSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	schizophrenia|anxiety
cyamemazine	HTR7	14050069	SLFGIOIONGJGRT-AWEZNQCLSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	schizophrenia|anxiety
cyanocobalamin	MUT		RMRCNWBMXRMIRW-WZHZPDAFSA-M	Launched	methylmalonyl CoA mutase stimulant|vitamin B	hematology|infectious disease|gastroenterology	anemia|fish tapeworm infestation|celiac disease
cyanopindolol	ADRB1	6604791	QXIUMMLTJVHILT-GFCCVEGCSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
cyanopindolol	HTR1A	6604791	QXIUMMLTJVHILT-GFCCVEGCSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
cyanopindolol	HTR1D	6604791	QXIUMMLTJVHILT-GFCCVEGCSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
cyclic-AMP	CNGA3	40467852	IVOMOUWHDPKRLL-DEGSGYPDSA-N	Preclinical		NA	NA
cyclic-AMP	TRPM7	40467852	IVOMOUWHDPKRLL-DEGSGYPDSA-N	Preclinical		NA	NA
cyclizine	HRH1	6726	UVKZSORBKUEBAZ-UHFFFAOYSA-N	Launched	histamine receptor modulator	gastroenterology|neurology/psychiatry	nausea|vomiting|vertigo|motion sickness
cyclizine	SULT1E1	6726	UVKZSORBKUEBAZ-UHFFFAOYSA-N	Launched	histamine receptor modulator	gastroenterology|neurology/psychiatry	nausea|vomiting|vertigo|motion sickness
cyclobenzaprine	HTR2A	2895	JURKNVYFZMSNLP-UHFFFAOYSA-N	Launched	adrenergic receptor agonist|serotonin receptor agonist	neurology/psychiatry	spasms
cycloheximide	RPL3	6197	YPHMISFOHDHNIV-FSZOTQKASA-N	Preclinical	protein synthesis inhibitor	NA	NA
cyclophosphamide	CYP2A6	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP2B6	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP2C18	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP2C19	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP2C8	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP2C9	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP2D6	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP3A4	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP3A5	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclophosphamide	CYP3A7	9554282	CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	DNA alkylating agent	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
cyclopiazonic-acid	ATP2A1	54682463	SZINUGQCTHLQAZ-DQYPLSBCSA-N	Preclinical	ATPase inhibitor	NA	NA
cycloserine-(D)	GRIN1	6234	DYDCUQKUCUHJBH-UWTATZPHSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	tuberculosis|tuberculosis
cyclosporin-A	ABCB11	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	CAMLG	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	FPR1	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	PPIA	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	PPIF	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	PPP3CA	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	PPP3R2	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	SLC10A1	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	SLCO1B1	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclosporin-A	SLCO1B3	5284373	PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis
cyclothiazide	CA2	101691640	BOCUKUHCLICSIY-JWUFEOHASA-N	Launched	glutamate receptor modulator	cardiology	hypertension
cyclothiazide	GRIA1	101691640	BOCUKUHCLICSIY-JWUFEOHASA-N	Launched	glutamate receptor modulator	cardiology	hypertension
cyclothiazide	GRIA2	101691640	BOCUKUHCLICSIY-JWUFEOHASA-N	Launched	glutamate receptor modulator	cardiology	hypertension
cyclothiazide	GRIA3	101691640	BOCUKUHCLICSIY-JWUFEOHASA-N	Launched	glutamate receptor modulator	cardiology	hypertension
cyclothiazide	GRIA4	101691640	BOCUKUHCLICSIY-JWUFEOHASA-N	Launched	glutamate receptor modulator	cardiology	hypertension
cyclothiazide	SLC12A3	101691640	BOCUKUHCLICSIY-JWUFEOHASA-N	Launched	glutamate receptor modulator	cardiology	hypertension
cyclovalone	ABCG2	1550234	DHKKONBXGAAFTB-OTYYAQKOSA-N	Launched	breast cancer resistance protein inhibitor	gastroenterology	bile stimulation
CYC116	AURKA	6420138	GPSZYOIFQZPWEJ-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
CYC116	AURKB	6420138	GPSZYOIFQZPWEJ-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
CYC116	KDR	6420138	GPSZYOIFQZPWEJ-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
CYM-50260	S1PR4	44620894	FHPOTBQOUBMMCI-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor agonist	NA	NA
CYM-50358	S1PR4	53358422	QWJOPXDAQCDRRM-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor antagonist	NA	NA
CYM-50769	NPBWR1	50904505	QHVSQUYCVUHYKT-UHFFFAOYSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
CYM-5442	S1PR1	93977386	NUIKTBLZSPQGCP-LJQANCHMSA-N	Preclinical	sphingosine 1-phosphate receptor agonist	NA	NA
CYM-5520	S1PR2	25110470	FMYGNANMYYHBSU-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor agonist	NA	NA
CYM-5541	S1PR3	17253208	NDKGACIWVAOUQH-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor agonist	NA	NA
cyproheptadine	ADRA1A	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	ADRA1B	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	ADRA1D	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	CHRM1	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	CHRM2	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	CHRM3	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	HRH1	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	HTR2A	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	HTR2C	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	HTR6	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproheptadine	HTR7	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
cyproterone-acetate	ADORA1	9880	UWFYSQMTEOIJJG-FDTZYFLXSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
cyproterone-acetate	AR	9880	UWFYSQMTEOIJJG-FDTZYFLXSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
cysteamine	NPY2R	6058	UFULAYFCSOUIOV-UHFFFAOYSA-N	Launched	tissue transglutaminase inhibitor	metabolism	cystinosis
cysteamine	SST	6058	UFULAYFCSOUIOV-UHFFFAOYSA-N	Launched	tissue transglutaminase inhibitor	metabolism	cystinosis
CYT-997	TUBB	11351021	MTJHLONVHHPNSI-IBGZPJMESA-N	Phase 2	tubulin polymerization inhibitor	NA	NA
cytarabine	POLA1	6253	UHDGCWIWMRVCDJ-CCXZUQQUSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)
cytarabine	POLB	6253	UHDGCWIWMRVCDJ-CCXZUQQUSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)
cytarabine	POLD1	6253	UHDGCWIWMRVCDJ-CCXZUQQUSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)
cytarabine	POLE	6253	UHDGCWIWMRVCDJ-CCXZUQQUSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)
cytisine	CHRNA2	10235	ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytisine	CHRNA3	10235	ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytisine	CHRNA4	10235	ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytisine	CHRNA6	10235	ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytisine	CHRNA7	10235	ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytisine	CHRNB2	10235	ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytisine	CHRNB4	10235	ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytochalasin-B	ACTB	5311281	GBOGMAARMMDZGR-TYHYBEHESA-N	Phase 2	microtubule inhibitor	NA	NA
cyt387	JAK1	25062766	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
cyt387	JAK2	25062766	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
cyt387	JAK3	25062766	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
CY208-243	CALY	58144	WRNKIDLXXXIELU-IEBWSBKVSA-N	Phase 2	dopamine receptor agonist	NA	NA
CZC-54252	LRRK2	44252734	CLGWUCNXOBLWFM-UHFFFAOYSA-N	Preclinical	leucine rich repeat kinase inhibitor	NA	NA
CZC24832	PIK3CG	42623951	RXRZPHQBTHQXSV-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
C11-Acetate	ABAT	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	ACE	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	AKR1C3	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	CA2	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	CELA1	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	ESR2	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	FFAR2	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	FFAR3	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	HPRT1	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	LTA4H	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	MMP12	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	NOS1	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	NOS3	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	PLA2G1B	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	PTPN1	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	SOD1	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C11-Acetate	TXN	168049	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3		NA	NA
C34	TLR4	91691128	KMIQMFHPUJUDMC-HHARLNAUSA-N	Preclinical	toll-like receptor inhibitor	NA	NA
C646	EP300	2871948	HEKJYZZSCQBJGB-UHFFFAOYSA-N	Preclinical	histone acetyltransferase inhibitor	NA	NA
D-(+)-maltose	MGAM	6255	GUBGYTABKSRVRQ-QUYVBRFLSA-N	Preclinical		NA	NA
D-phenylalanine	CCBL1	71567	COLNVLDHVKWLRT-MRVPVSSYSA-N	Preclinical	enkephalinase inhibitor	NA	NA
D-phenylalanine	CRH	71567	COLNVLDHVKWLRT-MRVPVSSYSA-N	Preclinical	enkephalinase inhibitor	NA	NA
D-phenylalanine	HCAR3	71567	COLNVLDHVKWLRT-MRVPVSSYSA-N	Preclinical	enkephalinase inhibitor	NA	NA
D-serine	GLRA1	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	glutamate receptor agonist	NA	NA
D-serine	GRIN1	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	glutamate receptor agonist	NA	NA
D-serine	GRIN2A	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	glutamate receptor agonist	NA	NA
D-serine	GRIN2B	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	glutamate receptor agonist	NA	NA
D-serine	GRIN2C	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	glutamate receptor agonist	NA	NA
D-serine	GRIN2D	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	glutamate receptor agonist	NA	NA
D-serine	SERPINB3	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	glutamate receptor agonist	NA	NA
D-4476	CSNK1A1	6419753	DPDZHVCKYBCJHW-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
D-4476	CSNK1D	6419753	DPDZHVCKYBCJHW-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
D-4476	TGFB1	6419753	DPDZHVCKYBCJHW-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
D-64131	TUBB	3921152	ICMIJSRDISNKOC-UHFFFAOYSA-N	Preclinical	microtubule inhibitor	NA	NA
DAA-1106	TSPO	10430788	DCRZYADKQRHHSF-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
dabigatran	F2	216210	YBSJFWOBGCMAKL-UHFFFAOYSA-N	Launched	thrombin inhibitor	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)
dabigatran-etexilate	F2	9578572	KSGXQBZTULBEEQ-UHFFFAOYSA-N	Launched	thrombin inhibitor	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)
dabrafenib	BRAF	44462760	BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched	RAF inhibitor	oncology	melanoma
dabrafenib	LIMK1	44462760	BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched	RAF inhibitor	oncology	melanoma
dabrafenib	NEK11	44462760	BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched	RAF inhibitor	oncology	melanoma
dabrafenib	RAF1	44462760	BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched	RAF inhibitor	oncology	melanoma
dabrafenib	SIK1	44462760	BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched	RAF inhibitor	oncology	melanoma
dacarbazine	PGD	135398738	FDKXTQMXEQVLRF-ZHACJKMWSA-N	Launched	DNA alkylating agent	oncology|hematologic malignancy	melanoma|Hodgkin's lymphoma
dacarbazine	POLA2	135398738	FDKXTQMXEQVLRF-ZHACJKMWSA-N	Launched	DNA alkylating agent	oncology|hematologic malignancy	melanoma|Hodgkin's lymphoma
dacinostat	HDAC1	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC2	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC3	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC4	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC5	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC6	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC7	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC8	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacinostat	HDAC9	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	HDAC inhibitor	NA	NA
dacomitinib	EGFR	11511120	LVXJQMNHJWSHET-AATRIKPKSA-N	Launched	EGFR inhibitor	NA	NA
dacomitinib	ERBB2	11511120	LVXJQMNHJWSHET-AATRIKPKSA-N	Launched	EGFR inhibitor	NA	NA
dacomitinib	ERBB4	11511120	LVXJQMNHJWSHET-AATRIKPKSA-N	Launched	EGFR inhibitor	NA	NA
dactinomycin	POLR2A	457193	RJURFGZVJUQBHK-IIXSONLDSA-N	Launched	RNA polymerase inhibitor	oncology	testicular carcinoma|Wilm's tumor|rhabdomyosarcoma|Ewing's sarcoma|gestational trophoblastic disease (GTD)
daidzein	ESRRA	5281708	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	Phase 2	estrogen receptor agonist	NA	NA
daidzein	ESRRB	5281708	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	Phase 2	estrogen receptor agonist	NA	NA
daidzein	ESRRG	5281708	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	Phase 2	estrogen receptor agonist	NA	NA
daidzein	TRPC5	5281708	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	Phase 2	estrogen receptor agonist	NA	NA
daidzin	ALDH2	107971	KYQZWONCHDNPDP-QNDFHXLGSA-N	Phase 1	antioxidant	NA	NA
dalargin	OPRM1	NA	GDPHPXYFLPDZGH-ABDYMBPTSA-N	Phase 2	opioid receptor agonist	NA	NA
dalbavancin	PNLIP	16134627	KGPGQDLTDHGEGT-SZUNQUCBSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	skin infections
dalcetrapib	CETP	6918540	YZQLWPMZQVHJED-UHFFFAOYSA-N	Phase 3	cholesteryl ester transfer protein inhibitor	NA	NA
dalfampridine	KCNA1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNA10	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNA2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNA3	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNA4	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNA5	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNA6	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNA7	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNB1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNB2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNC1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNC2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNC3	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNC4	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCND1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCND2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCND3	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNF1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNG1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNG2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNG3	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNG4	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH3	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH4	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH5	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH6	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH7	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNH8	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNJ13	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNJ5	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNQ1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNQ2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNQ3	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNQ4	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNQ5	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNS1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNS2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNS3	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNV1	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfampridine	KCNV2	1727	NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	potassium channel blocker	neurology/psychiatry	multiple sclerosis
daltroban	TBXA2R	54343	IULOBWFWYDMECP-UHFFFAOYSA-N	Phase 3	thromboxane receptor antagonist	NA	NA
daminozide	KDM2A	72200802	NOQGZXFMHARMLW-UHFFFAOYSA-N	Preclinical	KDM2A inhibitor	NA	NA
daminozide	KDM7A	72200802	NOQGZXFMHARMLW-UHFFFAOYSA-N	Preclinical	KDM2A inhibitor	NA	NA
daminozide	PHF8	72200802	NOQGZXFMHARMLW-UHFFFAOYSA-N	Preclinical	KDM2A inhibitor	NA	NA
danazol	AR	28417	POZRVZJJTULAOH-LHZXLZLDSA-N	Launched	estrogen receptor antagonist|progesterone receptor agonist	obstetrics/gynecology|cardiology	endometriosis|angioedema
danazol	CCL2	28417	POZRVZJJTULAOH-LHZXLZLDSA-N	Launched	estrogen receptor antagonist|progesterone receptor agonist	obstetrics/gynecology|cardiology	endometriosis|angioedema
danazol	ESR1	28417	POZRVZJJTULAOH-LHZXLZLDSA-N	Launched	estrogen receptor antagonist|progesterone receptor agonist	obstetrics/gynecology|cardiology	endometriosis|angioedema
danazol	GNRHR	28417	POZRVZJJTULAOH-LHZXLZLDSA-N	Launched	estrogen receptor antagonist|progesterone receptor agonist	obstetrics/gynecology|cardiology	endometriosis|angioedema
danazol	GNRHR2	28417	POZRVZJJTULAOH-LHZXLZLDSA-N	Launched	estrogen receptor antagonist|progesterone receptor agonist	obstetrics/gynecology|cardiology	endometriosis|angioedema
danazol	PGR	28417	POZRVZJJTULAOH-LHZXLZLDSA-N	Launched	estrogen receptor antagonist|progesterone receptor agonist	obstetrics/gynecology|cardiology	endometriosis|angioedema
danirixin	CXCR2	24780598	NGYNBSHYFOFVLS-LBPRGKRZSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
dantrolene	RYR1	6914273	OZOMQRBLCMDCEG-VIZOYTHASA-N	Launched	calcium channel blocker	neurology/psychiatry|endocrinology	spasms|malignant hyperthermia (MH)
dantrolene	RYR3	6914273	OZOMQRBLCMDCEG-VIZOYTHASA-N	Launched	calcium channel blocker	neurology/psychiatry|endocrinology	spasms|malignant hyperthermia (MH)
danusertib	AURKA	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	NA	NA
danusertib	AURKB	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	NA	NA
danusertib	AURKC	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	NA	NA
danusertib	FGFR1	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	NA	NA
danusertib	NTRK1	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	NA	NA
danusertib	RET	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	NA	NA
danusertib	SLK	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	NA	NA
dapagliflozin	SLC5A1	9887712	JVHXJTBJCFBINQ-ADAARDCZSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
dapagliflozin	SLC5A2	9887712	JVHXJTBJCFBINQ-ADAARDCZSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
dapiprazole	ADRA1A	3033538	RFWZESUMWJKKRN-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	ophthalmology	mydriasis
dapiprazole	ADRA1B	3033538	RFWZESUMWJKKRN-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	ophthalmology	mydriasis
dapiprazole	ADRA1D	3033538	RFWZESUMWJKKRN-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	ophthalmology	mydriasis
dapivirine	CYP3A4	214347	ILAYIAGXTHKHNT-UHFFFAOYSA-N	Phase 3	non-nucleoside reverse transcriptase inhibitor	NA	NA
dapivirine	CYP3A5	214347	ILAYIAGXTHKHNT-UHFFFAOYSA-N	Phase 3	non-nucleoside reverse transcriptase inhibitor	NA	NA
dapoxetine	HTR1A	71353	USRHYDPUVLEVMC-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	urology	premature ejaculation (PE)
dapoxetine	HTR1B	71353	USRHYDPUVLEVMC-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	urology	premature ejaculation (PE)
dapoxetine	HTR2C	71353	USRHYDPUVLEVMC-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	urology	premature ejaculation (PE)
dapoxetine	SLC6A4	71353	USRHYDPUVLEVMC-FQEVSTJZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	urology	premature ejaculation (PE)
daprodustat	EGLN1	24831508	NVTKJBXOBFRPLQ-UHFFFAOYSA-N	Phase 3	hypoxia inducible factor inhibitor	NA	NA
dapsone	DHFR	2955	MQJKPEGWNLWLTK-UHFFFAOYSA-N	Launched	bacterial antifolate	dermatology|infectious disease	dermatitis herpetiformis (DH)|leprosy
darapladib	PLA2G7	9939609	WDPFJWLDPVQCAJ-UHFFFAOYSA-N	Phase 3	phospholipase inhibitor	NA	NA
darglitazone	PPARG	60870	QQKNSPHAFATFNQ-UHFFFAOYSA-N	Phase 2	PPAR receptor antagonist	NA	NA
darifenacin	CHRM1	444031	HXGBXQDTNZMWGS-RUZDIDTESA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
darifenacin	CHRM2	444031	HXGBXQDTNZMWGS-RUZDIDTESA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
darifenacin	CHRM3	444031	HXGBXQDTNZMWGS-RUZDIDTESA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
darifenacin	CHRM4	444031	HXGBXQDTNZMWGS-RUZDIDTESA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
darifenacin	CHRM5	444031	HXGBXQDTNZMWGS-RUZDIDTESA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
darolutamide	AR	121489720	BLIJXOOIHRSQRB-NWDGAFQWSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
darunavir	CYP3A4	213039	CJBJHOAVZSMMDJ-HEXNFIEUSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
darusentan	EDNRA	177236	FEJVSJIALLTFRP-LJQANCHMSA-N	Phase 3	endothelin receptor antagonist	NA	NA
dasatinib	ABL1	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	ABL2	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	BLK	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	EPHA2	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	FGR	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	FRK	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	FYN	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	HCK	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	KIT	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	LCK	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	LYN	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	PDGFRB	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	SRC	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	SRMS	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	STAT5B	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
dasatinib	YES1	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
DAU-5884	CHRM3	NA	NWXCDQHBVVPPTL-WDNDVIMCSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
daunorubicin	TOP2A	30323	STQGQHZAVUOBTE-VGBVRHCVSA-N	Launched	RNA synthesis inhibitor|topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)
daunorubicin	TOP2B	30323	STQGQHZAVUOBTE-VGBVRHCVSA-N	Launched	RNA synthesis inhibitor|topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)
dazmegrel	TBXAS1	53555	DEQLGSOHGTZKFB-UHFFFAOYSA-N	Phase 2	thromboxane synthase inhibitor	NA	NA
dazoxiben	TBXAS1	53001	XQGZSYKGWHUSDH-UHFFFAOYSA-N	Phase 2	thromboxane synthase inhibitor	NA	NA
DBeQ	CASP3	676352	QAIMUUJJAJBPCL-UHFFFAOYSA-N	Preclinical	ATPase inhibitor	NA	NA
DBPR108	DPP4	44201003	VQKSCYBKUIDZEI-STQMWFEESA-N	Phase 1	dipeptidyl peptidase inhibitor	NA	NA
DC-260126	FFAR1	2843133	CNGHPXKWPGIDSK-UHFFFAOYSA-N	Preclinical	free fatty acid receptor antagonist	NA	NA
DCC-2618	KIT	46208890	WWOXKWLDMLMYQY-UHFFFAOYSA-N	Phase 1	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	NA	NA
DCC-2618	PDGFRA	46208890	WWOXKWLDMLMYQY-UHFFFAOYSA-N	Phase 1	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	NA	NA
DCEBIO	KCNN2	656765	LKHRMULASXZCLG-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
DCEBIO	KCNN3	656765	LKHRMULASXZCLG-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
DCEBIO	KCNN4	656765	LKHRMULASXZCLG-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
DCPIB	SLC1A2	12761153	KHKGTPJPBOQECW-QFIPXVFZSA-N	Preclinical	chloride channel blocker|gap junction modulator|glutamate inhibitor	NA	NA
DDR1-IN-1	DDR1	72836888	AOZPVMOOEJAZGK-UHFFFAOYSA-N	Preclinical	discoidin domain receptor inhibitor	NA	NA
DDR1-IN-1	DDR2	72836888	AOZPVMOOEJAZGK-UHFFFAOYSA-N	Preclinical	discoidin domain receptor inhibitor	NA	NA
debrisoquin	SLC6A2	2966	JWPGJSVJDAJRLW-UHFFFAOYSA-N	Launched	adrenergic neuron blocker	cardiology	hypertension
decamethonium	ACHE	2968	MTCUAOILFDZKCO-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	muscle relaxant
decamethonium	CHRNA2	2968	MTCUAOILFDZKCO-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	muscle relaxant
decernotinib	JAK3	59422203	ASUGUQWIHMTFJL-QGZVFWFLSA-N	Phase 2/Phase 3	JAK inhibitor	NA	NA
decitabine	DNMT1	451668	XAUDJQYHKZQPEU-KVQBGUIXSA-N	Launched	DNA methyltransferase inhibitor	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)
decitabine	DNMT3A	451668	XAUDJQYHKZQPEU-KVQBGUIXSA-N	Launched	DNA methyltransferase inhibitor	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)
defactinib	PTK2	25117126	FWLMVFUGMHIOAA-UHFFFAOYSA-N	Phase 2	focal adhesion kinase inhibitor	NA	NA
deferasirox	CYP3A4	214348	BOFQWVMAQOTZIW-UHFFFAOYSA-N	Launched	chelating agent	hematology	transfusional hemosiderosis|thalassemia|iron overload
deferiprone	UGT1A6	2972	TZXKOCQBRNJULO-UHFFFAOYSA-N	Launched	chelating agent	hematology	transfusional hemosiderosis|thalassemia|iron overload
deflazacort	NR3C1	189821	FBHSPRKOSMHSIF-GRMWVWQJSA-N	Launched	glucocorticoid receptor agonist	rheumatology	joint inflammation
deforolimus	MTOR		BUROJSBIWGDYCN-LKLUGXJSSA-N	Phase 3	mTOR inhibitor	NA	NA
degarelix	GNRHR	16136245	MEUCPCLKGZSHTA-XYAYPHGZSA-N	Launched	gonadotropin releasing factor hormone receptor antagonist	oncology	prostate cancer
dehydrocorydaline	ACHE	34781	RFKQJTRWODZPHF-UHFFFAOYSA-N	Phase 3	acetylcholinesterase inhibitor	NA	NA
dehydroepiandrosterone	ESR1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	ESR2	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	G6PD	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRA1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRA2	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRA3	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRA4	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRA5	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRA6	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRB1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRB2	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRB3	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRD	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRE	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRG1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRG2	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRG3	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRP	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GABRQ	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GRIN1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GRIN2A	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GRIN2B	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GRIN2C	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GRIN2D	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GRIN3A	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	GRIN3B	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	HSD17B1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	NR1I2	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	NR1I3	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	PPARA	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	SIGMAR1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	SULT2A1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone	SULT2B1	5881	FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone-sulfate	AR	12594	CZWCKYRVOZZJNM-USOAJAOKSA-N	Launched	androgen receptor agonist|estrogen receptor agonist	endocrinology	menopause
dehydroepiandrosterone-sulfate	ESR1	12594	CZWCKYRVOZZJNM-USOAJAOKSA-N	Launched	androgen receptor agonist|estrogen receptor agonist	endocrinology	menopause
dehydroepiandrosterone-sulfate	ESR2	12594	CZWCKYRVOZZJNM-USOAJAOKSA-N	Launched	androgen receptor agonist|estrogen receptor agonist	endocrinology	menopause
delanzomib	CMA1	24800541	SJFBTAPEPRWNKH-CCKFTAQKSA-N	Phase 1/Phase 2	proteasome inhibitor	NA	NA
delanzomib	CTSG	24800541	SJFBTAPEPRWNKH-CCKFTAQKSA-N	Phase 1/Phase 2	proteasome inhibitor	NA	NA
delanzomib	CYP3A4	24800541	SJFBTAPEPRWNKH-CCKFTAQKSA-N	Phase 1/Phase 2	proteasome inhibitor	NA	NA
delanzomib	ELANE	24800541	SJFBTAPEPRWNKH-CCKFTAQKSA-N	Phase 1/Phase 2	proteasome inhibitor	NA	NA
delapril	ACE	5362116	WOUOLAUOZXOLJQ-MBSDFSHPSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
delavirdine	CYP3A4	5625	WHBIGIKBNXZKFE-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
delivert	AGTR1	78357780	CZGUSIXMZVURDU-FCWOTDAASA-N	Launched	angiotensin receptor agonist	critical care	sepsis
delivert	AGTR2	78357780	CZGUSIXMZVURDU-FCWOTDAASA-N	Launched	angiotensin receptor agonist	critical care	sepsis
delphinidin	GLO1	128853	JKHRCGUTYDNCLE-UHFFFAOYSA-O	Phase 2	membrane permeability inhibitor	NA	NA
delta-tocotrienol	HMGCR	5282350	ODADKLYLWWCHNB-LDYBVBFYSA-N	Phase 1	HMGCR inhibitor	NA	NA
deltarasin	KRAS	73292904	LTZKEDSUXKTTTC-KXQOOQHDSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
demecarium	ACHE	5966	RWZVPVOZTJJMNU-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	ophthalmology	intraocular pressure|glaucoma
demecarium	BCHE	5966	RWZVPVOZTJJMNU-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	ophthalmology	intraocular pressure|glaucoma
deoxycholic-acid	FPR1	222528	KXGVEGMKQFWNSR-LLQZFEROSA-N	Launched	biliverdin reductase A activator|G protein-coupled receptor agonist	endocrinology	submental fat
deoxycholic-acid	GPBAR1	222528	KXGVEGMKQFWNSR-LLQZFEROSA-N	Launched	biliverdin reductase A activator|G protein-coupled receptor agonist	endocrinology	submental fat
deoxycorticosterone-acetate	NR3C2	5952	VPGRYOFKCNULNK-ACXQXYJUSA-N	Preclinical	progestogen hormone	NA	NA
deoxyepinephrine	ADRA1A	4382	NGKZFDYBISXGGS-UHFFFAOYSA-N	Preclinical	adrenergic receptor agonist|dopamine receptor agonist	NA	NA
deoxyepinephrine	DRD1	4382	NGKZFDYBISXGGS-UHFFFAOYSA-N	Preclinical	adrenergic receptor agonist|dopamine receptor agonist	NA	NA
deoxyepinephrine	DRD2	4382	NGKZFDYBISXGGS-UHFFFAOYSA-N	Preclinical	adrenergic receptor agonist|dopamine receptor agonist	NA	NA
deptropine	HRH1	NA	ZWPODSUQWXAZNC-PMOLBWCYSA-N	Preclinical	histamine receptor antagonist	NA	NA
dequalinium	KCNN1	2993	PCSWXVJAIHCTMO-UHFFFAOYSA-P	Launched	PKC inhibitor	infectious disease	first-aid antiseptic
dequalinium	KCNN3	2993	PCSWXVJAIHCTMO-UHFFFAOYSA-P	Launched	PKC inhibitor	infectious disease	first-aid antiseptic
deracoxib	PTGS2	3058754	WAZQAZKAZLXFMK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis
deserpidine	ACE	8550	CVBMAZKKCSYWQR-WCGOZPBSSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
deserpidine	SLC18A2	8550	CVBMAZKKCSYWQR-WCGOZPBSSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
desipramine	ADRA1A	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	ADRA1B	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	ADRA1D	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	ADRA2A	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	ADRA2B	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	ADRA2C	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	ADRB1	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	ADRB2	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	CHRM1	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	CHRM2	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	CHRM3	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	CHRM4	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	CHRM5	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	DRD2	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	HRH1	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	HTR1A	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	HTR2A	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	HTR2C	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	SLC6A2	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	SLC6A4	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
desipramine	SMPD1	2995	HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
deslanoside	ATP1A1	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
deslanoside	ATP1A2	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
deslanoside	ATP1A3	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
deslanoside	ATP1A4	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
deslanoside	ATP1B1	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
deslanoside	ATP1B2	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
deslanoside	ATP1B3	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
deslanoside	FXYD2	28620	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	Na/K-ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
desloratadine	HRH1	124087	JAUOIFJMECXRGI-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis|urticaria
desmethylclozapine	HTR2C	135409468	JNNOSTQEZICQQP-UHFFFAOYSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
desmopressin-acetate	AVPR1A	NA	NFLWUMRGJYTJIN-AIOUAYLGSA-N	Launched	vasopressin receptor agonist	endocrinology|urology	central diabetes insipidus|nocturnal enuresis
desmopressin-acetate	AVPR1B	NA	NFLWUMRGJYTJIN-AIOUAYLGSA-N	Launched	vasopressin receptor agonist	endocrinology|urology	central diabetes insipidus|nocturnal enuresis
desmopressin-acetate	AVPR2	NA	NFLWUMRGJYTJIN-AIOUAYLGSA-N	Launched	vasopressin receptor agonist	endocrinology|urology	central diabetes insipidus|nocturnal enuresis
desmopressin-acetate	OXTR	NA	NFLWUMRGJYTJIN-AIOUAYLGSA-N	Launched	vasopressin receptor agonist	endocrinology|urology	central diabetes insipidus|nocturnal enuresis
desogestrel	ESR1	40973	RPLCPCMSCLEKRS-BPIQYHPVSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
desogestrel	PGR	40973	RPLCPCMSCLEKRS-BPIQYHPVSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
desonide	NR3C1	5311066	WBGKWQHBNHJJPZ-LECWWXJVSA-N	Launched	glucocorticoid receptor agonist	gastroenterology	Crohn's disease
desonide	PLA2G1B	5311066	WBGKWQHBNHJJPZ-LECWWXJVSA-N	Launched	glucocorticoid receptor agonist	gastroenterology	Crohn's disease
desoximetasone	NR3C1	5311067	VWVSBHGCDBMOOT-IIEHVVJPSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
desoximetasone	PLA2G1B	5311067	VWVSBHGCDBMOOT-IIEHVVJPSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
desoxycorticosterone-pivalate	NR3C2	11876263	VVOIQBFMTVCINR-WWMZEODYSA-N	Launched	corticosteroid agonist	endocrinology	Addison's disease
desoxycortone	NR3C1	6166	ZESRJSPZRDMNHY-YFWFAHHUSA-N	Preclinical	mineralocorticoid receptor agonist	NA	NA
desoxycortone	NR3C2	6166	ZESRJSPZRDMNHY-YFWFAHHUSA-N	Preclinical	mineralocorticoid receptor agonist	NA	NA
desoxypeganine	ACHE	442894	WUFQLZTXIWKION-UHFFFAOYSA-N	Phase 1	acetylcholinesterase inhibitor|monoamine oxidase inhibitor	NA	NA
desvenlafaxine	SLC6A2	12018336	KYYIDSXMWOZKMP-HNNXBMFYSA-N	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
desvenlafaxine	SLC6A3	12018336	KYYIDSXMWOZKMP-HNNXBMFYSA-N	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
desvenlafaxine	SLC6A4	12018336	KYYIDSXMWOZKMP-HNNXBMFYSA-N	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
detomidine	ADRA2A	56032	RHDJRPPFURBGLQ-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
dexamethasone	ANXA1	5743	UREBDLICKHMUKA-CXSFZGCWSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
dexamethasone	NOS2	5743	UREBDLICKHMUKA-CXSFZGCWSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
dexamethasone	NR0B1	5743	UREBDLICKHMUKA-CXSFZGCWSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
dexamethasone	NR3C1	5743	UREBDLICKHMUKA-CXSFZGCWSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
dexamethasone	NR3C2	5743	UREBDLICKHMUKA-CXSFZGCWSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
dexfosfoserine	CFTR	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	GRM4	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	GRM6	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	GRM7	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	GRM8	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	KCNC4	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	PDPK1	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	PIM1	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	PRKACA	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	PRKCQ	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	PYGL	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	PYGM	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	REG1A	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	RHO	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	SERPINB3	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	SMAD2	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexfosfoserine	TAOK2	68841	BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	membrane integrity inhibitor	NA	NA
dexlansoprazole	ATP4A	9578005	MJIHNNLFOKEZEW-RUZDIDTESA-N	Launched	ATPase inhibitor	gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)
dexloxiglumide	CCKAR	65937	QNQZBKQEIFTHFZ-GOSISDBHSA-N	Phase 3	CCK receptor antagonist	NA	NA
dexmedetomidine	ADRA2A	5311068	CUHVIMMYOGQXCV-NSHDSACASA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
dexmedetomidine	ADRA2B	5311068	CUHVIMMYOGQXCV-NSHDSACASA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
dexmedetomidine	ADRA2C	5311068	CUHVIMMYOGQXCV-NSHDSACASA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
dexniguldipine	ADORA3	6918097	SVJMLYUFVDMUHP-MGBGTMOVSA-N	Phase 2	calmodulin antagonist	NA	NA
dexrazoxane	TOP2A	71384	BMKDZUISNHGIBY-ZETCQYMHSA-N	Launched	chelating agent|topoisomerase inhibitor	cardiology	cardiomyopathy
dexrazoxane	TOP2B	71384	BMKDZUISNHGIBY-ZETCQYMHSA-N	Launched	chelating agent|topoisomerase inhibitor	cardiology	cardiomyopathy
dextromethorphan	CHRNA2	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	CHRNA3	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	CHRNA4	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	CHRNA7	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	CHRNB2	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	CHRNB4	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	CYBA	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	CYBB	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	GRIN3A	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	NCF1	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	NCF2	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	NCF4	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	OPRD1	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	OPRK1	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	OPRM1	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	PGRMC1	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	RAC1	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	RAC2	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	SIGMAR1	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	SLC6A2	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
dextromethorphan	SLC6A4	5360696	MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant
DFB	GRM5	6604893	YYMCVDNIIFNDJK-BEQMOXJMSA-N	Preclinical	glutamate receptor agonist	NA	NA
DG-172	PPARD	57342889	ZJMDTBBCNMGFMS-SAPNQHFASA-N	Preclinical	PPAR receptor inverse agonist	NA	NA
DH-97	MTNR1B	3467177	HDOIPCLEKCEANF-UHFFFAOYSA-N	Preclinical	melatonin receptor antagonist	NA	NA
diacerein	IL1B	26248	TYNLGDBUJLVSMA-UHFFFAOYSA-N	Launched	interleukin inhibitor	rheumatology	osteoarthritis
diadenosine-tetraphosphate	P2RY13	21706	YOAHKNVSNCMZGQ-XPWFQUROSA-N	Phase 1	adenosine kinase inhibitor	NA	NA
diadenosine-tetraphosphate	P2RY2	21706	YOAHKNVSNCMZGQ-XPWFQUROSA-N	Phase 1	adenosine kinase inhibitor	NA	NA
diarylpropionitrile	ESR2	6604873	GHZHWDWADLAOIQ-ZDUSSCGKSA-N	Preclinical	estrogen receptor agonist	NA	NA
diazoxide	ATP1A1	3019	GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	potassium channel activator	endocrinology	hypoglycemia
diazoxide	CA1	3019	GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	potassium channel activator	endocrinology	hypoglycemia
diazoxide	CA2	3019	GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	potassium channel activator	endocrinology	hypoglycemia
diazoxide	KCNJ11	3019	GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	potassium channel activator	endocrinology	hypoglycemia
diazoxide	KCNJ8	3019	GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	potassium channel activator	endocrinology	hypoglycemia
diazoxide	KCNMA1	3019	GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	potassium channel activator	endocrinology	hypoglycemia
diazoxide	SLC12A3	3019	GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	potassium channel activator	endocrinology	hypoglycemia
dibutyl-phthalate	TRPA1	3026	DOIRQSBPFJWKBE-UHFFFAOYSA-N	Preclinical		NA	NA
diclofenac	AKR1C3	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	ALOX5	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	ASIC1	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	ASIC3	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	KCNQ2	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	KCNQ3	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	PLA2G2A	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	PPARG	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	PTGS1	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	PTGS2	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenac	SCN4A	3033	DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache
diclofenamide	CA1	3038	GJQPMPFPNINLKP-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|neurology/psychiatry	glaucoma|epilepsy
diclofenamide	CA12	3038	GJQPMPFPNINLKP-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|neurology/psychiatry	glaucoma|epilepsy
diclofenamide	CA2	3038	GJQPMPFPNINLKP-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|neurology/psychiatry	glaucoma|epilepsy
diclofenamide	CA4	3038	GJQPMPFPNINLKP-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|neurology/psychiatry	glaucoma|epilepsy
diclofenamide	CA7	3038	GJQPMPFPNINLKP-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|neurology/psychiatry	glaucoma|epilepsy
diclofensine	DRD1	23872188	ZJDCGVDEEHWEIG-HNNXBMFYSA-N	Phase 3	dopamine reuptake inhibitor	NA	NA
diclofensine	MAOA	23872188	ZJDCGVDEEHWEIG-HNNXBMFYSA-N	Phase 3	dopamine reuptake inhibitor	NA	NA
diclofensine	MAOB	23872188	ZJDCGVDEEHWEIG-HNNXBMFYSA-N	Phase 3	dopamine reuptake inhibitor	NA	NA
dicoumarol	CRYZ	54676038	DOBMPNYZJYQDGZ-UHFFFAOYSA-N	Launched	NADPH inhibitor	hematology	deep vein thrombosis (DVT)
dicoumarol	NQO1	54676038	DOBMPNYZJYQDGZ-UHFFFAOYSA-N	Launched	NADPH inhibitor	hematology	deep vein thrombosis (DVT)
dicoumarol	VKORC1	54676038	DOBMPNYZJYQDGZ-UHFFFAOYSA-N	Launched	NADPH inhibitor	hematology	deep vein thrombosis (DVT)
dicycloverine	CHRM1	3042	CURUTKGFNZGFSE-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
dicycloverine	CHRM2	3042	CURUTKGFNZGFSE-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
dicycloverine	CHRM3	3042	CURUTKGFNZGFSE-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
didanosine	PNP	135398739	BXZVVICBKDXVGW-NKWVEPMBSA-N	Launched	nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
didox	RRM1	3045	QJMCKEPOKRERLN-UHFFFAOYSA-N	Launched	ribonucleotide reductase inhibitor	oncology	breast cancer
dienestrol	ESR1	667476	NFDFQCUYFHCNBW-SCGPFSFSSA-N	Launched	estrogen receptor agonist	endocrinology	menopause
dienogest	PGR	68861	AZFLJNIPTRTECV-FUMNGEBKSA-N	Launched	progesterone receptor agonist	endocrinology|obstetrics/gynecology	contraceptive|endometriosis
diethylcarbamazine	ALOX5	3052	RCKMWOKWVGPNJF-UHFFFAOYSA-N	Launched	lipoxygenase inhibitor	infectious disease	filariasis
diethylcarbamazine	PTGS1	3052	RCKMWOKWVGPNJF-UHFFFAOYSA-N	Launched	lipoxygenase inhibitor	infectious disease	filariasis
diethylstilbestrol	ESR1	448537	RGLYKWWBQGJZGM-ISLYRVAYSA-N	Withdrawn	estrogen receptor agonist	NA	NA
diethylstilbestrol	ESR2	448537	RGLYKWWBQGJZGM-ISLYRVAYSA-N	Withdrawn	estrogen receptor agonist	NA	NA
diethylstilbestrol	ESRRB	448537	RGLYKWWBQGJZGM-ISLYRVAYSA-N	Withdrawn	estrogen receptor agonist	NA	NA
diethylstilbestrol	ESRRG	448537	RGLYKWWBQGJZGM-ISLYRVAYSA-N	Withdrawn	estrogen receptor agonist	NA	NA
diflorasone-diacetate	NR3C1	51895260	BOBLHFUVNSFZPJ-OAEHMYPASA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
diflunisal	PTGS1	3059	HUPFGZXOMWLGNK-UHFFFAOYSA-N	Launched	prostanoid receptor antagonist	rheumatology	rheumatoid arthritis|osteoarthritis
diflunisal	PTGS2	3059	HUPFGZXOMWLGNK-UHFFFAOYSA-N	Launched	prostanoid receptor antagonist	rheumatology	rheumatoid arthritis|osteoarthritis
difluprednate	NR3C1	443936	WYQPLTPSGFELIB-JTQPXKBDSA-N	Launched	glucocorticoid receptor agonist	ophthalmology	endogenous uveitis
digitoxigenin	ATP1A1	4369270	XZTUSOXSLKTKJQ-CESUGQOBSA-N	Preclinical	ATPase inhibitor	NA	NA
digitoxin	ATP1A1	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digitoxin	ATP1A2	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digitoxin	ATP1A3	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digitoxin	ATP1A4	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digitoxin	ATP1B1	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digitoxin	ATP1B2	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digitoxin	ATP1B3	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digitoxin	FXYD2	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|cardiac arrythmia
digoxin	ATP1A1	12940973	LTMHDMANZUZIPE-SYUUTQQWSA-N	Launched	ATPase inhibitor	cardiology	congestive heart failure|atrial fibrillation (AF)
dihomo-gamma-linolenic-acid	PTGS1	5280581	HOBAELRKJCKHQD-QNEBEIHSSA-N	Phase 2	prostanoid receptor agonist	NA	NA
dihomo-gamma-linolenic-acid	PTGS2	5280581	HOBAELRKJCKHQD-QNEBEIHSSA-N	Phase 2	prostanoid receptor agonist	NA	NA
dihydrexidine	DRD1	6603820	BGOQGUHWXBGXJW-RHSMWYFYSA-N	Phase 2	dopamine receptor agonist	NA	NA
dihydrexidine	DRD2	6603820	BGOQGUHWXBGXJW-RHSMWYFYSA-N	Phase 2	dopamine receptor agonist	NA	NA
dihydrexidine	DRD3	6603820	BGOQGUHWXBGXJW-RHSMWYFYSA-N	Phase 2	dopamine receptor agonist	NA	NA
dihydrexidine	DRD4	6603820	BGOQGUHWXBGXJW-RHSMWYFYSA-N	Phase 2	dopamine receptor agonist	NA	NA
dihydrexidine	DRD5	6603820	BGOQGUHWXBGXJW-RHSMWYFYSA-N	Phase 2	dopamine receptor agonist	NA	NA
dihydroergocristine	ADRA1A	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	ADRB1	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	DRD1	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	DRD2	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	DRD3	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	DRD4	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	DRD5	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	HTR1A	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	HTR2A	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	HTR3A	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	HTR4	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	HTR5A	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	HTR6	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergocristine	HTR7	107715	DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	adrenergic receptor antagonist|prolactin inhibitor	neurology/psychiatry	senile dementia|cerebrovascular insufficiency
dihydroergotamine	ADRA2A	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydroergotamine	DRD2	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydroergotamine	HTR1B	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydroergotamine	HTR1D	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydroergotamine	HTR1E	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydroergotamine	HTR1F	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydroergotamine	HTR2B	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydroergotamine	HTR7	10531	LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydrotachysterol	VDR	NA	ILYCWAKSDCYMBB-CEQNRCNESA-N	Launched	vitamin analog	orthopedics|endocrinology	rickets|hypocalcemia|osteomalacia
dihydroxyphenylglycine	GRM1	10197959	HOOWCUZPEFNHDT-SSDOTTSWSA-N	Preclinical	glutamate receptor agonist	NA	NA
dihydroxyphenylglycine	GRM5	10197959	HOOWCUZPEFNHDT-SSDOTTSWSA-N	Preclinical	glutamate receptor agonist	NA	NA
dilazep	SLC29A1	3074	QVZCXCJXTMIDME-UHFFFAOYSA-N	Launched	adenosine reuptake inhibitor	cardiology	coronary heart disease
diltiazem	CACNA1C	39186	HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched	calcium channel blocker	cardiology	hypertension|angina pectoris
diltiazem	CACNA1S	39186	HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched	calcium channel blocker	cardiology	hypertension|angina pectoris
diltiazem	CACNA2D1	39186	HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched	calcium channel blocker	cardiology	hypertension|angina pectoris
diltiazem	CACNG1	39186	HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched	calcium channel blocker	cardiology	hypertension|angina pectoris
diltiazem	HTR3A	39186	HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched	calcium channel blocker	cardiology	hypertension|angina pectoris
diltiazem	KCNA5	39186	HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched	calcium channel blocker	cardiology	hypertension|angina pectoris
dimaprit	HRH2	3077	OLHQOJYVQUNWPL-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
dimaprit	HRH3	3077	OLHQOJYVQUNWPL-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
dimaprit	HRH4	3077	OLHQOJYVQUNWPL-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
dimemorfan	SIGMAR1	3037918	KBEZZLAAKIIPFK-NJAFHUGGSA-N	Launched	sigma receptor agonist	pulmonary	cough suppressant
dimenhydrinate	HRH1	10660	NFLLKCVHYJRNRH-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry|gastroenterology	motion sickness|nausea|vomiting
dimercaptosuccinic-acid	DNMT1	2724354	ACTRVOBWPAIOHC-XIXRPRMCSA-N	Launched	chelating agent	neurology/psychiatry	metal toxicity
dimethindene-(S)-(+)	HRH1	6604866	MVMQESMQSYOVGV-OAHLLOKOSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
dimethyl-fumarate	KEAP1	637568	LDCRTTXIJACKKU-ONEGZZNKSA-N	Launched	nuclear factor erythroid derived|like (NRF2) activator	neurology/psychiatry	multiple sclerosis
dimetindene	HRH1	6604866	MVMQESMQSYOVGV-OAHLLOKOSA-N	Launched	cholinergic receptor antagonist|histamine receptor antagonist	allergy	allergic rhinitis
diminazene-aceturate	AOC1	2354	XNYZHCFCZNMTFY-UHFFFAOYSA-N	Phase 3	angiotensin converting enzyme activator	NA	NA
diminazene-aceturate	PRDX5	2354	XNYZHCFCZNMTFY-UHFFFAOYSA-N	Phase 3	angiotensin converting enzyme activator	NA	NA
diminazene-aceturate	PRSS1	2354	XNYZHCFCZNMTFY-UHFFFAOYSA-N	Phase 3	angiotensin converting enzyme activator	NA	NA
dimpylate	ACHE	3017	FHIVAFMUCKRCQO-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	infectious disease	flea control
dinaciclib	CDK1	46926350	"InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1"	Phase 3	CDK inhibitor	NA	NA
dinaciclib	CDK2	46926350	"InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1"	Phase 3	CDK inhibitor	NA	NA
dinaciclib	CDK5	46926350	"InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1"	Phase 3	CDK inhibitor	NA	NA
dinaciclib	CDK9	46926350	"InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1"	Phase 3	CDK inhibitor	NA	NA
dinoprost	PTGDR	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprost	PTGDR2	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprost	PTGER1	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprost	PTGER2	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprost	PTGER3	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprost	PTGER4	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprost	PTGFR	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprost	TBXA2R	5280363	PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprostone	CATSPER1	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	CATSPER2	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	CATSPER3	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	CATSPER4	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	PTGDR	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	PTGDR2	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	PTGER1	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	PTGER2	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	PTGER3	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	PTGER4	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	PTGFR	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dinoprostone	TBXA2R	5280360	XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	prostanoid receptor agonist	NA	NA
dioscin	CXCR3	119245	VNONINPVFQTJOC-ZGXDEBHDSA-N	Preclinical	apoptosis stimulant	NA	NA
diosmetin	CYP1B1	5281612	MBNGWHIJMBWFHU-UHFFFAOYSA-N	Launched	aryl hydrocarbon receptor agonist	dermatology	cosmetic
diosmin	AHR	5281613	GZSOSUNBTXMUFQ-YFAPSIMESA-N	Launched	aryl hydrocarbon receptor agonist|capillary stabilizing agent	cardiology|hematology|dermatology	chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome
diphemanil	CHRM3	6127	LCTZPQRFOZKZNK-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	spasms
diphenhydramine	HRH1	3100	ZZVUWRFHKOJYTH-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry	headache
diphenidol	CHRM1	3055	OGAKLTJNUQRZJU-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	vertigo
diphenidol	CHRM2	3055	OGAKLTJNUQRZJU-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	vertigo
diphenidol	CHRM3	3055	OGAKLTJNUQRZJU-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	vertigo
diphenidol	CHRM4	3055	OGAKLTJNUQRZJU-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	vertigo
diphenyleneiodonium	NOS2	NA	ZSZPLBNCHKXQRY-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
diphenyleneiodonium	NOS3	NA	ZSZPLBNCHKXQRY-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
diphenylpyraline	HRH1	3103	OWQUZNMMYNAXSL-UHFFFAOYSA-N	Launched	dopamine reuptake inhibitor	allergy	allergic rhinitis
diphenylpyraline	SLC6A3	3103	OWQUZNMMYNAXSL-UHFFFAOYSA-N	Launched	dopamine reuptake inhibitor	allergy	allergic rhinitis
dipraglurant	GRM5	44557636	LZXMUJCJAWVHPZ-UHFFFAOYSA-N	Phase 2	glutamate receptor negative allosteric modulator	NA	NA
DIPT	HTR1A	26903	ZRVAAGAZUWXRIP-UHFFFAOYSA-N	Launched	dopamine reuptake inhibitor|serotonin reuptake inhibitor	NA	NA
DIPT	HTR2A	26903	ZRVAAGAZUWXRIP-UHFFFAOYSA-N	Launched	dopamine reuptake inhibitor|serotonin reuptake inhibitor	NA	NA
DIPT	HTR2C	26903	ZRVAAGAZUWXRIP-UHFFFAOYSA-N	Launched	dopamine reuptake inhibitor|serotonin reuptake inhibitor	NA	NA
dipyridamole	ADA	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE10A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE1A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE1B	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE1C	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE2A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE3A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE3B	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE4A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE4B	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE4C	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE4D	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE5A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE6A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE6B	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE6C	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE6D	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE6G	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE6H	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE7A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE7B	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE8A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE8B	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	PDE9A	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
dipyridamole	SLC29A1	3108	IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
disodium-sebacate	HBB	5192	CXMXRPHRNRROMY-UHFFFAOYSA-N	Phase 1		NA	NA
disopyramide	CHRM1	3114	UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias
disopyramide	CHRM2	3114	UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias
disopyramide	CHRM3	3114	UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias
disopyramide	KCND2	3114	UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias
disopyramide	KCND3	3114	UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias
disopyramide	KCNH2	3114	UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias
disopyramide	SCN5A	3114	UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias
disulfiram	ALDH2	3117	AUZONCFQVSMFAP-UHFFFAOYSA-N	Launched	aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist	neurology/psychiatry	abstinence from alcohol
disulfiram	DBH	3117	AUZONCFQVSMFAP-UHFFFAOYSA-N	Launched	aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist	neurology/psychiatry	abstinence from alcohol
ditiocarb-sodium-trihydrate	CA1	8987	LMBWSYZSUOEYSN-UHFFFAOYSA-N	Phase 3	immunostimulant	NA	NA
ditiocarb-sodium-trihydrate	CA2	8987	LMBWSYZSUOEYSN-UHFFFAOYSA-N	Phase 3	immunostimulant	NA	NA
ditiocarb-sodium-trihydrate	CA4	8987	LMBWSYZSUOEYSN-UHFFFAOYSA-N	Phase 3	immunostimulant	NA	NA
ditolylguanidine	GRIN1	7333	OPNUROKCUBTKLF-UHFFFAOYSA-N	Preclinical	sigma receptor agonist	NA	NA
ditolylguanidine	GRIN2A	7333	OPNUROKCUBTKLF-UHFFFAOYSA-N	Preclinical	sigma receptor agonist	NA	NA
ditolylguanidine	GRIN2B	7333	OPNUROKCUBTKLF-UHFFFAOYSA-N	Preclinical	sigma receptor agonist	NA	NA
ditolylguanidine	SIGMAR1	7333	OPNUROKCUBTKLF-UHFFFAOYSA-N	Preclinical	sigma receptor agonist	NA	NA
dizocilpine-(+)	GRIN1	180081	LBOJYSIDWZQNJS-CVEARBPZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
dizocilpine-(+)	GRIN2A	180081	LBOJYSIDWZQNJS-CVEARBPZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
dizocilpine-(+)	GRIN2B	180081	LBOJYSIDWZQNJS-CVEARBPZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
dizocilpine-(+)	GRIN2C	180081	LBOJYSIDWZQNJS-CVEARBPZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
dizocilpine-(+)	GRIN2D	180081	LBOJYSIDWZQNJS-CVEARBPZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DMAB-anabaseine	CHRNA7	9926048	KHUUTHZSRXABAC-DTQAZKPQSA-N	Preclinical	adrenergic receptor agonist	NA	NA
DMeOB	GRM5	6891506	FBNPHFBYHYNMHC-JYFOCSDGSA-N	Preclinical	glutamate receptor modulator	NA	NA
DMH1	ACVR1	50997747	JMIFGARJSWXZSH-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
DMH4	KDR	5329447	SKZQZGSPYYHTQG-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
DMP-777	MPO	177992	ZSDCIRYNTCVTMF-GIGWZHCTSA-N	Phase 2	elastase inhibitor	NA	NA
DNQX	GRIA1	3899541	RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DNQX	GRIA2	3899541	RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DNQX	GRIK1	3899541	RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DNQX	GRIN1	3899541	RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DNQX	GRIN2A	3899541	RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DNQX	GRIN2B	3899541	RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
dobutamine	ADRB1	65324	JRWZLRBJNMZMFE-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	congestive heart failure
dobutamine	ADRB2	65324	JRWZLRBJNMZMFE-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	congestive heart failure
docebenone	ALOX5	1967	WDEABJKSGGRCQA-UHFFFAOYSA-N	Phase 2	lipoxygenase inhibitor	NA	NA
docetaxel	BCL2	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	MAP2	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	MAP4	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	MAPT	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	NR1I2	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBA1A	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBA1B	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBA1C	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBA3C	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBA3D	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBA3E	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBA4A	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB1	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB2A	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB2B	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB3	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB4A	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB4B	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB6	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
docetaxel	TUBB8	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
doconexent	FFAR1	445580	MBMBGCFOFBJSGT-KUBAVDMBSA-N	Launched	PPAR receptor agonist	NA	NA
doconexent	PTGS1	445580	MBMBGCFOFBJSGT-KUBAVDMBSA-N	Launched	PPAR receptor agonist	NA	NA
doconexent	PTGS2	445580	MBMBGCFOFBJSGT-KUBAVDMBSA-N	Launched	PPAR receptor agonist	NA	NA
docosanol	TLR7	12620	NOPFSRXAKWQILS-UHFFFAOYSA-N	Launched	lipase clearing factor inhibitor	dental	cold sore
dodecyl-sulfate	LYZ	8778	MOTZDAYCYVMXPC-UHFFFAOYSA-N	Preclinical		NA	NA
dofequidar	ABCB1	9960287	KLWUUPVJTLHYIM-UHFFFAOYSA-N	Phase 3	MRP inhibitor|P glycoprotein inhibitor	NA	NA
dofetilide	KCNH1	71329	IXTMWRCNAAVVAI-UHFFFAOYSA-N	Withdrawn	potassium channel blocker	NA	NA
dofetilide	KCNH2	71329	IXTMWRCNAAVVAI-UHFFFAOYSA-N	Withdrawn	potassium channel blocker	NA	NA
dofetilide	KCNJ12	71329	IXTMWRCNAAVVAI-UHFFFAOYSA-N	Withdrawn	potassium channel blocker	NA	NA
dofetilide	KCNK2	71329	IXTMWRCNAAVVAI-UHFFFAOYSA-N	Withdrawn	potassium channel blocker	NA	NA
dolasetron	HTR3A		UKTAZPQNNNJVKR-YXSUXZIUSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
dolastatin-10	TUBB	9810929	OFDNQWIFNXBECV-VFSYNPLYSA-N	Phase 2	tubulin polymerization inhibitor	NA	NA
dolutegravir	CYP3A4	54726191	RHWKPHLQXYSBKR-BMIGLBTASA-N	Launched	HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
dolutegravir	CYP3A5	54726191	RHWKPHLQXYSBKR-BMIGLBTASA-N	Launched	HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
dolutegravir	CYP3A7	54726191	RHWKPHLQXYSBKR-BMIGLBTASA-N	Launched	HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
dolutegravir	POU2F2	54726191	RHWKPHLQXYSBKR-BMIGLBTASA-N	Launched	HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
dolutegravir	UGT1A1	54726191	RHWKPHLQXYSBKR-BMIGLBTASA-N	Launched	HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
domperidone	DRD2	3151	FGXWKSZFVQUSTL-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	infectious disease	fescue toxicosis
domperidone	DRD3	3151	FGXWKSZFVQUSTL-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	infectious disease	fescue toxicosis
donepezil	ACHE	1150567	ADEBPBSSDYVVLD-HXUWFJFHSA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease
donitriptan	HTR1A	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
donitriptan	HTR1B	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
donitriptan	HTR1D	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
donitriptan	HTR1E	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
donitriptan	HTR1F	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
donitriptan	HTR2A	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
donitriptan	HTR5A	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
donitriptan	HTR6	197706	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
dopamine	DBH	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	DRD1	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	DRD2	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	DRD3	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	DRD4	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	DRD5	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	HTR1A	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	HTR7	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	SLC6A2	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	SLC6A3	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
dopamine	SLC6A4	681	VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	dopamine receptor agonist	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors
doramapimod	MAPK11	156422	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
doramapimod	MAPK12	156422	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
doramapimod	MAPK13	156422	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
doramapimod	MAPK14	156422	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
doripenem	DPEP1	73303	AVAACINZEOAHHE-VFZPANTDSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis
dorsomorphin	ACVR1	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	BMPR1A	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	BMPR1B	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	EPHA2	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	FKBP1A	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	FLT1	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	FLT3	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	KDR	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	LCK	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	MKNK1	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	PRKAA1	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	RPS6KA1	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorsomorphin	SRC	11524144	"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2"	Preclinical	AMPK inhibitor	NA	NA
dorzolamide	CA1	5284549	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma
dorzolamide	CA12	5284549	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma
dorzolamide	CA14	5284549	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma
dorzolamide	CA2	5284549	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma
dorzolamide	CA4	5284549	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma
dorzolamide	CA7	5284549	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure|glaucoma
dosulepin	CHRM1	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dosulepin	CHRM2	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dosulepin	CHRM3	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dosulepin	CHRM4	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dosulepin	CHRM5	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dosulepin	HRH1	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dosulepin	SLC6A2	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dosulepin	SLC6A4	5284550	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression
dovitinib	CSF1R	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	EGFR	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	FGFR1	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	FGFR2	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	FGFR3	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	FLT1	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	FLT3	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	FLT4	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	INSR	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	KDR	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	KIT	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	PDGFRA	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
dovitinib	PDGFRB	135398510	PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
doxazosin	ADRA1A	6604102	RUZYUOTYCVRMRZ-HXUWFJFHSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
doxazosin	ADRA1B	6604102	RUZYUOTYCVRMRZ-HXUWFJFHSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
doxazosin	ADRA1D	6604102	RUZYUOTYCVRMRZ-HXUWFJFHSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
doxepin	HRH1	667468	ODQWQRRAPPTVAG-BOPFTXTBSA-N	Launched	histamine receptor antagonist	neurology/psychiatry	depression|anxiety
doxepin	SLC6A2	667468	ODQWQRRAPPTVAG-BOPFTXTBSA-N	Launched	histamine receptor antagonist	neurology/psychiatry	depression|anxiety
doxepin	SLC6A4	667468	ODQWQRRAPPTVAG-BOPFTXTBSA-N	Launched	histamine receptor antagonist	neurology/psychiatry	depression|anxiety
doxercalciferol	VDR	46931009	HKXBNHCUPKIYDM-ZKVKAWQFSA-N	Launched	vitamin D receptor agonist	nephrology|endocrinology	chronic kidney disease (CKD)|hyperparathyroidism
doxifluridine	TYMS	18343	ZWAOHEXOSAUJHY-ZIYNGMLESA-N	Launched	thymidylate synthase inhibitor	oncology	colorectal cancer
doxofylline	ADORA1	50942	HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma
doxofylline	PDE4A	50942	HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma
doxofylline	PDE4B	50942	HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma
doxofylline	PDE4C	50942	HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma
doxofylline	PDE4D	50942	HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma
doxorubicin	TOP2A	31703	AOJJSUZBOXZQNB-TZSSRYMLSA-N	Launched	topoisomerase inhibitor	hematologic malignancy|oncology	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma
doxycycline	MMP8		JBIWCJUYHHGXTC-AKNGSSGZSA-N	Launched	bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor	dental	periodontitis
doxylamine	HRH1	43833352	HCFDWZZGGLSKEP-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry	sedative
DPCPX	ADORA1	1329	FFBDFADSZUINTG-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
DPCPX	ADORA2A	1329	FFBDFADSZUINTG-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
DPCPX	ADORA2B	1329	FFBDFADSZUINTG-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
DPCPX	ADORA3	1329	FFBDFADSZUINTG-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
DPI-201106	ADRB2	10389826	BYBYHCOEAFHGJL-RUZDIDTESA-N	Phase 2	sodium channel activator	NA	NA
DPO-1	KCNA5	21678144	BPCNGVCAHAIZEE-COPCDDAFSA-N	Preclinical	potassium channel blocker	NA	NA
DPPE	ABCB1	108092	NFIXBCVWIPOYCD-UHFFFAOYSA-N	Phase 3	histamine receptor antagonist	NA	NA
DPPE	HRH1	108092	NFIXBCVWIPOYCD-UHFFFAOYSA-N	Phase 3	histamine receptor antagonist	NA	NA
DQP-1105	GRIN2C	136902743	MVYNQMRZRULRIE-DEOSSOPVSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DQP-1105	GRIN2D	136902743	MVYNQMRZRULRIE-DEOSSOPVSA-N	Preclinical	glutamate receptor antagonist	NA	NA
DR-2313	PARP1	135522417	HRYKZAKEAVZGJD-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
DR-2313	PARP3	135522417	HRYKZAKEAVZGJD-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
DR-4485	HTR7	92211523	SBTRHJHOLCAPFT-AREMUKBSSA-N	Preclinical	serotonin receptor antagonist	NA	NA
DRF053-(R)	CSNK1A1	25168304	LWANFAFTTOKZAX-QGZVFWFLSA-N	Preclinical	CDK inhibitor	NA	NA
droloxifene	ESR1	3033767	ZQZFYGIXNQKOAV-OCEACIFDSA-N	Phase 3	selective estrogen receptor modulator (SERM)	NA	NA
dromostanolone-propionate	AR	NA	NOTIQUSPUUHHEH-QOMQUSCHSA-N	Launched	androgen receptor modulator	oncology	breast cancer
dronedarone	ADRA1A	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	ADRA1B	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	ADRA1D	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	ADRA2A	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	ADRA2B	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	ADRA2C	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	ADRB1	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNA1C	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNA1D	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNA1F	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNA1S	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNB1	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNB2	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNB3	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	CACNB4	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	KCNA5	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	KCNH2	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	KCNK2	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
dronedarone	SCN1A	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
droperidol	ADRA1A	3168	RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
droperidol	DRD2	3168	RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
droperidol	DRD3	3168	RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
droperidol	DRD4	3168	RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
droperidol	HTR2A	3168	RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
drospirenone	AR	68873	METQSPRSQINEEU-HXCATZOESA-N	Launched	mineralocorticoid receptor antagonist	endocrinology	contraceptive
drospirenone	NR3C2	68873	METQSPRSQINEEU-HXCATZOESA-N	Launched	mineralocorticoid receptor antagonist	endocrinology	contraceptive
drospirenone	PGR	68873	METQSPRSQINEEU-HXCATZOESA-N	Launched	mineralocorticoid receptor antagonist	endocrinology	contraceptive
droxicam	PTGS1	65679	OEHFRZLKGRKFAS-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
droxidopa	ADRA1A	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRA1B	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRA1D	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRA2A	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRA2B	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRA2C	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRB1	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRB2	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	ADRB3	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxidopa	PAH	92974	QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease
droxinostat	HDAC6	568416	JHSXDAWGLCZYSM-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
droxinostat	HDAC8	568416	JHSXDAWGLCZYSM-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
DSR-6434	TLR7	25071151	SSZHESNDOMBSRV-UHFFFAOYSA-N	Preclinical	toll-like receptor agonist	NA	NA
DU-728	ITGA2B	107775	NNRFRJQMBSBXGO-CIUDSAMLSA-N	Phase 1	structural glycoprotein antagonist	NA	NA
DU-728	ITGB3	107775	NNRFRJQMBSBXGO-CIUDSAMLSA-N	Phase 1	structural glycoprotein antagonist	NA	NA
duloxetine	HTR2A	60835	ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
duloxetine	HTR2C	60835	ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
duloxetine	HTR6	60835	ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
duloxetine	SLC6A2	60835	ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
duloxetine	SLC6A3	60835	ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
duloxetine	SLC6A4	60835	ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
DUP-697	PTGS2	3177	AJFTZWGGHJXZOB-UHFFFAOYSA-N	Phase 1	cyclooxygenase inhibitor	NA	NA
dutasteride	SRD5A1	6918296	JWJOTENAMICLJG-QWBYCMEYSA-N	Launched	5 alpha reductase inhibitor	urology	benign prostatic hyperplasia (BPH)
dutasteride	SRD5A2	6918296	JWJOTENAMICLJG-QWBYCMEYSA-N	Launched	5 alpha reductase inhibitor	urology	benign prostatic hyperplasia (BPH)
dutasteride	SRD5A3	6918296	JWJOTENAMICLJG-QWBYCMEYSA-N	Launched	5 alpha reductase inhibitor	urology	benign prostatic hyperplasia (BPH)
duvelisib	PIK3CA	50905713	SJVQHLPISAIATJ-ZDUSSCGKSA-N	Launched	PI3K inhibitor	NA	NA
duvelisib	PIK3CB	50905713	SJVQHLPISAIATJ-ZDUSSCGKSA-N	Launched	PI3K inhibitor	NA	NA
duvelisib	PIK3CD	50905713	SJVQHLPISAIATJ-ZDUSSCGKSA-N	Launched	PI3K inhibitor	NA	NA
duvelisib	PIK3CG	50905713	SJVQHLPISAIATJ-ZDUSSCGKSA-N	Launched	PI3K inhibitor	NA	NA
dyclonine	SCN10A	3180	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
dyclonine	SCN5A	3180	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
dydrogesterone	PGR	9051	JGMOKGBVKVMRFX-HQZYFCCVSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	infertility
dynasore	DNM1	135533054	SYNDQCRDGGCQRZ-VXLYETTFSA-N	Preclinical	dynamin inhibitor	NA	NA
dynasore	DNM1L	135533054	SYNDQCRDGGCQRZ-VXLYETTFSA-N	Preclinical	dynamin inhibitor	NA	NA
dynasore	DNM2	135533054	SYNDQCRDGGCQRZ-VXLYETTFSA-N	Preclinical	dynamin inhibitor	NA	NA
dynole-34-2	DNM1	44157463	MYIMRONQBLZJFI-DYTRJAOYSA-N	Preclinical	dynamin inhibitor	NA	NA
dyphylline	PDE4A	688353	KSCFJBIXMNOVSH-ZCFIWIBFSA-N	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	pulmonary	asthma|bronchitis|emphysema
DY131	ESRRB	5497124	WLKOCYWYAWBGKY-CPNJWEJPSA-N	Preclinical	estrogen-related receptor agonist	NA	NA
DY131	ESRRG	5497124	WLKOCYWYAWBGKY-CPNJWEJPSA-N	Preclinical	estrogen-related receptor agonist	NA	NA
E-2012	APH1A	11560787	PUOAETJYKQITMO-LANLRWRYSA-N	Phase 1	gamma secretase modulator	NA	NA
E-2012	APH1B	11560787	PUOAETJYKQITMO-LANLRWRYSA-N	Phase 1	gamma secretase modulator	NA	NA
E-2012	PSENEN	11560787	PUOAETJYKQITMO-LANLRWRYSA-N	Phase 1	gamma secretase modulator	NA	NA
E-4031	KCNH1	3185	SRUISGSHWFJION-UHFFFAOYSA-N	Phase 1	potassium channel blocker	NA	NA
E-4031	KCNH2	3185	SRUISGSHWFJION-UHFFFAOYSA-N	Phase 1	potassium channel blocker	NA	NA
E-64	CTSS	123985	LTLYEAJONXGNFG-DCAQKATOSA-N	Preclinical	calpain inhibitor|cysteine protease inhibitor	NA	NA
eact	ANO1	3173542	ZUXNHFFVQWADJL-UHFFFAOYSA-N	Preclinical	calcium-activated chloride channel inhibitor	NA	NA
EB-47	PARP1	53229989	DDFLFKTXUWPNMV-LFALDJFMSA-N	Preclinical	PARP inhibitor	NA	NA
ebastine	CYP3A4	3191	MJJALKDDGIKVBE-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis|urticaria
ebastine	HRH1	3191	MJJALKDDGIKVBE-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis|urticaria
EBPC	AKR1B1	6919079	FQMSSTZJKSWSMP-LLVKDONJSA-N	Preclinical	aldose reductase inhibitor	NA	NA
ebrotidine	HRH2	65869	ZQHFZHPUZXNPMF-UHFFFAOYSA-N	Withdrawn	histamine receptor antagonist	NA	NA
ebselen	ALB	3194	DYEFUKCXAQOFHX-UHFFFAOYSA-N	Phase 2/Phase 3	cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor	NA	NA
EC-144	HSP90AA1	11517212	VOASEWXFCTZRDF-UHFFFAOYSA-N	Preclinical	HSP inhibitor	NA	NA
EC-144	HSP90AB1	11517212	VOASEWXFCTZRDF-UHFFFAOYSA-N	Preclinical	HSP inhibitor	NA	NA
EC-23	RARA	10314719	OQVLOWLEEHYBJH-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
EC-23	RARB	10314719	OQVLOWLEEHYBJH-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
EC-23	RARG	10314719	OQVLOWLEEHYBJH-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
ecabet	NOXO1	65781	IWCWQNVIUXZOMJ-MISYRCLQSA-N	Launched	gastrin inhibitor|urease inhibitor	ophthalmology	dry eye syndrome
econazole	NPY1R	6604378	LEZWWPYKPKIXLL-SFHVURJKSA-N	Launched	lanosterol demethylase inhibitor|sterol demethylase inhibitor	infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis
econazole	NPY2R	6604378	LEZWWPYKPKIXLL-SFHVURJKSA-N	Launched	lanosterol demethylase inhibitor|sterol demethylase inhibitor	infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis
econazole	TRPM2	6604378	LEZWWPYKPKIXLL-SFHVURJKSA-N	Launched	lanosterol demethylase inhibitor|sterol demethylase inhibitor	infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis
econazole	TRPV5	6604378	LEZWWPYKPKIXLL-SFHVURJKSA-N	Launched	lanosterol demethylase inhibitor|sterol demethylase inhibitor	infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis
edaglitazone	PPARG	76961439	HAAXAFNSRADSMK-FQEVSTJZSA-N	Phase 2	PPAR receptor agonist	NA	NA
edaravone	BCL2	70335	KZQYIMCESJLPQH-UHFFFAOYSA-N	Launched	nootropic agent	neurology/psychiatry	stroke
edoxaban	F10	10280735	HGVDHZBSSITLCT-JLJPHGGASA-N	Launched	coagulation factor inhibitor	neurology/psychiatry|hematology|cardiology	stroke|pulmonary embolism (PE)|systemic embolism|deep vein thrombosis (DVT)|atrial fibrillation (AF)
edrophonium	ACHE	3202	VWLHWLSRQJQWRG-UHFFFAOYSA-O	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
edrophonium	BCHE	3202	VWLHWLSRQJQWRG-UHFFFAOYSA-O	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
EED226	EED	123132228	DYIRSNMPIZZNBK-UHFFFAOYSA-N	Preclinical	polycomb protein inhibitor	NA	NA
efaproxiral	HBA1	122335	BNFRJXLZYUTIII-UHFFFAOYSA-N	Phase 3	hemoglobin oxygen release stimulant	NA	NA
efaproxiral	HBB	122335	BNFRJXLZYUTIII-UHFFFAOYSA-N	Phase 3	hemoglobin oxygen release stimulant	NA	NA
efaroxan	ADORA2A	11957548	RATZLMXRALDSJW-UHFFFAOYSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
efatutazone	PPARG	76962475	JCYNMRJCUYVDBC-HSZRJFAPSA-N	Phase 2	PPAR receptor agonist	NA	NA
efavirenz	CYP1A2	64139	XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
efavirenz	CYP2B6	64139	XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
efavirenz	CYP2C19	64139	XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
efavirenz	CYP2C9	64139	XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
efavirenz	CYP2D6	64139	XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
efavirenz	CYP3A4	64139	XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
efinaconazole	CYP51A1	9819704	NFEZZTICAUWDHU-KDOFPFPSSA-N	Launched	lanosterol demethylase inhibitor	infectious disease	onychomycosis
eflornithine	ARG2	3009	VLCYCQAOQCDTCN-UHFFFAOYSA-N	Launched	ornithine decarboxylase inhibitor	dermatology	facial hair reduction
eflornithine	ODC1	3009	VLCYCQAOQCDTCN-UHFFFAOYSA-N	Launched	ornithine decarboxylase inhibitor	dermatology	facial hair reduction
EGF816	EGFR	72703790	IOMMMLWIABWRKL-WUTDNEBXSA-N	Phase 2	EGFR inhibitor	NA	NA
eglumetad	GRM2	213056	VTAARTQTOOYTES-RGDLXGNYSA-N	Phase 2	glutamate receptor agonist	NA	NA
eglumetad	GRM3	213056	VTAARTQTOOYTES-RGDLXGNYSA-N	Phase 2	glutamate receptor agonist	NA	NA
eglumetad	GRM6	213056	VTAARTQTOOYTES-RGDLXGNYSA-N	Phase 2	glutamate receptor agonist	NA	NA
eglumetad	GRM8	213056	VTAARTQTOOYTES-RGDLXGNYSA-N	Phase 2	glutamate receptor agonist	NA	NA
EG00229	NRP1	44631827	ZWWMEDURALZMEV-NSHDSACASA-N	Preclinical	neuropilin receptor antagonist	NA	NA
EHop-016	RAC1	51031035	"InChI=1S/C25H30N6O/c1-2-31-22-7-4-3-6-20(22)21-18-19(8-9-23(21)31)28-24-10-12-27-25(29-24)26-11-5-13-30-14-16-32-17-15-30/h3-4,6-10,12,18H,2,5,11,13-17H2,1H3,(H2,26,27,28,29)"	Preclinical	Ras GTPase inhibitor	NA	NA
EHop-016	RAC3	51031035	"InChI=1S/C25H30N6O/c1-2-31-22-7-4-3-6-20(22)21-18-19(8-9-23(21)31)28-24-10-12-27-25(29-24)26-11-5-13-30-14-16-32-17-15-30/h3-4,6-10,12,18H,2,5,11,13-17H2,1H3,(H2,26,27,28,29)"	Preclinical	Ras GTPase inhibitor	NA	NA
EIPA	ADRA2A	1795	QDERNBXNXJCIQK-UHFFFAOYSA-N	Preclinical	sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor	NA	NA
EIPA	ASIC1	1795	QDERNBXNXJCIQK-UHFFFAOYSA-N	Preclinical	sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor	NA	NA
EIPA	PKD2L1	1795	QDERNBXNXJCIQK-UHFFFAOYSA-N	Preclinical	sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor	NA	NA
EIT-hydrobromide	NOS2	5139	VFIZBHJTOHUOEK-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
EIT-hydrobromide	NOS3	5139	VFIZBHJTOHUOEK-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
EI1	EZH2	72199293	PFHDWRIVDDIFRP-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
elacridar	ABCB1	119373	OSFCMRGOZNQUSW-UHFFFAOYSA-N	Phase 1	P glycoprotein inhibitor	NA	NA
elactocin	XPO1	16760536	YACHGFWEQXFSBS-ZNDZZNGASA-N	Phase 1	exportin antagonist	NA	NA
elacytarabine	DCK	6438895	FLFGNMFWNBOBGE-FNNZEKJRSA-N	Phase 3	antineoplastic agent	NA	NA
elafibranor	PPARA	9864881	AFLFKFHDSCQHOL-IZZDOVSWSA-N	Phase 3	PPAR receptor agonist	NA	NA
elafibranor	PPARD	9864881	AFLFKFHDSCQHOL-IZZDOVSWSA-N	Phase 3	PPAR receptor agonist	NA	NA
elafibranor	PPARG	9864881	AFLFKFHDSCQHOL-IZZDOVSWSA-N	Phase 3	PPAR receptor agonist	NA	NA
elagolix	GNRHR	11250647	HEAUOKZIVMZVQL-VWLOTQADSA-N	Launched	gonadotropin releasing factor hormone receptor antagonist	NA	NA
eldecalcitol	VDR	6918141	FZEXGDDBXLBRTD-AYIMTCTASA-N	Phase 3	bone formation stimulant	NA	NA
elesclomol	HSPA1A	300471	BKJIXTWSNXCKJH-UHFFFAOYSA-N	Phase 3	oxidative stress inducer	NA	NA
eletriptan	HTR1A	77993	PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
eletriptan	HTR1B	77993	PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
eletriptan	HTR1D	77993	PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
eletriptan	HTR1E	77993	PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
eletriptan	HTR1F	77993	PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
eletriptan	HTR2B	77993	PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
eletriptan	HTR7	77993	PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
eliglustat	UGCG	23652731	FJZZPCZKBUKGGU-AUSIDOKSSA-N	Launched	glycosyl transferase inhibitor	hematology	Gaucher disease
elinogrel	P2RY12	16066663	LGSDFTPAICUONK-UHFFFAOYSA-N	Phase 2	purinergic receptor antagonist	NA	NA
eliprodil	GRIN1	9798372	GGUSQTSTQSHJAH-FQEVSTJZSA-N	Phase 3	glutamate receptor antagonist	NA	NA
eliprodil	GRIN2B	9798372	GGUSQTSTQSHJAH-FQEVSTJZSA-N	Phase 3	glutamate receptor antagonist	NA	NA
ellagic-acid	CA1	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA12	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA14	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA2	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA3	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA4	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA5A	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA5B	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA6	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA7	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CA9	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	CSNK2A1	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	GSK3B	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	PRKACA	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	PRKCA	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	PRKCB	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	SQLE	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ellagic-acid	SYK	5281855	AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	NA	NA
ELN-441958	BDKRB1	11848206	ARYQHSWJGHCGJS-UHFFFAOYSA-N	Preclinical	bradykinin receptor antagonist	NA	NA
eltanolone	GABRA1	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltanolone	GABRA2	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltanolone	GABRA3	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltanolone	GABRA4	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltanolone	GABRA5	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltanolone	GABRA6	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltanolone	GABRB2	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltanolone	GABRG2	31402	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	GABA receptor positive allosteric modulator	NA	NA
eltoprazine	HTR1A	65853	WVLHGCRWEHCIOT-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
eltoprazine	HTR1B	65853	WVLHGCRWEHCIOT-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
eltrombopag	MPL	NA	XDXWLKQMMKQXPV-QYQHSDTDSA-N	Launched	thrombopoietin receptor agonist	hematology|infectious disease	anemia|hepatitis C|thrombocytopenia
eluxadoline	OPRD1	130406582	QFNHIDANIVGXPE-FNZWTVRRSA-N	Launched	opioid receptor agonist|opioid receptor antagonist	gastroenterology	irritable bowel syndrome
eluxadoline	OPRK1	130406582	QFNHIDANIVGXPE-FNZWTVRRSA-N	Launched	opioid receptor agonist|opioid receptor antagonist	gastroenterology	irritable bowel syndrome
eluxadoline	OPRM1	130406582	QFNHIDANIVGXPE-FNZWTVRRSA-N	Launched	opioid receptor agonist|opioid receptor antagonist	gastroenterology	irritable bowel syndrome
embelin	XIAP	NA	HQWGBIUMYSOPFP-UHFFFAOYSA-N	Preclinical	HCV inhibitor|XIAP inhibitor	NA	NA
EMD-1214063	MET	25171648	AHYMHWXQRWRBKT-UHFFFAOYSA-N	Phase 2	hepatocyte growth factor receptor inhibitor	NA	NA
EMD-386088	HTR6	10131112	BPPGPYJBCVXILI-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
EMD-53998	TNNC1	446286	IZLRMTJLQCLMKF-CYBMUJFWSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
EMD-66684	AGTR1	9892554	CQVJTTOZTTVVBK-UHFFFAOYSA-N	Preclinical	angiotensin receptor antagonist	NA	NA
emedastine	HRH1	3219	KBUZBQVCBVDWKX-UHFFFAOYSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
emetine	RPS2	10219	AUVVAXYIELKVAI-CKBKHPSWSA-N	Phase 2	protein synthesis inhibitor	NA	NA
emodin	CSNK2A1	3220	RHMXXJGYXNZAPX-UHFFFAOYSA-N	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	NA	NA
empagliflozin	SLC5A1	11949646	OBWASQILIWPZMG-QZMOQZSNSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
empagliflozin	SLC5A2	11949646	OBWASQILIWPZMG-QZMOQZSNSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
emricasan	CASP1	12000240	SCVHJVCATBPIHN-SJCJKPOMSA-N	Phase 2	caspase inhibitor	NA	NA
emricasan	CASP3	12000240	SCVHJVCATBPIHN-SJCJKPOMSA-N	Phase 2	caspase inhibitor	NA	NA
emricasan	CASP7	12000240	SCVHJVCATBPIHN-SJCJKPOMSA-N	Phase 2	caspase inhibitor	NA	NA
enalapril	ACE	5388962	GBXSMTUPTTWBMN-XIRDDKMYSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD)
enalaprilat	ACE	5462501	LZFZMUMEGBBDTC-QEJZJMRPSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
enasidenib	IDH1	89683805	DYLUUSLLRIQKOE-UHFFFAOYSA-N	Launched	isocitrate dehydrogenase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
enciprazine	GABRA1	29919953	KSQCNASWXSCJTD-QGZVFWFLSA-N	Phase 3	GABA receptor modulator	NA	NA
encorafenib	BRAF	50922675	CMJCXYNUCSMDBY-ZDUSSCGKSA-N	Launched	RAF inhibitor	oncology	melanoma
endo-IWR-1	TNKS	44483163	ZGSXEXBYLJIOGF-ALFLXDJESA-N	Preclinical	PARP inhibitor	NA	NA
endo-IWR-1	TNKS2	44483163	ZGSXEXBYLJIOGF-ALFLXDJESA-N	Preclinical	PARP inhibitor	NA	NA
endoxifen	ESR1	10090750	MHJBZVSGOZTKRH-IZHYLOQSSA-N	Phase 2	estrogen receptor antagonist	NA	NA
enflurane	GABRA1	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRA2	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRA3	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRA4	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRA5	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRA6	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRB1	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRB2	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRB3	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRD	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRE	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRG1	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRG2	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRG3	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRP	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GABRQ	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GLRA1	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	GLRB	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	KCNK10	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	KCNK18	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	KCNK2	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	KCNK3	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enflurane	KCNK9	7059516	JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enilconazole	CYP19A1	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	CYP1A2	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	CYP2B6	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	CYP2C9	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	CYP2J2	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	CYP3A4	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	CYP3A5	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	NR1I2	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	PPARA	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
enilconazole	PTGER2	6992070	PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	sterol demethylase inhibitor	infectious disease	skin infections
eniluracil	AOX1	43157	JOZGNYDSEBIJDH-UHFFFAOYSA-N	Phase 3	dihydropyrimidine dehydrogenase inhibitor	NA	NA
eniluracil	DPYD	43157	JOZGNYDSEBIJDH-UHFFFAOYSA-N	Phase 3	dihydropyrimidine dehydrogenase inhibitor	NA	NA
eniluracil	XDH	43157	JOZGNYDSEBIJDH-UHFFFAOYSA-N	Phase 3	dihydropyrimidine dehydrogenase inhibitor	NA	NA
ENMD-2076	AURKA	16041424	BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor	NA	NA
ENMD-2076	FLT3	16041424	BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor	NA	NA
ENMD-2076	KDR	16041424	BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor	NA	NA
ENMD-2076	PDGFRA	16041424	BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor	NA	NA
ENMD-2076	PTK2	16041424	BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor	NA	NA
ENMD-2076	SRC	16041424	BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor	NA	NA
enocitabine	CMPK1	71734	SAMRUMKYXPVKPA-VFKOLLTISA-N	Launched	DNA synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
enocitabine	RRM1	71734	SAMRUMKYXPVKPA-VFKOLLTISA-N	Launched	DNA synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
enocitabine	TYMS	71734	SAMRUMKYXPVKPA-VFKOLLTISA-N	Launched	DNA synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
enoxacin	TOP2A	3229	IDYZIJYBMGIQMJ-UHFFFAOYSA-N	Launched	topoisomerase inhibitor	infectious disease	urinary tract infections|gonorrhea
enoximone	PDE3A	53708	ZJKNESGOIKRXQY-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
enoxolone	HSD11B1	10114	MPDGHEJMBKOTSU-YKLVYJNSSA-N	Launched	gap junction modulator	gastroenterology|otolaryngology	peptic ulcer disease (PUD)|common cold
enprofylline	ADORA1	1676	SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
enprofylline	ADORA2A	1676	SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
enprofylline	ADORA2B	1676	SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
enprofylline	ADORA3	1676	SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
enprofylline	PDE4A	1676	SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
enprofylline	PDE4B	1676	SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
entacapone	COMT	5281081	JRURYQJSLYLRLN-BJMVGYQFSA-N	Launched	catechol O methyltransferase inhibitor	neurology/psychiatry	Parkinson's Disease
entinostat	HDAC1	4261	INVTYAOGFAGBOE-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
entinostat	HDAC2	4261	INVTYAOGFAGBOE-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
entinostat	HDAC3	4261	INVTYAOGFAGBOE-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
entinostat	HDAC9	4261	INVTYAOGFAGBOE-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
entrectinib	ALK	25141092	HAYYBYPASCDWEQ-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor	oncology	non-small cell lung cancer (NSCLC)
entrectinib	NTRK1	25141092	HAYYBYPASCDWEQ-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor	oncology	non-small cell lung cancer (NSCLC)
entrectinib	NTRK2	25141092	HAYYBYPASCDWEQ-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor	oncology	non-small cell lung cancer (NSCLC)
entrectinib	NTRK3	25141092	HAYYBYPASCDWEQ-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor	oncology	non-small cell lung cancer (NSCLC)
entrectinib	ROS1	25141092	HAYYBYPASCDWEQ-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor	oncology	non-small cell lung cancer (NSCLC)
enzalutamide	AR	15951529	WXCXUHSOUPDCQV-UHFFFAOYSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
enzastaurin	AKT1	176167	AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3	PKC inhibitor	NA	NA
enzastaurin	GSK3B	176167	AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3	PKC inhibitor	NA	NA
enzastaurin	PRKCA	176167	AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3	PKC inhibitor	NA	NA
enzastaurin	PRKCB	176167	AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3	PKC inhibitor	NA	NA
enzastaurin	PRKCD	176167	AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3	PKC inhibitor	NA	NA
enzastaurin	PRKCG	176167	AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3	PKC inhibitor	NA	NA
EN460	ERO1A	1016023	RSLFQCNAOMQAIH-WJDWOHSUSA-N	Preclinical	endoplasmic reticulum oxidation inhibitor	NA	NA
EO-1428	MAPK11	9801969	HDCLCHNAEZNGNV-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
EO-1428	MAPK14	9801969	HDCLCHNAEZNGNV-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
epacadostat	IDO1	135564890	FBKMWOJEPMPVTQ-UHFFFAOYSA-N	Phase 3	"indoleamine 2,3-dioxygenase inhibitor"	NA	NA
epalrestat	AKR1B1	1549120	CHNUOJQWGUIOLD-NFZZJPOKSA-N	Launched	aldose reductase inhibitor	nephrology	diabetic nephropathy
eperisone	CYP2J2	37888265	SQUNAWUMZGQQJD-AWEZNQCLSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)|spasms|head injury|spinal injury
ephedrine	ACHE	9294	KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine	ADRA1A	9294	KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine	ADRB2	9294	KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine	SLC18A2	9294	KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine	SLC6A2	9294	KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ADRA1A	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ADRA2A	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ADRB1	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ADRB2	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ATF1	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ATF2	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ATF3	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ATF4	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ATF5	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ATF6	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	ATF7	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	FOS	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	IL2	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	JDP2	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	JUN	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	NFATC1	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	SLC6A2	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	SLC6A3	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	SLC6A4	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
ephedrine-(racemic)	TNF	7028	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity
epiandrosterone	G6PD	441302	QGXBDMJGAMFCBF-LUJOEAJASA-N	Preclinical	steroid	NA	NA
epicatechin-gallate-(-)	BACE1	107905	LSHVYAFMTMFKBA-TZIWHRDSSA-N	Phase 2	bacterial DNA gyrase inhibitor	NA	NA
epicatechin-gallate-(-)	FASN	107905	LSHVYAFMTMFKBA-TZIWHRDSSA-N	Phase 2	bacterial DNA gyrase inhibitor	NA	NA
epigallocatechin-gallate-(-)	ELANE	65064	WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	NA	NA
epigallocatechin-gallate-(-)	EP300	65064	WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	NA	NA
epigallocatechin-gallate-(-)	FASN	65064	WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	NA	NA
epigallocatechin-gallate-(-)	KAT2B	65064	WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	NA	NA
epigallocatechin-gallate-(-)	MMP14	65064	WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	NA	NA
epigallocatechin-gallate-(-)	MMP2	65064	WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	NA	NA
epinastine	HRH1	15629776	WHWZLSFABNNENI-OAHLLOKOSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
epinephrine	ADRA1A	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRA1B	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRA1D	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRA2A	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRA2B	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRA2C	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRB1	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRB2	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	ADRB3	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	PAH	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epinephrine	TNF	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma
epirizole	PTGS1	3242	RHAXSHUQNIEUEY-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
epirizole	PTGS2	3242	RHAXSHUQNIEUEY-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
epirubicin	CHD1	41867	"InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1"	Launched	topoisomerase inhibitor	oncology	breast cancer
epirubicin	TOP2A	41867	"InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1"	Launched	topoisomerase inhibitor	oncology	breast cancer
epitiostanol	AR	443935	OBMLHUPNRURLOK-XGRAFVIBSA-N	Launched	androgen receptor agonist	oncology	breast cancer
eplerenone	NR3C2	443872	JUKPWJGBANNWMW-VWBFHTRKSA-N	Launched	cytochrome P450 inhibitor	cardiology	congestive heart failure|hypertension
epomediol	CYP7A1	NA	JSNQSLSBBZFGBM-XAKJDZQGSA-N	Launched	cholesterol inhibitor	neurology/psychiatry	itching
epoprostenol	P2RY12	5282411	"InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1"	Launched	prostacyclin analog	cardiology	hypertension
epoprostenol	PTGER1	5282411	"InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1"	Launched	prostacyclin analog	cardiology	hypertension
epoprostenol	PTGER4	5282411	"InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1"	Launched	prostacyclin analog	cardiology	hypertension
epoprostenol	PTGIR	5282411	"InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1"	Launched	prostacyclin analog	cardiology	hypertension
epoprostenol	PTGIS	5282411	"InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1"	Launched	prostacyclin analog	cardiology	hypertension
epothilone-B	TUBB	118184795	QXRSDHAAWVKZLJ-QBNZTRRJSA-N	Phase 3	microtubule stabilizing agent|tubulin polymerization inhibitor	NA	NA
epothilone-D	TUBB	NA	XOZIUKBZLSUILX-HFHFCCBWSA-N	Phase 2	microtubule stabilizing agent|tubulin polymerization inhibitor	NA	NA
EPPTB	TAAR1	25175634	KLFVWQCQUXXLOU-UHFFFAOYSA-N	Preclinical	trace amine associated receptor antagonist	NA	NA
eprobemide	MAOA	65659	YYFGRAGNYHYWEZ-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
eprodisate	SAA1	428573	MGNVWUDMMXZUDI-UHFFFAOYSA-N	Phase 3	amyloid protein inhibitor|antiamyloidogenic agent	NA	NA
eprosartan	AGTR1	5281037	OROAFUQRIXKEMV-LDADJPATSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
eptifibatide	ITGA2B	134812820	CZKPOZZJODAYPZ-IQENKEMDSA-N	Launched	platelet aggregation inhibitor	cardiology	acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI)
eptifibatide	ITGB3	134812820	CZKPOZZJODAYPZ-IQENKEMDSA-N	Launched	platelet aggregation inhibitor	cardiology	acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI)
EPZ-5676	DOT1L		LXFOLMYKSYSZQS-LURJZOHASA-N	Phase 1	histone lysine methyltransferase inhibitor	NA	NA
EPZ004777	DOT1L	56962336	WXRGFPHDRFQODR-ICLZECGLSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
EPZ005687	EZH2	60160561	ZOIBZSZLMJDVDQ-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
EPZ011989	EZH2	NA	XQFINGFCBFHOPE-WXUXXXNLSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
EPZ015666	PRMT5	90241673	ZKXZLIFRWWKZRY-KRWDZBQOSA-N	Preclinical	protein arginine N-methyltransferase inhibitor	NA	NA
EPZ020411	PRMT6	NA	QMDKVNSQXPVCRD-RQNOJGIXSA-N	Preclinical	protein arginine N-methyltransferase inhibitor	NA	NA
equilin	HSD17B1	41097932	WKRLQDKEXYKHJB-UWWQBHOKSA-N	Preclinical	estrogen receptor agonist	NA	NA
equol	ESR1	91469	ADFCQWZHKCXPAJ-GFCCVEGCSA-N	Launched	estrogen receptor agonist	NA	NA
equol	ESR2	91469	ADFCQWZHKCXPAJ-GFCCVEGCSA-N	Launched	estrogen receptor agonist	NA	NA
ER-27319	SYK	9799509	CFPDEQBPNROZDC-UHFFFAOYSA-N	Preclinical	mediator release inhibitor|SYK inhibitor	NA	NA
ER-50891	RARA	10094345	LSGNKLDHMQVTEK-UHFFFAOYSA-N	Preclinical	retinoid receptor antagonist	NA	NA
erastin	VDAC2	91669533	BKQFRNYHFIQEKN-OAQYLSRUSA-N	Preclinical	ion channel antagonist	NA	NA
erbstatin-analog	EGFR	5353609	BQCNSTFWSKOWMA-GORDUTHDSA-N	Preclinical	EGFR inhibitor|tyrosine kinase inhibitor	NA	NA
ercalcitriol	VDR	9547243	ZGLHBRQAEXKACO-XJRQOBMKSA-N	Phase 1	vitamin D receptor agonist	NA	NA
erdafitinib	FGFR1	67462786	OLAHOMJCDNXHFI-UHFFFAOYSA-N	Launched	FGFR inhibitor	NA	NA
erdafitinib	FGFR2	67462786	OLAHOMJCDNXHFI-UHFFFAOYSA-N	Launched	FGFR inhibitor	NA	NA
erdafitinib	FGFR3	67462786	OLAHOMJCDNXHFI-UHFFFAOYSA-N	Launched	FGFR inhibitor	NA	NA
erdafitinib	FGFR4	67462786	OLAHOMJCDNXHFI-UHFFFAOYSA-N	Launched	FGFR inhibitor	NA	NA
ergocalciferol	VDR	5280793	MECHNRXZTMCUDQ-RKHKHRCZSA-N	Launched	vitamin analog	endocrinology|orthopedics	hypoparathyroidism|rickets|hypophosphatemia
ergonovine	ADRA1A	443884	WVVSZNPYNCNODU-XTQGRXLLSA-N	Launched	adrenergic receptor agonist|serotonin receptor agonist	hematology	postpartum hemorrhage (PPH)
ergonovine	HTR1E	443884	WVVSZNPYNCNODU-XTQGRXLLSA-N	Launched	adrenergic receptor agonist|serotonin receptor agonist	hematology	postpartum hemorrhage (PPH)
ergotamine	ADRA1A	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	ADRA1B	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	ADRA1D	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	ADRA2A	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	ADRA2B	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	DRD1	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	DRD2	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	DRD5	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR1A	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR1B	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR1D	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR1E	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR1F	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR2A	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR2B	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR2C	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR5A	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	HTR6	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ergotamine	SLC6A2	8223	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
ERK5-IN-1	MAPK7	46844147	DDTPGANIPBKTNU-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
erlotinib	EGFR	176870	"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)"	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)|pancreatic cancer
erlotinib	NR1I2	176870	"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)"	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)|pancreatic cancer
erteberel	ESR1	10286159	XIESSJVMWNJCGZ-VKJFTORMSA-N	Phase 2	estrogen receptor agonist	NA	NA
erteberel	ESR2	10286159	XIESSJVMWNJCGZ-VKJFTORMSA-N	Phase 2	estrogen receptor agonist	NA	NA
ertugliflozin	SLC5A2	44814423	MCIACXAZCBVDEE-CUUWFGFTSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
erythromycin	MLNR		ULGZDMOVFRHVEP-BCQGSPHWSA-N	Launched	NFkB pathway inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-estolate	ABCB1	NA	TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-estolate	ALB	NA	TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-estolate	CYP3A4	NA	TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-estolate	CYP51A1	NA	TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-estolate	KCNH2	NA	TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-estolate	MLNR	NA	TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-estolate	SLC47A1	NA	TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-ethylsuccinate	ABCB1	132274075	NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-ethylsuccinate	ALB	132274075	NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-ethylsuccinate	CYP3A4	132274075	NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-ethylsuccinate	CYP51A1	132274075	NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-ethylsuccinate	KCNH2	132274075	NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-ethylsuccinate	MLNR	132274075	NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
erythromycin-ethylsuccinate	SLC47A1	132274075	NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
escitalopram	SLC6A4	146571	KTGRHKOEFSJQNS-BDQAORGHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)
eseroline-(-)	OPRD1	119198	HKGWQUVGHPDEBZ-OLZOCXBDSA-N	Preclinical	acetylcholinesterase inhibitor	NA	NA
eseroline-(-)	OPRM1	119198	HKGWQUVGHPDEBZ-OLZOCXBDSA-N	Preclinical	acetylcholinesterase inhibitor	NA	NA
ESI-09	RAPGEF3	6077765	DXEATJQGQHDURZ-DEDYPNTBSA-N	Preclinical	EPAC inhibitor	NA	NA
ESI-09	RAPGEF4	6077765	DXEATJQGQHDURZ-DEDYPNTBSA-N	Preclinical	EPAC inhibitor	NA	NA
eslicarbazepine-acetate	SCN10A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN11A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN1A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN2A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN3A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN4A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN5A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN7A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN8A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
eslicarbazepine-acetate	SCN9A	179344	QIALRBLEEWJACW-INIZCTEOSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
esmolol	ADRB1	28125476	AQNDDEOPVVGCPG-AWEZNQCLSA-N	Launched	adrenergic receptor antagonist	cardiology	ventricular tachycardia (VT)|hypertension
esomeprazole	ATP4A	9568614	SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched	ATPase inhibitor	gastroenterology	gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)
estetrol	ESR1	27125	AJIPIJNNOJSSQC-NYLIRDPKSA-N	Phase 3	selective estrogen receptor modulator (SERM)	NA	NA
estradiol	ESR1	5757	VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched	estrogen receptor agonist	endocrinology	contraceptive
estradiol	ESR2	5757	VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched	estrogen receptor agonist	endocrinology	contraceptive
estradiol	GPER1	5757	VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched	estrogen receptor agonist	endocrinology	contraceptive
estradiol	KCNMA1	5757	VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched	estrogen receptor agonist	endocrinology	contraceptive
estradiol	NR1I2	5757	VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched	estrogen receptor agonist	endocrinology	contraceptive
estradiol-acetate	ESR1	9818306	FHXBMXJMKMWVRG-SLHNCBLASA-N	Launched	estrogen receptor agonist	endocrinology|obstetrics/gynecology	menopause|vaginal atrophy
estradiol-benzoate	ESR1	222757	UYIFTLBWAOGQBI-BZDYCCQFSA-N	Preclinical	contraceptive agent	NA	NA
estradiol-cypionate	ESR1	9403	UOACKFBJUYNSLK-XRKIENNPSA-N	Launched	estrogen receptor agonist	endocrinology	hypoestrogenism|menopause
estradiol-valerate	ESR1	13791	RSEPBGGWRJCQGY-RBRWEJTLSA-N	Launched	estrogen receptor agonist	oncology|endocrinology|obstetrics/gynecology	prostate cancer|hypoestrogenism|menopause|vaginal atrophy
estramustine	ESR1	259331	FRPJXPJMRWBBIH-RBRWEJTLSA-N	Launched	DNA alkylating agent	oncology	prostate cancer
estramustine	ESR2	259331	FRPJXPJMRWBBIH-RBRWEJTLSA-N	Launched	DNA alkylating agent	oncology	prostate cancer
estramustine	MAP1A	259331	FRPJXPJMRWBBIH-RBRWEJTLSA-N	Launched	DNA alkylating agent	oncology	prostate cancer
estramustine	MAP2	259331	FRPJXPJMRWBBIH-RBRWEJTLSA-N	Launched	DNA alkylating agent	oncology	prostate cancer
estramustine-phosphate	ESR1	259329	ADFOJJHRTBFFOF-RBRWEJTLSA-N	Launched	DNA synthesis inhibitor|microtubule inhibitor	oncology	prostate cancer
estramustine-phosphate	ESR2	259329	ADFOJJHRTBFFOF-RBRWEJTLSA-N	Launched	DNA synthesis inhibitor|microtubule inhibitor	oncology	prostate cancer
estramustine-phosphate	MAP1A	259329	ADFOJJHRTBFFOF-RBRWEJTLSA-N	Launched	DNA synthesis inhibitor|microtubule inhibitor	oncology	prostate cancer
estramustine-phosphate	MAP2	259329	ADFOJJHRTBFFOF-RBRWEJTLSA-N	Launched	DNA synthesis inhibitor|microtubule inhibitor	oncology	prostate cancer
estriol	ESR1	5756	PROQIPRRNZUXQM-ZXXIGWHRSA-N	Launched	estrogen receptor agonist	endocrinology|obstetrics/gynecology|infectious disease	menopause|vaginal atrophy|urinary tract infections
estriol	ESR2	5756	PROQIPRRNZUXQM-ZXXIGWHRSA-N	Launched	estrogen receptor agonist	endocrinology|obstetrics/gynecology|infectious disease	menopause|vaginal atrophy|urinary tract infections
estrone	ESR1	5870	DNXHEGUUPJUMQT-CBZIJGRNSA-N	Launched	estrogen receptor agonist|estrogenic hormone	endocrinology	menopause
estrone	ESR2	5870	DNXHEGUUPJUMQT-CBZIJGRNSA-N	Launched	estrogen receptor agonist|estrogenic hormone	endocrinology	menopause
estropipate	ESR1	3001028	JKKFKPJIXZFSSB-CBZIJGRNSA-N	Launched	estrogen receptor agonist	orthopedics|endocrinology|obstetrics/gynecology	osteoporosis|menopause|vaginal atrophy|hypoestrogenism
estropipate	ESR2	3001028	JKKFKPJIXZFSSB-CBZIJGRNSA-N	Launched	estrogen receptor agonist	orthopedics|endocrinology|obstetrics/gynecology	osteoporosis|menopause|vaginal atrophy|hypoestrogenism
etacrynic-acid	ATP1A1	3278	AVOLMBLBETYQHX-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|nephrology|rheumatology	hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome
etacrynic-acid	SLC12A1	3278	AVOLMBLBETYQHX-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|nephrology|rheumatology	hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome
etazolate	GABRB3	3277	OPQRBXUBWHDHPQ-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
etazolate	PDE4A	3277	OPQRBXUBWHDHPQ-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
ETC-159	PORCN	86280523	QTRXIFVSTWXRJJ-UHFFFAOYSA-N	Phase 1	beta catenin inhibitor|porcupine inhibitor	NA	NA
ethanolamine-oleate	F12	5282489	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched	immunostimulant	gastroenterology	esophageal varices
ethanolamine-oleate	FABP4	5282489	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched	immunostimulant	gastroenterology	esophageal varices
ethanolamine-oleate	FFAR1	5282489	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched	immunostimulant	gastroenterology	esophageal varices
ethanolamine-oleate	FFAR4	5282489	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched	immunostimulant	gastroenterology	esophageal varices
ethanolamine-oleate	PLD2	5282489	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched	immunostimulant	gastroenterology	esophageal varices
ethinyl-estradiol	ESR1	5991	BFPYWIDHMRZLRN-SLHNCBLASA-N	Launched	estrogen receptor agonist|estrogenic hormone	endocrinology	contraceptive
ethinyl-estradiol	ESR2	5991	BFPYWIDHMRZLRN-SLHNCBLASA-N	Launched	estrogen receptor agonist|estrogenic hormone	endocrinology	contraceptive
ethinyl-estradiol	NR1I2	5991	BFPYWIDHMRZLRN-SLHNCBLASA-N	Launched	estrogen receptor agonist|estrogenic hormone	endocrinology	contraceptive
ethisterone	TYR	5284557	CHNXZKVNWQUJIB-CEGNMAFCSA-N	Launched	progestogen hormone	endocrinology	amenorrhea
ethosuximide	CACNA1G	10630591	HAPOVYFOVVWLRS-ZETCQYMHSA-N	Launched	succinimide antiepileptic	neurology/psychiatry	epilepsy
ethosuximide	CACNA1H	10630591	HAPOVYFOVVWLRS-ZETCQYMHSA-N	Launched	succinimide antiepileptic	neurology/psychiatry	epilepsy
ethosuximide	CACNA1I	10630591	HAPOVYFOVVWLRS-ZETCQYMHSA-N	Launched	succinimide antiepileptic	neurology/psychiatry	epilepsy
ethotoin	SCN5A	12309784	SZQIFWWUIBRPBZ-SECBINFHSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
ethoxzolamide	CA1	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA12	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA13	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA14	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA2	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA3	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA4	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA5A	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA5B	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA6	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA7	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethoxzolamide	CA9	3295	OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease
ethynodiol-diacetate	ESR1	9270	ONKUMRGIYFNPJW-KIEAKMPYSA-N	Launched		endocrinology	contraceptive
ethynodiol-diacetate	PGR	9270	ONKUMRGIYFNPJW-KIEAKMPYSA-N	Launched		endocrinology	contraceptive
eticlopride	DRD2	57267	AADCDMQTJNYOSS-LBPRGKRZSA-N	Preclinical	dopamine receptor antagonist	NA	NA
eticlopride	DRD3	57267	AADCDMQTJNYOSS-LBPRGKRZSA-N	Preclinical	dopamine receptor antagonist	NA	NA
eticlopride	DRD4	57267	AADCDMQTJNYOSS-LBPRGKRZSA-N	Preclinical	dopamine receptor antagonist	NA	NA
etidronic-acid	ATP6V1A	3305	DBVJJBKOTRCVKF-UHFFFAOYSA-N	Launched	bone resorption inhibitor	endocrinology|orthopedics	Paget's disease|heterotopic ossification
etidronic-acid	PTPRS	3305	DBVJJBKOTRCVKF-UHFFFAOYSA-N	Launched	bone resorption inhibitor	endocrinology|orthopedics	Paget's disease|heterotopic ossification
etifoxine	GABRA1	135564604	IBYCYJFUEJQSMK-KRWDZBQOSA-N	Launched	GABA receptor modulator	neurology/psychiatry	anxiety
etifoxine	GABRA2	135564604	IBYCYJFUEJQSMK-KRWDZBQOSA-N	Launched	GABA receptor modulator	neurology/psychiatry	anxiety
etifoxine	GABRA3	135564604	IBYCYJFUEJQSMK-KRWDZBQOSA-N	Launched	GABA receptor modulator	neurology/psychiatry	anxiety
etifoxine	GABRA5	135564604	IBYCYJFUEJQSMK-KRWDZBQOSA-N	Launched	GABA receptor modulator	neurology/psychiatry	anxiety
etilefrine	ADRA1A	164652	SQVIAVUSQAWMKL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry|otolaryngology|endocrinology|pulmonary	headache|nasal congestion|fever|cough suppressant|common cold
etilefrine	ADRB1	164652	SQVIAVUSQAWMKL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry|otolaryngology|endocrinology|pulmonary	headache|nasal congestion|fever|cough suppressant|common cold
etilevodopa	DRD3	170345	NULMGOSOSZBEQL-QMMMGPOBSA-N	Phase 3	dopamine receptor agonist	NA	NA
etizolam	GABRA1	3307	VMZUTJCNQWMAGF-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	insomnia|anxiety
etodolac	PTGS2	688461	NNYBQONXHNTVIJ-KRWDZBQOSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
etofenamate	PTGS1	35375	XILVEPYQJIOVNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain
etofenamate	PTGS2	35375	XILVEPYQJIOVNB-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain
etofibrate	PPARA	65777	XXRVYAFBUDSLJX-UHFFFAOYSA-N	Launched	PPAR receptor agonist	endocrinology	hypertriglyceridemia
etofylline	ADORA1	1892	NWPRCRWQMGIBOT-UHFFFAOYSA-N	Launched	adenosine receptor antagonist	pulmonary	asthma|bronchitis
etofylline-clofibrate	PPARA	41109	KYAKGJDISSNVPZ-UHFFFAOYSA-N	Launched	platelet aggregation inhibitor	endocrinology	hyperlipidemia
etomidate	ADRA2B	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRA1	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRA2	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRA3	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRA4	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRA5	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRA6	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRB1	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRB2	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRB3	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRD	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRE	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRG1	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRG2	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRG3	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRP	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomidate	GABRQ	667484	NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomoxir	CPT1A	9840324	DZLOHEOHWICNIL-QGZVFWFLSA-N	Phase 2	carnitine palmitoyltransferase inhibitor	NA	NA
etonogestrel	ESR1	6917715	GCKFUYQCUCGESZ-BPIQYHPVSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
etonogestrel	PGR	6917715	GCKFUYQCUCGESZ-BPIQYHPVSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
etoposide	TOP2A	36462	VJJPUSNTGOMMGY-MRVIYFEKSA-N	Launched	topoisomerase inhibitor	oncology	non-small cell lung cancer (NSCLC)
etoposide	TOP2B	36462	VJJPUSNTGOMMGY-MRVIYFEKSA-N	Launched	topoisomerase inhibitor	oncology	non-small cell lung cancer (NSCLC)
etoposide-phosphate	TOP2A	6918092	LIQODXNTTZAGID-OCBXBXKTSA-N	Launched	topoisomerase inhibitor	oncology	testicular carcinoma|small cell lung cancer
etoricoxib	PTGS2	123619	MNJVRJDLRVPLFE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|psoriatic arthritis|osteoarthritis|gout|ankylosing spondylitis
ETP-45658	PIK3CA	25229608	BJVRNXSHJLDZJR-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
ETP-45658	PIK3CB	25229608	BJVRNXSHJLDZJR-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
ETP-45658	PIK3CD	25229608	BJVRNXSHJLDZJR-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
ETP-45658	PIK3CG	25229608	BJVRNXSHJLDZJR-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
etravirine	CYP2C19	193962	PYGWGZALEOIKDF-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
etravirine	CYP2C9	193962	PYGWGZALEOIKDF-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
etravirine	CYP3A4	193962	PYGWGZALEOIKDF-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
etretinate	RARA	5282375	HQMNCQVAMBCHCO-DJRRULDNSA-N	Withdrawn	protein synthesis inhibitor	NA	NA
etretinate	RXRG	5282375	HQMNCQVAMBCHCO-DJRRULDNSA-N	Withdrawn	protein synthesis inhibitor	NA	NA
eucalyptol	ACHE	2758	WEEGYLXZBRQIMU-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	dental	gingivitis
eugenol	AR	3314	RRAFCDWBNXTKKO-UHFFFAOYSA-N	Launched	androgen receptor antagonist	dental	toothache
EUK-134	APP		QCAWBJDECIOVBU-GAMUHHASSA-K	Preclinical	catalase stimulant	NA	NA
EUK-134	SOD2		QCAWBJDECIOVBU-GAMUHHASSA-K	Preclinical	catalase stimulant	NA	NA
evacetrapib	CETP	NA	IHIUGIVXARLYHP-YBXDKENTSA-N	Phase 3	cholesteryl ester transfer protein inhibitor	NA	NA
evans-blue	GRIA1	6804600	LIRUWPZKVZZTHC-UHFFFAOYSA-N	Launched	glutamate receptor negative allosteric modulator	NA	NA
evans-blue	PTPN1	6804600	LIRUWPZKVZZTHC-UHFFFAOYSA-N	Launched	glutamate receptor negative allosteric modulator	NA	NA
evatanepag	PTGER2	9890801	WOHRHWDYFNWPNG-UHFFFAOYSA-N	Phase 2	prostaglandin inhibitor	NA	NA
evatanepag	PTGER4	9890801	WOHRHWDYFNWPNG-UHFFFAOYSA-N	Phase 2	prostaglandin inhibitor	NA	NA
everolimus	MTOR		HKVAMNSJSFKALM-FLOWVUKKSA-N	Launched	mTOR inhibitor	oncology|neurology/psychiatry|genetics|urology	breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma
evodiamine	TRPV1	442088	TXDUTHBFYKGSAH-SFHVURJKSA-N	Preclinical	ATPase inhibitor|TRPV agonist	NA	NA
EVP-6124	CHRNA7	46196517	SSRDSYXGYPJKRR-ZDUSSCGKSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
EW-7197	ACVR1B	54766013	FJCDSQATIJKQKA-UHFFFAOYSA-N	Phase 2	TGF beta receptor inhibitor	NA	NA
EW-7197	TGFBR1	54766013	FJCDSQATIJKQKA-UHFFFAOYSA-N	Phase 2	TGF beta receptor inhibitor	NA	NA
EX-527	SIRT1	707029	FUZYTVDVLBBXDL-VIFPVBQESA-N	Phase 2	SIRT inhibitor	NA	NA
examorelin	GHRHR	6918297	RVWNMGKSNGWLOL-GIIHNPQRSA-N	Phase 2	growth hormone releasing factor agonist	NA	NA
examorelin	GHSR	6918297	RVWNMGKSNGWLOL-GIIHNPQRSA-N	Phase 2	growth hormone releasing factor agonist	NA	NA
exatecan-mesylate	TOP1	151115	ZVYVPGLRVWUPMP-FYSMJZIKSA-N	Phase 3	topoisomerase inhibitor	NA	NA
exemestane	CYP19A1	60198	BFYIZQONLCFLEV-DAELLWKTSA-N	Launched	aromatase inhibitor	oncology	breast cancer
exenatide	GLP1R	91935542	HTQBXNHDCUEHJF-XWLPCZSASA-N	Launched	GLP receptor agonist	endocrinology	diabetes mellitus
exherin	CDH2	NA	FQVLRGLGWNWPSS-XDKAFHOCSA-N	Phase 2	cadherin antagonist	NA	NA
exifone	TYR	40399	XEDWWPGWIXPVRQ-UHFFFAOYSA-N	Withdrawn	nootropic agent	NA	NA
exisulind	PDE5A	5472495	MVGSNCBCUWPVDA-MFOYZWKCSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
exo-IWR-1	TNKS	1163034	ZGSXEXBYLJIOGF-BTYSMDAFSA-N	Preclinical	WNT signaling inhibitor negative control	NA	NA
ezatiostat	GSTP1	5310939	GWEJFLVSOGNLSS-WPFOTENUSA-N	Phase 2	glutathione transferase inhibitor	NA	NA
ezetimibe	ANPEP	150311	OLNTVTPDXPETLC-XPWALMASSA-N	Launched	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia
ezetimibe	NPC1L1	150311	OLNTVTPDXPETLC-XPWALMASSA-N	Launched	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia
ezetimibe	SOAT1	150311	OLNTVTPDXPETLC-XPWALMASSA-N	Launched	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia
ezutromid	UTRN	886736	WRIPKYOZKAJHRL-UHFFFAOYSA-N	Phase 2	utrophin enhancer	NA	NA
E7449	PARP1	135565981	JLFSBHQQXIAQEC-UHFFFAOYSA-N	Phase 2	PARP inhibitor	NA	NA
E7449	PARP2	135565981	JLFSBHQQXIAQEC-UHFFFAOYSA-N	Phase 2	PARP inhibitor	NA	NA
E7449	TNKS	135565981	JLFSBHQQXIAQEC-UHFFFAOYSA-N	Phase 2	PARP inhibitor	NA	NA
E7449	TNKS2	135565981	JLFSBHQQXIAQEC-UHFFFAOYSA-N	Phase 2	PARP inhibitor	NA	NA
F-11440	HTR1A	208928	NMYAHEULKSYAPP-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
fadrozole	CYP11B1	9815923	CLPFFLWZZBQMAO-CQSZACIVSA-N	Launched	aromatase inhibitor	oncology	breast cancer
fadrozole	CYP19A1	9815923	CLPFFLWZZBQMAO-CQSZACIVSA-N	Launched	aromatase inhibitor	oncology	breast cancer
fagomine	GLB1	72259	YZNNBIPIQWYLDM-HSUXUTPPSA-N	Phase 2	glucosidase inhibitor	NA	NA
falecalcitriol	VDR	5282190	XPYGGHVSFMUHLH-UUSULHAXSA-N	Launched	vitamin D receptor agonist	endocrinology	hyperparathyroidism
famotidine	HRH2	5702160	XUFQPHANEAPEMJ-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology	heartburn
fananserin	HTR2A	60785	VGIGHGMPMUCLIQ-UHFFFAOYSA-N	Phase 2	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
farnesyl-thiosalicylic-acid-amide	HRAS	25187973	GZTMFRUGZMZCRD-CFBAGHHKSA-N	Phase 1	Ras GTPase inhibitor	NA	NA
fasudil	PKIA	3547	NGOGFTYYXHNFQH-UHFFFAOYSA-N	Launched	rho associated kinase inhibitor	neurology/psychiatry	cerebral vasospasm
fasudil	PRKACA	3547	NGOGFTYYXHNFQH-UHFFFAOYSA-N	Launched	rho associated kinase inhibitor	neurology/psychiatry	cerebral vasospasm
fasudil	ROCK1	3547	NGOGFTYYXHNFQH-UHFFFAOYSA-N	Launched	rho associated kinase inhibitor	neurology/psychiatry	cerebral vasospasm
fasudil	ROCK2	3547	NGOGFTYYXHNFQH-UHFFFAOYSA-N	Launched	rho associated kinase inhibitor	neurology/psychiatry	cerebral vasospasm
febuxostat	XDH	134018	BQSJTQLCZDPROO-UHFFFAOYSA-N	Launched	xanthine oxidase inhibitor	nephrology	hyperuricemia
fedratinib	BRD4	16722836	JOOXLOJCABQBSG-UHFFFAOYSA-N	Launched	FLT3 inhibitor|JAK inhibitor	hematologic malignancy	myelofibrosis
fedratinib	JAK1	16722836	JOOXLOJCABQBSG-UHFFFAOYSA-N	Launched	FLT3 inhibitor|JAK inhibitor	hematologic malignancy	myelofibrosis
fedratinib	JAK2	16722836	JOOXLOJCABQBSG-UHFFFAOYSA-N	Launched	FLT3 inhibitor|JAK inhibitor	hematologic malignancy	myelofibrosis
fedratinib	JAK3	16722836	JOOXLOJCABQBSG-UHFFFAOYSA-N	Launched	FLT3 inhibitor|JAK inhibitor	hematologic malignancy	myelofibrosis
fedratinib	TYK2	16722836	JOOXLOJCABQBSG-UHFFFAOYSA-N	Launched	FLT3 inhibitor|JAK inhibitor	hematologic malignancy	myelofibrosis
felbamate	GRIN1	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbamate	GRIN2A	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbamate	GRIN2B	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbamate	GRIN2C	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbamate	GRIN2D	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbamate	GRIN3A	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbamate	GRIN3B	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbinac	CTSL	3332	QRZAKQDHEVVFRX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain
felbinac-ethyl	PTGS1	26436	NPPJLSILDPVHCM-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	NA	NA
felbinac-ethyl	PTGS2	26436	NPPJLSILDPVHCM-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	NA	NA
felodipine	CFTR	941699	RZTAMFZIAATZDJ-HNNXBMFYSA-N	Launched	calcium channel blocker	cardiology	hypertension
fenbendazole	TUBB	3334	HDDSHPAODJUKPD-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	gastrointestinal parasites|gastrointestinal roundworms
fenbufen	PTGS1	3335	ZPAKPRAICRBAOD-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
fenbufen	PTGS2	3335	ZPAKPRAICRBAOD-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
fenclonine-(+/-)	PAH	736190	NIGWMJHCCYYCSF-QMMMGPOBSA-N	Preclinical	tryptophan hydroxylase inhibitor	NA	NA
fenclonine-(+/-)	TPH1	736190	NIGWMJHCCYYCSF-QMMMGPOBSA-N	Preclinical	tryptophan hydroxylase inhibitor	NA	NA
fenclonine-(+/-)	TPH2	736190	NIGWMJHCCYYCSF-QMMMGPOBSA-N	Preclinical	tryptophan hydroxylase inhibitor	NA	NA
fendiline	HTR2B	36687769	NMKSAYKQLCHXDK-LJQANCHMSA-N	Preclinical	calcium channel blocker	NA	NA
fenigam	GABBR1	685623	DAFOCGYVTAOKAJ-SECBINFHSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	posttraumatic stress disorder|anxiety|depression
fenigam	GABBR2	685623	DAFOCGYVTAOKAJ-SECBINFHSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	posttraumatic stress disorder|anxiety|depression
fenobam	GRM5	135659063	DWPQODZAOSWNHB-UHFFFAOYSA-N	Phase 2	glutamate receptor antagonist	NA	NA
fenofibrate	MMP25	3339	YMTINGFKWWXKFG-UHFFFAOYSA-N	Launched	PPAR receptor agonist	endocrinology	hypercholesterolemia|hypertriglyceridemia
fenofibrate	PPARA	3339	YMTINGFKWWXKFG-UHFFFAOYSA-N	Launched	PPAR receptor agonist	endocrinology	hypercholesterolemia|hypertriglyceridemia
fenofibric-acid	CLCN1	64929	MQOBSOSZFYZQOK-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor	cardiology	dyslipidemia
fenofibric-acid	PPARA	64929	MQOBSOSZFYZQOK-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor	cardiology	dyslipidemia
fenoldopam	DRD1	30026875	TVURRHSHRRELCG-CYBMUJFWSA-N	Launched	dopamine receptor agonist	cardiology	hypertension
fenoldopam	DRD4	30026875	TVURRHSHRRELCG-CYBMUJFWSA-N	Launched	dopamine receptor agonist	cardiology	hypertension
fenoprofen	PTGS1	41097863	RDJGLLICXDHJDY-LLVKDONJSA-N	Launched	prostaglandin inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
fenoprofen	SLC5A8	41097863	RDJGLLICXDHJDY-LLVKDONJSA-N	Launched	prostaglandin inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
fenoterol	ADRB2	688469	LSLYOANBFKQKPT-APPDUMDISA-N	Withdrawn	adrenergic receptor agonist	NA	NA
fenoxaprop-p-ethyl	NOS3	91707	PQKBPHSEKWERTG-LLVKDONJSA-N	Preclinical		NA	NA
fenretinide	RARA	5288209	AKJHMTWEGVYYSE-FXILSDISSA-N	Phase 3	apoptosis stimulant|retinoid receptor agonist	NA	NA
fentiazac	PTGS1	28871	JIEKMACRVQTPRC-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain
fentiazac	PTGS2	28871	JIEKMACRVQTPRC-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain
FERb-033	ERBB2	135931707	LRRMQNGSYOUANY-OMCISZLKSA-N	Preclinical	EGFR inhibitor	NA	NA
ferulic-acid	CA1	445858	KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	antioxidant	NA	NA
ferulic-acid	CA12	445858	KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	antioxidant	NA	NA
ferulic-acid	CA14	445858	KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	antioxidant	NA	NA
ferulic-acid	CA2	445858	KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	antioxidant	NA	NA
ferulic-acid	CA4	445858	KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	antioxidant	NA	NA
ferulic-acid	CA6	445858	KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	antioxidant	NA	NA
ferulic-acid	CA9	445858	KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	antioxidant	NA	NA
fesoterodine	CHRM1	6918558	DCCSDBARQIPTGU-HSZRJFAPSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
fesoterodine	CHRM2	6918558	DCCSDBARQIPTGU-HSZRJFAPSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
fesoterodine	CHRM3	6918558	DCCSDBARQIPTGU-HSZRJFAPSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
fesoterodine	CHRM4	6918558	DCCSDBARQIPTGU-HSZRJFAPSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
fesoterodine	CHRM5	6918558	DCCSDBARQIPTGU-HSZRJFAPSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
fexaramine	NR1H4	5326713	VLQTUNDJHLEFEQ-KGENOOAVSA-N	Preclinical	FXR agonist	NA	NA
fexofenadine	HRH1	6603853	RWTNPBWLLIMQHL-LJAQVGFWSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis|urticaria
FG-2216	EGLN1	6914666	OUQVKRKGTAUJQA-UHFFFAOYSA-N	Phase 2	hypoxia inducible factor prolyl hydroxylase inhibitor	NA	NA
FG-2216	EGLN2	6914666	OUQVKRKGTAUJQA-UHFFFAOYSA-N	Phase 2	hypoxia inducible factor prolyl hydroxylase inhibitor	NA	NA
FG-2216	HIF1A	6914666	OUQVKRKGTAUJQA-UHFFFAOYSA-N	Phase 2	hypoxia inducible factor prolyl hydroxylase inhibitor	NA	NA
FG-4592	EGLN1	11256664	YOZBGTLTNGAVFU-UHFFFAOYSA-N	Phase 3	hypoxia inducible factor prolyl hydroxylase inhibitor	NA	NA
FG-4592	EGLN2	11256664	YOZBGTLTNGAVFU-UHFFFAOYSA-N	Phase 3	hypoxia inducible factor prolyl hydroxylase inhibitor	NA	NA
FG-4592	EGLN3	11256664	YOZBGTLTNGAVFU-UHFFFAOYSA-N	Phase 3	hypoxia inducible factor prolyl hydroxylase inhibitor	NA	NA
FGIN-1-27	TSPO	132496	VUWXAQFLTSBUDB-UHFFFAOYSA-N	Preclinical	inositol monophosphatase inhibitor	NA	NA
FGIN-1-43	TSPO	3995234	XTZUPNNVXIMWAR-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
FH-535	PPARD	3463933	AXNUEXXEQGQWPA-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist|WNT signaling inhibitor	NA	NA
FH-535	PPARG	3463933	AXNUEXXEQGQWPA-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist|WNT signaling inhibitor	NA	NA
fidarestat	AKR1B1	449156	WAAPEIZFCHNLKK-PELKAZGASA-N	Phase 3	aldose reductase inhibitor	NA	NA
filanesib	KIF11	44224257	LLXISKGBWFTGEI-FQEVSTJZSA-N	Phase 3	kinesin inhibitor|kinesin-like spindle protein inhibitor	NA	NA
filgotinib	JAK1	49831257	RIJLVEAXPNLDTC-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
filgotinib	JAK2	49831257	RIJLVEAXPNLDTC-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
filgotinib	JAK3	49831257	RIJLVEAXPNLDTC-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
filgotinib	TYK2	49831257	RIJLVEAXPNLDTC-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
fimasartan	AGTR1	9870652	AMEROGPZOLAFBN-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension|congestive heart failure
finasteride	AKR1D1	57363	DBEPLOCGEIEOCV-WSBQPABSSA-N	Launched	5 alpha reductase inhibitor	endocrinology	androgenetic alopecia
finasteride	SRD5A1	57363	DBEPLOCGEIEOCV-WSBQPABSSA-N	Launched	5 alpha reductase inhibitor	endocrinology	androgenetic alopecia
finasteride	SRD5A2	57363	DBEPLOCGEIEOCV-WSBQPABSSA-N	Launched	5 alpha reductase inhibitor	endocrinology	androgenetic alopecia
fingolimod	S1PR1	107970	KKGQTZUTZRNORY-UHFFFAOYSA-N	Launched	immunosuppressant|sphingosine 1-phosphate receptor agonist	neurology/psychiatry	multiple sclerosis
fingolimod	S1PR5	107970	KKGQTZUTZRNORY-UHFFFAOYSA-N	Launched	immunosuppressant|sphingosine 1-phosphate receptor agonist	neurology/psychiatry	multiple sclerosis
FIPI	PLD1	16739265	LHABRXRGDLASIH-UHFFFAOYSA-N	Preclinical	phospholipase inhibitor	NA	NA
FIPI	PLD2	16739265	LHABRXRGDLASIH-UHFFFAOYSA-N	Preclinical	phospholipase inhibitor	NA	NA
firategrast	ITGA4	9935681	YLFZHHDVRSYTKT-NRFANRHFSA-N	Phase 2	integrin antagonist	NA	NA
firocoxib	PTGS2	208910	FULAPETWGIGNMT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis
fisetin	CDK6	5281614	XHEFDIBZLJXQHF-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
fisetin	FASN	5281614	XHEFDIBZLJXQHF-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
FIT	OPRD1	84008	VDKBIFPJULZUPU-UHFFFAOYSA-N	Preclinical	opioid receptor agonist	NA	NA
FK-33-824	OPRM1	NA	HYZHONGSQNXMPH-YJRDZJJMSA-N	Phase 2	opioid receptor agonist	NA	NA
FK-3311	PTGS2	164009	DIIYLGZNZGPXRR-UHFFFAOYSA-N	Phase 2	cyclooxygenase inhibitor	NA	NA
FK-866	NAMPT	6914657	KPBNHDGDUADAGP-VAWYXSNFSA-N	Phase 2	niacinamide phosphoribosyltransferase inhibitor	NA	NA
FK-888	TACR1	107967	BFNKQTIJVFGCKQ-PDJGWCFMSA-N	Phase 2	tachykinin antagonist	NA	NA
FK-888	TACR2	107967	BFNKQTIJVFGCKQ-PDJGWCFMSA-N	Phase 2	tachykinin antagonist	NA	NA
flavin-adenine-dinucleotide	ACAD8	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	ACADM	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	ACADS	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	ACOX1	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	AIFM1	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	CYB5R1	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	CYB5R3	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	DAO	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	DLD	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	DPYD	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	ERO1LB	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	FDXR	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	GCDH	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	GFER	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	GSR	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	IL4I1	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	IVD	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	MAOA	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	MAOB	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	NOS1	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	NQO1	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	NQO2	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	POR	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	TXNRD1	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavin-adenine-dinucleotide	XDH	643975	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical		NA	NA
flavoxate	CHRM1	3354	SPIUTQOUKAMGCX-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis
flavoxate	CHRM2	3354	SPIUTQOUKAMGCX-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis
flecainide	KCNA5	46864232	DJBNUMBKLMJRSA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias
flecainide	KCNA7	46864232	DJBNUMBKLMJRSA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias
flecainide	SCN5A	46864232	DJBNUMBKLMJRSA-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias
fleroxacin	TOP2A	40466912	XBJBPGROQZJDOJ-UHFFFAOYSA-N	Launched	topoisomerase inhibitor	infectious disease|gastroenterology	gonorrhea|enteritis|diarrhea|respiratory tract infections
flibanserin	DRD4	6918248	PPRRDFIXUUSXRA-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
flibanserin	HTR1A	6918248	PPRRDFIXUUSXRA-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
flibanserin	HTR2A	6918248	PPRRDFIXUUSXRA-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
flindokalner	KCNMA1	214350	ULYONBAOIMCNEH-HNNXBMFYSA-N	Phase 3	potassium channel agonist	NA	NA
flindokalner	KCNN4	214350	ULYONBAOIMCNEH-HNNXBMFYSA-N	Phase 3	potassium channel agonist	NA	NA
flindokalner	KCNQ2	214350	ULYONBAOIMCNEH-HNNXBMFYSA-N	Phase 3	potassium channel agonist	NA	NA
flindokalner	KCNQ4	214350	ULYONBAOIMCNEH-HNNXBMFYSA-N	Phase 3	potassium channel agonist	NA	NA
flindokalner	KCNQ5	214350	ULYONBAOIMCNEH-HNNXBMFYSA-N	Phase 3	potassium channel agonist	NA	NA
floctafenine	PTGS1	76958517	APQPGQGAWABJLN-GFCCVEGCSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
floctafenine	PTGS2	76958517	APQPGQGAWABJLN-GFCCVEGCSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
flopropione	HTR1A	3362	PTHLEKANMPKYDB-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	spasms
floxuridine	TYMS	5790	"InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1"	Launched	DNA synthesis inhibitor	oncology	colorectal cancer
flubendazole	TUBB	35802	CPEUVMUXAHMANV-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	gastrointestinal parasites
fluconazole	CYP51A1	3365	RFHAOTPXVQNOHP-UHFFFAOYSA-N	Launched	sterol demethylase inhibitor	infectious disease	esophageal candidiasis|meningitis
flucytosine	DNMT1	3366	XRECTZIEBJDKEO-UHFFFAOYSA-N	Launched	other antifungal	infectious disease	bacterial septicemia|endocarditis|urinary tract infections|meningitis
fludarabine	ADA	657237	HBUBKKRHXORPQB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine	DCK	657237	HBUBKKRHXORPQB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine	POLA1	657237	HBUBKKRHXORPQB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine	RRM1	657237	HBUBKKRHXORPQB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine	RRM2	657237	HBUBKKRHXORPQB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine-phosphate	POLA1	30751	GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine-phosphate	POLD1	30751	GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine-phosphate	POLE	30751	GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine-phosphate	RRM1	30751	GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine-phosphate	RRM2	30751	GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine-phosphate	RRM2B	30751	GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludrocortisone-acetate	NR3C2	225609	SYWHXTATXSMDSB-GSLJADNHSA-N	Launched		endocrinology	Addison's disease|adrenogenital syndrome
fludroxycortide	NR3C1	15209	POPFMWWJOGLOIF-XWCQMRHXSA-N	Launched	glucocorticoid receptor agonist	infectious disease|dermatology	skin infections|psoriasis
fludroxycortide	SERPINA6	15209	POPFMWWJOGLOIF-XWCQMRHXSA-N	Launched	glucocorticoid receptor agonist	infectious disease|dermatology	skin infections|psoriasis
flufenamic-acid	AKR1C3	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	ANO1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	AR	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJA1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJA10	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJA3	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJA4	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJA5	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJA8	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJA9	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJB1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJB2	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJB3	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJB4	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJB5	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJB6	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJB7	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJC1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJC2	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJC3	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJD2	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJD3	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJD4	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	GJE1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	PANX1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	PANX2	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	PANX3	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	PKD2L1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	PTGS1	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	PTGS2	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	TRPC5	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	TRPM2	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flufenamic-acid	TRPM5	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
flumatinib	ABL1	46848036	BJCJYEYYYGBROF-UHFFFAOYSA-N	Phase 3	Bcr-Abl kinase inhibitor	NA	NA
flumatinib	PDGFRB	46848036	BJCJYEYYYGBROF-UHFFFAOYSA-N	Phase 3	Bcr-Abl kinase inhibitor	NA	NA
flumazenil	GABRA1	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRA2	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRA3	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRA4	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRA5	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRA6	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRB1	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRB2	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRB3	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRD	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRE	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRG1	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRG2	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRG3	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRP	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumazenil	GABRQ	3373	OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumethasone	NR3C1	16490	WXURHACBFYSXBI-GQKYHHCASA-N	Launched	glucocorticoid receptor agonist	otolaryngology|infectious disease|dermatology	otitis|ear infections|corticosteroid-responsive dermatoses
flumethasone	PLA2G1B	16490	WXURHACBFYSXBI-GQKYHHCASA-N	Launched	glucocorticoid receptor agonist	otolaryngology|infectious disease|dermatology	otitis|ear infections|corticosteroid-responsive dermatoses
flumethasone-pivalate	NR3C1	443980	JWRMHDSINXPDHB-OJAGFMMFSA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
flumethasone-pivalate	SERPINA6	443980	JWRMHDSINXPDHB-OJAGFMMFSA-N	Launched	glucocorticoid receptor agonist	allergy	allergic rhinitis
flunarizine	CACNA1G	941361	SMANXXCATUTDDT-QPJJXVBHSA-N	Launched	calcium channel blocker	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)
flunarizine	CACNA1H	941361	SMANXXCATUTDDT-QPJJXVBHSA-N	Launched	calcium channel blocker	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)
flunarizine	CACNA1I	941361	SMANXXCATUTDDT-QPJJXVBHSA-N	Launched	calcium channel blocker	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)
flunarizine	CALM1	941361	SMANXXCATUTDDT-QPJJXVBHSA-N	Launched	calcium channel blocker	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)
flunarizine	HRH1	941361	SMANXXCATUTDDT-QPJJXVBHSA-N	Launched	calcium channel blocker	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)
flunisolide	NR3C1	82153	XSFJVAJPIHIPKU-XWCQMRHXSA-N	Launched	cytochrome P450 inhibitor	allergy	allergic rhinitis
fluocinolone-acetonide	NR3C1	6215	FEBLZLNTKCEFIT-VSXGLTOVSA-N	Launched	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis
fluocinolone-acetonide	SERPINA6	6215	FEBLZLNTKCEFIT-VSXGLTOVSA-N	Launched	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis
fluocinonide	NR3C1	9642	WJOHZNCJWYWUJD-IUGZLZTKSA-N	Launched	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis|eczema
fluocinonide	SERPINA6	9642	WJOHZNCJWYWUJD-IUGZLZTKSA-N	Launched	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis|eczema
fluocinonide	SMO	9642	WJOHZNCJWYWUJD-IUGZLZTKSA-N	Launched	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis|eczema
fluorescein	SLC22A6	16850	GNBHRKFJIUUOQI-UHFFFAOYSA-N	Launched		ophthalmology	ophthalmology diagnostic
fluorometholone	NR3C1	9878	FAOZLTXFLGPHNG-KNAQIMQKSA-N	Launched	glucocorticoid receptor agonist	ophthalmology	eye inflammation
fluorometholone-acetate	NR3C1	240767	YRFXGQHBPBMFHW-SBTZIJSASA-N	Launched		ophthalmology	eye inflammation
fluoxetine	ANO1	657320	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder
fluoxetine	HTR2B	657320	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder
fluoxetine	SLC6A4	657320	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder
flupentixol	ADRA1A	5281881	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|depression
flupentixol	CHRM1	5281881	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|depression
flupentixol	DRD1	5281881	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|depression
flupentixol	DRD2	5281881	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|depression
flupentixol	DRD3	5281881	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|depression
flupentixol	DRD5	5281881	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|depression
flupentixol	HTR2A	5281881	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|depression
fluphenazine	CALM1	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine	DRD1	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine	DRD2	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine	DRD5	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine	HRH1	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine	HTR2A	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine	HTR6	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine	HTR7	3372	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine-decanoate	DRD2	3388	VIQCGTZFEYDQMR-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine-decanoate	HTR1B	3388	VIQCGTZFEYDQMR-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine-decanoate	HTR4	3388	VIQCGTZFEYDQMR-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
flupirtine	ADRA2A	53276	JUUFBMODXQKSTD-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	pain relief
flupirtine	KCNQ1	53276	JUUFBMODXQKSTD-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	pain relief
flupirtine	KCNQ2	53276	JUUFBMODXQKSTD-UHFFFAOYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	pain relief
fluprazine	HTR1A	71153	CHQKHXJPWDSTPY-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
fluprazine	HTR1B	71153	CHQKHXJPWDSTPY-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
flurbiprofen-(S)-(+)	PTGS1	72099	SYTBZMRGLBWNTM-JTQLQIEISA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
flurbiprofen-(S)-(+)	PTGS2	72099	SYTBZMRGLBWNTM-JTQLQIEISA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
flurizan	APH1B	92337	SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	gamma secretase inhibitor	NA	NA
flurizan	BACE1	92337	SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	gamma secretase inhibitor	NA	NA
flurizan	IKBKG	92337	SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	gamma secretase inhibitor	NA	NA
flurizan	PSEN1	92337	SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	gamma secretase inhibitor	NA	NA
flurizan	PSEN2	92337	SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	gamma secretase inhibitor	NA	NA
flurizan	PTGS1	92337	SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	gamma secretase inhibitor	NA	NA
flurizan	PTGS2	92337	SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	gamma secretase inhibitor	NA	NA
fluspirilene	CACNG1	3396	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluspirilene	DRD2	3396	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluspirilene	HRH1	3396	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluspirilene	HTR1A	3396	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluspirilene	HTR1D	3396	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluspirilene	HTR1E	3396	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluspirilene	HTR2A	3396	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
flutamide	AHR	3397	MKXKFYHWDHIYRV-UHFFFAOYSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
flutamide	AR	3397	MKXKFYHWDHIYRV-UHFFFAOYSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
fluticasone-propionate	NR3C1	444036	WMWTYOKRWGGJOA-CENSZEJFSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
fluticasone-propionate	NR3C2	444036	WMWTYOKRWGGJOA-CENSZEJFSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
fluticasone-propionate	PGR	444036	WMWTYOKRWGGJOA-CENSZEJFSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
fluticasone-propionate	PLA2G4A	444036	WMWTYOKRWGGJOA-CENSZEJFSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
fluvastatin	HMGCR	446155	FJLGEFLZQAZZCD-MCBHFWOFSA-N	Launched	HMGCR inhibitor	endocrinology|cardiology	hypercholesterolemia|congenital heart defects
fluvoxamine	SLC6A4	5324346	CJOFXWAVKWHTFT-XSFVSMFZSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	obsessive compulsive disorder (OCD)
folic-acid	FOLR2	6037	OVBPIULPVIDEAO-LBPRGKRZSA-N	Launched	folate receptor ligand	hematology	megaloblastic anemia
folic-acid	FOLR3	6037	OVBPIULPVIDEAO-LBPRGKRZSA-N	Launched	folate receptor ligand	hematology	megaloblastic anemia
folic-acid	SLC19A1	6037	OVBPIULPVIDEAO-LBPRGKRZSA-N	Launched	folate receptor ligand	hematology	megaloblastic anemia
folic-acid	SLC46A1	6037	OVBPIULPVIDEAO-LBPRGKRZSA-N	Launched	folate receptor ligand	hematology	megaloblastic anemia
fomepizole	ADH1A	3406	RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched	alcohol dehydrogenase inhibitor	critical care	poison antidote
fomepizole	ADH1B	3406	RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched	alcohol dehydrogenase inhibitor	critical care	poison antidote
fomepizole	ADH1C	3406	RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched	alcohol dehydrogenase inhibitor	critical care	poison antidote
fomepizole	AKR1A1	3406	RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched	alcohol dehydrogenase inhibitor	critical care	poison antidote
fomepizole	CAT	3406	RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched	alcohol dehydrogenase inhibitor	critical care	poison antidote
fondaparinux	F10	5282448	KANJSNBRCNMZMV-ABRZTLGGSA-N	Launched	coagulation factor inhibitor	hematology	deep vein thrombosis (DVT)
fondaparinux	SERPINC1	5282448	KANJSNBRCNMZMV-ABRZTLGGSA-N	Launched	coagulation factor inhibitor	hematology	deep vein thrombosis (DVT)
foretinib	FLT1	42642645	"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)"	Phase 2	VEGFR inhibitor	NA	NA
foretinib	FLT4	42642645	"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)"	Phase 2	VEGFR inhibitor	NA	NA
foretinib	KDR	42642645	"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)"	Phase 2	VEGFR inhibitor	NA	NA
foretinib	MET	42642645	"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)"	Phase 2	VEGFR inhibitor	NA	NA
formestane	CYP19A1		ZMEULISFKSVRLQ-LZBOESDWSA-N	Launched	aromatase inhibitor	oncology	breast cancer
formononetin	ADH1C	5280378	HKQYGTCOTHHOMP-UHFFFAOYSA-N	Preclinical	alcohol dehydrogenase inhibitor	NA	NA
formononetin	SLC5A2	5280378	HKQYGTCOTHHOMP-UHFFFAOYSA-N	Preclinical	alcohol dehydrogenase inhibitor	NA	NA
formoterol	ADRB2	3034756	BPZSYCZIITTYBL-ORAYPTAESA-N	Launched	adrenergic receptor agonist	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm
forodesine	PNP	135409409	IWKXDMQDITUYRK-KUBHLMPHSA-N	Launched	purinergic receptor antagonist	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
foropafant	PTAFR	119368	VVBFISAUNSXQGZ-UHFFFAOYSA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
forskolin	ADCY2	47936	OHCQJHSOBUTRHG-KGGHGJDLSA-N	Launched	adenylyl cyclase activator	NA	NA
forskolin	ADCY5	47936	OHCQJHSOBUTRHG-KGGHGJDLSA-N	Launched	adenylyl cyclase activator	NA	NA
forskolin	GNAS	47936	OHCQJHSOBUTRHG-KGGHGJDLSA-N	Launched	adenylyl cyclase activator	NA	NA
fosaprepitant-dimeglumine	TACR1	135413538	BARDROPHSZEBKC-OITMNORJSA-N	Launched	tachykinin antagonist	gastroenterology	nausea|vomiting
fosbretabulin	CDH5	5351387	WDOGQTQEKVLZIJ-WAYWQWQTSA-N	Phase 3	tubulin polymerization inhibitor|VE-cadherin antagonist	NA	NA
fosfestrol	ESR1	3032325	NLORYLAYLIXTID-ISLYRVAYSA-N	Launched	synthetic estrogen	oncology	prostate cancer
fosfestrol	ESR2	3032325	NLORYLAYLIXTID-ISLYRVAYSA-N	Launched	synthetic estrogen	oncology	prostate cancer
fosfosal	PTGS1	3418	FFKUDWZICMJVPA-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	neurology/psychiatry	pain relief
fosfosal	PTGS2	3418	FFKUDWZICMJVPA-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	neurology/psychiatry	pain relief
fosinopril	ACE	6708482	BIDNLKIUORFRQP-AJTMIRJTSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|congestive heart failure
fosinoprilat	ACE	62956	WOIWWYDXDVSWAZ-RTWAWAEBSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
fosphenytoin	SCN5A	56339	XWLUWCNOOVRFPX-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
fostamatinib	SYK	11671467	GKDRMWXFWHEQQT-UHFFFAOYSA-N	Launched	SYK inhibitor	hematology	chronic immune thrombocytopenia (ITP)
foxy-5	WNT5A	44628955	WFZPJYYCTSHDJI-ATIWLJMLSA-N	Phase 2	WNT5a peptide mimetic	NA	NA
FPL-64176	CACNA1C	3423	MDMWHKZANMNXTF-UHFFFAOYSA-N	Preclinical	calcium channel activator	NA	NA
FPL-64176	CACNA1S	3423	MDMWHKZANMNXTF-UHFFFAOYSA-N	Preclinical	calcium channel activator	NA	NA
FPS-ZM1	AGER	24752728	XDFKWGIBQMHSOH-UHFFFAOYSA-N	Preclinical	RAGE receptor antagonist	NA	NA
FR-139317	EDNRA	107810	LIOKMIQQPDDTNO-UPRLRBBYSA-N	Phase 1	endothelin receptor antagonist	NA	NA
FR-180204	MAPK1	53338808	XVECMUKVOMUNLE-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
FR-180204	MAPK3	53338808	XVECMUKVOMUNLE-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
FRAX486	PAK1	68060125	DHKFOIHIUYFSOF-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
FRAX486	PAK2	68060125	DHKFOIHIUYFSOF-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
FRAX486	PAK3	68060125	DHKFOIHIUYFSOF-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
FRAX486	PAK4	68060125	DHKFOIHIUYFSOF-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
freselestat	CELA1	46936829	HMPQTEPEMQZWQH-QZTJIDSGSA-N	Preclinical	elastase inhibitor	NA	NA
freselestat	ELANE	46936829	HMPQTEPEMQZWQH-QZTJIDSGSA-N	Preclinical	elastase inhibitor	NA	NA
frovatriptan	HTR1A	77992	XPSQPHWEGNHMSK-SECBINFHSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
frovatriptan	HTR1B	77992	XPSQPHWEGNHMSK-SECBINFHSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
frovatriptan	HTR1D	77992	XPSQPHWEGNHMSK-SECBINFHSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
fruquintinib	KDR	44480399	BALLNEJQLSTPIO-UHFFFAOYSA-N	Launched	VEGFR inhibitor	oncology	colorectal cancer
ftorafur	TYMS	288216	WFWLQNSHRPWKFK-ZCFIWIBFSA-N	Launched	thymidylate synthase inhibitor	oncology	colorectal cancer
fulvestrant	ESR1	57300161	VWUXBMIQPBEWFH-CIAKRVSBSA-N	Launched	estrogen receptor antagonist	oncology	breast cancer
fulvestrant	ESR2	57300161	VWUXBMIQPBEWFH-CIAKRVSBSA-N	Launched	estrogen receptor antagonist	oncology	breast cancer
fulvestrant	GPER1	57300161	VWUXBMIQPBEWFH-CIAKRVSBSA-N	Launched	estrogen receptor antagonist	oncology	breast cancer
fumagillin	METAP2	12015870	NGGMYCMLYOUNGM-FKSJYSFPSA-N	Launched	methionine aminopeptidase inhibitor	infectious disease	microsporidiosis
fumonisin-B1	CERS1	2733487	UVBUBMSSQKOIBE-DSLOAKGESA-N	Preclinical		NA	NA
furamidine	PRMT1	126437	ZJHZBDRZEZEDGB-UHFFFAOYSA-N	Preclinical	protein arginine N-methyltransferase inhibitor	NA	NA
furegrelate	TBXAS1	3437	VHWFITPGPFLBGT-UHFFFAOYSA-N	Phase 1	thromboxane synthase inhibitor	NA	NA
furosemide	CA2	3440	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	Launched	diuretic	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome
furosemide	GPR35	3440	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	Launched	diuretic	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome
furosemide	SLC12A1	3440	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	Launched	diuretic	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome
furosemide	SLC12A2	3440	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	Launched	diuretic	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome
F351	TGFB1	11217901	NETTXQJYJRFTFS-UHFFFAOYSA-N	Phase 2	TGF beta receptor inhibitor	NA	NA
g-caryophyllene	ACHE	5281515	NPNUFJAVOOONJE-GFUGXAQUSA-N	Preclinical	acetylcholinesterase inhibitor	NA	NA
G-1	GPER1	5322399	VHSVKVWHYFBIFJ-HKZYLEAXSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
G-15	GPER1	25727983	YOLTZIVRJAPVPH-MVBJNABHSA-N	Preclinical	estrogen receptor antagonist	NA	NA
gabapentin	ADORA1	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1A	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1B	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1C	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1D	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1E	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1F	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1G	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1H	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1I	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA1S	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA2D1	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA2D2	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA2D3	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNA2D4	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNB1	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNB2	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNB3	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNB4	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG1	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG2	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG3	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG4	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG5	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG6	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG7	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	CACNG8	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	GRIN1	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	GRIN2A	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	GRIN2B	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	GRIN2C	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	GRIN2D	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	GRIN3A	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin	GRIN3B	6919078	UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	calcium channel blocker	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
gabapentin-enacarbil	CACNA1G	66864580	TZDUHAJSIBHXDL-GFCCVEGCSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	restless leg syndrome|postherpetic neuralgia
gabazine	GABRA1	107896	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
gabazine	GABRA2	107896	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
gabazine	GABRA3	107896	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
gabazine	GABRA4	107896	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
gabazine	GABRA5	107896	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
gabazine	GABRA6	107896	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
gabazine	GABRG2	107896	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
gabexate	PRSS1	3447	YKGYIDJEEQRWQH-UHFFFAOYSA-N	Launched	serine protease inhibitor	gastroenterology	pancreatitis
gabexate	TPSAB1	3447	YKGYIDJEEQRWQH-UHFFFAOYSA-N	Launched	serine protease inhibitor	gastroenterology	pancreatitis
gaboxadol	GABRA1	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRA2	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRA3	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRA4	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRA5	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRA6	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRD	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRR1	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRR2	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gaboxadol	GABRR3	3448	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
gadopentetic-acid	PGD	6857474	IZOOGPBRAOKZFK-UHFFFAOYSA-K	Launched	contrast agent	radiology	contrast agent
galantamine	ACHE	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	BCHE	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA1	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA10	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA2	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA3	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA4	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA5	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA6	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA7	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNA9	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNB1	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNB2	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNB3	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNB4	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRND	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNE	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galantamine	CHRNG	9651	ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galeterone	AR	11188409	PAFKTGFSEFKSQG-PAASFTFBSA-N	Phase 3	androgen receptor modulator	NA	NA
galeterone	CYP17A1	11188409	PAFKTGFSEFKSQG-PAASFTFBSA-N	Phase 3	androgen receptor modulator	NA	NA
gallamine-triethiodide	CHRM2	3450	OZLPUNFFCJDMJD-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
gallamine-triethiodide	CHRNA1	3450	OZLPUNFFCJDMJD-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
gallic-acid	CA1	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallic-acid	CA12	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallic-acid	CA14	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallic-acid	CA2	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallic-acid	CA4	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallic-acid	CA6	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallic-acid	CA9	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallic-acid	SELP	370	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	NA	NA
gallopamil	ATP2A2	1234	XQLWNAFCTODIRK-UHFFFAOYSA-N	Launched	L-type calcium channel blocker	cardiology	hypertension|cardiac arrythmia
gambogic-acid	BCL2	9852185	GEZHEQNLKAOMCA-RRZNCOCZSA-N	Phase 2	caspase activator	NA	NA
gamma-aminobutyric-acid	GABBR1	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GABBR2	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GABRA1	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GABRA2	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GABRA3	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GABRA5	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GABRB2	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GABRG2	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	GATM	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	KCTD12	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	KCTD16	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	KCTD8	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-aminobutyric-acid	SLC6A1	6992099	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
gamma-linolenic-acid	PTGS1	5280933	VZCCETWTMQHEPK-QNEBEIHSSA-N	Phase 2	cyclooxygenase inhibitor|prostanoid receptor agonist	NA	NA
gamma-linolenic-acid	PTGS2	5280933	VZCCETWTMQHEPK-QNEBEIHSSA-N	Phase 2	cyclooxygenase inhibitor|prostanoid receptor agonist	NA	NA
ganaxolone	GABRA1	6918305	PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3	GABA receptor modulator	NA	NA
ganaxolone	GABRA2	6918305	PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3	GABA receptor modulator	NA	NA
ganaxolone	GABRA3	6918305	PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3	GABA receptor modulator	NA	NA
ganaxolone	GABRA4	6918305	PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3	GABA receptor modulator	NA	NA
ganaxolone	GABRA5	6918305	PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3	GABA receptor modulator	NA	NA
ganaxolone	GABRA6	6918305	PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3	GABA receptor modulator	NA	NA
ganetespib	HSP90AA1	135564985	RVAQIUULWULRNW-UHFFFAOYSA-N	Phase 3	HSP inhibitor	NA	NA
GANT-58	GLI1	253078	USWLOKMMUTWFMD-UHFFFAOYSA-N	Preclinical	GLI antagonist	NA	NA
GANT-61	GLI1	421610	KVQOGDQTWWCZFX-UHFFFAOYSA-N	Preclinical	GLI antagonist	NA	NA
GANT-61	GLI2	421610	KVQOGDQTWWCZFX-UHFFFAOYSA-N	Preclinical	GLI antagonist	NA	NA
garenoxacin	TOP2A	40461170	NJDRXTDGYFKORP-LLVKDONJSA-N	Launched	topoisomerase inhibitor	infectious disease	respiratory tract infections
gavestinel	GLRB	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
gavestinel	GRIN1	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
gavestinel	GRIN2A	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
gavestinel	GRIN2B	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
gavestinel	GRIN2C	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
gavestinel	GRIN2D	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
gavestinel	GRIN3A	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
gavestinel	GRIN3B	6450546	WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	glutamate receptor antagonist	NA	NA
GBR-12935	AGTR1	3456	RAQPOZGWANIDQT-UHFFFAOYSA-N	Preclinical	dopamine reuptake inhibitor	NA	NA
GBR-12935	SLC6A3	3456	RAQPOZGWANIDQT-UHFFFAOYSA-N	Preclinical	dopamine reuptake inhibitor	NA	NA
GBR-13069	SLC6A3	5974189	DASHZBBQOARCMQ-QPJJXVBHSA-N	Preclinical	dopamine reuptake inhibitor	NA	NA
GDC-0068	AKT1	24788740	GRZXWCHAXNAUHY-NSISKUIASA-N	Phase 3	AKT inhibitor	NA	NA
GDC-0068	AKT2	24788740	GRZXWCHAXNAUHY-NSISKUIASA-N	Phase 3	AKT inhibitor	NA	NA
GDC-0068	AKT3	24788740	GRZXWCHAXNAUHY-NSISKUIASA-N	Phase 3	AKT inhibitor	NA	NA
GDC-0068	PRKG1	24788740	GRZXWCHAXNAUHY-NSISKUIASA-N	Phase 3	AKT inhibitor	NA	NA
GDC-0152	BIRC2	46940575	WZRFLSDVFPIXOV-LRQRDZAKSA-N	Phase 1	XIAP inhibitor	NA	NA
GDC-0152	BIRC3	46940575	WZRFLSDVFPIXOV-LRQRDZAKSA-N	Phase 1	XIAP inhibitor	NA	NA
GDC-0152	BIRC7	46940575	WZRFLSDVFPIXOV-LRQRDZAKSA-N	Phase 1	XIAP inhibitor	NA	NA
GDC-0152	XIAP	46940575	WZRFLSDVFPIXOV-LRQRDZAKSA-N	Phase 1	XIAP inhibitor	NA	NA
GDC-0349	PIK3CA	59239165	RGJOJUGRHPQXGF-INIZCTEOSA-N	Phase 1	Pim kinase inhibitor	NA	NA
GDC-0810	ESR1	56941241	BURHGPHDEVGCEZ-KJGLQBJMSA-N	Phase 2	selective estrogen receptor destabilizer	NA	NA
GDC-0834	BTK	25234917	CDOOFZZILLRUQH-LJAQVGFWSA-N	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
GDC-0879	BRAF	11717001	DEZZLWQELQORIU-RELWKKBWSA-N	Preclinical	RAF inhibitor	NA	NA
GDC-0941	PIK3CA	17755052	"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)"	Phase 2	PI3K inhibitor	NA	NA
GDC-0941	PIK3CB	17755052	"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)"	Phase 2	PI3K inhibitor	NA	NA
GDC-0941	PIK3CD	17755052	"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)"	Phase 2	PI3K inhibitor	NA	NA
GDC-0941	PIK3CG	17755052	"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)"	Phase 2	PI3K inhibitor	NA	NA
GDC-0980	FGR	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0980	MAP3K9	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0980	MTOR	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0980	PIK3CA	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0980	PIK3CB	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0980	PIK3CD	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0980	PIK3CG	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0980	SYK	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
GDC-0994	MAPK1	124583908	RZUOCXOYPYGSKL-SFHVURJKSA-N	Phase 1	MAP kinase inhibitor	NA	NA
GDC-0994	MAPK3	124583908	RZUOCXOYPYGSKL-SFHVURJKSA-N	Phase 1	MAP kinase inhibitor	NA	NA
gedunin	HSP90AA1	12004512	YJXDGWUNRYLINJ-BHAPSIHVSA-N	Preclinical	HSP inhibitor	NA	NA
gefitinib	EGFR	123631	XGALLCVXEZPNRQ-UHFFFAOYSA-N	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
geldanamycin	HSP90AA1		QTQAWLPCGQOSGP-SLOAUYBXSA-N	Preclinical	HSP inhibitor	NA	NA
gemcitabine	CMPK1	60750	SDUQYLNIPVEERB-QPPQHZFASA-N	Launched	ribonucleotide reductase inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer
gemcitabine	RRM1	60750	SDUQYLNIPVEERB-QPPQHZFASA-N	Launched	ribonucleotide reductase inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer
gemcitabine	RRM2	60750	SDUQYLNIPVEERB-QPPQHZFASA-N	Launched	ribonucleotide reductase inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer
gemcitabine	TYMS	60750	SDUQYLNIPVEERB-QPPQHZFASA-N	Launched	ribonucleotide reductase inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer
gemcitabine-elaidate	CMPK1	9828310	HESSNRGIEVBPRB-QDDPNBLJSA-N	Phase 1	apoptosis inhibitor|DNA synthesis inhibitor	NA	NA
gemcitabine-elaidate	RRM1	9828310	HESSNRGIEVBPRB-QDDPNBLJSA-N	Phase 1	apoptosis inhibitor|DNA synthesis inhibitor	NA	NA
gemcitabine-elaidate	TYMS	9828310	HESSNRGIEVBPRB-QDDPNBLJSA-N	Phase 1	apoptosis inhibitor|DNA synthesis inhibitor	NA	NA
gemfibrozil	LPL	3463	HEMJJKBWTPKOJG-UHFFFAOYSA-N	Launched	lipoprotein lipase activator	endocrinology|cardiology	hyperlipidemia|coronary heart disease
gemfibrozil	PPARA	3463	HEMJJKBWTPKOJG-UHFFFAOYSA-N	Launched	lipoprotein lipase activator	endocrinology|cardiology	hyperlipidemia|coronary heart disease
gemfibrozil	SLCO1B1	3463	HEMJJKBWTPKOJG-UHFFFAOYSA-N	Launched	lipoprotein lipase activator	endocrinology|cardiology	hyperlipidemia|coronary heart disease
gemfibrozil	SLCO1B3	3463	HEMJJKBWTPKOJG-UHFFFAOYSA-N	Launched	lipoprotein lipase activator	endocrinology|cardiology	hyperlipidemia|coronary heart disease
gemfibrozil	SLCO2B1	3463	HEMJJKBWTPKOJG-UHFFFAOYSA-N	Launched	lipoprotein lipase activator	endocrinology|cardiology	hyperlipidemia|coronary heart disease
geniposide	GLP1R	107848	IBFYXTRXDNAPMM-BVTMAQQCSA-N	Preclinical	GLP receptor agonist	NA	NA
genistein	CFTR	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	ESR1	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	ESR2	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	ESRRA	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	ESRRB	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	ESRRG	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	NCOA1	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	NCOA2	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	PPARG	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	PTK2B	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	TOP2A	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
genistein	TRPC5	5280961	TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	tyrosine kinase inhibitor	NA	NA
gentamycin	HSPA8	72395	CEAZRRDELHUEMR-CAMVTXANSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease|critical care	bone and joint infections|endocarditis|pelvic inflammatory disease|meningitis|pneumonia|urinary tract infections|sepsis
gentiopicrin	GRIN2B	88708	DUAGQYUORDTXOR-GPQRQXLASA-N	Phase 3	glutamate receptor downregulator	NA	NA
genz-123346	UGCG	23652732	JMNXWOFCUJJYEO-HYBUGGRVSA-N	Preclinical	glucosylceramidase inhibitor	NA	NA
genz-644282	TOP1	10294813	BAORCAMWLWRZQG-UHFFFAOYSA-N	Phase 1	topoisomerase inhibitor	NA	NA
gestrinone	AR	27812	BJJXHLWLUDYTGC-ANULTFPQSA-N	Launched	progesterone receptor antagonist	obstetrics/gynecology	endometriosis
gestrinone	ESR1	27812	BJJXHLWLUDYTGC-ANULTFPQSA-N	Launched	progesterone receptor antagonist	obstetrics/gynecology	endometriosis
gestrinone	PGR	27812	BJJXHLWLUDYTGC-ANULTFPQSA-N	Launched	progesterone receptor antagonist	obstetrics/gynecology	endometriosis
GF109203X	PDPK1	2396	"InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)"	Preclinical	PKC inhibitor	NA	NA
GF109203X	PIM1	2396	"InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)"	Preclinical	PKC inhibitor	NA	NA
GF109203X	PRKCI	2396	"InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)"	Preclinical	PKC inhibitor	NA	NA
GF109203X	PRKCZ	2396	"InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)"	Preclinical	PKC inhibitor	NA	NA
GGsTop	GGT1	139340107	NTFPDEDRMYYPAC-FAYKFVSFSA-N	Preclinical	gamma glutamyltransferase Inhibitor	NA	NA
GGTI-298	CDKN1A	9811606	XVWPFYDMUFBHBF-CLOONOSVSA-N	Preclinical	GGTase inhibitor	NA	NA
gilteritinib	FLT3	49803313	GYQYAJJFPNQOOW-UHFFFAOYSA-N	Launched	FLT3 inhibitor	NA	NA
gimeracil	DPYD	54679224	ZPLQIPFOCGIIHV-UHFFFAOYSA-N	Launched	dihydropyrimidine dehydrogenase inhibitor	oncology	gastric adenocarcinoma
ginkgolide-A	GLRA1	NA	FPUXKXIZEIDQKW-UEHATNFXSA-N	Preclinical	GABA receptor antagonist	NA	NA
ginkgolide-A	GLRB	NA	FPUXKXIZEIDQKW-UEHATNFXSA-N	Preclinical	GABA receptor antagonist	NA	NA
ginkgolide-B	GLRA1		SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
ginkgolide-B	GLRA2		SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
ginkgolide-B	GLRA3		SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
ginkgolide-B	GLRB		SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
ginkgolide-B	HTR3A		SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
ginkgolide-B	HTR3B		SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3	platelet activating factor receptor antagonist	NA	NA
ginsenoside-C-K	PTGS2	9852086	FVIZARNDLVOMSU-IRFFNABBSA-N	Phase 1	NFkB pathway inhibitor|nitric oxide synthase inhibitor	NA	NA
ginsenoside-RE3	KCNH2	46887680	RWXIFXNRCLMQCD-CZIWJLDFSA-N	Launched	angiogenesis inhibitor|apoptosis stimulant	NA	NA
givinostat	HDAC1	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC2	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC3	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC4	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC5	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC6	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC7	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC8	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
givinostat	HDAC9	9804992	"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)"	Phase 3	HDAC inhibitor	NA	NA
GKA-50	GCK	11340230	OCBMECSFDVUYQN-ROUUACIJSA-N	Preclinical	glucokinase activator	NA	NA
GKT137831	NOX1	58496428	RGYQPQARIQKJKH-UHFFFAOYSA-N	Phase 2	NADPH oxidase inhibitor	NA	NA
GKT137831	NOX4	58496428	RGYQPQARIQKJKH-UHFFFAOYSA-N	Phase 2	NADPH oxidase inhibitor	NA	NA
GK921	TGM2	56682080	MNYJJHBAEYKXEG-UHFFFAOYSA-N	Preclinical	transglutaminase inhibitor	NA	NA
glafenine	CFTR	969495	GWOFUCIGLDBNKM-CYBMUJFWSA-N	Withdrawn	DeltaF508-CFTR Correctors	NA	NA
glasdegib	SMO	25166913	SFNSLLSYNZWZQG-VQIMIIECSA-N	Launched	hedgehog pathway inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
glimepiride	ABCC8	NA	WIGIZIANZCJQQY-RUCARUNLSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
glimepiride	KCNJ1	NA	WIGIZIANZCJQQY-RUCARUNLSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
glimepiride	KCNJ11	NA	WIGIZIANZCJQQY-RUCARUNLSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
glipizide	ABCC8	3478	ZJJXGWJIGJFDTL-UHFFFAOYSA-N	Launched	sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glipizide	KCNJ10	3478	ZJJXGWJIGJFDTL-UHFFFAOYSA-N	Launched	sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glipizide	KCNJ11	3478	ZJJXGWJIGJFDTL-UHFFFAOYSA-N	Launched	sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glipizide	PPARG	3478	ZJJXGWJIGJFDTL-UHFFFAOYSA-N	Launched	sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
gliquidone	ABCC8	91610	LLJFMFZYVVLQKT-UHFFFAOYSA-N	Launched	sulfonylurea	endocrinology	diabetes mellitus
gliquidone	KCNJ10	91610	LLJFMFZYVVLQKT-UHFFFAOYSA-N	Launched	sulfonylurea	endocrinology	diabetes mellitus
gliquidone	KCNJ8	91610	LLJFMFZYVVLQKT-UHFFFAOYSA-N	Launched	sulfonylurea	endocrinology	diabetes mellitus
GLPG0492	AR	59317190	VAJGULUVTFDTAS-GOSISDBHSA-N	Phase 1	androgen receptor modulator	NA	NA
GLPG0492-R-enantiomer	AR	59317173	VAJGULUVTFDTAS-SFHVURJKSA-N	Phase 1	androgen receptor modulator	NA	NA
gluconolactone	LCT	1549082	PHOQVHQSTUBQQK-KLVWXMOXSA-N	Launched		NA	NA
glucosamine	IL1B	441477	MSWZFWKMSRAUBD-QZABAPFNSA-N	Launched	glycosylated protein precursor	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis|joint pain|backache
glutathione	ESD	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GGT1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GLO1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GLRX	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GLRX2	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX2	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX3	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX4	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX5	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX6	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX7	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GPX8	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSR	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSS	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTA1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTA2	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTA3	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTA4	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTA5	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTK1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTM1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTM2	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTM3	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTM4	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTM5	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTO1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTO2	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTP1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTT1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	GSTZ1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	HAGH	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	HPGDS	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	LTC4S	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	MGST1	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	MGST2	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	MGST3	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glutathione	TXNDC12	25246407	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	antioxidant	NA	NA
glyburide	ABCA1	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	ABCB11	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	ABCC8	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	ABCC9	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	CFTR	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	CPT1A	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	KCNJ1	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	KCNJ11	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	KCNJ5	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	KCNJ8	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glyburide	SLCO2B1	3488	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology	diabetes mellitus|hyperglycemia
glycitein	TNF	5317750	DXYUAIFZCFRPTH-UHFFFAOYSA-N	Phase 3	tumor necrosis factor release inhibitor	NA	NA
glycopyrrolate	CHRM1	9933193	ANGKOCUUWGHLCE-HKUYNNGSSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
glycopyrrolate	CHRM2	9933193	ANGKOCUUWGHLCE-HKUYNNGSSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
glycopyrrolate	CHRM3	9933193	ANGKOCUUWGHLCE-HKUYNNGSSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
glycopyrrolate	CHRM4	9933193	ANGKOCUUWGHLCE-HKUYNNGSSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
glycopyrrolate	CHRM5	9933193	ANGKOCUUWGHLCE-HKUYNNGSSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
GM-1485	FKBP1A	9837656	FOPALECPEUVCTL-QMMMGPOBSA-N	Preclinical	immunophilin ligand	NA	NA
GMX1778	NAMPT	148198	BOIPLTNGIAPDBY-UHFFFAOYSA-N	Phase 1/Phase 2	NAMPT inhibitor	NA	NA
GNF-2	ABL1	5311510	WEVYNIUIFUYDGI-UHFFFAOYSA-N	Preclinical	Bcr-Abl kinase inhibitor	NA	NA
GNF-2	BCR	5311510	WEVYNIUIFUYDGI-UHFFFAOYSA-N	Preclinical	Bcr-Abl kinase inhibitor	NA	NA
GNF-5	ABL1	44129660	IIQUYGWWHIHOCF-UHFFFAOYSA-N	Preclinical	Bcr-Abl kinase inhibitor	NA	NA
GNF-5	BCR	44129660	IIQUYGWWHIHOCF-UHFFFAOYSA-N	Preclinical	Bcr-Abl kinase inhibitor	NA	NA
GNF-5837	NTRK1	59397065	"InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-"	Preclinical	growth factor receptor inhibitor	NA	NA
GNF-5837	NTRK2	59397065	"InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-"	Preclinical	growth factor receptor inhibitor	NA	NA
GNF-5837	NTRK3	59397065	"InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-"	Preclinical	growth factor receptor inhibitor	NA	NA
GNF-7	GCK	11478363	SZNYUUZOQHNEKB-UHFFFAOYSA-N	Preclinical	glucokinase inhibitor|protein kinase inhibitor	NA	NA
GNF-7	TNK2	11478363	SZNYUUZOQHNEKB-UHFFFAOYSA-N	Preclinical	glucokinase inhibitor|protein kinase inhibitor	NA	NA
GNTI	OPRK1	9826034	VLNHDKDBGWXJEE-GYHUNEDQSA-N	Preclinical	opioid receptor antagonist	NA	NA
GNTI	OPRM1	9826034	VLNHDKDBGWXJEE-GYHUNEDQSA-N	Preclinical	opioid receptor antagonist	NA	NA
go-6983	PRKCA	3499	LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
go-6983	PRKCB	3499	LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
go-6983	PRKCD	3499	LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
go-6983	PRKCG	3499	LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
go-6983	PRKCZ	3499	LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
golgicide-A	GBF1	1085377	NJZHEQOUHLZCOX-WOSRLPQWSA-N	Preclinical	ARF inhibitor	NA	NA
golvatinib	KDR	16118392	UQRCJCNVNUFYDX-UHFFFAOYSA-N	Phase 2	VEGFR inhibitor	NA	NA
golvatinib	MET	16118392	UQRCJCNVNUFYDX-UHFFFAOYSA-N	Phase 2	VEGFR inhibitor	NA	NA
gonadorelin	GNRHR	638793	XLXSAKCOAKORKW-AQJXLSMYSA-N	Launched	gonadotropin releasing factor hormone receptor agonist	obstetrics/gynecology	cystic ovaries|reproductive synchrony
goserelin-acetate	GNRHR	5311128	BLCLNMBMMGCOAS-URPVMXJPSA-N	Launched	gonadotropin releasing factor hormone receptor agonist	oncology|obstetrics/gynecology	prostate cancer|breast cancer|endometriosis
goserelin-acetate	LHCGR	5311128	BLCLNMBMMGCOAS-URPVMXJPSA-N	Launched	gonadotropin releasing factor hormone receptor agonist	oncology|obstetrics/gynecology	prostate cancer|breast cancer|endometriosis
gossypol	BCL2	3503	QBKSWRVVCFFDOT-UHFFFAOYSA-N	Phase 2	BCL inhibitor|MCL1 inhibitor	NA	NA
GPBAR-A	GPBAR1	11656002	ZIXNJVGTAXRKAP-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
GPI-1046	FKBP1A	445501	OQAHHWOPVDDWHD-INIZCTEOSA-N	Preclinical	FKBP inhibitor	NA	NA
GPP-78	NAMPT	44819697	SJOLTIOPWDLDEB-UHFFFAOYSA-N	Preclinical	NAMPT inhibitor	NA	NA
GPR120-modulator-1	FFAR4	25017320	FONSSTYHKIFEBM-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor modulator	NA	NA
GP1a	CNR2	10252734	FNOMTMVRTBHRET-UHFFFAOYSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
GP2a	CNR2	16094766	SPEFJYZGXZENAF-UHFFFAOYSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
GR-103691	DRD3	4302960	JARNORYOPMINDY-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
GR-113808	HTR4	119376	MOZPSIXKYJUTKI-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR1A	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR1B	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR1D	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR1E	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR1F	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR2A	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR2B	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR2C	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-127935	HTR6	107780	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR-144053	ITGA2B	173614	QGEGSJUSWLLZLH-UHFFFAOYSA-N	Preclinical	integrin antagonist	NA	NA
GR-144053	ITGB3	173614	QGEGSJUSWLLZLH-UHFFFAOYSA-N	Preclinical	integrin antagonist	NA	NA
GR-159897	TAC1	9953599	BANYJBHWTOJQDU-GDLZYMKVSA-N	Preclinical	tachykinin antagonist	NA	NA
GR-159897	TACR2	9953599	BANYJBHWTOJQDU-GDLZYMKVSA-N	Preclinical	tachykinin antagonist	NA	NA
GR-235	NR1H4	146898	WDXRGPWQVHZTQJ-NRJJLHBYSA-N	Launched	estrogen receptor agonist|FXR antagonist|progesterone receptor agonist	NA	NA
GR-79236	ADORA1	9884817	GYWXTRVEUURNEW-TVDBPQCTSA-N	Phase 1	adenosine receptor agonist	NA	NA
GR-79236	ADORA2A	9884817	GYWXTRVEUURNEW-TVDBPQCTSA-N	Phase 1	adenosine receptor agonist	NA	NA
granisetron	HTR3A	NA	MFWNKCLOYSRHCJ-BTTYYORXSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
grapiprant	PTGER4	11677589	HZVLFTCYCLXTGV-UHFFFAOYSA-N	Launched	prostaglandin inhibitor	rheumatology	osteoarthritis
griseofulvin	KRT12	441140	DDUHZTYCFQRHIY-RBHXEPJQSA-N	Launched	tubulin polymerization inhibitor	infectious disease	ringworm|tinea pedis
GR125487	HTR4	4284721	SSPCCAYAIDNNJX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
GR46611	HTR1D	6160690	LBVZWEWTNUDWNS-YRNVUSSQSA-N	Preclinical	serotonin receptor agonist	NA	NA
GS-143	BTRC	121513876	IZPMWFSVTDOCDI-HAVVHWLPSA-N	Preclinical	ubiquitin ligase inhibitor	NA	NA
GS-143	NFKBIA	121513876	IZPMWFSVTDOCDI-HAVVHWLPSA-N	Preclinical	ubiquitin ligase inhibitor	NA	NA
GS-39783	GABBR1	6604928	GSGVDKOCBKBMGG-UHFFFAOYSA-N	Preclinical	GABA receptor modulator	NA	NA
GS-6201	ADORA1	11270783	KOYXXLLNCXWUNF-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
GS-6201	ADORA2A	11270783	KOYXXLLNCXWUNF-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
GS-6201	ADORA2B	11270783	KOYXXLLNCXWUNF-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
GS-6201	ADORA3	11270783	KOYXXLLNCXWUNF-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
GS-9620	TLR7	46241268	VFOKSTCIRGDTBR-UHFFFAOYSA-N	Phase 2	toll-like receptor agonist	NA	NA
GS-9973	SYK	59473233	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	Phase 2	SYK inhibitor	NA	NA
GSK-J1	KDM6B	56963315	AVZCPICCWKMZDT-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
GSK-J4	KDM6A	71729975	WBKCKEHGXNWYMO-UHFFFAOYSA-N	Preclinical	histone lysine demethylase inhibitor	NA	NA
GSK-J4	KDM6B	71729975	WBKCKEHGXNWYMO-UHFFFAOYSA-N	Preclinical	histone lysine demethylase inhibitor	NA	NA
GSK-LSD-1	KDM1A	71522234	"InChI=1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2/t13-,14+/m0/s1"	Preclinical	histone lysine demethylase inhibitor	NA	NA
GSK-3-inhibitor-IX	GSK3A	NA	DDLZLOKCJHBUHD-UJZLGWIISA-N	Preclinical	glycogen synthase kinase inhibitor|lipoxygenase inhibitor	NA	NA
GSK-3-inhibitor-IX	GSK3B	NA	DDLZLOKCJHBUHD-UJZLGWIISA-N	Preclinical	glycogen synthase kinase inhibitor|lipoxygenase inhibitor	NA	NA
GSK0660	PPARD	46233311	NDFKBGWLUHKMFY-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist	NA	NA
GSK1059615	PIK3CG	23582824	QDITZBLZQQZVEE-YBEGLDIGSA-N	Phase 1	PI3K inhibitor	NA	NA
GSK1070916	AURKA	46885626	QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
GSK1070916	AURKB	46885626	QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
GSK1070916	AURKC	46885626	QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
GSK1070916	CYP2D6	46885626	QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
GSK1070916	CYP3A4	46885626	QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
GSK1292263	GRPR	24996872	AYJRTVVIBJSSKN-UHFFFAOYSA-N	Phase 2	glucose dependent insulinotropic receptor agonist	NA	NA
GSK1562590	UTS2R	46846503	QDUMEBKFKOODFN-SANMLTNESA-N	Preclinical	urotensin receptor antagonist	NA	NA
GSK163090	HTR1A	11292933	ANGUXJDGJCHGOG-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
GSK163090	HTR1B	11292933	ANGUXJDGJCHGOG-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
GSK163090	HTR1D	11292933	ANGUXJDGJCHGOG-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
GSK1838705A	ALK	25182616	HZTYDQRUAWIZRE-UHFFFAOYSA-N	Preclinical	insulin growth factor receptor inhibitor	NA	NA
GSK1838705A	IGF1R	25182616	HZTYDQRUAWIZRE-UHFFFAOYSA-N	Preclinical	insulin growth factor receptor inhibitor	NA	NA
GSK1838705A	INSR	25182616	HZTYDQRUAWIZRE-UHFFFAOYSA-N	Preclinical	insulin growth factor receptor inhibitor	NA	NA
GSK1838705A	RPS6KA1	25182616	HZTYDQRUAWIZRE-UHFFFAOYSA-N	Preclinical	insulin growth factor receptor inhibitor	NA	NA
GSK1904529A	IGF1R	25124816	MOSKATHMXWSZTQ-UHFFFAOYSA-N	Preclinical	IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand	NA	NA
GSK1904529A	INSR	25124816	MOSKATHMXWSZTQ-UHFFFAOYSA-N	Preclinical	IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand	NA	NA
GSK2110183	AKT1	46843057	AFJRDFWMXUECEW-LBPRGKRZSA-N	Phase 2	AKT inhibitor	NA	NA
GSK2110183	AKT2	46843057	AFJRDFWMXUECEW-LBPRGKRZSA-N	Phase 2	AKT inhibitor	NA	NA
GSK2110183	AKT3	46843057	AFJRDFWMXUECEW-LBPRGKRZSA-N	Phase 2	AKT inhibitor	NA	NA
GSK2126458	MTOR	25167777	CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
GSK2126458	PIK3CA	25167777	CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
GSK2126458	PIK3CB	25167777	CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
GSK2126458	PIK3CD	25167777	CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
GSK2126458	PIK3CG	25167777	CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
GSK2190915	ALOX5AP	44473151	DFQGDHBGRSTTHX-UHFFFAOYSA-N	Phase 2	lipoxygenase inhibitor	NA	NA
GSK2193874	TRPV4	53464483	UIVOZBSCHXCGPS-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
GSK2194069	FASN	67376285	AQTPWCUIYUOEMG-INIZCTEOSA-N	Preclinical	fatty acid synthase inhibitor	NA	NA
GSK2256294A	EPHX2	59448236	LQHDJQIMETZMPH-ZBFHGGJFSA-N	Phase 1	epoxide hydolase inhibitor	NA	NA
GSK2330672	SLC10A2	53492727	CZGVOBIGEBDYTP-VSGBNLITSA-N	Phase 2	bile acid transporter inhibitor	NA	NA
GSK2334470	AURKA	46215815	QLPHOXTXAKOFMU-WBVHZDCISA-N	Preclinical	phosphoinositide dependent kinase inhibitor	NA	NA
GSK2334470	AURKB	46215815	QLPHOXTXAKOFMU-WBVHZDCISA-N	Preclinical	phosphoinositide dependent kinase inhibitor	NA	NA
GSK2334470	PDPK1	46215815	QLPHOXTXAKOFMU-WBVHZDCISA-N	Preclinical	phosphoinositide dependent kinase inhibitor	NA	NA
GSK256066	PDE4A	9827968	JFHROPTYMMSOLG-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
GSK2578215A	LRRK2	68107965	WCIGMFCFPXZRMQ-UHFFFAOYSA-N	Preclinical	leucine rich repeat kinase inhibitor	NA	NA
GSK2606414	EIF2AK3	53469448	SIXVRXARNAVBTC-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
GSK2606414	MYLK2	53469448	SIXVRXARNAVBTC-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
GSK2636771	PIK3CB	56949517	XTKLTGBKIDQGQL-UHFFFAOYSA-N	Phase 2	PI3K inhibitor	NA	NA
GSK269962	ROCK1	16095342	YOVNFNXUCOWYSG-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
GSK269962	ROCK2	16095342	YOVNFNXUCOWYSG-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
GSK2801	BAZ2A	73010930	KHWCPNJRJCNVRI-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
GSK2801	BAZ2B	73010930	KHWCPNJRJCNVRI-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
GSK2816126	EZH2	68210102	FKSFKBQGSFSOSM-QFIPXVFZSA-N	Phase 1	histone lysine methyltransferase inhibitor	NA	NA
GSK2830371	PPM1D	70983932	IVDUVEGCMXCMSO-FQEVSTJZSA-N	Preclinical	protein phosphatase inhibitor	NA	NA
GSK2837808A	LDHA	71533725	RZBCPMYJIARMGV-UHFFFAOYSA-N	Preclinical	lactate dehydrogenase inhibitor	NA	NA
GSK2879552	KDM1A	66571643	LRULVYSBRWUVGR-FCHUYYIVSA-N	Phase 1/Phase 2	histone lysine demethylase inhibitor	NA	NA
GSK37647	FFAR4	743974	FQUAFMNPXPXOJE-UHFFFAOYSA-N	Preclinical	free fatty acid receptor agonist	NA	NA
GSK3787	PPARD	2800647	JFUIMTGOQCQTPF-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist	NA	NA
GSK429286A	ROCK1	92472001	OLIIUAHHAZEXEX-AWEZNQCLSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
GSK461364	PLK1	15983966	ZHJGWYRLJUCMRT-QGZVFWFLSA-N	Phase 1	PLK inhibitor	NA	NA
GSK503	EZH2	67469117	HRDQQHUKUIKFHT-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
GSK650394	SGK1	25022668	WVSBGSNVCDAMCF-UHFFFAOYSA-N	Preclinical	serum/glucocorticoid regulated kinase inhibitor	NA	NA
GSK650394	SGK2	25022668	WVSBGSNVCDAMCF-UHFFFAOYSA-N	Preclinical	serum/glucocorticoid regulated kinase inhibitor	NA	NA
GSK690693	AKT1	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	AKT2	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	AKT3	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	PAK4	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	PAK6	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	PAK7	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	PRKCQ	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	PRKG1	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK690693	PRKX	16725726	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	AKT inhibitor	NA	NA
GSK9027	NR3C1	24882669	DXBJGDVBQPEMOB-UHFFFAOYSA-N	Preclinical	glucocorticoid receptor agonist	NA	NA
GSK923295	CENPE	46898058	WHMXDBPHBVLYRC-OFVILXPXSA-N	Phase 1	centromere associated protein inhibitor	NA	NA
GTP-14564	CSF1R	3385203	DZQLVVLATXPWBK-UHFFFAOYSA-N	Preclinical	FLT3 inhibitor|tyrosine kinase inhibitor	NA	NA
GTP-14564	FLT3	3385203	DZQLVVLATXPWBK-UHFFFAOYSA-N	Preclinical	FLT3 inhibitor|tyrosine kinase inhibitor	NA	NA
GTP-14564	KIT	3385203	DZQLVVLATXPWBK-UHFFFAOYSA-N	Preclinical	FLT3 inhibitor|tyrosine kinase inhibitor	NA	NA
GTP-14564	PDGFRB	3385203	DZQLVVLATXPWBK-UHFFFAOYSA-N	Preclinical	FLT3 inhibitor|tyrosine kinase inhibitor	NA	NA
GTS21	CHRNA7	5310985	RPYWXZCFYPVCNQ-RVDMUPIBSA-N	Phase 1/Phase 2	cholinergic receptor agonist	NA	NA
guaiacol	CA2	460	LHGVFZTZFXWLCP-UHFFFAOYSA-N	Launched	local anesthetic	pulmonary	cough suppressant
guanaben-acetate	ADRA2A	5702063	WDZVGELJXXEGPV-YIXHJXPBSA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
guanaben-acetate	ADRA2B	5702063	WDZVGELJXXEGPV-YIXHJXPBSA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
guanaben-acetate	ADRA2C	5702063	WDZVGELJXXEGPV-YIXHJXPBSA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
guanethidine	SLC6A2	3518	ACGDKVXYNVEAGU-UHFFFAOYSA-N	Launched	adrenergic inhibitor	cardiology	hypertension
guanfacine	ADRA2A	3519	INJOMKTZOLKMBF-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
guanfacine	ADRA2B	3519	INJOMKTZOLKMBF-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
guanfacine	ADRA2C	3519	INJOMKTZOLKMBF-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
guanidine	ALDH2	3520	ZRALSGWEFCBTJO-UHFFFAOYSA-N	Launched	HSP inhibitor	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)
guanidine	DLG4	3520	ZRALSGWEFCBTJO-UHFFFAOYSA-N	Launched	HSP inhibitor	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)
guanidine	GAMT	3520	ZRALSGWEFCBTJO-UHFFFAOYSA-N	Launched	HSP inhibitor	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)
guanidine	RNASE1	3520	ZRALSGWEFCBTJO-UHFFFAOYSA-N	Launched	HSP inhibitor	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)
guanidinoethyldisulfide-bicarbonate	NOS2	3521	IRMTXMJNHRISQH-UHFFFAOYSA-N	Phase 2	nitric oxide synthase inhibitor	NA	NA
guanidinopropionic-acid	CKM	67701	KMXXSJLYVJEBHI-UHFFFAOYSA-N	Phase 2	creatine kinase inhibitor	NA	NA
guanosine	PNP	135398635	NYHBQMYGNKIUIF-UUOKFMHZSA-N	Preclinical		NA	NA
Gue-1654	OXER1	5066134	UFOBDFMYJABXGK-UHFFFAOYSA-N	Preclinical	oxoeicosanoid receptor modulator	NA	NA
guvacine	SLC6A1	40468028	QTDZOWFRBNTPQR-UHFFFAOYSA-N	Preclinical	GABA uptake inhibitor	NA	NA
guvacine	SLC6A11	40468028	QTDZOWFRBNTPQR-UHFFFAOYSA-N	Preclinical	GABA uptake inhibitor	NA	NA
guvacine	SLC6A12	40468028	QTDZOWFRBNTPQR-UHFFFAOYSA-N	Preclinical	GABA uptake inhibitor	NA	NA
guvacine	SLC6A13	40468028	QTDZOWFRBNTPQR-UHFFFAOYSA-N	Preclinical	GABA uptake inhibitor	NA	NA
GW-0742	PPARD	9934458	HWVNEWGKWRGSRK-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
GW-1100	FFAR1	11692123	PTPNCCWOTBBVJR-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
GW-1929	PPARG	6518171	QTQMRBZOBKYXCG-MHZLTWQESA-N	Preclinical	PPAR receptor agonist	NA	NA
GW-2580	CSF1R	11617559	MYQAUKPBNJWPIE-UHFFFAOYSA-N	Preclinical	cFMS kinase inhibitor	NA	NA
GW-311616	ELANE	9800961	NDNKNUMSTIMSHQ-URZKGLGPSA-N	Phase 1	elastase inhibitor|leukocyte elastase inhibitor	NA	NA
GW-3965	NR1H2	72199895	NAXSRXHZFIBFMI-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
GW-3965	NR1H3	72199895	NAXSRXHZFIBFMI-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
GW-405833	CNR2	9911463	FSFZRNZSZYDVLI-UHFFFAOYSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
GW-4064	NR1H4	9893571	BYTNEISLBIENSA-MDZDMXLPSA-N	Preclinical	FXR agonist	NA	NA
GW-438014A	NPY5R	6918627	CDUDZZGLFOFINU-UHFFFAOYSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
GW-441756	NTRK1	9943465	NXNQLECPAXXYTR-LCYFTJDESA-N	Preclinical	growth factor receptor inhibitor	NA	NA
GW-501516	PPARA	9803963	YDBLKRPLXZNVNB-UHFFFAOYSA-N	Phase 2	PPAR receptor agonist	NA	NA
GW-501516	PPARD	9803963	YDBLKRPLXZNVNB-UHFFFAOYSA-N	Phase 2	PPAR receptor agonist	NA	NA
GW-5074	NTRK1	5034	LMXYVLFTZRPNRV-UHFFFAOYSA-N	Phase 1/Phase 2	leucine rich repeat kinase inhibitor|RAF inhibitor	NA	NA
GW-5074	RAF1	5034	LMXYVLFTZRPNRV-UHFFFAOYSA-N	Phase 1/Phase 2	leucine rich repeat kinase inhibitor|RAF inhibitor	NA	NA
GW-542573X	KCNN1	24885053	SAXGSDIZIYFNKD-UHFFFAOYSA-N	Preclinical	calcium channel activator	NA	NA
GW-583340	EGFR	5329480	MNNXRVSQOABRRP-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
GW-583340	ERBB2	5329480	MNNXRVSQOABRRP-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
GW-627368	PTGER4	5312130	XREWXJVMYAXCJV-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
GW-6471	PPARA	446738	TYEFSRMOUXWTDN-DYQICHDWSA-N	Preclinical	PPAR receptor antagonist	NA	NA
GW-7647	PPARA	3392731	PKNYXWMTHFMHKD-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
GW-788388	LCK	10202642	SAGZIBJAQGBRQA-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
GW-788388	MAPK14	10202642	SAGZIBJAQGBRQA-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
GW-788388	TGFBR1	10202642	SAGZIBJAQGBRQA-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
GW-803430	KCNH2	9826520	MWULMTACIBZPGN-UHFFFAOYSA-N	Phase 1	melanin inhibitor	NA	NA
GW-803430	MCHR1	9826520	MWULMTACIBZPGN-UHFFFAOYSA-N	Phase 1	melanin inhibitor	NA	NA
GW-842166	CNR2	10253143	TWQYWUXBZHPIIV-UHFFFAOYSA-N	Phase 2	cannabinoid receptor agonist	NA	NA
GW-843682X	PLK1	9826308	JSKUWFIZUALZLX-UHFFFAOYSA-N	Preclinical	PLK inhibitor	NA	NA
GW-843682X	PLK3	9826308	JSKUWFIZUALZLX-UHFFFAOYSA-N	Preclinical	PLK inhibitor	NA	NA
GW-9508	FFAR1	11595431	DGENZVKCTGIDRZ-UHFFFAOYSA-N	Preclinical	free fatty acid receptor agonist|G protein-coupled receptor agonist	NA	NA
GW-9508	FFAR4	11595431	DGENZVKCTGIDRZ-UHFFFAOYSA-N	Preclinical	free fatty acid receptor agonist|G protein-coupled receptor agonist	NA	NA
GW-9662	NCOA2	644213	DNTSIBUQMRRYIU-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist	NA	NA
GW-9662	PPARG	644213	DNTSIBUQMRRYIU-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist	NA	NA
GW-9662	RXRA	644213	DNTSIBUQMRRYIU-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist	NA	NA
GYKI-52466	GRIA1	3538	"InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3"	Preclinical	glutamate receptor antagonist	NA	NA
GYKI-52466	GRIA2	3538	"InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3"	Preclinical	glutamate receptor antagonist	NA	NA
GYKI-52466	GRIA3	3538	"InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3"	Preclinical	glutamate receptor antagonist	NA	NA
GYKI-52466	GRIA4	3538	"InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3"	Preclinical	glutamate receptor antagonist	NA	NA
GZD824	ABL1	51038269	TZKBVRDEOITLRB-UHFFFAOYSA-N	Preclinical	Bcr-Abl kinase inhibitor	NA	NA
GZD824	BCR	51038269	TZKBVRDEOITLRB-UHFFFAOYSA-N	Preclinical	Bcr-Abl kinase inhibitor	NA	NA
G007-LK	TNKS	67960134	HIWVLHPKZNBSBE-OUKQBFOZSA-N	Preclinical	tankyrase inhibitor	NA	NA
G007-LK	TNKS2	67960134	HIWVLHPKZNBSBE-OUKQBFOZSA-N	Preclinical	tankyrase inhibitor	NA	NA
H-89	GSG2	449241	ZKZXNDJNWUTGDK-NSCUHMNNSA-N	Preclinical	PKA inhibitor	NA	NA
H-89	PKIA	449241	ZKZXNDJNWUTGDK-NSCUHMNNSA-N	Preclinical	PKA inhibitor	NA	NA
H-89	PRKACA	449241	ZKZXNDJNWUTGDK-NSCUHMNNSA-N	Preclinical	PKA inhibitor	NA	NA
HA-130	ENPP2	46911532	VTNKMYWFWQTEHE-XKZIYDEJSA-N	Preclinical	autotaxin inhibitor	NA	NA
HA-966-(R)-(+)	GRIA1	6603720	HCKUBNLZMKAEIN-GSVOUGTGSA-N	Preclinical	glutamate receptor agonist	NA	NA
HA-966-(S)-(-)	GRIA1	183351	HCKUBNLZMKAEIN-VKHMYHEASA-N	Preclinical	glutamate receptor antagonist	NA	NA
halcinonide	NR3C1	443943	MUQNGPZZQDCDFT-JNQJZLCISA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
halobetasol-propionate	NR3C1	6918178	BDSYKGHYMJNPAB-LICBFIPMSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
halobetasol-propionate	PLA2G1B	6918178	BDSYKGHYMJNPAB-LICBFIPMSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
halofantrine	KCNN4	36688213	FOHHNHSLJDZUGQ-RUZDIDTESA-N	Launched	antimalarial agent	infectious disease	malaria
halofuginone	COL1A1	456390	LVASCWIMLIKXLA-CABCVRRESA-N	Launched	collagenase inhibitor	rheumatology	scleroderma
halofuginone	MMP2	456390	LVASCWIMLIKXLA-CABCVRRESA-N	Launched	collagenase inhibitor	rheumatology	scleroderma
halopemide	PLD1	65490	NBHPRWLFLUBAIE-UHFFFAOYSA-N	Phase 2	phospholipase inhibitor	NA	NA
halopemide	PLD2	65490	NBHPRWLFLUBAIE-UHFFFAOYSA-N	Phase 2	phospholipase inhibitor	NA	NA
haloperidol	DRD1	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	DRD2	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	DRD3	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	DRD4	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	DRD5	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	GRIN2B	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	HRH1	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	HTR1A	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	HTR1D	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	HTR2A	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	HTR2B	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	HTR7	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol	KCNH1	3559	LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|Tourette's disorder
haloperidol-decanoate	DRD2	52919	GUTXTARXLVFHDK-UHFFFAOYSA-N	Launched	psychoactive drug	neurology/psychiatry	schizophrenia
haloperidol-decanoate	DRD3	52919	GUTXTARXLVFHDK-UHFFFAOYSA-N	Launched	psychoactive drug	neurology/psychiatry	schizophrenia
haloperidol-decanoate	DRD4	52919	GUTXTARXLVFHDK-UHFFFAOYSA-N	Launched	psychoactive drug	neurology/psychiatry	schizophrenia
haloperidol-decanoate	HTR2A	52919	GUTXTARXLVFHDK-UHFFFAOYSA-N	Launched	psychoactive drug	neurology/psychiatry	schizophrenia
halothane	GABRA1	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRA2	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRA3	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRA4	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRA5	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRA6	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRB1	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRB2	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRB3	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRD	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRE	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRG1	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRG2	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRG3	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRP	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GABRQ	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GLRA1	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	GLRB	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK10	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK12	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK13	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK15	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK18	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK2	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK3	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
halothane	KCNK9	4369439	BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
harmane	MAOA	5281404	PSFDQSOCUJVVGF-UHFFFAOYSA-N	Preclinical	monoamine oxidase inhibitor	NA	NA
harmane	MAOB	5281404	PSFDQSOCUJVVGF-UHFFFAOYSA-N	Preclinical	monoamine oxidase inhibitor	NA	NA
HA14-1	BCL2	6976314	SXJDCULZDFWMJC-AAEUAGOBSA-N	Preclinical	BCL inhibitor	NA	NA
HC-030031	TRPA1	1150897	HEQDZPHDVAOBLN-UHFFFAOYSA-N	Phase 1	TRPA1 channel blocker	NA	NA
HC-067047	TRPV4	2742550	NCZYSQOTAYFTNM-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
heclin	NEDD4	7464118	SPTWXRJNCFIDRQ-ZHACJKMWSA-N	Preclinical	ubiquitin ligase inhibitor	NA	NA
heclin	SMURF2	7464118	SPTWXRJNCFIDRQ-ZHACJKMWSA-N	Preclinical	ubiquitin ligase inhibitor	NA	NA
heclin	WWP1	7464118	SPTWXRJNCFIDRQ-ZHACJKMWSA-N	Preclinical	ubiquitin ligase inhibitor	NA	NA
HEMADO	ADORA1	10981286	KOCIMZNSNPOGOP-IWCJZZDYSA-N	Preclinical	adenosine receptor agonist	NA	NA
HEMADO	ADORA2A	10981286	KOCIMZNSNPOGOP-IWCJZZDYSA-N	Preclinical	adenosine receptor agonist	NA	NA
HEMADO	ADORA2B	10981286	KOCIMZNSNPOGOP-IWCJZZDYSA-N	Preclinical	adenosine receptor agonist	NA	NA
HEMADO	ADORA3	10981286	KOCIMZNSNPOGOP-IWCJZZDYSA-N	Preclinical	adenosine receptor agonist	NA	NA
hemomex-s	PPARG	11468733	SHCBCKBYTHZQGZ-CJPZEJHVSA-N	Launched		NA	NA
hesperadin	AURKB	NA	GLDSKRNGVVYJAB-DQSJHHFOSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
hesperetin	DGAT1	72281	AIONOLUJZLIMTK-AWEZNQCLSA-N	Launched	ACAT inhibitor	NA	NA
hesperetin	MTTP	72281	AIONOLUJZLIMTK-AWEZNQCLSA-N	Launched	ACAT inhibitor	NA	NA
hesperetin	SOAT1	72281	AIONOLUJZLIMTK-AWEZNQCLSA-N	Launched	ACAT inhibitor	NA	NA
hesperetin	SOAT2	72281	AIONOLUJZLIMTK-AWEZNQCLSA-N	Launched	ACAT inhibitor	NA	NA
hesperidin	AURKB	10621	QUQPHWDTPGMPEX-QJBIFVCTSA-N	Launched	flavanone glycoside	NA	NA
hesperidin	CACNA1B	10621	QUQPHWDTPGMPEX-QJBIFVCTSA-N	Launched	flavanone glycoside	NA	NA
hexachlorophene	GLUD1	3598	ACGUYXCXAPNIKK-UHFFFAOYSA-N	Launched	potassium channel activator	infectious disease	gram-positive bacterial infections
hexachlorophene	SDHD	3598	ACGUYXCXAPNIKK-UHFFFAOYSA-N	Launched	potassium channel activator	infectious disease	gram-positive bacterial infections
hexamethonium	CHRNA2	3604	VZJFGSRCJCXDSG-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
hexamethonium	CHRNA3	3604	VZJFGSRCJCXDSG-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
hexamethonium	CHRNA4	3604	VZJFGSRCJCXDSG-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
hexamethonium	CHRNA6	3604	VZJFGSRCJCXDSG-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
hexamethylenebisacetamide	AKT1	3616	BNQSTAOJRULKNX-UHFFFAOYSA-N	Phase 2	AKT inhibitor|differentiation inducer|NFKB pathway inhibitor	NA	NA
hexestrol	AKR1C1	192197	PBBGSZCBWVPOOL-HDICACEKSA-N	Launched	synthetic estrogen	endocrinology	hypoestrogenism
hexestrol	ESR1	192197	PBBGSZCBWVPOOL-HDICACEKSA-N	Launched	synthetic estrogen	endocrinology	hypoestrogenism
hexestrol	ESR2	192197	PBBGSZCBWVPOOL-HDICACEKSA-N	Launched	synthetic estrogen	endocrinology	hypoestrogenism
hexoprenaline	ADRB2	24993924	OXLZNBCNGJWPRV-SZPZYZBQSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
hexylcaine	SCN5A	6604266	DKLKMKYDWHYZTD-ZDUSSCGKSA-N	Launched	sodium channel blocker	neurology/psychiatry	local anesthetic
hexylene-glycol	AKR1C3	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	CTPS1	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	DLG4	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	HSP90AA1	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	NOS3	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	PGF	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	PLA2G1B	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	PTPN1	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylene-glycol	SELP	5288845	SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical		NA	NA
hexylresorcinol	TYR	3610	WFJIVOKAWHGMBH-UHFFFAOYSA-N	Launched	local anesthetic	infectious disease	skin infections|first-aid antiseptic
higenamine	ADRB2	440988	WZRCQWQRFZITDX-CQSZACIVSA-N	Phase 1	adrenergic receptor agonist	NA	NA
histamine	HRH1	774	NTYJJOPFIAHURM-UHFFFAOYSA-N	Launched	histamine receptor agonist	allergy	allergic rhinitis
histamine	HRH2	774	NTYJJOPFIAHURM-UHFFFAOYSA-N	Launched	histamine receptor agonist	allergy	allergic rhinitis
histamine	HRH3	774	NTYJJOPFIAHURM-UHFFFAOYSA-N	Launched	histamine receptor agonist	allergy	allergic rhinitis
histamine	HRH4	774	NTYJJOPFIAHURM-UHFFFAOYSA-N	Launched	histamine receptor agonist	allergy	allergic rhinitis
HJC-0350	RAPGEF4	22200891	AFZWZVLPIMHLSE-UHFFFAOYSA-N	Preclinical	GTPase inhibitor	NA	NA
HKI-357	EGFR	11238512	NERXPXBELDBEPZ-RMKNXTFCSA-N	Phase 1	EGFR inhibitor	NA	NA
HLCL-61	PRMT5	2250650	FIOIJUCPVZEPFX-UHFFFAOYSA-N	Preclinical	protein arginine N-methyltransferase inhibitor	NA	NA
HMN-214	PLK1	9888590	OCKHRKSTDPOHEN-BQYQJAHWSA-N	Phase 1	PLK inhibitor	NA	NA
homatropine	CHRM1		ZTVIKZXZYLEVOL-YJNKXOJESA-N	Launched	acetylcholine receptor antagonist	ophthalmology	uveal tract inflammation|pupil dilation
homatropine-methylbromide	CHRM5	NA	WKWOJBUWWZTUQV-JJXSEGSLSA-N	Launched	acetylcholine receptor antagonist	ophthalmology	uveal tract inflammation
homochlorcyclizine	HRH1	5393145	WEUCDJCFJHYFRL-IBGZPJMESA-N	Launched	antihistamine	allergy	allergic rhinitis
homoharringtonine	RPL3	285033	HYFHYPWGAURHIV-JFIAXGOJSA-N	Launched	protein synthesis inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
homoquinolinic-acid	GRIN1	3080554	HQPMJFFEXJELOQ-UHFFFAOYSA-N	Preclinical	glutamate receptor agonist	NA	NA
homoquinolinic-acid	GRIN2A	3080554	HQPMJFFEXJELOQ-UHFFFAOYSA-N	Preclinical	glutamate receptor agonist	NA	NA
homoquinolinic-acid	GRIN2B	3080554	HQPMJFFEXJELOQ-UHFFFAOYSA-N	Preclinical	glutamate receptor agonist	NA	NA
homoquinolinic-acid	GRIN2C	3080554	HQPMJFFEXJELOQ-UHFFFAOYSA-N	Preclinical	glutamate receptor agonist	NA	NA
homoquinolinic-acid	GRIN2D	3080554	HQPMJFFEXJELOQ-UHFFFAOYSA-N	Preclinical	glutamate receptor agonist	NA	NA
honokiol	ALOX5	72303	FVYXIJYOAGAUQK-UHFFFAOYSA-N	Phase 3	AKT inhibitor	NA	NA
honokiol	PTGS1	72303	FVYXIJYOAGAUQK-UHFFFAOYSA-N	Phase 3	AKT inhibitor	NA	NA
honokiol	PTGS2	72303	FVYXIJYOAGAUQK-UHFFFAOYSA-N	Phase 3	AKT inhibitor	NA	NA
HTH-01-015	NUAK1	78357766	CHSDJDLAKKAWCI-UHFFFAOYSA-N	Preclinical	protein kinase inhibitor	NA	NA
HTMT	HRH4	6604743	PMKJGGBYYNEYPA-AWEZNQCLSA-N	Preclinical	histamine receptor agonist	NA	NA
huperzine-A	ACHE	854026	ZRJBHWIHUMBLCN-YQEJDHNASA-N	Phase 2	acetylcholinesterase inhibitor	NA	NA
hyaluronic-acid	C1QBP	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	CD44	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	HABP2	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	HAPLN1	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	HAPLN3	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	HAPLN4	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	HMMR	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	ICAM1	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	NCAN	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hyaluronic-acid	VCAN	6852395	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)
hydrochlorothiazide	CA1	3639	JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
hydrochlorothiazide	CA12	3639	JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
hydrochlorothiazide	CA2	3639	JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
hydrochlorothiazide	CA4	3639	JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
hydrochlorothiazide	CA9	3639	JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
hydrochlorothiazide	KCNMA1	3639	JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
hydrochlorothiazide	SLC12A3	3639	JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
hydrocortisone	ANXA1	5754	JYGXADMDTFJGBT-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching
hydrocortisone	NOS2	5754	JYGXADMDTFJGBT-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching
hydrocortisone	NR3C1	5754	JYGXADMDTFJGBT-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching
hydrocortisone	NR3C2	5754	JYGXADMDTFJGBT-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching
hydrocortisone-acetate	NR3C1	5744	ALEXXDVDDISNDU-JZYPGELDSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
hydrocortisone-butyrate	NR3C1	26133	BMCQMVFGOVHVNG-TUFAYURCSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses|eczema
hydrocortisone-valerate	NR3C1	5282494	FZCHYNWYXKICIO-FZNHGJLXSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
hydroflumethiazide	ATP1A1	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	CA1	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	CA12	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	CA2	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	CA4	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	CA9	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	KCNMA1	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	SLC12A1	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroflumethiazide	SLC12A3	3647	DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	sodium/potassium/chloride transporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
hydroquinone	TYR	785	QIGBRXMKCJKVMJ-UHFFFAOYSA-N	Launched	melanin inhibitor	dermatology	dyschromia
hydroxyamphetamine	TAAR1	12234986	GIKNHHRFLCDOEU-SSDOTTSWSA-N	Launched	trace amine associated receptor agonist	ophthalmology	mydriasis
hydroxychloroquine	TLR7	12947	XXSMGPRMXLTPCZ-UHFFFAOYSA-N	Launched	antimalarial agent	infectious disease	malaria
hydroxychloroquine	TLR9	12947	XXSMGPRMXLTPCZ-UHFFFAOYSA-N	Launched	antimalarial agent	infectious disease	malaria
hydroxyfasudil	PKIA	3064778	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
hydroxyfasudil	PRKACA	3064778	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
hydroxyfasudil	ROCK1	3064778	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
hydroxyprogesterone	PGR	6238	DBPWSSGDRRHUNT-CEGNMAFCSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
hydroxyprogesterone-acetate	PGR	10156152	VTHUYJIXSMGYOQ-KOORYGTMSA-N	Launched	progesterone receptor agonist	NA	NA
"hydroxytacrine-maleate-(R,S)"	ACHE	667530	HLVVITIHAZBPKB-NSHDSACASA-N	Preclinical	cholinesterase inhibitor	NA	NA
hydroxyurea	RRM1	3657	VSNHCAURESNICA-UHFFFAOYSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)
hydroxyurea	RRM2	3657	VSNHCAURESNICA-UHFFFAOYSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)
hydroxyurea	RRM2B	3657	VSNHCAURESNICA-UHFFFAOYSA-N	Launched	ribonucleotide reductase inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)
hydroxyzine	HRH1	1548976	ZQDWXGKKHFNSQK-NRFANRHFSA-N	Launched	antihistamine	neurology/psychiatry|allergy|dermatology	anxiety|urticaria|itching|dermatosis
hymecromone	MAOA	5280567	HSHNITRMYYLLCV-UHFFFAOYSA-N	Phase 2	monoamine oxidase inhibitor	NA	NA
hymecromone	MAOB	5280567	HSHNITRMYYLLCV-UHFFFAOYSA-N	Phase 2	monoamine oxidase inhibitor	NA	NA
hyoscyamine	CHRM1		RKUNBYITZUJHSG-FXUDXRNXSA-N	Launched	acetylcholine receptor antagonist	gastroenterology|urology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis
hyoscyamine	CHRM2		RKUNBYITZUJHSG-FXUDXRNXSA-N	Launched	acetylcholine receptor antagonist	gastroenterology|urology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis
hyoscyamine	CHRM3		RKUNBYITZUJHSG-FXUDXRNXSA-N	Launched	acetylcholine receptor antagonist	gastroenterology|urology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis
hyoscyamine	CHRM4		RKUNBYITZUJHSG-FXUDXRNXSA-N	Launched	acetylcholine receptor antagonist	gastroenterology|urology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis
hyperin	ACE	5742688	OVSQVDMCBVZWGM-FHYQVQSVSA-N	Preclinical	aldose reductase inhibitor	NA	NA
hyperin	AKR1B1	5742688	OVSQVDMCBVZWGM-FHYQVQSVSA-N	Preclinical	aldose reductase inhibitor	NA	NA
hypoestoxide	IKBKB	11199742	HNPAHGHFONBTLV-KSJQNFQUSA-N	Phase 1	IKK inhibitor	NA	NA
hypoestoxide	IL1B	11199742	HNPAHGHFONBTLV-KSJQNFQUSA-N	Phase 1	IKK inhibitor	NA	NA
hypoestoxide	TNF	11199742	HNPAHGHFONBTLV-KSJQNFQUSA-N	Phase 1	IKK inhibitor	NA	NA
hypoxanthine	PNP	790	FDGQSTZJBFJUBT-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
H2L-5765834	LPAR1	1365686	HFYPTENHTPNXGP-UHFFFAOYSA-N	Preclinical	lysophosphatidic acid receptor antagonist	NA	NA
H2L-5765834	LPAR3	1365686	HFYPTENHTPNXGP-UHFFFAOYSA-N	Preclinical	lysophosphatidic acid receptor antagonist	NA	NA
I-BET-762	BRD2	46943432	"InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1"	Phase 2	bromodomain inhibitor	NA	NA
I-BET-762	BRD3	46943432	"InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1"	Phase 2	bromodomain inhibitor	NA	NA
I-BET-762	BRD4	46943432	"InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1"	Phase 2	bromodomain inhibitor	NA	NA
I-BET151	BRD2	52912189	VUVUVNZRUGEAHB-CYBMUJFWSA-N	Preclinical	bromodomain inhibitor	NA	NA
I-BET151	BRD3	52912189	VUVUVNZRUGEAHB-CYBMUJFWSA-N	Preclinical	bromodomain inhibitor	NA	NA
I-BET151	BRD4	52912189	VUVUVNZRUGEAHB-CYBMUJFWSA-N	Preclinical	bromodomain inhibitor	NA	NA
I-BRD9	BRD9	91668541	WRUWGLUCNBMGPS-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
I-CBP-112	CREBBP	90488984	YKNAKDFZAWQEEO-IBGZPJMESA-N	Preclinical	bromodomain inhibitor	NA	NA
I-CBP-112	EP300	90488984	YKNAKDFZAWQEEO-IBGZPJMESA-N	Preclinical	bromodomain inhibitor	NA	NA
IB-MECA	ADORA1	123683	HUJXGQILHAUCCV-MOROJQBDSA-N	Phase 3	adenosine receptor agonist	NA	NA
IB-MECA	ADORA2A	123683	HUJXGQILHAUCCV-MOROJQBDSA-N	Phase 3	adenosine receptor agonist	NA	NA
IB-MECA	ADORA2B	123683	HUJXGQILHAUCCV-MOROJQBDSA-N	Phase 3	adenosine receptor agonist	NA	NA
IB-MECA	ADORA3	123683	HUJXGQILHAUCCV-MOROJQBDSA-N	Phase 3	adenosine receptor agonist	NA	NA
ibandronate	FDPS	60852	MPBVHIBUJCELCL-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
IBC-293	HCAR3	2736690	RUTVRAJKELSHCC-UHFFFAOYSA-N	Preclinical	hydroxycarboxylic acid receptor agonist	NA	NA
IBMX	ADORA1	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE2A	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE3B	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE4D	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE5A	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE6G	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE7A	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE8A	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
IBMX	PDE9A	3758	APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
ibotenic-acid	GRIN1	6971210	IRJCBFDCFXCWGO-SCSAIBSYSA-N	Preclinical	glutamate receptor agonist	NA	NA
ibrolipim	LPL	131601	KPRTURMJVWXURQ-UHFFFAOYSA-N	Phase 2	lipoprotein lipase activator	NA	NA
ibrutinib	BLK	24821094	"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1"	Launched	Bruton's tyrosine kinase (BTK) inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)
ibrutinib	BMX	24821094	"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1"	Launched	Bruton's tyrosine kinase (BTK) inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)
ibrutinib	BTK	24821094	"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1"	Launched	Bruton's tyrosine kinase (BTK) inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)
ibudilast	IL1B	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibudilast	IL6	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibudilast	PDE3A	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibudilast	PDE4A	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibudilast	PDE4B	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibudilast	PDE4C	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibudilast	PDE4D	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibudilast	PDE5A	3671	ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke
ibuprofen-(S)	ASIC1	39912	HEFNNWSXXWATRW-JTQLQIEISA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuprofen-(S)	PTGS1	39912	HEFNNWSXXWATRW-JTQLQIEISA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuprofen-(S)	PTGS2	39912	HEFNNWSXXWATRW-JTQLQIEISA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuprofen-(S)	SLC5A8	39912	HEFNNWSXXWATRW-JTQLQIEISA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuprofen-piconol	PTGS1	76968625	ACEWLPOYLGNNHV-OAHLLOKOSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuprofen-piconol	PTGS2	76968625	ACEWLPOYLGNNHV-OAHLLOKOSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuproxam	ALOX5	11458696	BYPIURIATSUHDW-SNVBAGLBSA-N	Launched	cyclooxygenase inhibitor|prostaglandin inhibitor	endocrinology|rheumatology|neurology/psychiatry	fever|joint inflammation|pain relief
ibutamoren	GHR	178024	UMUPQWIGCOZEOY-JOCHJYFZSA-N	Phase 2	growth hormone secretagogue receptor agonist	NA	NA
ibutamoren	GHSR	178024	UMUPQWIGCOZEOY-JOCHJYFZSA-N	Phase 2	growth hormone secretagogue receptor agonist	NA	NA
ibutilide	CACNA1C	21149973	ALOBUEHUHMBRLE-HXUWFJFHSA-N	Launched	potassium channel blocker	cardiology	atrial fibrillation (AF)
ibutilide	KCNH2	21149973	ALOBUEHUHMBRLE-HXUWFJFHSA-N	Launched	potassium channel blocker	cardiology	atrial fibrillation (AF)
ICA-069673	KCNQ2	10149311	IIBSHMFXVWTQSJ-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
ICA-069673	KCNQ3	10149311	IIBSHMFXVWTQSJ-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
ICA-110381	KCNQ2	4314115	FOYOGIUAMYSVIT-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
ICA-121431	SCN1A	998021	URSQNPPONHUJDL-UHFFFAOYSA-N	Preclinical	sodium channel blocker	NA	NA
ICA-121431	SCN3A	998021	URSQNPPONHUJDL-UHFFFAOYSA-N	Preclinical	sodium channel blocker	NA	NA
icariin	PDE5A	5318997	TZJALUIVHRYQQB-XLRXWWTNSA-N	Phase 3	phosphodiesterase inhibitor	NA	NA
icaritin	PDE5A	5318980	TUUXBSASAQJECY-UHFFFAOYSA-N	Phase 3	PPAR receptor antagonist	NA	NA
icatibant-acetate	BDKRB2	6918173	QURWXBZNHXJZBE-SKXRKSCCSA-N	Launched	bradykinin receptor antagonist	cardiology	angioedema
ICG-001	CTNNB1	11238147	HQWTUOLCGKIECB-XZWHSSHBSA-N	Preclinical	beta-catenin inhibitor	NA	NA
"ICI-118,551"	ADRB2	5311179	VFIDUCMKNJIJTO-XJKSGUPXSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
"ICI-118,551"	ADRB3	5311179	VFIDUCMKNJIJTO-XJKSGUPXSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
ICI-162846	HRH2	134778	ALCSGJCIESECFD-UHFFFAOYSA-N	Phase 1	histamine receptor antagonist	NA	NA
ICI-192605	TBXA2R	6604763	WHUIENZXNGAHQI-GKZDNZBASA-N	Phase 2	thromboxane receptor antagonist	NA	NA
ICI-199441	CYP2D6	3082718	AEJOEPSMZCEYJN-HXUWFJFHSA-N	Preclinical	opioid receptor agonist	NA	NA
ICI-199441	OPRD1	3082718	AEJOEPSMZCEYJN-HXUWFJFHSA-N	Preclinical	opioid receptor agonist	NA	NA
ICI-199441	OPRK1	3082718	AEJOEPSMZCEYJN-HXUWFJFHSA-N	Preclinical	opioid receptor agonist	NA	NA
ICI-199441	OPRM1	3082718	AEJOEPSMZCEYJN-HXUWFJFHSA-N	Preclinical	opioid receptor agonist	NA	NA
ICI-199441	UTS2R	3082718	AEJOEPSMZCEYJN-HXUWFJFHSA-N	Preclinical	opioid receptor agonist	NA	NA
"ICI-215,001"	ADRB3	164451	MXWICZOXPUWAHY-HNNXBMFYSA-N	Preclinical	adrenergic receptor agonist	NA	NA
ICI-89406	ADRB1	92211532	HTLWRKRZKFAAAH-KRWDZBQOSA-N	Phase 1	adrenergic receptor antagonist	NA	NA
ICI-89406	ADRB2	92211532	HTLWRKRZKFAAAH-KRWDZBQOSA-N	Phase 1	adrenergic receptor antagonist	NA	NA
icilin	TRPA1	161930	RCEFMOGVOYEGJN-UHFFFAOYSA-N	Phase 1	TRPV agonist	NA	NA
icilin	TRPM8	161930	RCEFMOGVOYEGJN-UHFFFAOYSA-N	Phase 1	TRPV agonist	NA	NA
icomucret	LTB4R2	5280724	JSFATNQSLKRBCI-VAEKSGALSA-N	Phase 3	mucin production enhancer	NA	NA
icosapent	ACSL3	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	ACSL4	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	FADS1	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	FFAR1	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	PPARD	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	PPARG	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	PTGS1	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	PTGS2	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	SLC8A1	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icosapent	TRPV1	446284	JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icotinib	EGFR	22024915	QQLKULDARVNMAL-UHFFFAOYSA-N	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
iCRT-14	CTNNB1	5967294	NCSHZXNGQYSKLR-UNOMPAQXSA-N	Preclinical	beta catenin inhibitor|WNT signaling inhibitor	NA	NA
iCRT-14	TCF4	5967294	NCSHZXNGQYSKLR-UNOMPAQXSA-N	Preclinical	beta catenin inhibitor|WNT signaling inhibitor	NA	NA
IC261	CSNK1A1	5288600	JBJYTZXCZDNOJW-JLHYYAGUSA-N	Preclinical	casein kinase inhibitor	NA	NA
IC261	CSNK1D	5288600	JBJYTZXCZDNOJW-JLHYYAGUSA-N	Preclinical	casein kinase inhibitor	NA	NA
IC261	CSNK1E	5288600	JBJYTZXCZDNOJW-JLHYYAGUSA-N	Preclinical	casein kinase inhibitor	NA	NA
IC261	CSNK1G2	5288600	JBJYTZXCZDNOJW-JLHYYAGUSA-N	Preclinical	casein kinase inhibitor	NA	NA
ID-1101	INS	6918732	OSCCDBFHNMXNME-YUPRTTJUSA-N	Phase 1	insulin sensitizer	NA	NA
idalopirdine	HTR6	21071390	YBAWYTYNMZWMMJ-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
idarubicin	TOP2A	42890	XDXDZDZNSLXDNA-TZNDIEGXSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
idasanutlin	MDM2	53358942	"InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1"	Phase 3	MDM inhibitor	NA	NA
idasanutlin	TP53	53358942	"InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1"	Phase 3	MDM inhibitor	NA	NA
idazoxan	ADRA2A	12866829	HPMRFMKYPGXPEP-SNVBAGLBSA-N	Phase 3	adrenergic receptor antagonist	NA	NA
idazoxan	PTGS2	12866829	HPMRFMKYPGXPEP-SNVBAGLBSA-N	Phase 3	adrenergic receptor antagonist	NA	NA
idelalisib	PIK3CA	11625818	"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1"	Launched	PI3K inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
idelalisib	PIK3CB	11625818	"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1"	Launched	PI3K inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
idelalisib	PIK3CD	11625818	"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1"	Launched	PI3K inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
idelalisib	PIK3CG	11625818	"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1"	Launched	PI3K inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
IDO5L	IDO1	135424953	HGXSLPIXNPASGZ-UHFFFAOYSA-N	Preclinical	"indoleamine 2,3-dioxygenase inhibitor"	NA	NA
IDRA-21	GRIA1	7048549	VZRNTCHTJRLTMU-YFKPBYRVSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
IDRA-21	GRIA2	7048549	VZRNTCHTJRLTMU-YFKPBYRVSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
IDRA-21	GRIA3	7048549	VZRNTCHTJRLTMU-YFKPBYRVSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
IDRA-21	GRIA4	7048549	VZRNTCHTJRLTMU-YFKPBYRVSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
idronoxil	ENOX2	219100	ZZUBHVMHNVYXRR-UHFFFAOYSA-N	Phase 3	XIAP inhibitor	NA	NA
idronoxil	SPHK1	219100	ZZUBHVMHNVYXRR-UHFFFAOYSA-N	Phase 3	XIAP inhibitor	NA	NA
IEM1460	GRIA2	3248290	IWYZMMIPAJDJBN-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
IEM1754	GRIA1	9887868	UWWMQHVWAYFCDT-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
ifenprodil	GRIN2B	6604117	UYNVMODNBIQBMV-KKSFZXQISA-N	Launched	adrenergic receptor antagonist|glutamate receptor antagonist	NA	NA
ifosfamide	CYP2A6	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP2B6	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP2C18	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP2C19	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP2C8	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP2C9	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP3A4	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP3A5	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	CYP3A7	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
ifosfamide	PTGS1	9588020	HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis
igmesine	SIGMAR1	6438340	VCZSWYIFCKGTJI-JLHYYAGUSA-N	Phase 2	sigma receptor agonist	NA	NA
iguratimod	PTGS2	124246	ANMATWQYLIFGOK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|NFkB pathway inhibitor	rheumatology	rheumatoid arthritis
IKK-16	IKBKB	9549298	BWZJBXAPRCVCKQ-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
IKK-2-inhibitor	IKBKB	2807869	BMUACLADCKCNKZ-UHFFFAOYSA-N	Preclinical	IKK inhibitor|SYK inhibitor	NA	NA
IKK-2-inhibitor-V	IKBKB	5081913	CHILCFMQWMQVAL-UHFFFAOYSA-N	Phase 1	IKK inhibitor|NFkB pathway inhibitor	NA	NA
ilomastat	ACAN	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	ADAM28	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP1	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP12	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP13	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP14	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP2	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP3	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP8	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
ilomastat	MMP9	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	matrix metalloprotease inhibitor	NA	NA
iloperidone	ADRA1A	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	ADRA2C	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	DRD1	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	DRD2	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	DRD3	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	DRD4	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	HRH1	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	HTR1A	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	HTR2A	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	HTR6	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloperidone	HTR7	71360	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloprost	PTGDR	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
iloprost	PTGER1	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
iloprost	PTGER2	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
iloprost	PTGER3	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
iloprost	PTGER4	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
iloprost	PTGFR	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
iloprost	PTGIR	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
iloprost	TBXA2R	51397006	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
imatinib	ABL1	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imatinib	CSF1R	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imatinib	DDR1	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imatinib	KIT	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imatinib	NTRK1	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imatinib	PDGFRA	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imatinib	PDGFRB	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imatinib	RET	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
imetit	HRH3	3692	PEHSVUKQDJULKE-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
imetit	HRH4	3692	PEHSVUKQDJULKE-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
imidafenacin	CHRM1	6433090	SQKXYSGRELMAAU-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	spasms
imidafenacin	CHRM3	6433090	SQKXYSGRELMAAU-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	spasms
imidapril	ACE	5464343	KLZWOWYOHUKJIG-BPUTZDHNSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|congestive heart failure
imiloxan	ADRA2A	76966048	UXABARREKCJULM-NSHDSACASA-N	Phase 1	adrenergic receptor antagonist	NA	NA
imiloxan	ADRA2B	76966048	UXABARREKCJULM-NSHDSACASA-N	Phase 1	adrenergic receptor antagonist	NA	NA
imipramine	ADRA1A	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	ADRA1B	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	ADRA1D	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	CHRM1	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	CHRM2	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	CHRM3	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	CHRM4	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	CHRM5	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	DRD1	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	DRD2	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	DRD5	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	HRH1	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	HTR1A	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	HTR2A	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	HTR2C	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	HTR6	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	HTR7	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	KCND2	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	KCND3	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	KCNH1	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	KCNH2	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	SLC6A2	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	SLC6A3	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imipramine	SLC6A4	3696	BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis
imiquimod	TLR7	57469	DOUYETYNHWVLEO-UHFFFAOYSA-N	Launched	interferon inducer|toll-like receptor agonist	dermatology|infectious disease|oncology	actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)
imiquimod	TLR8	57469	DOUYETYNHWVLEO-UHFFFAOYSA-N	Launched	interferon inducer|toll-like receptor agonist	dermatology|infectious disease|oncology	actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)
immepip	HRH3	3035842	MCNGUYXRBCIGOV-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
immepip	HRH4	3035842	MCNGUYXRBCIGOV-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
immethridine	HRH3	9989505	DFVSGZHJSIEEQQ-UHFFFAOYSA-N	Phase 1	histamine receptor agonist	NA	NA
impentamine	HRH3	9793868	MZCJWLAXZRFUPI-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
INC-280	MET	25145656	LIOLIMKSCNQPLV-UHFFFAOYSA-N	Phase 3	c-Met inhibitor	NA	NA
INCA-6	NFATC1	230748	GCHPUOHXXCNSQL-UHFFFAOYSA-N	Preclinical	calcineurin inhibitor	NA	NA
INCB-3284	CCR2	NA	NXZNYBUBXWWKCP-DNRQZRRGSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
indacaterol	ADRB1	6918554	QZZUEBNBZAPZLX-QFIPXVFZSA-N	Launched	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)
indacaterol	ADRB2	6918554	QZZUEBNBZAPZLX-QFIPXVFZSA-N	Launched	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)
indalpine	SLC6A4	44668	SADQVAVFGNTEOD-UHFFFAOYSA-N	Withdrawn	selective serotonin reuptake inhibitor (SSRI)	NA	NA
indapamide	CA2	12598931	NDDAHWYSQHTHNT-JTQLQIEISA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
indapamide	HTR3A	12598931	NDDAHWYSQHTHNT-JTQLQIEISA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
indapamide	KCNQ1	12598931	NDDAHWYSQHTHNT-JTQLQIEISA-N	Launched	thiazide diuretic	cardiology	hypertension|congestive heart failure
indatraline	MAOA	126280	SVFXPTLYMIXFRX-XJKSGUPXSA-N	Preclinical	norepinephrine transporter inhibitor	NA	NA
indatraline	MAOB	126280	SVFXPTLYMIXFRX-XJKSGUPXSA-N	Preclinical	norepinephrine transporter inhibitor	NA	NA
indeglitazar	NCOA1	11395145	YMPALHOKRBVHOJ-UHFFFAOYSA-N	Phase 2	PPAR receptor agonist	NA	NA
indeglitazar	PPARA	11395145	YMPALHOKRBVHOJ-UHFFFAOYSA-N	Phase 2	PPAR receptor agonist	NA	NA
indeglitazar	PPARD	11395145	YMPALHOKRBVHOJ-UHFFFAOYSA-N	Phase 2	PPAR receptor agonist	NA	NA
indeglitazar	PPARG	11395145	YMPALHOKRBVHOJ-UHFFFAOYSA-N	Phase 2	PPAR receptor agonist	NA	NA
indinavir	CYP3A4	5362440	"InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
indinavir	CYP3A5	5362440	"InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
indinavir	CYP3A7	5362440	"InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
indiplon	GABRA1	6450813	CBIAWPMZSFFRGN-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
indirubin	CDK1	NA	CRDNMYFJWFXOCH-YPKPFQOOSA-N	Phase 2/Phase 3	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indirubin	CDK5	NA	CRDNMYFJWFXOCH-YPKPFQOOSA-N	Phase 2/Phase 3	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indirubin	GSK3A	NA	CRDNMYFJWFXOCH-YPKPFQOOSA-N	Phase 2/Phase 3	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indirubin-3-monoxime	CDK1	NA	HBDSHCUSXQATPO-BGBJRWHRSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indirubin-3-monoxime	CDK2	NA	HBDSHCUSXQATPO-BGBJRWHRSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indirubin-3-monoxime	CDK5	NA	HBDSHCUSXQATPO-BGBJRWHRSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indirubin-3-monoxime	CDK5R1	NA	HBDSHCUSXQATPO-BGBJRWHRSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indirubin-3-monoxime	GSK3B	NA	HBDSHCUSXQATPO-BGBJRWHRSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
indisulam	CA1	216468	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
indisulam	CA12	216468	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
indisulam	CA14	216468	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
indisulam	CA2	216468	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
indisulam	CA6	216468	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
indisulam	CA7	216468	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
indisulam	CA9	216468	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	CDK inhibitor	NA	NA
indobufen	PTGS1	189556	AYDXAULLCROVIT-OAHLLOKOSA-N	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor	hematology	thrombosis
indobufen	PTGS2	189556	AYDXAULLCROVIT-OAHLLOKOSA-N	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor	hematology	thrombosis
indocyanine-green	SLCO1B1	9919342	BDBMLMBYCXNVMC-UHFFFAOYSA-O	Launched	contrast agent	cardiology	vascular imaging agent
indole-3-carbinol	AHR	3712	IVYPNXXAYMYVSP-UHFFFAOYSA-N	Phase 2/Phase 3	"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor"	NA	NA
indomethacin	GLO1	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	PLA2G2A	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	PPARA	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	PPARG	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	PTGDR2	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	PTGR2	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	PTGS1	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	PTGS2	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indomethacin	SLC46A1	3715	CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
indoprofen	CXCR1	93283	RJMIEHBSYVWVIN-LLVKDONJSA-N	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	NA	NA
indoprofen	CXCR2	93283	RJMIEHBSYVWVIN-LLVKDONJSA-N	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	NA	NA
indoprofen	PTGS1	93283	RJMIEHBSYVWVIN-LLVKDONJSA-N	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	NA	NA
indoprofen	PTGS2	93283	RJMIEHBSYVWVIN-LLVKDONJSA-N	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	NA	NA
indoramin	ADRA1A	33625	JXZZEXZZKAWDSP-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
indoramin	ADRA1B	33625	JXZZEXZZKAWDSP-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
indoramin	ADRA1D	33625	JXZZEXZZKAWDSP-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
indoramin	ADRA2B	33625	JXZZEXZZKAWDSP-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
indoramin	ADRA2C	33625	JXZZEXZZKAWDSP-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
indoximod	IDO1	6920151	ZADWXFSZEAPBJS-SNVBAGLBSA-N	Phase 2	"indoleamine 2,3-dioxygenase inhibitor"	NA	NA
ingenol	PRKCD	442042	VEBVPUXQAPLADL-POYOOMFHSA-N	Launched	PKC activator	dermatology	keratosis
ingenol	PRKCE	442042	VEBVPUXQAPLADL-POYOOMFHSA-N	Launched	PKC activator	dermatology	keratosis
ingenol-mebutate	PRKCA	6918670	VDJHFHXMUKFKET-WDUFCVPESA-N	Launched	PKC activator	dermatology	actinic keratosis (AK)
ingenol-mebutate	PRKCB	6918670	VDJHFHXMUKFKET-WDUFCVPESA-N	Launched	PKC activator	dermatology	actinic keratosis (AK)
ingenol-mebutate	PRKCD	6918670	VDJHFHXMUKFKET-WDUFCVPESA-N	Launched	PKC activator	dermatology	actinic keratosis (AK)
ingenol-mebutate	PRKCE	6918670	VDJHFHXMUKFKET-WDUFCVPESA-N	Launched	PKC activator	dermatology	actinic keratosis (AK)
ingenol-mebutate	PRKCG	6918670	VDJHFHXMUKFKET-WDUFCVPESA-N	Launched	PKC activator	dermatology	actinic keratosis (AK)
INH1	NDC80	959043	JPMOKRWIYQGMJL-UHFFFAOYSA-N	Preclinical	Hec1 inhibitor	NA	NA
iniparib	PARP1	9796068	MDOJTZQKHMAPBK-UHFFFAOYSA-N	Phase 3	PARP inhibitor	NA	NA
inosine	PARP1	135398641	UGQMRVRMYYASKQ-KQYNXXCUSA-N	Launched	neurotrophic agent	NA	NA
inosine	PNP	135398641	UGQMRVRMYYASKQ-KQYNXXCUSA-N	Launched	neurotrophic agent	NA	NA
inositol	CDIPT	NA	CDAISMWEOUEBRE-GPIVLXJGSA-N	Launched	insulin sensitizer	obstetrics/gynecology	polycystic ovary syndrom (PCOS)
INT-767	GPBAR1	23642339	XGIYOABXZNJOHV-APIYUPOTSA-N	Phase 1	FXR agonist	NA	NA
integrin-antagonist-1	ITGAV	86272865	ZMXBIIQMSGOIRZ-RCZVLFRGSA-N	Phase 1	integrin antagonist	NA	NA
integrin-antagonist-1	ITGB6	86272865	ZMXBIIQMSGOIRZ-RCZVLFRGSA-N	Phase 1	integrin antagonist	NA	NA
iodipamide	ALB	3739	FFINMCNLQNTKLU-UHFFFAOYSA-N	Launched	radiopaque medium	radiology	contrast agent
iodophenpropit	HRH3	3035746	UBHYDQAARZKHEZ-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
iodophenpropit	HRH4	3035746	UBHYDQAARZKHEZ-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
IOWH032	CFTR	135565181	DSFNLJXHXBIKDS-UHFFFAOYSA-N	Phase 2	CFTR channel antagonist	NA	NA
IOX1	EGLN1	459617	JGRPKOGHYBAVMW-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
IOX1	KDM3A	459617	JGRPKOGHYBAVMW-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
IOX1	KDM4C	459617	JGRPKOGHYBAVMW-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
IOX1	KDM6B	459617	JGRPKOGHYBAVMW-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
IOX2	EGLN1	54685215	CAOSCCRYLYQBES-UHFFFAOYSA-N	Preclinical	hypoxia inducible factor inhibitor	NA	NA
IOX2	KDM2A	54685215	CAOSCCRYLYQBES-UHFFFAOYSA-N	Preclinical	hypoxia inducible factor inhibitor	NA	NA
IOX2	KDM5C	54685215	CAOSCCRYLYQBES-UHFFFAOYSA-N	Preclinical	hypoxia inducible factor inhibitor	NA	NA
IPA-3	PAK1	521106	RFAXLXKIAKIUDT-UHFFFAOYSA-N	Preclinical	p21 activated kinase inhibitor	NA	NA
ipidacrine	ACHE	604519	YLUSMKAJIQOXPV-UHFFFAOYSA-N	Phase 3	acetylcholinesterase inhibitor	NA	NA
ipragliflozin-L-proline	SLC5A2	10453870	AHFWIQIYAXSLBA-RQXATKFSSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
ipratropium	CHRM1	NA	OEXHQOGQTVQTAT-KKKDIUQISA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
ipratropium	CHRM2	NA	OEXHQOGQTVQTAT-KKKDIUQISA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
ipratropium	CHRM3	NA	OEXHQOGQTVQTAT-KKKDIUQISA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
ipratropium	CHRM4	NA	OEXHQOGQTVQTAT-KKKDIUQISA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
ipratropium	CHRM5	NA	OEXHQOGQTVQTAT-KKKDIUQISA-N	Launched	acetylcholine receptor antagonist	pulmonary	bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
iproniazid	MAOA	3748	NYMGNSNKLVNMIA-UHFFFAOYSA-N	Withdrawn	monoamine oxidase inhibitor	NA	NA
iproniazid	MAOB	3748	NYMGNSNKLVNMIA-UHFFFAOYSA-N	Withdrawn	monoamine oxidase inhibitor	NA	NA
ipsapirone	HTR1A	56971	TZJUVVIWVWFLCD-UHFFFAOYSA-N	Phase 3	serotonin receptor agonist	NA	NA
irbesartan	AGTR1	3749	YOSHYTLCDANDAN-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology|nephrology	hypertension|diabetic nephropathy
irbesartan	JUN	3749	YOSHYTLCDANDAN-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology|nephrology	hypertension|diabetic nephropathy
irbesartan	SLC10A1	3749	YOSHYTLCDANDAN-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology|nephrology	hypertension|diabetic nephropathy
irinotecan	TOP1	60838	UWKQSNNFCGGAFS-XIFFEERXSA-N	Launched	topoisomerase inhibitor	oncology	colorectal cancer
irinotecan	TOP1MT	60838	UWKQSNNFCGGAFS-XIFFEERXSA-N	Launched	topoisomerase inhibitor	oncology	colorectal cancer
IRL-2500	EDNRB	5311192	UZDORQWMYRRLQV-JHOUSYSJSA-N	Preclinical	endothelin receptor antagonist	NA	NA
irosustat	CA2	5287541	DSLPMJSGSBLWRE-UHFFFAOYSA-N	Phase 2	steroid sulfatase inhibitor	NA	NA
irosustat	STS	5287541	DSLPMJSGSBLWRE-UHFFFAOYSA-N	Phase 2	steroid sulfatase inhibitor	NA	NA
irsogladine	PDE4A	3752	ATCGGEJZONJOCL-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	gastroenterology	peptic ulcer disease (PUD)
isamoltane	HTR1A	6604790	XVTVPGKWYHWYAD-CQSZACIVSA-N	Phase 1	adrenergic receptor antagonist	NA	NA
isamoltane	HTR1B	6604790	XVTVPGKWYHWYAD-CQSZACIVSA-N	Phase 1	adrenergic receptor antagonist	NA	NA
isavuconazole	CYP3A4	92043107	DDFOUSQFMYRUQK-FPTDNZKUSA-N	Phase 3	cytochrome P450 inhibitor	NA	NA
ISO-1	MIF	5288525	AIXMJTYHQHQJLU-SNVBAGLBSA-N	Preclinical	macrophage migration inhibiting factor inhibitor	NA	NA
isobutyramide	HBE1	68424	WFKAJVHLWXSISD-UHFFFAOYSA-N	Phase 2	gene expression stimulant	NA	NA
isobutyramide	HBG1	68424	WFKAJVHLWXSISD-UHFFFAOYSA-N	Phase 2	gene expression stimulant	NA	NA
isocarboxazid	MAOA	3759	XKFPYPQQHFEXRZ-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
isocarboxazid	MAOB	3759	XKFPYPQQHFEXRZ-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
isoconazole	CYP17A1	25273632	MPIPASJGOJYODL-GOSISDBHSA-N	Launched	fungal lanosterol demethylase inhibitor	infectious disease	gram-positive bacterial infections
isoflupredone-acetate	NR3C1	224246	ZOCUOMKMBMEYQV-GSLJADNHSA-N	Preclinical		NA	NA
isoflurane	GABRA1	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRA2	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRA3	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRA4	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRA5	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRA6	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRB1	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRB2	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRB3	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRD	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRE	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRG1	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRG2	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRG3	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRP	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GABRQ	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GLRA1	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	GLRB	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	KCNK10	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	KCNK18	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	KCNK2	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	KCNK3	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurane	KCNK9	4369440	PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurophate	ACHE	5936	MUCZHBLJLSDCSD-UHFFFAOYSA-N	Launched	cholinesterase inhibitor	ophthalmology	glaucoma
isoflurophate	BCHE	5936	MUCZHBLJLSDCSD-UHFFFAOYSA-N	Launched	cholinesterase inhibitor	ophthalmology	glaucoma
isoguvacine	GABRA1	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRA2	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRA3	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRA4	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRA5	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRA6	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRR1	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRR2	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoguvacine	GABRR3	7059534	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
isoliquiritigenin	GABBR1	638278	DXDRHHKMWQZJHT-FPYGCLRLSA-N	Preclinical	guanylate cyclase activator	NA	NA
isoniazid	CYP1A2	3767	QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched	FABI inhibitor	infectious disease	tuberculosis
isoniazid	CYP2C19	3767	QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched	FABI inhibitor	infectious disease	tuberculosis
isoniazid	CYP2C8	3767	QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched	FABI inhibitor	infectious disease	tuberculosis
isoniazid	CYP2E1	3767	QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched	FABI inhibitor	infectious disease	tuberculosis
isoniazid	CYP3A4	3767	QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched	FABI inhibitor	infectious disease	tuberculosis
isoprenaline	ADRB1	5808	JWZZKOKVBUJMES-LLVKDONJSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary	bradycardia|heart block|asthma
isoprenaline	ADRB2	5808	JWZZKOKVBUJMES-LLVKDONJSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary	bradycardia|heart block|asthma
isoprenaline	ADRB3	5808	JWZZKOKVBUJMES-LLVKDONJSA-N	Launched	adrenergic receptor agonist	cardiology|pulmonary	bradycardia|heart block|asthma
isopropamide-iodide	CHRM3	3775	JTPUMZTWMWIVPA-UHFFFAOYSA-O	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)|gastrointestinal acidosis
isopropamide-iodide	CHRM4	3775	JTPUMZTWMWIVPA-UHFFFAOYSA-O	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)|gastrointestinal acidosis
isosorbide-dinitrate	GUCY1A2	6883	MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-dinitrate	GUCY1A3	6883	MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-dinitrate	GUCY1B2	6883	MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-dinitrate	GUCY1B3	6883	MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-dinitrate	NPR1	6883	MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-mononitrate	GUCY1A2	27661	YWXYYJSYQOXTPL-SLPGGIOYSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-mononitrate	GUCY1A3	27661	YWXYYJSYQOXTPL-SLPGGIOYSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-mononitrate	GUCY1B2	27661	YWXYYJSYQOXTPL-SLPGGIOYSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isosorbide-mononitrate	GUCY1B3	27661	YWXYYJSYQOXTPL-SLPGGIOYSA-N	Launched	nitric oxide stimulant	cardiology	angina pectoris|coronary artery disease (CAD)
isotretinoin	RARA	5282379	SHGAZHPCJJPHSC-XFYACQKRSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
isotretinoin	RARB	5282379	SHGAZHPCJJPHSC-XFYACQKRSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
isotretinoin	RARG	5282379	SHGAZHPCJJPHSC-XFYACQKRSA-N	Launched	retinoid receptor agonist	dermatology	acne vulgaris (AV)
isoxicam	PTGS1	54677972	YYUAYBYLJSNDCX-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
isoxicam	PTGS2	54677972	YYUAYBYLJSNDCX-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
isoxsuprine	ADRB2	42066885	BMUKKTUHUDJSNZ-PMUMKWKESA-N	Launched	adrenergic receptor agonist	rheumatology|cardiology	Raynaud's disease|arteriosclerosis|Buerger's disease
ispinesib	KIF11	6851740	QJZRFPJCWMNVAV-HHHXNRCGSA-N	Phase 2	kinesin inhibitor	NA	NA
isradipine	CACNA1D	13773524	HMJIYCCIJYRONP-MRXNPFEDSA-N	Launched	calcium channel blocker	cardiology	hypertension
isradipine	CACNA1F	13773524	HMJIYCCIJYRONP-MRXNPFEDSA-N	Launched	calcium channel blocker	cardiology	hypertension
isradipine	CACNA2D1	13773524	HMJIYCCIJYRONP-MRXNPFEDSA-N	Launched	calcium channel blocker	cardiology	hypertension
ISRIB	EIF2A	NA	HJGMCDHQPXTGAV-IYARVYRRSA-N	Preclinical	eukaryotic translation initiation factor inhibitor|PERK inhibitor	NA	NA
ISRIB	EIF2AK3	NA	HJGMCDHQPXTGAV-IYARVYRRSA-N	Preclinical	eukaryotic translation initiation factor inhibitor|PERK inhibitor	NA	NA
istaroxime	ATP1A1	9841834	MPYLDWFDPHRTEG-PAAYLBSLSA-N	Phase 2	ATPase inhibitor	NA	NA
istradefylline	ADORA1	5311037	IQVRBWUUXZMOPW-PKNBQFBNSA-N	Launched	adenosine receptor antagonist	neurology/psychiatry	Parkinson's Disease|dyskinesia
istradefylline	ADORA2A	5311037	IQVRBWUUXZMOPW-PKNBQFBNSA-N	Launched	adenosine receptor antagonist	neurology/psychiatry	Parkinson's Disease|dyskinesia
istradefylline	ADORA2B	5311037	IQVRBWUUXZMOPW-PKNBQFBNSA-N	Launched	adenosine receptor antagonist	neurology/psychiatry	Parkinson's Disease|dyskinesia
istradefylline	ADORA3	5311037	IQVRBWUUXZMOPW-PKNBQFBNSA-N	Launched	adenosine receptor antagonist	neurology/psychiatry	Parkinson's Disease|dyskinesia
ISX-9	NEUROD1	19582717	SYENTKHGMVKGAQ-UHFFFAOYSA-N	Preclinical	neural stem cell inducer	NA	NA
itacitinib	JAK1	53380437	KTBSXLIQKWEBRB-UHFFFAOYSA-N	Phase 3	JAK inhibitor	NA	NA
ITD-1	TGFBR2	71512660	ULFUJLFTRWWLPO-XMMPIXPASA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
ITE	AHR	4668801	KDDXOGDIPZSCTM-UHFFFAOYSA-N	Preclinical	aryl hydrocarbon receptor agonist	NA	NA
ITI214	PDE1A	42639643	BBIPVJCGIASXJB-PKTZIBPZSA-N	Phase 1/Phase 2	phosphodiesterase inhibitor	NA	NA
itopride	CHRM3	3792	QQQIECGTIMUVDS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology|neurology/psychiatry	dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia
itopride	DRD2	3792	QQQIECGTIMUVDS-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology|neurology/psychiatry	dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia
ITX3	TRIO	1362865	SJMYMKPBODEZSH-DEDYPNTBSA-N	Preclinical	GEF inhibitor	NA	NA
IT1t	CXCR4	25147749	OOSUDWRRWZVFEB-UHFFFAOYSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
IU1	USP14	675434	JUWDSDKJBMFLHE-UHFFFAOYSA-N	Preclinical	ubiquitin C-terminal hydrolase inhibitor	NA	NA
ivabradine	HCN1	132999	ACRHBAYQBXXRTO-OAQYLSRUSA-N	Launched	HCN channel blocker|potassium channel blocker|sodium channel blocker	cardiology	angina pectoris
ivabradine	HCN3	132999	ACRHBAYQBXXRTO-OAQYLSRUSA-N	Launched	HCN channel blocker|potassium channel blocker|sodium channel blocker	cardiology	angina pectoris
ivabradine	HCN4	132999	ACRHBAYQBXXRTO-OAQYLSRUSA-N	Launched	HCN channel blocker|potassium channel blocker|sodium channel blocker	cardiology	angina pectoris
ivacaftor	CFTR	16220172	PURKAOJPTOLRMP-UHFFFAOYSA-N	Launched	CFTR channel potentiator	pulmonary	cystic fibrosis
ivermectin	CHRNA7	6321424	AZSNMRSAGSSBNP-XPNPUAGNSA-N	Launched	benzodiazepine receptor agonist	infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies
ivermectin	P2RX7	6321424	AZSNMRSAGSSBNP-XPNPUAGNSA-N	Launched	benzodiazepine receptor agonist	infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies
ivosidenib	IDH1	71657455	WIJZXSAJMHAVGX-DHLKQENFSA-N	Launched	isocitrate dehydrogenase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
IWP-L6	PORCN	71601111	QESQGTFWEQMCMH-UHFFFAOYSA-N	Preclinical	porcupine inhibitor	NA	NA
ixabepilone	TUBB	NA	FABUFPQFXZVHFB-QBNZTRRJSA-N	Launched	microtubule stabilizing agent	oncology	breast cancer
JAK3-inhibitor-V	JAK3	3799	FOTCGZPFSUWZBN-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
JDTic	OPRK1	9956146	ZLVXBBHTMQJRSX-VMGNSXQWSA-N	Phase 1	opioid receptor antagonist	NA	NA
JHW-007	SLC6A3	NA	HZEVDVGPBUFIAW-JKHIJQBDSA-N	Preclinical	dopamine reuptake inhibitor	NA	NA
JIB04	KDM4E	6519698	YHHFKWKMXWRVTJ-OQKWZONESA-N	Preclinical	histone lysine demethylase inhibitor	NA	NA
JLK-6	PSEN1	3803	AMDGKLWVCUXONP-UHFFFAOYSA-N	Preclinical	gamma secretase inhibitor	NA	NA
JNJ-10191584	HRH4	10446295	MOIWSUQWIOVGRH-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
JNJ-10397049	HCRTR1	9869934	RBKIJGLHFFQHBE-IRXDYDNUSA-N	Preclinical	orexin receptor antagonist	NA	NA
JNJ-10397049	HCRTR2	9869934	RBKIJGLHFFQHBE-IRXDYDNUSA-N	Preclinical	orexin receptor antagonist	NA	NA
JNJ-16259685	GRM1	NA	QOTAQTRFJWLFCR-XFHMXUHZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
JNJ-1661010	FAAH	2809273	BHBOSTKQCZEAJM-UHFFFAOYSA-N	Preclinical	FAAH inhibitor	NA	NA
JNJ-17203212	TRPV1	11339118	JFRYYGVYCWYIDQ-UHFFFAOYSA-N	Preclinical	TRPV antagonist	NA	NA
JNJ-26481585	HDAC1	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC10	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC11	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC2	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC3	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC4	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC5	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC6	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC7	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC8	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	HDAC9	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-26481585	MDM2	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
JNJ-27141491	CCR2	11703589	SYARXICKXVXWNA-LBPRGKRZSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
JNJ-37822681	DRD2	16058752	UVUYWJWYRLJHEN-UHFFFAOYSA-N	Phase 2	dopamine receptor antagonist	NA	NA
JNJ-38877605	MET	46911863	JRWCBEOAFGHNNU-UHFFFAOYSA-N	Phase 1	tyrosine kinase inhibitor	NA	NA
JNJ-40411813	GRM2	25195461	HYOGJHCDLQSAHX-UHFFFAOYSA-N	Phase 2	glutamate receptor positive allosteric modulator	NA	NA
JNJ-42041935	PDK2	45102710	FXHHASJVTYRJHH-UHFFFAOYSA-N	Preclinical	hypoxia inducible factor prolyl hydroxylase inhibitor	NA	NA
JNJ-42165279	FAAH	54576693	YWGYNGCRVZLMCS-UHFFFAOYSA-N	Phase 2	FAAH inhibitor	NA	NA
JNJ-47965567	P2RX7	66553218	XREFXUCWSYMIOG-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
JNJ-63533054	GPR139	2548547	MWDVCHRYCKXEBY-LBPRGKRZSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
JNJ-7706621	AURKA	5330790	"InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)"	Preclinical	CDK inhibitor	NA	NA
JNJ-7706621	AURKB	5330790	"InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)"	Preclinical	CDK inhibitor	NA	NA
JNJ-7706621	CDK1	5330790	"InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)"	Preclinical	CDK inhibitor	NA	NA
JNJ-7706621	CDK2	5330790	"InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)"	Preclinical	CDK inhibitor	NA	NA
JNJ-7777120	HRH4	4908365	HUQJRYMLJBBEDO-UHFFFAOYSA-N	Preclinical	histamine receptor antagonist	NA	NA
JQ1-(+)	BRD4	46907787	DNVXATUJJDPFDM-KRWDZBQOSA-N	Preclinical	bromodomain inhibitor	NA	NA
JQ1-(+)	BRDT	46907787	DNVXATUJJDPFDM-KRWDZBQOSA-N	Preclinical	bromodomain inhibitor	NA	NA
JTC-801	OPRL1	5311340	VTGBZWHPJFMTKS-UHFFFAOYSA-N	Phase 2	opioid receptor antagonist	NA	NA
JTE-013	P2RY10	10223146	RNSLRQNDXRSASX-UHFFFAOYSA-N	Preclinical	lysophospholipid receptor antagonist	NA	NA
JTE-013	S1PR2	10223146	RNSLRQNDXRSASX-UHFFFAOYSA-N	Preclinical	lysophospholipid receptor antagonist	NA	NA
JTE-607	IL10	9938545	IPSSXIMJJXSJQB-FQEVSTJZSA-N	Phase 2	cytokine production inhibitor	NA	NA
JTE-607	IL1B	9938545	IPSSXIMJJXSJQB-FQEVSTJZSA-N	Phase 2	cytokine production inhibitor	NA	NA
JTE-607	IL6	9938545	IPSSXIMJJXSJQB-FQEVSTJZSA-N	Phase 2	cytokine production inhibitor	NA	NA
JTE-607	TNF	9938545	IPSSXIMJJXSJQB-FQEVSTJZSA-N	Phase 2	cytokine production inhibitor	NA	NA
JTE-907	CNR2	9867770	GRAJFFFXJYFVOC-UHFFFAOYSA-N	Phase 1	cannabinoid receptor inverse agonist	NA	NA
JW-55	TNKS	2946601	ZJZWZIXSGNFWQQ-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor	NA	NA
JW-55	TNKS2	2946601	ZJZWZIXSGNFWQQ-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor	NA	NA
JW-642	MGLL	71656520	AVSCNEOUWSVZEY-UHFFFAOYSA-N	Preclinical	monoacylglycerol lipase inhibitor	NA	NA
JW-67	APC	644733	BTXRSHKJNDFHGA-UHFFFAOYSA-N	Preclinical	WNT pathway inhibitor	NA	NA
JW-67	AXIN1	644733	BTXRSHKJNDFHGA-UHFFFAOYSA-N	Preclinical	WNT pathway inhibitor	NA	NA
JW-67	GSK3B	644733	BTXRSHKJNDFHGA-UHFFFAOYSA-N	Preclinical	WNT pathway inhibitor	NA	NA
JW-74	TNKS	16013152	KRIKILRRJCIWNB-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor|WNT signaling inhibitor	NA	NA
JW-74	TNKS2	16013152	KRIKILRRJCIWNB-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor|WNT signaling inhibitor	NA	NA
JX-401	MAPK14	1126109	OMGLGPKQUFSRNN-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
JZL-184	MGLL	25021165	SEGYOKHGGFKMCX-UHFFFAOYSA-N	Preclinical	monoacylglucerol lipase inhibitor	NA	NA
JZL-195	FAAH	46232606	QNYRAEKLMNDRFY-UHFFFAOYSA-N	Preclinical	FAAH inhibitor|monoacylglycerol lipase inhibitor	NA	NA
JZL-195	MGLL	46232606	QNYRAEKLMNDRFY-UHFFFAOYSA-N	Preclinical	FAAH inhibitor|monoacylglycerol lipase inhibitor	NA	NA
K-Ras(G12C)-inhibitor-12	KRAS	73555129	JFIFBWVNHLXJFY-UHFFFAOYSA-N	Preclinical	K-Ras inhibitor	NA	NA
K-strophanthidin	ATP1A1	6185	ODJLBQGVINUMMR-HZXDTFASSA-N	Phase 2	ATPase inhibitor	NA	NA
K-858	KIF11	686905	JEFVYQYZCAVNTP-ZDUSSCGKSA-N	Preclinical	kinesin-like spindle protein inhibitor	NA	NA
kaempferol	AKR1B1	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kaempferol	ALOX15B	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kaempferol	ALOX5	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kaempferol	AR	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kaempferol	CYP1B1	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kaempferol	GLO1	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kaempferol	HSD17B1	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kaempferol	UGT3A1	5280863	IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	NA	NA
kainic-acid	GRIA1	44338126	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical	kainate receptor agonist	NA	NA
kainic-acid	GRIK1	44338126	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical	kainate receptor agonist	NA	NA
kainic-acid	GRIK2	44338126	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical	kainate receptor agonist	NA	NA
kainic-acid	GRIK3	44338126	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical	kainate receptor agonist	NA	NA
kainic-acid	GRIK4	44338126	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical	kainate receptor agonist	NA	NA
kainic-acid	GRIK5	44338126	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical	kainate receptor agonist	NA	NA
karenitecin	TOP1	148202	POADTFBBIXOWFJ-VWLOTQADSA-N	Phase 3	topoisomerase inhibitor	NA	NA
kartogenin	FLNA	2826191	SLUINPGXGFUMLL-UHFFFAOYSA-N	Preclinical	chondrocyte differentiation stimulator	NA	NA
KB-R7943	SLC8A1	4534086	UMJUNUMSJDTYTM-UHFFFAOYSA-N	Preclinical	sodium/calcium exchange inhibitor	NA	NA
KB-R7943	TRPC3	4534086	UMJUNUMSJDTYTM-UHFFFAOYSA-N	Preclinical	sodium/calcium exchange inhibitor	NA	NA
KB-R7943	TRPC5	4534086	UMJUNUMSJDTYTM-UHFFFAOYSA-N	Preclinical	sodium/calcium exchange inhibitor	NA	NA
KB-R7943	TRPC6	4534086	UMJUNUMSJDTYTM-UHFFFAOYSA-N	Preclinical	sodium/calcium exchange inhibitor	NA	NA
KB-SRC-4	SRC	73349077	UHIZYQVRKSWIFO-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
KBG	MME	92461199	FOLRUCXBTYDAQK-PTEOKISQSA-N	Phase 2	neprilysin inhibitor	NA	NA
KD-023	ACACA	115175	CZRCFAOMWRAFIC-UHFFFAOYSA-N	Phase 2	ACAT inhibitor	NA	NA
KD-023	ACACB	115175	CZRCFAOMWRAFIC-UHFFFAOYSA-N	Phase 2	ACAT inhibitor	NA	NA
KD025	ROCK2	11950170	GKHIVNAUVKXIIY-UHFFFAOYSA-N	Phase 2	rho associated kinase inhibitor	NA	NA
kenpaullone	CCNB1	3820	QQUXFYAWXPMDOE-UHFFFAOYSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
kenpaullone	CDK1	3820	QQUXFYAWXPMDOE-UHFFFAOYSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
kenpaullone	CDK5	3820	QQUXFYAWXPMDOE-UHFFFAOYSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
kenpaullone	GSK3B	3820	QQUXFYAWXPMDOE-UHFFFAOYSA-N	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	NA	NA
ketanserin	ADRA1A	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	ADRA1B	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	ADRA1D	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	DRD1	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	DRD5	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR1A	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR1B	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR1D	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR2A	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR2B	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR2C	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR5A	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	HTR7	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	SLC18A1	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketanserin	SLC18A2	3822	FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	cardiology	hypertension
ketoconazole	KCNA10	47576	XMAYWYJOQHXEEK-ZEQKJWHPSA-N	Launched	sterol demethylase inhibitor	dermatology	seborrheic dermatitis
ketoprofen	PTGS1	180540	DKYWVDODHFEZIM-LLVKDONJSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
ketoprofen	PTGS2	180540	DKYWVDODHFEZIM-LLVKDONJSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
ketoprofen	SLC5A8	180540	DKYWVDODHFEZIM-LLVKDONJSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
ketorolac	PTGS1	181817	OZWKMVRBQXNZKK-NSHDSACASA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ketorolac	PTGS2	181817	OZWKMVRBQXNZKK-NSHDSACASA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ketotifen	HRH1	57392700	OVJRNFMIYGGLDL-UHFFFAOYSA-N	Launched	histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	itching
KF-38789	SELP	135565372	NHFIAAAMCYVRIW-QGZVFWFLSA-N	Preclinical	P selectin inhibitor	NA	NA
KG-5	BRAF	53328059	CMYHZFCJPORPHY-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
KG-5	FLT3	53328059	CMYHZFCJPORPHY-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
KG-5	KIT	53328059	CMYHZFCJPORPHY-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
KG-5	PDGFRB	53328059	CMYHZFCJPORPHY-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
KH-CB19	CLK1	91899919	DXZRBHUCOHBAHP-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
KH-CB19	CLK3	91899919	DXZRBHUCOHBAHP-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
KH-CB19	DYRK1A	91899919	DXZRBHUCOHBAHP-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
KHK-IN-1	KHK	53348216	HFLMLZKGLUEWBU-UHFFFAOYSA-N	Preclinical	hexokinase inhibitor	NA	NA
KHS-101	TACC3	71304818	DGRJOOOHPBSAHD-UHFFFAOYSA-N	Preclinical	neural stem cell inducer	NA	NA
KI-16425	LPAR1	40467027	LLIFMNUXGDHTRO-OAHLLOKOSA-N	Preclinical	lysophosphatidic acid receptor antagonist	NA	NA
KI-16425	LPAR3	40467027	LLIFMNUXGDHTRO-OAHLLOKOSA-N	Preclinical	lysophosphatidic acid receptor antagonist	NA	NA
KI-20227	CSF1R	57881591	SHPFDGWALWEPGS-AWEZNQCLSA-N	Preclinical	c-Fms inhibitor	NA	NA
KI-20227	KDR	57881591	SHPFDGWALWEPGS-AWEZNQCLSA-N	Preclinical	c-Fms inhibitor	NA	NA
KI-20227	KIT	57881591	SHPFDGWALWEPGS-AWEZNQCLSA-N	Preclinical	c-Fms inhibitor	NA	NA
KI-20227	PDGFRB	57881591	SHPFDGWALWEPGS-AWEZNQCLSA-N	Preclinical	c-Fms inhibitor	NA	NA
KI-8751	KDR	11317348	LFKQSJNCVRGFCC-UHFFFAOYSA-N	Preclinical	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
kifunensine	MAN1B1	130611	OIURYJWYVIAOCW-PQMKYFCFSA-N	Phase 1	mannosidase inhibitor	NA	NA
kifunensine	MAN2A1	130611	OIURYJWYVIAOCW-PQMKYFCFSA-N	Phase 1	mannosidase inhibitor	NA	NA
ki16198	LPA	92461210	HHVJBROTJWPHHX-INIZCTEOSA-N	Preclinical	lipoprotein antagonist	NA	NA
KL-001	CRY1	1367681	OQAFDLPAPSSOHY-MRXNPFEDSA-N	Preclinical	proteasome inhibitor	NA	NA
KL-001	CRY2	1367681	OQAFDLPAPSSOHY-MRXNPFEDSA-N	Preclinical	proteasome inhibitor	NA	NA
KML29	MGLL	71656212	SXHQLPHDBLTFPM-UHFFFAOYSA-N	Preclinical	monoacylglucerol lipase inhibitor	NA	NA
KN-62	AKT1	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	CAMK2A	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	CHEK1	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	LCK	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	MAPK1	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	MAPK11	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	MAPK12	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	MAPK14	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	MAPK8	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	P2RX7	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	PRKCA	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	ROCK1	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	RPS6KB1	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-62	SGK1	5312126	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	NA	NA
KN-93	CAMK2A	5312122	LLLQTDSSHZREGW-AATRIKPKSA-N	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	NA	NA
Ko143	ABCB1	10322450	NXNRAECHCJZNRF-JBACZVJFSA-N	Preclinical	BCRP inhibitor	NA	NA
Ko143	ABCC1	10322450	NXNRAECHCJZNRF-JBACZVJFSA-N	Preclinical	BCRP inhibitor	NA	NA
KPT-185	XPO1	53495165	NLNGWFLRRRYNIL-PLNGDYQASA-N	Preclinical	exportin antagonist	NA	NA
KPT-276	XPO1	71496742	JCHAWRDHMUSLMM-UPHRSURJSA-N	Preclinical	exportin antagonist	NA	NA
KRCA-0008	ALK	72547474	TXDIRJCYNAWBOS-UHFFFAOYSA-N	Preclinical	ALK inihibitor	NA	NA
KRN-633	FLT1	9549295	VPBYZLCHOKSGRX-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
KRN-633	FLT4	9549295	VPBYZLCHOKSGRX-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
KRN-633	KDR	9549295	VPBYZLCHOKSGRX-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
KS-176	ABCG2	49779726	LTWQQWSXYYXVGA-UHFFFAOYSA-N	Preclinical	BCRP inhibitor	NA	NA
KU-0063794	MTOR	16736978	RFSMUFRPPYDYRD-CALCHBBNSA-N	Preclinical	mTOR inhibitor	NA	NA
KU-55933	ATM	5278396	XRKYMMUGXMWDAO-UHFFFAOYSA-N	Preclinical	ATM kinase inhibitor	NA	NA
KU-55933	PRKDC	5278396	XRKYMMUGXMWDAO-UHFFFAOYSA-N	Preclinical	ATM kinase inhibitor	NA	NA
KU-60019	ATM	15953870	SCELLOWTHJGVIC-BGYRXZFFSA-N	Preclinical	ATM kinase inhibitor	NA	NA
kuromanin	CD38	441667	RKWHWFONKJEUEF-GQUPQBGVSA-O	Preclinical	ribosyl cyclase inhibitor	NA	NA
KW-2449	ABL1	11427553	YYLKKYCXAOBSRM-JXMROGBWSA-N	Phase 1	Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor	NA	NA
KW-2449	AURKA	11427553	YYLKKYCXAOBSRM-JXMROGBWSA-N	Phase 1	Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor	NA	NA
KW-2449	AURKB	11427553	YYLKKYCXAOBSRM-JXMROGBWSA-N	Phase 1	Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor	NA	NA
KW-2449	FLT3	11427553	YYLKKYCXAOBSRM-JXMROGBWSA-N	Phase 1	Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor	NA	NA
KW-3902	ADORA1	NA	PJBFVWGQFLYWCB-XEDLVCFGSA-N	Phase 3	adenosine receptor antagonist	NA	NA
KW-3902	ADORA2A	NA	PJBFVWGQFLYWCB-XEDLVCFGSA-N	Phase 3	adenosine receptor antagonist	NA	NA
KW-3902	ADORA2B	NA	PJBFVWGQFLYWCB-XEDLVCFGSA-N	Phase 3	adenosine receptor antagonist	NA	NA
KW-3902	ADORA3	NA	PJBFVWGQFLYWCB-XEDLVCFGSA-N	Phase 3	adenosine receptor antagonist	NA	NA
KX2-391	SRC	23635314	"InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)"	Phase 3	SRC inhibitor|tubulin polymerization inhibitor	NA	NA
kynurenic-acid	GPR35	3845	HCZHHEIFKROPDY-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
kynurenic-acid	GRIN1	3845	HCZHHEIFKROPDY-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
kynurenic-acid	GRIN2A	3845	HCZHHEIFKROPDY-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
kynurenic-acid	GRIN2B	3845	HCZHHEIFKROPDY-UHFFFAOYSA-N	Phase 1	glutamate receptor antagonist	NA	NA
KY02111	DKK1	8582409	LXFKEVQQSKQXPR-UHFFFAOYSA-N	Preclinical	WNT pathway inhibitor	NA	NA
K02288	BMP1	46173038	CJLMANFTWLNAKC-UHFFFAOYSA-N	Preclinical	bone morphogenic protein inhibitor	NA	NA
K145	SPHK2	71714682	MPZXLTZVPUSTFY-SOFYXZRVSA-N	Preclinical	sphingosine kinase inhibitor	NA	NA
L-alanine	AARS	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	AARS2	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	ABAT	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	AGXT	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	AGXT2	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	GPRC6A	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	GPT	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	GPT2	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	KYNU	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	NFS1	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	PHYKPL	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	SLC1A4	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	SLC36A1	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-alanine	SLC7A8	7311724	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched		NA	NA
L-arginine	ARG2	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	ASL	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	ASS1	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	AZIN2	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	GPRC6A	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	NOS2	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	NOS3	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	SLC7A1	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	SLC7A3	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-arginine	SLC7A4	6322	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	nitric oxide precursor	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
L-asparagine	ASNS	6992089	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3		NA	NA
L-asparagine	ASRGL1	6992089	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3		NA	NA
L-asparagine	NARS	6992089	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3		NA	NA
L-asparagine	NARS2	6992089	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3		NA	NA
L-asparagine	SLC1A5	6992089	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3		NA	NA
L-asparagine	SLC38A3	6992089	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3		NA	NA
L-aspartic-acid	ACY1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ACY3	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ADSS	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ADSSL1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ASNS	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ASPA	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ASPH	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ASRGL1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	ASS1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	CAD	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	DARS	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	DARS2	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	GOT1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	GOT2	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	GRIN1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	GRIN2A	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	GRIN2B	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	GRIN2C	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	GRIN2D	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	LYZ	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	PAICS	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	RNASE1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	SLC1A1	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	SLC25A12	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-aspartic-acid	SLC25A13	5960	CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	metallic radical formation stimulant	NA	NA
L-citrulline	ASS1	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	DDAH1	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	DDAH2	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	GPRC6A	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	NOS1	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	NOS2	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	NOS3	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	OTC	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	PADI1	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	PADI2	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	PADI3	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	PADI4	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-citrulline	PADI6	9750	RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction
L-cysteine	CARS	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	CARS2	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	CBS	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	CDO-1	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	CDO1	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	CSAD	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	CTH	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	GCLC	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	GCLM	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	GOT1	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	GSS	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	MGMT	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	NFS1	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteine	SLC19A3	6419722	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched		rheumatology	osteoarthritis|rheumatoid arthritis
L-cysteinesulfinic-acid	GRM1	28167170	ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-cysteinesulfinic-acid	GRM5	28167170	ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-cysteinesulfinic-acid	GSR	28167170	ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-cysteinesulfinic-acid	HMGCS2	28167170	ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-cysteinesulfinic-acid	PAPOLA	28167170	ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-cysteinesulfinic-acid	PRDX2	28167170	ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-cystine	CTNS	6992103	LEVWYRKDKASIDU-IMJSIDKUSA-N	Launched		NA	NA
L-cystine	SLC3A1	6992103	LEVWYRKDKASIDU-IMJSIDKUSA-N	Launched		NA	NA
L-cystine	SLC7A11	6992103	LEVWYRKDKASIDU-IMJSIDKUSA-N	Launched		NA	NA
L-cystine	SLC7A9	6992103	LEVWYRKDKASIDU-IMJSIDKUSA-N	Launched		NA	NA
L-glutamic-acid	AADAT	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	AASS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	ABAT	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	ALDH18A1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	ASNS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	BCAT1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	BCAT2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	CCBL2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	DNPEP	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	EARS2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	ENPEP	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	EPRS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	FOLH1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	FPGS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	FTCD	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GAD1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GAD2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GATB	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GCLC	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GCLM	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GGCX	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GLS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GLS2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GLUD1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GLUD2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GLUL	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GMPS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GOT1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GOT2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GPT	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GPT2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIA1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIA2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIA3	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIA4	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRID1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRID2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIK1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIK2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIK3	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIK4	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIK5	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIN1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIN2A	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIN2B	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIN2C	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIN2D	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIN3A	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRIN3B	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRM1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRM2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRM3	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRM4	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRM6	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRM7	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	GRM8	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	LGSN	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	NADSYN1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	NAGS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	OPLAH	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	PFAS	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	PGCP	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	PSAT1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC1A1	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC1A2	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC1A3	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC1A6	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC1A7	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC25A18	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC25A22	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	SLC7A11	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamic-acid	TAT	88747398	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	glutamate receptor agonist	NA	NA
L-glutamine	CTPS1	6992086	ZDXPYRJPNDTMRX-VKHMYHEASA-N	Launched		gastroenterology|dental|neurology/psychiatry|rheumatology	diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia
L-glutamine	GLUL	6992086	ZDXPYRJPNDTMRX-VKHMYHEASA-N	Launched		gastroenterology|dental|neurology/psychiatry|rheumatology	diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia
L-glutamine	GPRC6A	6992086	ZDXPYRJPNDTMRX-VKHMYHEASA-N	Launched		gastroenterology|dental|neurology/psychiatry|rheumatology	diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia
L-glutamine	PPAT	6992086	ZDXPYRJPNDTMRX-VKHMYHEASA-N	Launched		gastroenterology|dental|neurology/psychiatry|rheumatology	diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia
L-leucine	BCAT1	7045798	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3		NA	NA
L-leucine	BCAT2	7045798	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3		NA	NA
L-leucine	LARS	7045798	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3		NA	NA
L-leucine	LARS2	7045798	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3		NA	NA
L-leucine	LCMT1	7045798	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3		NA	NA
L-leucine	LCMT2	7045798	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3		NA	NA
L-lysine	GPRC6A	71774817	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2	serotonin receptor agonist	NA	NA
L-lysine	KARS	71774817	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2	serotonin receptor agonist	NA	NA
L-lysine	SLC7A1	71774817	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2	serotonin receptor agonist	NA	NA
L-lysine	SLC7A2	71774817	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2	serotonin receptor agonist	NA	NA
L-lysine	SLC7A3	71774817	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2	serotonin receptor agonist	NA	NA
L-lysine	SLC7A4	71774817	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2	serotonin receptor agonist	NA	NA
L-methionine	BHMT	6992087	FFEARJCKVFRZRR-BYPYZUCNSA-N	Launched	voltage-gated calcium channel ligand	pulmonary|allergy|neurology/psychiatry	asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia
L-methionine	BHMT2	6992087	FFEARJCKVFRZRR-BYPYZUCNSA-N	Launched	voltage-gated calcium channel ligand	pulmonary|allergy|neurology/psychiatry	asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia
L-methionine	METAP2	6992087	FFEARJCKVFRZRR-BYPYZUCNSA-N	Launched	voltage-gated calcium channel ligand	pulmonary|allergy|neurology/psychiatry	asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia
L-methionine	MTR	6992087	FFEARJCKVFRZRR-BYPYZUCNSA-N	Launched	voltage-gated calcium channel ligand	pulmonary|allergy|neurology/psychiatry	asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia
L-methionine	MTRR	6992087	FFEARJCKVFRZRR-BYPYZUCNSA-N	Launched	voltage-gated calcium channel ligand	pulmonary|allergy|neurology/psychiatry	asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia
L-mimosine	DBH	129010056	BLYDGIISUNWHLF-YFKPBYRVSA-N	Preclinical	dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor	NA	NA
L-mimosine	EIF5A	129010056	BLYDGIISUNWHLF-YFKPBYRVSA-N	Preclinical	dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor	NA	NA
L-monomethylarginine	NOS1	73046	NTWVQPHTOUKMDI-YFKPBYRVSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
L-monomethylarginine	NOS2	73046	NTWVQPHTOUKMDI-YFKPBYRVSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
L-NAME	NOS3	39836	KCWZGJVSDFYRIX-YFKPBYRVSA-N	Phase 2/Phase 3	nitric oxide synthase inhibitor	NA	NA
L-NIL	NOS1	2733506	ONYFNWIHJBLQKE-ZETCQYMHSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
L-NIL	NOS2	2733506	ONYFNWIHJBLQKE-ZETCQYMHSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
L-NIL	NOS3	2733506	ONYFNWIHJBLQKE-ZETCQYMHSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
L-proline	EPRS	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	L3HYPDH	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	P3H1	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	P3H2	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	P3H3	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	P4HA1	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	P4HA2	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PARS2	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PPIA	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PPIB	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PPIC	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PPIF	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PPIG	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PPIH	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PRODH	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PROSC	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PYCR1	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PYCR2	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	PYCRL	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	SLC6A14	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-proline	SLC6A7	6971047	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	glutamate receptor agonist	NA	NA
L-quisqualic-acid	FOLH1	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRIA2	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRIK1	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRIK2	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRM1	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRM2	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRM3	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRM5	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRM7	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-quisqualic-acid	GRM8	6971145	ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	glutamate receptor agonist	NA	NA
L-threonine	TARS	6971019	AYFVYJQAPQTCCC-GBXIJSLDSA-N	Phase 2		NA	NA
L-threonine	TARS2	6971019	AYFVYJQAPQTCCC-GBXIJSLDSA-N	Phase 2		NA	NA
L-threonine	THNSL1	6971019	AYFVYJQAPQTCCC-GBXIJSLDSA-N	Phase 2		NA	NA
L-152804	NPY5R	969478	XQDXIHYKAGHZRX-LJQANCHMSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
L-161982	PTGER4	9961192	MMDNKTXNUZFVKD-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
L-165041	PPARD	6603901	HBBVCKCCQCQCTJ-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
L-168049	GCGR	5311276	HHBOWXZOLYQFNY-UHFFFAOYSA-N	Preclinical	glucagon receptor antagonist	NA	NA
L-365260	CCKAR	5311201	KDFQABSFVYLGPM-QFIPXVFZSA-N	Phase 2	CCK receptor antagonist	NA	NA
L-365260	CCKBR	5311201	KDFQABSFVYLGPM-QFIPXVFZSA-N	Phase 2	CCK receptor antagonist	NA	NA
L-365260	KCNQ1	5311201	KDFQABSFVYLGPM-QFIPXVFZSA-N	Phase 2	CCK receptor antagonist	NA	NA
L-368899	AVPR1A	9872389	MWIASLNTAGRGGA-ZJPWWDJASA-N	Phase 1	oxytocin receptor antagonist	NA	NA
L-368899	AVPR2	9872389	MWIASLNTAGRGGA-ZJPWWDJASA-N	Phase 1	oxytocin receptor antagonist	NA	NA
L-368899	OXTR	9872389	MWIASLNTAGRGGA-ZJPWWDJASA-N	Phase 1	oxytocin receptor antagonist	NA	NA
"L-655,708"	GABRA1	5311203	YKYOQIXTECBVBB-AWEZNQCLSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
"L-655,708"	GABRA2	5311203	YKYOQIXTECBVBB-AWEZNQCLSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
"L-655,708"	GABRA3	5311203	YKYOQIXTECBVBB-AWEZNQCLSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
"L-655,708"	GABRA5	5311203	YKYOQIXTECBVBB-AWEZNQCLSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
"L-655,708"	GABRG2	5311203	YKYOQIXTECBVBB-AWEZNQCLSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
L-655240	PTGES	122070	JLPYLHLUHJOPNL-UHFFFAOYSA-N	Phase 1	thromboxane receptor antagonist	NA	NA
L-689560	GRIN1	6604749	UCKHICKHGAOGAP-UONOGXRCSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-689560	GRIN2A	6604749	UCKHICKHGAOGAP-UONOGXRCSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-689560	GRIN2B	6604749	UCKHICKHGAOGAP-UONOGXRCSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-689560	GRIN2C	6604749	UCKHICKHGAOGAP-UONOGXRCSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-689560	GRIN2D	6604749	UCKHICKHGAOGAP-UONOGXRCSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-690330	IMPA1	132449	JKOCAAWWDVHWKB-UHFFFAOYSA-N	Preclinical	inositol monophosphatase inhibitor	NA	NA
L-693403	DRD2	4687238	GSXJSGMDWKPVBY-UHFFFAOYSA-N	Preclinical	sigma receptor agonist|sigma receptor antagonist	NA	NA
L-693403	SIGMAR1	4687238	GSXJSGMDWKPVBY-UHFFFAOYSA-N	Preclinical	sigma receptor agonist|sigma receptor antagonist	NA	NA
L-694247	HTR1A	132059	HKXMQLISPYELRD-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
L-694247	HTR1B	132059	HKXMQLISPYELRD-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
L-694247	HTR1D	132059	HKXMQLISPYELRD-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
L-701252	GRIN1	54687453	MXEFWCFPCLDOOG-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-701324	GRIN1	54682505	FLVRDMUHUXVRET-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-701324	GRIN2A	54682505	FLVRDMUHUXVRET-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-701324	GRIN2B	54682505	FLVRDMUHUXVRET-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-701324	GRIN2C	54682505	FLVRDMUHUXVRET-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
L-701324	GRIN2D	54682505	FLVRDMUHUXVRET-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
"L-732,138"	TACR1	44396853	BYYQYXVAWXAYQC-LJQANCHMSA-N	Preclinical	tachykinin antagonist	NA	NA
"L-732,138"	TACR2	44396853	BYYQYXVAWXAYQC-LJQANCHMSA-N	Preclinical	tachykinin antagonist	NA	NA
L-733060	TACR1	132846	FCDRFVCGMLUYPG-ROUUACIJSA-N	Preclinical	tachykinin antagonist	NA	NA
L-741742	DRD3	133008	QDMAKDIDFJTXEL-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-741742	DRD4	133008	QDMAKDIDFJTXEL-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-741742	SCN1A	133008	QDMAKDIDFJTXEL-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-741742	SCN3A	133008	QDMAKDIDFJTXEL-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	DRD1	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	DRD2	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	DRD3	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	DRD4	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	HTR1A	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	HTR2A	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	HTR6	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-745870	HTR7	5311200	OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
L-755507	ADRB1	9829836	NYYJKMXNVNFOFQ-MHZLTWQESA-N	Preclinical	adrenergic receptor agonist	NA	NA
L-755507	ADRB2	9829836	NYYJKMXNVNFOFQ-MHZLTWQESA-N	Preclinical	adrenergic receptor agonist	NA	NA
L-755507	ADRB3	9829836	NYYJKMXNVNFOFQ-MHZLTWQESA-N	Preclinical	adrenergic receptor agonist	NA	NA
L-760735	TACR1	9809077	USRYEHHMJIRICK-ZNZBMKLDSA-N	Preclinical	tachykinin antagonist	NA	NA
L-778123	FNTA	216454	JNUGFGAVPBYSHF-UHFFFAOYSA-N	Phase 1	farnesyltransferase inhibitor	NA	NA
L-778123	FNTB	216454	JNUGFGAVPBYSHF-UHFFFAOYSA-N	Phase 1	farnesyltransferase inhibitor	NA	NA
L-778123	PGGT1B	216454	JNUGFGAVPBYSHF-UHFFFAOYSA-N	Phase 1	farnesyltransferase inhibitor	NA	NA
L-798106	PTGER3	15551229	ODTKFNUPVBULRJ-NTCAYCPXSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
L-838417	GABRA1	9908880	BQDUNOMMYOKHEP-UHFFFAOYSA-N	Preclinical	GABA receptor partial agonist	NA	NA
L-838417	GABRA2	9908880	BQDUNOMMYOKHEP-UHFFFAOYSA-N	Preclinical	GABA receptor partial agonist	NA	NA
L-838417	GABRA3	9908880	BQDUNOMMYOKHEP-UHFFFAOYSA-N	Preclinical	GABA receptor partial agonist	NA	NA
L-838417	GABRA5	9908880	BQDUNOMMYOKHEP-UHFFFAOYSA-N	Preclinical	GABA receptor partial agonist	NA	NA
labetalol	ADRA1D	134043	SGUAFYQXFOLMHL-SCLBCKFNSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
labetalol	ADRB1	134043	SGUAFYQXFOLMHL-SCLBCKFNSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
labetalol	ADRB2	134043	SGUAFYQXFOLMHL-SCLBCKFNSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
lacidipine	CACNA1C	5311217	GKQPCPXONLDCMU-CCEZHUSRSA-N	Launched	calcium channel blocker	cardiology	hypertension
lafutidine	HRH2	40490609	KMZQAVXSMUKBPD-FCRIZLRQSA-N	Launched	histamine receptor antagonist	gastroenterology	duodenal ulcer disease|peptic ulcer disease (PUD)
lamotrigine	SCN10A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN11A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN1A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN2A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN3A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN4A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN5A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN7A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN8A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
lamotrigine	SCN9A	3878	PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry	epilepsy|bipolar disorder
landiolol	ADRB1	114905	WMDSZGFJQKSLLH-RBBKRZOGSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia
lansoprazole	ATP4A	9578005	MJIHNNLFOKEZEW-RUZDIDTESA-N	Launched	ATPase inhibitor	gastroenterology	heartburn
lansoprazole	ATP4B	9578005	MJIHNNLFOKEZEW-RUZDIDTESA-N	Launched	ATPase inhibitor	gastroenterology	heartburn
lapatinib	EGFR	208908	BCFGMOOMADDAQU-UHFFFAOYSA-N	Launched	EGFR inhibitor	oncology	breast cancer
lapatinib	ERBB2	208908	BCFGMOOMADDAQU-UHFFFAOYSA-N	Launched	EGFR inhibitor	oncology	breast cancer
laquinimod	CXCL2	54677946	GKWPCEFFIHSJOE-UHFFFAOYSA-N	Phase 3	immunosuppressant	NA	NA
laropiprant	PTGDR	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
laropiprant	PTGDR2	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
laropiprant	PTGER1	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
laropiprant	PTGER2	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
laropiprant	PTGER3	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
laropiprant	PTGFR	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
laropiprant	PTGIR	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
laropiprant	TBXA2R	9867642	NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	prostanoid receptor antagonist	cardiology	cholesterol
larotrectinib	NTRK1	46188928	NYNZQNWKBKUAII-KBXCAEBGSA-N	Launched	tropomyosin receptor kinase inhibitor	NA	NA
larotrectinib	NTRK2	46188928	NYNZQNWKBKUAII-KBXCAEBGSA-N	Launched	tropomyosin receptor kinase inhibitor	NA	NA
larotrectinib	NTRK3	46188928	NYNZQNWKBKUAII-KBXCAEBGSA-N	Launched	tropomyosin receptor kinase inhibitor	NA	NA
lasofoxifene	ESR1	3081919	INEHJXCWEVNEDZ-LUDNRVPPSA-N	Launched	selective estrogen receptor modulator (SERM)	orthopedics|oncology	osteoporosis|breast cancer
lasofoxifene	ESR2	3081919	INEHJXCWEVNEDZ-LUDNRVPPSA-N	Launched	selective estrogen receptor modulator (SERM)	orthopedics|oncology	osteoporosis|breast cancer
latanoprost	PTGFR	5311221	GGXICVAJURFBLW-CEYXHVGTSA-N	Launched	prostanoid receptor agonist	ophthalmology	ocular hypertension|glaucoma
latrepirdine	HRH1	197033	JNODQFNWMXFMEV-UHFFFAOYSA-N	Phase 3	glutamate receptor antagonist	NA	NA
latrepirdine	HTR6	197033	JNODQFNWMXFMEV-UHFFFAOYSA-N	Phase 3	glutamate receptor antagonist	NA	NA
latrunculin-B	ACTA1	6436219	NSHPHXHGRHSMIK-JRIKCGFMSA-N	Phase 1	actin polymerization inhibitor	NA	NA
latrunculin-B	MKL1	6436219	NSHPHXHGRHSMIK-JRIKCGFMSA-N	Phase 1	actin polymerization inhibitor	NA	NA
latrunculin-B	SPIRE2	6436219	NSHPHXHGRHSMIK-JRIKCGFMSA-N	Phase 1	actin polymerization inhibitor	NA	NA
lauric-acid	GPR84	3893	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3	bacterial permeability inducer	NA	NA
lauric-acid	HNF4A	3893	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3	bacterial permeability inducer	NA	NA
lauric-acid	LTF	3893	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3	bacterial permeability inducer	NA	NA
lauric-acid	LY96	3893	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3	bacterial permeability inducer	NA	NA
lauric-acid	PLA2G2A	3893	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3	bacterial permeability inducer	NA	NA
lauric-acid	TLR4	3893	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3	bacterial permeability inducer	NA	NA
lazabemide	MAOB	71307	JZXRLKWWVNUZRB-UHFFFAOYSA-N	Phase 3	monoamine oxidase inhibitor	NA	NA
LCL-161	BIRC2	24737642	UFPFGVNKHCLJJO-SSKFGXFMSA-N	Phase 2	XIAP inhibitor	NA	NA
LCL-161	XIAP	24737642	UFPFGVNKHCLJJO-SSKFGXFMSA-N	Phase 2	XIAP inhibitor	NA	NA
LCQ908	DGAT1	NA	GXALXAKNHIROPE-QAQDUYKDSA-N	Phase 3	diacylglycerol O acyltransferase inhibitor	NA	NA
LDC1267	AXL	56847486	ISPBCAXOSOLFME-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
LDC1267	MERTK	56847486	ISPBCAXOSOLFME-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
LDC1267	TYRO3	56847486	ISPBCAXOSOLFME-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
LDN-209929	GSG2	46871867	XMMAOXMYUGQGJD-UHFFFAOYSA-N	Preclinical	haspin kinase inhibitor	NA	NA
LDN-212854	ABL1	60182388	BBDGBGOVJPEFBT-UHFFFAOYSA-N	Preclinical	bone morphogenic protein inhibitor	NA	NA
LDN-212854	ACVR1	60182388	BBDGBGOVJPEFBT-UHFFFAOYSA-N	Preclinical	bone morphogenic protein inhibitor	NA	NA
LDN-212854	RIPK2	60182388	BBDGBGOVJPEFBT-UHFFFAOYSA-N	Preclinical	bone morphogenic protein inhibitor	NA	NA
LDN-27219	TGM2	1150683	WLBUICQBNZXIDJ-UHFFFAOYSA-N	Preclinical	tissue transglutaminase inhibitor	NA	NA
LDN193189	ACVR1	25195294	CDOVNWNANFFLFJ-UHFFFAOYSA-N	Preclinical	bone morphogenic protein inhibitor	NA	NA
LDN193189	BMPR1A	25195294	CDOVNWNANFFLFJ-UHFFFAOYSA-N	Preclinical	bone morphogenic protein inhibitor	NA	NA
LE-135	RARB	10410894	YZZAIQOVMHVWBS-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
leflunomide	AHR	3899	VHOGYURTWQBHIL-UHFFFAOYSA-N	Launched	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	rheumatology	rheumatoid arthritis
leflunomide	DHODH	3899	VHOGYURTWQBHIL-UHFFFAOYSA-N	Launched	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	rheumatology	rheumatoid arthritis
leflunomide	PTK2B	3899	VHOGYURTWQBHIL-UHFFFAOYSA-N	Launched	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	rheumatology	rheumatoid arthritis
lemborexant	HCRTR1	56944144	MUGXRYIUWFITCP-PGRDOPGGSA-N	Launched	orexin receptor antagonist	NA	NA
lemborexant	HCRTR2	56944144	MUGXRYIUWFITCP-PGRDOPGGSA-N	Launched	orexin receptor antagonist	NA	NA
lenalidomide	TNF	12044976	GOTYRUGSSMKFNF-JTQLQIEISA-N	Launched	anticancer agent	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)|myelodysplastic diseases (MDS)
lenvatinib	FLT4	9823820	WOSKHXYHFSIKNG-UHFFFAOYSA-N	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	thyroid cancer
lenvatinib	KDR	9823820	WOSKHXYHFSIKNG-UHFFFAOYSA-N	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	thyroid cancer
lercanidipine	CACNA2D1	9809926	ZDXUKAKRHYTAKV-MGBGTMOVSA-N	Launched	calcium channel blocker	cardiology	hypertension
lerisetron	HTR3A	65997	PWWDCRQZITYKDV-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
lesinurad	SLC22A12	53465279	FGQFOYHRJSUHMR-UHFFFAOYSA-N	Launched	uric acid diuretic	rheumatology	gout
lestaurtinib	FLT3	9932888	UIARLYUEJFELEN-DMVVYWCZSA-N	Phase 3	FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor	NA	NA
lestaurtinib	NTRK1	9932888	UIARLYUEJFELEN-DMVVYWCZSA-N	Phase 3	FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor	NA	NA
letrozole	CYP19A1	3902	HPJKCIUCZWXJDR-UHFFFAOYSA-N	Launched	aromatase inhibitor	oncology	breast cancer
leucomethylene-blue	MAPT	164695	QTWZICCBKBYHDM-UHFFFAOYSA-N	Phase 3	nitric oxide production inhibitor|tau aggregation inhibitor	NA	NA
leuprolide	GNRHR	657181	GFIJNRVAKGFPGQ-LIJARHBVSA-N	Launched	gonadotropin releasing factor hormone receptor agonist	oncology	prostate cancer
levalbuterol	ADRB2	123600	NDAUXUAQIAJITI-LBPRGKRZSA-N	Launched	adrenergic receptor agonist	pulmonary	bronchospasm
levallorphan	CHRNA2	5359371	OZYUPQUCAUTOBP-QXAKKESOSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
levallorphan	OPRM1	5359371	OZYUPQUCAUTOBP-QXAKKESOSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
levamisole	ALPL	26879	HLFSDGLLUJUHTE-SNVBAGLBSA-N	Withdrawn	acetylcholine receptor agonist	NA	NA
levcromakalim	KCNJ5	93504	TVZCRIROJQEVOT-CABCVRRESA-N	Phase 3	potassium channel activator	NA	NA
levetiracetam	CACNA1B	5284583	HPHUVLMMVZITSG-LURJTMIESA-N	Launched	calcium channel blocker	neurology/psychiatry	seizures
levetiracetam	SCN1A	5284583	HPHUVLMMVZITSG-LURJTMIESA-N	Launched	calcium channel blocker	neurology/psychiatry	seizures
levetiracetam	SV2A	5284583	HPHUVLMMVZITSG-LURJTMIESA-N	Launched	calcium channel blocker	neurology/psychiatry	seizures
levo-phencynonate	CHRM1	NA	ROZOEEGFKDFEFP-AXRVMRSRSA-N	Launched	acetylcholine receptor antagonist	NA	NA
levobetaxolol	ADRB1	60657	NWIUTZDMDHAVTP-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist	ophthalmology	intraocular pressure|glaucoma
levobetaxolol	ADRB2	60657	NWIUTZDMDHAVTP-KRWDZBQOSA-N	Launched	adrenergic receptor antagonist	ophthalmology	intraocular pressure|glaucoma
levobunolol	ADRB1	39468	IXHBTMCLRNMKHZ-LBPRGKRZSA-N	Launched	adrenergic receptor antagonist	ophthalmology	glaucoma|ocular hypertension
levobunolol	ADRB2	39468	IXHBTMCLRNMKHZ-LBPRGKRZSA-N	Launched	adrenergic receptor antagonist	ophthalmology	glaucoma|ocular hypertension
levobunolol	ADRB3	39468	IXHBTMCLRNMKHZ-LBPRGKRZSA-N	Launched	adrenergic receptor antagonist	ophthalmology	glaucoma|ocular hypertension
levocabastine	HRH1	NA	ZCGOMHNNNFPNMX-KYTRFIICSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
levocabastine	NTSR2	NA	ZCGOMHNNNFPNMX-KYTRFIICSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
levocarnitine	CRAT	10918	PHIQHXFUZVPYII-ZCFIWIBFSA-O	Launched		endocrinology	carnitine deficiency
levocarnitine	CROT	10918	PHIQHXFUZVPYII-ZCFIWIBFSA-O	Launched		endocrinology	carnitine deficiency
levocarnitine-propionate	CRAT	157837	UFAHZIUFPNSHSL-MRVPVSSYSA-O	Launched	carnitine palmitoyltransferase inhibitor	neurology/psychiatry|endocrinology	peripheral neuropathy|carnitine deficiency
levocetirizine	HRH1	28145931	ZKLPARSLTMPFCP-OAQYLSRUSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis|urticaria
levodopa	DRD1	6971033	WTDRDQBEARUVNC-LURJTMIESA-N	Launched	dopamine precursor	neurology/psychiatry	Parkinson's Disease
levodopa	DRD2	6971033	WTDRDQBEARUVNC-LURJTMIESA-N	Launched	dopamine precursor	neurology/psychiatry	Parkinson's Disease
levodopa	DRD3	6971033	WTDRDQBEARUVNC-LURJTMIESA-N	Launched	dopamine precursor	neurology/psychiatry	Parkinson's Disease
levodopa	DRD4	6971033	WTDRDQBEARUVNC-LURJTMIESA-N	Launched	dopamine precursor	neurology/psychiatry	Parkinson's Disease
levodopa	DRD5	6971033	WTDRDQBEARUVNC-LURJTMIESA-N	Launched	dopamine precursor	neurology/psychiatry	Parkinson's Disease
levodopa	GPR143	6971033	WTDRDQBEARUVNC-LURJTMIESA-N	Launched	dopamine precursor	neurology/psychiatry	Parkinson's Disease
levofloxacin	TOP2A	6956357	GSDSWSVVBLHKDQ-JTQLQIEISA-N	Launched	bacterial DNA gyrase inhibitor	infectious disease|otolaryngology|pulmonary|urology	pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague
levomenthol	OPRK1	16666	NOOLISFMXDJSKH-KXUCPTDWSA-N	Launched		neurology/psychiatry	pain relief
levomenthol	TRPA1	16666	NOOLISFMXDJSKH-KXUCPTDWSA-N	Launched		neurology/psychiatry	pain relief
levomenthol	TRPM8	16666	NOOLISFMXDJSKH-KXUCPTDWSA-N	Launched		neurology/psychiatry	pain relief
levomenthol	TRPV3	16666	NOOLISFMXDJSKH-KXUCPTDWSA-N	Launched		neurology/psychiatry	pain relief
levomepromazine	ADRA1A	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	ADRA1B	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	ADRA1D	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	ADRA2A	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	ADRA2B	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	ADRA2C	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	CHRM1	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	CHRM2	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	CHRM3	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	CHRM4	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	CHRM5	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	DRD1	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	DRD2	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	DRD3	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	DRD4	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	DRD5	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	HRH1	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	HTR2A	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomepromazine	HTR2C	72287	VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia
levomequitazine	HRH1	3246605	HOKDBMAJZXIPGC-MRXNPFEDSA-N	Phase 2	histamine receptor antagonist	NA	NA
levonordefrin	ADRA1A	164739	GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	vasodilator	hematology	hemorrhage
levonordefrin	ADRA1B	164739	GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	vasodilator	hematology	hemorrhage
levonordefrin	ADRA1D	164739	GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	vasodilator	hematology	hemorrhage
levonordefrin	ADRA2A	164739	GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	vasodilator	hematology	hemorrhage
levonordefrin	ADRA2B	164739	GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	vasodilator	hematology	hemorrhage
levonordefrin	ADRA2C	164739	GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	vasodilator	hematology	hemorrhage
levonordefrin	SLC6A2	164739	GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	vasodilator	hematology	hemorrhage
levonorgestrel	PGR	13109	WWYNJERNGUHSAO-XUDSTZEESA-N	Launched	estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist	endocrinology	contraceptive
levosimendan	KCNJ11	3033825	WHXMKTBCFHIYNQ-SECBINFHSA-N	Launched	calcium sensitizer	cardiology	congestive heart failure
levosimendan	KCNJ8	3033825	WHXMKTBCFHIYNQ-SECBINFHSA-N	Launched	calcium sensitizer	cardiology	congestive heart failure
levosimendan	PDE3A	3033825	WHXMKTBCFHIYNQ-SECBINFHSA-N	Launched	calcium sensitizer	cardiology	congestive heart failure
levosimendan	TNNC1	3033825	WHXMKTBCFHIYNQ-SECBINFHSA-N	Launched	calcium sensitizer	cardiology	congestive heart failure
levosulpiride	CA1	688272	BGRJTUBHPOOWDU-NSHDSACASA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)
levosulpiride	CA12	688272	BGRJTUBHPOOWDU-NSHDSACASA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)
levosulpiride	CA7	688272	BGRJTUBHPOOWDU-NSHDSACASA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)
levosulpiride	DRD2	688272	BGRJTUBHPOOWDU-NSHDSACASA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)
levosulpiride	DRD3	688272	BGRJTUBHPOOWDU-NSHDSACASA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)
levothyroxine	THRA	5819	XUIIKFGFIJCVMT-LBPRGKRZSA-N	Launched	thyroid hormone stimulant	endocrinology	myxedema coma
levothyroxine	THRB	5819	XUIIKFGFIJCVMT-LBPRGKRZSA-N	Launched	thyroid hormone stimulant	endocrinology	myxedema coma
LFM-A13	BTK	NA	BQLDGDMKDYAGNE-MRVPVSSYSA-N	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
LGK-974	PORCN	46926973	XXYGTCZJJLTAGH-UHFFFAOYSA-N	Phase 2	porcupine inhibitor	NA	NA
LH846	CSNK1D	851474	DYHAMRNAHTWYKY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
liarozole	CYP19A1	76956376	UGFHIPBXIWJXNA-QGZVFWFLSA-N	Phase 2/Phase 3	cytochrome P450 inhibitor	NA	NA
liarozole	CYP26A1	76956376	UGFHIPBXIWJXNA-QGZVFWFLSA-N	Phase 2/Phase 3	cytochrome P450 inhibitor	NA	NA
licarbazepine	SCN5A	9816485	BMPDWHIDQYTSHX-CQSZACIVSA-N	Phase 3	voltage-gated sodium channel blocker	NA	NA
licochalcone-A	PTPN1	5318998	KAZSKMJFUPEHHW-DHZHZOJOSA-N	Phase 3	topoisomerase inhibitor	NA	NA
licofelone	ALOX5	133021	UAWXGRJVZSAUSZ-UHFFFAOYSA-N	Phase 3	cyclooxygenase inhibitor|lipoxygenase inhibitor	NA	NA
licofelone	PLA2G2E	133021	UAWXGRJVZSAUSZ-UHFFFAOYSA-N	Phase 3	cyclooxygenase inhibitor|lipoxygenase inhibitor	NA	NA
licofelone	PTGS2	133021	UAWXGRJVZSAUSZ-UHFFFAOYSA-N	Phase 3	cyclooxygenase inhibitor|lipoxygenase inhibitor	NA	NA
lidocaine	EGFR	3676	NNJVILVZKWQKPM-UHFFFAOYSA-N	Launched	histamine receptor agonist	neurology/psychiatry|dermatology|hematology	itching|eczema|hemorrhage
lidocaine	SCN10A	3676	NNJVILVZKWQKPM-UHFFFAOYSA-N	Launched	histamine receptor agonist	neurology/psychiatry|dermatology|hematology	itching|eczema|hemorrhage
lidocaine	SCN5A	3676	NNJVILVZKWQKPM-UHFFFAOYSA-N	Launched	histamine receptor agonist	neurology/psychiatry|dermatology|hematology	itching|eczema|hemorrhage
lidocaine	SCN9A	3676	NNJVILVZKWQKPM-UHFFFAOYSA-N	Launched	histamine receptor agonist	neurology/psychiatry|dermatology|hematology	itching|eczema|hemorrhage
lidoflazine	SCN1A	3926	ZBIAKUMOEKILTF-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	coronary artery disease (CAD)
lidoflazine	SCN3A	3926	ZBIAKUMOEKILTF-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	coronary artery disease (CAD)
lidoflazine	SLC29A1	3926	ZBIAKUMOEKILTF-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	coronary artery disease (CAD)
ligustilide	TNF	5319022	IQVQXVFMNOFTMU-FLIBITNWSA-N	Preclinical	tumor necrosis factor production inhibitor	NA	NA
limaprost-alfadex	PTGER1	6438378	OJZYRQPMEIEQFC-UAWLTFRCSA-N	Launched	prostanoid receptor agonist	cardiology	claudication
LIMKi-3	LIMK1	56965901	IVUGBSGLHRJSSP-UHFFFAOYSA-N	Preclinical	LIM kinase inhibitor	NA	NA
linaclotide	GUCY2C	16158208	KXGCNMMJRFDFNR-WDRJZQOASA-N	Launched	guanylate cyclase activator	gastroenterology	irritable bowel syndrome|constipation
linagliptin	DPP4	10096344	LTXREWYXXSTFRX-QGZVFWFLSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
lindane	GABRB1	NA	JLYXXMFPNIAWKQ-GNIYUCBRSA-N	Launched		infectious disease	scabies
lindane	GLRA1	NA	JLYXXMFPNIAWKQ-GNIYUCBRSA-N	Launched		infectious disease	scabies
lindane	GLRA2	NA	JLYXXMFPNIAWKQ-GNIYUCBRSA-N	Launched		infectious disease	scabies
lindane	GLRA3	NA	JLYXXMFPNIAWKQ-GNIYUCBRSA-N	Launched		infectious disease	scabies
lindane	GLRB	NA	JLYXXMFPNIAWKQ-GNIYUCBRSA-N	Launched		infectious disease	scabies
linezolid	MAOA	441401	TYZROVQLWOKYKF-ZDUSSCGKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia|skin infections
linezolid	MAOB	441401	TYZROVQLWOKYKF-ZDUSSCGKSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia|skin infections
linifanib	CSF1	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	CSF1R	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	FLT1	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	FLT3	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	FLT4	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	KDR	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	KIT	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	PDGFRB	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	RET	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linifanib	TEK	11485656	MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
linoleic-acid	FABP4	5280450	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	oxidative stress inducer	NA	NA
linoleic-acid	FFAR1	5280450	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	oxidative stress inducer	NA	NA
linoleic-acid	FFAR4	5280450	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	oxidative stress inducer	NA	NA
linoleic-acid	HNF4A	5280450	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	oxidative stress inducer	NA	NA
linoleic-acid	KCNB1	5280450	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	oxidative stress inducer	NA	NA
linoleic-acid	PPARG	5280450	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	oxidative stress inducer	NA	NA
linoleic-acid	TRPM8	5280450	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	oxidative stress inducer	NA	NA
linopirdine	KCNQ2	3932	YEJCDKJIEMIWRQ-UHFFFAOYSA-N	Phase 3	potassium channel blocker	NA	NA
linopirdine	KCNQ3	3932	YEJCDKJIEMIWRQ-UHFFFAOYSA-N	Phase 3	potassium channel blocker	NA	NA
linopirdine	KCNQ4	3932	YEJCDKJIEMIWRQ-UHFFFAOYSA-N	Phase 3	potassium channel blocker	NA	NA
linopirdine	KCNQ5	3932	YEJCDKJIEMIWRQ-UHFFFAOYSA-N	Phase 3	potassium channel blocker	NA	NA
linsitinib	IGF1R	NA	PKCDDUHJAFVJJB-VLZXCDOPSA-N	Phase 3	IGF-1 inhibitor	NA	NA
linsitinib	INSR	NA	PKCDDUHJAFVJJB-VLZXCDOPSA-N	Phase 3	IGF-1 inhibitor	NA	NA
linsitinib	INSRR	NA	PKCDDUHJAFVJJB-VLZXCDOPSA-N	Phase 3	IGF-1 inhibitor	NA	NA
liothyronine	THRA	7048703	AUYYCJSJGJYCDS-LBPRGKRZSA-N	Launched	thyroid hormone stimulant	endocrinology	hypothyroidism|myxedema coma
liothyronine	THRB	7048703	AUYYCJSJGJYCDS-LBPRGKRZSA-N	Launched	thyroid hormone stimulant	endocrinology	hypothyroidism|myxedema coma
liraglutide	GLP1R	16153050	YSDQQAXHVYUZIW-QCIJIYAXSA-N	Launched	GLP receptor agonist	endocrinology	weight-loss aid|diabetes mellitus
lisinopril	ACE	5362119	RLAWWYSOJDYHDC-BZSNNMDCSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology|endocrinology	hypertension|congestive heart failure|diabetes mellitus
lisinopril	ACE2	5362119	RLAWWYSOJDYHDC-BZSNNMDCSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology|endocrinology	hypertension|congestive heart failure|diabetes mellitus
lisuride	ADRA1A	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	ADRA2A	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	ADRA2B	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	ADRA2C	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	DRD1	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	DRD2	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	DRD3	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	DRD4	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	DRD5	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	HTR1A	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	HTR1B	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	HTR1D	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	HTR2A	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	HTR2B	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	HTR2C	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lisuride	HTR6	28864	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lithium-acetoacetate	FAH	96	WDJHALXBUFZDSR-UHFFFAOYSA-N	Preclinical		NA	NA
lithocholic-acid	GPBAR1	9903	SMEROWZSTRWXGI-HVATVPOCSA-N	Preclinical	FXR antagonist|vitamin D receptor agonist	NA	NA
lithocholic-acid	NR1H4	9903	SMEROWZSTRWXGI-HVATVPOCSA-N	Preclinical	FXR antagonist|vitamin D receptor agonist	NA	NA
lithocholic-acid	NR1I2	9903	SMEROWZSTRWXGI-HVATVPOCSA-N	Preclinical	FXR antagonist|vitamin D receptor agonist	NA	NA
lithocholic-acid	VDR	9903	SMEROWZSTRWXGI-HVATVPOCSA-N	Preclinical	FXR antagonist|vitamin D receptor agonist	NA	NA
litronesib	KIF11	25167017	YVAFBXLHPINSIK-QHCPKHFHSA-N	Phase 2	kinesin-like spindle protein inhibitor	NA	NA
lixivaptan	AVPR2	172997	PPHTXRNHTVLQED-UHFFFAOYSA-N	Phase 3	vasopressin receptor antagonist	NA	NA
LM-22A4	NTRK2	2054170	RGWJKANXFYJKHN-UHFFFAOYSA-N	Preclinical	tropomyosin receptor kinase inhibitor	NA	NA
LMI070	SMN1	135565042	STWTUEAWRAIWJG-UHFFFAOYSA-N	Phase 1/Phase 2	survival motor neuron protein modulator	NA	NA
LMK-235	HDAC4	71520717	"InChI=1S/C15H22N2O4/c1-11-8-12(2)10-13(9-11)15(19)17-21-7-5-3-4-6-14(18)16-20/h8-10,20H,3-7H2,1-2H3,(H,16,18)(H,17,19)"	Preclinical	HDAC inhibitor	NA	NA
LMK-235	HDAC5	71520717	"InChI=1S/C15H22N2O4/c1-11-8-12(2)10-13(9-11)15(19)17-21-7-5-3-4-6-14(18)16-20/h8-10,20H,3-7H2,1-2H3,(H,16,18)(H,17,19)"	Preclinical	HDAC inhibitor	NA	NA
LM11A-31	NGFR	28174760	YNMUTYLWSRFTPX-GHMZBOCLSA-N	Phase 1	neurotrophic agent	NA	NA
lobeline	CHRNA10	101616	MXYUKLILVYORSK-HBMCJLEFSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	smoking cessation
lobeline	CHRNA9	101616	MXYUKLILVYORSK-HBMCJLEFSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	smoking cessation
lobeline	SLC18A2	101616	MXYUKLILVYORSK-HBMCJLEFSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	smoking cessation
lofepramine	HTR1A	3947	SAPNXPWPAUFAJU-UHFFFAOYSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
lofepramine	SLC6A2	3947	SAPNXPWPAUFAJU-UHFFFAOYSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
lofepramine	SLC6A4	3947	SAPNXPWPAUFAJU-UHFFFAOYSA-N	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
lomeguatrib	MGMT	3025944	JUJPKFNFCWJBCX-UHFFFAOYSA-N	Phase 2	O6-alkylguanine-DNA alkyltransferase inhibitor	NA	NA
lomerizine	CACNA1B	3949	JQSAYKKFZOSZGJ-UHFFFAOYSA-N	Launched	calcium channel blocker	neurology/psychiatry	migraine headache
lomerizine	SCN5A	3949	JQSAYKKFZOSZGJ-UHFFFAOYSA-N	Launched	calcium channel blocker	neurology/psychiatry	migraine headache
lometrexol	GART	135413518	ZUQBAQVRAURMCL-DOMZBBRYSA-N	Phase 2	glycinamide ribonucleotide formyltransferase inhibitor	NA	NA
lomitapide	MTTP	9853053	MBBCVAKAJPKAKM-UHFFFAOYSA-N	Launched	microsomal trigylceride transfer protein inhibitor	endocrinology	hypercholesterolemia
lonafarnib	FNTA	148195	"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1"	Phase 3	farnesyltransferase inhibitor	NA	NA
lonafarnib	HRAS	148195	"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1"	Phase 3	farnesyltransferase inhibitor	NA	NA
lonafarnib	KRAS	148195	"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1"	Phase 3	farnesyltransferase inhibitor	NA	NA
lonafarnib	NRAS	148195	"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1"	Phase 3	farnesyltransferase inhibitor	NA	NA
lonidamine	GCK	39562	WDRYRZXSPDWGEB-UHFFFAOYSA-N	Launched	glucokinase inhibitor	NA	NA
loperamide	CACNA1A	3955	RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched	opioid receptor agonist	gastroenterology	diarrhea
loperamide	CALM1	3955	RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched	opioid receptor agonist	gastroenterology	diarrhea
loperamide	OPRD1	3955	RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched	opioid receptor agonist	gastroenterology	diarrhea
loperamide	OPRK1	3955	RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched	opioid receptor agonist	gastroenterology	diarrhea
loperamide	OPRM1	3955	RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched	opioid receptor agonist	gastroenterology	diarrhea
loperamide	POMC	3955	RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched	opioid receptor agonist	gastroenterology	diarrhea
loratadine	HRH1	3957	JCCNYMKQOSZNPW-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy|neurology/psychiatry	allergic rhinitis|itching
loreclezole	GABRB2	3034012	XGLHZTBDUXXHOM-WMZJFQQLSA-N	Phase 2	benzodiazepine receptor agonist	NA	NA
loreclezole	GABRB3	3034012	XGLHZTBDUXXHOM-WMZJFQQLSA-N	Phase 2	benzodiazepine receptor agonist	NA	NA
lorediplon	GABRA1	12004146	NQPOCLFSADOXBR-UHFFFAOYSA-N	Phase 2	GABA receptor modulator	NA	NA
lorglumide	CCKAR	13605417	IEKOTSCYBBDIJC-LJQANCHMSA-N	Phase 1	CCK receptor antagonist	NA	NA
lorglumide	CCKBR	13605417	IEKOTSCYBBDIJC-LJQANCHMSA-N	Phase 1	CCK receptor antagonist	NA	NA
lorlatinib	ALK	78162481	IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
lornoxicam	PTGS1	54690031	WLHQHAUOOXYABV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	osteoarthritis|sciata
lornoxicam	PTGS2	54690031	WLHQHAUOOXYABV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	osteoarthritis|sciata
losartan	AGTR1	3961	PSIFNNKUMBGKDQ-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology|nephrology	hypertension|diabetic nephropathy|hypertension
losmapimod	MAPK14	11552706	KKYABQBFGDZVNQ-UHFFFAOYSA-N	Phase 3	p38 MAPK inhibitor	NA	NA
loteprednol	NR3C1	444025	DMKSVUSAATWOCU-HROMYWEYSA-N	Launched	glucocorticoid receptor agonist|phospholipase inhibitor	ophthalmology	conjunctivitis
lovastatin	HDAC2	53232	PCZOHLXUXFIOCF-BXMDZJJMSA-N	Launched	HMGCR inhibitor	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia
lovastatin	HMGCR	53232	PCZOHLXUXFIOCF-BXMDZJJMSA-N	Launched	HMGCR inhibitor	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia
lovastatin	ITGAL	53232	PCZOHLXUXFIOCF-BXMDZJJMSA-N	Launched	HMGCR inhibitor	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia
lovastatin	NR1I2	53232	PCZOHLXUXFIOCF-BXMDZJJMSA-N	Launched	HMGCR inhibitor	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia
loxapine	ADRA1A	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	ADRA1B	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	ADRA2A	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	ADRA2B	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	ADRA2C	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	ADRB1	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	CHRM1	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	CHRM2	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	CHRM3	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	CHRM4	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	CHRM5	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	DRD1	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	DRD2	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	DRD3	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	DRD4	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	DRD5	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HRH1	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HRH2	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HRH4	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR1A	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR1B	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR1D	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR1E	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR2A	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR2C	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR3A	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR5A	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR6	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	HTR7	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	SLC6A2	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	SLC6A3	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxapine	SLC6A4	3964	XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxistatin-acid	CTSB	123664	SCMSYZJDIQPSDI-SRVKXCTJSA-N	Preclinical	cysteine peptidase inhibitor	NA	NA
loxoprofen	PTGS2	13049027	YMBXTVYHTMGZDW-ZWNOBZJWSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	neurology/psychiatry	pain relief
LPA2-antagonist-1	LPAR2	24882686	BPRNMVDTWIHULJ-AWEZNQCLSA-N	Preclinical	lysophosphatidic acid receptor antagonist	NA	NA
LRRK2-IN-1	LRRK2	46843906	IWMCPJZTADUIFX-UHFFFAOYSA-N	Preclinical	leucine rich repeat kinase inhibitor	NA	NA
LSN-2463359	GRM5	72551298	STAFRSGTRKNXHF-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
LTB4	LTB4R	5280492	VNYSSYRCGWBHLG-AMOLWHMGSA-N	Phase 2	leukocyte activator	NA	NA
LTB4	LTB4R2	5280492	VNYSSYRCGWBHLG-AMOLWHMGSA-N	Phase 2	leukocyte activator	NA	NA
Lu-AA-47070	ADORA2A	NA	MSWIQSFUBYCFJE-PGMHBOJBSA-N	Phase 2	adenosine receptor antagonist	NA	NA
lubiprostone	CLCN2	9800568	DBVFKLAGQHYVGQ-BFYDXBDKSA-N	Launched	chloride channel activator	gastroenterology	constipation|irritable bowel syndrome
lucanthone	APEX1	10180	FBQPGGIHOFZRGH-UHFFFAOYSA-N	Phase 2	endonuclease inhibitor	NA	NA
lucanthone	TOP1	10180	FBQPGGIHOFZRGH-UHFFFAOYSA-N	Phase 2	endonuclease inhibitor	NA	NA
lucanthone	TOP2A	10180	FBQPGGIHOFZRGH-UHFFFAOYSA-N	Phase 2	endonuclease inhibitor	NA	NA
lucitanib	FGFR1	25031915	"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)"	Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
lucitanib	FLT1	25031915	"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)"	Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
lucitanib	KDR	25031915	"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)"	Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
lucitanib	KIT	25031915	"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)"	Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
lucitanib	PDGFRA	25031915	"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)"	Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
lucitanib	PDGFRB	25031915	"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)"	Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
lucitanib	RET	25031915	"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)"	Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
LUF-5834	ADORA2A	135543624	OFHKDLYFKPBXER-UHFFFAOYSA-N	Preclinical	adenosine receptor agonist	NA	NA
LUF-5834	ADORA2B	135543624	OFHKDLYFKPBXER-UHFFFAOYSA-N	Preclinical	adenosine receptor agonist	NA	NA
lumacaftor	CFTR	16678941	UFSKUSARDNFIRC-UHFFFAOYSA-N	Launched	CFTR channel agonist	pulmonary	cystic fibrosis
lumateperone	DRD2	21302490	HOIIHACBCFLJET-SFTDATJTSA-N	Launched	dopamine receptor modulator|serotonin receptor antagonist	NA	NA
lumateperone	HTR2A	21302490	HOIIHACBCFLJET-SFTDATJTSA-N	Launched	dopamine receptor modulator|serotonin receptor antagonist	NA	NA
lumefantrine	ATP1A1	73416445	DYLGFOYVTXJFJP-OXTLUBNBSA-N	Launched	antimalarial agent	infectious disease	malaria
lumiracoxib	PTGS1	151166	KHPKQFYUPIUARC-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
lumiracoxib	PTGS2	151166	KHPKQFYUPIUARC-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
lupanine	INS	91471	JYIJIIVLEOETIQ-XDQVBPFNSA-N	Phase 1	sodium channel blocker	NA	NA
lurasidone	ADRA2A	213046	PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
lurasidone	ADRA2C	213046	PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
lurasidone	DRD2	213046	PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
lurasidone	HTR1A	213046	PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
lurasidone	HTR2A	213046	PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
lurasidone	HTR7	213046	PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
luteolin	TOP1	5280445	IQPNAANSBPBGFQ-UHFFFAOYSA-N	Phase 2	glucosidase inhibitor	NA	NA
luzindole	MTNR1A	122162	WVVXBPKOIZGVNS-UHFFFAOYSA-N	Preclinical	melatonin receptor antagonist	NA	NA
luzindole	MTNR1B	122162	WVVXBPKOIZGVNS-UHFFFAOYSA-N	Preclinical	melatonin receptor antagonist	NA	NA
LXR-623	AR	16734800	KYWWJENKIMRJBI-UHFFFAOYSA-N	Phase 1	LXR agonist	NA	NA
LXR-623	NR1H2	16734800	KYWWJENKIMRJBI-UHFFFAOYSA-N	Phase 1	LXR agonist	NA	NA
LXR-623	NR1H3	16734800	KYWWJENKIMRJBI-UHFFFAOYSA-N	Phase 1	LXR agonist	NA	NA
LXR-623	NR1I2	16734800	KYWWJENKIMRJBI-UHFFFAOYSA-N	Phase 1	LXR agonist	NA	NA
LXR-623	NR3C1	16734800	KYWWJENKIMRJBI-UHFFFAOYSA-N	Phase 1	LXR agonist	NA	NA
LX1031	TPH1	23633604	XNMUICFMGGQSMZ-WIOPSUGQSA-N	Phase 2	tryptophan hydroxylase inhibitor	NA	NA
LX7101	LIMK2	56962369	PWPNYABQEOGNNC-UHFFFAOYSA-N	Phase 1/Phase 2	LIM kinase inhibitor|rho associated kinase inhibitor	NA	NA
LX7101	ROCK1	56962369	PWPNYABQEOGNNC-UHFFFAOYSA-N	Phase 1/Phase 2	LIM kinase inhibitor|rho associated kinase inhibitor	NA	NA
LX7101	ROCK2	56962369	PWPNYABQEOGNNC-UHFFFAOYSA-N	Phase 1/Phase 2	LIM kinase inhibitor|rho associated kinase inhibitor	NA	NA
lylamine	CNR1	62034	JVVXZOOGOGPDRZ-SLFFLAALSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
lypressin	AVPR1A	133588927	BJFIDCADFRDPIO-KKSWSVFASA-N	Launched	vasopressin receptor agonist	endocrinology	central diabetes insipidus
lypressin	AVPR1B	133588927	BJFIDCADFRDPIO-KKSWSVFASA-N	Launched	vasopressin receptor agonist	endocrinology	central diabetes insipidus
lypressin	AVPR2	133588927	BJFIDCADFRDPIO-KKSWSVFASA-N	Launched	vasopressin receptor agonist	endocrinology	central diabetes insipidus
LY2090314	GSK3B	10029385	HRJWTAWVFDCTGO-UHFFFAOYSA-N	Phase 2	glycogen synthase kinase inhibitor	NA	NA
LY2109761	TGFBR1	11655119	IHLVSLOZUHKNMQ-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
LY2109761	TGFBR2	11655119	IHLVSLOZUHKNMQ-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
LY2140023	GRM3	9834591	AVDUGNCTZRCAHH-MDASVERJSA-N	Phase 3	glutamate receptor agonist	NA	NA
LY215490	GRIA1	127894	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	Phase 1	glutamate receptor antagonist	NA	NA
LY215490	GRIA2	127894	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	Phase 1	glutamate receptor antagonist	NA	NA
LY215490	GRIA3	127894	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	Phase 1	glutamate receptor antagonist	NA	NA
LY215490	GRIA4	127894	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	Phase 1	glutamate receptor antagonist	NA	NA
LY215490	GRIK1	127894	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	Phase 1	glutamate receptor antagonist	NA	NA
LY2157299	TGFBR1	10090485	IVRXNBXKWIJUQB-UHFFFAOYSA-N	Phase 2/Phase 3	TGF beta receptor inhibitor	NA	NA
LY2183240	FAAH	11507802	GZNIYOXWFCDBBJ-UHFFFAOYSA-N	Preclinical	FAAH inhibitor|FAAH reuptake inhibitor	NA	NA
LY2228820	MAPK14	11539025	XPPBBJCBDOEXDN-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
LY223982	LTB4R	6444688	SYZSSLLFRVDRHL-QPJJXVBHSA-N	Phase 2	leukotriene receptor antagonist	NA	NA
LY225910	CCKBR	4355450	KUECXUACQOYKNB-UHFFFAOYSA-N	Preclinical	CCK receptor antagonist	NA	NA
LY2365109	SLC6A9	11552757	FKPLJWGRBCQLTL-UHFFFAOYSA-N	Preclinical	glycine transporter inhibitor	NA	NA
LY2452473	AR	24963749	IHIWYQYVBNODSV-KRWDZBQOSA-N	Phase 2	androgen receptor modulator	NA	NA
LY255283	LTB4R	122023	WCGXJPFHTHQNJL-UHFFFAOYSA-N	Preclinical	leukotriene receptor antagonist	NA	NA
LY255283	LTB4R2	122023	WCGXJPFHTHQNJL-UHFFFAOYSA-N	Preclinical	leukotriene receptor antagonist	NA	NA
LY2584702	RPS6KB1	25118925	FYXRSVDHGLUMHB-UHFFFAOYSA-N	Phase 1	ribosomal protein inhibitor	NA	NA
LY2603618	CHEK1	11955855	SYYBDNPGDKKJDU-ZDUSSCGKSA-N	Phase 2	CHK inhibitor	NA	NA
LY2606368	CHEK1	46700756	DOTGPNHGTYJDEP-UHFFFAOYSA-N	Phase 2	CHK inhibitor	NA	NA
LY2608204	GCK	46832368	QIIVJLHCZUTGSD-CUBQBAPOSA-N	Phase 2	glucokinase activator	NA	NA
LY266097	HTR2B	92845961	NJLHHCITDFZZSE-QGZVFWFLSA-N	Preclinical	serotonin receptor antagonist	NA	NA
LY2784544	JAK2	46213929	"InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)"	Phase 2	JAK inhibitor	NA	NA
LY2784544	JAK3	46213929	"InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)"	Phase 2	JAK inhibitor	NA	NA
LY2801653	MET	44603533	QHADVLVFMKEIIP-UHFFFAOYSA-N	Phase 2	MET inhibitor	NA	NA
LY2811376	BACE1	44251605	MJQMRGWYPNIERM-HNNXBMFYSA-N	Phase 1	beta-secretase inhibitor	NA	NA
LY2857785	CDK9	NA	LHIUZPIDLZYPRL-MXVIHJGJSA-N	Preclinical	CDK inhibitor	NA	NA
LY2874455	FGFR1	46944259	GKJCVYLDJWTWQU-CXLRFSCWSA-N	Phase 1	FGFR antagonist	NA	NA
LY2874455	FGFR2	46944259	GKJCVYLDJWTWQU-CXLRFSCWSA-N	Phase 1	FGFR antagonist	NA	NA
LY2874455	FGFR3	46944259	GKJCVYLDJWTWQU-CXLRFSCWSA-N	Phase 1	FGFR antagonist	NA	NA
LY2874455	FGFR4	46944259	GKJCVYLDJWTWQU-CXLRFSCWSA-N	Phase 1	FGFR antagonist	NA	NA
LY2874455	KDR	46944259	GKJCVYLDJWTWQU-CXLRFSCWSA-N	Phase 1	FGFR antagonist	NA	NA
LY288513	CCKBR	2802894	LMUQHXHWJWQXSD-PMACEKPBSA-N	Preclinical	CCK receptor antagonist	NA	NA
LY2886721	BACE1	49837968	NIDRNVHMMDAAIK-YPMLDQLKSA-N	Phase 1/Phase 2	beta-secretase inhibitor	NA	NA
LY294002	AKT1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	CHEK1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	GSK3B	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	LCK	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	MAPK1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	MAPK11	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	MAPK12	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	MAPK14	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	MAPK8	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	MTOR	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PIK3CA	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PIK3CB	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PIK3CD	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PIK3CG	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PIM1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PLK1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PRKCA	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	PRKDC	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	ROCK1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	RPS6KB1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY294002	SGK1	3973	CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	NA	NA
LY2979165	GRM2	53246986	BBGHHIUQOKQCBW-LDZWZCGGSA-N	Phase 1	glutamate receptor agonist	NA	NA
LY3000328	CTSS	67475270	NDEBZCZEAVMSQF-GOTSBHOMSA-N	Phase 1	cathepsin inhibitor	NA	NA
LY3009120	BRAF	71721540	HHCBMISMPSAZBF-UHFFFAOYSA-N	Phase 1	RAF inhibitor	NA	NA
LY3009120	RAF1	71721540	HHCBMISMPSAZBF-UHFFFAOYSA-N	Phase 1	RAF inhibitor	NA	NA
LY3023414	MTOR	57519748	ACCFLVVUVBJNGT-AWEZNQCLSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
LY303511	BRD2	3971	NGAGMBNBKCDCDJ-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	NA	NA
LY303511	BRD3	3971	NGAGMBNBKCDCDJ-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	NA	NA
LY303511	BRD4	3971	NGAGMBNBKCDCDJ-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	NA	NA
LY310762	HTR1D	4282258	KDXISMANFPJVJY-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
LY320135	CNR1	5311257	RYNSGDFWBJWWSZ-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
LY344864	HTR1A	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR1B	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR1D	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR1E	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR1F	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR2A	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR2B	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR2C	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY344864	HTR7	5311097	GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	serotonin receptor agonist	NA	NA
LY364947	TGFBR1	447966	IBCXZJCWDGCXQT-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor|TGF beta receptor inhibitor	NA	NA
LY393558	HTR1B	10347428	QUSLYAPLTMMCFE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
LY393558	HTR1D	10347428	QUSLYAPLTMMCFE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
LY393558	HTR2A	10347428	QUSLYAPLTMMCFE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
LY393558	HTR2B	10347428	QUSLYAPLTMMCFE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
LY404187	GRIA1	66857735	HOQAVGZLYRYHSO-HNNXBMFYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
LY404187	GRIA2	66857735	HOQAVGZLYRYHSO-HNNXBMFYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
LY404187	GRIA3	66857735	HOQAVGZLYRYHSO-HNNXBMFYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
LY404187	GRIA4	66857735	HOQAVGZLYRYHSO-HNNXBMFYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
LY456236	GRM1	9926999	XPJOMFBGKIABQW-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
m-chlorophenylbiguanide	HTR3A	1354	DIHXJZHAIHGSAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
m-chlorophenylbiguanide	HTR3B	1354	DIHXJZHAIHGSAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
M-14157	KCNQ1	1825	LMHJFKYQYDSOQO-UHFFFAOYSA-N	Phase 2	ATP-sensitive potassium channel antagonist	NA	NA
M-25	DHH	44250034	WATNXVHKRRTUFK-UHFFFAOYSA-N	Preclinical	smoothened receptor antagonist	NA	NA
M-25	IHH	44250034	WATNXVHKRRTUFK-UHFFFAOYSA-N	Preclinical	smoothened receptor antagonist	NA	NA
M-25	SMO	44250034	WATNXVHKRRTUFK-UHFFFAOYSA-N	Preclinical	smoothened receptor antagonist	NA	NA
m-3M3FBS	PLCB2	761523	ZIIUUSVHCHPIQD-UHFFFAOYSA-N	Preclinical	phospholipase activator	NA	NA
m-3M3FBS	PLCB3	761523	ZIIUUSVHCHPIQD-UHFFFAOYSA-N	Preclinical	phospholipase activator	NA	NA
m-3M3FBS	PLCD1	761523	ZIIUUSVHCHPIQD-UHFFFAOYSA-N	Preclinical	phospholipase activator	NA	NA
m-3M3FBS	PLCG1	761523	ZIIUUSVHCHPIQD-UHFFFAOYSA-N	Preclinical	phospholipase activator	NA	NA
m-3M3FBS	PLCG2	761523	ZIIUUSVHCHPIQD-UHFFFAOYSA-N	Preclinical	phospholipase activator	NA	NA
M-344	HDAC8	3994	MXWDSZWTBOCWBK-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
mabuterol	ADRB2	11551355	JSJCTEKTBOKRST-SNVBAGLBSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
macitentan	EDNRA	16004692	JGCMEBMXRHSZKX-UHFFFAOYSA-N	Launched	endothelin receptor antagonist	endocrinology	contraceptive
macitentan	EDNRB	16004692	JGCMEBMXRHSZKX-UHFFFAOYSA-N	Launched	endothelin receptor antagonist	endocrinology	contraceptive
mafenide	CA12	3998	TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	first-aid antibiotic|skin infections
mafenide	CA14	3998	TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	first-aid antibiotic|skin infections
mafenide	CA2	3998	TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	first-aid antibiotic|skin infections
mafenide	CA4	3998	TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	first-aid antibiotic|skin infections
mafenide	CA6	3998	TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	first-aid antibiotic|skin infections
mafenide	CA9	3998	TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	first-aid antibiotic|skin infections
magnolol	GABRA1	72300	VVOAZFWZEDHOOU-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
magnolol	PPARG	72300	VVOAZFWZEDHOOU-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
malathion	ACHE	12358970	JXSJBGJIGXNWCI-MRVPVSSYSA-N	Launched	cholinesterase inhibitor	infectious disease	lice
malic-acid	PKD2L1	222656	BJEPYKJPYRNKOW-REOHCLBHSA-N	Launched		NA	NA
manidipine	CACNA1C	13632719	ANEBWFXPVPTEET-JGCGQSQUSA-N	Launched	calcium channel blocker	cardiology	hypertension
manidipine	CACNA1D	13632719	ANEBWFXPVPTEET-JGCGQSQUSA-N	Launched	calcium channel blocker	cardiology	hypertension
maprotiline	SLC6A2	NA	QSLMDECMDJKHMQ-GSXCWMCISA-N	Launched	norepinephrine reputake inhibitor|tricyclic antidepressant	neurology/psychiatry	depression|dysthymic disorder
maraviroc	CCR5	NA	GSNHKUDZZFZSJB-QYOOZWMWSA-N	Launched	CC chemokine receptor antagonist	infectious disease	human immunodeficiency virus (HIV-1)
maribavir	PYGM	471161	KJFBVJALEQWJBS-XUXIUFHCSA-N	Phase 3	cytomegalovirus inhibitor|protein kinase inhibitor	NA	NA
marimastat	MMP1	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP10	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP11	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP12	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP13	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP14	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP15	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP16	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP17	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP19	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP2	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP20	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP21	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP23A	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP24	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP25	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP26	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP27	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP28	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP3	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP7	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP8	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
marimastat	MMP9	119031	"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1"	Phase 3	matrix metalloprotease inhibitor	NA	NA
maropitant	TACR1	204108	OMPCVMLFFSQFIX-CONSDPRKSA-N	Launched	neurokinin receptor antagonist	gastroenterology	vomiting
masitinib	FGFR3	10074640	WJEOLQLKVOPQFV-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor	dermatology	mastocytoma
masitinib	KIT	10074640	WJEOLQLKVOPQFV-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor	dermatology	mastocytoma
masitinib	PDGFRA	10074640	WJEOLQLKVOPQFV-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor	dermatology	mastocytoma
masitinib	PDGFRB	10074640	WJEOLQLKVOPQFV-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor	dermatology	mastocytoma
masoprocol	ALOX5	688035	HCZKYJDFEPMADG-RYUDHWBXSA-N	Launched	lipoxygenase inhibitor	dermatology	actinic keratosis (AK)
matrine	OPRK1	91466	ZSBXGIUJOOQZMP-JLNYLFASSA-N	Phase 2	opioid receptor agonist	NA	NA
mavoglurant	GRM5	9926832	ZFPZEYHRWGMJCV-ZHALLVOQSA-N	Phase 2	glutamate receptor antagonist	NA	NA
maxacalcitol	VDR	6398761	DTXXSJZBSTYZKE-ZDQKKZTESA-N	Launched	vitamin D receptor agonist	endocrinology	hyperparathyroidism
MBX-2982	GPR119	25025505	NFTMKHWBOINJGM-UHFFFAOYSA-N	Phase 2	glucose dependent insulinotropic receptor agonist	NA	NA
MC-1	AADAT	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	ABAT	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	AGXT	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	AGXT2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	ALAS1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	AZIN2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	BCAT1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	BCAT2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	CBS	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	CCBL1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	CCBL2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	CSAD	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	CTH	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	DDC	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	FTCD	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GAD1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GAD2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GADL1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GCAT	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GLDC	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GOT1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GOT2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GPT	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	GPT2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	HDC	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	IGSF10	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	KYNU	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	MOCOS	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	NFS1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	OAT	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	ODC1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PDXDC1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PDXP	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PHYKPL	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PNPO	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PROSC	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PSAT1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PYGB	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PYGL	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	PYGM	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SCLY	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SDS	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SDSL	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SEPSECS	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SGPL1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SHMT1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SHMT2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SPTLC1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SPTLC2	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SPTLC3	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	SRR	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	TAT	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MC-1	THNSL1	1051	NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3		NA	NA
MCC950	NLRP3	9910393	HUUSXLKCTQDPGL-UHFFFAOYSA-N	Preclinical	NOD like receptor inhibitor	NA	NA
MCOPPB	OPRL1	24800108	CYYNMPPFEJPBJD-OAQYLSRUSA-N	Preclinical	nociceptin/orphanin FQ receptor agonist	NA	NA
mCPP	HTR1A	1355	VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
mCPP	HTR1D	1355	VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
mCPP	HTR1E	1355	VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
mCPP	HTR2A	1355	VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
mCPP	HTR2B	1355	VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
mCPP	HTR2C	1355	VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
mCPP	HTR6	1355	VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
MC1568	HDAC2	71311876	QQDIFLSJMFDTCQ-FIFLTTCUSA-N	Preclinical	HDAC inhibitor	NA	NA
MD-920	AADACL2	6466	IXORZMNAPKEEDV-OBDJNFEBSA-N	Phase 1	NFkB pathway inhibitor	NA	NA
mdivi-1	DNM1	3825829	NZJKEVWTYMOYOR-UHFFFAOYSA-N	Preclinical	dynamin inhibitor	NA	NA
MDL-11939	HTR2A	76958673	AXNGJCOYCMDPQG-HXUWFJFHSA-N	Phase 2	serotonin receptor antagonist	NA	NA
MDL-11939	HTR2B	76958673	AXNGJCOYCMDPQG-HXUWFJFHSA-N	Phase 2	serotonin receptor antagonist	NA	NA
MDL-11939	HTR2C	76958673	AXNGJCOYCMDPQG-HXUWFJFHSA-N	Phase 2	serotonin receptor antagonist	NA	NA
MDL-29951	FBP1	446916	KNBSYZNKEAWABY-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
MDL-72832	HTR1A	6604720	HCVRCHQFYYZPHT-KRWDZBQOSA-N	Preclinical	serotonin receptor agonist	NA	NA
MDL-73005EF	HTR1A	6604719	BVMYCHKQPGEOSI-HNNXBMFYSA-N	Phase 1	serotonin receptor antagonist	NA	NA
ME-0328	PARP3	135566764	QIHBWVVVRYYYRO-ZDUSSCGKSA-N	Preclinical	PPAR receptor antagonist	NA	NA
mebendazole	TUBA1A	4030	OPXLLQIJSORQAM-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	pinworm|whipworm|hookworm|ascariasis
mebendazole	TUBB	4030	OPXLLQIJSORQAM-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	pinworm|whipworm|hookworm|ascariasis
mebendazole	TUBB4B	4030	OPXLLQIJSORQAM-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	pinworm|whipworm|hookworm|ascariasis
mebeverine	CHRM1	6604311	VYVKHNNGDFVQGA-IBGZPJMESA-N	Launched	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
mecamylamine	CHRNA1	46912050	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	cardiology	hypertension
mecamylamine	CHRNA2	46912050	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	cardiology	hypertension
mecamylamine	CHRNA3	46912050	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	cardiology	hypertension
mecamylamine	CHRNA4	46912050	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	cardiology	hypertension
mecamylamine	CHRNA6	46912050	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	cardiology	hypertension
mecamylamine	CHRNA7	46912050	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	cardiology	hypertension
mecamylamine	CHRNB4	46912050	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	cardiology	hypertension
meclinertant	NTSR1	119192	DYLJVOXRWLXDIG-UHFFFAOYSA-N	Phase 2/Phase 3	neurotensin receptor antagonist	NA	NA
meclinertant	NTSR2	119192	DYLJVOXRWLXDIG-UHFFFAOYSA-N	Phase 2/Phase 3	neurotensin receptor antagonist	NA	NA
meclizine	NR1I3	6604289	OCJYIGYOJCODJL-VWLOTQADSA-N	Launched	constitutive androstane receptor (CAR) agonist	gastroenterology|neurology/psychiatry	nausea|vomiting|motion sickness
meclofenamic-acid	ALOX5	4037	SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
meclofenamic-acid	CNR1	4037	SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
meclofenamic-acid	KCNQ2	4037	SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
meclofenamic-acid	KCNQ3	4037	SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
meclofenamic-acid	PTGS1	4037	SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
meclofenamic-acid	PTGS2	4037	SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
medetomidine	ADRA1A	60612	CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
medetomidine	ADRA1B	60612	CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
medetomidine	ADRA1D	60612	CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
medetomidine	ADRA2A	60612	CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
medetomidine	ADRA2B	60612	CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
medetomidine	ADRA2C	60612	CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	sedative
medica-16	FFAR1	121871	HYSMCRNFENOHJH-UHFFFAOYSA-N	Phase 2	ATP citrase lyase inhibitor	NA	NA
medroxyprogesterone	PGR	10631	FRQMUZJSZHZSGN-HBNHAYAOSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
medroxyprogesterone-acetate	ESR1	6279	PSGAAPLEWMOORI-PEINSRQWSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
medroxyprogesterone-acetate	PGR	6279	PSGAAPLEWMOORI-PEINSRQWSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
medrysone	NR3C1	247839	GZENKSODFLBBHQ-ILSZZQPISA-N	Launched	glucocorticoid receptor agonist	ophthalmology	conjunctivitis|episcleritis
mefenamic-acid	KCNQ1	4044	HYYBABOKPJLUIN-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	endocrinology	primary dysmenorrhea (PD)
mefenamic-acid	PTGS1	4044	HYYBABOKPJLUIN-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	endocrinology	primary dysmenorrhea (PD)
mefenamic-acid	PTGS2	4044	HYYBABOKPJLUIN-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	endocrinology	primary dysmenorrhea (PD)
mefenamic-acid	TRPM3	4044	HYYBABOKPJLUIN-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	endocrinology	primary dysmenorrhea (PD)
megestrol-acetate	NR3C1	11683	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	Launched	progesterone receptor agonist	neurology/psychiatry|endocrinology	anorexia|cachexia
megestrol-acetate	PGR	11683	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	Launched	progesterone receptor agonist	neurology/psychiatry|endocrinology	anorexia|cachexia
meglitinide	CCR2	41214	SWLAMJPTOQZTAE-UHFFFAOYSA-N	Phase 2	potassium channel blocker	NA	NA
meglutol	HMGCR	1662	NPOAOTPXWNWTSH-UHFFFAOYSA-N	Launched	HMGCR inhibitor	NA	NA
meisoindigo	STAT3	NA	QNOCRUSVMMAKSC-CCEZHUSRSA-N	Phase 3	STAT inhibitor	NA	NA
MEK1-2-inhibitor	MAP2K2	54483521	XQRVCODIGHFXKQ-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
melatonin	ASMT	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	CALM1	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	CALR	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	EPX	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	ESR1	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	HTR2B	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	MPO	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	MTNR1A	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	MTNR1B	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	NQO2	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
melatonin	RORB	896	DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
meldonium	BBOX1	123869	PVBQYTCFVWZSJK-UHFFFAOYSA-O	Launched	gamma butyrobetaine hydroxylase inhibitor	cardiology	coronary artery disease (CAD)
melevodopa	DDC	23497	XBBDACCLCFWBSI-ZETCQYMHSA-N	Launched	dopamine precursor|dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
meloxicam	PTGS1	54677470	ZRVUJXDFFKFLMG-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
meloxicam	PTGS2	54677470	ZRVUJXDFFKFLMG-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
melperone	DRD2	15387	DKMFBWQBDIGMHM-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	psychosis
melperone	HTR2A	15387	DKMFBWQBDIGMHM-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	psychosis
melphalan-n-oxide	HIF1A	11234795	GSKQMLGAUOTSKT-LBPRGKRZSA-N	Phase 1	hypoxia inducible factor inhibitor	NA	NA
menadione	AOX1	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	BGLAP	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	F10	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	F2	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	F7	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	F9	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	GGCX	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	NQO1	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	NQO2	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	PROC	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	PROS1	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	PROZ	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	VKORC1	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione	VKORC1L1	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
menadione-bisulfite	GGCX	1711949	WIXFIQKTHUVFDI-LLVKDONJSA-N	Phase 2	vitamin K	NA	NA
menadione-bisulfite	VKORC1	1711949	WIXFIQKTHUVFDI-LLVKDONJSA-N	Phase 2	vitamin K	NA	NA
menadione-bisulfite	VKORC1L1	1711949	WIXFIQKTHUVFDI-LLVKDONJSA-N	Phase 2	vitamin K	NA	NA
mepacrine	PLA2G1B	446536	GPKJTRJOBQGKQK-MRXNPFEDSA-N	Launched	cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator	infectious disease	giardiasis
mepazine	MALT1	7047378	CBHCDHNUZWWAPP-OAHLLOKOSA-N	Phase 2	MALT1 inhibitor (JH)	NA	NA
mephentermine	ADRA1A	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRA1B	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRA1D	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRA2A	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRA2B	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRA2C	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRB1	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRB2	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephentermine	ADRB3	3677	RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
mephenytoin	SCN5A	107921	GMHKMTDVRCWUDX-LBPRGKRZSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
meprednisone	NR3C1	5284587	PIDANAQULIKBQS-RNUIGHNZSA-N	Launched		NA	NA
meptazinol	BCHE	25271754	JLICHNCFTLFZJN-OAHLLOKOSA-N	Launched	opioid receptor agonist	neurology/psychiatry	pain relief
mepyramine	HRH1	4992	YECBIJXISLIIDS-UHFFFAOYSA-N	Launched	histamine receptor antagonist	otolaryngology|obstetrics/gynecology	common cold|menstrual pain
mequinol	TYR	9015	NWVVVBRKAWDGAB-UHFFFAOYSA-N	Launched		dermatology	skin depigmentation
merbarone	TOP2A	3000671	GFYRZTLCYQQVHZ-UHFFFAOYSA-N	Phase 2	topoisomerase inhibitor	NA	NA
mercaptopurine	HPRT1	667490	GLVAUDGFNGKCSF-UHFFFAOYSA-N	Launched	immunosuppressant|protein synthesis inhibitor|purine antagonist	hematologic malignancy	acute lymphoblastic leukemia (ALL)
mercaptopurine	IMPDH1	667490	GLVAUDGFNGKCSF-UHFFFAOYSA-N	Launched	immunosuppressant|protein synthesis inhibitor|purine antagonist	hematologic malignancy	acute lymphoblastic leukemia (ALL)
mercaptopurine	IMPDH2	667490	GLVAUDGFNGKCSF-UHFFFAOYSA-N	Launched	immunosuppressant|protein synthesis inhibitor|purine antagonist	hematologic malignancy	acute lymphoblastic leukemia (ALL)
mercaptopurine	PPAT	667490	GLVAUDGFNGKCSF-UHFFFAOYSA-N	Launched	immunosuppressant|protein synthesis inhibitor|purine antagonist	hematologic malignancy	acute lymphoblastic leukemia (ALL)
Merck60	HDAC1	6918878	ABZSPJVXTTUFAA-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
Merck60	HDAC2	6918878	ABZSPJVXTTUFAA-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
merimepodib	IMPDH1	153241	JBPUGFODGPKTDW-SFHVURJKSA-N	Phase 2	inosine monophosphate dehydrogenase inhibitor	NA	NA
mesalazine	ALOX5	4075	KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology	ulcerative colitis|inflammatory bowel disease
mesalazine	CHUK	4075	KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology	ulcerative colitis|inflammatory bowel disease
mesalazine	IKBKB	4075	KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology	ulcerative colitis|inflammatory bowel disease
mesalazine	MPO	4075	KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology	ulcerative colitis|inflammatory bowel disease
mesalazine	PPARG	4075	KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology	ulcerative colitis|inflammatory bowel disease
mesalazine	PTGS1	4075	KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology	ulcerative colitis|inflammatory bowel disease
mesalazine	PTGS2	4075	KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology	ulcerative colitis|inflammatory bowel disease
mesoridazine	DRD2	57146948	SLVMESMUVMCQIY-AKJBCIBTSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
mesoridazine	HTR2A	57146948	SLVMESMUVMCQIY-AKJBCIBTSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
mestinon	ACHE	4991	RVOLLAQWKVFTGE-UHFFFAOYSA-N	Launched	cholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
mestinon	BCHE	4991	RVOLLAQWKVFTGE-UHFFFAOYSA-N	Launched	cholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
mestranol	ESR1	6291	IMSSROKUHAOUJS-MJCUULBUSA-N	Launched	estrogen receptor agonist	endocrinology	contraceptive
mesulergine	HTR2A	68848	JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	dopamine receptor agonist	NA	NA
mesulergine	HTR2B	68848	JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	dopamine receptor agonist	NA	NA
mesulergine	HTR2C	68848	JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	dopamine receptor agonist	NA	NA
mesulergine	HTR3A	68848	JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	dopamine receptor agonist	NA	NA
mesulergine	HTR3B	68848	JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	dopamine receptor agonist	NA	NA
mesulergine	HTR6	68848	JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	dopamine receptor agonist	NA	NA
mesulergine	HTR7	68848	JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	dopamine receptor agonist	NA	NA
metacresol	INS	342	RLSSMJSEOOYNOY-UHFFFAOYSA-N	Launched		NA	NA
metamizole	PTGS1	3111	LVWZTYCIRDMTEY-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor|opioid receptor agonist	NA	NA
metaproterenol	ADRB2	25271693	LMOINURANNBYCM-LLVKDONJSA-N	Launched	adrenergic receptor agonist	pulmonary	bronchospasm|asthma|bronchitis|emphysema
metaraminol	ADRA1A	5906	WXFIGDLSSYIKKV-RCOVLWMOSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
metatinib	ABL1	44155856	PDYXPCKITKHFOZ-UHFFFAOYSA-N	Phase 1	Bcr-Abl kinase inhibitor	NA	NA
metatinib	BCR	44155856	PDYXPCKITKHFOZ-UHFFFAOYSA-N	Phase 1	Bcr-Abl kinase inhibitor	NA	NA
metazosin	ADRA1A	51057264	YEOTYALSMRNXLJ-NSHDSACASA-N	Phase 2	adrenergic receptor antagonist	NA	NA
metenkephalin	OPRD1	73265283	YFGBQHOOROIVKG-BHDDXSALSA-N	Phase 2	immunostimulant	NA	NA
metergoline	HTR1A	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR1B	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR1D	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR1E	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR1F	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR2A	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR2B	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR2C	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR5A	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR6	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metergoline	HTR7	28693	WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia
metformin	ACACB	4091	XZWYZXLIPXDOLR-UHFFFAOYSA-N	Launched	insulin sensitizer	endocrinology	diabetes mellitus
metformin	PRKAB1	4091	XZWYZXLIPXDOLR-UHFFFAOYSA-N	Launched	insulin sensitizer	endocrinology	diabetes mellitus
methacholine	CHRM2	6603706	NZWOPGCLSHLLPA-ZETCQYMHSA-N	Launched	acetylcholine receptor agonist	pulmonary	bronchial hyperresponsiveness diagnostic
methacholine	CHRM4	6603706	NZWOPGCLSHLLPA-ZETCQYMHSA-N	Launched	acetylcholine receptor agonist	pulmonary	bronchial hyperresponsiveness diagnostic
methanesulfonyl-fluoride	ACHE	11207	KNWQLFOXPQZGPX-UHFFFAOYSA-N	Phase 2	acetylcholinesterase inhibitor	NA	NA
methantheline	CHRM1	4097	GZHFODJQISUKAY-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology|neurology/psychiatry|urology	peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder
methantheline	HRH2	4097	GZHFODJQISUKAY-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology|neurology/psychiatry|urology	peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder
methapyrilene	HRH1	4098	HNJJXZKZRAWDPF-UHFFFAOYSA-N	Withdrawn	histamine receptor antagonist	NA	NA
metharbital	CHRNA4	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	CHRNA7	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRA1	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRA2	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRA3	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRA4	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRA5	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRA6	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRB1	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRB2	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRB3	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRD	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRE	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRG1	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRG2	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRG3	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRP	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GABRQ	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GRIA2	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
metharbital	GRIK2	4099	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	GABA receptor modulator	neurology/psychiatry	epilepsy
methazolamide	CA1	4100	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma|intraocular pressure
methazolamide	CA12	4100	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma|intraocular pressure
methazolamide	CA14	4100	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma|intraocular pressure
methazolamide	CA2	4100	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma|intraocular pressure
methazolamide	CA4	4100	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma|intraocular pressure
methazolamide	CA7	4100	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	ophthalmology	glaucoma|intraocular pressure
methimazole	TPO	1349907	PMRYVIKBURPHAH-UHFFFAOYSA-N	Launched	antithyroid agent	endocrinology	hyperthyroidism
methionine	METAP2	84815	FFEARJCKVFRZRR-SCSAIBSYSA-N	Launched		NA	NA
methiopril	ACE	667560	JHFOAISYWJRTIM-PSASIEDQSA-N	Phase 2	angiotensin converting enzyme inhibitor	NA	NA
methocarbamol	CA1	688484	GNXFOGHNGIVQEH-MRVPVSSYSA-N	Launched	muscle relaxant	neurology/psychiatry	muscle relaxant
methotrexate	DHFR	126941	FBOZXECLQNJBKD-ZDUSSCGKSA-N	Launched	dihydrofolate reductase inhibitor	oncology|hematologic malignancy|dermatology|rheumatology	gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis
methoxamine	ADRA1A	657286	WJAJPNHVVFWKKL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
methoxamine	ADRA1B	657286	WJAJPNHVVFWKKL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
methoxamine	ADRA1D	657286	WJAJPNHVVFWKKL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	cardiology	hypotension
methoxsalen	CYP1A1	4114	QXKHYNVANLEOEG-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	dermatology	psoriasis
methoxsalen	CYP1A2	4114	QXKHYNVANLEOEG-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	dermatology	psoriasis
methoxsalen	CYP2A13	4114	QXKHYNVANLEOEG-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	dermatology	psoriasis
methoxsalen	CYP2A6	4114	QXKHYNVANLEOEG-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	dermatology	psoriasis
methoxsalen	CYP3A4	4114	QXKHYNVANLEOEG-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	dermatology	psoriasis
methoxyamine	APEX1	4113	GMPKIPWJBDOURN-UHFFFAOYSA-N	Phase 2	DNA repair enzyme inhibitor	NA	NA
methoxyflurane	ATP2C1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	ATP5D	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRA1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRA2	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRA3	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRA4	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRA5	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRA6	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRB1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRB2	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRB3	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRD	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRE	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRG1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRG2	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRG3	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRP	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GABRQ	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GLRA1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GLRB	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	GRIA1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	KCNA1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyflurane	MT-ND1	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methscopolamine	CHRM1		LZCOQTDXKCNBEE-IKIFYQGPSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
methscopolamine	CHRM2		LZCOQTDXKCNBEE-IKIFYQGPSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
methscopolamine	CHRM3		LZCOQTDXKCNBEE-IKIFYQGPSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
methsuximide	CACNA1G	25271978	AJXPJJZHWIXJCJ-GFCCVEGCSA-N	Launched	T-type calcium channel blocker	neurology/psychiatry	seizures
methsuximide	CACNA1H	25271978	AJXPJJZHWIXJCJ-GFCCVEGCSA-N	Launched	T-type calcium channel blocker	neurology/psychiatry	seizures
methsuximide	CACNA1I	25271978	AJXPJJZHWIXJCJ-GFCCVEGCSA-N	Launched	T-type calcium channel blocker	neurology/psychiatry	seizures
methyclothiazide	SLC12A1	12309469	CESYKOGBSMNBPD-VIFPVBQESA-N	Launched	chloride reabsorption inhibitor	cardiology	hypertension|edema
methyclothiazide	SLC12A3	12309469	CESYKOGBSMNBPD-VIFPVBQESA-N	Launched	chloride reabsorption inhibitor	cardiology	hypertension|edema
methyl-aminolevulinate	FCGR1A	157922	YUUAYBAIHCDHHD-UHFFFAOYSA-N	Launched	oxidizing agent	dermatology	actinic keratosis (AK)
methyl-aminolevulinate	FECH	157922	YUUAYBAIHCDHHD-UHFFFAOYSA-N	Launched	oxidizing agent	dermatology	actinic keratosis (AK)
methylatropine-nitrate	CHRM1	NA	PIPAJLPNWZMYQA-HZMVEIRTSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
methyldopa	ADRA2A	6919173	CJCSPKMFHVPWAR-JTQLQIEISA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
methyldopa	ADRA2B	6919173	CJCSPKMFHVPWAR-JTQLQIEISA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
methyldopa	ADRA2C	6919173	CJCSPKMFHVPWAR-JTQLQIEISA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
methyldopa	DDC	6919173	CJCSPKMFHVPWAR-JTQLQIEISA-N	Launched	adrenergic receptor agonist	cardiology	hypertension
methylene-blue	ACHE	4139	RBTBFTRPCNLSDE-UHFFFAOYSA-N	Launched	guanylyl cyclase inhibitor|nitric oxide production inhibitor	hematology	methemoglobinemia
methylergometrine	DRD1	8226	UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache
methylergometrine	HTR1E	8226	UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache
methylergometrine	HTR1F	8226	UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache
methylergometrine	HTR2A	8226	UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache
methylergometrine	HTR2B	8226	UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache
methylergometrine	HTR2C	8226	UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache
methyllycaconitine	CHRNA7	5288811	XLTANAWLDBYGFU-VTLKBQQISA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
methylnaltrexone	OPRD1	16089915	JVLBPIPGETUEET-WIXLDOGYSA-O	Launched	opioid receptor antagonist	gastroenterology	constipation
methylnaltrexone	OPRK1	16089915	JVLBPIPGETUEET-WIXLDOGYSA-O	Launched	opioid receptor antagonist	gastroenterology	constipation
methylnaltrexone	OPRM1	16089915	JVLBPIPGETUEET-WIXLDOGYSA-O	Launched	opioid receptor antagonist	gastroenterology	constipation
methylprednisolone	NR3C1	6741	VHRSUDSXCMQTMA-PJHHCJLFSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology	hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis
methylprednisolone-aceponate	NR3C1	63019	DALKLAYLIPSCQL-YPYQNWSCSA-N	Launched	anti-inflammatory agent|glucocorticoid receptor agonist	endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology	congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia
methysergide	HTR1B	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR1D	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR1E	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR1F	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR2A	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR2B	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR2C	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR5A	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR6	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
methysergide	HTR7	9681	KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	headache
metirosine	TH	6918925	NHTGHBARYWONDQ-JTQLQIEISA-N	Launched	tyrosine hydroxylase inhibitor	cardiology	hypertension
metitepine	HTR1A	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR1B	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR1D	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR1E	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR1F	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR2A	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR2B	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR2C	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR5A	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR6	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metitepine	HTR7	969502	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	anti-HCVE2	NA	NA
metixene	CHRM5	6604302	MJFJKKXQDNNUJF-HNNXBMFYSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
metoclopramide	CHRM1	4168	TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	gastroenterology	gastroparesis|nausea|vomiting
metoclopramide	DRD2	4168	TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	gastroenterology	gastroparesis|nausea|vomiting
metoclopramide	HTR3A	4168	TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	gastroenterology	gastroparesis|nausea|vomiting
metoclopramide	HTR3B	4168	TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	gastroenterology	gastroparesis|nausea|vomiting
metoclopramide	HTR4	4168	TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	gastroenterology	gastroparesis|nausea|vomiting
metocurine	CHRM2	21233	JFXBEKISTKFVAB-AJQTZOPKSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
metocurine	CHRNA2	21233	JFXBEKISTKFVAB-AJQTZOPKSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
metolazone	SLC12A3	28125490	AQCHWTWZEMGIFD-JTQLQIEISA-N	Launched	carbonic anhydrase inhibitor	cardiology	edema|hypertension
metoprolol	ADRB1	157716	IUBSYMUCCVWXPE-AWEZNQCLSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension|angina pectoris|myocardial infarction
metoprolol	ADRB2	157716	IUBSYMUCCVWXPE-AWEZNQCLSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension|angina pectoris|myocardial infarction
metoxibutropate	PTGS1	836891	FVRWRGBTEHAPDI-HNNXBMFYSA-N	Launched	cyclooxygenase inhibitor	NA	NA
metoxibutropate	PTGS2	836891	FVRWRGBTEHAPDI-HNNXBMFYSA-N	Launched	cyclooxygenase inhibitor	NA	NA
metrifonate	ACHE	6604183	NFACJZMKEDPNKN-GSVOUGTGSA-N	Phase 3	acetylcholinesterase inhibitor	NA	NA
metronidazole	CYP2C9	4173	VAOCPAMSLUNLGC-UHFFFAOYSA-N	Launched	DNA inhibitor	dermatology	rosacea
metronidazole	CYP3A4	4173	VAOCPAMSLUNLGC-UHFFFAOYSA-N	Launched	DNA inhibitor	dermatology	rosacea
metyrapone	CYP11B1	4174	FJLBFSROUSIWMA-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor	nephrology	adrenal diagnostic agent
mevastatin	HMGCR	64715	AJLFOPYRIVGYMJ-INTXDZFKSA-N	Preclinical	HMGCR inhibitor	NA	NA
mexiletine	PLAU	180621	VLPIATFUUWWMKC-SNVBAGLBSA-N	Launched	sodium channel blocker	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)
mexiletine	SCN4A	180621	VLPIATFUUWWMKC-SNVBAGLBSA-N	Launched	sodium channel blocker	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)
mexiletine	SCN5A	180621	VLPIATFUUWWMKC-SNVBAGLBSA-N	Launched	sodium channel blocker	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)
ME0328	PARP3	136229577	QIHBWVVVRYYYRO-CYBMUJFWSA-N	Preclinical	PARP inhibitor	NA	NA
MF-101	CYP19A1	114829	FURUXTVZLHCCNA-AWEZNQCLSA-N	Phase 3	estrogen receptor agonist	NA	NA
MF-101	XDH	114829	FURUXTVZLHCCNA-AWEZNQCLSA-N	Phase 3	estrogen receptor agonist	NA	NA
MG-132	PSMB1	462382	TZYWCYJVHRLUCT-VABKMULXSA-N	Preclinical	proteasome inhibitor	NA	NA
MG-624	CHRNA7	5824382	YIMFXBPXUPTIEJ-OUKQBFOZSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
MGCD-265	AXL	24901704	UFICVEHDQUKCEA-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
MGCD-265	MET	24901704	UFICVEHDQUKCEA-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
MI-14	PI4KB	91758319	PSTAJIONBVMKLA-UHFFFAOYSA-N	Preclinical	PI4K inhibitor	NA	NA
mianserin	ADRA1A	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	ADRA1B	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	ADRA1D	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	HRH1	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	HRH2	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	HTR2A	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	HTR2B	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	HTR2C	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	HTR6	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mianserin	HTR7	68551	UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	depression
mibampator	GRIA1	9889366	ULRDYYKSPCRXAJ-KRWDZBQOSA-N	Phase 2	glutamate receptor modulator	NA	NA
mibefradil	ANO1	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNA1C	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNA1D	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNA1F	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNA1G	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNA1H	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNA1I	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNA1S	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNB1	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNB2	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNB3	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CACNB4	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CATSPER1	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CATSPER2	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CATSPER3	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
mibefradil	CATSPER4	60663	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	T-type calcium channel blocker	NA	NA
miconazole	TRPM2	1150344	BYBLEWFAAKGYCD-SFHVURJKSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|neurology/psychiatry	yeast infection|itching
miconazole	TRPV5	1150344	BYBLEWFAAKGYCD-SFHVURJKSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|neurology/psychiatry	yeast infection|itching
midafotel	GRIN2A	6435801	VZXMZMJSGLFKQI-ABVWVHJUSA-N	Phase 3	glutamate receptor antagonist	NA	NA
midafotel	GRIN2B	6435801	VZXMZMJSGLFKQI-ABVWVHJUSA-N	Phase 3	glutamate receptor antagonist	NA	NA
midafotel	GRIN2C	6435801	VZXMZMJSGLFKQI-ABVWVHJUSA-N	Phase 3	glutamate receptor antagonist	NA	NA
midafotel	GRIN2D	6435801	VZXMZMJSGLFKQI-ABVWVHJUSA-N	Phase 3	glutamate receptor antagonist	NA	NA
midostaurin	FLT3	9829523	BMGQWWVMWDBQGC-IIFHNQTCSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PKC inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
midostaurin	PRKCG	9829523	BMGQWWVMWDBQGC-IIFHNQTCSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PKC inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
mifepristone	AR	55245	VKHAHZOOUSRJNA-GCNJZUOMSA-N	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	endocrinology	hyperglycemia|diabetes mellitus
mifepristone	NR1I2	55245	VKHAHZOOUSRJNA-GCNJZUOMSA-N	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	endocrinology	hyperglycemia|diabetes mellitus
mifepristone	NR3C1	55245	VKHAHZOOUSRJNA-GCNJZUOMSA-N	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	endocrinology	hyperglycemia|diabetes mellitus
mifepristone	PGR	55245	VKHAHZOOUSRJNA-GCNJZUOMSA-N	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	endocrinology	hyperglycemia|diabetes mellitus
mifobate	PPARG	76958126	VQHUQHAPWMNBLP-LLVKDONJSA-N	Phase 2	PPAR receptor antagonist	NA	NA
miglitol	GAA	441314	IBAQFPQHRJAVAV-ULAWRXDQSA-N	Launched	glucosidase inhibitor	endocrinology	diabetes mellitus
miglitol	GANAB	441314	IBAQFPQHRJAVAV-ULAWRXDQSA-N	Launched	glucosidase inhibitor	endocrinology	diabetes mellitus
miglitol	GANC	441314	IBAQFPQHRJAVAV-ULAWRXDQSA-N	Launched	glucosidase inhibitor	endocrinology	diabetes mellitus
miglitol	MGAM	441314	IBAQFPQHRJAVAV-ULAWRXDQSA-N	Launched	glucosidase inhibitor	endocrinology	diabetes mellitus
miglustat	UGCG	51634	UQRORFVVSGFNRO-UTINFBMNSA-N	Launched	glycosyl transferase inhibitor	hematology	Gaucher disease
milacemide	MAOB	53569	GJNNXIYZWIZFRH-UHFFFAOYSA-N	Phase 3	monoamine oxidase inhibitor	NA	NA
milnacipran	SLC6A2	6917779	GJJFMKBJSRMPLA-DZGCQCFKSA-N	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	rheumatology	fibromyalgia
milnacipran	SLC6A4	6917779	GJJFMKBJSRMPLA-DZGCQCFKSA-N	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	rheumatology	fibromyalgia
milrinone	PDE2A	4197	PZRHRDRVRGEVNW-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
milrinone	PDE3A	4197	PZRHRDRVRGEVNW-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
milrinone	PDE3B	4197	PZRHRDRVRGEVNW-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
milrinone	PDE5A	4197	PZRHRDRVRGEVNW-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
miltefosine	PLA2G1B	3600	PQLXHQMOHUQAKB-UHFFFAOYSA-O	Launched	membrane integrity inhibitor	infectious disease	leishmaniasis
mimosine	CCL2	6971294	WZNJWVWKTVETCG-YFKPBYRVSA-N	Preclinical	DNA replication inhibitor	NA	NA
mimosine	SHMT1	6971294	WZNJWVWKTVETCG-YFKPBYRVSA-N	Preclinical	DNA replication inhibitor	NA	NA
mimosine	SHMT2	6971294	WZNJWVWKTVETCG-YFKPBYRVSA-N	Preclinical	DNA replication inhibitor	NA	NA
mimosine	TYR	6971294	WZNJWVWKTVETCG-YFKPBYRVSA-N	Preclinical	DNA replication inhibitor	NA	NA
minaprine	ACHE	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	CHRM1	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	DRD1	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	DRD2	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	HTR2A	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	HTR2B	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	HTR2C	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	MAOA	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minaprine	SLC6A4	4199	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	serotonin reuptake inhibitor	NA	NA
minodronic-acid	FDPS	130956	VMMKGHQPQIEGSQ-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
minodronic-acid	GGPS1	130956	VMMKGHQPQIEGSQ-UHFFFAOYSA-N	Launched	bone resorption inhibitor	orthopedics	osteoporosis
minoxidil	ABCC9		ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	endocrinology	androgenetic alopecia
minoxidil	KCNJ1		ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	endocrinology	androgenetic alopecia
minoxidil	KCNJ10		ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	endocrinology	androgenetic alopecia
minoxidil	KCNJ11		ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	endocrinology	androgenetic alopecia
minoxidil	KCNJ8		ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	endocrinology	androgenetic alopecia
minoxidil	PTGS1		ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	endocrinology	androgenetic alopecia
mirabegron	ADRB1	9865528	PBAPPPCECJKMCM-IBGZPJMESA-N	Launched	adrenergic receptor agonist	urology	urinary incontinence
mirabegron	ADRB2	9865528	PBAPPPCECJKMCM-IBGZPJMESA-N	Launched	adrenergic receptor agonist	urology	urinary incontinence
mirabegron	ADRB3	9865528	PBAPPPCECJKMCM-IBGZPJMESA-N	Launched	adrenergic receptor agonist	urology	urinary incontinence
mirin	MRE11A	137319711	"InChI=1S/C10H8N2O2S/c11-10-12-9(14)8(15-10)5-6-1-3-7(13)4-2-6/h1-5,13H,(H2,11,12,14)/b8-5-"	Preclinical	MRE11A exonuclease inhibitor	NA	NA
mirodenafil	PDE5A	135497803	MIJFNYMSCFYZNY-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
mirtazapine	ADRA2A	3085219	RONZAEMNMFQXRA-INIZCTEOSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	depression
mirtazapine	ADRA2B	3085219	RONZAEMNMFQXRA-INIZCTEOSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	depression
mirtazapine	ADRA2C	3085219	RONZAEMNMFQXRA-INIZCTEOSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	depression
mirtazapine	HTR2A	3085219	RONZAEMNMFQXRA-INIZCTEOSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	depression
mirtazapine	HTR2C	3085219	RONZAEMNMFQXRA-INIZCTEOSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	depression
misoprostol	PTGER2	5282381	OJLOPKGSLYJEMD-URPKTTJQSA-N	Launched	prostanoid receptor agonist	gastroenterology	duodenal ulcer disease
misoprostol	PTGER3	5282381	OJLOPKGSLYJEMD-URPKTTJQSA-N	Launched	prostanoid receptor agonist	gastroenterology	duodenal ulcer disease
misoprostol	PTGER4	5282381	OJLOPKGSLYJEMD-URPKTTJQSA-N	Launched	prostanoid receptor agonist	gastroenterology	duodenal ulcer disease
misoprostol	PTGIR	5282381	OJLOPKGSLYJEMD-URPKTTJQSA-N	Launched	prostanoid receptor agonist	gastroenterology	duodenal ulcer disease
mitiglinide	ABCC8	121891	WPGGHFDDFPHPOB-BBWFWOEESA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
mitiglinide	KCNJ10	121891	WPGGHFDDFPHPOB-BBWFWOEESA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
mitiglinide	PPARG	121891	WPGGHFDDFPHPOB-BBWFWOEESA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
mitoflaxone	VWF	55748	TZZNWMJZDWYJAZ-UHFFFAOYSA-N	Phase 2	antitumor agent	NA	NA
mitotane	CYP11A1	6603772	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	Launched	antineoplastic agent	oncology	adrenal cortical carcinoma
mitotane	CYP11B1	6603772	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	Launched	antineoplastic agent	oncology	adrenal cortical carcinoma
mitotane	ESR1	6603772	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	Launched	antineoplastic agent	oncology	adrenal cortical carcinoma
mitoxantrone	TOP2A	4212	KKZJGLLVHKMTCM-UHFFFAOYSA-N	Launched	topoisomerase inhibitor	neurology/psychiatry|oncology|hematologic malignancy	multiple sclerosis|prostate cancer|acute myeloid leukemia (AML)
mivacurium	CHRNA2	22839211	ILVYCEVXHALBSC-GZICNWBJSA-N	Launched	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant
mizolastine	HRH1	65906	PVLJETXTTWAYEW-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy	urticaria|allergic rhinitis
mizoribine	IMPDH1	11949547	OPMVDWXPLVKNQN-AAXBYFMASA-N	Launched	immunosuppressant|inosine monophosphate dehydrogenase inhibitor	transplant|rheumatology	organ rejection|nephrotic syndrome
MJ-15	CNR1	59377482	PJEIKJFNEFJFLA-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
MK-0354	HCAR2	11159621	LTQYSJKGRPGMPO-UHFFFAOYSA-N	Phase 2	niacin receptor agonist	NA	NA
MK-0354	HCAR3	11159621	LTQYSJKGRPGMPO-UHFFFAOYSA-N	Phase 2	niacin receptor agonist	NA	NA
MK-0773	AR	11950726	GBEUKTWTUSPHEE-JWJWXJQQSA-N	Phase 2	androgen receptor modulator	NA	NA
MK-0812	CCR2	11180808	MTMDXAIUENDNDL-RJSMDTJLSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
MK-0893	GCGR	11570626	DNTVJEMGHBIUMW-IBGZPJMESA-N	Phase 2	glucagon receptor antagonist	NA	NA
MK-1775	WEE1	24856436	"InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)"	Phase 2	WEE1 kinase inhibitor	NA	NA
MK-2206	AKT1	24964624	"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)"	Phase 2	AKT inhibitor	NA	NA
MK-2206	AKT2	24964624	"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)"	Phase 2	AKT inhibitor	NA	NA
MK-2206	AKT3	24964624	"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)"	Phase 2	AKT inhibitor	NA	NA
MK-2295	TRPV1	11247522	VTANGSDRFFLTSQ-UHFFFAOYSA-N	Phase 2	TRPV antagonist	NA	NA
MK-2461	FGFR1	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	FGFR2	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	FGFR3	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	FLT1	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	FLT3	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	FLT4	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	KDR	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	MERTK	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	MET	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	MST1R	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	NTRK1	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	NTRK2	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2461	PDGFRB	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	NA	NA
MK-2894	PTGER4	24952929	QJZQFVRFJCGDKF-UHFFFAOYSA-N	Preclinical	prostaglandin inhibitor	NA	NA
MK-3207	CALCA	25019940	AZAANWYREOQRFB-SETSBSEESA-N	Phase 2	calcitonin antagonist	NA	NA
MK-3697	HCRTR2	46190695	VSOUDUXMPUHJEU-UHFFFAOYSA-N	Phase 2	orexin receptor antagonist	NA	NA
MK-5046	BRS3	49871766	UJINBEQCDMOAHM-SFHVURJKSA-N	Preclinical	bombesin receptor agonist	NA	NA
MK-5046	GRPR	49871766	UJINBEQCDMOAHM-SFHVURJKSA-N	Preclinical	bombesin receptor agonist	NA	NA
MK-5046	NMBR	49871766	UJINBEQCDMOAHM-SFHVURJKSA-N	Preclinical	bombesin receptor agonist	NA	NA
MK-5108	AURKA	NA	LCVIRAZGMYMNNT-VVONHTQRSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
MK-5108	AURKB	NA	LCVIRAZGMYMNNT-VVONHTQRSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
MK-5108	AURKC	NA	LCVIRAZGMYMNNT-VVONHTQRSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
MK-571	ABCC2	14325224	AXUZQJFHDNNPFG-JORPFSLRSA-N	Phase 2	leukotriene receptor antagonist	NA	NA
MK-571	CYSLTR1	14325224	AXUZQJFHDNNPFG-JORPFSLRSA-N	Phase 2	leukotriene receptor antagonist	NA	NA
MK-6096	HCRTR1	25128145	NPFDWHQSDBWQLH-QZTJIDSGSA-N	Phase 2	orexin receptor antagonist	NA	NA
MK-6096	HCRTR2	25128145	NPFDWHQSDBWQLH-QZTJIDSGSA-N	Phase 2	orexin receptor antagonist	NA	NA
MK-8033	MET	45142457	VMJFTOSOFDEKTM-UHFFFAOYSA-N	Phase 1	c-Met inhibitor	NA	NA
MK-8245	SCD	24988881	UJEAABFSXKCSGI-UHFFFAOYSA-N	Phase 2	stearoyl-CoA desaturase inhibitor	NA	NA
MK-8745	AURKA	11676373	YCRFPWKUUNKNDN-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
MK2-IN-1	MAPKAPK2	53475321	LIPNXDIBECKOMJ-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
MLN0128	MTOR	45375953	GYLDXIAOMVERTK-UHFFFAOYSA-N	Phase 2	mTOR inhibitor	NA	NA
MLN0128	PIK3CA	45375953	GYLDXIAOMVERTK-UHFFFAOYSA-N	Phase 2	mTOR inhibitor	NA	NA
MLN0128	PIK3CD	45375953	GYLDXIAOMVERTK-UHFFFAOYSA-N	Phase 2	mTOR inhibitor	NA	NA
MLN0128	PIK3CG	45375953	GYLDXIAOMVERTK-UHFFFAOYSA-N	Phase 2	mTOR inhibitor	NA	NA
MLN1117	PIK3CA	70798655	BLGWHBSBBJNKJO-UHFFFAOYSA-N	Phase 2	PI3K inhibitor	NA	NA
MLN8054	AURKA	11712649	HHFBDROWDBDFBR-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
ML10302	HTR3A	5311299	RVFIAQAAZUEPPE-UHFFFAOYSA-N	Preclinical	serotonin receptor partial agonist	NA	NA
ML10302	HTR3B	5311299	RVFIAQAAZUEPPE-UHFFFAOYSA-N	Preclinical	serotonin receptor partial agonist	NA	NA
ML10302	HTR4	5311299	RVFIAQAAZUEPPE-UHFFFAOYSA-N	Preclinical	serotonin receptor partial agonist	NA	NA
ML141	CDC42	7454812	QBNZBMVRFYREHK-JOCHJYFZSA-N	Preclinical	GTPase inhibitor	NA	NA
ML167	CLK4	44968231	ROCFOIBAEVAOLQ-UHFFFAOYSA-N	Preclinical	CLK inhibitor|DYRK inhibitor	NA	NA
ML167	DYRK1B	44968231	ROCFOIBAEVAOLQ-UHFFFAOYSA-N	Preclinical	CLK inhibitor|DYRK inhibitor	NA	NA
ML179	NR5A2	45100448	MFABFKUNLDYKGH-UHFFFAOYSA-N	Preclinical	liver receptor homolog inverse agonist	NA	NA
ML193	GPR55	1261822	HTSLEZOTMYUPLU-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor antagonist	NA	NA
ML204	TRPC4	230710	USYRQXDHKXGTCK-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
ML204	TRPC5	230710	USYRQXDHKXGTCK-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
ML213	KCNQ4	1219187	SIQGKPGBLYKQBB-RRFJBIMHSA-N	Preclinical	potassium channel activator	NA	NA
ML218	CACNA1G	NA	GSJIGYLGKSBYBC-OSYLJGHBSA-N	Preclinical	T-type calcium channel blocker	NA	NA
ML218	CACNA1H	NA	GSJIGYLGKSBYBC-OSYLJGHBSA-N	Preclinical	T-type calcium channel blocker	NA	NA
ML218	CACNA1I	NA	GSJIGYLGKSBYBC-OSYLJGHBSA-N	Preclinical	T-type calcium channel blocker	NA	NA
ML228	HIF1A	46742353	"InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32)"	Preclinical	hypoxia inducible factor activator	NA	NA
ML277	KCNQ1	53347902	OXQNLLVUVDAEHC-OAQYLSRUSA-N	Preclinical	potassium channel activator	NA	NA
ML281	STK33	53377448	HWOYIOLMBQSTQS-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
ML297	KCNJ3	56642816	"InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24)"	Preclinical	inward rectifier potassium channel activator	NA	NA
ML298	PLD2	53393916	XAPVAKKLQGLNOY-UHFFFAOYSA-N	Preclinical	phospholipase inhibitor	NA	NA
ML314	NTSR1	53245590	SWEOAXMICIJCQC-UHFFFAOYSA-N	Preclinical	neurotensin agonist	NA	NA
ML323	USP1	60167849	VUIRVWPJNKZOSS-UHFFFAOYSA-N	Preclinical	ubiquitin specific protease inhibitor	NA	NA
ML324	KDM4A	44143209	QDBVSOZTVKXUES-UHFFFAOYSA-N	Preclinical	histone lysine demethylase inhibitor	NA	NA
ML3403	CYP3A4	10938334	VXPWQNBKEIVYIS-HNNXBMFYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
ML3403	MAPK11	10938334	VXPWQNBKEIVYIS-HNNXBMFYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
ML3403	MAPK12	10938334	VXPWQNBKEIVYIS-HNNXBMFYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
ML3403	MAPK14	10938334	VXPWQNBKEIVYIS-HNNXBMFYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
ML347	ACVR1	44577753	FVRYPYDPKSZGNS-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
ML347	ACVRL1	44577753	FVRYPYDPKSZGNS-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
ML347	BMPR1A	44577753	FVRYPYDPKSZGNS-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
ML348	LYPLA1	3238952	OXKNHBBDOIMFFQ-UHFFFAOYSA-N	Preclinical	lysophospholipase inhibitor	NA	NA
ML365	KCNK3	46785920	UTAJHKSGYJSZBR-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
ML365	KCNK9	46785920	UTAJHKSGYJSZBR-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
ML786	BRAF	50992247	GXEGTVQATHKFDH-OAQYLSRUSA-N	Preclinical	RAF inhibitor	NA	NA
ML786	RAF1	50992247	GXEGTVQATHKFDH-OAQYLSRUSA-N	Preclinical	RAF inhibitor	NA	NA
ML9	TRPC6	4217	OZSMSRIUUDGTEP-UHFFFAOYSA-N	Preclinical	myosin light chain kinase inhibitor	NA	NA
MM-11253	RARG	10389639	DPVGXUNWCVEIGT-UHFFFAOYSA-N	Preclinical	retinoid receptor antagonist	NA	NA
MM77	HTR1A	3994476	MQHOGPLXAXSQAJ-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
MN-64	TNKS	2802462	PYTOHIUBXSJKQH-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor	NA	NA
mocetinostat	HDAC1	9865515	HRNLUBSXIHFDHP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
mocetinostat	HDAC11	9865515	HRNLUBSXIHFDHP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
mocetinostat	HDAC2	9865515	HRNLUBSXIHFDHP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
mocetinostat	HDAC3	9865515	HRNLUBSXIHFDHP-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
moclobemide	MAOA	4235	YHXISWVBGDMDLQ-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression|anxiety
moclobemide	MAOB	4235	YHXISWVBGDMDLQ-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression|anxiety
moexipril	ACE	91270	UWWDHYUMIORJTA-HSQYWUDLSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
moexipril	ACE2	91270	UWWDHYUMIORJTA-HSQYWUDLSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
mofegiline	MAOA	6437850	VXLBSYHAEKDUSU-JXMROGBWSA-N	Phase 1	monoamine oxidase inhibitor	NA	NA
mofegiline	MAOB	6437850	VXLBSYHAEKDUSU-JXMROGBWSA-N	Phase 1	monoamine oxidase inhibitor	NA	NA
mofezolac	PTGS1	4237	DJEIHHYCDCTAAH-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|osteoporosis
molidustat	EGLN2	59603622	IJMBOKOTALXLKS-UHFFFAOYSA-N	Phase 3	hypoxia inducible factor inhibitor	NA	NA
molindone	DRD2	6604347	KLPWJLBORRMFGK-LBPRGKRZSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
molindone	HRH1	6604347	KLPWJLBORRMFGK-LBPRGKRZSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
molindone	HTR2A	6604347	KLPWJLBORRMFGK-LBPRGKRZSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
molsidomine	GUCY1A3	4239	XLFWDASMENKTKL-UHFFFAOYSA-O	Launched	guanylate cyclase stimulant	cardiology	coronary artery disease (CAD)
mometasone	NR3C1	441335	QLIIKPVHVRXHRI-CXSFZGCWSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
mometasone-furoate	NR3C1	441336	WOFMFGQZHJDGCX-ZULDAHANSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
monastrol	KIF11	794325	LOBCDGHHHHGHFA-GFCCVEGCSA-N	Preclinical	kinesin inhibitor	NA	NA
monobenzone	TYR	7638	VYQNWZOUAUKGHI-UHFFFAOYSA-N	Launched	melanin inhibitor	dermatology	skin depigmentation
montelukast	ALOX5	5281040	UCHDWCPVSPXUMX-TZIWLTJVSA-N	Launched	leukotriene receptor antagonist	pulmonary|allergy	asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)
montelukast	CYSLTR1	5281040	UCHDWCPVSPXUMX-TZIWLTJVSA-N	Launched	leukotriene receptor antagonist	pulmonary|allergy	asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)
moracizine	SCN5A	34633	FUBVWMNBEHXPSU-UHFFFAOYSA-N	Withdrawn	sodium channel blocker	cardiology	ventricular arrhythmias
morin	ADORA2A	5281670	YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical	cytochrome P450 inhibitor	NA	NA
morin	ESR2	5281670	YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical	cytochrome P450 inhibitor	NA	NA
morin	FASN	5281670	YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical	cytochrome P450 inhibitor	NA	NA
morin	MCL1	5281670	YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical	cytochrome P450 inhibitor	NA	NA
morin	SLC22A12	5281670	YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical	cytochrome P450 inhibitor	NA	NA
morinidazole	CYP51A1	102486242	GAZGHCHCYRSPIV-JTQLQIEISA-N	Launched	other antibiotic	NA	NA
mosapride	HTR4	9979608	YPELFRMCRYSPKZ-INIZCTEOSA-N	Launched	serotonin receptor agonist	gastroenterology	hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome
motesanib	FLT1	11667893	RAHBGWKEPAQNFF-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
motesanib	FLT4	11667893	RAHBGWKEPAQNFF-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
motesanib	KDR	11667893	RAHBGWKEPAQNFF-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
motesanib	KIT	11667893	RAHBGWKEPAQNFF-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
motolimod	TLR8	16049404	QSPOQCXMGPDIHI-UHFFFAOYSA-N	Phase 2	toll-like receptor agonist	NA	NA
moxifloxacin	TOP2A	40467042	FABPRXSRWADJSP-MEDUHNTESA-N	Launched	bacterial DNA gyrase inhibitor	otolaryngology|pulmonary|infectious disease	sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections
moxonidine	ADRA2A	4810	WPNJAUFVNXKLIM-UHFFFAOYSA-N	Launched	imidazoline receptor agonist	cardiology	hypertension
moxonidine	ADRA2B	4810	WPNJAUFVNXKLIM-UHFFFAOYSA-N	Launched	imidazoline receptor agonist	cardiology	hypertension
moxonidine	ADRA2C	4810	WPNJAUFVNXKLIM-UHFFFAOYSA-N	Launched	imidazoline receptor agonist	cardiology	hypertension
mozavaptan	AVPR1A	11441742	WRNXUQJJCIZICJ-DEOSSOPVSA-N	Launched	vasopressin receptor antagonist	endocrinology	hyponatremia
mozavaptan	AVPR1B	11441742	WRNXUQJJCIZICJ-DEOSSOPVSA-N	Launched	vasopressin receptor antagonist	endocrinology	hyponatremia
mozavaptan	AVPR2	11441742	WRNXUQJJCIZICJ-DEOSSOPVSA-N	Launched	vasopressin receptor antagonist	endocrinology	hyponatremia
MPEP	GRM1	3025961	NEWKHUASLBMWRE-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
MPEP	GRM4	3025961	NEWKHUASLBMWRE-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
MPEP	GRM5	3025961	NEWKHUASLBMWRE-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
MPI-0479605	TTK	46909588	OVJBNYKNHXJGSA-UHFFFAOYSA-N	Preclinical	mitotic kinase inhibitor	NA	NA
Mps-BAY-2a	TTK	57381882	MDYKTGNHXNTATG-UHFFFAOYSA-N	Preclinical	monopolar spindle 1 kinase inhibitor	NA	NA
Mps1-IN-1	TTK	25195352	NMJMRSQTDLRCRQ-UHFFFAOYSA-N	Preclinical	monopolar spindle 1 kinase inhibitor	NA	NA
MR-948	TBXAS1	10443938	LQQIZTXSZOYPPS-UHFFFAOYSA-N	Phase 1	thromboxane synthase inhibitor	NA	NA
MRK-016	GABRA1	6918583	QYSYOGCIDRANAR-UHFFFAOYSA-N	Phase 1	GABA receptor inverse agonist	NA	NA
MRK-016	GABRA2	6918583	QYSYOGCIDRANAR-UHFFFAOYSA-N	Phase 1	GABA receptor inverse agonist	NA	NA
MRK-016	GABRA3	6918583	QYSYOGCIDRANAR-UHFFFAOYSA-N	Phase 1	GABA receptor inverse agonist	NA	NA
MRK-016	GABRA5	6918583	QYSYOGCIDRANAR-UHFFFAOYSA-N	Phase 1	GABA receptor inverse agonist	NA	NA
MRK-560	APP	NA	WDZVWDXOIGQJIO-UJKQEGAGSA-N	Preclinical	gamma secretase inhibitor	NA	NA
MRS-1220	ADORA2B	393595	TWWFAXQOKNBUCR-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
MRS-1220	ADORA3	393595	TWWFAXQOKNBUCR-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
MRS-1334	ADORA3	6604859	QFLOJAMZLQXHFS-AREMUKBSSA-N	Preclinical	adenosine receptor antagonist	NA	NA
MRS-2578	P2RY6	16078986	QOHNRGHTJPFMSL-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
MRS-3777	ADORA1	11771279	OGCQBCHLFMBCCE-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
MRS-3777	ADORA2A	11771279	OGCQBCHLFMBCCE-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
MRS-3777	ADORA2B	11771279	OGCQBCHLFMBCCE-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
MRS-3777	ADORA3	11771279	OGCQBCHLFMBCCE-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
MSX-122	CXCR4	11687907	PXZXYRKDDXKDTK-UHFFFAOYSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
MTPG	GRM2	10752093	OZBFBAYESADVDX-JTQLQIEISA-N	Preclinical	glutamate receptor antagonist	NA	NA
MTPG	GRM3	10752093	OZBFBAYESADVDX-JTQLQIEISA-N	Preclinical	glutamate receptor antagonist	NA	NA
mubritinib	EGFR	6444692	ZTFBIUXIQYRUNT-MDWZMJQESA-N	Phase 1	protein tyrosine kinase inhibitor	NA	NA
mubritinib	ERBB2	6444692	ZTFBIUXIQYRUNT-MDWZMJQESA-N	Phase 1	protein tyrosine kinase inhibitor	NA	NA
muscimol	GABRA1	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRA2	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRA3	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRA4	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRA5	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRA6	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRR1	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRR2	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
muscimol	GABRR3	4266	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist	NA	NA
MY-5445	PDE5A	1348	CEHQLKSLMFIHBF-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor|platelet aggregation inhibitor	NA	NA
mycophenolate-mofetil	IMPDH1	5281078	RTGDFNSFWBGLEC-SYZQJQIISA-N	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	transplant	organ rejection
mycophenolate-mofetil	IMPDH2	5281078	RTGDFNSFWBGLEC-SYZQJQIISA-N	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	transplant	organ rejection
mycophenolic-acid	IMPDH1	446541	HPNSFSBZBAHARI-RUDMXATFSA-N	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	transplant	organ rejection
mycophenolic-acid	IMPDH2	446541	HPNSFSBZBAHARI-RUDMXATFSA-N	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	transplant	organ rejection
myricetin	PIK3CG	5281672	IKMDFBPHZNJCSN-UHFFFAOYSA-N	Preclinical	androgen receptor agonist|cytochrome P450 inhibitor	NA	NA
myricitrin	NOS1	5281673	DCYOADKBABEMIQ-OWMUPTOHSA-N	Preclinical	PKC inhibitor	NA	NA
myricitrin	PRKCA	5281673	DCYOADKBABEMIQ-OWMUPTOHSA-N	Preclinical	PKC inhibitor	NA	NA
M8-B	TRPM8	11675630	UOGGWHBYFVBUIY-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
N-acetyl-D-glucosamine	B4GALT1	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-acetyl-D-glucosamine	B4GALT2	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-acetyl-D-glucosamine	B4GALT3	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-acetyl-D-glucosamine	B4GALT4	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-acetyl-D-glucosamine	NAGK	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-acetyl-D-glucosamine	NAGLU	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-acetyl-D-glucosamine	NAGPA	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-acetyl-D-glucosamine	RENBP	1738118	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3		NA	NA
N-alpha-methylhistamine-dihydrochloride	HRH4	912	PHSPJQZRQAJPPF-UHFFFAOYSA-N	Phase 3	histamine receptor agonist	NA	NA
NAB-2	NEDD4	82017756	CZSLEMCYYGEGKP-UHFFFAOYSA-N	Preclinical	ubiquitin ligase transport promoter	NA	NA
nabumetone	PTGS1	4409	BLXXJMDCKKHMKV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
nabumetone	PTGS2	4409	BLXXJMDCKKHMKV-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
nadide	AHCY	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	AKR1A1	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	ALDH2	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	BLVRA	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	DHPS	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	DLD	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	GALE	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	HMGCR	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	HSD17B1	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	HSD17B4	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	IMPDH2	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	MGAM	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	P2RY11	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	SORD	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadide	TRPM2	5893	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	free radical scavenger	NA	NA
nadolol	ADRB1	7048578	VWPOSFSPZNDTMJ-YUELXQCFSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris|hypertension
nadolol	ADRB2	7048578	VWPOSFSPZNDTMJ-YUELXQCFSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris|hypertension
nadolol	ADRB3	7048578	VWPOSFSPZNDTMJ-YUELXQCFSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris|hypertension
NADPH	DRD2	71312102	PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical		NA	NA
NADPH	DRD3	71312102	PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical		NA	NA
NADPH	DRD4	71312102	PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical		NA	NA
NADPH	GHSR	71312102	PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical		NA	NA
NADPH	HTR2A	71312102	PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical		NA	NA
NADPH	HTR2C	71312102	PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical		NA	NA
nafadotride	DRD2	6604854	IDZASIQMRGPBCQ-QGZVFWFLSA-N	Preclinical	dopamine receptor antagonist	NA	NA
nafadotride	DRD3	6604854	IDZASIQMRGPBCQ-QGZVFWFLSA-N	Preclinical	dopamine receptor antagonist	NA	NA
nafadotride	HTR1A	6604854	IDZASIQMRGPBCQ-QGZVFWFLSA-N	Preclinical	dopamine receptor antagonist	NA	NA
nafamostat	ASIC1	4413	MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	serine protease inhibitor	cardiology	anticoagulent
nafamostat	ASIC2	4413	MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	serine protease inhibitor	cardiology	anticoagulent
nafamostat	ASIC3	4413	MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	serine protease inhibitor	cardiology	anticoagulent
nafamostat	C1R	4413	MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	serine protease inhibitor	cardiology	anticoagulent
nafamostat	PRSS1	4413	MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	serine protease inhibitor	cardiology	anticoagulent
nafamostat	TPSAB1	4413	MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	serine protease inhibitor	cardiology	anticoagulent
nafamostat	TRPM7	4413	MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	serine protease inhibitor	cardiology	anticoagulent
nafcillin	CYP1A2	8982	GPXLMGHLHQJAGZ-JTDSTZFVSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
nafcillin	CYP3A4	8982	GPXLMGHLHQJAGZ-JTDSTZFVSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
nafcillin	SLC22A6	8982	GPXLMGHLHQJAGZ-JTDSTZFVSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
naftopidil	ADRA1A	6603939	HRRBJVNMSRJFHQ-HXUWFJFHSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
nalbuphine	OPRD1	5311304	NETZHAKZCGBWSS-CEDHKZHLSA-N	Launched	opioid receptor agonist|opioid receptor antagonist	neurology/psychiatry	pain relief
nalbuphine	OPRK1	5311304	NETZHAKZCGBWSS-CEDHKZHLSA-N	Launched	opioid receptor agonist|opioid receptor antagonist	neurology/psychiatry	pain relief
nalbuphine	OPRM1	5311304	NETZHAKZCGBWSS-CEDHKZHLSA-N	Launched	opioid receptor agonist|opioid receptor antagonist	neurology/psychiatry	pain relief
nalfurafine	OPRK1	6445230	XGZZHZMWIXFATA-UEZBDDGYSA-N	Launched	opioid receptor agonist	nephrology	uremic pruritus
nalfurafine	OPRM1	6445230	XGZZHZMWIXFATA-UEZBDDGYSA-N	Launched	opioid receptor agonist	nephrology	uremic pruritus
nalmefene	OPRD1	5284594	WJBLNOPPDWQMCH-MBPVOVBZSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
nalmefene	OPRK1	5284594	WJBLNOPPDWQMCH-MBPVOVBZSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
nalmefene	OPRM1	5284594	WJBLNOPPDWQMCH-MBPVOVBZSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
naloxegol	OPRM1	56959087	XNKCCCKFOQNXKV-ZRSCBOBOSA-N	Launched	opioid receptor antagonist	gastroenterology	constipation
naloxone	CREB1	5284596	UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
naloxone	ESR1	5284596	UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
naloxone	OPRD1	5284596	UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
naloxone	OPRK1	5284596	UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
naloxone	OPRM1	5284596	UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
naloxone	TLR4	5284596	UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched	opioid receptor antagonist	pulmonary	respiratory depression
naloxone-benzoylhydrazone	OPRK1	9601084	AKXCFAYOTIEFOH-XTNAHFASSA-N	Preclinical	opioid receptor antagonist	NA	NA
naloxone-benzoylhydrazone	OPRM1	9601084	AKXCFAYOTIEFOH-XTNAHFASSA-N	Preclinical	opioid receptor antagonist	NA	NA
naltrexone	OPRD1	5360515	DQCKKXVULJGBQN-XFWGSAIBSA-N	Launched	opioid receptor antagonist	neurology/psychiatry	abstinence from alcohol
naltrexone	OPRK1	5360515	DQCKKXVULJGBQN-XFWGSAIBSA-N	Launched	opioid receptor antagonist	neurology/psychiatry	abstinence from alcohol
naltrexone	OPRM1	5360515	DQCKKXVULJGBQN-XFWGSAIBSA-N	Launched	opioid receptor antagonist	neurology/psychiatry	abstinence from alcohol
naltrexone	SIGMAR1	5360515	DQCKKXVULJGBQN-XFWGSAIBSA-N	Launched	opioid receptor antagonist	neurology/psychiatry	abstinence from alcohol
naltriben	OPRD1	5486827	ZHVWWEYETMPAMX-IFKAHUTRSA-N	Preclinical	opioid receptor antagonist	NA	NA
naltriben	OPRK1	5486827	ZHVWWEYETMPAMX-IFKAHUTRSA-N	Preclinical	opioid receptor antagonist	NA	NA
naltriben	OPRM1	5486827	ZHVWWEYETMPAMX-IFKAHUTRSA-N	Preclinical	opioid receptor antagonist	NA	NA
naltrindole	OPRD1	5497186	WIYUZYBFCWCCQJ-IFKAHUTRSA-N	Preclinical	opioid receptor antagonist	NA	NA
naltrindole	OPRK1	5497186	WIYUZYBFCWCCQJ-IFKAHUTRSA-N	Preclinical	opioid receptor antagonist	NA	NA
naltrindole	OPRM1	5497186	WIYUZYBFCWCCQJ-IFKAHUTRSA-N	Preclinical	opioid receptor antagonist	NA	NA
NAN-190	ADRA1A	4431	SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
NAN-190	ADRA1B	4431	SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
NAN-190	ADRA1D	4431	SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
NAN-190	HTR1A	4431	SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
NAN-190	HTR1F	4431	SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
napabucasin	STAT3	10331844	DPHUWDIXHNQOSY-UHFFFAOYSA-N	Phase 3	STAT inhibitor	NA	NA
naphazoline	ADRA1A	4436	CNIIGCLFLJGOGP-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	eye irritation
naphazoline	ADRA2A	4436	CNIIGCLFLJGOGP-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	ophthalmology	eye irritation
naproxen	PTGS1	156391	CMWTZPSULFXXJA-VIFPVBQESA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology	pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever
naproxen	PTGS2	156391	CMWTZPSULFXXJA-VIFPVBQESA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology	pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever
naratriptan	HTR1A	4440	AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
naratriptan	HTR1B	4440	AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
naratriptan	HTR1D	4440	AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
naratriptan	HTR1E	4440	AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
naratriptan	HTR1F	4440	AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
naringenin	CYP19A1	439246	FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1	aromatase inhibitor|TRPV antagonist	NA	NA
naringenin	CYP1B1	439246	FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1	aromatase inhibitor|TRPV antagonist	NA	NA
naringenin	ESR2	439246	FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1	aromatase inhibitor|TRPV antagonist	NA	NA
naringenin	GLO1	439246	FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1	aromatase inhibitor|TRPV antagonist	NA	NA
naringenin	HSD17B1	439246	FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1	aromatase inhibitor|TRPV antagonist	NA	NA
naringeninic-acid	HCAR2	637542	NGSWKAQJJWESNS-ZZXKWVIFSA-N	Phase 1		NA	NA
naringeninic-acid	PTGR1	637542	NGSWKAQJJWESNS-ZZXKWVIFSA-N	Phase 1		NA	NA
naringin	SLCO1A2	442428	DFPMSGMNTNDNHN-ZPHOTFPESA-N	Preclinical	cytochrome P450 inhibitor	NA	NA
NAS-181	HTR1B	9955015	RTKDBEOSPDFLGD-QGZVFWFLSA-N	Preclinical	serotonin receptor antagonist	NA	NA
nastorazepide	CCKBR	9872609	VIJCCFFEBCOOIE-JOCHJYFZSA-N	Phase 2	CCK receptor antagonist	NA	NA
nateglinide	ABCC8	NA	OELFLUMRDSZNSF-BRWVUGGUSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
nateglinide	KCNJ10	NA	OELFLUMRDSZNSF-BRWVUGGUSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
nateglinide	KCNJ11	NA	OELFLUMRDSZNSF-BRWVUGGUSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
nateglinide	PPARG	NA	OELFLUMRDSZNSF-BRWVUGGUSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
NAV-26	SCN9A	60201418	ICGMZCVSHDKQTE-IBGZPJMESA-N	Preclinical	voltage-gated sodium channel blocker	NA	NA
navarixin	CXCR1	9865554	RXIUEIPPLAFSDF-CYBMUJFWSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
navarixin	CXCR2	9865554	RXIUEIPPLAFSDF-CYBMUJFWSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
navitoclax	BCL2	24978538	JLYAXFNOILIKPP-KXQOOQHDSA-N	Phase 2	BCL inhibitor	NA	NA
navitoclax	BCL2L1	24978538	JLYAXFNOILIKPP-KXQOOQHDSA-N	Phase 2	BCL inhibitor	NA	NA
navitoclax	BCL2L2	24978538	JLYAXFNOILIKPP-KXQOOQHDSA-N	Phase 2	BCL inhibitor	NA	NA
NBI-27914	CRHR1	176157	KNADXBVKFAUMCR-UHFFFAOYSA-N	Preclinical	corticotropin releasing factor receptor antagonist	NA	NA
NBI-74330-(+/-)	CXCR3	45784923	XMRGQUDUVGRCBS-HXUWFJFHSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
NBQX	GRIA1	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NBQX	GRIA2	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NBQX	GRIA3	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NBQX	GRIA4	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NBQX	GRIK1	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NBQX	GRIN1	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NBQX	GRIN2A	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NBQX	GRIN2B	3272524	UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
NCS-382	GABBR1	6604757	UADPGHINQMWEAG-FROQITRMSA-N	Preclinical	GABA receptor antagonist	NA	NA
NCS-382	GABBR2	6604757	UADPGHINQMWEAG-FROQITRMSA-N	Preclinical	GABA receptor antagonist	NA	NA
NCS-382	SLC52A2	6604757	UADPGHINQMWEAG-FROQITRMSA-N	Preclinical	GABA receptor antagonist	NA	NA
NDT-9513727	C5AR1	10210160	ITACCRHKSPSKKL-UHFFFAOYSA-N	Preclinical	complement antagonist	NA	NA
NE-100	SIGMAR1	9841596	YBLIQJGXRLZBCZ-UHFFFAOYSA-N	Phase 2	sigma receptor antagonist	NA	NA
nebivolol	ADRB1	189562	KOHIRBRYDXPAMZ-YHBROIRLSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
nebracetam	CHRM1	25136943	LCAFGJGYCUMTGS-NSHDSACASA-N	Phase 3	acetylcholine receptor agonist	NA	NA
NECA	ADORA1	448222	JADDQZYHOWSFJD-FLNNQWSLSA-N	Launched	adenosine receptor agonist	NA	NA
NECA	ADORA2A	448222	JADDQZYHOWSFJD-FLNNQWSLSA-N	Launched	adenosine receptor agonist	NA	NA
NECA	ADORA2B	448222	JADDQZYHOWSFJD-FLNNQWSLSA-N	Launched	adenosine receptor agonist	NA	NA
NECA	ADORA3	448222	JADDQZYHOWSFJD-FLNNQWSLSA-N	Launched	adenosine receptor agonist	NA	NA
necrostatin-1	RIPK1	738301	TXUWMXQFNYDOEZ-NSHDSACASA-N	Preclinical	RIPK inhibitor	NA	NA
necrostatin-2	RIPK2	11288934	WIKGAEMMNQTUGL-SNVBAGLBSA-N	Preclinical	necroptosis inhibitor|RIPK inhibitor	NA	NA
nedocromil	CYSLTR1	50294	RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry|ophthalmology	itching|conjunctivitis
nedocromil	CYSLTR2	50294	RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry|ophthalmology	itching|conjunctivitis
nedocromil	FPR1	50294	RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry|ophthalmology	itching|conjunctivitis
nedocromil	HSP90AA1	50294	RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry|ophthalmology	itching|conjunctivitis
nedocromil	PTGDR	50294	RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry|ophthalmology	itching|conjunctivitis
nefazodone	ADRA1A	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	ADRA1B	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	ADRA2A	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	CYP3A4	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	HTR1A	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	HTR2A	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	HTR2C	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	SLC6A2	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	SLC6A3	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefazodone	SLC6A4	4449	VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	NA	NA
nefiracetam	CHRM1	71157	NGHTXZCKLWZPGK-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist|benzodiazepine receptor agonist	NA	NA
nelarabine	POLA1	3011155	IXOXBSCIXZEQEQ-UHTZMRCNSA-N	Launched	DNA synthesis inhibitor|T cell inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
nelfinavir	CYP1A2	64143	"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nelfinavir	CYP2B6	64143	"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nelfinavir	CYP2C19	64143	"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nelfinavir	CYP2C9	64143	"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nelfinavir	CYP2D6	64143	"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nelfinavir	CYP3A4	64143	"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nelfinavir	CYP3A7	64143	"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nemonapride	DRD2	156333	KRVOJOCLBAAKSJ-RDTXWAMCSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
nemonapride	DRD3	156333	KRVOJOCLBAAKSJ-RDTXWAMCSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
nemonapride	DRD4	156333	KRVOJOCLBAAKSJ-RDTXWAMCSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
nemorubicin	TOP1	65907	CTMCWCONSULRHO-UHQPFXKFSA-N	Phase 2	topoisomerase inhibitor	NA	NA
nemorubicin	TOP2A	65907	CTMCWCONSULRHO-UHQPFXKFSA-N	Phase 2	topoisomerase inhibitor	NA	NA
neomycin	CXCR4	8378	PGBHMTALBVVCIT-VCIWKGPPSA-N	Launched	bacterial 30S ribosomal subunit inhibitor	infectious disease|gastroenterology	first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections
neostigmine	ACHE	4456	ALWKGYPQUAPLQC-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
nepafenac	PTGS1	151075	QEFAQIPZVLVERP-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	ophthalmology	eye inflammation
nepafenac	PTGS2	151075	QEFAQIPZVLVERP-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	ophthalmology	eye inflammation
nepicastat	DBH	9796181	YZZVIKDAOTXDEB-JTQLQIEISA-N	Phase 2	dopamine beta hydroxylase inhibitor	NA	NA
neratinib	EGFR	9915743	JWNPDZNEKVCWMY-VQHVLOKHSA-N	Launched	EGFR inhibitor	oncology	breast cancer
neratinib	ERBB2	9915743	JWNPDZNEKVCWMY-VQHVLOKHSA-N	Launched	EGFR inhibitor	oncology	breast cancer
neratinib	KDR	9915743	JWNPDZNEKVCWMY-VQHVLOKHSA-N	Launched	EGFR inhibitor	oncology	breast cancer
neridronic-acid	FDPS	71237	PUUSSSIBPPTKTP-UHFFFAOYSA-N	Launched	bone resorption inhibitor	endocrinology	brittle bone disease|Paget's disease
netupitant	TACR1	6451149	WAXQNWCZJDTGBU-UHFFFAOYSA-N	Launched	tachykinin antagonist	gastroenterology	nausea|vomiting
neuropathiazol	BMP2	11667240	"InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3"	Preclinical	neural stem cell inducer	NA	NA
neuropathiazol	LIF	11667240	"InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3"	Preclinical	neural stem cell inducer	NA	NA
nevirapine	CYP1A2	4463	NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nevirapine	CYP2A6	4463	NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nevirapine	CYP2B6	4463	NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nevirapine	CYP2C9	4463	NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nevirapine	CYP2D6	4463	NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nevirapine	CYP3A4	4463	NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nevirapine	CYP3A5	4463	NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nexturastat-A	HDAC1	71462653	JZWXMCPARMXZQV-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
nexturastat-A	HDAC6	71462653	JZWXMCPARMXZQV-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
NFKB-activation-inhibitor-II	RELA	16760588	YMFNPBSZFWXMAD-UHFFFAOYSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
NG-nitro-arginine	NOS1	440005	MRAUNPAHJZDYCK-BYPYZUCNSA-N	Phase 1	nitric oxide synthase inhibitor	NA	NA
NG-nitro-arginine	NOS2	440005	MRAUNPAHJZDYCK-BYPYZUCNSA-N	Phase 1	nitric oxide synthase inhibitor	NA	NA
NG-nitro-arginine	NOS3	440005	MRAUNPAHJZDYCK-BYPYZUCNSA-N	Phase 1	nitric oxide synthase inhibitor	NA	NA
NGB-2904	DRD3	9891901	YJPWVCIGSHWNON-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
NGD-94-1	DRD4	188942	OTVQCHUIPJYASM-UHFFFAOYSA-N	Phase 1	dopamine receptor antagonist	NA	NA
NGD-98-2	CRHR1	9822241	PSUFQBRCUSJTDO-UHFFFAOYSA-N	Preclinical	corticotropin releasing factor receptor antagonist	NA	NA
NHI-2	LDHA	51355147	YPPFWRWCZNXINO-UHFFFAOYSA-N	Preclinical	lactate dehydrogenase inhibitor	NA	NA
NI-57	BRD1	91827373	UEMQPCYDWCSVCU-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
NI-57	BRPF1	91827373	UEMQPCYDWCSVCU-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
NI-57	BRPF3	91827373	UEMQPCYDWCSVCU-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
niacin	DGAT2	938	PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched	NAD precursor|vitamin B	endocrinology	hypertriglyceridemia
niacin	HCAR1	938	PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched	NAD precursor|vitamin B	endocrinology	hypertriglyceridemia
niacin	HCAR2	938	PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched	NAD precursor|vitamin B	endocrinology	hypertriglyceridemia
niacin	HCAR3	938	PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched	NAD precursor|vitamin B	endocrinology	hypertriglyceridemia
niacin	NNMT	938	PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched	NAD precursor|vitamin B	endocrinology	hypertriglyceridemia
niacin	QPRT	938	PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched	NAD precursor|vitamin B	endocrinology	hypertriglyceridemia
nialamide	COMT	4472	NOIIUHRQUVNIDD-UHFFFAOYSA-N	Withdrawn	monoamine oxidase inhibitor	NA	NA
nialamide	MAOA	4472	NOIIUHRQUVNIDD-UHFFFAOYSA-N	Withdrawn	monoamine oxidase inhibitor	NA	NA
nialamide	MAOB	4472	NOIIUHRQUVNIDD-UHFFFAOYSA-N	Withdrawn	monoamine oxidase inhibitor	NA	NA
nicardipine	ADORA3	6603948	ZBBHBTPTTSWHBA-XMMPIXPASA-N	Launched	calcium channel blocker	cardiology	chronic stable angina|hypertension
nicergoline	ADRA1A	34040	YSEXMKHXIOCEJA-FVFQAYNVSA-N	Launched	adrenergic receptor antagonist	rheumatology|neurology/psychiatry|cardiology|hematology	Raynaud's disease|migraine headache|atherosclerosis|thrombosis
niclosamide	STAT3	4477	RJMUSRYZPJIFPJ-UHFFFAOYSA-N	Launched	DNA replication inhibitor|STAT inhibitor	infectious disease	tapeworm
nicorandil	KCNJ11	47528	LBHIOVVIQHSOQN-UHFFFAOYSA-N	Launched	nitric oxide donor|potassium channel activator	cardiology	angina pectoris
nicotinamide	BST1	936	DFPAKSUCGFBDDF-UHFFFAOYSA-N	Launched	protein synthesis stimulant	dermatology	acne vulgaris (AV)
nicotinamide	LDHA	936	DFPAKSUCGFBDDF-UHFFFAOYSA-N	Launched	protein synthesis stimulant	dermatology	acne vulgaris (AV)
nicotinamide	PARP1	936	DFPAKSUCGFBDDF-UHFFFAOYSA-N	Launched	protein synthesis stimulant	dermatology	acne vulgaris (AV)
nicotinamide	SIRT5	936	DFPAKSUCGFBDDF-UHFFFAOYSA-N	Launched	protein synthesis stimulant	dermatology	acne vulgaris (AV)
nicotine	CHAT	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA10	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA2	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA3	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA4	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA5	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA6	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA7	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNA9	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNB2	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNB3	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CHRNB4	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	CYP19A1	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	TBXAS1	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotine	TRPA1	89594	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
NIDA-41020	CNR1	11037861	KWDBQJRWPWTGPF-UHFFFAOYSA-N	Preclinical	cannabinoid receptor antagonist	NA	NA
nifedipine	CACNA1C	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	CACNA1D	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	CACNA1F	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	CACNA1H	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	CACNA1S	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	CACNA2D1	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	CACNB2	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	CALM1	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	GLRA1	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	GLRA3	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	GLRB	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	KCNA1	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	KCNA5	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	NR1I2	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifedipine	TRPM3	4485	HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	vasospastic angina|chronic stable angina
nifenalol	ADRB1	202035	UAORFCGRZIGNCI-LLVKDONJSA-N	Launched	adrenergic receptor antagonist	NA	NA
nifenalol	ADRB2	202035	UAORFCGRZIGNCI-LLVKDONJSA-N	Launched	adrenergic receptor antagonist	NA	NA
niflumic-acid	ANO1	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	CLCN1	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	CLCNKA	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	CLCNKB	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	KCNQ1	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	PLA2G1B	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	PLA2G4A	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	PTGS1	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	PTGS2	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niflumic-acid	UGT1A9	4488	JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain
niguldipine-(S)-(+)	ADRA1A	60602	SVJMLYUFVDMUHP-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
nilotinib	ABL1	644241	HHZIURLSWUIHRB-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
nilotinib	KIT	644241	HHZIURLSWUIHRB-UHFFFAOYSA-N	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
nilutamide	AR	4493	XWXYUMMDTVBTOU-UHFFFAOYSA-N	Launched	androgen receptor antagonist	oncology	prostate cancer
nilvadipine	CACNA1C	10340038	FAIIFDPAEUKBEP-INIZCTEOSA-N	Launched	calcium channel blocker	cardiology	hypertension|cerebral artery occlusion
nilvadipine	CACNA1D	10340038	FAIIFDPAEUKBEP-INIZCTEOSA-N	Launched	calcium channel blocker	cardiology	hypertension|cerebral artery occlusion
nimesulide	LTF	4495	HYWYRSMBCFDLJT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain
nimesulide	PLA2G2E	4495	HYWYRSMBCFDLJT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain
nimesulide	PTGS1	4495	HYWYRSMBCFDLJT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain
nimesulide	PTGS2	4495	HYWYRSMBCFDLJT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain
nimodipine	CFTR	157132	UIAGMCDKSXEBJQ-LJQANCHMSA-N	Launched	calcium channel blocker	hematology	hemorrhage
nimodipine	NR3C2	157132	UIAGMCDKSXEBJQ-LJQANCHMSA-N	Launched	calcium channel blocker	hematology	hemorrhage
nintedanib	FGFR1	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	FGFR2	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	FGFR3	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	FGFR4	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	FLT1	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	FLT4	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	KDR	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	PDGFRA	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
nintedanib	PDGFRB	NA	XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
niraparib	PARP1	24958200	PCHKPVIQAHNQLW-CQSZACIVSA-N	Launched	PARP inhibitor	oncology	primary peritoneal cancer (PPC)
nisoldipine	CACNA1C	28248400	VKQFCGNPDRICFG-GOSISDBHSA-N	Launched	calcium channel blocker	cardiology	hypertension
nisoldipine	CACNA1D	28248400	VKQFCGNPDRICFG-GOSISDBHSA-N	Launched	calcium channel blocker	cardiology	hypertension
nisoldipine	CACNA1F	28248400	VKQFCGNPDRICFG-GOSISDBHSA-N	Launched	calcium channel blocker	cardiology	hypertension
nisoldipine	CACNA1S	28248400	VKQFCGNPDRICFG-GOSISDBHSA-N	Launched	calcium channel blocker	cardiology	hypertension
nisoxetine	SLC6A2	10107248	ITJNARMNRKSWTA-OAHLLOKOSA-N	Phase 1	norepinephrine reuptake inhibitor	NA	NA
nisoxetine	SLC6A3	10107248	ITJNARMNRKSWTA-OAHLLOKOSA-N	Phase 1	norepinephrine reuptake inhibitor	NA	NA
nisoxetine	SLC6A4	10107248	ITJNARMNRKSWTA-OAHLLOKOSA-N	Phase 1	norepinephrine reuptake inhibitor	NA	NA
nitecapone	COMT	5464105	UPMRZALMHVUCIN-UHFFFAOYSA-N	Phase 2	catechol O methyltransferase inhibitor	NA	NA
nitrendipine	CACNA1D	157702	PVHUJELLJLJGLN-INIZCTEOSA-N	Launched	calcium channel blocker	cardiology	hypertension
nitrendipine	CACNA2D1	157702	PVHUJELLJLJGLN-INIZCTEOSA-N	Launched	calcium channel blocker	cardiology	hypertension
nitrendipine	KCNN4	157702	PVHUJELLJLJGLN-INIZCTEOSA-N	Launched	calcium channel blocker	cardiology	hypertension
nitrocaramiphen	CHRM1	3941250	NSHMVLOWOAQFTP-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
nitroxoline	METAP2	19910	RJIWZDNTCBHXAL-UHFFFAOYSA-N	Launched	cathepsin inhibitor	infectious disease	urinary tract infections
nizatidine	HRH2	3033637	SGXXNSQHWDMGGP-IZZDOVSWSA-N	Launched	histamine receptor antagonist	gastroenterology	duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD)
NK-252	NFE2L2	71618700	FNSCFQXZZNCDAI-UHFFFAOYSA-N	Preclinical	nuclear factor erythroid derived|like (NRF2) activator	NA	NA
NKY-80	ADCY5	777417	SOJUSNIBPPMLCC-SSDOTTSWSA-N	Preclinical	adenylyl cyclase inhibitor	NA	NA
NLG919	IDO1	70874604	YTRRAUACYORZLX-WMZOPIPTSA-N	Phase 1	"indoleamine 2,3-dioxygenase inhibitor"	NA	NA
NMDA	GRIN1	22880	HOKKHZGPKSLGJE-GSVOUGTGSA-N	Preclinical	glutamate receptor agonist	NA	NA
NMDA	GRIN2A	22880	HOKKHZGPKSLGJE-GSVOUGTGSA-N	Preclinical	glutamate receptor agonist	NA	NA
NMDA	GRIN2B	22880	HOKKHZGPKSLGJE-GSVOUGTGSA-N	Preclinical	glutamate receptor agonist	NA	NA
NMDA	GRIN2C	22880	HOKKHZGPKSLGJE-GSVOUGTGSA-N	Preclinical	glutamate receptor agonist	NA	NA
NMDA	GRIN2D	22880	HOKKHZGPKSLGJE-GSVOUGTGSA-N	Preclinical	glutamate receptor agonist	NA	NA
NMS-1286937	FLT3	49792852	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	Phase 2	PLK inhibitor	NA	NA
NMS-1286937	PLK1	49792852	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	Phase 2	PLK inhibitor	NA	NA
NMS-1286937	PLK2	49792852	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	Phase 2	PLK inhibitor	NA	NA
NMS-1286937	PLK3	49792852	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	Phase 2	PLK inhibitor	NA	NA
NMS-873	VCP	71521142	UJGTUKMAJVCBIS-UHFFFAOYSA-N	Preclinical	ATPase inhibitor	NA	NA
NN-DNJ	GBA	501640	FTSCEGKYKXESFF-LXTVHRRPSA-N	Preclinical	glucosidase inhibitor	NA	NA
NNC-05-2090	SLC6A12	9888030	XZZYCJOGZYEPPW-UHFFFAOYSA-N	Preclinical	GABA uptake inhibitor|GAT inhibitor	NA	NA
NNC-55-0396	CATSPER1	9957280	VHHVPDKNKPNKHY-JDXGNMNLSA-N	Preclinical	T-type calcium channel blocker	NA	NA
NNC-55-0396	CATSPER2	9957280	VHHVPDKNKPNKHY-JDXGNMNLSA-N	Preclinical	T-type calcium channel blocker	NA	NA
NNC-55-0396	CATSPER3	9957280	VHHVPDKNKPNKHY-JDXGNMNLSA-N	Preclinical	T-type calcium channel blocker	NA	NA
NNC-55-0396	CATSPER4	9957280	VHHVPDKNKPNKHY-JDXGNMNLSA-N	Preclinical	T-type calcium channel blocker	NA	NA
NNC-63-0532	OPRL1	9803475	AQMPIDSGLFVVPL-UHFFFAOYSA-N	Preclinical	opioid receptor agonist	NA	NA
NNC-711	SIGMAR1	4515	NGNALWDRPKNJGR-UHFFFAOYSA-N	Preclinical	GABA uptake inhibitor	NA	NA
NNC-711	SLC6A1	4515	NGNALWDRPKNJGR-UHFFFAOYSA-N	Preclinical	GABA uptake inhibitor	NA	NA
NO-ASA	PTGS2	119032	IOJUJUOXKXMJNF-UHFFFAOYSA-N	Phase 2	cyclooxygenase inhibitor	NA	NA
nobiletin	MAP2K1	72344	MRIAQLRQZPPODS-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
nocodazole	HPGDS	4122	KYRVNWMVYQXFEU-UHFFFAOYSA-N	Preclinical	tubulin polymerization inhibitor	NA	NA
nolatrexed	TYMS	135400184	XHWRWCSCBDLOLM-UHFFFAOYSA-N	Phase 3	thymidylate synthase inhibitor	NA	NA
nomegestrol-acetate	PGR	91668	IIVBFTNIGYRNQY-YQLZSBIMSA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
nomifensine	DRD2	55993	XXPANQJNYNUNES-AWEZNQCLSA-N	Withdrawn	dopamine reuptake inhibitor|noradrenaline uptake inhibitor	NA	NA
nomifensine	SLC6A2	55993	XXPANQJNYNUNES-AWEZNQCLSA-N	Withdrawn	dopamine reuptake inhibitor|noradrenaline uptake inhibitor	NA	NA
nomifensine	SLC6A3	55993	XXPANQJNYNUNES-AWEZNQCLSA-N	Withdrawn	dopamine reuptake inhibitor|noradrenaline uptake inhibitor	NA	NA
nonivamide	TRPV1	2998	RGOVYLWUIBMPGK-UHFFFAOYSA-N	Launched	TRPV agonist	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain
nor-binaltorphimine	OPRD1	5480230	APSUXPSYBJVPPS-YAUKWVCOSA-N	Preclinical	opioid receptor antagonist	NA	NA
nor-binaltorphimine	OPRK1	5480230	APSUXPSYBJVPPS-YAUKWVCOSA-N	Preclinical	opioid receptor antagonist	NA	NA
nor-binaltorphimine	OPRM1	5480230	APSUXPSYBJVPPS-YAUKWVCOSA-N	Preclinical	opioid receptor antagonist	NA	NA
norelgestromin	PGR	9568628	ISHXLNHNDMZNMC-VTKCIJPMSA-N	Launched		endocrinology	contraceptive
norepinephrine	ADRA1A	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRA1B	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRA1D	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRA2A	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRA2B	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRA2C	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRB1	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRB2	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	ADRB3	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	PAH	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	SLC18A1	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norepinephrine	SLC18A2	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder
norethindrone	PGR	6230	VIKNJXKGJWUCNN-XGXHKTLJSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	endometriosis
norethindrone-acetate	PGR	5832	IMONTRJLAWHYGT-ZCPXKWAGSA-N	Launched	progesterone receptor agonist	endocrinology|orthopedics|obstetrics/gynecology	menopause|osteoporosis|vaginal atrophy
noretynodrel	PGR	6231	ICTXHFFSOAJUMG-SLHNCBLASA-N	Launched	progestogen hormone	endocrinology	contraceptive
norfloxacin	TOP2A	6919051	OGJPXUAPXNRGGI-UHFFFAOYSA-N	Launched	bacterial DNA gyrase inhibitor	infectious disease|urology	urinary tract infections|gonorrhea|prostatitis
norfluoxetine	HTR2B	9797657	WIQRCHMSJFFONW-OAHLLOKOSA-N	Phase 1	selective serotonin reuptake inhibitor (SSRI)	NA	NA
norgestimate	ESR1	6540478	KIQQMECNKUGGKA-NMYWJIRASA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
norgestimate	PGR	6540478	KIQQMECNKUGGKA-NMYWJIRASA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
norgestrel	AR	13109	WWYNJERNGUHSAO-XUDSTZEESA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
norgestrel	ESR1	13109	WWYNJERNGUHSAO-XUDSTZEESA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
norgestrel	PGR	13109	WWYNJERNGUHSAO-XUDSTZEESA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
norgestrel	SRD5A1	13109	WWYNJERNGUHSAO-XUDSTZEESA-N	Launched	progesterone receptor agonist	endocrinology	contraceptive
nortriptyline	ADRA1A	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRA1B	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRA1D	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRA2A	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRA2B	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRA2C	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRB1	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRB2	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	ADRB3	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	CHRM1	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	CHRM2	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	CHRM3	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	CHRM4	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	CHRM5	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	DRD2	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	HRH1	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	HTR1A	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	HTR2A	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	HTR2C	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	HTR6	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	KCNJ10	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	PGRMC1	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	SIGMAR1	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	SLC6A2	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
nortriptyline	SLC6A4	4543	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
noscapine	SIGMAR1	275196	AKNNEGZIBPJZJG-MSOLQXFVSA-N	Launched	bradykinin receptor antagonist|tubulin polymerization inhibitor	pulmonary	cough suppressant
NOV-002	GSR	16401161	YPZRWBKMTBYPTK-USZNOCQGSA-N	Phase 3		NA	NA
NPC-15199	PPARG	1549477	CBPJQFCAFFNICX-LJQANCHMSA-N	Phase 2	ICAM1 antagonist	NA	NA
NPPB	ANO1	4549	WBSMIPAMAXNXFS-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
NPPB	CLCN2	4549	WBSMIPAMAXNXFS-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
NPPB	CLCN7	4549	WBSMIPAMAXNXFS-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
NPPB	TRPA1	4549	WBSMIPAMAXNXFS-UHFFFAOYSA-N	Preclinical	chloride channel blocker	NA	NA
NPS-2143	CASR	6918446	PZUJQWHTIRWCID-HXUWFJFHSA-N	Preclinical	calcium receptor antagonist	NA	NA
NPY-5RA972	NPY5R	9884833	ZNFMHLDBJPAFEQ-UHFFFAOYSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
NQDI-1	CASP3	5522952	UFJGFNHRMPMALC-UHFFFAOYSA-N	Preclinical	caspase inhibitor	NA	NA
NS-018	JAK1	46866319	UQTPDWDAYHAZNT-AWEZNQCLSA-N	Phase 1/Phase 2	JAK inhibitor	NA	NA
NS-018	JAK2	46866319	UQTPDWDAYHAZNT-AWEZNQCLSA-N	Phase 1/Phase 2	JAK inhibitor	NA	NA
NS-018	JAK3	46866319	UQTPDWDAYHAZNT-AWEZNQCLSA-N	Phase 1/Phase 2	JAK inhibitor	NA	NA
NS-018	TYK2	46866319	UQTPDWDAYHAZNT-AWEZNQCLSA-N	Phase 1/Phase 2	JAK inhibitor	NA	NA
NS-11021	KCNMA1	24825677	MDKAFDIKYQMOMF-UHFFFAOYSA-N	Preclinical	calcium-activated potassium channel activator	NA	NA
NS-1643	KCNH2	10177784	NJFVQMRYJZHGME-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
NS-1643	KCNH6	10177784	NJFVQMRYJZHGME-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
NS-1643	KCNMA1	10177784	NJFVQMRYJZHGME-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
NS-19504	KCNMA1	727750	HGWLTZOMQZIUBW-UHFFFAOYSA-N	Preclinical	calcium-activated potassium channel activator	NA	NA
NS-309	KCNN1	NA	CVOUSAVHMDXCKG-UHFFFAOYSA-N	Preclinical	calcium-activated potassium channel activator	NA	NA
NS-309	KCNN2	NA	CVOUSAVHMDXCKG-UHFFFAOYSA-N	Preclinical	calcium-activated potassium channel activator	NA	NA
NS-309	KCNN3	NA	CVOUSAVHMDXCKG-UHFFFAOYSA-N	Preclinical	calcium-activated potassium channel activator	NA	NA
NS-309	KCNN4	NA	CVOUSAVHMDXCKG-UHFFFAOYSA-N	Preclinical	calcium-activated potassium channel activator	NA	NA
NS-3623	KCNH2	9954236	JXPULDIATMTIIN-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
NS-3861	CHRNA3	NA	ZJCNRVHZJADROC-VHSXEESVSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
NS-3861	CHRNB4	NA	ZJCNRVHZJADROC-VHSXEESVSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
NS-5806	KCND3	11642685	UZWJWROOLOOCPQ-UHFFFAOYSA-N	Preclinical	voltage-gated potassium channel activator	NA	NA
NS-8	KCNMA1	10176749	KVDWOQGDMAEJLM-UHFFFAOYSA-N	Phase 2	potassium channel agonist	NA	NA
NS-8593	KCNN1	11587013	XZIZUQSOFMLIIR-CQSZACIVSA-N	Preclinical	calcium-activated potassium channel modulator	NA	NA
NS-8593	KCNN2	11587013	XZIZUQSOFMLIIR-CQSZACIVSA-N	Preclinical	calcium-activated potassium channel modulator	NA	NA
NS-8593	KCNN3	11587013	XZIZUQSOFMLIIR-CQSZACIVSA-N	Preclinical	calcium-activated potassium channel modulator	NA	NA
NS-9283	CHRNA4	11998180	HGFXDSQLRSWUBO-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
NSC-3852	HDAC1	19103	RZWRYPGAUIOOMK-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
NSC-405020	MMP1	879610	ARDYECYBETXQFD-MRVPVSSYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
NSC-4644	PYGM	72326	FVWJYYTZTCVBKE-ROUWMTJPSA-N	Phase 2	ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor	NA	NA
NSC-5844	CCR1	221354	SSXYXSMMVMVYEV-UHFFFAOYSA-N	Preclinical	CC chemokine receptor agonist	NA	NA
NSC-625987	CDK2	3004085	KFAKESMKRPNZTM-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
NSC-625987	CDK4	3004085	KFAKESMKRPNZTM-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
NSC-632839	SENP2	5351363	PKCYYPHSCUSQDK-AYKLPDECSA-N	Preclinical	ubiquitin specific protease inhibitor	NA	NA
NSC-632839	USP1	5351363	PKCYYPHSCUSQDK-AYKLPDECSA-N	Preclinical	ubiquitin specific protease inhibitor	NA	NA
NSC-632839	USP2	5351363	PKCYYPHSCUSQDK-AYKLPDECSA-N	Preclinical	ubiquitin specific protease inhibitor	NA	NA
NSC-632839	USP7	5351363	PKCYYPHSCUSQDK-AYKLPDECSA-N	Preclinical	ubiquitin specific protease inhibitor	NA	NA
NSC-636819	KDM4A	6288112	YYZPXBXVBQSBDG-IJIVKGSJSA-N	Preclinical	histone demethylase inhibitor	NA	NA
NSC-636819	KDM4B	6288112	YYZPXBXVBQSBDG-IJIVKGSJSA-N	Preclinical	histone demethylase inhibitor	NA	NA
NSC-663284	CDC25A	379077	BMKPVDQDJQWBPD-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
NSC-663284	CDC25B	379077	BMKPVDQDJQWBPD-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
NSC-663284	CDC25C	379077	BMKPVDQDJQWBPD-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
NSC-697923	UBE2N	394449	GAUHIPWCDXOLCZ-UHFFFAOYSA-N	Preclinical	ubiquitin-conjugating enzyme inhibitor	NA	NA
NSC-95397	CDC25A	262093	MAASHDQFQDDECQ-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
NSC-95397	CDC25B	262093	MAASHDQFQDDECQ-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
NSC-9965	CHRNA4	31762	ALSKYCOJJPXPFS-BBRMVZONSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
NSC-9965	CHRNB2	31762	ALSKYCOJJPXPFS-BBRMVZONSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
NTNCB	NPY5R	NA	ISSSVYKMIIAPTH-ACRUOGEOSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
NTRC-824	NTSR2	101873359	SOOLLEBJNGCDOZ-FQEVSTJZSA-N	Preclinical	neurotensin receptor antagonist	NA	NA
nTZDpa	PPARG	9954280	VUPOTURDKDMIGQ-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
NT157	IGF1R	135398520	NIPUPOUEGOSAAO-OWOJBTEDSA-N	Preclinical	IGF-1 inhibitor	NA	NA
NU-1025	PARP1	135398517	YJDAOHJWLUNFLX-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
NU-2058	CCNA2	4564	MWGXGTJJAOZBNW-UHFFFAOYSA-N	Preclinical	cyclin D inhibitor	NA	NA
NU-2058	CDK2	4564	MWGXGTJJAOZBNW-UHFFFAOYSA-N	Preclinical	cyclin D inhibitor	NA	NA
NU-6027	CCNA2	398148	DGWXOLHKVGDQLN-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
NU-6027	CDK2	398148	DGWXOLHKVGDQLN-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
NU-7026	PRKDC	9860529	KKTZALUTXUZPSN-UHFFFAOYSA-N	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	NA	NA
NU-7441	PRKDC	11327430	"InChI=1S/C25H19NO3S/c27-21-15-23(26-11-13-28-14-12-26)29-24-17(6-3-9-20(21)24)19-8-4-7-18-16-5-1-2-10-22(16)30-25(18)19/h1-10,15H,11-14H2"	Preclinical	DNA dependent protein kinase inhibitor	NA	NA
nutlin-3	MDM2	11433190	BDUHCSBCVGXTJM-WUFINQPMSA-N	Preclinical	MDM inhibitor	NA	NA
nutlin-3	TP53	11433190	BDUHCSBCVGXTJM-WUFINQPMSA-N	Preclinical	MDM inhibitor	NA	NA
NVP-ADW742	IGF1R	NA	LSFLAQVDISHMNB-AFARHQOCSA-N	Preclinical	insulin growth factor receptor inhibitor	NA	NA
NVP-AEW541	IGF1R	NA	AECDBHGVIIRMOI-GRGXKFILSA-N	Preclinical	IGF-1 inhibitor	NA	NA
NVP-AEW541	INSR	NA	AECDBHGVIIRMOI-GRGXKFILSA-N	Preclinical	IGF-1 inhibitor	NA	NA
NVP-AUY922	HSP90AA1	135539077	NDAZATDQFDPQBD-UHFFFAOYSA-N	Phase 2	HSP inhibitor	NA	NA
NVP-AUY922	HSP90AB1	135539077	NDAZATDQFDPQBD-UHFFFAOYSA-N	Phase 2	HSP inhibitor	NA	NA
NVP-BEZ235	ATR	11977753	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	Phase 3	mTOR inhibitor|PI3K inhibitor	NA	NA
NVP-BEZ235	MTOR	11977753	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	Phase 3	mTOR inhibitor|PI3K inhibitor	NA	NA
NVP-BEZ235	PIK3CA	11977753	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	Phase 3	mTOR inhibitor|PI3K inhibitor	NA	NA
NVP-BEZ235	PIK3CD	11977753	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	Phase 3	mTOR inhibitor|PI3K inhibitor	NA	NA
NVP-BEZ235	PIK3CG	11977753	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	Phase 3	mTOR inhibitor|PI3K inhibitor	NA	NA
NVP-BGJ398	FGFR1	53235510	QADPYRIHXKWUSV-UHFFFAOYSA-N	Phase 3	FGFR inhibitor	NA	NA
NVP-BGJ398	FGFR2	53235510	QADPYRIHXKWUSV-UHFFFAOYSA-N	Phase 3	FGFR inhibitor	NA	NA
NVP-BGJ398	FGFR3	53235510	QADPYRIHXKWUSV-UHFFFAOYSA-N	Phase 3	FGFR inhibitor	NA	NA
NVP-BGJ398	FGFR4	53235510	QADPYRIHXKWUSV-UHFFFAOYSA-N	Phase 3	FGFR inhibitor	NA	NA
NVP-BGJ398	KDR	53235510	QADPYRIHXKWUSV-UHFFFAOYSA-N	Phase 3	FGFR inhibitor	NA	NA
NVP-BHG712	EPHB4	16747388	ZCCPLJOKGAACRT-UHFFFAOYSA-N	Preclinical	ephrin inhibitor	NA	NA
NVP-BSK805	JAK2	46398810	IBPVXAOOVUAOKJ-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
NVP-BVU972	MET	44206063	RNCNPRCUHHDYPC-UHFFFAOYSA-N	Preclinical	MET inhibitor	NA	NA
NVP-DPP728	DPP4	9796290	VFFZWMWTUSXDCB-ZDUSSCGKSA-N	Phase 2	dipeptidyl peptidase inhibitor	NA	NA
NVP-HSP990	HSP90AA1	46216556	WSMQUUGTQYPVPD-OAHLLOKOSA-N	Phase 1	HSP inhibitor	NA	NA
NVP-HSP990	HSP90AB1	46216556	WSMQUUGTQYPVPD-OAHLLOKOSA-N	Phase 1	HSP inhibitor	NA	NA
NVP-TAE226	PTK2	9934347	UYJNQQDJUOUFQJ-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
NVP-TAE684	ALK	16038120	QQWUGDVOUVUTOY-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
NVP-TAE684	INSR	16038120	QQWUGDVOUVUTOY-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
NVP-TNKS656	TNKS2	136237316	DYGBNAYFDZEYBA-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor	NA	NA
NVP-231	CERK	4096211	MVSSJPGNLQPWSW-UHFFFAOYSA-N	Preclinical	ceramidase inhibitor	NA	NA
NVS-PAK1-1	PAK1	137125241	OINGHOPGNMYCAB-INIZCTEOSA-N	Preclinical	p21 activated kinase inhibitor	NA	NA
N6-cyclopentyladenosine	ADORA1	657378	SQMWSBKSHWARHU-SDBHATRESA-N	Preclinical	adenosine receptor agonist	NA	NA
N6-cyclopentyladenosine	ADORA2A	657378	SQMWSBKSHWARHU-SDBHATRESA-N	Preclinical	adenosine receptor agonist	NA	NA
N6-cyclopentyladenosine	ADORA2B	657378	SQMWSBKSHWARHU-SDBHATRESA-N	Preclinical	adenosine receptor agonist	NA	NA
N6-cyclopentyladenosine	ADORA3	657378	SQMWSBKSHWARHU-SDBHATRESA-N	Preclinical	adenosine receptor agonist	NA	NA
N6-cyclopentyladenosine	SLC29A1	657378	SQMWSBKSHWARHU-SDBHATRESA-N	Preclinical	adenosine receptor agonist	NA	NA
N6022	ADH5	44623946	YVPGZQLRPAGKLA-UHFFFAOYSA-N	Phase 1/Phase 2	alcohol dehydrogenase inhibitor	NA	NA
O-acetyl-L-serine	PTGS1	99478	VZXPDPZARILFQX-BYPYZUCNSA-N	Preclinical		NA	NA
OAC2	POU5F1	2814138	JCAFGYWSIWYMOX-UHFFFAOYSA-N	Preclinical	Oct activator	NA	NA
obatoclax	BCL2	NA	RFTSSZJZXOSICM-GRSHGNNSSA-N	Phase 3	BCL inhibitor	NA	NA
obeticholic-acid	NR1H4	NA	ZXERDUOLZKYMJM-XNNZWSTBSA-N	Launched	FXR agonist	gastroenterology	primary biliary cholangitis
obidoxime	ACHE	8251	HIGRLDNHDGYWQJ-UHFFFAOYSA-P	Launched	cholinesterase reactivator	critical care|neurology/psychiatry	poison antidote|nerve gas poisoning
ochromycinone	STAT3	11808929	ZAWXOCUFQSQDJS-VIFPVBQESA-N	Phase 1	STAT inhibitor	NA	NA
ocinaplon	GABRA1	216456	OQJFBUOFGHPMSR-UHFFFAOYSA-N	Phase 3	GABA receptor modulator	NA	NA
ocinaplon	GABRA2	216456	OQJFBUOFGHPMSR-UHFFFAOYSA-N	Phase 3	GABA receptor modulator	NA	NA
ocinaplon	GABRA3	216456	OQJFBUOFGHPMSR-UHFFFAOYSA-N	Phase 3	GABA receptor modulator	NA	NA
ocinaplon	GABRA5	216456	OQJFBUOFGHPMSR-UHFFFAOYSA-N	Phase 3	GABA receptor modulator	NA	NA
octopamine	F10	657354	QHGUCRYDKWKLMG-UHFFFAOYSA-N	Preclinical	trace amine associated receptor agonist	NA	NA
octopamine	TAAR1	657354	QHGUCRYDKWKLMG-UHFFFAOYSA-N	Preclinical	trace amine associated receptor agonist	NA	NA
octreotide	SSTR2	NA	DEQANNDTNATYII-KWPKQMLXSA-N	Launched	somatostatin receptor agonist	gastroenterology|endocrinology|oncology	diarrhea|acromegaly|carcinoid tumors
octreotide	SSTR3	NA	DEQANNDTNATYII-KWPKQMLXSA-N	Launched	somatostatin receptor agonist	gastroenterology|endocrinology|oncology	diarrhea|acromegaly|carcinoid tumors
octreotide	SSTR5	NA	DEQANNDTNATYII-KWPKQMLXSA-N	Launched	somatostatin receptor agonist	gastroenterology|endocrinology|oncology	diarrhea|acromegaly|carcinoid tumors
OC000459	PTGDR2	11462174	FATGTHLOZSXOBC-UHFFFAOYSA-N	Phase 2	CRTH receptor antagonist	NA	NA
odanacatib	CTSK	10152654	FWIVDMJALNEADT-SFTDATJTSA-N	Phase 3	cathepsin inhibitor	NA	NA
ODQ	GUCY1A2	1456	LZMHWZHOZLVYDL-UHFFFAOYSA-N	Preclinical	guanylyl cyclase inhibitor	NA	NA
ODQ	GUCY1A3	1456	LZMHWZHOZLVYDL-UHFFFAOYSA-N	Preclinical	guanylyl cyclase inhibitor	NA	NA
ODQ	GUCY1B3	1456	LZMHWZHOZLVYDL-UHFFFAOYSA-N	Preclinical	guanylyl cyclase inhibitor	NA	NA
OF-1	BRD1	35397514	YUNQZQREIHWDQT-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
OG-L002	KDM1A	56639570	DSOJSZXQRJGBCW-CABCVRRESA-N	Preclinical	histone lysine demethylase inhibitor	NA	NA
OICR-9429	WDR5	91623360	DJOVLOYCGXNVPI-UHFFFAOYSA-N	Preclinical	WDR5/MLL interaction inhibitor	NA	NA
olanzapine	ADRA1A	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	ADRA1B	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	ADRA2A	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	ADRA2B	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	ADRA2C	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	ADRB1	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	ADRB2	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	ADRB3	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	CHRM1	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	CHRM2	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	CHRM3	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	CHRM4	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	CHRM5	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	DRD1	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	DRD2	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	DRD3	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	DRD4	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	DRD5	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRA1	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRA2	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRA3	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRA4	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRA5	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRA6	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRB1	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRB2	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRB3	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRD	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRE	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRG1	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRG2	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRG3	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRP	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	GABRQ	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HRH1	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HRH2	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HRH4	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR1A	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR1B	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR1D	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR1E	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR1F	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR2A	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR2B	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR2C	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR3A	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR5A	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR6	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olanzapine	HTR7	135398745	KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
olaparib	PARP1	23725625	FDLYAMZZIXQODN-UHFFFAOYSA-N	Launched	PARP inhibitor	oncology	ovarian cancer
olaparib	PARP2	23725625	FDLYAMZZIXQODN-UHFFFAOYSA-N	Launched	PARP inhibitor	oncology	ovarian cancer
OLDA	GPR119	5282106	QQBPLXNESPTPNU-KTKRTIGZSA-N	Preclinical	TRPV agonist	NA	NA
oleamide	HTR7	5283387	FATBGEAMYMYZAF-KTKRTIGZSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
oleamide	PLA2G2A	5283387	FATBGEAMYMYZAF-KTKRTIGZSA-N	Preclinical	cannabinoid receptor agonist	NA	NA
oleanolic-acid	GPBAR1	10494	MIJYXULNPSFWEK-GTOFXWBISA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
oleoylethanolamide	CNR1	5283454	BOWVQLFMWHZBEF-KTKRTIGZSA-N	Preclinical	cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist	NA	NA
oleoylethanolamide	GPR119	5283454	BOWVQLFMWHZBEF-KTKRTIGZSA-N	Preclinical	cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist	NA	NA
oleoylethanolamide	GPR55	5283454	BOWVQLFMWHZBEF-KTKRTIGZSA-N	Preclinical	cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist	NA	NA
oleoylethanolamide	PPARA	5283454	BOWVQLFMWHZBEF-KTKRTIGZSA-N	Preclinical	cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist	NA	NA
oleuropein	GPER1	NA	RFWGABANNQMHMZ-JIBQERFGSA-N	Phase 2	estrogen receptor agonist	NA	NA
oligomycin-A	ATP5A1	133268482	MNULEGDCPYONBU-BGLGBHOCSA-N	Preclinical	ATP synthase inhibitor|ATPase inhibitor	NA	NA
olmesartan	AGTR1	158781	VTRAEEWXHOVJFV-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
olmesartan-medoxomil	AGTR1	130881	UQGKUQLKSCSZGY-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
olmutinib	BTK	54758501	FDMQDKQUTRLUBU-UHFFFAOYSA-N	Launched	Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
olmutinib	EGFR	54758501	FDMQDKQUTRLUBU-UHFFFAOYSA-N	Launched	Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
olomoucine	CDK1	4592	GTVPOLSIJWJJNY-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
olomoucine	CDK2	4592	GTVPOLSIJWJJNY-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
olomoucine	CDK5	4592	GTVPOLSIJWJJNY-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
olomoucine	MAPK1	4592	GTVPOLSIJWJJNY-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
olopatadine	HRH1	5281071	JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
olopatadine	S100A1	5281071	JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
olopatadine	S100A12	5281071	JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
olopatadine	S100A13	5281071	JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
olopatadine	S100A2	5281071	JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
olopatadine	S100B	5281071	JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched	histamine receptor antagonist	ophthalmology	conjunctivitis
olprinone	PDE3A	4593	JPAWFIIYTJQOKW-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
olsalazine	IFNG	NA	QQBDLJCYGRGAKP-FOCLMDBBSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
olsalazine	TPMT	NA	QQBDLJCYGRGAKP-FOCLMDBBSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
oltipraz	ANG	47318	CKNAQFVBEHDJQV-UHFFFAOYSA-N	Phase 3	nuclear factor erythroid derived|like (NRF2) activator	NA	NA
olvanil	CNR1	5311093	OPZKBPQVWDSATI-KHPPLWFESA-N	Preclinical	TRPV agonist	NA	NA
olvanil	GPR119	5311093	OPZKBPQVWDSATI-KHPPLWFESA-N	Preclinical	TRPV agonist	NA	NA
olvanil	TRPV1	5311093	OPZKBPQVWDSATI-KHPPLWFESA-N	Preclinical	TRPV agonist	NA	NA
omapatrilat	ACE	656629	LVRLSYPNFFBYCZ-VGWMRTNUSA-N	Preclinical	metalloproteinase inhibitor	NA	NA
omapatrilat	MME	656629	LVRLSYPNFFBYCZ-VGWMRTNUSA-N	Preclinical	metalloproteinase inhibitor	NA	NA
omarigliptin	DPP4	46209133	MKMPWKUAHLTIBJ-ISTRZQFTSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
OMDM-2	GPR119	6604915	ICDMLAQPOAVWNH-HAAQQRBASA-N	Preclinical	FAAH inhibitor	NA	NA
omecamtiv-mecarbil	MYBPC3	11689883	RFUBTTPMWSKEIW-UHFFFAOYSA-N	Phase 3	cardiac myosin activator	NA	NA
omeprazole	ATP4A	9568614	SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched	ATPase inhibitor	gastroenterology	heartburn
omeprazole	CLCN2	9568614	SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched	ATPase inhibitor	gastroenterology	heartburn
omeprazole-magnesium	ATP4A	9601083	KWORUUGOSLYAGD-YPPDDXJESA-N	Launched	proton pump inhibitor	gastroenterology	gastroesophageal reflux disease (GERD)|heartburn
omeprazole-magnesium	ATP4B	9601083	KWORUUGOSLYAGD-YPPDDXJESA-N	Launched	proton pump inhibitor	gastroenterology	gastroesophageal reflux disease (GERD)|heartburn
ONC201	TNFSF10	73777259	VLULRUCCHYVXOH-UHFFFAOYSA-N	Phase 2	AKT inhibitor|MAP kinase inhibitor	NA	NA
ondansetron	HTR3A	667538	FELGMEQIXOGIFQ-CYBMUJFWSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
ondansetron	HTR3B	667538	FELGMEQIXOGIFQ-CYBMUJFWSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
ONO-AE3-208	PTGER4	92978378	MTDIMKNAJUQTIO-OAHLLOKOSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
ONO-4059	BTK	54755438	SEJLPXCPMNSRAM-GOSISDBHSA-N	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
ONO-4817	MMP8	9888141	HDWWQELUBWGQGA-WMZOPIPTSA-N	Phase 1	matrix metalloprotease inhibitor	NA	NA
ONO-8130	PTGER1	9827317	IOXMDBQCUCDLAF-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
ON123300	CDK4	56649281	VADOZMZXXRBXNY-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
ON123300	NUAK1	56649281	VADOZMZXXRBXNY-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
ON123300	PDGFRB	56649281	VADOZMZXXRBXNY-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
OPC-21268	AVPR1A	114904	KSNUCNRMDYJBKT-UHFFFAOYSA-N	Phase 1	vasopressin receptor antagonist	NA	NA
OPC-21268	AVPR2	114904	KSNUCNRMDYJBKT-UHFFFAOYSA-N	Phase 1	vasopressin receptor antagonist	NA	NA
OPC-21268	OXTR	114904	KSNUCNRMDYJBKT-UHFFFAOYSA-N	Phase 1	vasopressin receptor antagonist	NA	NA
opicapone	COMT	135565903	ASOADIZOVZTJSR-UHFFFAOYSA-N	Phase 3	catechol O methyltransferase inhibitor	NA	NA
OR-486	COMT	3870203	VDCDWNDTNSWDFJ-UHFFFAOYSA-N	Preclinical	catechol O methyltransferase inhibitor	NA	NA
orantinib	AURKA	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
orantinib	AURKB	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
orantinib	EGFR	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
orantinib	FGFR1	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
orantinib	FGFR2	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
orantinib	KDR	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
orantinib	PDGFRA	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
orantinib	PDGFRB	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
ORE1001	ACE2	448281	NTCCRGGIJNDEAB-IRXDYDNUSA-N	Phase 1/Phase 2	angiotensin converting enzyme inhibitor	NA	NA
ORG-12962	HTR2A	9796408	QZYYPQAYSFBKPW-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
ORG-12962	HTR2B	9796408	QZYYPQAYSFBKPW-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
ORG-12962	HTR2C	9796408	QZYYPQAYSFBKPW-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
ORG-25543	GLRB	5311287	ZCYOBMASPXQBSZ-UHFFFAOYSA-N	Preclinical	glycine transporter inhibitor	NA	NA
ORG-25543	SLC6A5	5311287	ZCYOBMASPXQBSZ-UHFFFAOYSA-N	Preclinical	glycine transporter inhibitor	NA	NA
ORG-27569	CNR1	44828492	AHFZDNYNXFMRFQ-UHFFFAOYSA-N	Preclinical	cannabinoid receptor modulator	NA	NA
ORG-9768	ADRA2A	22152353	JOLKQWPKJFRPOU-UHFFFAOYSA-N	Phase 1	adrenergic receptor antagonist	NA	NA
oridonin	BCL2	5321010	SDHTXBWLVGWJFT-XKCURVIJSA-N	Preclinical	BCL inhibitor	NA	NA
orlistat	CNR1	3034010	AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched	lipase inhibitor	endocrinology	weight-loss aid
orlistat	DAGLA	3034010	AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched	lipase inhibitor	endocrinology	weight-loss aid
orlistat	DAGLB	3034010	AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched	lipase inhibitor	endocrinology	weight-loss aid
orlistat	FASN	3034010	AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched	lipase inhibitor	endocrinology	weight-loss aid
orlistat	LIPF	3034010	AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched	lipase inhibitor	endocrinology	weight-loss aid
orlistat	PNLIP	3034010	AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched	lipase inhibitor	endocrinology	weight-loss aid
ornithine	GPRC6A	74765349	GGTYBZJRPHEQDG-PGMHMLKASA-N	Launched	NFkB pathway modulator	NA	NA
orotic-acid	DHODH	967	PXQPEWDEAKTCGB-UHFFFAOYSA-N	Phase 2		NA	NA
orphanin-fq	OPRL1	56947112	PULGYDLMFSFVBL-SMFNREODSA-N	Phase 1	opioid receptor agonist	NA	NA
orphanin-fq	OPRM1	56947112	PULGYDLMFSFVBL-SMFNREODSA-N	Phase 1	opioid receptor agonist	NA	NA
orteronel	CYP17A1	10335364	OZPFIJIOIVJZMN-GOSISDBHSA-N	Phase 3	androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor	NA	NA
ORY-1001	KDM1A	71543365	ALHBJBCQLJZYON-PFSRBDOWSA-N	Phase 1/Phase 2	histone lysine demethylase inhibitor	NA	NA
oseltamivir-phosphate	CES1	65028	VSZGPKBBMSAYNT-RRFJBIMHSA-N	Launched	neuraminidase inhibitor	infectious disease	influenza A virus infection
oseltamivir-phosphate	NEU1	65028	VSZGPKBBMSAYNT-RRFJBIMHSA-N	Launched	neuraminidase inhibitor	infectious disease	influenza A virus infection
oseltamivir-phosphate	NEU2	65028	VSZGPKBBMSAYNT-RRFJBIMHSA-N	Launched	neuraminidase inhibitor	infectious disease	influenza A virus infection
osemozotan	HTR1A	198747	MEEQBDCQPIZMLY-HNNXBMFYSA-N	Phase 2/Phase 3	serotonin receptor agonist	NA	NA
OSI-027	MTOR	NA	JROFGZPOBKIAEW-HAQNSBGRSA-N	Phase 1	mTOR inhibitor	NA	NA
OSI-420	EGFR	10317566	KOQIAZNBAWFSQM-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
OSI-930	FLT1	9868037	FGTCROZDHDSNIO-UHFFFAOYSA-N	Phase 1	KIT inhibitor|VEGFR inhibitor	NA	NA
OSI-930	KDR	9868037	FGTCROZDHDSNIO-UHFFFAOYSA-N	Phase 1	KIT inhibitor|VEGFR inhibitor	NA	NA
OSI-930	KIT	9868037	FGTCROZDHDSNIO-UHFFFAOYSA-N	Phase 1	KIT inhibitor|VEGFR inhibitor	NA	NA
osimertinib	EGFR	71496458	DUYJMQONPNNFPI-UHFFFAOYSA-N	Launched	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
ospemifene	ESR1	3036505	LUMKNAVTFCDUIE-VHXPQNKSSA-N	Launched	selective estrogen receptor modulator (SERM)	obstetrics/gynecology|endocrinology	vaginal atrophy|dyspareunia|menopause
ospemifene	ESR2	3036505	LUMKNAVTFCDUIE-VHXPQNKSSA-N	Launched	selective estrogen receptor modulator (SERM)	obstetrics/gynecology|endocrinology	vaginal atrophy|dyspareunia|menopause
ostarine	AR	11326715	JNGVJMBLXIUVRD-SFHVURJKSA-N	Phase 3	androgen receptor modulator	NA	NA
OT-R-antagonist-1	AVPR1A	9690136	IBXGJPAYWMFXSF-UEEONYLUSA-N	Preclinical	oxytocin receptor antagonist	NA	NA
OT-R-antagonist-1	OXTR	9690136	IBXGJPAYWMFXSF-UEEONYLUSA-N	Preclinical	oxytocin receptor antagonist	NA	NA
otamixaban	F10	5496659	PFGVNLZDWRZPJW-OPAMFIHVSA-N	Phase 3	coagulation factor inhibitor	NA	NA
otenzepad	CHRM1	76966449	UBRKDAVQCKZSPO-GOSISDBHSA-N	Phase 3	acetylcholine receptor antagonist	NA	NA
otenzepad	CHRM2	76966449	UBRKDAVQCKZSPO-GOSISDBHSA-N	Phase 3	acetylcholine receptor antagonist	NA	NA
otenzepad	CHRM3	76966449	UBRKDAVQCKZSPO-GOSISDBHSA-N	Phase 3	acetylcholine receptor antagonist	NA	NA
otenzepad	CHRM4	76966449	UBRKDAVQCKZSPO-GOSISDBHSA-N	Phase 3	acetylcholine receptor antagonist	NA	NA
otenzepad	CHRM5	76966449	UBRKDAVQCKZSPO-GOSISDBHSA-N	Phase 3	acetylcholine receptor antagonist	NA	NA
otilonium	CACNA1C	72093	NQHNLNLJPDMBFN-UHFFFAOYSA-O	Launched	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
OTS167	MELK	NA	DKZYXHCYPUVGAF-JCNLHEQBSA-N	Phase 1/Phase 2	maternal embryonic leucine zipper kinase inhibitor	NA	NA
OTX015	BRD2	9936746	GNMUEVRJHCWKTO-FQEVSTJZSA-N	Phase 1/Phase 2	bromodomain inhibitor	NA	NA
OTX015	BRD3	9936746	GNMUEVRJHCWKTO-FQEVSTJZSA-N	Phase 1/Phase 2	bromodomain inhibitor	NA	NA
OTX015	BRD4	9936746	GNMUEVRJHCWKTO-FQEVSTJZSA-N	Phase 1/Phase 2	bromodomain inhibitor	NA	NA
ouabain	ATP1A1	11527152	LPMXVESGRSUGHW-VGFRVVOQSA-N	Launched	ATPase inhibitor	cardiology	hypertension|cardiac arrythmia
OXA-06	ROCK1	24857242	XUIUXXQVHPEQNM-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
OXA-06	ROCK2	24857242	XUIUXXQVHPEQNM-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
oxaprozin	PTGS1	4614	OFPXSFXSNFPTHF-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
oxaprozin	PTGS2	4614	OFPXSFXSNFPTHF-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
oxatomide	HRH1	4615	BAINIUMDFURPJM-UHFFFAOYSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis
oxcarbazepine	SCN10A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN11A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN1A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN2A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN3A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN4A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN5A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN7A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN8A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
oxcarbazepine	SCN9A	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	seizures
OXF-BD-02	BRD4	70699441	FEQUIPXIENTMJN-SFHVURJKSA-N	Preclinical	bromodomain inhibitor	NA	NA
oxfenicine	CPT1A	89853	LJCWONGJFPCTTL-SSDOTTSWSA-N	Phase 1	carnitine palmitoyltransferase inhibitor	NA	NA
oxfenicine	CPT1B	89853	LJCWONGJFPCTTL-SSDOTTSWSA-N	Phase 1	carnitine palmitoyltransferase inhibitor	NA	NA
oxibendazole	TUBB	4622	RAOCRURYZCVHMG-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	strongyles
oxibendazole	TUBB4B	4622	RAOCRURYZCVHMG-UHFFFAOYSA-N	Launched	tubulin polymerization inhibitor	infectious disease	strongyles
oxotremorine-M	CHRM1	4629	CANZROMYQDHYHR-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
oxotremorine-M	CHRM2	4629	CANZROMYQDHYHR-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
oxotremorine-M	CHRM3	4629	CANZROMYQDHYHR-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
oxotremorine-M	CHRM4	4629	CANZROMYQDHYHR-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
oxotremorine-sesquifumarate	CHRM1	4630	RSDOPYMFZBJHRL-UHFFFAOYSA-N	Preclinical	cholinergic receptor agonist	NA	NA
oxotremorine-sesquifumarate	CHRM2	4630	RSDOPYMFZBJHRL-UHFFFAOYSA-N	Preclinical	cholinergic receptor agonist	NA	NA
oxotremorine-sesquifumarate	CHRM3	4630	RSDOPYMFZBJHRL-UHFFFAOYSA-N	Preclinical	cholinergic receptor agonist	NA	NA
oxotremorine-sesquifumarate	CHRM4	4630	RSDOPYMFZBJHRL-UHFFFAOYSA-N	Preclinical	cholinergic receptor agonist	NA	NA
oxprenolol	ADRB1	94423	CEMAWMOMDPGJMB-CYBMUJFWSA-N	Launched	adrenergic receptor antagonist	cardiology	angina pectoris|hypertension|cardiac arrythmia
oxybenzone	LIPE	4632	DXGLGDHPHMLXJC-UHFFFAOYSA-N	Launched	lipase inhibitor	dermatology	sunscreen lotion
oxybuprocaine	SCN10A	4633	CMHHMUWAYWTMGS-UHFFFAOYSA-N	Launched	local anesthetic	neurology/psychiatry	local anesthetic
oxybutynin	CHRM1	6098167	XIQVNETUBQGFHX-QFIPXVFZSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
oxybutynin	CHRM2	6098167	XIQVNETUBQGFHX-QFIPXVFZSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
oxybutynin	CHRM3	6098167	XIQVNETUBQGFHX-QFIPXVFZSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
oxymetazoline	ADRA1A	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	ADRA1B	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	ADRA1D	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	ADRA2A	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	ADRA2B	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	ADRA2C	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	HTR1B	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	HTR1D	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxymetazoline	HTR2C	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology	nasal congestion
oxyphenonium	CHRM1	5748	GFRUPHOKLBPHTQ-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
oxyphenonium	CHRM3	5748	GFRUPHOKLBPHTQ-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
oxypurinol	XDH	135398752	HXNFUBHNUDHIGC-UHFFFAOYSA-N	Phase 2/Phase 3	xanthine oxidase inhibitor	NA	NA
oxyquinoline	METAP2	1923	MCJGNVYPOGVAJF-UHFFFAOYSA-N	Launched	chelating agent	dermatology	cosmetic
oxytocin	AVPR1A	133698923	XNOPRXBHLZRZKH-LGMJNFKNSA-N	Launched	oxytocin receptor agonist	obstetrics/gynecology	labor induction
oxytocin	AVPR1B	133698923	XNOPRXBHLZRZKH-LGMJNFKNSA-N	Launched	oxytocin receptor agonist	obstetrics/gynecology	labor induction
oxytocin	AVPR2	133698923	XNOPRXBHLZRZKH-LGMJNFKNSA-N	Launched	oxytocin receptor agonist	obstetrics/gynecology	labor induction
oxytocin	OXTR	133698923	XNOPRXBHLZRZKH-LGMJNFKNSA-N	Launched	oxytocin receptor agonist	obstetrics/gynecology	labor induction
ozagrel	TBXAS1	5282440	SHZKQBHERIJWAO-AATRIKPKSA-N	Launched	thromboxane synthase inhibitor	neurology/psychiatry	stroke
ozanimod	S1PR1	52938427	XRVDGNKRPOAQTN-FQEVSTJZSA-N	Phase 3	sphingosine 1-phosphate receptor agonist	NA	NA
O4I1	POU5F1	2774690	QJEJLARVLKHYFW-UHFFFAOYSA-N	Preclinical	Oct inducer	NA	NA
O6-benzylguanine	MGMT	4578	KRWMERLEINMZFT-UHFFFAOYSA-N	Phase 3	O6-alkylguanine-DNA alkyltransferase inhibitor	NA	NA
PA-452	RXRA	9803242	JJUUTJCZMGZJDZ-UHFFFAOYSA-N	Preclinical	retinoid receptor antagonist	NA	NA
PAC-1	CASP3	9675990	YQNRVGJCPCNMKT-LFVJCYFKSA-N	Phase 1	caspase activator	NA	NA
paclitaxel	BCL2	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	MAP2	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	MAP4	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	MAPT	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	NR1I2	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TLR4	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBA1A	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBA1B	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBA1C	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBA3C	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBA3D	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBA3E	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBA4A	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB1	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB2A	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB2B	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB3	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB4A	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB4B	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB6	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
paclitaxel	TUBB8	36314	RCINICONZNJXQF-MZXODVADSA-N	Launched	tubulin polymerization inhibitor	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
PACOCF3	PLA2G4A	4670	MAHYXYTYTLCTQD-UHFFFAOYSA-N	Preclinical	phospholipase inhibitor	NA	NA
pacritinib	FLT3	46216796	HWXVIOGONBBTBY-ONEGZZNKSA-N	Phase 3	FLT3 inhibitor|JAK inhibitor	NA	NA
pacritinib	JAK1	46216796	HWXVIOGONBBTBY-ONEGZZNKSA-N	Phase 3	FLT3 inhibitor|JAK inhibitor	NA	NA
pacritinib	JAK2	46216796	HWXVIOGONBBTBY-ONEGZZNKSA-N	Phase 3	FLT3 inhibitor|JAK inhibitor	NA	NA
pacritinib	JAK3	46216796	HWXVIOGONBBTBY-ONEGZZNKSA-N	Phase 3	FLT3 inhibitor|JAK inhibitor	NA	NA
palbociclib	CDK4	5330286	"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)"	Launched	CDK inhibitor	oncology	breast cancer
palbociclib	CDK6	5330286	"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)"	Launched	CDK inhibitor	oncology	breast cancer
paliperidone	DRD2	9823781	PMXMIIMHBWHSKN-IBGZPJMESA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
paliperidone	HTR2A	9823781	PMXMIIMHBWHSKN-IBGZPJMESA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
palmatine-chloride	CYP3A4	19009	QUCQEUCGKKTEBI-UHFFFAOYSA-N	Preclinical	dopamine synthesis inhibitor	NA	NA
palmitoylethanolamide	CNR2	4671	HXYVTAGFYLMHSO-UHFFFAOYSA-N	Launched	cannabinoid receptor agonist	NA	NA
palmitoylethanolamide	GPR119	4671	HXYVTAGFYLMHSO-UHFFFAOYSA-N	Launched	cannabinoid receptor agonist	NA	NA
palmitoylethanolamide	GPR55	4671	HXYVTAGFYLMHSO-UHFFFAOYSA-N	Launched	cannabinoid receptor agonist	NA	NA
palomid-529	MTOR	86324425	YEAHTLOYHVWAKW-CQSZACIVSA-N	Phase 1	AKT inhibitor|mTOR inhibitor	NA	NA
palonosetron	HTR3A	6337614	CPZBLNMUGSZIPR-NVXWUHKLSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
palosuran	UTS2R	10173280	WYJCYXOCHXWTHG-UHFFFAOYSA-N	Phase 2	urotensin receptor antagonist	NA	NA
palovarotene	RARG	10295295	YTFHCXIPDIHOIA-DHZHZOJOSA-N	Phase 3	retinoid receptor agonist	NA	NA
pamidronate	FDPS	4674	WRUUGTRCQOWXEG-UHFFFAOYSA-N	Launched	bone resorption inhibitor	endocrinology|oncology|hematologic malignancy	hypercalcemia|Paget's disease|breast cancer|multiple myeloma
pancuronium	CHRM2	441289	GVEAYVLWDAFXET-XGHATYIMSA-N	Launched	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant
pancuronium	CHRM3	441289	GVEAYVLWDAFXET-XGHATYIMSA-N	Launched	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant
pancuronium	CHRNA1	441289	GVEAYVLWDAFXET-XGHATYIMSA-N	Launched	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant
pancuronium	CHRNA2	441289	GVEAYVLWDAFXET-XGHATYIMSA-N	Launched	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant
panobinostat	HDAC1	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
panobinostat	HDAC2	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
panobinostat	HDAC3	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
panobinostat	HDAC4	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
panobinostat	HDAC6	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
panobinostat	HDAC7	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
panobinostat	HDAC8	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
panobinostat	HDAC9	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	HDAC inhibitor	hematologic malignancy	multiple myeloma
pantoprazole	ATP4A	11181988	IQPSEEYGBUAQFF-AREMUKBSSA-N	Launched	ATPase inhibitor	gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)|Zollinger-Ellison syndrome
PAOPA	DRD2	44281634	QXHVGEXNEZRSGG-JGVFFNPUSA-N	Preclinical	dopamine receptor modulator	NA	NA
papaverine	PDE10A	4680	XQYZDYMELSJDRZ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology|hematology|gastroenterology	myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm
papaverine	PDE4B	4680	XQYZDYMELSJDRZ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology|hematology|gastroenterology	myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm
papaverine	PDE5A	4680	XQYZDYMELSJDRZ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology|hematology|gastroenterology	myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm
para-toluenesulfonamide	CA12	6269	LMYRWZFENFIFIT-UHFFFAOYSA-N	Phase 3		NA	NA
para-toluenesulfonamide	CA2	6269	LMYRWZFENFIFIT-UHFFFAOYSA-N	Phase 3		NA	NA
para-toluenesulfonamide	CA6	6269	LMYRWZFENFIFIT-UHFFFAOYSA-N	Phase 3		NA	NA
para-toluenesulfonamide	CA9	6269	LMYRWZFENFIFIT-UHFFFAOYSA-N	Phase 3		NA	NA
paracetamol	FAAH	1983	"InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)"	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology	pain relief|fever
paracetamol	PTGS1	1983	"InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)"	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology	pain relief|fever
paracetamol	PTGS2	1983	"InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)"	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology	pain relief|fever
paracetamol	TRPV1	1983	"InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)"	Launched	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology	pain relief|fever
paramethadione	CACNA1G	51380897	VQASKUSHBVDKGU-SSDOTTSWSA-N	Launched	anticonvulsant	neurology/psychiatry	seizures
parbendazole	TUBB	26596	YRWLZFXJFBZBEY-UHFFFAOYSA-N	Preclinical	tubulin polymerization inhibitor	NA	NA
pardoprunox	DRD2	6918525	YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3	dopamine receptor agonist|serotonin receptor agonist	NA	NA
pardoprunox	DRD3	6918525	YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3	dopamine receptor agonist|serotonin receptor agonist	NA	NA
pardoprunox	DRD4	6918525	YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3	dopamine receptor agonist|serotonin receptor agonist	NA	NA
pardoprunox	HTR1A	6918525	YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3	dopamine receptor agonist|serotonin receptor agonist	NA	NA
pardoprunox	HTR7	6918525	YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3	dopamine receptor agonist|serotonin receptor agonist	NA	NA
parecoxib	LTF	119828	TZRHLKRLEZJVIJ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
pargyline	MAOA	4688	DPWPWRLQFGFJFI-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	cardiology	hypertension
pargyline	MAOB	4688	DPWPWRLQFGFJFI-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	cardiology	hypertension
paricalcitol	VDR	5281104	BPKAHTKRCLCHEA-UBFJEZKGSA-N	Launched	vitamin D receptor agonist	nephrology|endocrinology	chronic kidney disease (CKD)|hyperthyroidism
paroxetine	CHRM1	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
paroxetine	CHRM2	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
paroxetine	CHRM3	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
paroxetine	CHRM4	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
paroxetine	CHRM5	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
paroxetine	HTR2A	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
paroxetine	SLC6A2	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
paroxetine	SLC6A4	43815	AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
parthenolide-(-)	HDAC1	5420805	KTEXNACQROZXEV-QLIGOWBFSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
parthenolide-(alternate-stereo)	IKBKB	7251185	KTEXNACQROZXEV-PVLRGYAZSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
parthenolide-(alternate-stereo)	RELA	7251185	KTEXNACQROZXEV-PVLRGYAZSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
pasireotide	SSTR1	9941444	VMZMNAABQBOLAK-DBILLSOUSA-N	Launched	somatostatin receptor agonist	endocrinology	Cushing's syndrome|acromegaly
pasireotide	SSTR2	9941444	VMZMNAABQBOLAK-DBILLSOUSA-N	Launched	somatostatin receptor agonist	endocrinology	Cushing's syndrome|acromegaly
pasireotide	SSTR3	9941444	VMZMNAABQBOLAK-DBILLSOUSA-N	Launched	somatostatin receptor agonist	endocrinology	Cushing's syndrome|acromegaly
pasireotide	SSTR5	9941444	VMZMNAABQBOLAK-DBILLSOUSA-N	Launched	somatostatin receptor agonist	endocrinology	Cushing's syndrome|acromegaly
pazopanib	CSF1R	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	FGF1	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	FGFR1	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	FGFR3	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	FLT1	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	FLT4	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	ITK	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	KDR	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	KIT	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	PDGFRA	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	PDGFRB	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
pazopanib	SH2B3	10113978	CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
PCA-4248	PTAFR	6604734	DHCNAWNKZMNTIS-GFCCVEGCSA-N	Phase 1	platelet activating factor receptor antagonist	NA	NA
PCI-24781	HDAC1	11749858	MAUCONCHVWBMHK-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
PCI-24781	HDAC2	11749858	MAUCONCHVWBMHK-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
PCI-24781	HDAC3	11749858	MAUCONCHVWBMHK-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
PCI-24781	HDAC6	11749858	MAUCONCHVWBMHK-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
PCI-29732	BTK	22347110	GMJUPMONHWAZCP-UHFFFAOYSA-N	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
PCI-34051	HDAC1	24753719	AJRGHIGYPXNABY-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
PCI-34051	HDAC10	24753719	AJRGHIGYPXNABY-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
PCI-34051	HDAC6	24753719	AJRGHIGYPXNABY-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
PCI-34051	HDAC8	24753719	AJRGHIGYPXNABY-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
PCO-400	KCNJ8	129348	WJBHHTPFTVKZCV-CVEARBPZSA-N	Phase 1	potassium channel activator	NA	NA
PD-0325901	MAP2K1	9826528	SUDAHWBOROXANE-SECBINFHSA-N	Phase 2	MEK inhibitor	NA	NA
PD-102807	CHRM4	92845316	VDDUJINYXKGZLV-JOCHJYFZSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
PD-118057	KCNH2	9864959	ZCQOSCDABPVAFB-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
PD-123319	AGTR2	5311345	YSTVFDAKLDMYCR-NDEPHWFRSA-N	Phase 1	angiotensin antagonist	NA	NA
PD-128907	DRD2	5311346	YOILXOMTHPUMRG-TZMCWYRMSA-N	Preclinical	dopamine receptor agonist	NA	NA
PD-128907	DRD3	5311346	YOILXOMTHPUMRG-TZMCWYRMSA-N	Preclinical	dopamine receptor agonist	NA	NA
PD-153035	EGFR	4705	LSPANGZZENHZNJ-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
PD-153035	KDR	4705	LSPANGZZENHZNJ-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
PD-156707	EDNRA	9871594	OFCTYBMKKTVKCR-QQTULTPQSA-N	Preclinical	endothelin receptor antagonist	NA	NA
PD-156707	EDNRB	9871594	OFCTYBMKKTVKCR-QQTULTPQSA-N	Preclinical	endothelin receptor antagonist	NA	NA
PD-158780	EGFR	4707	"InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20)"	Preclinical	EGFR inhibitor	NA	NA
PD-160170	NPY1R	9820766	YUVNGBZROXQYQH-UHFFFAOYSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
PD-161570	FGFR1	5328135	MKVMEJKNLUWFSQ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor	NA	NA
PD-166285	EGFR	5311382	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PD-166285	FGFR1	5311382	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PD-166285	PDGFRB	5311382	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PD-166285	PKMYT1	5311382	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PD-166285	SRC	5311382	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PD-166285	WEE1	5311382	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PD-166793	MMP13	9887870	GJOCABIDMCKCEG-INIZCTEOSA-N	Preclinical	collagenase inhibitor|metalloproteinase inhibitor	NA	NA
PD-166793	MMP2	9887870	GJOCABIDMCKCEG-INIZCTEOSA-N	Preclinical	collagenase inhibitor|metalloproteinase inhibitor	NA	NA
PD-166793	MMP3	9887870	GJOCABIDMCKCEG-INIZCTEOSA-N	Preclinical	collagenase inhibitor|metalloproteinase inhibitor	NA	NA
PD-168077	DRD2	3645619	DNULYRGWTFLJQL-UHFFFAOYSA-N	Preclinical	dopamine receptor agonist	NA	NA
PD-168393	EGFR	4708	"InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)"	Preclinical	EGFR inhibitor	NA	NA
PD-168393	ERBB2	4708	"InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)"	Preclinical	EGFR inhibitor	NA	NA
PD-168393	SRC	4708	"InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)"	Preclinical	EGFR inhibitor	NA	NA
PD-168568	DRD2	9928335	WQEPZBNLBWDIRZ-OAQYLSRUSA-N	Preclinical	dopamine receptor antagonist	NA	NA
PD-168568	DRD4	9928335	WQEPZBNLBWDIRZ-OAQYLSRUSA-N	Preclinical	dopamine receptor antagonist	NA	NA
PD-173074	FGFR1	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	FGFR2	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	FGFR3	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	FGFR4	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	FLT1	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	FLT4	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	KDR	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	PDGFRA	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173074	PDGFRB	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	FGFR inhibitor|VEGFR inhibitor	NA	NA
PD-173212	CACNA1B	9916734	GCDHMGROXQUFNR-HEVIKAOCSA-N	Preclinical	calcium channel blocker	NA	NA
PD-184352	MAP2K1	6918454	"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)"	Phase 2	MEK inhibitor	NA	NA
PD-184352	MAP3K1	6918454	"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)"	Phase 2	MEK inhibitor	NA	NA
PD-184352	MAP3K2	6918454	"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)"	Phase 2	MEK inhibitor	NA	NA
PD-198306	MAP2K1	9956637	UHAXDAKQGVISBZ-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor|MEK inhibitor	NA	NA
PD-198306	MAP2K2	9956637	UHAXDAKQGVISBZ-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor|MEK inhibitor	NA	NA
PD-407824	WEE1	4369491	IAUZTOZLTFSMIE-UHFFFAOYSA-N	Preclinical	PKC inhibitor	NA	NA
PD-81723	ADORA1	122028	KKDKAWKYGCUOGR-UHFFFAOYSA-N	Preclinical	adenosine receptor agonist	NA	NA
PD-98059	AKT1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	CHEK1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	GSK3B	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	LCK	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	MAP2K1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	MAPK1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	MAPK11	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	MAPK12	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	MAPK14	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	MAPK8	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	PRKCA	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	RAF1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	ROCK1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	RPS6KB1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PD-98059	SGK1	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
PDE10-IN-1	PDE10A	72709059	ZLHNYULRKIEGAY-HZPDHXFCSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
PDP-EA	FAAH	69724031	BIOVSNWTCKRADD-UHFFFAOYSA-N	Preclinical	FAAH activator	NA	NA
PD1-PDL-inhibitor-1	CD274	91663303	ZBOYJODMIAUJHH-SANMLTNESA-N	Preclinical	programmed death ligand inhibitor	NA	NA
peficitinib	JAK1		DREIJXJRTLTGJC-ZKVNVPQCSA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
peficitinib	JAK2		DREIJXJRTLTGJC-ZKVNVPQCSA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
peficitinib	JAK3		DREIJXJRTLTGJC-ZKVNVPQCSA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
pefloxacin	TOP2A	6919009	FHFYDNQZQSQIAI-UHFFFAOYSA-N	Launched	bacterial DNA gyrase inhibitor	infectious disease|urology	gastrointestinal infections|urethritis|gonorrhea|urinary tract infections
pelanserin	HTR2A	65435	WPKPLSFHHBBLRY-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
pelitinib	EGFR	6445562	WVUNYSQLFKLYNI-AATRIKPKSA-N	Phase 2	EGFR inhibitor	NA	NA
pemetrexed	ATIC	135410875	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	oncology	non-small cell lung cancer (NSCLC)|mesothelioma
pemetrexed	DHFR	135410875	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	oncology	non-small cell lung cancer (NSCLC)|mesothelioma
pemetrexed	GART	135410875	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	oncology	non-small cell lung cancer (NSCLC)|mesothelioma
pemetrexed	TYMS	135410875	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	oncology	non-small cell lung cancer (NSCLC)|mesothelioma
pemirolast	HRH1	57697	HIANJWSAHKJQTH-UHFFFAOYSA-N	Launched	mediator release inhibitor	pulmonary	asthma
penbutolol	ADRB1	37464	KQXKVJAGOJTNJS-HNNXBMFYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
penbutolol	ADRB2	37464	KQXKVJAGOJTNJS-HNNXBMFYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
penbutolol	HTR1A	37464	KQXKVJAGOJTNJS-HNNXBMFYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
penbutolol	HTR1B	37464	KQXKVJAGOJTNJS-HNNXBMFYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
penfluridol	CACNA1G	33630	MDLAAYDRRZXJIF-UHFFFAOYSA-N	Launched	T-type calcium channel blocker	neurology/psychiatry	schizophrenia
pentagastrin	CCKBR	9853654	NEYNJQRKHLUJRU-DZUOILHNSA-N	Launched	CCK receptor agonist	gastroenterology	anacidity diagnostic|gastric hypersecretion diagnostic
pentamidine	TRDMT1	4735	XDRYMKDFEDOLFX-UHFFFAOYSA-N	Launched	anti-pneumocystis agent	infectious disease	pneumonia
pentolinium	CHRNA10	5850	XSBSKEQEUFOSDD-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	cardiology	hypertension
pentolinium	CHRNA3	5850	XSBSKEQEUFOSDD-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	cardiology	hypertension
pentolinium	CHRNA4	5850	XSBSKEQEUFOSDD-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	cardiology	hypertension
pentolinium	CHRNB4	5850	XSBSKEQEUFOSDD-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	cardiology	hypertension
pentostatin	ADA	439693	FPVKHBSQESCIEP-JQCXWYLXSA-N	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
pentoxifylline	ADORA1	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	ADORA2A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	ADORA2B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	ADRA2B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	NT5E	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE10A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE1A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE1B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE1C	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE2A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE3A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE3B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE4A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE4B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE4C	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE4D	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE5A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE6A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE6B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE6C	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE6D	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE6G	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE6H	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE7A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE7B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE8A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE8B	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	PDE9A	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pentoxifylline	TNF	4740	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	claudication
pepstatin	CTSB	5478883	FAXGPCHRFPCXOO-LXTPJMTPSA-N	Preclinical	aspartic protease inhibitor	NA	NA
pepstatin	CTSD	5478883	FAXGPCHRFPCXOO-LXTPJMTPSA-N	Preclinical	aspartic protease inhibitor	NA	NA
pepstatin	CTSL	5478883	FAXGPCHRFPCXOO-LXTPJMTPSA-N	Preclinical	aspartic protease inhibitor	NA	NA
pepstatin	REN	5478883	FAXGPCHRFPCXOO-LXTPJMTPSA-N	Preclinical	aspartic protease inhibitor	NA	NA
peretinoin	RXRA	6437836	UUBHZHZSIKRVIV-KCXSXWJSSA-N	Phase 3	retinoid receptor agonist	NA	NA
pergolide	ADRA1A	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	ADRA1B	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	ADRA1D	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	ADRA2A	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	ADRA2B	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	ADRA2C	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	DRD1	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	DRD2	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	DRD3	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	DRD4	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	DRD5	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	HTR1A	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	HTR1B	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	HTR1D	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	HTR2A	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	HTR2B	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
pergolide	HTR2C	47811	YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	dopamine receptor agonist	NA	NA
perhexiline	CPT1A	38988177	"InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2/t18-/m1/s1"	Launched	carnitine palmitoyltransferase inhibitor	cardiology	angina pectoris
perifosine	AKT1	148178	SZFPYBIJACMNJV-UHFFFAOYSA-O	Phase 3	AKT inhibitor	NA	NA
perillyl-alcohol	FNTA	369312	NDTYTMIUWGWIMO-SNVBAGLBSA-N	Phase 2	apoptosis stimulant|farnesyltransferase inhibitor	NA	NA
perindopril	ACE	40466996	IPVQLZZIHOAWMC-QXKUPLGCSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|myocardial infarction|coronary artery disease (CAD)
perindoprilat	ACE	72022	ODAIHABQVKJNIY-PEDHHIEDSA-N	Phase 2	angiotensin converting enzyme inhibitor	NA	NA
perospirone	DRD2	115368	FBVFZWUMDDXLLG-HDICACEKSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
perospirone	DRD3	115368	FBVFZWUMDDXLLG-HDICACEKSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
perospirone	DRD4	115368	FBVFZWUMDDXLLG-HDICACEKSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
perphenazine	CALM1	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perphenazine	DRD1	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perphenazine	DRD2	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perphenazine	HRH1	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perphenazine	HTR2A	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perphenazine	HTR2C	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perphenazine	HTR6	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perphenazine	HTR7	4748	RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting
perzinfotel	GRIN1	6918236	BDABGOLMYNHHTR-UHFFFAOYSA-N	Phase 2	glutamate receptor antagonist	NA	NA
perzinfotel	GRIN2A	6918236	BDABGOLMYNHHTR-UHFFFAOYSA-N	Phase 2	glutamate receptor antagonist	NA	NA
perzinfotel	GRIN2B	6918236	BDABGOLMYNHHTR-UHFFFAOYSA-N	Phase 2	glutamate receptor antagonist	NA	NA
PETCM	CASP3	736879	NGTDJJKTGRNNAU-ZETCQYMHSA-N	Preclinical	caspase activator	NA	NA
pevonedistat	NAE1	16720766	"InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1"	Phase 3	nedd activating enzyme inhibitor	NA	NA
pevonedistat	UBA3	16720766	"InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1"	Phase 3	nedd activating enzyme inhibitor	NA	NA
pexidartinib	CSF1R	25151352	JGWRKYUXBBNENE-UHFFFAOYSA-N	Launched	tyrosine kinase inhibitor	NA	NA
pexidartinib	FLT3	25151352	JGWRKYUXBBNENE-UHFFFAOYSA-N	Launched	tyrosine kinase inhibitor	NA	NA
pexidartinib	KIT	25151352	JGWRKYUXBBNENE-UHFFFAOYSA-N	Launched	tyrosine kinase inhibitor	NA	NA
pexmetinib	MAPK14	24765037	LNMRSSIMGCDUTP-UHFFFAOYSA-N	Phase 1	MAP kinase inhibitor|TIE tyrosine kinase inhibitor	NA	NA
pexmetinib	TEK	24765037	LNMRSSIMGCDUTP-UHFFFAOYSA-N	Phase 1	MAP kinase inhibitor|TIE tyrosine kinase inhibitor	NA	NA
PF-02545920	PDE10A	11581936	AZEXWHKOMMASPA-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
PF-03049423	PDE5A	24963293	MNLNAGRCHNMKKJ-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
PF-03758309	PAK4	25227462	"InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1"	Phase 1	p21 activated kinase inhibitor	NA	NA
PF-03814735	AURKA	51346455	RYYNGWLOYLRZLK-RBUKOAKNSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
PF-03814735	AURKB	51346455	RYYNGWLOYLRZLK-RBUKOAKNSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
PF-04217903	MET	17754438	"InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2"	Phase 1	c-Met inhibitor	NA	NA
PF-04418948	PTGER2	25114442	LWJGMYMNSNVCEM-UHFFFAOYSA-N	Phase 1	prostaglandin inhibitor	NA	NA
PF-04447943	PDE9A	135564558	IWXUVYOOUMLUTQ-CZUORRHYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
PF-04457845	FAAH	24771824	BATCTBJIJJEPHM-UHFFFAOYSA-N	Phase 2	FAAH inhibitor	NA	NA
PF-04620110	DGAT1	NA	GEVVQZHMFVFGLN-HDJSIYSDSA-N	Phase 1	diacylglycerol O acyltransferase inhibitor	NA	NA
PF-04691502	MTOR	NA	XDLYKKIQACFMJG-WKILWMFISA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
PF-04691502	PIK3CA	NA	XDLYKKIQACFMJG-WKILWMFISA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
PF-04885614	SCN10A	65459349	AGORGFNWYAUYSU-UHFFFAOYSA-N	Preclinical	voltage-gated sodium channel blocker	NA	NA
PF-04937319	GCK	46916694	MASKQITXHVYVFL-UHFFFAOYSA-N	Phase 2	glucokinase activator	NA	NA
PF-05190457	GHSR	58438464	ZIUDADZJCKGWKR-AREMUKBSSA-N	Phase 2	growth hormone secretagogue receptor inverse agonist	NA	NA
PF-05212384	MTOR	44516953	DWZAEMINVBZMHQ-UHFFFAOYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
PF-05212384	PIK3CA	44516953	DWZAEMINVBZMHQ-UHFFFAOYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
PF-06447475	LRRK2	72706840	BHTWDJBVZQBRKP-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
PF-06463922	ALK	78162481	IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
PF-06463922	FES	78162481	IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
PF-06463922	ROS1	78162481	IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
PF-3274167	AVPR1A	11683187	HNIFCPBQMKPRCX-UHFFFAOYSA-N	Phase 2	oxytocin receptor antagonist	NA	NA
PF-3274167	OXTR	11683187	HNIFCPBQMKPRCX-UHFFFAOYSA-N	Phase 2	oxytocin receptor antagonist	NA	NA
PF-3845	FAAH	25154867	NBOJHRYUGLRASX-UHFFFAOYSA-N	Preclinical	FAAH inhibitor	NA	NA
PF-429242	MBTPS1	23661637	XKPJTOHUPQWSOJ-HSZRJFAPSA-N	Preclinical	SREBP inhibitor	NA	NA
PF-431396	PTK2	11598628	POJZIZBONPAWIV-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
PF-431396	PTK2B	11598628	POJZIZBONPAWIV-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
PF-4708671	RPS6KB1	51371303	FBLPQCAQRNSVHB-UHFFFAOYSA-N	Preclinical	ribosomal protein inhibitor	NA	NA
PF-477736	CHEK1	135565545	NDEXUOWTGYUVGA-LJQANCHMSA-N	Phase 1	CHK inhibitor	NA	NA
PF-477736	CHEK2	135565545	NDEXUOWTGYUVGA-LJQANCHMSA-N	Phase 1	CHK inhibitor	NA	NA
PF-4800567	CSNK1D	53472153	AUMDBEHGJRZSOO-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
PF-4800567	CSNK1E	53472153	AUMDBEHGJRZSOO-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
PF-4981517	CYP3A4	71315139	WDWIMDKOXZZYHH-FQEVSTJZSA-N	Preclinical	cytochrome P450 inhibitor	NA	NA
PF-5274857	SMO	56956240	BBVNTTZIOTWDSV-UHFFFAOYSA-N	Preclinical	smoothened receptor antagonist	NA	NA
PF-562271	PTK2	11713159	MZDKLVOWGIOKTN-UHFFFAOYSA-N	Phase 1	focal adhesion kinase inhibitor	NA	NA
PF-562271	PTK2B	11713159	MZDKLVOWGIOKTN-UHFFFAOYSA-N	Phase 1	focal adhesion kinase inhibitor	NA	NA
PF-573228	CDK1	11612883	HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
PF-573228	CDK2	11612883	HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
PF-573228	CDK7	11612883	HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
PF-573228	GSK3B	11612883	HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
PF-573228	IKBKB	11612883	HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
PF-670462	CSNK1D	11681588	WUDBUIUHVNECTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
PF-670462	CSNK1E	11681588	WUDBUIUHVNECTM-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
PF-750	FAAH	25154868	BIODYGOZWZNCAG-UHFFFAOYSA-N	Preclinical	FAAH inhibitor	NA	NA
PF-8380	ENPP2	25265312	JMSUDQYHPSNBSN-UHFFFAOYSA-N	Preclinical	autotaxin inhibitor	NA	NA
PF-915275	HSD11B1	23725123	ZESFDAKNYJQYKO-UHFFFAOYSA-N	Phase 1	11-beta hydroxysteroid dehydrogenase inhibitor	NA	NA
PFI-1	BRD4	71271629	TXZPMHLMPKIUGK-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
PFI-3	PBRM1	78243717	INAICWLVUAKEPB-QSTFCLMHSA-N	Preclinical	bromodomain inhibitor	NA	NA
PFI-3	SMARCA4	78243717	INAICWLVUAKEPB-QSTFCLMHSA-N	Preclinical	bromodomain inhibitor	NA	NA
PFI-4	BRPF1	40642506	QCIJLRJBZDBVDB-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
PFK-015	PFKFB3	25142799	UJJUKZPBUMCSJZ-BQYQJAHWSA-N	Phase 1	phosphofructokinase inhibitor	NA	NA
PFK-158	PFKFB3	71730058	IAJOMYABKVAZCN-AATRIKPKSA-N	Phase 1	phosphofructokinase inhibitor	NA	NA
PGL5001	MAPK10	76969933	XCPPIJCBCWUBNT-HXUWFJFHSA-N	Phase 2	JNK inhibitor	NA	NA
PGL5001	MAPK8	76969933	XCPPIJCBCWUBNT-HXUWFJFHSA-N	Phase 2	JNK inhibitor	NA	NA
PGL5001	MAPK9	76969933	XCPPIJCBCWUBNT-HXUWFJFHSA-N	Phase 2	JNK inhibitor	NA	NA
PH-797804	MAPK11	22049997	KCAJXIDMCNPGHZ-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
PH-797804	MAPK14	22049997	KCAJXIDMCNPGHZ-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
PHA-568487	CHRNA7	9932000	LUVXHMJTVXZFPD-ZDUSSCGKSA-N	Preclinical	nicotinic receptor agonist	NA	NA
PHA-665752	MET	10461815	OYONTEXKYJZFHA-SSHUPFPWSA-N	Preclinical	c-Met inhibitor	NA	NA
PHA-680632	AURKA	11249084	OBWNXGOQPLDDPS-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
PHA-680632	AURKB	11249084	OBWNXGOQPLDDPS-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
PHA-680632	AURKC	11249084	OBWNXGOQPLDDPS-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
PHA-767491	CDK1	11715767	DKXHSOUZPMHNIZ-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
PHA-767491	RPS6KB1	11715767	DKXHSOUZPMHNIZ-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
PHA-793887	CDK1	46191454	HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
PHA-793887	CDK2	46191454	HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
PHA-793887	CDK4	46191454	HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
PHA-793887	CDK5	46191454	HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
PHA-793887	CDK7	46191454	HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
PHA-793887	CDK9	46191454	HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
PHA-848125	CDK2	16718576	RXZMYLDMFYNEIM-UHFFFAOYSA-N	Phase 2	CDK inhibitor|growth factor receptor inhibitor	NA	NA
PHA-848125	CDK4	16718576	RXZMYLDMFYNEIM-UHFFFAOYSA-N	Phase 2	CDK inhibitor|growth factor receptor inhibitor	NA	NA
PHA-848125	CDK7	16718576	RXZMYLDMFYNEIM-UHFFFAOYSA-N	Phase 2	CDK inhibitor|growth factor receptor inhibitor	NA	NA
PHA-848125	NTRK1	16718576	RXZMYLDMFYNEIM-UHFFFAOYSA-N	Phase 2	CDK inhibitor|growth factor receptor inhibitor	NA	NA
PHCCC	GRM1	44572113	FPXPIEZPAXSELW-RGNAGUPPSA-N	Preclinical	glutamate receptor agonist	NA	NA
PHCCC	GRM4	44572113	FPXPIEZPAXSELW-RGNAGUPPSA-N	Preclinical	glutamate receptor agonist	NA	NA
phenacemide	SCN10A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN11A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN1A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN2A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN3A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN4A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN5A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN7A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN8A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacemide	SCN9A	4753	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	epilepsy|seizures
phenacetin	PTGS1	4754	CPJSUEIXXCENMM-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
phenazone	PTGS1	2206	VEQOALNAAJBPNY-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
phenazone	PTGS2	2206	VEQOALNAAJBPNY-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
phenazopyridine	SCN1A	NA	QPFYXYFORQJZEC-FOCLMDBBSA-N	Launched	local anesthetic	infectious disease	urinary tract infections
phenelzine	ABAT	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	AOC3	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	GAD2	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	GPT	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	GPT2	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	MAOA	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	MAOB	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	SLC6A2	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	SLC6A3	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenelzine	SLC6A4	3675	RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenethyl-isothiocyanate	CYP2E1	16741	IZJDOKYDEWTZSO-UHFFFAOYSA-N	Phase 2	anticancer agent	NA	NA
phenformin	KCNJ8	8249	ICFJFFQQTFMIBG-UHFFFAOYSA-N	Withdrawn	AMPK activator	NA	NA
phenformin	PRKAA1	8249	ICFJFFQQTFMIBG-UHFFFAOYSA-N	Withdrawn	AMPK activator	NA	NA
phenindamine	HRH1	57086802	ISFHAYSTHMVOJR-LJQANCHMSA-N	Launched	histamine receptor antagonist	allergy|otolaryngology	allergic rhinitis|common cold
phenindione	VKORC1	4760	NFBAXHOPROOJAW-UHFFFAOYSA-N	Launched	vitamin K antagonist	hematology	deep vein thrombosis (DVT)
pheniramine	HRH1	667440	IJHNSHDBIRRJRN-HNNXBMFYSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis|urticaria
phenol	CA1	996	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical		otolaryngology	pharyngitis
phenol	CA12	996	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical		otolaryngology	pharyngitis
phenol	CA14	996	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical		otolaryngology	pharyngitis
phenol	CA2	996	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical		otolaryngology	pharyngitis
phenol	CA4	996	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical		otolaryngology	pharyngitis
phenol	CA9	996	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical		otolaryngology	pharyngitis
phenolphthalein	UGT1A9	4764	KJFMBFZCATUALV-UHFFFAOYSA-N	Withdrawn	indicator dye	NA	NA
phenoxybenzamine	ADRA1A	657233	QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|endocrinology	hypertension|pheochromocytoma
phenoxybenzamine	ADRA1B	657233	QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|endocrinology	hypertension|pheochromocytoma
phenoxybenzamine	ADRA1D	657233	QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|endocrinology	hypertension|pheochromocytoma
phenoxybenzamine	ADRA2A	657233	QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|endocrinology	hypertension|pheochromocytoma
phenoxybenzamine	ADRA2B	657233	QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|endocrinology	hypertension|pheochromocytoma
phenoxybenzamine	ADRA2C	657233	QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|endocrinology	hypertension|pheochromocytoma
phenprocoumon	VKORC1	54681533	DQDAYGNAKTZFIW-ZDUSSCGKSA-N	Launched	vitamin K antagonist	hematology	thrombosis|pulmonary embolism (PE)
phenserine	ACHE	192706	PBHFNBQPZCRWQP-QUCCMNQESA-N	Phase 3	acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor	NA	NA
phenserine	BCHE	192706	PBHFNBQPZCRWQP-QUCCMNQESA-N	Phase 3	acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor	NA	NA
phentolamine	ADRA1A	5775	MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	endocrinology|cardiology	pheochromocytoma|hypertension
phentolamine	ADRA1B	5775	MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	endocrinology|cardiology	pheochromocytoma|hypertension
phentolamine	ADRA1D	5775	MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	endocrinology|cardiology	pheochromocytoma|hypertension
phentolamine	ADRA2A	5775	MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	endocrinology|cardiology	pheochromocytoma|hypertension
phentolamine	ADRA2B	5775	MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	endocrinology|cardiology	pheochromocytoma|hypertension
phentolamine	ADRA2C	5775	MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	endocrinology|cardiology	pheochromocytoma|hypertension
phenylbutazone	PTGIS	4781	VYMDGNCVAMGZFE-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	NA	NA
phenylbutazone	PTGS1	4781	VYMDGNCVAMGZFE-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	NA	NA
phenylbutazone	PTGS2	4781	VYMDGNCVAMGZFE-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	NA	NA
phenylbutyrate	HDAC1	4775	OBKXEAXTFZPCHS-UHFFFAOYSA-N	Launched	HDAC inhibitor	metabolism	urea cycle disorders
phenylephrine	ADRA1A	6041	SONNWYBIRXJNDC-VIFPVBQESA-N	Launched	adrenergic receptor agonist	otolaryngology|gastroenterology|cardiology	nasal congestion|hemorrhoids|hypotension
phenylephrine	ADRA1B	6041	SONNWYBIRXJNDC-VIFPVBQESA-N	Launched	adrenergic receptor agonist	otolaryngology|gastroenterology|cardiology	nasal congestion|hemorrhoids|hypotension
phenylephrine	ADRA1D	6041	SONNWYBIRXJNDC-VIFPVBQESA-N	Launched	adrenergic receptor agonist	otolaryngology|gastroenterology|cardiology	nasal congestion|hemorrhoids|hypotension
phenytoin	SCN10A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN11A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN1A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN2A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN3A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN4A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN5A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN7A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN8A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
phenytoin	SCN9A	1775	CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	hydantoin antiepileptic	neurology/psychiatry	seizures
PhiKan-083	TP53	4722579	LBPNOEAFWYTTEB-UHFFFAOYSA-N	Preclinical	p53 stabilizing agent	NA	NA
phloretin	AQP9	4788	VGEREEWJJVICBM-UHFFFAOYSA-N	Launched	sodium/glucose cotransporter inhibitor	NA	NA
phloretin	CLCN3	4788	VGEREEWJJVICBM-UHFFFAOYSA-N	Launched	sodium/glucose cotransporter inhibitor	NA	NA
phloretin	SLC23A1	4788	VGEREEWJJVICBM-UHFFFAOYSA-N	Launched	sodium/glucose cotransporter inhibitor	NA	NA
phlorizin	SLC5A1	6072	IOUVKUPGCMBWBT-QNDFHXLGSA-N	Preclinical	sodium/glucose cotransporter inhibitor	NA	NA
phlorizin	SLC5A11	6072	IOUVKUPGCMBWBT-QNDFHXLGSA-N	Preclinical	sodium/glucose cotransporter inhibitor	NA	NA
phlorizin	SLC5A2	6072	IOUVKUPGCMBWBT-QNDFHXLGSA-N	Preclinical	sodium/glucose cotransporter inhibitor	NA	NA
phlorizin	SLC5A3	6072	IOUVKUPGCMBWBT-QNDFHXLGSA-N	Preclinical	sodium/glucose cotransporter inhibitor	NA	NA
phortress	AHR	399465	LFDOEFHQLNGBQQ-HNNXBMFYSA-N	Phase 1	aryl hydrocarbon receptor ligand	NA	NA
PHP-501	GABRA1	46204221	UHEYIOPHTBWBQN-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
PHP-501	GABRB2	46204221	UHEYIOPHTBWBQN-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
PHP-501	GABRG2	46204221	UHEYIOPHTBWBQN-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
PHT-427	AKT2	44240850	BYWWNRBKPCPJMG-UHFFFAOYSA-N	Preclinical	AKT inhibitor|pyruvate dehydrogenase inhibitor	NA	NA
PHT-427	PDPK1	44240850	BYWWNRBKPCPJMG-UHFFFAOYSA-N	Preclinical	AKT inhibitor|pyruvate dehydrogenase inhibitor	NA	NA
PHTPP	ESR2	11201035	AEZPAUSGTAHLOQ-UHFFFAOYSA-N	Preclinical	estrogen receptor antagonist	NA	NA
physostigmine	ACHE	5983	PIJVFDBKTWXHHD-HIFRSBDPSA-N	Launched	acetylcholinesterase inhibitor|cholinesterase inhibitor	cardiology|neurology/psychiatry|ophthalmology|gastroenterology	hypotension|Alzheimer's disease|glaucoma|gastroparesis
physostigmine	BCHE	5983	PIJVFDBKTWXHHD-HIFRSBDPSA-N	Launched	acetylcholinesterase inhibitor|cholinesterase inhibitor	cardiology|neurology/psychiatry|ophthalmology|gastroenterology	hypotension|Alzheimer's disease|glaucoma|gastroparesis
phytonadione	BGLAP	5284607	MBWXNTAXLNYFJB-NKFFZRIASA-N	Launched		hematology	vitamin K deficiency|anticoagulation reversal
phytonadione	GGCX	5284607	MBWXNTAXLNYFJB-NKFFZRIASA-N	Launched		hematology	vitamin K deficiency|anticoagulation reversal
PI-103	MTOR	9884685	"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2"	Preclinical	mTOR inhibitor|PI3K inhibitor	NA	NA
PI-103	PIK3CA	9884685	"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2"	Preclinical	mTOR inhibitor|PI3K inhibitor	NA	NA
PI-103	PIK3CB	9884685	"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2"	Preclinical	mTOR inhibitor|PI3K inhibitor	NA	NA
PI-103	PIK3CD	9884685	"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2"	Preclinical	mTOR inhibitor|PI3K inhibitor	NA	NA
PI-103	PIK3CG	9884685	"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2"	Preclinical	mTOR inhibitor|PI3K inhibitor	NA	NA
PI-103	PRKDC	9884685	"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2"	Preclinical	mTOR inhibitor|PI3K inhibitor	NA	NA
piboserod	HTR2B	177336	KVCSJPATKXABRQ-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
piboserod	HTR4	177336	KVCSJPATKXABRQ-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
picartamide	ATP4A	76960918	ITNLONMDUMHEOK-NSHDSACASA-N	Phase 2	H+/K+-ATPase inhibitor	NA	NA
piceatannol	ATP5A1	667639	CDRPUGZCRXZLFL-OWOJBTEDSA-N	Preclinical	SYK inhibitor	NA	NA
piceatannol	ATP5B	667639	CDRPUGZCRXZLFL-OWOJBTEDSA-N	Preclinical	SYK inhibitor	NA	NA
piceatannol	ATP5C1	667639	CDRPUGZCRXZLFL-OWOJBTEDSA-N	Preclinical	SYK inhibitor	NA	NA
piceatannol	IRF3	667639	CDRPUGZCRXZLFL-OWOJBTEDSA-N	Preclinical	SYK inhibitor	NA	NA
piclamilast	PDE4A	154575	RRRUXBQSQLKHEL-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
piclamilast	PDE4B	154575	RRRUXBQSQLKHEL-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
piclamilast	PDE4C	154575	RRRUXBQSQLKHEL-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
piclamilast	PDE4D	154575	RRRUXBQSQLKHEL-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
picotamide	TBXA2R	4814	KYWCWBXGRWWINE-UHFFFAOYSA-N	Launched	thromboxane receptor antagonist|thromboxane synthase inhibitor	hematology	thrombosis
picrotin	GLRA1	NA	RYEFFICCPKWYML-XSVQNFTRSA-N	Phase 2	GABA receptor antagonist	NA	NA
picrotin	GLRA2	NA	RYEFFICCPKWYML-XSVQNFTRSA-N	Phase 2	GABA receptor antagonist	NA	NA
picrotin	GLRA3	NA	RYEFFICCPKWYML-XSVQNFTRSA-N	Phase 2	GABA receptor antagonist	NA	NA
picrotin	GLRB	NA	RYEFFICCPKWYML-XSVQNFTRSA-N	Phase 2	GABA receptor antagonist	NA	NA
picrotoxinin	GLRA1	7098683	PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical	GABA receptor antagonist	NA	NA
picrotoxinin	GLRA2	7098683	PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical	GABA receptor antagonist	NA	NA
picrotoxinin	GLRA3	7098683	PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical	GABA receptor antagonist	NA	NA
picrotoxinin	GLRB	7098683	PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical	GABA receptor antagonist	NA	NA
picrotoxinin	HTR3A	7098683	PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical	GABA receptor antagonist	NA	NA
picrotoxinin	HTR3B	7098683	PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical	GABA receptor antagonist	NA	NA
pidolic-acid	ADAM28	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	AMY1A	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	AMY2A	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	AMY2B	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	ANG	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	CCL8	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	HCRT	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	IGLC1	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	KRTAP5-2	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	TFF2	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pidolic-acid	VEGFA	7405	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched		dermatology	xerosis cutis
pifithrin-alpha	TP53	4817	OLTZHXYLLRJLST-UHFFFAOYSA-N	Preclinical	TP53 inhibitor	NA	NA
pifithrin-cyclic	TP53	443278	IMUKUMUNZJILCG-UHFFFAOYSA-N	Preclinical	TP53 inhibitor	NA	NA
pifithrin-mu	HSPA1A	327653	ZZUZYEMRHCMVTB-UHFFFAOYSA-N	Preclinical	HSP inhibitor	NA	NA
pifithrin-mu	TP53	327653	ZZUZYEMRHCMVTB-UHFFFAOYSA-N	Preclinical	HSP inhibitor	NA	NA
PIK-293	PIK3CA	53245636	KQDBVHKNIYROHU-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-293	PIK3CB	53245636	KQDBVHKNIYROHU-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-293	PIK3CD	53245636	KQDBVHKNIYROHU-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-293	PIK3CG	53245636	KQDBVHKNIYROHU-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-294	PIK3CB	24905149	WFSLJOPRIJSOJR-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-294	PIK3CD	24905149	WFSLJOPRIJSOJR-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-294	PIK3CG	24905149	WFSLJOPRIJSOJR-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-75	PIK3CA	10275789	QTHCAAFKVUWAFI-DJKKODMXSA-N	Preclinical	DNA protein kinase inhibitor|PI3K inhibitor	NA	NA
PIK-75	PIK3CB	10275789	QTHCAAFKVUWAFI-DJKKODMXSA-N	Preclinical	DNA protein kinase inhibitor|PI3K inhibitor	NA	NA
PIK-75	PIK3CD	10275789	QTHCAAFKVUWAFI-DJKKODMXSA-N	Preclinical	DNA protein kinase inhibitor|PI3K inhibitor	NA	NA
PIK-75	PIK3CG	10275789	QTHCAAFKVUWAFI-DJKKODMXSA-N	Preclinical	DNA protein kinase inhibitor|PI3K inhibitor	NA	NA
PIK-75	PRKDC	10275789	QTHCAAFKVUWAFI-DJKKODMXSA-N	Preclinical	DNA protein kinase inhibitor|PI3K inhibitor	NA	NA
PIK-93	PI4KB	6852167	JFVNFXCESCXMBC-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-93	PIK3C3	6852167	JFVNFXCESCXMBC-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
PIK-93	PIK3CG	6852167	JFVNFXCESCXMBC-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
pilocarpine	CHRM1	5910	QCHFTSOMWOSFHM-WPRPVWTQSA-N	Launched	acetylcholine receptor agonist	ophthalmology|cardiology	glaucoma|hypertension
pilocarpine	CHRM2	5910	QCHFTSOMWOSFHM-WPRPVWTQSA-N	Launched	acetylcholine receptor agonist	ophthalmology|cardiology	glaucoma|hypertension
pilocarpine	CHRM3	5910	QCHFTSOMWOSFHM-WPRPVWTQSA-N	Launched	acetylcholine receptor agonist	ophthalmology|cardiology	glaucoma|hypertension
pilocarpine	CHRM4	5910	QCHFTSOMWOSFHM-WPRPVWTQSA-N	Launched	acetylcholine receptor agonist	ophthalmology|cardiology	glaucoma|hypertension
pilocarpine	CHRM5	5910	QCHFTSOMWOSFHM-WPRPVWTQSA-N	Launched	acetylcholine receptor agonist	ophthalmology|cardiology	glaucoma|hypertension
pilsicainide	SCN5A	4820	BCQTVJKBTWGHCX-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	cardiac arrythmia
PIM-1-Inhibitor-2	PIM1	2765355	AQVFETGXIRKVAQ-UHFFFAOYSA-N	Preclinical	Pim kinase inhibitor	NA	NA
pimavanserin	DRD2	10071196	RKEWSXXUOLRFBX-UHFFFAOYSA-N	Launched	serotonin receptor inverse agonist	neurology/psychiatry	Parkinson's Disease
pimavanserin	HTR2A	10071196	RKEWSXXUOLRFBX-UHFFFAOYSA-N	Launched	serotonin receptor inverse agonist	neurology/psychiatry	Parkinson's Disease
pimobendan	PDE3A	7120080	GLBJJMFZWDBELO-LLVKDONJSA-N	Launched	calcium sensitizer|phosphodiesterase inhibitor	cardiology	congestive heart failure
pimozide	CACNA1I	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	CALM1	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	DRD1	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	DRD2	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	DRD3	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	DRD4	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	DRD5	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	HRH1	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	HTR1A	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	HTR2A	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	KCNA10	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pimozide	KCNH2	16362	YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pinacidil	ABCC8	12428581	IVVNZDGDKPTYHK-SNVBAGLBSA-N	Launched	ATP channel activator|potassium channel activator	cardiology	hypertension
pinacidil	ABCC9	12428581	IVVNZDGDKPTYHK-SNVBAGLBSA-N	Launched	ATP channel activator|potassium channel activator	cardiology	hypertension
pinaverium	CACNA1C	73416161	DDHUTBKXLWCZCO-CEMLEFRQSA-N	Launched	T-type calcium channel blocker	gastroenterology	irritable bowel syndrome
pindolol	ADRB1	155030	JZQKKSLKJUAGIC-LLVKDONJSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
pindolol	ADRB2	155030	JZQKKSLKJUAGIC-LLVKDONJSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
pindolol	HTR1A	155030	JZQKKSLKJUAGIC-LLVKDONJSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
pindolol	HTR2A	155030	JZQKKSLKJUAGIC-LLVKDONJSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
pindolol	HTR2B	155030	JZQKKSLKJUAGIC-LLVKDONJSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
pindolol-(-)	HTR1A	688095	JZQKKSLKJUAGIC-NSHDSACASA-N	Phase 2	adrenergic receptor antagonist|serotonin receptor antagonist	NA	NA
pinocembrin	CYP1B1	68071	URFCJEUYXNAHFI-ZDUSSCGKSA-N	Phase 2	cytochrome P450 inhibitor	NA	NA
pioglitazone	PPARG	29010894	HYAFETHFCAUJAY-QGZVFWFLSA-N	Launched	insulin sensitizer|PPAR receptor agonist	endocrinology	diabetes mellitus
pioglitazone	TRPM3	29010894	HYAFETHFCAUJAY-QGZVFWFLSA-N	Launched	insulin sensitizer|PPAR receptor agonist	endocrinology	diabetes mellitus
pipamperone	DRD2	4830	AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipamperone	HRH1	4830	AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipamperone	HTR1A	4830	AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipamperone	HTR1B	4830	AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipamperone	HTR1D	4830	AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipamperone	HTR2A	4830	AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipecuronium	CHRM2	50192	OWWLUIWOFHMHOQ-XGHATYIMSA-N	Launched	neuromuscular blocker	neurology/psychiatry	anesthetic
pipecuronium	CHRM3	50192	OWWLUIWOFHMHOQ-XGHATYIMSA-N	Launched	neuromuscular blocker	neurology/psychiatry	anesthetic
pipecuronium	CHRNA2	50192	OWWLUIWOFHMHOQ-XGHATYIMSA-N	Launched	neuromuscular blocker	neurology/psychiatry	anesthetic
pipenzolate	CHRM1	16048561	WPUKUEMZZRVAKZ-REWPJTCUSA-N	Launched	cholinergic receptor antagonist	neurology/psychiatry	spasms
piperazine	GABRB3	4837	GLUUGHFHXGJENI-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	infectious disease	gastrointestinal roundworms
piperidolate	CHRM1	688565	KTHVBAZBLKXIHZ-IBGZPJMESA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	spasms
piperine	MAOA	638024	MXXWOMGUGJBKIW-YPCIICBESA-N	Phase 1	monoamine oxidase inhibitor	NA	NA
piperine	MAOB	638024	MXXWOMGUGJBKIW-YPCIICBESA-N	Phase 1	monoamine oxidase inhibitor	NA	NA
piperine	TRPV1	638024	MXXWOMGUGJBKIW-YPCIICBESA-N	Phase 1	monoamine oxidase inhibitor	NA	NA
pipotiazine	DRD1	62867	JOMHSQGEWSNUKU-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine	DRD2	62867	JOMHSQGEWSNUKU-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine	HTR1A	62867	JOMHSQGEWSNUKU-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine	HTR2A	62867	JOMHSQGEWSNUKU-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine-palmitate	DRD1	37767	KTOYYUONFQWSMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine-palmitate	DRD2	37767	KTOYYUONFQWSMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine-palmitate	HTR1A	37767	KTOYYUONFQWSMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine-palmitate	HTR2A	37767	KTOYYUONFQWSMW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
piracetam	GRIA1	4843	GMZVRMREEHBGGF-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	senile dementia
piracetam	GRIA2	4843	GMZVRMREEHBGGF-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	senile dementia
piracetam	GRIA3	4843	GMZVRMREEHBGGF-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	senile dementia
piracetam	GRIA4	4843	GMZVRMREEHBGGF-UHFFFAOYSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	senile dementia
pirarubicin	TOP2A	11296583	KMSKQZKKOZQFFG-YXRRJAAWSA-N	Launched	topoisomerase inhibitor	oncology	breast cancer
pirenperone	HTR2A	4847	HXCNRYXBZNHDNE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
pirenperone	HTR7	4847	HXCNRYXBZNHDNE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
pirenzepine	CHRM1	4848	RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
pirenzepine	CHRM2	4848	RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
pirenzepine	CHRM3	4848	RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
pirenzepine	CHRM4	4848	RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
pirenzepine	CHRM5	4848	RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
piretanide	SLC12A1	4849	UJEWTUDSLQGTOA-UHFFFAOYSA-N	Launched	glucocorticoid receptor agonist	cardiology	hypertension|edema
piretanide	SLC12A2	4849	UJEWTUDSLQGTOA-UHFFFAOYSA-N	Launched	glucocorticoid receptor agonist	cardiology	hypertension|edema
pirfenidone	FURIN	40632	ISWRGOKTTBVCFA-UHFFFAOYSA-N	Launched	TGF beta receptor inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
pirfenidone	TNF	40632	ISWRGOKTTBVCFA-UHFFFAOYSA-N	Launched	TGF beta receptor inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
piribedil	ADRA1A	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piribedil	ADRA2A	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piribedil	ADRA2C	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piribedil	DRD2	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piribedil	DRD3	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piribedil	DRD4	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piribedil	HTR1A	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piribedil	HTR2B	4850	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|dizziness
piricapiron	HTR2A	5545745	NCMIPRCQUMYAEC-JPYJTQIMSA-N	Phase 2	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
pirinixic-acid	PPARA	5694	SZRPDCCEHVWOJX-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
pirlindole	MAOA	667444	IWVRVEIKCBFZNF-ZDUSSCGKSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
piroxicam	PTGS1	54676228	QYSPLQLAKJAUJT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
piroxicam	PTGS2	54676228	QYSPLQLAKJAUJT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
piroximone	PDE3A	55263	OQGWJZOWLHWFME-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
PIT	P2RY1	124334	LXEZPPZLNVOLDI-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
pitavastatin	HMGCR	5282452	VGYFMXBACGZSIL-MCBHFWOFSA-N	Launched	HMGCR inhibitor	endocrinology	hyperlipidemia
pitolisant	HRH3	9948102	NNACHAUCXXVJSP-UHFFFAOYSA-N	Launched	histamine receptor antagonist	NA	NA
pivagabine	CRHR1	68888	SRPNQDXRVRCTNK-UHFFFAOYSA-N	Launched	corticotropin releasing factor receptor antagonist	neurology/psychiatry	depression
pivagabine	CRHR2	68888	SRPNQDXRVRCTNK-UHFFFAOYSA-N	Launched	corticotropin releasing factor receptor antagonist	neurology/psychiatry	depression
pivanex	HDAC1	60748	GYKLFBYWXZYSOW-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
pivanex	HDAC2	60748	GYKLFBYWXZYSOW-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
pivanex	HDAC3	60748	GYKLFBYWXZYSOW-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
pivanex	HDAC8	60748	GYKLFBYWXZYSOW-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
pixantrone	TOP2A	134019	PEZPMAYDXJQYRV-UHFFFAOYSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	non-Hodgkin lymphoma (NHL)
pizotifen	HTR1A	27400	FIADGNVRKBPQEU-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	migraine headache
pizotifen	HTR2A	27400	FIADGNVRKBPQEU-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	migraine headache
pizotifen	HTR2C	27400	FIADGNVRKBPQEU-UHFFFAOYSA-N	Launched	serotonin receptor antagonist	neurology/psychiatry	migraine headache
PI4KIII-beta-inhibitor-1	PI4K2B	71549093	PLUYFBRIGUAKBR-UHFFFAOYSA-N	Preclinical	PI4K inhibitor	NA	NA
PJ-34	EEF2	4858	UYJZZVDLGDDTCL-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
PJ-34	PARP1	4858	UYJZZVDLGDDTCL-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
PJ-34	PARP15	4858	UYJZZVDLGDDTCL-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
PJ-34	PARP3	4858	UYJZZVDLGDDTCL-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
PK-THPP	KCNK9	53464059	CJZGRIRZVHNUSM-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
PK-11195	TSPO	24839733	RAVIZVQZGXBOQO-CQSZACIVSA-N	Phase 1	benzodiazepine receptor antagonist	NA	NA
PK-44	DPP4	46208486	LIPWZZYFIVYJSI-MRVPVSSYSA-N	Preclinical	dipeptidyl peptidase inhibitor	NA	NA
PKI-166	EGFR	6918403	XRYJULCDUUATMC-CYBMUJFWSA-N	Phase 1	EGFR inhibitor	NA	NA
PKI-179	MTOR	76958312	WXUUCRLKXQMWRY-OYRHEFFESA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
plerixafor	ACKR3	65015	YIQPUIGJQJDJOS-UHFFFAOYSA-N	Launched	CC chemokine receptor antagonist	hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma
plerixafor	CCR4	65015	YIQPUIGJQJDJOS-UHFFFAOYSA-N	Launched	CC chemokine receptor antagonist	hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma
plerixafor	CXCR4	65015	YIQPUIGJQJDJOS-UHFFFAOYSA-N	Launched	CC chemokine receptor antagonist	hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma
plovamer-acetate	TAT	6942100	OUYCCCASQSFEME-QMMMGPOBSA-N	Phase 2		NA	NA
plovamer-acetate	TH	6942100	OUYCCCASQSFEME-QMMMGPOBSA-N	Phase 2		NA	NA
plovamer-acetate	YARS	6942100	OUYCCCASQSFEME-QMMMGPOBSA-N	Phase 2		NA	NA
plovamer-acetate	YARS2	6942100	OUYCCCASQSFEME-QMMMGPOBSA-N	Phase 2		NA	NA
plurisin-1	SCD	225362	HUDWXDLBWRHCKO-UHFFFAOYSA-N	Preclinical	stearoyl-CoA desaturase inhibitor	NA	NA
PLX4720	BRAF	24180719	YZDJQTHVDDOVHR-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
PLX4720	KDR	24180719	YZDJQTHVDDOVHR-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
PLX647	CSF1R	11545419	NODCQQSEMCESEC-UHFFFAOYSA-N	Preclinical	receptor tyrosine protein kinase inhibitor	NA	NA
PLX647	KIT	11545419	NODCQQSEMCESEC-UHFFFAOYSA-N	Preclinical	receptor tyrosine protein kinase inhibitor	NA	NA
PLX8394	BRAF	90116675	YYACLQUDUDXAPA-MRXNPFEDSA-N	Phase 1/Phase 2	serine/threonine kinase inhibitor	NA	NA
PMPA	FOLH1	11031538	ISEYJGQFXSTPMQ-BYPYZUCNSA-N	Preclinical	glutamate receptor antagonist	NA	NA
PNU-120596	CHRNA7	311434	CEIIEALEIHQDBX-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
PNU-142633	HTR1D	9845148	PNTVCCRNJOGKGA-QFIPXVFZSA-N	Phase 2	serotonin receptor agonist	NA	NA
PNU-177864	DRD3	9887351	JGGQWSXZZQPZTR-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
PNU-22394	HTR2A	27559	ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
PNU-22394	HTR2B	27559	ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
PNU-22394	HTR2C	27559	ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
PNU-22394	MAOA	27559	ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
PNU-22394	MAOB	27559	ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
PNU-282987	CHRNA7	9795278	WECKJONDRAUFDD-ZDUSSCGKSA-N	Preclinical	cholinergic receptor agonist	NA	NA
PNU-74654	CTNNB1	9836739	JJEDWBQZCRESJL-DEDYPNTBSA-N	Preclinical	beta-catenin inhibitor	NA	NA
PNU-74654	TCF4	9836739	JJEDWBQZCRESJL-DEDYPNTBSA-N	Preclinical	beta-catenin inhibitor	NA	NA
PNU-89843	GABBR1	154689	UADIKEUOAMACNA-UHFFFAOYSA-N	Preclinical	benzodiazepine receptor agonist	NA	NA
podophyllotoxin	IGF1R	10607	YJGVMLPVUAXIQN-XVVDYKMHSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	genital warts
podophyllotoxin	TOP2A	10607	YJGVMLPVUAXIQN-XVVDYKMHSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	genital warts
podophyllotoxin	TUBA4A	10607	YJGVMLPVUAXIQN-XVVDYKMHSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	genital warts
podophyllotoxin	TUBB	10607	YJGVMLPVUAXIQN-XVVDYKMHSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	genital warts
polydatin	ICAM1	5281718	HSTZMXCBWJGKHG-CUYWLFDKSA-N	Phase 2	ICAM1 expression inhibitor	NA	NA
polyinosine	HPRT1	138454308	GRSZFWQUAKGDAV-SQQSDITASA-N	Preclinical	immunostimulant	NA	NA
polyinosine	IMPDH2	138454308	GRSZFWQUAKGDAV-SQQSDITASA-N	Preclinical	immunostimulant	NA	NA
polyinosine	PYGM	138454308	GRSZFWQUAKGDAV-SQQSDITASA-N	Preclinical	immunostimulant	NA	NA
polythiazide	SLC12A3	12876779	CYLWJCABXYDINA-JTQLQIEISA-N	Launched	sodium/chloride cotransporter inhibitor	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure|hypertension
ponatinib	ABL1	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	BCR	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	FGFR1	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	FGFR2	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	FGFR3	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	FGFR4	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	FLT3	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	KDR	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	KIT	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	LCK	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	LYN	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	PDGFRA	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	RET	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	SRC	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponatinib	TEK	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
ponesimod	S1PR1	NA	LPAUOXUZGSBGDU-STDDISTJSA-N	Phase 3	sphingosine 1-phosphate receptor agonist	NA	NA
posaconazole	CYP3A4	468595	RAGOYPUPXAKGKH-XAKZXMRKSA-N	Launched	sterol demethylase inhibitor	infectious disease	oropharyngeal candidiasis
potassium-canrenoate	NR3C2	656615	PBKZPPIHUVSDNM-WNHSNXHDSA-N	Launched	mineralocorticoid receptor antagonist	cardiology	edema
pozanicline	CHRNA4	178052	YRVIKLBSVVNSHF-JTQLQIEISA-N	Phase 2	acetylcholine receptor antagonist	NA	NA
pozanicline	CHRNB2	178052	YRVIKLBSVVNSHF-JTQLQIEISA-N	Phase 2	acetylcholine receptor antagonist	NA	NA
poziotinib	EGFR	25127713	LPFWVDIFUFFKJU-UHFFFAOYSA-N	Phase 2	EGFR inhibitor	NA	NA
poziotinib	ERBB2	25127713	LPFWVDIFUFFKJU-UHFFFAOYSA-N	Phase 2	EGFR inhibitor	NA	NA
poziotinib	ERBB4	25127713	LPFWVDIFUFFKJU-UHFFFAOYSA-N	Phase 2	EGFR inhibitor	NA	NA
PP-1	HCK	1400	ZVPDNRVYHLRXLX-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PP-1	RET	1400	ZVPDNRVYHLRXLX-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PP-121	ABL1	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	EGFR	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	HCK	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	KDR	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	MTOR	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	PDGFRA	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	PIK3CA	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	PIK3CB	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	PIK3CD	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	PIK3CG	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	PRKDC	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-121	SRC	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
PP-2	ABL1	4878	PBBRWFOVCUAONR-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PP-2	LCK	4878	PBBRWFOVCUAONR-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PP-2	RIPK2	4878	PBBRWFOVCUAONR-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PP-2	SRC	4878	PBBRWFOVCUAONR-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
PPT	ESR1	5040063	IOTXSIGGFRQYKW-UHFFFAOYSA-N	Preclinical	estrogen receptor agonist	NA	NA
PPY-A	ABL1	16750094	GYQRHHQPEMOLKH-UHFFFAOYSA-N	Preclinical	Abl kinase inhibitor	NA	NA
PPY-A	BCR	16750094	GYQRHHQPEMOLKH-UHFFFAOYSA-N	Preclinical	Abl kinase inhibitor	NA	NA
PP242	MTOR	135565635	MFAQYJIYDMLAIM-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
PP242	PASK	135565635	MFAQYJIYDMLAIM-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
PQ-401	IGF1R	9549305	YBLWOZUPHDKFOT-UHFFFAOYSA-N	Preclinical	IGF-1 inhibitor	NA	NA
practolol	ADRB1	6918924	DURULFYMVIFBIR-CYBMUJFWSA-N	Withdrawn	adrenergic receptor antagonist	NA	NA
pralatrexate	DHFR	11155808	"InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14-,16+/m1/s1"	Launched	dihydrofolate reductase inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
pralidoxime	ACHE	4884	JBKPUQTUERUYQE-UHFFFAOYSA-O	Launched	acetylcholinesterase inhibitor	critical care	organophosphate poisoning
pralidoxime	BCHE	4884	JBKPUQTUERUYQE-UHFFFAOYSA-O	Launched	acetylcholinesterase inhibitor	critical care	organophosphate poisoning
pralidoxime-chloride	ACHE	54072659	MHOAUIZFSQGCNM-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	pulmonary	respiratory depression
pralidoxime-chloride	BCHE	54072659	MHOAUIZFSQGCNM-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	pulmonary	respiratory depression
pramipexole	ADRA2A	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	ADRA2B	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	ADRA2C	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	DRD1	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	DRD2	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	DRD3	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	DRD4	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	DRD5	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	HTR1A	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	HTR1B	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	HTR1D	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	HTR2A	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	HTR2B	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramipexole	HTR2C	119570	FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pranidipine	CACNA1C	29986494	XTFPDGZNWTZCMF-OXHGWOFKSA-N	Phase 2	calcium channel blocker	NA	NA
pranlukast	CYSLTR1	4887	NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	bronchospasm|asthma
pranlukast	CYSLTR2	4887	NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	bronchospasm|asthma
pranlukast	IL5	4887	NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	bronchospasm|asthma
pranlukast	MUC2	4887	NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	bronchospasm|asthma
pranlukast	NFKB1	4887	NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	bronchospasm|asthma
pranlukast	RNASE3	4887	NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	bronchospasm|asthma
pranlukast	TNF	4887	NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	bronchospasm|asthma
prasugrel	P2RY12	51698431	DTGLZDAWLRGWQN-LJQANCHMSA-N	Launched	purinergic receptor antagonist	cardiology	myocardial infarction|acute coronary syndrome (ACS)
pravadoline	CNR1	56463	MEUQWHZOUDZXHH-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
pravadoline	CNR2	56463	MEUQWHZOUDZXHH-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
pravastatin	HMGCR	54687	TUZYXOIXSAXUGO-PZAWKZKUSA-N	Launched	HMGCR inhibitor	endocrinology|cardiology	hypercholesterolemia|myocardial infarction|hyperlipidemia
pravastatin	SLCO1B1	54687	TUZYXOIXSAXUGO-PZAWKZKUSA-N	Launched	HMGCR inhibitor	endocrinology|cardiology	hypercholesterolemia|myocardial infarction|hyperlipidemia
prazosin	ADRA1A	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	ADRA1B	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	ADRA1D	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	ADRA2A	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	ADRA2B	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	ADRA2C	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	KCNH2	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	KCNH6	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
prazosin	KCNH7	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
PRE-084	SIGMAR1	126402	RQHKZUBCUZVZEF-UHFFFAOYSA-N	Preclinical	sigma receptor agonist	NA	NA
preclamol	DRD2	202478	HTSNFXAICLXZMA-ZDUSSCGKSA-N	Phase 2	dopamine receptor agonist	NA	NA
prednicarbate	PLA2G1B	NA	FNPXMHRZILFCKX-HGVFMWMISA-N	Launched	phospholipase activator	dermatology|ophthalmology|neurology/psychiatry	eczema|contact dermatitis|itching
prednisolone	NR3C1	5755	OIGNJSKKLXVSLS-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
prednisolone	NR3C2	5755	OIGNJSKKLXVSLS-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
prednisolone	SERPINA6	5755	OIGNJSKKLXVSLS-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
prednisolone-acetate	NR3C1	5834	LRJOMUJRLNCICJ-JZYPGELDSA-N	Launched	glucocorticoid receptor agonist	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
prednisolone-hemisuccinate	NR3C1	656804	APGDTXUMTIZLCJ-CGVGKPPMSA-N	Preclinical	glucocorticoid receptor agonist	NA	NA
prednisolone-sodium-phosphate	NR3C1	72078	JDOZJEUDSLGTLU-VWUMJDOOSA-N	Launched	glucocorticoid receptor agonist	allergy|pulmonary|ophthalmology|infectious disease|rheumatology|endocrinology|neurology/psychiatry|gastroenterology|hematology	allergic rhinitis|asthma|contact dermatitis|mycosis|lupus|hypercalcemia|thyroiditis|congenital adrenal hyperplasia|multiple sclerosis|ulcerative colitis|enteritis|thrombocythemia|pneumonia|meningitis|psoriatic arthritis|rheumatoid arthritis
prednisone	HSD11B1	5865	XOFYZVNMUHMLCC-ZPOLXVRWSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry	congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis
prednisone	NR3C1	5865	XOFYZVNMUHMLCC-ZPOLXVRWSA-N	Launched	glucocorticoid receptor agonist	endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry	congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis
pregnenolone	SULT2B1	8955	ORNBQBCIOKFOEO-QGVNFLHTSA-N	Launched	glutamate receptor modulator	rheumatology	rheumatoid arthritis
pregnenolone-succinate	CYP17A1	NA	OZZAYJQNMKMUSD-VQLNUFJUSA-N	Preclinical	GABA receptor negative allosteric modulator	NA	NA
preladenant	ADORA1	10117987	DTYWJKSSUANMHD-UHFFFAOYSA-N	Phase 3	adenosine receptor antagonist	NA	NA
preladenant	ADORA2A	10117987	DTYWJKSSUANMHD-UHFFFAOYSA-N	Phase 3	adenosine receptor antagonist	NA	NA
preladenant	ADORA2B	10117987	DTYWJKSSUANMHD-UHFFFAOYSA-N	Phase 3	adenosine receptor antagonist	NA	NA
preladenant	ADORA3	10117987	DTYWJKSSUANMHD-UHFFFAOYSA-N	Phase 3	adenosine receptor antagonist	NA	NA
pretomanid	FASN	456199	ZLHZLMOSPGACSZ-NSHDSACASA-N	Launched	nitric oxide donor	NA	NA
prilocaine	SCN5A	6603976	MVFGUOIZUNYYSO-NSHDSACASA-N	Launched	local anesthetic	neurology/psychiatry	anesthetic
PRIMA1	ACHE	322968	RFBVBRVVOPAAFS-UHFFFAOYSA-N	Preclinical	TP53 inhibitor	NA	NA
primidone	CHRNA4	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	CHRNA7	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRA1	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRA2	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRA3	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRA4	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRA5	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRA6	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRB1	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRB2	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRB3	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRD	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRE	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRG1	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRG2	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRG3	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRP	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GABRQ	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GRIA2	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	GRIK2	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN10A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN11A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN1A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN2A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN3A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN4A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN5A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN7A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN8A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
primidone	SCN9A	4909	DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	seizures
prinaberel	ESR2	656954	MQIMZDXIAHJKQP-UHFFFAOYSA-N	Phase 2	estrogen receptor agonist	NA	NA
prinaberel	NCOA1	656954	MQIMZDXIAHJKQP-UHFFFAOYSA-N	Phase 2	estrogen receptor agonist	NA	NA
priralfinamide	CACNA1B	5745207	BHJIBOFHEFDSAU-LBPRGKRZSA-N	Phase 3	sodium channel blocker	NA	NA
proadifen	NOS1	4910	SNTQPLDRUZOSDP-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
probenecid	PANX1	4911	DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched	uricosuric blocker	nephrology|rheumatology	hyperuricemia|gout
probenecid	SLC22A11	4911	DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched	uricosuric blocker	nephrology|rheumatology	hyperuricemia|gout
probenecid	SLC22A6	4911	DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched	uricosuric blocker	nephrology|rheumatology	hyperuricemia|gout
probenecid	SLC22A8	4911	DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched	uricosuric blocker	nephrology|rheumatology	hyperuricemia|gout
probenecid	SLCO1C1	4911	DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched	uricosuric blocker	nephrology|rheumatology	hyperuricemia|gout
probucol	ABCA1	4912	FYPMFJGVHOHGLL-UHFFFAOYSA-N	Launched	atherogenesis inhibitor	cardiology	coronary artery disease (CAD)
probucol	ABCB11	4912	FYPMFJGVHOHGLL-UHFFFAOYSA-N	Launched	atherogenesis inhibitor	cardiology	coronary artery disease (CAD)
probucol	CES1	4912	FYPMFJGVHOHGLL-UHFFFAOYSA-N	Launched	atherogenesis inhibitor	cardiology	coronary artery disease (CAD)
procainamide	DNMT1	4913	REQCZEXYDRLIBE-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)
procainamide	SCN5A	4913	REQCZEXYDRLIBE-UHFFFAOYSA-N	Launched	sodium channel blocker	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)
procaine	CHRNA2	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	GRIN3A	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	HTR3A	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNMA1	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNMB1	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNMB2	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNMB3	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNMB4	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNN1	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNN2	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNN3	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	KCNN4	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	MAOA	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	MAOB	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	RYR1	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	RYR2	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	SCN10A	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaine	SLC6A3	4914	MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	HMGCR inhibitor	neurology/psychiatry	anesthetic
procaterol	ADRB2	688561	FKNXQNWAXFXVNW-BLLLJJGKSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
prochlorperazine	DRD1	4917	WIKYUJGCLQQFNW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
prochlorperazine	DRD2	4917	WIKYUJGCLQQFNW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
prochlorperazine	DRD3	4917	WIKYUJGCLQQFNW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
prochlorperazine	DRD4	4917	WIKYUJGCLQQFNW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea|vomiting
profenamine	CHRM1	667534	CDOZDBSBBXSXLB-HNNXBMFYSA-N	Launched	butyrylcholinesterase inhibitor|cholinergic receptor antagonist	neurology/psychiatry	Parkinson's Disease
proflavine-hemisulfate	F2	7099	WDVSHHCDHLJJJR-UHFFFAOYSA-N	Phase 2	topical anesthetic	NA	NA
progesterone	CATSPER1	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	CATSPER2	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	CATSPER3	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	CATSPER4	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	CYP17A1	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	ESR1	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	NR3C2	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	OPRK1	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	PGR	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
progesterone	TRPC5	5994	RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea
proglumetacin	PTGS1	76965948	PTXGHCGBYMQQIG-RRHRGVEJSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
proglumetacin	PTGS2	76965948	PTXGHCGBYMQQIG-RRHRGVEJSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
proglumide	CCKAR	6603906	DGMKFQYCZXERLX-OAHLLOKOSA-N	Withdrawn	CCK receptor antagonist	NA	NA
proglumide	CCKBR	6603906	DGMKFQYCZXERLX-OAHLLOKOSA-N	Withdrawn	CCK receptor antagonist	NA	NA
proguanil	DHFR	6178111	SSOLNOMRVKKSON-UHFFFAOYSA-N	Launched	dihydrofolate reductase inhibitor	infectious disease	malaria
promazine	ADRA1A	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	ADRA1B	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	ADRA1D	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	CHRM1	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	CHRM2	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	CHRM3	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	CHRM4	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	CHRM5	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	DRD1	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	DRD2	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	DRD3	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	DRD4	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	HRH1	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	HTR2A	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promazine	HTR2C	4926	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promestriene	ESR1	9883915	IUWKNLFTJBHTSD-AANPDWTMSA-N	Launched	estrogen receptor agonist	endocrinology	androgenetic alopecia
promethazine	HRH1	89044377	PWWVAXIEGOYWEE-UHFFFAOYSA-N	Launched	histamine receptor antagonist	neurology/psychiatry|allergy	sedative|allergic rhinitis
propacetamol	PTGS2	68865	QTGAJCQTLIRCFL-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	endocrinology|neurology/psychiatry	fever|pain relief
propafenone	ADRB1	184819	JWHAUXFOSRPERK-GOSISDBHSA-N	Launched	antiarrhythmic	cardiology	atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias
propafenone	ADRB2	184819	JWHAUXFOSRPERK-GOSISDBHSA-N	Launched	antiarrhythmic	cardiology	atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias
propafenone	KCNA5	184819	JWHAUXFOSRPERK-GOSISDBHSA-N	Launched	antiarrhythmic	cardiology	atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias
propafenone	KCNH2	184819	JWHAUXFOSRPERK-GOSISDBHSA-N	Launched	antiarrhythmic	cardiology	atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias
propagermanium	CCR2	83030	XEABSBMNTNXEJM-UHFFFAOYSA-N	Launched	CCR agonist|interferon receptor agonist	infectious disease	hepatitis B
propantheline	CHRM1	4934	VVWYOYDLCMFIEM-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
propantheline	CHRM2	4934	VVWYOYDLCMFIEM-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
propantheline	CHRM3	4934	VVWYOYDLCMFIEM-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
propantheline	CHRM4	4934	VVWYOYDLCMFIEM-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
propentofylline	PDE1A	4938	RBQOQRRFDPXAGN-UHFFFAOYSA-N	Launched	adenosine reuptake inhibitor|phosphodiesterase inhibitor	neurology/psychiatry	stroke
propidium-iodide	ACHE	4939	ZDWVWKDAWBGPDN-UHFFFAOYSA-O	Preclinical		NA	NA
propiverine	CHRM1	4942	QPCVHQBVMYCJOM-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence
propofol	FAAH	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRA1	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRA2	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRA3	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRA4	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRA5	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRA6	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRB1	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRB2	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRB3	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRD	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRE	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRG1	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRG2	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRG3	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRP	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	GABRQ	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	SCN2A	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propofol	SCN4A	4943	OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propranolol	ADRB1	62882	AQHHHDLHHXJYJD-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|neurology/psychiatry	hypertension|angina pectoris|migraine headache
propranolol	ADRB2	62882	AQHHHDLHHXJYJD-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology|neurology/psychiatry	hypertension|angina pectoris|migraine headache
propranolol-(R)	ADRB2	21138	AQHHHDLHHXJYJD-CQSZACIVSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
propranolol-(R)	ADRB3	21138	AQHHHDLHHXJYJD-CQSZACIVSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
propranolol-(S)	ADRB1	91536	AQHHHDLHHXJYJD-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
propranolol-(S)	HTR1A	91536	AQHHHDLHHXJYJD-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
propranolol-(S)	HTR5A	91536	AQHHHDLHHXJYJD-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
propranolol-(S)	SLC10A1	91536	AQHHHDLHHXJYJD-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
propylthiouracil	DIO1	657298	KNAHARQHSZJURB-UHFFFAOYSA-N	Launched	thyroid peroxidase inhibitor	endocrinology	hyperthyroidism|Grave's disease|goiter
propylthiouracil	TPO	657298	KNAHARQHSZJURB-UHFFFAOYSA-N	Launched	thyroid peroxidase inhibitor	endocrinology	hyperthyroidism|Grave's disease|goiter
proquazone	PTGS1	31508	JTIGKVIOEQASGT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
proquazone	PTGS2	31508	JTIGKVIOEQASGT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
protirelin	TRHR	638678	XNSAINXGIQZQOO-SRVKXCTJSA-N	Launched	thyrotropin releasing hormone receptor agonist	radiology	thyroid function diagnostic
protoporphyrin-IX	HMOX1	NA	HGXFBVDWWKPUKZ-UJJXFSCMSA-N	Preclinical	heme oxygenase inhibitor	NA	NA
protriptyline	SLC6A2	4976	BWPIARFWQZKAIA-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
protriptyline	SLC6A4	4976	BWPIARFWQZKAIA-UHFFFAOYSA-N	Launched	tricyclic antidepressant	neurology/psychiatry	depression
proxyfan	HRH3	6421522	WNWALBVQAAIULR-UHFFFAOYSA-N	Preclinical	histamine receptor modulator	NA	NA
proxymetacaine	SCN10A	4935	KCLANYCVBBTKTO-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	anesthetic
proxymetacaine	SCN5A	4935	KCLANYCVBBTKTO-UHFFFAOYSA-N	Launched	sodium channel blocker	neurology/psychiatry	anesthetic
PRT062070	SYK	44595079	BGLPECHZZQDNCD-UHFFFAOYSA-N	Phase 2/Phase 3	JAK inhibitor|SYK inhibitor	NA	NA
PRT062607	FGR	44462758	"InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1"	Phase 2	SYK inhibitor	NA	NA
PRT062607	MAP3K9	44462758	"InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1"	Phase 2	SYK inhibitor	NA	NA
PRT062607	SYK	44462758	"InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1"	Phase 2	SYK inhibitor	NA	NA
PRT4165	PRC1	207893	OMHZFEWYVFWVLI-UHFFFAOYSA-N	Preclinical	polycomb repressive complex inhibitor	NA	NA
prucalopride	HTR4	3052762	ZPMNHBXQOOVQJL-UHFFFAOYSA-N	Launched	serotonin receptor agonist	gastroenterology	constipation
pruvanserin	HTR2A	6433122	AQRLDDAFYYAIJP-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
pruvanserin	HTR2C	6433122	AQRLDDAFYYAIJP-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
PRX-08066	HTR2B	11502243	IENZFHBNCRQMNP-UHFFFAOYSA-N	Phase 2	serotonin receptor antagonist	NA	NA
PSB-06126	ENTPD3	25124826	ZHQRPIRGSWEALJ-UHFFFAOYSA-N	Preclinical	NTPDase inhibitor	NA	NA
PSB-11	ADORA1	NA	RGDHRCXUMURWBJ-LLVKDONJSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-11	ADORA2A	NA	RGDHRCXUMURWBJ-LLVKDONJSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-11	ADORA3	NA	RGDHRCXUMURWBJ-LLVKDONJSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-1115	ADORA1	5311479	UYDRRQPGDSIMNU-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-1115	ADORA2B	5311479	UYDRRQPGDSIMNU-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-1115	ADORA3	5311479	UYDRRQPGDSIMNU-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-36	ADORA1	NA	CIBIXJYFYPFMTN-FZUGUKJMSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-36	ADORA2A	NA	CIBIXJYFYPFMTN-FZUGUKJMSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-36	ADORA2B	NA	CIBIXJYFYPFMTN-FZUGUKJMSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-36	ADORA3	NA	CIBIXJYFYPFMTN-FZUGUKJMSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-603	ADORA1	44185871	OVHCTHHFOHMNFV-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-603	ADORA2A	44185871	OVHCTHHFOHMNFV-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-603	ADORA2B	44185871	OVHCTHHFOHMNFV-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSB-603	ADORA3	44185871	OVHCTHHFOHMNFV-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
PSN-375963	GPR119	2875918	OAVLEYPTWABFLF-UHFFFAOYSA-N	Preclinical	glucose dependent insulinotropic receptor agonist	NA	NA
PSNCBAM-1	CNR1	11560249	HDAYFSFWIPRJSO-UHFFFAOYSA-N	Preclinical	cannabinoid receptor modulator	NA	NA
psoralen	MAOA	6199	ZCCUUQDIBDJBTK-UHFFFAOYSA-N	Launched		dermatology	psoriasis|eczema|vitiligo
psoralen	MAOB	6199	ZCCUUQDIBDJBTK-UHFFFAOYSA-N	Launched		dermatology	psoriasis|eczema|vitiligo
PS178990	AR	9882972	KEJORAMIZFOODM-PWSUYJOCSA-N	Phase 1	androgen receptor modulator	NA	NA
PT-2385	EPAS1	91754484	ONBSHRSJOPSEGS-INIZCTEOSA-N	Phase 1	hypoxia inducible factor inhibitor	NA	NA
pterostilbene	PTGS2	5281727	VLEUZFDZJKSGMX-ONEGZZNKSA-N	Phase 2/Phase 3	cyclooxygenase inhibitor|PPAR receptor agonist	NA	NA
PU-H71	HSP90AA1	9549213	SUPVGFZUWFMATN-UHFFFAOYSA-N	Phase 1	HSP inhibitor	NA	NA
pumosetrag	HTR3A	154104	AFUWQWYPPZFWCO-LBPRGKRZSA-N	Phase 2	serotonin receptor agonist	NA	NA
pumosetrag	HTR4	154104	AFUWQWYPPZFWCO-LBPRGKRZSA-N	Phase 2	serotonin receptor agonist	NA	NA
purmorphamine	SMO	5284329	FYBHCRQFSFYWPY-UHFFFAOYSA-N	Preclinical	smoothened receptor agonist	NA	NA
puromycin	NHP2L1	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL10L	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL11	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL13A	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL15	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL19	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL23	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL23A	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL26L1	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL3	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL37	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RPL8	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
puromycin	RSL24D1	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	protein synthesis inhibitor	NA	NA
purvalanol-A	CDK1	456214	PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	CDK inhibitor	NA	NA
purvalanol-A	CDK2	456214	PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	CDK inhibitor	NA	NA
purvalanol-A	CDK4	456214	PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	CDK inhibitor	NA	NA
purvalanol-A	CDK5	456214	PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	CDK inhibitor	NA	NA
purvalanol-A	CSNK1G3	456214	PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	CDK inhibitor	NA	NA
purvalanol-A	RPS6KA1	456214	PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	CDK inhibitor	NA	NA
purvalanol-A	SRC	456214	PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	CDK inhibitor	NA	NA
purvalanol-B	CDK2	448991	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
purvalanol-B	CDK4	448991	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
purvalanol-B	CDK5	448991	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
purvalanol-B	MAPK1	448991	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
purvalanol-B	MAPK3	448991	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
purvalanol-B	SRPK2	448991	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
putrescine	AMD1	1045	KIDHWZJUCRJVML-UHFFFAOYSA-N	Phase 2	tissue transglutaminase inhibitor	NA	NA
putrescine	KCNJ4	1045	KIDHWZJUCRJVML-UHFFFAOYSA-N	Phase 2	tissue transglutaminase inhibitor	NA	NA
putrescine	ODC1	1045	KIDHWZJUCRJVML-UHFFFAOYSA-N	Phase 2	tissue transglutaminase inhibitor	NA	NA
PX-12	CNR1	86308851	BPBPYQWMFCTCNG-ZCFIWIBFSA-N	Phase 2	thioredoxin inhibitor	NA	NA
PX-12	TXN	86308851	BPBPYQWMFCTCNG-ZCFIWIBFSA-N	Phase 2	thioredoxin inhibitor	NA	NA
pyrazinamide	FASN	1046	IPEHBUMCGVEMRF-UHFFFAOYSA-N	Launched	fatty acid synthase inhibitor	infectious disease	tuberculosis
pyrazolanthrone	MAPK10	8515	ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
pyrazolanthrone	MAPK8	8515	ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
pyrazolanthrone	MAPK8IP1	8515	ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
pyrazolanthrone	MAPK9	8515	ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
pyrazolanthrone	TTK	8515	ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
pyrazoloacridine	TOP1	NA	HVRZAFDJOWIDMM-UHFFFAOYSA-N	Phase 2	topoisomerase inhibitor	NA	NA
pyrazoloacridine	TOP2A	NA	HVRZAFDJOWIDMM-UHFFFAOYSA-N	Phase 2	topoisomerase inhibitor	NA	NA
pyridoxal	PDXK	1050	RADKZDMFGJYCBB-UHFFFAOYSA-N	Launched		neurology/psychiatry	epilepsy
pyridoxine	DDC	1054	LXNHXLLTXMVWPM-UHFFFAOYSA-N	Launched	vitamin B	metabolism	vitamin B6 deficiency
pyridoxine	PDXK	1054	LXNHXLLTXMVWPM-UHFFFAOYSA-N	Launched	vitamin B	metabolism	vitamin B6 deficiency
pyrimethamine	DHFR	4993	WKSAUQYGYAYLPV-UHFFFAOYSA-N	Launched	dihydrofolate reductase inhibitor	infectious disease	malaria
pyrimethamine	SLC47A1	4993	WKSAUQYGYAYLPV-UHFFFAOYSA-N	Launched	dihydrofolate reductase inhibitor	infectious disease	malaria
pyrithione-zinc	KCNQ1		KTIHEFSORPLWRR-UHFFFAOYSA-L	Launched	ATP synthase inhibitor	dermatology	dandruff|cosmetic
pyrithione-zinc	KCNQ2		KTIHEFSORPLWRR-UHFFFAOYSA-L	Launched	ATP synthase inhibitor	dermatology	dandruff|cosmetic
pyrithione-zinc	KCNQ4		KTIHEFSORPLWRR-UHFFFAOYSA-L	Launched	ATP synthase inhibitor	dermatology	dandruff|cosmetic
pyrithione-zinc	KCNQ5		KTIHEFSORPLWRR-UHFFFAOYSA-L	Launched	ATP synthase inhibitor	dermatology	dandruff|cosmetic
pyroxamide	HDAC1	4996	PTJGLFIIZFVFJV-UHFFFAOYSA-N	Phase 1	HDAC inhibitor	NA	NA
pyrrolidine-dithiocarbamate	HSD11B1	65351	VSWDORGPIHIGNW-UHFFFAOYSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
pyrrolidine-dithiocarbamate	RELA	65351	VSWDORGPIHIGNW-UHFFFAOYSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
pyrvinium-pamoate	AR	5281035	QMHSXPLYMTVAMK-UHFFFAOYSA-N	Launched	androgen receptor antagonist	infectious disease	pinworm
P22077	USP7	46931953	RMAMGGNACJHXHO-UHFFFAOYSA-N	Preclinical	ubiquitin specific protease inhibitor	NA	NA
P276-00	CDK1	23643976	QLUYMIVVAYRECT-OCCSQVGLSA-N	Phase 2	CDK inhibitor	NA	NA
P276-00	CDK4	23643976	QLUYMIVVAYRECT-OCCSQVGLSA-N	Phase 2	CDK inhibitor	NA	NA
P276-00	CDK9	23643976	QLUYMIVVAYRECT-OCCSQVGLSA-N	Phase 2	CDK inhibitor	NA	NA
P5091	USP7	2819993	LKZLGMAAKNEGCH-UHFFFAOYSA-N	Preclinical	ubiquitin specific protease inhibitor	NA	NA
P7C3	NAMPT	981442	FZHHRERIIVOATI-KRWDZBQOSA-N	Preclinical	NAMPT inhibitor	NA	NA
quazinone	PDE3A	135511466	BHZFZYLBVSWUMT-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
quazinone	PDE3B	135511466	BHZFZYLBVSWUMT-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
quercetin	ATP5A1	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	ATP5B	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	ATP5C1	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	HCK	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	HIBCH	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	PIK3CG	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	PIM1	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	STK17B	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quercetin	UGT3A1	5280343	REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	polar auxin transport inhibitor	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness
quetiapine	ADRA1A	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	ADRA1B	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	ADRA1D	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	ADRA2A	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	ADRA2B	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	ADRA2C	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	CHRM1	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	CHRM2	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	CHRM3	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	CHRM4	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	CHRM5	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	DRD1	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	DRD2	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	DRD3	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	DRD4	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	DRD5	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HRH1	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR1A	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR1B	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR1D	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR1E	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR1F	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR2A	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR2C	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR3A	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR6	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	HTR7	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quetiapine	SLC6A2	5002	URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
quiflapon	ALOX5	60923	NZOONKHCNQFYCI-UHFFFAOYSA-N	Phase 2	leukotriene synthesis inhibitor	NA	NA
quiflapon	ALOX5AP	60923	NZOONKHCNQFYCI-UHFFFAOYSA-N	Phase 2	leukotriene synthesis inhibitor	NA	NA
quinagolide	DRD2	3086401	GDFGTRDCCWFXTG-ZIFCJYIRSA-N	Launched	dopamine receptor agonist	endocrinology	hyperprolactinemia
quinapril	ACE	54892	JSDRRTOADPPCHY-HSQYWUDLSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|congestive heart failure|angioedema
quinaprilat	ACE	107994	FLSLEGPOVLMJMN-YSSFQJQWSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|angioedema
quinelorane	DRD2	57242	TUFADSGTJUOBEH-ZWNOBZJWSA-N	Phase 3	dopamine receptor agonist	NA	NA
quinelorane	DRD3	57242	TUFADSGTJUOBEH-ZWNOBZJWSA-N	Phase 3	dopamine receptor agonist	NA	NA
quinestrol	ESR1	9046	PWZUUYSISTUNDW-VAFBSOEGSA-N	Launched	estrogen receptor agonist	endocrinology	menopause
quinestrol	ESR2	9046	PWZUUYSISTUNDW-VAFBSOEGSA-N	Launched	estrogen receptor agonist	endocrinology	menopause
quinidine	KCNA5	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	KCNA7	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	KCNH1	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	KCNH2	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	KCNH5	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	KCNK1	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	KCNK6	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	SCN5A	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinidine	SLC29A4	441074	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	sodium channel blocker	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias
quinine	GP9	3034034	LOUPRKONTZGTKE-WZBLMQSHSA-N	Launched	hemozoin biocrystallization inhibitor	infectious disease	malaria
quinine	KCNB2	3034034	LOUPRKONTZGTKE-WZBLMQSHSA-N	Launched	hemozoin biocrystallization inhibitor	infectious disease	malaria
quinine	KCNN4	3034034	LOUPRKONTZGTKE-WZBLMQSHSA-N	Launched	hemozoin biocrystallization inhibitor	infectious disease	malaria
quinine	SLC29A4	3034034	LOUPRKONTZGTKE-WZBLMQSHSA-N	Launched	hemozoin biocrystallization inhibitor	infectious disease	malaria
quinpirol-(-)	DRD1	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quinpirol-(-)	DRD2	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quinpirol-(-)	DRD3	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quinpirol-(-)	DRD4	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quinpirol-(-)	HTR1A	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quinpirol-(-)	HTR2A	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quinpirol-(-)	HTR2B	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quinpirol-(-)	HTR2C	54562	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	dopamine receptor agonist	NA	NA
quipazine	HTR1A	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	HTR1D	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	HTR2A	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	HTR2B	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	HTR2C	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	HTR3A	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	HTR3B	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	HTR6	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quipazine	SLC6A4	5011	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
quizartinib	CSF1R	24889392	CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3	FLT3 inhibitor	NA	NA
quizartinib	FLT3	24889392	CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3	FLT3 inhibitor	NA	NA
quizartinib	KIT	24889392	CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3	FLT3 inhibitor	NA	NA
quizartinib	PDGFRA	24889392	CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3	FLT3 inhibitor	NA	NA
quizartinib	PDGFRB	24889392	CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3	FLT3 inhibitor	NA	NA
quizartinib	RET	24889392	CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3	FLT3 inhibitor	NA	NA
QX-314	MAPK14	3925	PYEBKOFMWAMBFV-UHFFFAOYSA-O	Preclinical	sodium channel blocker	NA	NA
QX-314	TGFBR1	3925	PYEBKOFMWAMBFV-UHFFFAOYSA-O	Preclinical	sodium channel blocker	NA	NA
R-1485	HTR6	11689373	UPROBLPRPWYJGN-UHFFFAOYSA-N	Phase 1	serotonin receptor antagonist	NA	NA
R-268712	TGFBR1	11703284	JQGOCCALXFSRHZ-UHFFFAOYSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
R-428	AXL	46215462	KXMZDGSRSGHMMK-VWLOTQADSA-N	Phase 2	AXL kinase inhibitor	NA	NA
R-59022	DGKA	3012	MFVJXLPANKSLLD-UHFFFAOYSA-N	Preclinical	diacylglycerol kinase inhibitor|protein kinase inhibitor	NA	NA
R-96544	HTR2A	10668211	AFZLABYDOCWQBQ-WOJBJXKFSA-N	Preclinical	serotonin receptor antagonist	NA	NA
rabeprazole	ATP4A	9906855	YREYEVIYCVEVJK-RUZDIDTESA-N	Launched	ATPase inhibitor|gastrin inhibitor	gastroenterology	gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome
rac-BHFF	GABBR1	7023847	RVNOANDLZIIFHB-MRXNPFEDSA-N	Preclinical	GABA receptor positive allosteric modulator	NA	NA
racecadotril	MME	60561	ODUOJXZPIYUATO-LJQANCHMSA-N	Launched	enkephalinase inhibitor	gastroenterology	diarrhea
raclopride	DRD2	3033769	WAOQONBSWFLFPE-VIFPVBQESA-N	Launched	dopamine receptor antagonist	NA	NA
raclopride	DRD3	3033769	WAOQONBSWFLFPE-VIFPVBQESA-N	Launched	dopamine receptor antagonist	NA	NA
raclopride	HTR1A	3033769	WAOQONBSWFLFPE-VIFPVBQESA-N	Launched	dopamine receptor antagonist	NA	NA
radafaxine	SLC6A3	9795056	RCOBKSKAZMVBHT-TVQRCGJNSA-N	Phase 2	dopamine-norepinephrine reuptake inhibitor	NA	NA
RAF265	BRAF	11656518	YABJJWZLRMPFSI-UHFFFAOYSA-N	Phase 2	RAF inhibitor|VEGFR inhibitor	NA	NA
raloxifene	ESR1	5035	GZUITABIAKMVPG-UHFFFAOYSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	orthopedics|oncology	osteoporosis|breast cancer
raloxifene	ESR2	5035	GZUITABIAKMVPG-UHFFFAOYSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	orthopedics|oncology	osteoporosis|breast cancer
raltitrexed	FPGS	135400182	IVTVGDXNLFLDRM-HNNXBMFYSA-N	Launched	thymidylate synthase inhibitor	oncology	mesothelioma
raltitrexed	TYMS	135400182	IVTVGDXNLFLDRM-HNNXBMFYSA-N	Launched	thymidylate synthase inhibitor	oncology	mesothelioma
ramatroban	PTGDR2	123879	LDXDSHIEDAPSSA-OAHLLOKOSA-N	Launched	prostanoid receptor antagonist	cardiology|pulmonary	coronary artery disease (CAD)|asthma
ramatroban	TBXA2R	123879	LDXDSHIEDAPSSA-OAHLLOKOSA-N	Launched	prostanoid receptor antagonist	cardiology|pulmonary	coronary artery disease (CAD)|asthma
ramelteon	MTNR1A	208902	YLXDSYKOBKBWJQ-LBPRGKRZSA-N	Launched	melatonin receptor agonist	neurology/psychiatry	insomnia
ramelteon	MTNR1B	208902	YLXDSYKOBKBWJQ-LBPRGKRZSA-N	Launched	melatonin receptor agonist	neurology/psychiatry	insomnia
ramipril	ACE	6992028	HDACQVRGBOVJII-JBDAPHQKSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
ramosetron	HTR3A	135418340	NTHPAPBPFQJABD-LLVKDONJSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting|irritable bowel syndrome
ranirestat	AKR1B1	153948	QCVNMNYRNIMDKV-QGZVFWFLSA-N	Phase 3	aldose reductase inhibitor	NA	NA
ranitidine	HRH2	9883333	SYNOVMDJYWJCON-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology	heartburn
ranolazine	SCN10A	13560750	XKLMZUWKNUAPSZ-FQEVSTJZSA-N	Launched	sodium channel blocker	cardiology	chronic stable angina
ranolazine	SCN9A	13560750	XKLMZUWKNUAPSZ-FQEVSTJZSA-N	Launched	sodium channel blocker	cardiology	chronic stable angina
rasagiline	BCL2	3052776	RUOKEQAAGRXIBM-GFCCVEGCSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
rasagiline	MAOB	3052776	RUOKEQAAGRXIBM-GFCCVEGCSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
rauwolscine	ADRA2A	643606	BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
rauwolscine	ADRA2B	643606	BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
rauwolscine	ADRA2C	643606	BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
rauwolscine	HTR1B	643606	BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
rauwolscine	HTR1D	643606	BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
rauwolscine	HTR1E	643606	BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
rauwolscine	HTR2B	643606	BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
ravoxertinib	MAPK1	71727581	RZUOCXOYPYGSKL-GOSISDBHSA-N	Phase 1	ERK1 and ERK2 phosphorylation inhibitor	NA	NA
ravoxertinib	MAPK3	71727581	RZUOCXOYPYGSKL-GOSISDBHSA-N	Phase 1	ERK1 and ERK2 phosphorylation inhibitor	NA	NA
RBC8	RALA	NA	RFEAEBNMNYRJFD-VGAJERRHSA-N	Preclinical	Ral GTPase inhibitor	NA	NA
RBC8	RALB	NA	RFEAEBNMNYRJFD-VGAJERRHSA-N	Preclinical	Ral GTPase inhibitor	NA	NA
rebamipide	FPR1	969464	ALLWOAVDORUJLA-MRXNPFEDSA-N	Launched	free radical scavenger	gastroenterology	peptic ulcer disease (PUD)|gastritis
rebastinib	ABL1	25066467	WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
rebastinib	BCR	25066467	WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
rebastinib	FGR	25066467	WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
rebastinib	FLT3	25066467	WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
rebastinib	HCK	25066467	WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
rebastinib	LYN	25066467	WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
rebastinib	SRC	25066467	WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
reboxetine	SLC6A2	127151	CBQGYUDMJHNJBX-RTBURBONSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	depression
Rec-15/2615	ADRA1A	9891980	ZZMFJJDBKSYGRM-UHFFFAOYSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
refametinib	MAP2K1	44182295	RDSACQWTXKSHJT-NSHDSACASA-N	Phase 2	MEK inhibitor	NA	NA
refametinib	MAP2K2	44182295	RDSACQWTXKSHJT-NSHDSACASA-N	Phase 2	MEK inhibitor	NA	NA
regadenoson	ADORA1	219024	LZPZPHGJDAGEJZ-AKAIJSEGSA-N	Launched	adenosine receptor agonist	radiology	myocardial perfusion imaging (MPI)
regadenoson	ADORA2A	219024	LZPZPHGJDAGEJZ-AKAIJSEGSA-N	Launched	adenosine receptor agonist	radiology	myocardial perfusion imaging (MPI)
regadenoson	ADORA2B	219024	LZPZPHGJDAGEJZ-AKAIJSEGSA-N	Launched	adenosine receptor agonist	radiology	myocardial perfusion imaging (MPI)
regadenoson	ADORA3	219024	LZPZPHGJDAGEJZ-AKAIJSEGSA-N	Launched	adenosine receptor agonist	radiology	myocardial perfusion imaging (MPI)
regorafenib	ABL1	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	BRAF	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	DDR2	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	EPHA2	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	FGFR1	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	FGFR2	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	FLT1	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	FLT4	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	FRK	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	KDR	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	KIT	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	MAPK11	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	NTRK1	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	PDGFRA	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	PDGFRB	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	RAF1	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	RET	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
regorafenib	TEK	11167602	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)
relcovaptan	AVPR1A	60943	CEBYCSRFKCEUSW-NAYZPBBASA-N	Phase 2	vasopressin receptor antagonist	NA	NA
relcovaptan	AVPR1B	60943	CEBYCSRFKCEUSW-NAYZPBBASA-N	Phase 2	vasopressin receptor antagonist	NA	NA
relcovaptan	AVPR2	60943	CEBYCSRFKCEUSW-NAYZPBBASA-N	Phase 2	vasopressin receptor antagonist	NA	NA
relcovaptan	OXTR	60943	CEBYCSRFKCEUSW-NAYZPBBASA-N	Phase 2	vasopressin receptor antagonist	NA	NA
remacemide	GRIN1	760423	YSGASDXSLKIKOD-KRWDZBQOSA-N	Phase 3	glutamate receptor antagonist	NA	NA
remimazolam	GABBR1	9867812	CYHWMBVXXDIZNZ-KRWDZBQOSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
remodelin	NAT10	44442376	XAEJIFARBQJLML-UHFFFAOYSA-N	Preclinical	transferase inhibitor	NA	NA
remoxipride	DRD2	54477	GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn	dopamine receptor antagonist	NA	NA
remoxipride	DRD3	54477	GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn	dopamine receptor antagonist	NA	NA
remoxipride	DRD4	54477	GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn	dopamine receptor antagonist	NA	NA
remoxipride	HTR2A	54477	GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn	dopamine receptor antagonist	NA	NA
remoxipride	SIGMAR1	54477	GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn	dopamine receptor antagonist	NA	NA
repaglinide	ABCC8	65981	FAEKWTJYAYMJKF-QHCPKHFHSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
repaglinide	KCNJ11	65981	FAEKWTJYAYMJKF-QHCPKHFHSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
repaglinide	PPARG	65981	FAEKWTJYAYMJKF-QHCPKHFHSA-N	Launched	insulin secretagogue	endocrinology	diabetes mellitus
reparixin	CXCR1	9838712	KQDRVXQXKZXMHP-LLVKDONJSA-N	Phase 3	CC chemokine receptor antagonist	NA	NA
reparixin	CXCR2	9838712	KQDRVXQXKZXMHP-LLVKDONJSA-N	Phase 3	CC chemokine receptor antagonist	NA	NA
repsox	TGFBR1	449054	LBPKYPYHDKKRFS-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
resatorvid	TLR4	11703255	LEEIJTHMHDMWLJ-CQSZACIVSA-N	Phase 3	toll-like receptor inhibitor	NA	NA
reserpine	SLC18A1	5770	QEVHRUUCFGRFIF-MDEJGZGSSA-N	Launched	vesicular monoamine transporter inhibitor	cardiology	hypertension
reserpine	SLC18A2	5770	QEVHRUUCFGRFIF-MDEJGZGSSA-N	Launched	vesicular monoamine transporter inhibitor	cardiology	hypertension
resiquimod	TLR7	159603	BXNMTOQRYBFHNZ-UHFFFAOYSA-N	Phase 3	toll-like receptor agonist	NA	NA
resiquimod	TLR8	159603	BXNMTOQRYBFHNZ-UHFFFAOYSA-N	Phase 3	toll-like receptor agonist	NA	NA
resminostat	HDAC1	11609955	FECGNJPYVFEKOD-VMPITWQZSA-N	Phase 2	HDAC inhibitor	NA	NA
resminostat	HDAC3	11609955	FECGNJPYVFEKOD-VMPITWQZSA-N	Phase 2	HDAC inhibitor	NA	NA
resminostat	HDAC6	11609955	FECGNJPYVFEKOD-VMPITWQZSA-N	Phase 2	HDAC inhibitor	NA	NA
resminostat	HDAC8	11609955	FECGNJPYVFEKOD-VMPITWQZSA-N	Phase 2	HDAC inhibitor	NA	NA
resorcinol	CA12	5054	GHMLBKRAJCXXBS-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis
resorcinol	CA14	5054	GHMLBKRAJCXXBS-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis
resorcinol	CA2	5054	GHMLBKRAJCXXBS-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis
resorcinol	PTGS1	5054	GHMLBKRAJCXXBS-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	dermatology	acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis
resveratrol	CSNK2A1	445154	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	Launched	cytochrome P450 inhibitor|SIRT activator	NA	NA
resveratrol	NQO2	445154	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	Launched	cytochrome P450 inhibitor|SIRT activator	NA	NA
resveratrol	PTGS1	445154	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	Launched	cytochrome P450 inhibitor|SIRT activator	NA	NA
resveratrol	PTGS2	445154	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	Launched	cytochrome P450 inhibitor|SIRT activator	NA	NA
retaspimycin	HSP90AA1	25169033	OAKGNIRUXAZDQF-FBDSWQSESA-N	Phase 3	HSP inhibitor	NA	NA
retinol	ALDH1A1	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	ALDH1A2	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	ALDH1A3	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	DHRS3	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	DHRS4	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	LRAT	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	NR2C2	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RBP1	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RBP3	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RDH11	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RDH12	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RDH13	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RDH14	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RDH5	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RDH8	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RETSAT	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RHO	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RLBP1	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RXRA	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RXRB	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
retinol	RXRG	445354	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	retinoid receptor ligand	dermatology	cosmetic|acne vulgaris (AV)|keratosis
REV-5901	ALOX5	40428144	JRLOEMCOOZSCQP-JOCHJYFZSA-N	Phase 2	leukotriene receptor antagonist|lipoxygenase inhibitor	NA	NA
revaprazan	ATP4A	40462255	LECZXZOBEZITCL-MRXNPFEDSA-N	Launched	potassium-competitive acid antagonist	gastroenterology	gastritis
reversan	ABCC1	2298706	JTRXWCLQFAZHGP-UHFFFAOYSA-N	Preclinical	MRP inhibitor	NA	NA
reversine	AURKB	210332	ZFLJHSQHILSNCM-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
reversine	INCENP	210332	ZFLJHSQHILSNCM-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
reversine	MAP2K1	210332	ZFLJHSQHILSNCM-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
RGB-286638	CDK1	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	CDK2	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	CDK3	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	CDK4	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	CDK5	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	CDK6	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	CDK7	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	CDK9	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	FLT3	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	GSK3B	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	JAK2	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	MAP3K7	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGB-286638	MAPK9	11285002	XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
RGFP966	HDAC3	56650312	BLVQHYHDYFTPDV-VCABWLAWSA-N	Preclinical	HDAC inhibitor	NA	NA
RG108	DNMT1	702558	HPTXLHAHLXOAKV-INIZCTEOSA-N	Preclinical	DNA methyltransferase inhibitor	NA	NA
RG108	DNMT3B	702558	HPTXLHAHLXOAKV-INIZCTEOSA-N	Preclinical	DNA methyltransferase inhibitor	NA	NA
RG1530	FGFR1	NA	XXAKBYBCWYYQTL-UHFFFAOYSA-N	Phase 1	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
RG1530	FGFR2	NA	XXAKBYBCWYYQTL-UHFFFAOYSA-N	Phase 1	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
RG2833	HDAC1	56654642	VOPDXHFYDJAYNS-UHFFFAOYSA-N	Phase 1	HDAC inhibitor	NA	NA
RG2833	HDAC3	56654642	VOPDXHFYDJAYNS-UHFFFAOYSA-N	Phase 1	HDAC inhibitor	NA	NA
RG4733	PSEN1	49867930	OJPLJFIFUQPSJR-INIZCTEOSA-N	Phase 2	gamma secretase inhibitor	NA	NA
RG7112	MDM2	57406853	QBGKPEROWUKSBK-QPPIDDCLSA-N	Phase 1	MDM inhibitor	NA	NA
RHC-80267	DAGLA	5063	RXSVYGIGWRDVQC-UHFFFAOYSA-N	Preclinical	triacylglycerol lipase inhibitor	NA	NA
RHC-80267	DAGLB	5063	RXSVYGIGWRDVQC-UHFFFAOYSA-N	Preclinical	triacylglycerol lipase inhibitor	NA	NA
rhein	HSP90AA1	10168	FCDLCPWAQCPTKC-UHFFFAOYSA-N	Phase 1		NA	NA
rheochrysidin	PTPN1	10639	FFWOKTFYGVYKIR-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
RI-1	RAD51	1074953	MWSUIZKGNWELRF-UHFFFAOYSA-N	Preclinical		NA	NA
ribavirin	ADK	37542	IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched	antiviral	infectious disease	hepatitis C
ribavirin	ENPP1	37542	IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched	antiviral	infectious disease	hepatitis C
ribavirin	IMPDH1	37542	IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched	antiviral	infectious disease	hepatitis C
ribavirin	IMPDH2	37542	IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched	antiviral	infectious disease	hepatitis C
ribavirin	NT5C2	37542	IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched	antiviral	infectious disease	hepatitis C
ribociclib	CDK4	44631912	RHXHGRAEPCAFML-UHFFFAOYSA-N	Launched	CDK inhibitor	oncology	breast cancer
ribociclib	CDK6	44631912	RHXHGRAEPCAFML-UHFFFAOYSA-N	Launched	CDK inhibitor	oncology	breast cancer
riboflavin	BLVRB	493570	AUNGANRZJHBGPY-SCRDCRAPSA-N	Launched	vitamin B	gastroenterology	jaundice
riboflavin	RFK	493570	AUNGANRZJHBGPY-SCRDCRAPSA-N	Launched	vitamin B	gastroenterology	jaundice
riboflavin-5-phosphate-sodium	BLVRB	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	DHODH	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	DPYD	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	HAO1	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	HAO2	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	MT-ND1	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	NOS1	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	PNPO	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	POR	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	PPCDC	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	RFK	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	RPS6KA4	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
riboflavin-5-phosphate-sodium	SGK1	643976	FVTCRASFADXXNN-SCRDCRAPSA-N	Launched		NA	NA
ribostamycin	P4HB	33042	NSKGQURZWSPSBC-VVPCINPTSA-N	Launched	bacterial 30S ribosomal subunit inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ricinoleic-acid	PTGER3	643684	WBHHMMIMDMUBKC-QJWNTBNXSA-N	Launched	prostanoid receptor agonist	NA	NA
rifampin	NR1I2	135925261	JQXXHWHPUNPDRT-YOPQJBRCSA-N	Launched	RNA polymerase inhibitor	infectious disease	tuberculosis|meningitis
rifampin	SLCO1A2	135925261	JQXXHWHPUNPDRT-YOPQJBRCSA-N	Launched	RNA polymerase inhibitor	infectious disease	tuberculosis|meningitis
rifampin	SLCO1B1	135925261	JQXXHWHPUNPDRT-YOPQJBRCSA-N	Launched	RNA polymerase inhibitor	infectious disease	tuberculosis|meningitis
rifampin	SLCO1B3	135925261	JQXXHWHPUNPDRT-YOPQJBRCSA-N	Launched	RNA polymerase inhibitor	infectious disease	tuberculosis|meningitis
rifamycin	SLCO1A2	5282048	HJYYPODYNSCCOU-WURVRSKISA-N	Launched	DNA directed RNA polymerase inhibitor	infectious disease	tuberculosis|leprosy
rifamycin	SLCO1B1	5282048	HJYYPODYNSCCOU-WURVRSKISA-N	Launched	DNA directed RNA polymerase inhibitor	infectious disease	tuberculosis|leprosy
rifamycin	SLCO1B3	5282048	HJYYPODYNSCCOU-WURVRSKISA-N	Launched	DNA directed RNA polymerase inhibitor	infectious disease	tuberculosis|leprosy
rifamycin	SLCO2B1	5282048	HJYYPODYNSCCOU-WURVRSKISA-N	Launched	DNA directed RNA polymerase inhibitor	infectious disease	tuberculosis|leprosy
rifapentine	CYP2C8	136238508	WDZCUPBHRAEYDL-NAFQJNKLSA-N	Launched	RNA polymerase inhibitor	infectious disease	tuberculosis
rifapentine	CYP2C9	136238508	WDZCUPBHRAEYDL-NAFQJNKLSA-N	Launched	RNA polymerase inhibitor	infectious disease	tuberculosis
rifapentine	CYP3A4	136238508	WDZCUPBHRAEYDL-NAFQJNKLSA-N	Launched	RNA polymerase inhibitor	infectious disease	tuberculosis
rigosertib	PLK1	6918736	OWBFCJROIKNMGD-BQYQJAHWSA-N	Phase 3	cell cycle inhibitor|PLK inhibitor	NA	NA
rilmenidine	ADRA2A	68712	CQXADFVORZEARL-UHFFFAOYSA-N	Launched	adrenergic receptor agonist|imidazoline receptor agonist	cardiology	hypertension
rilpivirine	NR1I2	6451164	YIBOMRUWOWDFLG-ONEGZZNKSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
rilpivirine	SCN10A	6451164	YIBOMRUWOWDFLG-ONEGZZNKSA-N	Launched	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
riluzole	KCNK10	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	KCNK2	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	KCNK4	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	KCNN4	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN10A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN11A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN1A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN2A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN3A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN4A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN5A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN7A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN8A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SCN9A	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
riluzole	SLC7A11	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
rimcazole	SIGMAR1	53389	GUDVQJXODNJRIJ-CALCHBBNSA-N	Phase 1	sigma receptor antagonist	NA	NA
rimegepant	CALCA	51049968	KRNAOFGYEFKHPB-ANJVHQHFSA-N	Launched	calcitonin antagonist	NA	NA
rimexolone	NR3C1	5311412	QTTRZHGPGKRAFB-OOKHYKNYSA-N	Launched	glucocorticoid receptor agonist	ophthalmology	anterior uveitis
rimexolone	SERPINA6	5311412	QTTRZHGPGKRAFB-OOKHYKNYSA-N	Launched	glucocorticoid receptor agonist	ophthalmology	anterior uveitis
rimonabant	CNR1	104850	JZCPYUJPEARBJL-UHFFFAOYSA-N	Withdrawn	cannabinoid receptor antagonist	NA	NA
rimonabant	GPR55	104850	JZCPYUJPEARBJL-UHFFFAOYSA-N	Withdrawn	cannabinoid receptor antagonist	NA	NA
riociguat	GUCY1A2	11304743	WXXSNCNJFUAIDG-UHFFFAOYSA-N	Launched	guanylate cyclase stimulant	cardiology	hypertension
riociguat	GUCY1A3	11304743	WXXSNCNJFUAIDG-UHFFFAOYSA-N	Launched	guanylate cyclase stimulant	cardiology	hypertension
riociguat	GUCY1B2	11304743	WXXSNCNJFUAIDG-UHFFFAOYSA-N	Launched	guanylate cyclase stimulant	cardiology	hypertension
riociguat	GUCY1B3	11304743	WXXSNCNJFUAIDG-UHFFFAOYSA-N	Launched	guanylate cyclase stimulant	cardiology	hypertension
ripasudil	ROCK1	9863672	QSKQVZWVLOIIEV-NSHDSACASA-N	Launched	rho associated kinase inhibitor	ophthalmology	glaucoma|ocular hypertension
ripasudil	ROCK2	9863672	QSKQVZWVLOIIEV-NSHDSACASA-N	Launched	rho associated kinase inhibitor	ophthalmology	glaucoma|ocular hypertension
ripazepam	GABRA1	33474	YFHYNLHGFKXAIQ-UHFFFAOYSA-N	Phase 2	benzodiazepine receptor agonist	NA	NA
risedronate	FDPS	5245	IIDJRNMFWXDHID-UHFFFAOYSA-N	Launched	osteoclast inhibitor	orthopedics|endocrinology	osteoporosis|Paget's disease
risperidone	ADRA1A	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	ADRA1B	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	ADRA1D	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	ADRA2A	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	ADRA2B	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	ADRA2C	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	DRD1	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	DRD2	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	DRD3	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	DRD4	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HRH1	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR1A	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR1B	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR1D	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR1E	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR1F	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR2A	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR2C	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR6	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
risperidone	HTR7	5073	RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder|irritability
RITA	MDM2	374536	KZENBFUSKMWCJF-UHFFFAOYSA-N	Preclinical	MDM inhibitor	NA	NA
ritanserin	ADRA1A	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	ADRA1B	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	ADRA1D	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR1A	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR1B	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR1D	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR2A	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR2B	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR2C	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR5A	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR6	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritanserin	HTR7	5074	JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
ritonavir	CYP1A2	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP2B6	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP2C19	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP2C8	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP2C9	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP2D6	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP2E1	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP3A4	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP3A5	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ritonavir	CYP3A7	392622	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
rivanicline	CHRNA4	5310967	JUOSGGQXEBBCJB-GORDUTHDSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
rivanicline	CHRNB2	5310967	JUOSGGQXEBBCJB-GORDUTHDSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
rivanicline	CXCL8	5310967	JUOSGGQXEBBCJB-GORDUTHDSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
rivaroxaban	F10	9875401	KGFYHTZWPPHNLQ-AWEZNQCLSA-N	Launched	coagulation factor inhibitor	neurology/psychiatry|hematology|cardiology	stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE)
rivastigmine	ACHE	77991	XSVMFMHYUFZWBK-NSHDSACASA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia
rivastigmine	BCHE	77991	XSVMFMHYUFZWBK-NSHDSACASA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia
rizatriptan	HTR1A	5078	ULFRLSNUDGIQQP-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
rizatriptan	HTR1B	5078	ULFRLSNUDGIQQP-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
rizatriptan	HTR1D	5078	ULFRLSNUDGIQQP-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
rizatriptan	HTR1E	5078	ULFRLSNUDGIQQP-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
rizatriptan	HTR1F	5078	ULFRLSNUDGIQQP-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
RKI-1447	CDC42BPA	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RKI-1447	DMPK	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RKI-1447	LIMK1	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RKI-1447	MYLK	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RKI-1447	PAK1	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RKI-1447	PKN1	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RKI-1447	ROCK1	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RKI-1447	ROCK2	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
RN-1	KDM1A	45376076	YAMSXCOVJUUMCT-FCHUYYIVSA-N	Preclinical	histone demethylase inhibitor	NA	NA
RN-1734	TRPV4	3601086	IHYZMEAZAIFMTN-UHFFFAOYSA-N	Preclinical	TRPV antagonist	NA	NA
RN-1747	TRPV4	5068295	ZNLVYSJQUMALEO-UHFFFAOYSA-N	Preclinical	TRPV agonist	NA	NA
Ro-04-5595	GRIN2B	92169474	DSTWURHEHMZWEI-KRWDZBQOSA-N	Preclinical	glutamate receptor antagonist	NA	NA
Ro-08-2750	NGF	17756791	JDEMVNYMYPJJIM-UHFFFAOYSA-N	Preclinical	NGF binding inhibitor	NA	NA
Ro-08-2750	NGFR	17756791	JDEMVNYMYPJJIM-UHFFFAOYSA-N	Preclinical	NGF binding inhibitor	NA	NA
Ro-10-5824	DRD4	16759175	KABDATZAOUSYES-UHFFFAOYSA-N	Preclinical	dopamine receptor agonist	NA	NA
Ro-1138452	PTGIR	9839644	GYYRMJMXXLJZAB-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
Ro-15-4513	GABRA1	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-15-4513	GABRA2	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-15-4513	GABRA3	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-15-4513	GABRA4	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-15-4513	GABRA5	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-15-4513	GABRA6	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-15-4513	GABRB2	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-15-4513	GABRG2	5081	CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-19-4605	GABRA1	127382	ZIGMMUKDYCABPW-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-19-4605	GABRA2	127382	ZIGMMUKDYCABPW-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-19-4605	GABRA3	127382	ZIGMMUKDYCABPW-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-19-4605	GABRA5	127382	ZIGMMUKDYCABPW-UHFFFAOYSA-N	Preclinical	GABA benzodiazepine site receptor inverse agonist	NA	NA
Ro-20-1724	PDE3A	6998998	PDMUULPVBYQBBK-LBPRGKRZSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
Ro-20-1724	PDE4A	6998998	PDMUULPVBYQBBK-LBPRGKRZSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
Ro-20-1724	PDE4B	6998998	PDMUULPVBYQBBK-LBPRGKRZSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
Ro-20-1724	PDE4C	6998998	PDMUULPVBYQBBK-LBPRGKRZSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
Ro-20-1724	PDE4D	6998998	PDMUULPVBYQBBK-LBPRGKRZSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
Ro-25-6981	GRIN2B	6604887	WVZSEUPGUDIELE-HTAPYJJXSA-N	Preclinical	glutamate receptor antagonist|monamine transporter modulator	NA	NA
Ro-28-1675	GCK	9886086	NEQSWPCDHDQINX-MRXNPFEDSA-N	Preclinical	glucokinase activator	NA	NA
Ro-3	P2RX3	11289644	PYNPWUIBJMVRIG-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
Ro-3306	CDK1	135400873	XOLMRFUGOINFDQ-YBEGLDIGSA-N	Preclinical	CDK inhibitor	NA	NA
Ro-48-8071	LSS	1949	CMYCCJYVZIMDFU-UHFFFAOYSA-N	Preclinical	oxidosqualene cyclase inhibitor	NA	NA
Ro-4987655	MAP2K1	11548630	FIMYFEGKMOCQKT-UHFFFAOYSA-N	Phase 1	MEK inhibitor	NA	NA
Ro-5126766	BRAF	16719221	LMMJFBMMJUMSJS-UHFFFAOYSA-N	Phase 1	MEK inhibitor|RAF inhibitor	NA	NA
Ro-5126766	MAP2K1	16719221	LMMJFBMMJUMSJS-UHFFFAOYSA-N	Phase 1	MEK inhibitor|RAF inhibitor	NA	NA
Ro-5126766	MAP2K2	16719221	LMMJFBMMJUMSJS-UHFFFAOYSA-N	Phase 1	MEK inhibitor|RAF inhibitor	NA	NA
Ro-5126766	RAF1	16719221	LMMJFBMMJUMSJS-UHFFFAOYSA-N	Phase 1	MEK inhibitor|RAF inhibitor	NA	NA
Ro-60-0175	HTR2A	3045227	XJJZQXUGLLXTHO-ZETCQYMHSA-N	Preclinical	serotonin receptor agonist	NA	NA
Ro-60-0175	HTR2B	3045227	XJJZQXUGLLXTHO-ZETCQYMHSA-N	Preclinical	serotonin receptor agonist	NA	NA
Ro-60-0175	HTR2C	3045227	XJJZQXUGLLXTHO-ZETCQYMHSA-N	Preclinical	serotonin receptor agonist	NA	NA
Ro-61-8048	KMO	5282337	NDPBMCKQJOZAQX-UHFFFAOYSA-N	Preclinical	kynurenine 3-monooxygenase inhibitor	NA	NA
Ro-67-7476	GRM1	32681978	DAEHFYNGSSBGSS-KRWDZBQOSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
Ro-90-7501	APP	824226	PAGZCEHLFCJSPV-UHFFFAOYSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor	NA	NA
robalzotan	HTR1A	3055171	MQTUXRKNJYPMCG-CYBMUJFWSA-N	Phase 2	serotonin receptor antagonist	NA	NA
rociletinib	EGFR	57335384	"InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)"	Phase 3	EGFR inhibitor	NA	NA
rocuronium	CHRM2	441290	YXRDKMPIGHSVRX-OOJCLDBCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
rocuronium	CHRNA2	441290	YXRDKMPIGHSVRX-OOJCLDBCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
rocuronium	HTR3A	441290	YXRDKMPIGHSVRX-OOJCLDBCSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
rofecoxib	ELN	5090	RZJQGNCSTQAWON-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
rofecoxib	PTGS2	5090	RZJQGNCSTQAWON-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
roflumilast	PDE4A	449193	MNDBXUUTURYVHR-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis
roflumilast	PDE4B	449193	MNDBXUUTURYVHR-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis
roflumilast	PDE4C	449193	MNDBXUUTURYVHR-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis
roflumilast	PDE4D	449193	MNDBXUUTURYVHR-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis
romidepsin	HDAC1	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC2	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC3	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC4	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC5	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC6	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC7	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC8	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
romidepsin	HDAC9	56840936	"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1"	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
ropinirole	ADRA2A	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	ADRA2B	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	ADRA2C	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	DRD1	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	DRD2	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	DRD3	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	DRD4	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	DRD5	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	HTR1A	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	HTR1B	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	HTR1D	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	HTR2A	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	HTR2B	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropinirole	HTR2C	5095	UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
ropivacaine	SCN10A	175805	ZKMNUMMKYBVTFN-HNNXBMFYSA-N	Launched	sodium channel blocker	neurology/psychiatry	anesthetic
roscovitine	CDK2	160355	BTIHMVBBUGXLCJ-OAHLLOKOSA-N	Phase 2	CDK inhibitor	NA	NA
roscovitine	CDK9	160355	BTIHMVBBUGXLCJ-OAHLLOKOSA-N	Phase 2	CDK inhibitor	NA	NA
rosiglitazone	FFAR1	10021239	YASAKCUCGLMORW-OAHLLOKOSA-N	Withdrawn	insulin sensitizer|PPAR receptor agonist	NA	NA
rosiglitazone	PPARG	10021239	YASAKCUCGLMORW-OAHLLOKOSA-N	Withdrawn	insulin sensitizer|PPAR receptor agonist	NA	NA
rosiglitazone	TRPC5	10021239	YASAKCUCGLMORW-OAHLLOKOSA-N	Withdrawn	insulin sensitizer|PPAR receptor agonist	NA	NA
rosiglitazone	TRPM3	10021239	YASAKCUCGLMORW-OAHLLOKOSA-N	Withdrawn	insulin sensitizer|PPAR receptor agonist	NA	NA
rosmarinic-acid	MCL1	5281792	DOUMFZQKYFQNTF-WUTVXBCWSA-N	Launched	GABA transaminase inhibitor	NA	NA
rosmarinic-acid	TYR	5281792	DOUMFZQKYFQNTF-WUTVXBCWSA-N	Launched	GABA transaminase inhibitor	NA	NA
rostafuroxine	ATP1A1	153976	AEAPORIZZWBIEX-DTBDINHYSA-N	Phase 2	ATPase inhibitor	NA	NA
rosuvastatin	HMGCR	446157	BPRHUIZQVSMCRT-VEUZHWNKSA-N	Launched	HMGCR inhibitor	endocrinology|cardiology	hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis
rotigotine	ADRA2B	59227	KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
rotigotine	DRD1	59227	KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
rotigotine	DRD2	59227	KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
rotigotine	DRD3	59227	KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
rotigotine	DRD4	59227	KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
rotigotine	DRD5	59227	KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
rotigotine	HTR1A	59227	KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease|restless leg syndrome
rotundine	DRD1	72301	AEQDJSLRWYMAQI-KRWDZBQOSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	anxiety|sedative
rotundine	DRD2	72301	AEQDJSLRWYMAQI-KRWDZBQOSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	anxiety|sedative
rotundine	DRD3	72301	AEQDJSLRWYMAQI-KRWDZBQOSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	anxiety|sedative
rotundine	HTR1A	72301	AEQDJSLRWYMAQI-KRWDZBQOSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	anxiety|sedative
roxatidine-acetate	HRH2	5105	SMTZFNFIKUPEJC-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology	Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis
roxithromycin	MLNR		RXZBMPWDPOLZGW-SWCVOMKCSA-N	Launched	bacterial 50S ribosomal subunit inhibitor	infectious disease	respiratory tract infections|urinary tract infections|skin infections
RP-001	S1PR1	58344861	WNDDDFYFTSGSEC-HXUWFJFHSA-N	Preclinical	sphingosine 1-phosphate receptor agonist	NA	NA
RQ-00203078	TRPM8	49783953	IJGQFZYYEHCCIZ-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
RRx-001	G6PD	15950826	JODKFOVZURLVTG-UHFFFAOYSA-N	Phase 3	glucose 6-phosphate dehydrogenase inhibitor	NA	NA
RS-100329	ADRA1A	3567002	RCOBWVAGWYRNHZ-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RS-100329	ADRA1D	3567002	RCOBWVAGWYRNHZ-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RS-102221	HTR2A	3693566	HZZZZODVDSHQRG-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
RS-102221	HTR2B	3693566	HZZZZODVDSHQRG-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
RS-102221	HTR2C	3693566	HZZZZODVDSHQRG-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
RS-102895	CCR2	10000456	HIDWEYPGMLIQSN-UHFFFAOYSA-N	Preclinical	CCR antagonist	NA	NA
RS-127445	HTR2A	196968	ZZZQXCUPAJFVBN-UHFFFAOYSA-N	Phase 1	serotonin receptor antagonist	NA	NA
RS-127445	HTR2B	196968	ZZZQXCUPAJFVBN-UHFFFAOYSA-N	Phase 1	serotonin receptor antagonist	NA	NA
RS-127445	HTR2C	196968	ZZZQXCUPAJFVBN-UHFFFAOYSA-N	Phase 1	serotonin receptor antagonist	NA	NA
RS-17053	ADRA1A	3894573	XLZHXAXXJVKTFM-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RS-17053	ADRA1D	3894573	XLZHXAXXJVKTFM-UHFFFAOYSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RS-23597-190	HTR4	182593	RLSGBCUXLRMTPF-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
RS-39604	HTR4	5145950	BKVIWGRFRKLFIO-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
RS-504393	CCL2	9953769	ODNICNWASXKNNQ-UHFFFAOYSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
RS-504393	CCR2	9953769	ODNICNWASXKNNQ-UHFFFAOYSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
RS-56812	HTR3A	6604789	ZNAPADWWBWFMCQ-HNNXBMFYSA-N	Preclinical	serotonin receptor partial agonist	NA	NA
RS-67333	HTR4	183782	JBHLYIVFFLNISJ-UHFFFAOYSA-N	Preclinical	serotonin receptor partial agonist	NA	NA
RS-67506	HTR4	133076	UATDVRSFFGFTAI-UHFFFAOYSA-N	Preclinical	serotonin receptor partial agonist	NA	NA
RS-79948	ADRA2A	9908992	UMGBFFAJXFXOIL-MNEFBYGVSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RTA-408	NFE2L2	71811910	RJCWBNBKOKFWNY-IDPLTSGASA-N	Phase 2	nitric oxide production inhibitor	NA	NA
RU-SKI-43	HHAT	93160320	AEENEMOEBJOKGN-UZLBHIALSA-N	Preclinical	hedgehog pathway inhibitor	NA	NA
RU-24969	HTR1A	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-24969	HTR1B	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-24969	HTR1D	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-24969	HTR2A	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-24969	HTR2B	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-24969	HTR2C	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-24969	HTR5A	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-24969	HTR6	108029	KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
RU-28318	NR3C2	3034004	DNHCHRGCTVRAFT-JEHIOXJOSA-N	Phase 2	cytochrome P450 inhibitor	NA	NA
RU-42173	ADRB2	3086576	ZSTCZWJCLIRCOJ-DGCLKSJQSA-N	Phase 2	adrenergic receptor agonist	NA	NA
RU-58841	AR	132981	ARBYGDBJECGMGA-UHFFFAOYSA-N	Phase 2	androgen receptor antagonist	NA	NA
rubitecan	TOP1	472335	VHXNKPBCCMUMSW-FQEVSTJZSA-N	Phase 3	topoisomerase inhibitor	NA	NA
rucaparib	PARP1	9931954	HMABYWSNWIZPAG-UHFFFAOYSA-N	Phase 3	PARP inhibitor	NA	NA
rucaparib	PARP2	9931954	HMABYWSNWIZPAG-UHFFFAOYSA-N	Phase 3	PARP inhibitor	NA	NA
rucinol	TYR	205912	CSHZYWUPJWVTMQ-UHFFFAOYSA-N	Phase 1	tyrosinase inhibitor	NA	NA
rufinamide	GRM5	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN10A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN11A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN1A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN2A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN3A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN4A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN5A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN7A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN8A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufinamide	SCN9A	129228	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rupatadine	HRH1	133017	WUZYKBABMWJHDL-UHFFFAOYSA-N	Launched	histamine receptor antagonist|platelet activating factor receptor antagonist	allergy	allergic rhinitis|urticaria
rupatadine	PTAFR	133017	WUZYKBABMWJHDL-UHFFFAOYSA-N	Launched	histamine receptor antagonist|platelet activating factor receptor antagonist	allergy	allergic rhinitis|urticaria
rutaecarpine	PTGS2	65752	ACVGWSKVRYFWRP-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
rutin	AKR1C3	5280805	IKGXIBQEEMLURG-NVPNHPEKSA-N	Launched	antioxidant|capillary stabilizing agent|nitric oxide scavenger	rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy	joint pain|nasal congestion|constipation|irritability|allergic rhinitis
ruxolitinib	JAK1	25126798	HFNKQEVNSGCOJV-OAHLLOKOSA-N	Launched	JAK inhibitor	hematologic malignancy|hematology	myelofibrosis|polycythemia vera
ruxolitinib	JAK2	25126798	HFNKQEVNSGCOJV-OAHLLOKOSA-N	Launched	JAK inhibitor	hematologic malignancy|hematology	myelofibrosis|polycythemia vera
ruxolitinib	JAK3	25126798	HFNKQEVNSGCOJV-OAHLLOKOSA-N	Launched	JAK inhibitor	hematologic malignancy|hematology	myelofibrosis|polycythemia vera
ruxolitinib	TYK2	25126798	HFNKQEVNSGCOJV-OAHLLOKOSA-N	Launched	JAK inhibitor	hematologic malignancy|hematology	myelofibrosis|polycythemia vera
ruxolitinib-(S)	JAK1	50878566	HFNKQEVNSGCOJV-HNNXBMFYSA-N	Preclinical	JAK inhibitor	NA	NA
ruxolitinib-(S)	JAK2	50878566	HFNKQEVNSGCOJV-HNNXBMFYSA-N	Preclinical	JAK inhibitor	NA	NA
RWJ-21757	TLR7	135410906	VDCRFBBZFHHYGT-IOSLPCCCSA-N	Phase 2	toll-like receptor agonist	NA	NA
RWJ-50271	ICAM1	9953357	HOFGTYCLOKDAES-UHFFFAOYSA-N	Preclinical	integrin inhibitor	NA	NA
RWJ-67657	MAPK14	3008319	QSUSKMBNZQHHPA-UHFFFAOYSA-N	Phase 1	MAP kinase inhibitor	NA	NA
RWJ-67657	PTGS2	3008319	QSUSKMBNZQHHPA-UHFFFAOYSA-N	Phase 1	MAP kinase inhibitor	NA	NA
RX-3117	CDK2	11242315	QLLGKCJUPWYJON-HLTSFMKQSA-N	Phase 1/Phase 2	CDK inhibitor|DNA synthesis inhibitor	NA	NA
RX-3117	DNMT1	11242315	QLLGKCJUPWYJON-HLTSFMKQSA-N	Phase 1/Phase 2	CDK inhibitor|DNA synthesis inhibitor	NA	NA
RX-821002	ADRA1A	67743720	HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RX-821002	ADRA1B	67743720	HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RX-821002	ADRA1D	67743720	HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RX-821002	ADRA2A	67743720	HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RX-821002	ADRA2B	67743720	HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
RX-821002	ADRA2C	67743720	HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
ryuvidine	CDK2	481747	HFPLHASLIOXVGS-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
ryuvidine	CDK4	481747	HFPLHASLIOXVGS-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
R112	SYK	9904854	TVKGTSHBQZEFEE-UHFFFAOYSA-N	Phase 1	SYK inhibitor	NA	NA
R406	RET	11213558	NHHQJBCNYHBUSI-UHFFFAOYSA-N	Phase 1	SYK inhibitor	NA	NA
R406	SYK	11213558	NHHQJBCNYHBUSI-UHFFFAOYSA-N	Phase 1	SYK inhibitor	NA	NA
R547	CDK1	6918852	JRNJNYBQQYBCLE-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
R547	CDK2	6918852	JRNJNYBQQYBCLE-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
R547	CDK4	6918852	JRNJNYBQQYBCLE-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
R547	CDK7	6918852	JRNJNYBQQYBCLE-UHFFFAOYSA-N	Phase 1	CDK inhibitor	NA	NA
S-isopropylisothiourea	NOS3	445319	XSSNABKEYXKKMK-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
S-methylcysteine	CTSD	7058174	IDIDJDIHTAOVLG-VKHMYHEASA-N	Phase 1		NA	NA
S-methylcysteine	MGMT	7058174	IDIDJDIHTAOVLG-VKHMYHEASA-N	Phase 1		NA	NA
S-nitrosoglutathione	PTPN1	104858	HYHSBSXUHZOYLX-WDSKDSINSA-N	Phase 1	nitric oxide stimulant	NA	NA
S-07662	NR1I3	2732040	UITFWLJMEZPXOF-UHFFFAOYSA-N	Preclinical	CAR antagonist	NA	NA
S-111	PARP1	11213350	PYXFVCFISTUSOO-HKUCOEKDSA-N	Phase 2	PARP inhibitor	NA	NA
S-14506	HTR1A	131906	IFMQODYDAUKKEN-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
SA-47	FAAH	9840648	HSYCMGWPPRTNKH-UHFFFAOYSA-N	Preclinical	FAAH inhibitor	NA	NA
saccharin	CA1	5143	CVHZOJJKTDOEJC-UHFFFAOYSA-N	Launched	DNA polymerase inhibitor	NA	NA
saccharin	CA12	5143	CVHZOJJKTDOEJC-UHFFFAOYSA-N	Launched	DNA polymerase inhibitor	NA	NA
saccharin	CA2	5143	CVHZOJJKTDOEJC-UHFFFAOYSA-N	Launched	DNA polymerase inhibitor	NA	NA
saccharin	CA9	5143	CVHZOJJKTDOEJC-UHFFFAOYSA-N	Launched	DNA polymerase inhibitor	NA	NA
saclofen	GABBR1	57453816	JYLNVJYYQQXNEK-QMMMGPOBSA-N	Preclinical	GABA receptor antagonist	NA	NA
saclofen	GABBR2	57453816	JYLNVJYYQQXNEK-QMMMGPOBSA-N	Preclinical	GABA receptor antagonist	NA	NA
saclofen	KCTD12	57453816	JYLNVJYYQQXNEK-QMMMGPOBSA-N	Preclinical	GABA receptor antagonist	NA	NA
saclofen	KCTD16	57453816	JYLNVJYYQQXNEK-QMMMGPOBSA-N	Preclinical	GABA receptor antagonist	NA	NA
saclofen	KCTD8	57453816	JYLNVJYYQQXNEK-QMMMGPOBSA-N	Preclinical	GABA receptor antagonist	NA	NA
sacubitril	MME	9811834	PYNXFZCZUAOOQC-UTKZUKDTSA-N	Launched	neprilysin inhibitor	cardiology	congestive heart failure
safinamide	MAOB	131682	NEMGRZFTLSKBAP-LBPRGKRZSA-N	Launched	dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
safingol	TRPM3	91486	OTKJDMGTUTTYMP-ZWKOTPCHSA-N	Phase 1	PKC inhibitor	NA	NA
safranal	GABBR1	61041	SGAWOGXMMPSZPB-UHFFFAOYSA-N	Phase 2	benzodiazepine receptor agonist	NA	NA
SAG	SMO	NA	VFSUUTYAEQOIMW-YHBQERECSA-N	Preclinical	smoothened receptor agonist	NA	NA
SAG	TRPC6	NA	VFSUUTYAEQOIMW-YHBQERECSA-N	Preclinical	smoothened receptor agonist	NA	NA
salicylic-acid	AKR1C1	338	YGSDEFSMJLZEOE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief
salicylic-acid	ASIC3	338	YGSDEFSMJLZEOE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief
salicylic-acid	PTGS1	338	YGSDEFSMJLZEOE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief
salicylic-acid	PTGS2	338	YGSDEFSMJLZEOE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief
salidroside	APP	159278	ILRCGYURZSFMEG-RKQHYHRCSA-N	Preclinical	beta amyloid protein neurotoxicity inhibitor	NA	NA
salirasib	TRPA1	5469318	WUILNKCFCLNXOK-CFBAGHHKSA-N	Phase 2	mTOR inhibitor	NA	NA
salmeterol	ADRB2	6604001	GIIZNNXWQWCKIB-VWLOTQADSA-N	Launched	adrenergic receptor agonist	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm
salubrinal	EIF2S1	2305942	LCOIAYJMPKXARU-CVTTXWKISA-N	Preclinical	eukaryotic translation initiation factor inhibitor	NA	NA
salvianolic-acid-B	MMP9	11629084	SNKFFCBZYFGCQN-PDVBOLEISA-N	Phase 2	EGFR inhibitor|metalloproteinase inhibitor	NA	NA
salvinorin-A	OPRD1	128563	OBSYBRPAKCASQB-AGQYDFLVSA-N	Phase 1	opioid receptor agonist	NA	NA
salvinorin-A	OPRK1	128563	OBSYBRPAKCASQB-AGQYDFLVSA-N	Phase 1	opioid receptor agonist	NA	NA
salvinorin-A	OPRM1	128563	OBSYBRPAKCASQB-AGQYDFLVSA-N	Phase 1	opioid receptor agonist	NA	NA
sal003	EIF2A	2252542	TVNBASWNLOIQML-RFKZRZAASA-N	Preclinical	eukaryotic translation initiation factor inhibitor	NA	NA
sanguinarium-chloride	CASP3	5154	INVGWHRKADIJHF-UHFFFAOYSA-N	Phase 1	apoptosis stimulant	NA	NA
SANT-1	SHH	6878030	FOORCIAZMIWALX-JJIBRWJFSA-N	Preclinical	smoothened receptor antagonist	NA	NA
SANT-1	SMO	6878030	FOORCIAZMIWALX-JJIBRWJFSA-N	Preclinical	smoothened receptor antagonist	NA	NA
SANT-2	SHH	1367095	VQOJFGFKIVFMDH-UHFFFAOYSA-N	Preclinical	smoothened receptor antagonist	NA	NA
SANT-2	SMO	1367095	VQOJFGFKIVFMDH-UHFFFAOYSA-N	Preclinical	smoothened receptor antagonist	NA	NA
sapropterin	NOS3	135398654	FNKQXYHWGSIFBK-RPDRRWSUSA-N	Launched	phenylalanine 4-hydroxylase stimulant	metabolism	hyperphenylalaninemia (HPA)
sapropterin	PAH	135398654	FNKQXYHWGSIFBK-RPDRRWSUSA-N	Launched	phenylalanine 4-hydroxylase stimulant	metabolism	hyperphenylalaninemia (HPA)
sapropterin	TH	135398654	FNKQXYHWGSIFBK-RPDRRWSUSA-N	Launched	phenylalanine 4-hydroxylase stimulant	metabolism	hyperphenylalaninemia (HPA)
sapropterin	TPH1	135398654	FNKQXYHWGSIFBK-RPDRRWSUSA-N	Launched	phenylalanine 4-hydroxylase stimulant	metabolism	hyperphenylalaninemia (HPA)
saquinavir	CYP3A4	441243	QWAXKHKRTORLEM-UGJKXSETSA-N	Launched	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
SAR-245409	MTOR	49867926	HJSSPYJVWLTYHG-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
SAR-245409	PIK3CG	49867926	HJSSPYJVWLTYHG-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
saracatinib	ABL1	10302451	"InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)"	Phase 2/Phase 3	SRC inhibitor	NA	NA
saracatinib	LCK	10302451	"InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)"	Phase 2/Phase 3	SRC inhibitor	NA	NA
saracatinib	SRC	10302451	"InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)"	Phase 2/Phase 3	SRC inhibitor	NA	NA
saracatinib	YES1	10302451	"InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)"	Phase 2/Phase 3	SRC inhibitor	NA	NA
sarcosine	SLC6A9	7311726	FSYKKLYZXJSNPZ-UHFFFAOYSA-N	Phase 2	glycine transporter inhibitor	NA	NA
saroglitazar	PPARA	60151560	MRWFZSLZNUJVQW-DEOSSOPVSA-N	Launched	PPAR receptor agonist	endocrinology|cardiology|gastroenterology	diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH)
saroglitazar	PPARG	60151560	MRWFZSLZNUJVQW-DEOSSOPVSA-N	Launched	PPAR receptor agonist	endocrinology|cardiology|gastroenterology	diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH)
sarpogrelate	HTR2A	40468125	FFYNAVGJSYHHFO-OAQYLSRUSA-N	Launched	serotonin receptor antagonist	endocrinology|cardiology|rheumatology	diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease
sarpogrelate	HTR2B	40468125	FFYNAVGJSYHHFO-OAQYLSRUSA-N	Launched	serotonin receptor antagonist	endocrinology|cardiology|rheumatology	diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease
sarpogrelate	HTR2C	40468125	FFYNAVGJSYHHFO-OAQYLSRUSA-N	Launched	serotonin receptor antagonist	endocrinology|cardiology|rheumatology	diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease
SAR131675	FLT4	71295845	PFMPOBVAYMTUOX-GOSISDBHSA-N	Preclinical	VEGFR inhibitor	NA	NA
SAR405	PIK3C3	72709209	SPDQRCUBFSRAFI-DOMZBBRYSA-N	Preclinical	PI3K inhibitor	NA	NA
SAR405838	MDM2	NA	IDKAKZRYYDCJDU-HBMMIIHUSA-N	Phase 1	MDM inhibitor	NA	NA
SAR407899	ROCK1	15604510	IPEXHQGMTHOKQV-UHFFFAOYSA-N	Phase 2	rho associated kinase inhibitor	NA	NA
sasapyrine	PTGS1	5161	WVYADZUPLLSGPU-UHFFFAOYSA-N	Launched	NFkB pathway inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
sasapyrine	PTGS2	5161	WVYADZUPLLSGPU-UHFFFAOYSA-N	Launched	NFkB pathway inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis
savolitinib	MET	68289010	XYDNMOZJKOGZLS-NSHDSACASA-N	Phase 3	c-Met inhibitor	NA	NA
saxagliptin	DPP4	NA	QGJUIPDUBHWZPV-YQBUGCKMSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
SB-200646	HTR2B	126769	OJZZJTLBYXHUSJ-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-200646	HTR2C	126769	OJZZJTLBYXHUSJ-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-202190	AKT1	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	ALOX5	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	CHEK1	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	GSK3B	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	LCK	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	MAPK1	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	MAPK11	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	MAPK12	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	MAPK14	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	MAPK8	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	PRKCA	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	ROCK1	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	RPS6KB1	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-202190	SGK1	5169	QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203186	HTR4	3272300	YGKPIROTKVQCCU-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-203580	AKT1	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	ALOX5	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	CHEK1	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	CYP2D6	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	CYP3A4	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	GAK	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	GSK3B	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	LCK	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	MAPK1	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	MAPK10	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	MAPK11	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	MAPK12	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	MAPK14	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	MAPK8	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	MAPK9	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	PRKCA	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	RAF1	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	RIPK2	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	ROCK1	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	RPS6KB1	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	SGK1	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	SRC	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-203580	TNF	40467016	CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-205384	GABRA3	15991599	JDTZAGLGBRRCJT-JTQLQIEISA-N	Preclinical	GABA receptor modulator	NA	NA
SB-205384	GABRA5	15991599	JDTZAGLGBRRCJT-JTQLQIEISA-N	Preclinical	GABA receptor modulator	NA	NA
SB-205384	GABRA6	15991599	JDTZAGLGBRRCJT-JTQLQIEISA-N	Preclinical	GABA receptor modulator	NA	NA
SB-206553	HTR2A	5163	QJQORSLQNXDVGE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-206553	HTR2B	5163	QJQORSLQNXDVGE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-206553	HTR2C	5163	QJQORSLQNXDVGE-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-216641	HTR1A	3292447	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-216641	HTR1B	3292447	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-216641	HTR1D	3292447	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-216641	HTR2A	3292447	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-216641	HTR2B	3292447	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-216641	HTR2C	3292447	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-216763	CCNA2	176158	JCSGFHVFHSKIJH-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
SB-216763	CDK2	176158	JCSGFHVFHSKIJH-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
SB-216763	GSK3A	176158	JCSGFHVFHSKIJH-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
SB-216763	GSK3B	176158	JCSGFHVFHSKIJH-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
SB-218078	CHEK1	3387354	OTPNDVKVEAIXTI-UHFFFAOYSA-N	Preclinical	CHK inhibitor	NA	NA
SB-218795	TACR3	6604858	IUMQXQJZIHWLIN-HSZRJFAPSA-N	Preclinical	tachykinin antagonist	NA	NA
SB-221284	HTR2A	443389	OQZOXHCRSXYSPM-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-221284	HTR2B	443389	OQZOXHCRSXYSPM-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-221284	HTR2C	443389	OQZOXHCRSXYSPM-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-222200	TACR3	6604009	MQNYRKWJSMQECI-QFIPXVFZSA-N	Preclinical	tachykinin antagonist	NA	NA
SB-225002	CXCR2	3854666	MQBZVUNNWUIPMK-UHFFFAOYSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
SB-228357	HTR2A	443390	RRJLJKRFFRZRAF-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-228357	HTR2B	443390	RRJLJKRFFRZRAF-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-228357	HTR2C	443390	RRJLJKRFFRZRAF-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-2343	MTOR	46912230	QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
SB-2343	PIK3CA	46912230	QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
SB-2343	PIK3CB	46912230	QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
SB-2343	PIK3CD	46912230	QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
SB-2343	PIK3CG	46912230	QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1	mTOR inhibitor|PI3K inhibitor	NA	NA
SB-239063	MAPK11	NA	ZQUSFAUAYSEREK-WKILWMFISA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-239063	MAPK14	NA	ZQUSFAUAYSEREK-WKILWMFISA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-239063	PTGS2	NA	ZQUSFAUAYSEREK-WKILWMFISA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SB-242235	HSPB1	9863367	PDTYLGXVBIWRIM-UHFFFAOYSA-N	Phase 1	p38 MAPK inhibitor	NA	NA
SB-242235	MAPK14	9863367	PDTYLGXVBIWRIM-UHFFFAOYSA-N	Phase 1	p38 MAPK inhibitor	NA	NA
SB-243213	HTR2A	443391	ZETBBVYSBABLHL-UHFFFAOYSA-N	Phase 1	serotonin receptor inverse agonist	NA	NA
SB-243213	HTR2B	443391	ZETBBVYSBABLHL-UHFFFAOYSA-N	Phase 1	serotonin receptor inverse agonist	NA	NA
SB-243213	HTR2C	443391	ZETBBVYSBABLHL-UHFFFAOYSA-N	Phase 1	serotonin receptor inverse agonist	NA	NA
SB-243213	HTR6	443391	ZETBBVYSBABLHL-UHFFFAOYSA-N	Phase 1	serotonin receptor inverse agonist	NA	NA
SB-258585	HTR6	3248571	BDHMSYNBSBZCAF-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-268262	CALCA	93475590	YXHLPJQQPOMPGE-HHHXNRCGSA-N	Preclinical	calcitonin antagonist	NA	NA
SB-269970	HTR7	6604889	HWKROQUZSKPIKQ-MRXNPFEDSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-271046	HTR6	5312149	LOCQRDBFWSXQQI-UHFFFAOYSA-N	Phase 1	serotonin receptor antagonist	NA	NA
SB-297006	CCR3	9840971	BEZXGSZPWXRHIN-INIZCTEOSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
SB-334867	HCRTR1	6604926	AKMNUCBQGHFICM-UHFFFAOYSA-N	Preclinical	orexin receptor antagonist	NA	NA
SB-334867	HCRTR2	6604926	AKMNUCBQGHFICM-UHFFFAOYSA-N	Preclinical	orexin receptor antagonist	NA	NA
SB-366791	TRPV1	667594	RYAMDQKWNKKFHD-JXMROGBWSA-N	Preclinical	TRPV antagonist	NA	NA
SB-399885	HTR6	6918649	ATKZKAYWARYLBW-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SB-408124	HCRTR1	4331799	JTARFZSNUAGHRB-UHFFFAOYSA-N	Preclinical	orexin receptor antagonist	NA	NA
SB-408124	HCRTR2	4331799	JTARFZSNUAGHRB-UHFFFAOYSA-N	Preclinical	orexin receptor antagonist	NA	NA
SB-415286	GSK3A	4210951	PQCXVIPXISBFPN-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
SB-415286	GSK3B	4210951	PQCXVIPXISBFPN-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
SB-415286	RPS6KB1	4210951	PQCXVIPXISBFPN-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
SB-431542	ACVR1C	4521392	FHYUGAJXYORMHI-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
SB-431542	TGFBR1	4521392	FHYUGAJXYORMHI-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
SB-452533	TRPV1	9842609	IFJYEGJUQIBBQV-UHFFFAOYSA-N	Preclinical	TRPV antagonist	NA	NA
SB-505124	TGFBR1	9858940	WGZOTBUYUFBEPZ-UHFFFAOYSA-N	Preclinical	ALK tyrosine kinase receptor inhibitor	NA	NA
SB-525334	TGFBR1	9967941	DKPQHFZUICCZHF-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
SB-590885	BRAF	135421339	MLSAQOINCGAULQ-QFMPWRQOSA-N	Preclinical	RAF inhibitor	NA	NA
SB-612111	OPRL1	10047612	OHRDCQFCAWLDBP-SBUREZEXSA-N	Preclinical	nociceptin/orphanin FQ receptor antagonist	NA	NA
SB-657510	UTS2R	11272107	KQCZCINJGIRLCD-CYBMUJFWSA-N	Preclinical	urotensin receptor antagonist	NA	NA
SB-683698	ITGA4	9912743	DRSJLVGDSNWQBI-SFHVURJKSA-N	Phase 1	integrin antagonist	NA	NA
SB-683698	ITGAV	9912743	DRSJLVGDSNWQBI-SFHVURJKSA-N	Phase 1	integrin antagonist	NA	NA
SB-683698	ITGB1	9912743	DRSJLVGDSNWQBI-SFHVURJKSA-N	Phase 1	integrin antagonist	NA	NA
SB-683698	ITGB7	9912743	DRSJLVGDSNWQBI-SFHVURJKSA-N	Phase 1	integrin antagonist	NA	NA
SB-705498	TRPV1	9910486	JYILLRHXRVTRSH-GFCCVEGCSA-N	Phase 2	TRPV antagonist	NA	NA
SB-706375	UTS2R	21023902	BPOWQJYAMDEAFF-CYBMUJFWSA-N	Preclinical	urotensin receptor antagonist	NA	NA
SB-742457	HTR6	11256720	JJZFWROHYSMCMU-UHFFFAOYSA-N	Phase 3	serotonin receptor antagonist	NA	NA
SB-743921	KIF11	9936388	PGXYIBJJCLWJST-MUUNZHRXSA-N	Phase 1/Phase 2	kinesin-like spindle protein inhibitor	NA	NA
SB-747651A	AKT1	11393719	MBCJUIJWPYUEBX-UHFFFAOYSA-N	Preclinical	kinase inhibitor	NA	NA
SB-747651A	AKT3	11393719	MBCJUIJWPYUEBX-UHFFFAOYSA-N	Preclinical	kinase inhibitor	NA	NA
SB-747651A	ROCK1	11393719	MBCJUIJWPYUEBX-UHFFFAOYSA-N	Preclinical	kinase inhibitor	NA	NA
SB-747651A	RPS6KA5	11393719	MBCJUIJWPYUEBX-UHFFFAOYSA-N	Preclinical	kinase inhibitor	NA	NA
SB-747651A	RPS6KB1	11393719	MBCJUIJWPYUEBX-UHFFFAOYSA-N	Preclinical	kinase inhibitor	NA	NA
SB-756050	GPBAR1	1520267	GJUFPAZNBPFNRI-UHFFFAOYSA-N	Phase 1	G protein-coupled receptor agonist	NA	NA
SB-772077B	ROCK1	16095343	PHWHNHYZZNJPLB-QMMMGPOBSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
SB-772077B	ROCK2	16095343	PHWHNHYZZNJPLB-QMMMGPOBSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
SB-939	HDAC1	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SB-939	HDAC10	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SB-939	HDAC2	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SB-939	HDAC3	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SB-939	HDAC4	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SB-939	HDAC5	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SB-939	HDAC6	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SB-939	HDAC9	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	HDAC inhibitor	NA	NA
SBE-13	PLK1	4719406	XNPRQBVQOJZMMA-UHFFFAOYSA-N	Preclinical	PLK inhibitor	NA	NA
SBHA	HDAC1	5173	IDQPVOFTURLJPT-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
SBHA	HDAC3	5173	IDQPVOFTURLJPT-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
SC-10	PRKCA	5175	MJMJERJFCHYXEM-UHFFFAOYSA-N	Preclinical	protein kinase activator	NA	NA
SC-12267	IL17A	9820008	XPRDUGXOWVXZLL-UHFFFAOYSA-N	Phase 2	dihydroorotate dehydrogenase inhibitor	NA	NA
SC-19220	PTGER1	4336830	KNURFLJTOUGOOQ-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
SC-236	PTGS2	9865808	NSQNZEUFHPTJME-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
SC-51089	PTGER1	132749	XDJPQOUDGROSEU-UHFFFAOYSA-N	Preclinical	prostanoid receptor antagonist	NA	NA
SC-560	PTGS1	4306515	PQUGCKBLVKJMNT-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
SC-9	PRKCA	124172	YUXMTDYHFPRPLG-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase activator	NA	NA
SCH-202676	CHRM1	682802	FFUBTEITUNMMOK-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor modulator	NA	NA
SCH-202676	CHRM2	682802	FFUBTEITUNMMOK-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor modulator	NA	NA
SCH-202676	DRD1	682802	FFUBTEITUNMMOK-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor modulator	NA	NA
SCH-202676	DRD2	682802	FFUBTEITUNMMOK-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor modulator	NA	NA
SCH-221510	OPRL1	NA	LOSJNRBXNQTUNT-FOURXJPJSA-N	Preclinical	nociceptin/orphanin FQ receptor agonist	NA	NA
SCH-23390	DRD1	3036864	GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical	dopamine receptor antagonist	NA	NA
SCH-23390	DRD5	3036864	GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical	dopamine receptor antagonist	NA	NA
SCH-23390	HTR2C	3036864	GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical	dopamine receptor antagonist	NA	NA
SCH-23390	KCNJ4	3036864	GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical	dopamine receptor antagonist	NA	NA
SCH-23390	KCNJ6	3036864	GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical	dopamine receptor antagonist	NA	NA
SCH-28080	ATP4A	108137	PYKJFEPAUKAXNN-UHFFFAOYSA-N	Phase 1	ATPase inhibitor	NA	NA
SCH-51344	NUDT1	9995890	YWEGXZZAORIRQR-UHFFFAOYSA-N	Preclinical	MTH1 inhibitor	NA	NA
SCH-58261	ADORA1	176408	UTLPKQYUXOEJIL-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
SCH-58261	ADORA2A	176408	UTLPKQYUXOEJIL-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
SCH-58261	ADORA2B	176408	UTLPKQYUXOEJIL-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
SCH-58261	ADORA3	176408	UTLPKQYUXOEJIL-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
SCH-900776	CDK2	46239015	GMIZZEXBPRLVIV-SECBINFHSA-N	Phase 2	CHK inhibitor	NA	NA
SCH-900776	CHEK1	46239015	GMIZZEXBPRLVIV-SECBINFHSA-N	Phase 2	CHK inhibitor	NA	NA
schisandrin-B	ATR	174277	RTZKSTLPRTWFEV-QWHCGFSZSA-N	Preclinical	antioxidant	NA	NA
SCMC-Lys	GSTP1	193653	GBFLZEXEOZUWRN-VKHMYHEASA-N	Launched	mucolytic agent	pulmonary	chronic obstructive pulmonary disease (COPD)
scopolamine	CHRM1	NA	STECJAGHUSJQJN-FWXGHANASA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea
scopolamine	CHRM2	NA	STECJAGHUSJQJN-FWXGHANASA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea
scopolamine	CHRM3	NA	STECJAGHUSJQJN-FWXGHANASA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea
scopolamine	CHRM4	NA	STECJAGHUSJQJN-FWXGHANASA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea
scopolamine	CHRM5	NA	STECJAGHUSJQJN-FWXGHANASA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea
scopolamine	SI	NA	STECJAGHUSJQJN-FWXGHANASA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea
scopolamine-N-oxide	CHRM1	NA	GSYQNAMOFFWAPF-SXWCTKSRSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
scopolamine-N-oxide	CHRM2	NA	GSYQNAMOFFWAPF-SXWCTKSRSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
scopolamine-N-oxide	CHRM3	NA	GSYQNAMOFFWAPF-SXWCTKSRSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
scopolamine-N-oxide	CHRM4	NA	GSYQNAMOFFWAPF-SXWCTKSRSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
scriptaid	HDAC1	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC2	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC3	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC4	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC5	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC6	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC7	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC8	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
scriptaid	HDAC9	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
SD-169	MAPK14	14973220	GQMYQEAXTITUAE-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SD-208	TGFBR1	10316032	BERLXWPRSBJFHO-UHFFFAOYSA-N	Preclinical	TGF beta receptor inhibitor	NA	NA
SD-2590	MMP1	9892815	NXUHVWMBPOFLMA-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
SD-2590	MMP13	9892815	NXUHVWMBPOFLMA-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
SD-2590	MMP2	9892815	NXUHVWMBPOFLMA-UHFFFAOYSA-N	Preclinical	matrix metalloprotease inhibitor	NA	NA
SDM25N	OPRD1	9931601	ZFMVWAWSKLAVOE-IFKAHUTRSA-N	Preclinical	opioid receptor antagonist	NA	NA
SDZ-NKT-343	TACR1	9851211	PCVSIMQAFWRUEC-JDXGNMNLSA-N	Phase 1	tachykinin antagonist	NA	NA
SDZ-SER-082	HTR2A	9859407	YASBOGFWAMXINH-TZMCWYRMSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SDZ-SER-082	HTR2B	9859407	YASBOGFWAMXINH-TZMCWYRMSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SDZ-SER-082	HTR2C	9859407	YASBOGFWAMXINH-TZMCWYRMSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SDZ-WAG-994	ADORA1	164305	JAKAFSGZUXCHLF-LSCFUAHRSA-N	Phase 2	adenosine receptor agonist	NA	NA
SDZ-205-557	HTR3A	5191	FFNWMBDISAYHDC-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SDZ-205-557	HTR3B	5191	FFNWMBDISAYHDC-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
SDZ-21009	HTR1A	6604875	SJYFDORQYYEJLB-ZDUSSCGKSA-N	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	NA	NA
SDZ-21009	HTR1B	6604875	SJYFDORQYYEJLB-ZDUSSCGKSA-N	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	NA	NA
SDZ-220-040	GRIN1	6604839	NYZFUZCCDOSQBG-AWEZNQCLSA-N	Preclinical	glutamate receptor antagonist	NA	NA
SDZ-220-581	GRIN1	128019	VBRJFXSFCYEZMQ-HNNXBMFYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
secalciferol	VDR	5283748	FCKJYANJHNLEEP-XRWYNYHCSA-N	Launched	vitamin D receptor agonist	critical care	bone fracture
securinine	GABRA1	442872	SWZMSZQQJRKFBP-WZRBSPASSA-N	Preclinical	GABA receptor antagonist|TP53 activator	NA	NA
segesterone-acetate	PGR	108059	CKFBRGLGTWAVLG-GOMYTPFNSA-N	Launched	progesterone receptor agonist	NA	NA
selegiline	MAOA	26757	MEZLKOACVSPNER-GFCCVEGCSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
selegiline	MAOB	26757	MEZLKOACVSPNER-GFCCVEGCSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
selexipag	PTGIR	9913767	QXWZQTURMXZVHJ-UHFFFAOYSA-N	Launched	IP1 prostacyclin receptor agonist|platelet aggregation inhibitor	pulmonary	pulmonary arterial hypertension (PAH)
selfotel	GRIN2A	6604838	LPMRCCNDNGONCD-NTSWFWBYSA-N	Phase 3	glutamate receptor antagonist	NA	NA
selfotel	GRIN2B	6604838	LPMRCCNDNGONCD-NTSWFWBYSA-N	Phase 3	glutamate receptor antagonist	NA	NA
selfotel	GRIN2C	6604838	LPMRCCNDNGONCD-NTSWFWBYSA-N	Phase 3	glutamate receptor antagonist	NA	NA
selfotel	GRIN2D	6604838	LPMRCCNDNGONCD-NTSWFWBYSA-N	Phase 3	glutamate receptor antagonist	NA	NA
selinexor	XPO1	71481097	DEVSOMFAQLZNKR-RJRFIUFISA-N	Launched	exportin antagonist	hematologic malignancy	multiple myeloma
selumetinib	MAP2K1	10127622	CYOHGALHFOKKQC-UHFFFAOYSA-N	Phase 3	MEK inhibitor	NA	NA
semagacestat	PSEN1	9843750	PKXWXXPNHIWQHW-RCBQFDQVSA-N	Phase 3	gamma secretase inhibitor	NA	NA
semapimod	MAPK14	492132	PWDYHMBTPGXCSN-UHFFFAOYSA-N	Phase 2	cytokine production inhibitor|p38 MAPK inhibitor	NA	NA
semaxanib	FGFR1	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	VEGFR inhibitor	NA	NA
semaxanib	FLT1	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	VEGFR inhibitor	NA	NA
semaxanib	KDR	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	VEGFR inhibitor	NA	NA
semaxanib	KIT	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	VEGFR inhibitor	NA	NA
semaxanib	PDGFRA	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	VEGFR inhibitor	NA	NA
semaxanib	PDGFRB	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	VEGFR inhibitor	NA	NA
semaxanib	RET	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	VEGFR inhibitor	NA	NA
SEN-1269	APP	46835756	MFPAAKZZUIRMKR-UHFFFAOYSA-N	Preclinical	beta amyloid inhibitor	NA	NA
senicapoc	KCNN4	216327	SCTZUZTYRMOMKT-UHFFFAOYSA-N	Phase 3	intermediate conductance potassium channel blocker	NA	NA
seocalcitol	VDR	5288149	LVLLALCJVJNGQQ-SEODYNFXSA-N	Phase 3	vitamin D receptor agonist	NA	NA
SEP-227900	DAO	7141881	MMAIBGHDBYQYDI-UHFFFAOYSA-N	Phase 1	D-amino acid oxidase Inhibitor	NA	NA
seratrodast	TBXA2R	73346713	ZBVKEHDGYSLCCC-SFHVURJKSA-N	Launched	prostanoid receptor antagonist	pulmonary	asthma
serdemetan	MDM2	11609586	CEGSUKYESLWKJP-UHFFFAOYSA-N	Phase 1	MDM inhibitor	NA	NA
serotonin	DRD1	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	DRD5	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR1A	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR1B	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR1D	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR1E	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR1F	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR2A	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR2B	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR2C	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR3A	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR3B	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR4	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR5A	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR6	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	HTR7	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
serotonin	SLC36A1	5202	QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	growth factor receptor activator	neurology/psychiatry	anxiety|depression|sleeplessness
sertindole	ADRA1A	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	ADRA1B	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	ADRA1D	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	DRD2	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	DRD3	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	DRD4	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HRH1	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR1A	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR1B	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR1D	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR1E	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR1F	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR2A	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR2C	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	HTR6	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertindole	KCNH2	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	NA	NA
sertraline	SLC6A3	68617	VGKDLMBJGBXTGI-SJCJKPOMSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry|obstetrics/gynecology	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder
sertraline	SLC6A4	68617	VGKDLMBJGBXTGI-SJCJKPOMSA-N	Launched	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry|obstetrics/gynecology	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder
setipiprant	PTGDR2	49843471	IHAXLPDVOWLUOS-UHFFFAOYSA-N	Phase 3	prostaglandin inhibitor	NA	NA
setiptiline	HRH1	5205	GVPIXRLYKVFFMK-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	depression
setiptiline	HTR2A	5205	GVPIXRLYKVFFMK-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	depression
setiptiline	HTR2C	5205	GVPIXRLYKVFFMK-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	depression
sevoflurane	ATP2C1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	ATP5D	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRA1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRA2	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRA3	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRA4	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRA5	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRA6	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRB1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRB2	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRB3	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRD	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRE	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRG1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRG2	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRG3	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRP	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GABRQ	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GLRA1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GLRB	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	GRIA1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	KCNA1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	KCNK10	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	KCNK18	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	KCNK2	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	KCNK3	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	KCNK9	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
sevoflurane	MT-ND1	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
SEW-2871	S1PR1	4077460	OYMNPJXKQVTQTR-UHFFFAOYSA-N	Preclinical	lysophospholipid receptor agonist	NA	NA
SF-11	MCOLN3	2936384	PMEQBGAGFZDWQX-UHFFFAOYSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
SF-11	NPY2R	2936384	PMEQBGAGFZDWQX-UHFFFAOYSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
SGC-CBP30	CREBBP	72201027	GEPYBHCJBORHCE-SFHVURJKSA-N	Preclinical	bromodomain inhibitor	NA	NA
SGC-CBP30	EP300	72201027	GEPYBHCJBORHCE-SFHVURJKSA-N	Preclinical	bromodomain inhibitor	NA	NA
SGC-707	PRMT3	90642938	DMIDPTCQPIJYFE-UHFFFAOYSA-N	Preclinical	protein arginine N-methyltransferase inhibitor	NA	NA
SGI-1027	DNMT1	24858111	QSYLKMKIVWJAAK-UHFFFAOYSA-N	Preclinical	DNA methyltransferase inhibitor	NA	NA
SGI-1027	DNMT3A	24858111	QSYLKMKIVWJAAK-UHFFFAOYSA-N	Preclinical	DNA methyltransferase inhibitor	NA	NA
SGI-1027	DNMT3B	24858111	QSYLKMKIVWJAAK-UHFFFAOYSA-N	Preclinical	DNA methyltransferase inhibitor	NA	NA
SGI-1776	FLT3	24795070	MHXGEROHKGDZGO-UHFFFAOYSA-N	Phase 1	Pim kinase inhibitor	NA	NA
SGI-1776	PIM1	24795070	MHXGEROHKGDZGO-UHFFFAOYSA-N	Phase 1	Pim kinase inhibitor	NA	NA
SGI-1776	PIM2	24795070	MHXGEROHKGDZGO-UHFFFAOYSA-N	Phase 1	Pim kinase inhibitor	NA	NA
SGI-1776	PIM3	24795070	MHXGEROHKGDZGO-UHFFFAOYSA-N	Phase 1	Pim kinase inhibitor	NA	NA
SGS-742	GABBR1	130021	ONNMDRQRSGKZCN-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
SGS-742	GABBR2	130021	ONNMDRQRSGKZCN-UHFFFAOYSA-N	Preclinical	GABA receptor antagonist	NA	NA
SGX523	MET	24779724	BCZUAADEACICHN-UHFFFAOYSA-N	Phase 1	hepatocyte growth factor receptor inhibitor	NA	NA
SHA-68	NPSR1	52951680	SFRQIPRTNYHJHP-QHCPKHFHSA-N	Preclinical	neuropeptide receptor antagonist	NA	NA
SHP099	PTPN11	118238298	YGUFCDOEKKVKJK-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
SIB-1553A	CHRNB4	10609936	NVZGJSVPOOILDI-LLVKDONJSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
SIB-1757	GRM5	132466061	UOJMXHLMOUOGPY-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
SIB-1893	GRM4	5311432	SISOFUCTXZKSOQ-ZHACJKMWSA-N	Preclinical	glutamate receptor antagonist	NA	NA
SIB-1893	GRM5	5311432	SISOFUCTXZKSOQ-ZHACJKMWSA-N	Preclinical	glutamate receptor antagonist	NA	NA
SID-7969543	NR5A1	2149494	KWMBIIQCLUIHDI-OAHLLOKOSA-N	Preclinical	steroidogenic factor antagonist	NA	NA
siguazodan	PDE3A	6604007	NUHPODZZKHQQET-VIFPVBQESA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
sildenafil	PDE5A	135398744	BNRNXUUZRGQAQC-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
sildenafil	PDE6G	135398744	BNRNXUUZRGQAQC-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
sildenafil	PDE6H	135398744	BNRNXUUZRGQAQC-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
sildenafil	SLCO1B1	135398744	BNRNXUUZRGQAQC-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
sildenafil	SLCO1B3	135398744	BNRNXUUZRGQAQC-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
silibinin	ALOX5	31553	SEBFKMXJBCUCAI-HKTJVKLFSA-N	Launched	cytochrome P450 inhibitor	gastroenterology	hepatic cirrhosis
silodosin	ADRA1A	5312125	PNCPYILNMDWPEY-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
silodosin	ADRA1B	5312125	PNCPYILNMDWPEY-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
silodosin	ADRA1D	5312125	PNCPYILNMDWPEY-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
simeprevir	CYP1A2	24873435	JTZZSQYMACOLNN-VDWJNHBNSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
simeprevir	CYP3A4	24873435	JTZZSQYMACOLNN-VDWJNHBNSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
simvastatin	HMGCR	54454	RYMZZMVNJRMUDD-HGQWONQESA-N	Launched	HMGCR inhibitor	endocrinology|cardiology|neurology/psychiatry	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia
simvastatin	ITGB2	54454	RYMZZMVNJRMUDD-HGQWONQESA-N	Launched	HMGCR inhibitor	endocrinology|cardiology|neurology/psychiatry	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia
sinefungin	CARM1	65482	LMXOHSDXUQEUSF-YECHIGJVSA-N	Preclinical	DNA methyltransferase inhibitor|RNA synthesis inhibitor	NA	NA
sipatrigine	CACNA1D	60803	PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	voltage-gated sodium channel blocker	NA	NA
sipatrigine	SCN10A	60803	PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	voltage-gated sodium channel blocker	NA	NA
sipatrigine	SCN1A	60803	PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	voltage-gated sodium channel blocker	NA	NA
sipatrigine	SCN3A	60803	PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	voltage-gated sodium channel blocker	NA	NA
sipatrigine	SCN4A	60803	PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	voltage-gated sodium channel blocker	NA	NA
sipatrigine	SCN5A	60803	PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	voltage-gated sodium channel blocker	NA	NA
sipatrigine	SCN9A	60803	PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	voltage-gated sodium channel blocker	NA	NA
siponimod	S1PR1	44599207	KIHYPELVXPAIDH-HNSNBQBZSA-N	Launched	sphingosine 1-phosphate receptor modulator	neurology/psychiatry	multiple sclerosis
siramesine	ADRA1A	9829526	XWAONOGAGZNUSF-UHFFFAOYSA-N	Phase 2	sigma receptor antagonist	NA	NA
siramesine	ADRA1B	9829526	XWAONOGAGZNUSF-UHFFFAOYSA-N	Phase 2	sigma receptor antagonist	NA	NA
siramesine	ADRA1D	9829526	XWAONOGAGZNUSF-UHFFFAOYSA-N	Phase 2	sigma receptor antagonist	NA	NA
sirolimus	FKBP1A	134812764	QFJCIRLUMZQUOT-MHOZHFGWSA-N	Launched	mTOR inhibitor	transplant|pulmonary	organ rejection|lymphangioleiomyomatosis
sirolimus	MTOR	134812764	QFJCIRLUMZQUOT-MHOZHFGWSA-N	Launched	mTOR inhibitor	transplant|pulmonary	organ rejection|lymphangioleiomyomatosis
SirReal-2	SIRT2	1096292	MENNDDDTIIZDDN-UHFFFAOYSA-N	Preclinical	SIRT inhibitor	NA	NA
sirtinol	SIRT1	NA	UXJFDYIHRJGPFS-OVKKOYPGSA-N	Preclinical	SIRT inhibitor	NA	NA
sirtinol	SIRT2	NA	UXJFDYIHRJGPFS-OVKKOYPGSA-N	Preclinical	SIRT inhibitor	NA	NA
SIS3	SMAD3	10138988	IJYPHMXWKKKHGT-VAWYXSNFSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
SIS3	TGFBR1	10138988	IJYPHMXWKKKHGT-VAWYXSNFSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
sitagliptin	DPP4	4369359	MFFMDFFZMYYVKS-SECBINFHSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
sitaxentan	EDNRA	216235	PHWXUGHIIBDVKD-UHFFFAOYSA-N	Withdrawn	endothelin receptor antagonist	NA	NA
sitaxentan	EDNRB	216235	PHWXUGHIIBDVKD-UHFFFAOYSA-N	Withdrawn	endothelin receptor antagonist	NA	NA
sivelestat	CELA1	107706	BTGNGJJLZOIYID-UHFFFAOYSA-N	Launched	elastase inhibitor	pulmonary	acute lung injury
sivelestat	ELANE	107706	BTGNGJJLZOIYID-UHFFFAOYSA-N	Launched	elastase inhibitor	pulmonary	acute lung injury
SJ-172550	MDM4	1317464	RKKFQJXGAQWHBZ-LICLKQGHSA-N	Preclinical	MDM inhibitor	NA	NA
SK&F-10047-(+)	SIGMAR1	3036222	LGQCVMYAEFTEFN-DQYPLSBCSA-N	Phase 1	sigma receptor agonist	NA	NA
SKA-31	KCNN4	94880	FECQXVPRUCCUIL-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
skepinone-L	MAPK14	45279963	HXMGCTFLLWPVFM-GOSISDBHSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SKF-38393	CALY	6603799	JUDKOGFHZYMDMF-AWEZNQCLSA-N	Preclinical	dopamine receptor agonist	NA	NA
SKF-38393	DRD1	6603799	JUDKOGFHZYMDMF-AWEZNQCLSA-N	Preclinical	dopamine receptor agonist	NA	NA
SKF-38393	DRD5	6603799	JUDKOGFHZYMDMF-AWEZNQCLSA-N	Preclinical	dopamine receptor agonist	NA	NA
SKF-77434	DRD1	6603997	QBUVZVXIRYFENV-KRWDZBQOSA-N	Preclinical	dopamine receptor agonist	NA	NA
SKF-81297	DRD1	11957706	GHWJEDJMOVUXEC-UHFFFAOYSA-N	Preclinical	dopamine receptor agonist	NA	NA
SKF-81297	DRD5	11957706	GHWJEDJMOVUXEC-UHFFFAOYSA-N	Preclinical	dopamine receptor agonist	NA	NA
SKF-83566	DRD1	6604885	XFTVOHWWEQGXLS-HNNXBMFYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
SKF-83566	DRD5	6604885	XFTVOHWWEQGXLS-HNNXBMFYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
SKF-86002	ALOX5	5228	YOELZIQOLWZLQC-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SKF-86002	MAPK14	5228	YOELZIQOLWZLQC-UHFFFAOYSA-N	Preclinical	p38 MAPK inhibitor	NA	NA
SKF-89976A	SLC6A1	6604015	TXQKSMSLZVKQBI-FQEVSTJZSA-N	Preclinical	GABA uptake inhibitor	NA	NA
SKF-91488	HNMT	5227	UFYJLJINUGVUHO-UHFFFAOYSA-N	Preclinical	histamine N-methyltransferase inhibitor	NA	NA
SKF-96365	CYP3A4	6604827	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	calcium channel blocker	NA	NA
SKF-96365	PKD2	6604827	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	calcium channel blocker	NA	NA
SKF-96365	TRPC1	6604827	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	calcium channel blocker	NA	NA
SKF-96365	TRPC3	6604827	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	calcium channel blocker	NA	NA
SKF-96365	TRPC4	6604827	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	calcium channel blocker	NA	NA
SKF-96365	TRPC5	6604827	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	calcium channel blocker	NA	NA
SKF-96365	TRPV2	6604827	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	calcium channel blocker	NA	NA
SKI-II	SPHK1	753704	ZFGXZJKLOFCECI-UHFFFAOYSA-N	Preclinical	sphingosine kinase inhibitor	NA	NA
SKLB1002	KDR	71461003	RQVGFDBMONQTBC-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
SLV-319-(+/-)	CNR1	9826744	AXJQVVLKUYCICH-OAQYLSRUSA-N	Phase 2	cannabinoid receptor antagonist	NA	NA
SLV-319-(+/-)	DRD2	9826744	AXJQVVLKUYCICH-OAQYLSRUSA-N	Phase 2	cannabinoid receptor antagonist	NA	NA
SLV-319-(+/-)	HTR1A	9826744	AXJQVVLKUYCICH-OAQYLSRUSA-N	Phase 2	cannabinoid receptor antagonist	NA	NA
SLV-320	ADORA1	NA	RBZNJGHIKXAKQE-HDJSIYSDSA-N	Phase 2	adenosine receptor antagonist	NA	NA
SLV-320	ADORA2A	NA	RBZNJGHIKXAKQE-HDJSIYSDSA-N	Phase 2	adenosine receptor antagonist	NA	NA
SLV-320	ADORA2B	NA	RBZNJGHIKXAKQE-HDJSIYSDSA-N	Phase 2	adenosine receptor antagonist	NA	NA
SLV-320	ADORA3	NA	RBZNJGHIKXAKQE-HDJSIYSDSA-N	Phase 2	adenosine receptor antagonist	NA	NA
SM-164	BIRC2	17756618	LGYDZXNSSLRFJS-IOQQVAQYSA-N	Preclinical	XIAP inhibitor	NA	NA
SM-164	BIRC3	17756618	LGYDZXNSSLRFJS-IOQQVAQYSA-N	Preclinical	XIAP inhibitor	NA	NA
SM-164	XIAP	17756618	LGYDZXNSSLRFJS-IOQQVAQYSA-N	Preclinical	XIAP inhibitor	NA	NA
SM-21	PGRMC1	NA	WTPAXDRULIZRDJ-ABFRBSLYSA-N	Preclinical	sigma receptor antagonist	NA	NA
SMER-28	SNCA	1560402	BCPOLXUSCUFDGE-UHFFFAOYSA-N	Preclinical	autophagy inducer	NA	NA
SMI-4a	PIM1	1361334	NGJLOFCOEOHFKQ-YVMONPNESA-N	Preclinical	Pim kinase inhibitor	NA	NA
SN-2	MCOLN3	NA	WKLZNTYMDOPBSE-IARIHHJXSA-N	Preclinical	transient receptor potential channel agonist	NA	NA
SN-38	TOP1	104842	FJHBVJOVLFPMQE-QFIPXVFZSA-N	Launched	topoisomerase inhibitor	oncology	colorectal cancer
SNAP	PTPN1	NA	MLXCQEWOIZBBDM-YFKPBYRVSA-N	Phase 2	nitric oxide donor	NA	NA
SNAP-5089	ADRA1A	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-5089	ADRA1B	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-5089	ADRA1D	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-5089	ADRA2A	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-5089	ADRA2B	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-5089	ADRA2C	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-5089	CACNA1C	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-5089	CACNA1D	10326374	FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SNAP-94847	ADRA1A	16756754	VMLZFUVIKCGATC-UHFFFAOYSA-N	Preclinical		NA	NA
SNAP-94847	DRD2	16756754	VMLZFUVIKCGATC-UHFFFAOYSA-N	Preclinical		NA	NA
SNC-80	OPRD1	123924	KQWVAUSXZDRQPZ-UMTXDNHDSA-N	Preclinical		NA	NA
SNG-1153	ESR1	71621167	OXHMDMVBLQNMGP-UHFFFAOYSA-N	Preclinical	selective estrogen receptor modulator (SERM)	NA	NA
SNS-314	AURKA	24995524	FAYAUAZLLLJJGH-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
SNS-314	AURKB	24995524	FAYAUAZLLLJJGH-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
SNS-314	AURKC	24995524	FAYAUAZLLLJJGH-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
SNX-5422	HSP90AA1	NA	AVDSOVJPJZVBTC-CTYIDZIISA-N	Phase 1/Phase 2	HSP inhibitor	NA	NA
SNX-5422	HSP90AB1	NA	AVDSOVJPJZVBTC-CTYIDZIISA-N	Phase 1/Phase 2	HSP inhibitor	NA	NA
sobetirome	THRA	9862248	QNAZTOHXCZPOSA-UHFFFAOYSA-N	Phase 1/Phase 2	thyroid hormone receptor agonist	NA	NA
sobetirome	THRB	9862248	QNAZTOHXCZPOSA-UHFFFAOYSA-N	Phase 1/Phase 2	thyroid hormone receptor agonist	NA	NA
sodium-butyrate	BCHE	264	FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
sodium-butyrate	FFAR2	264	FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
sodium-butyrate	FFAR3	264	FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
sodium-butyrate	HDAC1	264	FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
sodium-butyrate	HDAC2	264	FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
sodium-butyrate	HDAC3	264	FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
sodium-butyrate	HDAC8	264	FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	HDAC inhibitor	NA	NA
sodium-dodecyl-sulfate	ALB	NA	ISYOIFGRKUYTGX-UHFFFAOYSA-N	Launched		NA	NA
sodium-monofluorophosphate	PYGM	24267	DWYMPOCYEZONEA-UHFFFAOYSA-N	Launched		dental	cavities
sodium-stibogluconate	PTPN6	NA	RPOBPHCDIPHDQL-XCCFGPONSA-L	Launched	tyrosine phosphatase inhibitor	infectious disease	leishmaniasis
sodium-tetradecyl-sulfate	PROC	51382662	GROJOWHVXQYQGN-KGLIPLIRSA-N	Launched		dermatology	varicose veins
sofalcone	CBR1	5282219	GFWRVVCDTLRWPK-KPKJPENVSA-N	Launched	mucus protecting agent	gastroenterology	peptic ulcer disease (PUD)
solcitinib	JAK1	44603362	MPYACSQFXVMWNO-UHFFFAOYSA-N	Phase 1	JAK inhibitor	NA	NA
solifenacin-succinate	CHRM1	154059	FBOUYBDGKBSUES-VXKWHMMOSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
solifenacin-succinate	CHRM2	154059	FBOUYBDGKBSUES-VXKWHMMOSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
solifenacin-succinate	CHRM3	154059	FBOUYBDGKBSUES-VXKWHMMOSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
solifenacin-succinate	CHRM4	154059	FBOUYBDGKBSUES-VXKWHMMOSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
solifenacin-succinate	CHRM5	154059	FBOUYBDGKBSUES-VXKWHMMOSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
somatostatin	OPRD1	NA	NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	somatostatin receptor agonist	hematology	hemorrhage
somatostatin	OPRM1	NA	NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	somatostatin receptor agonist	hematology	hemorrhage
somatostatin	SSTR1	NA	NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	somatostatin receptor agonist	hematology	hemorrhage
somatostatin	SSTR2	NA	NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	somatostatin receptor agonist	hematology	hemorrhage
somatostatin	SSTR3	NA	NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	somatostatin receptor agonist	hematology	hemorrhage
somatostatin	SSTR4	NA	NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	somatostatin receptor agonist	hematology	hemorrhage
somatostatin	SSTR5	NA	NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	somatostatin receptor agonist	hematology	hemorrhage
sonidegib	SMO	24775005	VZZJRYRQSPEMTK-CALCHBBNSA-N	Launched	smoothened receptor antagonist	oncology	basal cell carcinoma (BCC)
sorafenib	BRAF	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	DDR2	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	FGFR1	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	FLT1	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	FLT3	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	FLT4	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	KDR	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	KIT	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	PDGFRB	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	RAF1	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorafenib	RET	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
sorbinil	AKR1B1	337359	LXANPKRCLVQAOG-NSHDSACASA-N	Phase 3	aldose reductase inhibitor	NA	NA
sotagliflozin	SLC5A1	24831714	QKDRXGFQVGOQKS-CRSSMBPESA-N	Phase 3	sodium/glucose cotransporter inhibitor	NA	NA
sotagliflozin	SLC5A2	24831714	QKDRXGFQVGOQKS-CRSSMBPESA-N	Phase 3	sodium/glucose cotransporter inhibitor	NA	NA
sotalol	ADRB1	67108155	ZBMZVLHSJCTVON-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)|ventricular arrhythmias
sotalol	ADRB2	67108155	ZBMZVLHSJCTVON-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)|ventricular arrhythmias
sotalol	KCNH2	67108155	ZBMZVLHSJCTVON-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)|ventricular arrhythmias
sotrastaurin	PRKCA	10296883	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2	PKC inhibitor	NA	NA
sotrastaurin	PRKCB	10296883	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2	PKC inhibitor	NA	NA
sotrastaurin	PRKCD	10296883	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2	PKC inhibitor	NA	NA
sotrastaurin	PRKCE	10296883	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2	PKC inhibitor	NA	NA
sotrastaurin	PRKCH	10296883	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2	PKC inhibitor	NA	NA
sotrastaurin	PRKCQ	10296883	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2	PKC inhibitor	NA	NA
SP-100030	JUN	9910975	GHMKQBWHPQMXSH-UHFFFAOYSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
SP-100030	NFKB1	9910975	GHMKQBWHPQMXSH-UHFFFAOYSA-N	Preclinical	NFkB pathway inhibitor	NA	NA
SP-141	MDM2	59620153	AABFWJDLCCDJJN-UHFFFAOYSA-N	Preclinical	ubiquitin ligase inhibitor	NA	NA
spaglumic-acid	GRM3	188803	OPVPGKGADVGKTG-BQBZGAKWSA-N	Launched	glutamate receptor antagonist	allergy	allergic conjunctivitis|allergic rhinitis
sparfloxacin	TOP2A	6956367	DZZWHBIBMUVIIW-DTORHVGOSA-N	Withdrawn	bacterial DNA gyrase inhibitor	NA	NA
sparfosate	CA2	46936683	ZZKNRXZVGOYGJT-GSVOUGTGSA-N	Phase 3	aspartate carbamoyltransferase inhibitor	NA	NA
sparfosate	CA4	46936683	ZZKNRXZVGOYGJT-GSVOUGTGSA-N	Phase 3	aspartate carbamoyltransferase inhibitor	NA	NA
spautin-1	USP10	51037431	AWIVHRPYFSSVOG-UHFFFAOYSA-N	Preclinical	deubiquitinase inhibitor	NA	NA
spautin-1	USP13	51037431	AWIVHRPYFSSVOG-UHFFFAOYSA-N	Preclinical	deubiquitinase inhibitor	NA	NA
spermidine	KCNJ4	1102	ATHGHQPFGPMSJY-UHFFFAOYSA-N	Preclinical	glutamate receptor modulator	NA	NA
spermidine	TXNRD1	1102	ATHGHQPFGPMSJY-UHFFFAOYSA-N	Preclinical	glutamate receptor modulator	NA	NA
spermine	CA14	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	CA4	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	CA6	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	CA9	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	CASR	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	GRIN1	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	GRIN2A	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	KCNJ4	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	ODC1	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	SMOX	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	SMS	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	TRPM4	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
spermine	TRPM5	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical		NA	NA
sphingosylphosphorylcholine	GPR12	5280613	JLVSPVFPBBFMBE-HXSWCURESA-O	Preclinical	gene expression stimulant	NA	NA
spiperone	ADRA1A	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	ADRA1B	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	ADRA1D	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	DRD1	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	DRD2	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	DRD3	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	DRD4	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	DRD5	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	HTR1A	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	HTR1D	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	HTR2A	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	HTR2B	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	HTR2C	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	HTR6	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiperone	HTR7	5265	DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiradoline	OPRK1	55652	NYKCGQQJNVPOLU-ONTIZHBOSA-N	Phase 2	opioid receptor agonist	NA	NA
spironolactone	AR	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1A	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1B	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1C	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1D	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1F	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1G	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1H	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1I	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA1S	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA2D1	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA2D2	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNA2D3	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNB1	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNB2	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNB3	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNB4	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CACNG1	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	CYP11B2	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	NR3C1	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	NR3C2	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	PGR	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spironolactone	SHBG	5833	LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
spiroxatrine	ADRA1A	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
spiroxatrine	ADRA1B	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
spiroxatrine	ADRA1D	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
spiroxatrine	ADRA2A	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
spiroxatrine	ADRA2B	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
spiroxatrine	ADRA2C	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
spiroxatrine	HTR1A	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
spiroxatrine	HTR2B	6603993	JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	serotonin receptor antagonist	NA	NA
splitomycin	SIRT1	5269	ISFPDBUKMJDAJH-UHFFFAOYSA-N	Preclinical	SIRT inhibitor	NA	NA
SPP301	EDNRA	9912992	YBWLTKFZAOSWSM-UHFFFAOYSA-N	Phase 3	endothelin receptor antagonist	NA	NA
SPP86	RET	66549796	JQOIRTDBHMDWMT-UHFFFAOYSA-N	Preclinical	receptor tyrosine protein kinase inhibitor	NA	NA
SQ-109	FDFT1	NA	JFIBVDBTCDTBRH-UNRAVDGJSA-N	Phase 3	bacterial cell wall synthesis inhibitor	NA	NA
SQ-22536	ADCY1	22879197	UKHMZCMKHPHFOT-ZCFIWIBFSA-N	Preclinical	adenylyl cyclase inhibitor	NA	NA
SR-1078	RORA	17980288	DUXWIYXHHGNUJU-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
SR-1078	RORC	17980288	DUXWIYXHHGNUJU-UHFFFAOYSA-N	Preclinical	retinoid receptor agonist	NA	NA
SR-140333	TACR1	108167	RPDFDSQFBCJTDY-GAQXSTBRSA-N	Phase 2	neurokinin receptor antagonist	NA	NA
SR-1664	PPARG	53239854	IIJDFXNUWZTHIM-NRFANRHFSA-N	Preclinical	PPAR receptor ligand	NA	NA
SR-2211	RORC	51035449	KVHKWAZUPPBMLL-UHFFFAOYSA-N	Preclinical	retinoid receptor inverse agonist	NA	NA
SR-2640	CYSLTR1	128355	LMPZHLXYBWGGNT-UHFFFAOYSA-N	Phase 2	leukotriene receptor antagonist	NA	NA
SR-27897	CCKAR	122077	ILNRQFBVVQUOLP-UHFFFAOYSA-N	Phase 2	CCK receptor antagonist	NA	NA
SR-3306	MAPK10	57519510	QDMXVKKPYBGIAS-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
SR-3306	MAPK8	57519510	QDMXVKKPYBGIAS-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
SR-3306	MAPK9	57519510	QDMXVKKPYBGIAS-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
SR-3576	MAPK10	70702008	MTFAYLZZDJGFGV-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
SR-3677	ROCK2	93600633	OQWZIAVXCYIZNN-OAQYLSRUSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
SR-57227A	HTR3A	131747	WPVVMKYQOMJPIN-UHFFFAOYSA-N	Phase 2	serotonin receptor agonist	NA	NA
SR-59230A	ADRB1	5311452	VFDHMSXXELYMRW-ICSRJNTNSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SR-59230A	ADRB2	5311452	VFDHMSXXELYMRW-ICSRJNTNSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SR-59230A	ADRB3	5311452	VFDHMSXXELYMRW-ICSRJNTNSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
SR-95639A	CHRM1	195165	RUTYAHFAKWVMNH-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
SRC-kinase-inhibitor-I	CSK	1474853	DMWVGXGXHPOEPT-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
SRC-kinase-inhibitor-I	LCK	1474853	DMWVGXGXHPOEPT-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
SRC-kinase-inhibitor-I	RIPK2	1474853	DMWVGXGXHPOEPT-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
SRPIN340	SRPK1	2797577	DWFGGOFPIISJIT-UHFFFAOYSA-N	Preclinical	serine arginine protein kinase inhibitor	NA	NA
SRPIN340	SRPK2	2797577	DWFGGOFPIISJIT-UHFFFAOYSA-N	Preclinical	serine arginine protein kinase inhibitor	NA	NA
SRT1720	SIRT1	24180125	IASPBORHOMBZMY-UHFFFAOYSA-N	Preclinical	SIRT activator	NA	NA
SRT2104	SIRT1	25108829	LAMQVIQMVKWXOC-UHFFFAOYSA-N	Phase 2	SIRT activator	NA	NA
SSR180711	CHRNA7	9797360	RXLOZRCLQMJJLC-UHFFFAOYSA-N	Phase 2	acetylcholine receptor agonist	NA	NA
ST-2825	MYD88	24808138	HBLHLJXFIPCEMW-ZJSFPPFMSA-N	Preclinical	myeloid differentiation primary response inhibitor	NA	NA
STA-5326	IL12A	10173277	"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+"	Phase 2	interleukin synthesis inhibitor	NA	NA
STAT3-inhibitor-VI	STAT3	252682	HWNUSGNZBAISFM-UHFFFAOYSA-N	Preclinical	STAT inhibitor	NA	NA
stemregenin-1	AHR	46199207	BGFHMYJZJZLMHW-UHFFFAOYSA-N	Preclinical	aryl hydrocarbon receptor antagonist	NA	NA
STF-083010	ERN1	135398515	TVIVJHZHPKNDAQ-MHWRWJLKSA-N	Preclinical	serine/threonine kinase inhibitor	NA	NA
STF-118804	NAMPT	20916937	DLFCEZOMHBPDGI-UHFFFAOYSA-N	Preclinical	NAMPT inhibitor	NA	NA
STF-31	NAMPT	984333	NGQPRVWTFNBUHA-UHFFFAOYSA-N	Preclinical	NAMPT inhibitor	NA	NA
STF-31	SLC2A1	984333	NGQPRVWTFNBUHA-UHFFFAOYSA-N	Preclinical	NAMPT inhibitor	NA	NA
stiripentol	GABRA3	25271730	IBLNKMRFIPWSOY-IYNGYCSASA-N	Launched	GABA uptake inhibitor	neurology/psychiatry	epilepsy
stobadine	ADRA1A	108089	CYJQCYXRNNCURD-DGCLKSJQSA-N	Phase 2	adrenergic receptor antagonist	NA	NA
strontium-ranelate	CASR		TWHPPRXFYWSOQF-UHFFFAOYSA-J	Launched	bone formation stimulant|bone resorption inhibitor	orthopedics|rheumatology	osteoporosis|osteoarthritis
strychnine	CHRM1	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	CHRM2	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	CHRM3	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	CHRM4	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	CHRM5	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	CHRNA10	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	CHRNA9	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	GLRA1	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	GLRA2	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	GLRA3	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
strychnine	GLRB	441071	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	acetylcholine receptor antagonist	NA	NA
substance-P	TACR1	36511	ADNPLDHMAVUMIW-CUZNLEPHSA-N	Phase 1	neurokinin receptor antagonist	NA	NA
substance-P	TACR2	36511	ADNPLDHMAVUMIW-CUZNLEPHSA-N	Phase 1	neurokinin receptor antagonist	NA	NA
substance-P	TACR3	36511	ADNPLDHMAVUMIW-CUZNLEPHSA-N	Phase 1	neurokinin receptor antagonist	NA	NA
succinic-acid	ALDH5A1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	ASPH	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	BBOX1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	HSD17B6	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	OXCT1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	OXCT2	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	P3H1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	P3H2	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	P3H3	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	P4HA1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	P4HA2	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	PLOD1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	PLOD3	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SDHA	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SDHB	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SDHC	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SDHD	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SLC13A1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SLC13A2	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SLC13A3	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SLC25A10	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SUCLA2	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SUCLG1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SUCLG2	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	SUCNR1	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinic-acid	TMLHE	21952380	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched		NA	NA
succinobucol	VCAM1	216325	RKSMVPNZHBRNNS-UHFFFAOYSA-N	Phase 2/Phase 3	antioxidant	NA	NA
succinylcholine-chloride	CHRFAM7A	5314	AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched		neurology/psychiatry	muscle relaxant
succinylcholine-chloride	CHRM1	5314	AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched		neurology/psychiatry	muscle relaxant
succinylcholine-chloride	CHRM2	5314	AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched		neurology/psychiatry	muscle relaxant
succinylcholine-chloride	CHRM3	5314	AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched		neurology/psychiatry	muscle relaxant
succinylcholine-chloride	CHRNA1	5314	AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched		neurology/psychiatry	muscle relaxant
succinylcholine-chloride	CHRNA10	5314	AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched		neurology/psychiatry	muscle relaxant
succinylsulfathiazole	DHFR	5315	SKVLYVHULOWXTD-UHFFFAOYSA-N	Phase 2	dihydrofolate reductase inhibitor	NA	NA
sucrose	ACTA1	5988	CZMRCDWAGMRECN-UGDNZRGBSA-N	Launched		NA	NA
sucrose	ATOX1	5988	CZMRCDWAGMRECN-UGDNZRGBSA-N	Launched		NA	NA
sucrose	C22orf28	5988	CZMRCDWAGMRECN-UGDNZRGBSA-N	Launched		NA	NA
sucrose	LYZ	5988	CZMRCDWAGMRECN-UGDNZRGBSA-N	Launched		NA	NA
sulfameter	DHFR	5326	GPTONYMQFTZPKC-UHFFFAOYSA-N	Launched	dihydrofolate reductase inhibitor	infectious disease	urinary tract infections
sulfanilamide	CYP2C19	5333	FDDDEECHVMSUSB-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	vulvovaginal candidiasis
sulfanilamide	CYP2C9	5333	FDDDEECHVMSUSB-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	vulvovaginal candidiasis
sulfanilamide	CYP2D6	5333	FDDDEECHVMSUSB-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	vulvovaginal candidiasis
sulfanilamide	CYP2E1	5333	FDDDEECHVMSUSB-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	vulvovaginal candidiasis
sulfanilamide	CYP3A4	5333	FDDDEECHVMSUSB-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	infectious disease	vulvovaginal candidiasis
sulfaphenazole	DHPS	5335	QWCJHSGMANYXCW-UHFFFAOYSA-N	Launched	dihydropteroate synthetase inhibitor	infectious disease	urinary tract infections
sulfasalazine	ACAT1	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	ALOX5	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	CHUK	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	IKBKB	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	PLA2G1B	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	PPARG	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	PTGS1	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	PTGS2	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	SLC46A1	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	SLC7A11	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfasalazine	TBXAS1	NA	NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfinpyrazone	ABCC1	25273605	MBGGBVCUIVRRBF-LJAQVGFWSA-N	Launched	uricosuric blocker	rheumatology	gout
sulfinpyrazone	FPR1	25273605	MBGGBVCUIVRRBF-LJAQVGFWSA-N	Launched	uricosuric blocker	rheumatology	gout
sulfinpyrazone	SLC22A12	25273605	MBGGBVCUIVRRBF-LJAQVGFWSA-N	Launched	uricosuric blocker	rheumatology	gout
sulforaphane	NFE2L2	9577379	SUVMJBTUFCVSAD-SNVBAGLBSA-N	Phase 2	anticancer agent|aryl hydrocarbon receptor antagonist	NA	NA
sulindac	AKR1B1	16046677	MLKXDPUZXIRXEP-LQVWSKNFSA-N	Launched	cyclooxygenase inhibitor	rheumatology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis
sulmetozine	GAST	65790	MVOUIYUWRXPNKD-UHFFFAOYSA-N	Launched	gastrin inhibitor	gastroenterology	peptic ulcer disease (PUD)
sultiame	CA2	5356	HMHVCUVYZFYAJI-UHFFFAOYSA-N	Phase 3	carbonic anhydrase inhibitor	NA	NA
sumanirole	DRD2	9818479	RKZSNTNMEFVBDT-MRVPVSSYSA-N	Phase 3	dopamine receptor agonist	NA	NA
sumatriptan	HTR1A	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
sumatriptan	HTR1B	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
sumatriptan	HTR1D	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
sumatriptan	HTR1E	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
sumatriptan	HTR1F	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
sumatriptan	HTR5A	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
sumatriptan	HTR6	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
sumatriptan	HTR7	5358	KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
SUN-B-8155	CALCR	NA	SGJLINMLDNLWOS-CXUHLZMHSA-N	Preclinical	calcitonin agonist	NA	NA
SUN-11602	FGFR1	22245705	KCODNOOPOPTZMO-UHFFFAOYSA-N	Preclinical	fibroblast growth factor mimetic	NA	NA
sunitinib	CSF1R	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	FGFR1	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	FLT1	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	FLT3	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	FLT4	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	KDR	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	KIT	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	PDGFRA	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	PDGFRB	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
sunitinib	RET	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
suprofen	PTGS1	688581	MDKGKXOCJGEUJW-SECBINFHSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
suprofen	PTGS2	688581	MDKGKXOCJGEUJW-SECBINFHSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
suramin	F2	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	FSHR	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	P2RY1	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	P2RY11	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	P2RY13	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	P2RY2	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	PLA2G2A	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	RYR1	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	RYR2	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suramin	SIRT5	5361	FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	DNA synthesis inhibitor	infectious disease	African trypanosomiasis|onchocerciasis
suritozole	GABBR1	25431	IWDUZEHNLHFBRZ-UHFFFAOYSA-N	Phase 2	GABA receptor inverse agonist	NA	NA
SU014813	KDR	10138259	CTNPALGJUAXMMC-PMFHANACSA-N	Phase 2	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
SU11274	MET	9549297	FPYJSJDOHRDAMT-KQWNVCNZSA-N	Preclinical	hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor	NA	NA
SU16f	PDGFRB	5329150	APYYTEJNOZQZNA-MOSHPQCFSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor	NA	NA
SU3327	MAPK8	11837140	NQQBNZBOOHHVQP-UHFFFAOYSA-N	Preclinical	JNK inhibitor	NA	NA
SU4312	KDR	6450842	UAKWLVYMKBWHMX-PTNGSMBKSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
SU4312	PDGFRB	6450842	UAKWLVYMKBWHMX-PTNGSMBKSA-N	Preclinical	PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor	NA	NA
SU9516	CDK1	5289419	QNUKRWAIZMBVCU-WCIBSUBMSA-N	Preclinical	CDK inhibitor	NA	NA
SU9516	CDK2	5289419	QNUKRWAIZMBVCU-WCIBSUBMSA-N	Preclinical	CDK inhibitor	NA	NA
SU9516	CDK4	5289419	QNUKRWAIZMBVCU-WCIBSUBMSA-N	Preclinical	CDK inhibitor	NA	NA
SU9516	CDK5	5289419	QNUKRWAIZMBVCU-WCIBSUBMSA-N	Preclinical	CDK inhibitor	NA	NA
swainsonine	MAN2A1	51683	FXUAIOOAOAVCGD-WCTZXXKLSA-N	Phase 2	alpha mannosidase inhibitor	NA	NA
SX-011	MAPK14	9935015	GUTYHDCSDBBMGW-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
SYM-2081	GRIK1	95883	KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical	kainate receptor antagonist	NA	NA
SYM-2081	GRIK2	95883	KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical	kainate receptor antagonist	NA	NA
SYM-2081	GRIK3	95883	KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical	kainate receptor antagonist	NA	NA
SYM-2081	GRIK4	95883	KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical	kainate receptor antagonist	NA	NA
SYM-2081	GRIK5	95883	KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical	kainate receptor antagonist	NA	NA
SYM-2081	SLC1A2	95883	KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical	kainate receptor antagonist	NA	NA
SYM-2206	GRIA1	92209239	OFUDZKKOKPGXOH-LBPRGKRZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
SYM-2206	GRIA2	92209239	OFUDZKKOKPGXOH-LBPRGKRZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
SYM-2206	GRIA3	92209239	OFUDZKKOKPGXOH-LBPRGKRZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
SYM-2206	GRIA4	92209239	OFUDZKKOKPGXOH-LBPRGKRZSA-N	Preclinical	glutamate receptor antagonist	NA	NA
synephrine	ADRA1A	667452	YRCWQPVGYLYSOX-SECBINFHSA-N	Launched	adrenergic receptor agonist	otolaryngology	sinusitis
S1P1-agonist-III	S1PR1	54764919	MLDQTQOMWDNTNN-UHFFFAOYSA-N	Preclinical	sphingosine kinase inhibitor	NA	NA
S18986	GRIA1	637863	MNTIJYGEITVWHU-SNVBAGLBSA-N	Phase 2	glutamate receptor modulator	NA	NA
S18986	GRIA2	637863	MNTIJYGEITVWHU-SNVBAGLBSA-N	Phase 2	glutamate receptor modulator	NA	NA
S18986	GRIA3	637863	MNTIJYGEITVWHU-SNVBAGLBSA-N	Phase 2	glutamate receptor modulator	NA	NA
S18986	GRIA4	637863	MNTIJYGEITVWHU-SNVBAGLBSA-N	Phase 2	glutamate receptor modulator	NA	NA
S26948	PPARG	9958279	NSMJEHGOMXSLCW-UHFFFAOYSA-N	Preclinical	PPAR receptor agonist	NA	NA
S4	CA12	53342705	HGVHSNXRZYOTPD-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
S4	CA9	53342705	HGVHSNXRZYOTPD-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
T-0070907	PPARG	2777391	FRPJSHKMZHWJBE-UHFFFAOYSA-N	Preclinical	PPAR receptor antagonist	NA	NA
T-0156	PDE5A	5368	JEMJAABFSYOLAP-UHFFFAOYSA-N	Preclinical	phosphodiesterase inhibitor	NA	NA
T-0901317	NCOA1	447912	SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
T-0901317	NCOA2	447912	SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
T-0901317	NR1H2	447912	SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
T-0901317	NR1H3	447912	SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
T-0901317	NR1I2	447912	SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
T-0901317	RXRB	447912	SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical	LXR agonist	NA	NA
T-5224	JUN	23626877	DALCQQSLNPLQFZ-UHFFFAOYSA-N	Phase 2	AP inhibitor	NA	NA
T-5601640	LIMK2	9438169	XVOKFRPKSAWELK-UHFFFAOYSA-N	Preclinical	LIM kinase inhibitor	NA	NA
T-62	ADORA2A	855908	OTZVBZFYMFTYKH-UHFFFAOYSA-N	Phase 2	adenosine receptor modulator	NA	NA
TA-01	CSNK1D	91691129	TWPJJJZCYVFUOA-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|MAP kinase inhibitor	NA	NA
TA-01	CSNK1E	91691129	TWPJJJZCYVFUOA-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|MAP kinase inhibitor	NA	NA
TA-01	MAPK14	91691129	TWPJJJZCYVFUOA-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor|MAP kinase inhibitor	NA	NA
tabimorelin	GHSR	9810101	WURGZWOTGMLDJP-ZCYANPAGSA-N	Phase 2	growth hormone secretagogue receptor agonist	NA	NA
tacalcitol	VDR	5283734	BJYLYJCXYAMOFT-RSFVBTMBSA-N	Launched	vitamin D receptor agonist	dermatology	psoriasis|chapped lips
tacedinaline	HDAC1	2746	VAZAPHZUAVEOMC-UHFFFAOYSA-N	Phase 3	HDAC inhibitor	NA	NA
tacrine	ACHE	1935	YLJREFDVOIBQDA-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease
tacrine	BCHE	1935	YLJREFDVOIBQDA-UHFFFAOYSA-N	Launched	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease
tacrolimus	FKBP1A	445643	QJJXYPPXXYFBGM-LFZNUXCKSA-N	Launched	calcineurin inhibitor	transplant	organ rejection
tadalafil	PDE11A	110635	WOXKDUGGOYFFRN-IIBYNOLFSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
tadalafil	PDE5A	110635	WOXKDUGGOYFFRN-IIBYNOLFSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
tafamidis-meglumine	TTR	11001318	TXEIIPDJKFWEEC-UHFFFAOYSA-N	Launched	transthyretin amyloid inhibitor	neurology/psychiatry	familial amyloid polyneuropathy (FAP)
tafluprost	PTGFR	9868491	WSNODXPBBALQOF-VEJSHDCNSA-N	Launched	prostaglandin inhibitor	ophthalmology	glaucoma|ocular hypertension
tagatose	PYGL	92092	BJHIKXHVCXFQLS-PQLUHFTBSA-N	Launched	phosphorylase inhibitor	NA	NA
TAK-063	PDE10A	46848915	KVHRYLNQDWXAGI-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
TAK-220	CCR5	5275766	ASSJTMUEFHUKMJ-UHFFFAOYSA-N	Phase 1	CC chemokine receptor antagonist	NA	NA
TAK-285	ERBB2	11620908	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N	Phase 1	EGFR inhibitor	NA	NA
TAK-593	PDGFRA	24767976	DZFZXPPHBWCXPQ-UHFFFAOYSA-N	Phase 1	VEGFR inhibitor	NA	NA
TAK-632	BRAF	46209401	OJFKUJDRGJSAQB-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
TAK-715	MAPK14	9952773	HEKAIDKUDLCBRU-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
TAK-733	MAP2K1	24963252	RCLQNICOARASSR-SECBINFHSA-N	Phase 1	MEK inhibitor	NA	NA
TAK-875	FFAR1	24857286	BZCALJIHZVNMGJ-HSZRJFAPSA-N	Phase 3	insulin secretagogue	NA	NA
TAK-901	AURKB	16124208	WKDACQVEJIVHMZ-UHFFFAOYSA-N	Phase 1	Aurora kinase inhibitor	NA	NA
TAK-960	PLK1	53357478	GWRSATNRNFYMDI-UHFFFAOYSA-N	Phase 1	PLK inhibitor	NA	NA
talabostat	DPP4	6918572	FKCMADOPPWWGNZ-YUMQZZPRSA-N	Phase 3	dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor	NA	NA
taladegib	DHH	49848070	SZBGQDXLNMELTB-UHFFFAOYSA-N	Phase 2	smoothened receptor antagonist	NA	NA
taladegib	IHH	49848070	SZBGQDXLNMELTB-UHFFFAOYSA-N	Phase 2	smoothened receptor antagonist	NA	NA
taladegib	SMO	49848070	SZBGQDXLNMELTB-UHFFFAOYSA-N	Phase 2	smoothened receptor antagonist	NA	NA
talampanel	GRIA1	164509	JACAAXNEHGBPOQ-LLVKDONJSA-N	Phase 2	glutamate receptor antagonist	NA	NA
talampanel	GRIA2	164509	JACAAXNEHGBPOQ-LLVKDONJSA-N	Phase 2	glutamate receptor antagonist	NA	NA
talampanel	GRIA3	164509	JACAAXNEHGBPOQ-LLVKDONJSA-N	Phase 2	glutamate receptor antagonist	NA	NA
talampanel	GRIA4	164509	JACAAXNEHGBPOQ-LLVKDONJSA-N	Phase 2	glutamate receptor antagonist	NA	NA
talarozole	CYP26A1	76958553	SNFYYXUGUBUECJ-FQEVSTJZSA-N	Phase 2	cytochrome P450 inhibitor	NA	NA
talazoparib	PARP2	135565082	HWGQMRYQVZSGDQ-HZPDHXFCSA-N	Launched	PARP inhibitor	oncology	breast cancer
talinolol	ADRB1	156154	MXFWWQICDIZSOA-QGZVFWFLSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
talipexole	ADRA2A	5374	DHSSDEDRBUKTQY-UHFFFAOYSA-N	Launched	adrenergic receptor agonist|dopamine receptor agonist	infectious disease	genitial herpes
talipexole	DRD2	5374	DHSSDEDRBUKTQY-UHFFFAOYSA-N	Launched	adrenergic receptor agonist|dopamine receptor agonist	infectious disease	genitial herpes
talipexole	HTR3A	5374	DHSSDEDRBUKTQY-UHFFFAOYSA-N	Launched	adrenergic receptor agonist|dopamine receptor agonist	infectious disease	genitial herpes
talmapimod	IL1B	9871074	ZMELOYOKMZBMRB-DLBZAZTESA-N	Phase 2	p38 MAPK inhibitor	NA	NA
talmapimod	MAPK11	9871074	ZMELOYOKMZBMRB-DLBZAZTESA-N	Phase 2	p38 MAPK inhibitor	NA	NA
talmapimod	MAPK14	9871074	ZMELOYOKMZBMRB-DLBZAZTESA-N	Phase 2	p38 MAPK inhibitor	NA	NA
talmapimod	MT-CO2	9871074	ZMELOYOKMZBMRB-DLBZAZTESA-N	Phase 2	p38 MAPK inhibitor	NA	NA
talmapimod	TNF	9871074	ZMELOYOKMZBMRB-DLBZAZTESA-N	Phase 2	p38 MAPK inhibitor	NA	NA
talnetant	TACR2	5311424	BIAVGWDGIJKWRM-FQEVSTJZSA-N	Phase 2	tachykinin antagonist	NA	NA
talnetant	TACR3	5311424	BIAVGWDGIJKWRM-FQEVSTJZSA-N	Phase 2	tachykinin antagonist	NA	NA
talniflumate	CLCA1	25273599	ANMLJLFWUCQGKZ-HXUWFJFHSA-N	Launched	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
talopram	SLC6A2	76958671	LJBBMCNHIUJBDU-FQEVSTJZSA-N	Phase 2	adrenergic inhibitor	NA	NA
taltirelin	TRHR	114750	LQZAIAZUDWIVPM-SRVKXCTJSA-N	Launched	thyrotropin releasing hormone receptor agonist	neurology/psychiatry	spinocerebellar ataxia
tamibarotene	RARA	108143	"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)"	Launched	retinoid receptor agonist	hematologic malignancy	acute promyelocytic leukemia (APL)
tamibarotene	RARB	108143	"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)"	Launched	retinoid receptor agonist	hematologic malignancy	acute promyelocytic leukemia (APL)
tamoxifen	EBP	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	ESR1	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	ESR2	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	GPER1	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCA	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCB	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCD	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCE	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCG	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCI	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCQ	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamoxifen	PRKCZ	2733526	NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamsulosin	ADRA1A	129211	DRHKJLXJIQTDTD-OAHLLOKOSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
tamsulosin	ADRA1B	129211	DRHKJLXJIQTDTD-OAHLLOKOSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
tamsulosin	ADRA1D	129211	DRHKJLXJIQTDTD-OAHLLOKOSA-N	Launched	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
tanaproget	PGR	4369524	PYVFWTPEBMRKSR-UHFFFAOYSA-N	Phase 2	progesterone receptor agonist	NA	NA
tandospirone	HTR1A	91273	CEIJFEGBUDEYSX-FZDBZEDMSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD)|dysthymic disorder
tandutinib	CSF1R	3038522	UXXQOJXBIDBUAC-UHFFFAOYSA-N	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	NA	NA
tandutinib	FLT3	3038522	UXXQOJXBIDBUAC-UHFFFAOYSA-N	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	NA	NA
tandutinib	KIT	3038522	UXXQOJXBIDBUAC-UHFFFAOYSA-N	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	NA	NA
tandutinib	PDGFD	3038522	UXXQOJXBIDBUAC-UHFFFAOYSA-N	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	NA	NA
tandutinib	PDGFRB	3038522	UXXQOJXBIDBUAC-UHFFFAOYSA-N	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	NA	NA
tanespimycin	HSP90AA1	59996479	AYUNIORJHRXIBJ-FBDSWQSESA-N	Phase 3	HSP inhibitor	NA	NA
tannic-acid	ANO1	16129778	LRBQNJMCXXYXIU-PPKXGCFTSA-N	Launched	PARG inhibitor	gastroenterology	constipation
tanshinone-I	IFNG	114917	AIGAZQPHXLWMOJ-UHFFFAOYSA-N	Phase 2	AP inhibitor	NA	NA
tanshinone-IIA	IL1B	164676	HYXITZLLTYIPOF-UHFFFAOYSA-N	Phase 2/Phase 3	anti-inflammatory agent|interleukin inhibitor	NA	NA
tanshinone-IIA	NR1I2	164676	HYXITZLLTYIPOF-UHFFFAOYSA-N	Phase 2/Phase 3	anti-inflammatory agent|interleukin inhibitor	NA	NA
tanshinone-IIA	TNF	164676	HYXITZLLTYIPOF-UHFFFAOYSA-N	Phase 2/Phase 3	anti-inflammatory agent|interleukin inhibitor	NA	NA
taprenepag	PTGER2	18376177	MFFBXYNKZHTCEY-UHFFFAOYSA-N	Phase 2	prostaglandin receptor agonist	NA	NA
tarafenacin	CHRM3	25147683	UXZDMXYRRQJIBJ-IBGZPJMESA-N	Phase 2	acetylcholine receptor antagonist	NA	NA
taranabant	CNR1	11226090	QLYKJCMUNUWAGO-GAJHUEQPSA-N	Phase 3	cannabinoid receptor inverse agonist	NA	NA
targinine	NOS3	46906075	NTNWOCRCBQPEKQ-YFKPBYRVSA-N	Phase 3	nitric oxide synthase inhibitor	NA	NA
tariquidar	ABCB1	148201	"InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)"	Phase 3	P glycoprotein inhibitor	NA	NA
TAS-103	TOP1	135413533	ROWSTIYZUWEOMM-UHFFFAOYSA-N	Phase 1	topoisomerase inhibitor	NA	NA
taselisib	PIK3CA	51001932	"InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)"	Phase 3	PI3K inhibitor	NA	NA
tasimelteon	MTNR1A	10220503	PTOIAAWZLUQTIO-GXFFZTMASA-N	Launched	melatonin receptor agonist	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder
tasimelteon	MTNR1B	10220503	PTOIAAWZLUQTIO-GXFFZTMASA-N	Launched	melatonin receptor agonist	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder
tasquinimod	HDAC4	54682876	ONDYALNGTUAJDX-UHFFFAOYSA-N	Phase 3	angiogenesis inhibitor|S100A9 inhibitor	NA	NA
taurocholate	CEL	6675	WBWWGRHZICKQGZ-HZAMXZRMSA-N	Phase 1	G protein-coupled receptor agonist	NA	NA
taurocholate	FABP6	6675	WBWWGRHZICKQGZ-HZAMXZRMSA-N	Phase 1	G protein-coupled receptor agonist	NA	NA
taurocholate	SLCO1C1	6675	WBWWGRHZICKQGZ-HZAMXZRMSA-N	Phase 1	G protein-coupled receptor agonist	NA	NA
taxifolin	ADIPOR2	439533	CXQWRCVTCMQVQX-LSDHHAIUSA-N	Phase 2	opioid receptor antagonist	NA	NA
tazarotene	RARA	5381	OGQICQVSFDPSEI-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	cosmetic|sunscreen lotion
tazarotene	RARB	5381	OGQICQVSFDPSEI-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	cosmetic|sunscreen lotion
tazarotene	RARG	5381	OGQICQVSFDPSEI-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	cosmetic|sunscreen lotion
tazarotene	RXRB	5381	OGQICQVSFDPSEI-UHFFFAOYSA-N	Launched	retinoid receptor agonist	dermatology	cosmetic|sunscreen lotion
tazemetostat	EZH2	66558664	NSQSAUGJQHDYNO-UHFFFAOYSA-N	Launched	histone lysine methyltransferase inhibitor	NA	NA
TBOA-(DL)	SLC1A1	90479771	CSEZCYBVEGIYNG-MFBWXLJUSA-N	Preclinical	excitatory amino acid transporter inhibitor	NA	NA
TBOA-(DL)	SLC1A2	90479771	CSEZCYBVEGIYNG-MFBWXLJUSA-N	Preclinical	excitatory amino acid transporter inhibitor	NA	NA
TBOA-(DL)	SLC1A3	90479771	CSEZCYBVEGIYNG-MFBWXLJUSA-N	Preclinical	excitatory amino acid transporter inhibitor	NA	NA
TBOA-(DL)	SLC1A6	90479771	CSEZCYBVEGIYNG-MFBWXLJUSA-N	Preclinical	excitatory amino acid transporter inhibitor	NA	NA
TBOA-(DL)	SLC1A7	90479771	CSEZCYBVEGIYNG-MFBWXLJUSA-N	Preclinical	excitatory amino acid transporter inhibitor	NA	NA
TC-A-2317	AURKA	24783396	XHHRGYCOEVNAKV-ZDUSSCGKSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
TC-ASK-10	MAP3K5	24944925	SMJAMOAYGIVKRI-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
TC-ASK-10	MAP3K6	24944925	SMJAMOAYGIVKRI-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
TC-E-5002	KDM2A	71735843	NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
TC-E-5002	KDM4A	71735843	NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
TC-E-5002	KDM4C	71735843	NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
TC-E-5002	KDM5A	71735843	NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
TC-E-5002	KDM6A	71735843	NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
TC-E-5002	KDM7A	71735843	NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
TC-E-5002	PHF8	71735843	NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	histone demethylase inhibitor	NA	NA
TC-E-5006	APP	97289132	ONYWALXTZFPKAS-WINIVTDRSA-N	Preclinical	gamma secretase modulator	NA	NA
TC-F-2	FAAH	25198728	NXTBLPPTZRPJCA-IBGZPJMESA-N	Preclinical	FAAH inhibitor	NA	NA
TC-FPR-43	FPR2	24776341	PAEBEUZTAPIOIO-UHFFFAOYSA-N	Preclinical	formyl peptide receptor agonist	NA	NA
TC-G-1000	ADRA2A	10220232	RLKWQKZPCMICPS-UHFFFAOYSA-N	Preclinical	adrenergic receptor agonist	NA	NA
TC-G-1000	ADRA2B	10220232	RLKWQKZPCMICPS-UHFFFAOYSA-N	Preclinical	adrenergic receptor agonist	NA	NA
TC-G-1000	ADRA2C	10220232	RLKWQKZPCMICPS-UHFFFAOYSA-N	Preclinical	adrenergic receptor agonist	NA	NA
TC-G-1004	ADORA2A	25074316	JENSDTKXNVHSSN-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
TC-G-1005	GPBAR1	71450251	JQULIQJSYPZQMA-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
TC-G-1008	GPR39	91826086	DRSZMILOMUPIBJ-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
TC-H-106	HDAC1	16070100	"InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25)"	Preclinical	HDAC inhibitor	NA	NA
TC-H-106	HDAC2	16070100	"InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25)"	Preclinical	HDAC inhibitor	NA	NA
TC-H-106	HDAC3	16070100	"InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25)"	Preclinical	HDAC inhibitor	NA	NA
TC-H-106	HDAC8	16070100	"InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25)"	Preclinical	HDAC inhibitor	NA	NA
TC-I-15	ITGA2	90488948	XKLHCUGVLCGKKX-RBUKOAKNSA-N	Preclinical	integrin inhibitor	NA	NA
TC-I-15	ITGB1	90488948	XKLHCUGVLCGKKX-RBUKOAKNSA-N	Preclinical	integrin inhibitor	NA	NA
TC-I-2000	TRPM8	57326391	ADCDUDFEGFKKQH-NRFANRHFSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
TC-I-2014	TRPM8	135883253	VSMFCZZEKTVDHM-UHFFFAOYSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
TC-LPA5-4	LPAR5	66552906	BNALUYKEGYUHQC-UHFFFAOYSA-N	Preclinical	lysophosphatidic acid receptor antagonist	NA	NA
TC-Mps1-12	TTK	70682875	XDEFNAWAKYQBQY-UHFFFAOYSA-N	Preclinical	monopolar spindle 1 kinase inhibitor	NA	NA
TC-N-1752	SCN9A	53361524	QLKAFHZJICDACE-UHFFFAOYSA-N	Preclinical	sodium channel blocker	NA	NA
TC-NTR1-17	NTSR1	44157038	ZQUSYVORYNBGLG-FQEVSTJZSA-N	Preclinical	neurotensin agonist	NA	NA
TC-O-9311	GPR139	3376937	KPTMSQHTGZMEFU-UHFFFAOYSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
TC-OT-39	AVPR1A	135413563	KSNHHKZYKYNBEI-NDEPHWFRSA-N	Preclinical	oxytocin receptor agonist|vasopressin receptor agonist	NA	NA
TC-OT-39	OXT	135413563	KSNHHKZYKYNBEI-NDEPHWFRSA-N	Preclinical	oxytocin receptor agonist|vasopressin receptor agonist	NA	NA
TC-S-7003	LCK	11785878	BHJJWVDKNXABFS-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
TC-S-7004	DYRK1A	57523919	CQKBSRPVZZLCJE-UHFFFAOYSA-N	Preclinical	DYRK inhibitor	NA	NA
TC-S-7004	DYRK1B	57523919	CQKBSRPVZZLCJE-UHFFFAOYSA-N	Preclinical	DYRK inhibitor	NA	NA
TC-S-7005	PLK2	24971422	DAAGOCSHXCDWDY-ZDUSSCGKSA-N	Preclinical	PLK inhibitor	NA	NA
TC-S-7006	MAP3K8	9549300	NMEUKWOOQOHUNA-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
TC-S-7009	EPAS1	70697712	CDQUJZKBRAFWNG-UHFFFAOYSA-N	Preclinical	hypoxia inducible factor inhibitor	NA	NA
TC-SP-14	S1PR1	51346934	GVXGVDIXINMAAL-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor agonist	NA	NA
TCN201	GRIN2A	4787937	FYIBXBFDXNPBSF-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
TCN238	GRM4	46911068	LNUXNUNUGIHCPA-VOTSOKGWSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
TCS-HDAC6-20b	HDAC6	23636017	DQZMLPMCOMRJOR-MOVGKWKRSA-N	Preclinical	HDAC inhibitor	NA	NA
TCS-OX2-29	HCRTR2	10408514	"InChI=1S/C23H31N3O3/c1-23(2,3)21(25-14-16-6-9-24-10-7-16)22(27)26-11-8-17-12-19(28-4)20(29-5)13-18(17)15-26/h6-7,9-10,12-13,21,25H,8,11,14-15H2,1-5H3/t21-/m1/s1"	Preclinical	orexin receptor antagonist	NA	NA
TCS-PIM-1-1	PIM1	1235170	SVSYJTYGPLVUOZ-UHFFFAOYSA-N	Preclinical	Pim kinase inhibitor	NA	NA
TCS-2002	GSK3B	44247646	RCKYSTKYIVULEK-DEOSSOPVSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
TCS-21311	JAK3	50925411	CLGRAWDGLMENOD-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
TCS-2314	ITGA4	11226207	ITXAAOWFOURIHK-DEOSSOPVSA-N	Preclinical	integrin inhibitor	NA	NA
TCS-2314	ITGB1	11226207	ITXAAOWFOURIHK-DEOSSOPVSA-N	Preclinical	integrin inhibitor	NA	NA
TCS-3035	GPR35	2295463	WXMCOLGPDOYHNK-UITAMQMPSA-N	Preclinical	G protein-coupled receptor agonist	NA	NA
TCS-359	FLT3	1048845	FSPQCTGGIANIJZ-UHFFFAOYSA-N	Preclinical	FLT3 inhibitor	NA	NA
TCS-5861528	TRPA1	1116244	ZUTUWJYMCADJHD-GFCCVEGCSA-N	Preclinical	transient receptor potential channel antagonist	NA	NA
TC1	BACE1	NA	"InChI=1S/C19H20FNO/c20-9-3-1-2-8(6-9)4-5-21-18-14-10-7-11-13-12(10)15(18)17(13)19(21,22)16(11)14/h1-3,6,10-18,22H,4-5,7H2/t10-,11+,12+,13-,14+,15+,16-,17+,18-,19-/m1/s1"	Preclinical	beta-secretase inhibitor	NA	NA
TC2559	CHRNA4	9823180	HFZDMKMXPGRKCK-GQCTYLIASA-N	Preclinical	acetylcholine receptor agonist	NA	NA
tebipenem	CNR1	9892071	SNUDIPVBUUXCDG-QHSBEEBCSA-N	Launched	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology	pneumonia|otitis
tecadenoson	ADORA1	158795	OESBDSFYJMDRJY-BAYCTPFLSA-N	Phase 2	adenosine receptor agonist	NA	NA
tecalcet	CASR	158797	ZVQUCWXZCKWZBP-CQSZACIVSA-N	Phase 2	calcium-sensing receptor agonist	NA	NA
tecastemizole	KCNH2	123618	SFOVDSLXFUGAIV-UHFFFAOYSA-N	Phase 3	histamine receptor antagonist	NA	NA
tegaserod	HTR2A	135409453	IKBKZGMPCYNSLU-RGVLZGJSSA-N	Withdrawn	serotonin receptor partial agonist	NA	NA
tegaserod	HTR2B	135409453	IKBKZGMPCYNSLU-RGVLZGJSSA-N	Withdrawn	serotonin receptor partial agonist	NA	NA
tegaserod	HTR2C	135409453	IKBKZGMPCYNSLU-RGVLZGJSSA-N	Withdrawn	serotonin receptor partial agonist	NA	NA
tegaserod	HTR4	135409453	IKBKZGMPCYNSLU-RGVLZGJSSA-N	Withdrawn	serotonin receptor partial agonist	NA	NA
teijin-compound-1	CCR2	44453327	BAOQJSULMWXFRK-GOSISDBHSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
telaprevir	CTSA	3010818	BBAWEDCPNXPBQM-GDEBMMAJSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
telaprevir	PGR	3010818	BBAWEDCPNXPBQM-GDEBMMAJSA-N	Launched	HCV inhibitor	infectious disease	hepatitis C
telatinib	KDR	9808844	QFCXANHHBCGMAS-UHFFFAOYSA-N	Phase 2	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
telcagepant	CALCRL	11319053	CGDZXLJGHVKVIE-DNVCBOLYSA-N	Phase 3	calcitonin antagonist	NA	NA
telcagepant	RAMP1	11319053	CGDZXLJGHVKVIE-DNVCBOLYSA-N	Phase 3	calcitonin antagonist	NA	NA
telenzepine	CHRM1	5387	VSWPGAIWKHPTKX-UHFFFAOYSA-N	Phase 3	acetylcholine receptor antagonist	NA	NA
telithromycin	CYP1A2	NA	LJVAJPDWBABPEJ-PIRKDXADSA-N	Launched	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia
telithromycin	CYP2D6	NA	LJVAJPDWBABPEJ-PIRKDXADSA-N	Launched	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia
telithromycin	CYP3A4	NA	LJVAJPDWBABPEJ-PIRKDXADSA-N	Launched	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia
telithromycin	CYP3A5	NA	LJVAJPDWBABPEJ-PIRKDXADSA-N	Launched	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia
telithromycin	CYP3A7	NA	LJVAJPDWBABPEJ-PIRKDXADSA-N	Launched	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia
telmisartan	AGTR1	65999	RMMXLENWKUUMAY-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
telmisartan	PPARG	65999	RMMXLENWKUUMAY-UHFFFAOYSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension
telotristat	TPH1	25025298	NCLGDOBQAWBXRA-PGRDOPGGSA-N	Launched	tryptophan hydroxylase inhibitor	gastroenterology	diarrhea
telotristat-ethyl	TPH1	25181577	MDSQOJYHHZBZKA-GBXCKJPGSA-N	Launched	tryptophan hydroxylase inhibitor	gastroenterology	diarrhea
temocapril	ACE	443874	FIQOFIRCTOWDOW-BJLQDIEVSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology|nephrology	hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD)
temozolomide	MGMT	5394	BPEGJWRSRHCHSN-UHFFFAOYSA-N	Launched	DNA alkylating agent	oncology	glioblastoma|astrocytoma
temsirolimus	MTOR	134812825	CBPNZQVSJQDFBE-NRNHWJPGSA-N	Launched	mTOR inhibitor	oncology	renal cell carcinoma (RCC)
tenatoprazole	IDO1	11552393	ZBFDAUIVDSSISP-DEOSSOPVSA-N	Phase 2	ATPase inhibitor	NA	NA
teneligliptin	DPP4	11949652	WGRQANOPCQRCME-PMACEKPBSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
tenidap	KCNJ4	NA	IGPDWKCUDHIIRL-LLVKDONJSA-N	Phase 3	cyclooxygenase inhibitor	NA	NA
tenidap	PTGS1	NA	IGPDWKCUDHIIRL-LLVKDONJSA-N	Phase 3	cyclooxygenase inhibitor	NA	NA
teniposide	TOP2A	452548	NRUKOCRGYNPUPR-QBPJDGROSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
teniposide	TOP2B	452548	NRUKOCRGYNPUPR-QBPJDGROSA-N	Launched	topoisomerase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
tenofovir-disoproxil	CYP1A2	5481350	JFVZFKDSXNQEJW-CQSZACIVSA-N	Launched	nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B
tenovin-1	SIRT1	1013376	WOWJIWFCOPZFGV-UHFFFAOYSA-N	Preclinical	SIRT inhibitor|TP53 activator	NA	NA
tenovin-6	SIRT1	24772043	BVJSXSQRIUSRCO-UHFFFAOYSA-N	Preclinical	SIRT inhibitor	NA	NA
tenovin-6	SIRT2	24772043	BVJSXSQRIUSRCO-UHFFFAOYSA-N	Preclinical	SIRT inhibitor	NA	NA
tenovin-6	SIRT3	24772043	BVJSXSQRIUSRCO-UHFFFAOYSA-N	Preclinical	SIRT inhibitor	NA	NA
tenoxicam	PTGS1	54677971	LZNWYQJJBLGYLT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis
tenoxicam	PTGS2	54677971	LZNWYQJJBLGYLT-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis
tepoxalin	ALOX5	59757	XYKWNRUXCOIMFZ-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|hip dysplasia
TEPP-46	PKM	60156291	ZWKJWVSEDISQIS-RUZDIDTESA-N	Preclinical	pyruvate kinase isozyme activator	NA	NA
terameprocol	BIRC5	476861	ORQFDHFZSMXRLM-IYBDPMFKSA-N	Phase 1/Phase 2	lipoxygenase inhibitor	NA	NA
terameprocol	CDK1	476861	ORQFDHFZSMXRLM-IYBDPMFKSA-N	Phase 1/Phase 2	lipoxygenase inhibitor	NA	NA
terazosin	ADRA1A	1398859	VCKUSRYTPJJLNI-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
terazosin	ADRA1B	1398859	VCKUSRYTPJJLNI-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
terazosin	ADRA1D	1398859	VCKUSRYTPJJLNI-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension
terbinafine	SQLE	1549008	DOMXUEMWDBAQBQ-WEVVVXLNSA-N	Launched	fungal squalene epoxidase inhibitor	infectious disease	tinea pedis|tinea cruris|tinea corporis
terbutaline	ADRB2	11354816	XWTYSIMOBUGWOL-LLVKDONJSA-N	Launched	adrenergic receptor agonist	pulmonary	bronchospasm|bronchitis|emphysema
terfenadine	HRH1	6604035	GUGOEEXESWIERI-PMERELPUSA-N	Withdrawn	histamine receptor antagonist	NA	NA
terfenadine	KCNH1	6604035	GUGOEEXESWIERI-PMERELPUSA-N	Withdrawn	histamine receptor antagonist	NA	NA
terfenadine	KCNH2	6604035	GUGOEEXESWIERI-PMERELPUSA-N	Withdrawn	histamine receptor antagonist	NA	NA
terguride	ADRA1A	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	ADRA2A	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	ADRA2B	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	ADRA2C	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	DRD2	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	DRD3	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	DRD4	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	HTR1A	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	HTR1B	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	HTR1D	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	HTR2A	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	HTR2B	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
terguride	HTR2C	443951	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	dopamine receptor agonist|serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
teriflunomide	DHODH	NA	NABQBYDEMLGCEO-SNVBAGLBSA-N	Launched	dihydroorotate dehydrogenase inhibitor	neurology/psychiatry	multiple sclerosis
terlipressin	AVPR1A	133566182	BENFXAYNYRLAIU-WBNRJDGRSA-N	Launched	vasopressin receptor agonist	cardiology	hypotension
terreic-acid-(-)	BTK	NA	NYFMSQHOGRWGFD-OOVQLBIQSA-N	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	NA	NA
terutroban	TBXA2R	9938840	HWEOXFSBSQIWSY-MRXNPFEDSA-N	Phase 3	prostanoid receptor antagonist	NA	NA
tesaglitazar	PPARA	208901	CXGTZJYQWSUFET-IBGZPJMESA-N	Phase 3	insulin sensitizer|PPAR receptor agonist	NA	NA
tesaglitazar	PPARG	208901	CXGTZJYQWSUFET-IBGZPJMESA-N	Phase 3	insulin sensitizer|PPAR receptor agonist	NA	NA
tetomilast	PDE4D	3025803	XDBHURGONHZNJF-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
tetrabenazine	SLC18A1	11634155	MKJIEFSOBYUXJB-HOCLYGCPSA-N	Launched	vesicular monoamine transporter inhibitor	infectious disease|neurology/psychiatry	cholera|Huntington's disease
tetrabenazine	SLC18A2	11634155	MKJIEFSOBYUXJB-HOCLYGCPSA-N	Launched	vesicular monoamine transporter inhibitor	infectious disease|neurology/psychiatry	cholera|Huntington's disease
tetracaine	SCN10A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN11A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN1A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN2A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN3A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN4A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN5A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN7A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN8A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracaine	SCN9A	5411	GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetraethylenepentamine	SOD1	8197	FAGUFWYHJQFNRV-UHFFFAOYSA-N	Phase 2/Phase 3	superoxide dismutase inhibitor	NA	NA
tetraethylenepentamine	SOD2	8197	FAGUFWYHJQFNRV-UHFFFAOYSA-N	Phase 2/Phase 3	superoxide dismutase inhibitor	NA	NA
tetrahydrofolic-acid	FOLR2	135398650	MSTNYGQPCMXVAQ-RYUDHWBXSA-N	Launched		NA	NA
tetrahydrouridine	CDA	9543506	UCKYOOZPSJFJIZ-FMDGEEDCSA-N	Phase 2	cytidine deaminase inhibitor	NA	NA
tetramisole	ALPPL2	26879	HLFSDGLLUJUHTE-SNVBAGLBSA-N	Launched	immunostimulant	infectious disease	gastrointestinal parasites
tetramisole	CHRNA3	26879	HLFSDGLLUJUHTE-SNVBAGLBSA-N	Launched	immunostimulant	infectious disease	gastrointestinal parasites
tetrandrine	SLC6A3	73078	WVTKBKWTSCPRNU-KYJUHHDHSA-N	Preclinical	calcium channel blocker	NA	NA
tetrazol-5-yl-glycine-(RS)	GRIN1	15024268	UKBRUIZWQZHXFL-PVQJCKRUSA-N	Preclinical	glutamate receptor agonist	NA	NA
tetrazol-5-yl-glycine-(RS)	GRIN2A	15024268	UKBRUIZWQZHXFL-PVQJCKRUSA-N	Preclinical	glutamate receptor agonist	NA	NA
tetrazol-5-yl-glycine-(RS)	GRIN2B	15024268	UKBRUIZWQZHXFL-PVQJCKRUSA-N	Preclinical	glutamate receptor agonist	NA	NA
tetrazol-5-yl-glycine-(RS)	GRIN2C	15024268	UKBRUIZWQZHXFL-PVQJCKRUSA-N	Preclinical	glutamate receptor agonist	NA	NA
tetrazol-5-yl-glycine-(RS)	GRIN2D	15024268	UKBRUIZWQZHXFL-PVQJCKRUSA-N	Preclinical	glutamate receptor agonist	NA	NA
tetrindole	MAOA	54792409	AUXCHYJDVJZEPG-UHFFFAOYSA-N	Phase 3	monoamine oxidase inhibitor	NA	NA
TFC-007	HPGDS	16040067	NLSSUSRERAMBTA-UHFFFAOYSA-N	Preclinical	prostaglandin inhibitor	NA	NA
TG-003	CLK1	1893668	BGVLELSCIHASRV-QPEQYQDCSA-N	Preclinical	CLK inhibitor	NA	NA
TG-003	CLK4	1893668	BGVLELSCIHASRV-QPEQYQDCSA-N	Preclinical	CLK inhibitor	NA	NA
TG-003	DYRK1A	1893668	BGVLELSCIHASRV-QPEQYQDCSA-N	Preclinical	CLK inhibitor	NA	NA
TG-003	DYRK1B	1893668	BGVLELSCIHASRV-QPEQYQDCSA-N	Preclinical	CLK inhibitor	NA	NA
TG-02	CDK1	16739650	VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
TG-02	CDK2	16739650	VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
TG-02	CDK7	16739650	VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
TG-02	CDK9	16739650	VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
TG-02	FLT3	16739650	VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
TG-02	JAK2	16739650	VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
TG-100572	KDR	11712625	AQSSMEORRLJZLU-UHFFFAOYSA-N	Preclinical	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-100572	SRC	11712625	AQSSMEORRLJZLU-UHFFFAOYSA-N	Preclinical	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-100801	CSK	11973736	JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-100801	FGFR1	11973736	JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-100801	FLT1	11973736	JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-100801	FLT4	11973736	JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-100801	KDR	11973736	JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-100801	SRC	11973736	JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2	SRC inhibitor|VEGFR inhibitor	NA	NA
TG-101209	JAK2	16722832	JVDOKQYTTYUYDV-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
TG-101209	JAK3	16722832	JVDOKQYTTYUYDV-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
TGX-221	PIK3CB	51601993	CPRAGQJXBLMUEL-MRXNPFEDSA-N	Preclinical	PI3K inhibitor	NA	NA
TGX-221	PIK3CD	51601993	CPRAGQJXBLMUEL-MRXNPFEDSA-N	Preclinical	PI3K inhibitor	NA	NA
TG100-115	PIK3CA	10427712	UJIAQDJKSXQLIT-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
TG100-115	PIK3CB	10427712	UJIAQDJKSXQLIT-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
TG100-115	PIK3CD	10427712	UJIAQDJKSXQLIT-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
TG100-115	PIK3CG	10427712	UJIAQDJKSXQLIT-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
TH-588	NUDT1	73389731	PNMYJIOQIAEYQL-UHFFFAOYSA-N	Preclinical	MTH1 inhibitor	NA	NA
thalidomide	TNF	92142	UEJJHQNACJXSKW-VIFPVBQESA-N	Launched	tumor necrosis factor production inhibitor	oncology	myeloma
theobromine	ADORA1	5429	YAPQBXQYLJRXSA-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	NA	NA
theobromine	ADORA2A	5429	YAPQBXQYLJRXSA-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	NA	NA
theobromine	PDE4B	5429	YAPQBXQYLJRXSA-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	NA	NA
thiamet-g	MGEA5	24808478	PPAIMZHKIXDJRN-FMDGEEDCSA-N	Preclinical	GLCNAC phosphotransferase inhibitor	NA	NA
thiamine	SLC19A2	1130	JZRWCGZRTZMZEH-UHFFFAOYSA-N	Launched	vitamin B	metabolism	thiamine deficiency
thiamine	SLC19A3	1130	JZRWCGZRTZMZEH-UHFFFAOYSA-N	Launched	vitamin B	metabolism	thiamine deficiency
thiamine	TPK1	1130	JZRWCGZRTZMZEH-UHFFFAOYSA-N	Launched	vitamin B	metabolism	thiamine deficiency
thiamylal	GABRA1	3033021	XLOMZPUITCYLMJ-MRVPVSSYSA-N	Launched	glutamate receptor antagonist	neurology/psychiatry	sedative
thiethylperazine	DRD1	5440	XCTYLCDETUVOIP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea
thiethylperazine	DRD2	5440	XCTYLCDETUVOIP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea
thiethylperazine	DRD4	5440	XCTYLCDETUVOIP-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	gastroenterology	nausea
thiocolchicoside	GABRA1	9915886	LEQAKWQJCITZNK-AXHKHJLKSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	muscle relaxant
thiocolchicoside	GABRB2	9915886	LEQAKWQJCITZNK-AXHKHJLKSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	muscle relaxant
thiocolchicoside	GABRG2	9915886	LEQAKWQJCITZNK-AXHKHJLKSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	muscle relaxant
thiocolchicoside	GLRA1	9915886	LEQAKWQJCITZNK-AXHKHJLKSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	muscle relaxant
thiocolchicoside	GLRB	9915886	LEQAKWQJCITZNK-AXHKHJLKSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	muscle relaxant
thioctic-acid	ACHE	445125	AGBQKNBQESQNJD-ZETCQYMHSA-N	Launched	reducing agent	nephrology	diabetic nephropathy
thioctic-acid	PTGS2	445125	AGBQKNBQESQNJD-ZETCQYMHSA-N	Launched	reducing agent	nephrology	diabetic nephropathy
thioguanine	IMPDH1	2723601	WYWHKKSPHMUBEB-UHFFFAOYSA-N	Launched	purine antagonist	hematologic malignancy	acute myeloid leukemia (AML)
thioguanine	IMPDH2	2723601	WYWHKKSPHMUBEB-UHFFFAOYSA-N	Launched	purine antagonist	hematologic malignancy	acute myeloid leukemia (AML)
thiomersal	OXCT1	67361	HXQVQGWHFRNKMS-UHFFFAOYSA-M	Launched	other antibiotic	infectious disease	preservative
thiopental	FAAH	3033017	IUJDSEJGGMCXSG-SSDOTTSWSA-N	Launched	GABA receptor antagonist	neurology/psychiatry	anesthetic
thioperamide	HRH3	6604452	JFAYRTHYLOZRNL-CQSZACIVSA-N	Preclinical	histamine receptor antagonist	NA	NA
thioperamide	HRH4	6604452	JFAYRTHYLOZRNL-CQSZACIVSA-N	Preclinical	histamine receptor antagonist	NA	NA
thioproperazine	ADRA1A	9429	VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thioproperazine	ADRA1B	9429	VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thioproperazine	DRD1	9429	VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thioproperazine	DRD2	9429	VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thioproperazine	HTR1A	9429	VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thioproperazine	HTR2A	9429	VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thioridazine	DRD1	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	DRD2	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	DRD3	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	DRD4	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	DRD5	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	HRH1	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	HTR1A	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	HTR2A	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	HTR2C	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	HTR6	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thioridazine	HTR7	66062	KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	dopamine receptor antagonist	NA	NA
thiorphan	MME	4369380	LJJKNPQAGWVLDQ-SNVBAGLBSA-N	Phase 1	membrane metalloendopeptidase inhibitor	NA	NA
thiostrepton	FOXM1	16154490	NSFFHOGKXHRQEW-AIHSUZKVSA-N	Launched	FOXM1 inhibitor|protein synthesis inhibitor	obstetrics/gynecology	mastitis
thiotepa	CYP2B6	5453	FOCVUCIESVLUNU-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor	oncology	breast cancer|ovarian cancer|bladder cancer
thiotepa	CYP3A4	5453	FOCVUCIESVLUNU-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor	oncology	breast cancer|ovarian cancer|bladder cancer
thiothixene	DRD1	941651	GFBKORZTTCHDGY-UWVJOHFNSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thiothixene	DRD2	941651	GFBKORZTTCHDGY-UWVJOHFNSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thiothixene	HRH1	941651	GFBKORZTTCHDGY-UWVJOHFNSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thiothixene	HTR2A	941651	GFBKORZTTCHDGY-UWVJOHFNSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thiram	JAK2	5455	KUAZQDVKQLNFPE-UHFFFAOYSA-N	Launched		ophthalmology	contact dermatitis
thymol	TRPA1	6989	MGSRCZKZVOBKFT-UHFFFAOYSA-N	Launched	GABA receptor positive allosteric modulator	infectious disease	ringworm|antiseptic
THZ1	CDK7	73602827	OBJNFLYHUXWUPF-IZZDOVSWSA-N	Preclinical	CDK inhibitor	NA	NA
THZ1-R	CDK7	119081415	TUERFPPIPKZNKE-UHFFFAOYSA-N	Preclinical	CDK inhibitor	NA	NA
THZ2	CDK7	78357763	FONRCZUZCHXWBD-VGOFMYFVSA-N	Preclinical	CDK inhibitor	NA	NA
tiagabine	SLC6A1	60648	PBJUNZJWGZTSKL-MRXNPFEDSA-N	Launched	GABA uptake inhibitor	neurology/psychiatry	seizures
tianeptine	OPRD1	37888263	JICJBGPOMZQUBB-OAQYLSRUSA-N	Launched	selective serotonin reuptake enhancer (SSRE)	neurology/psychiatry|pulmonary|gastroenterology	depression|asthma|irritable bowel syndrome
tianeptine	OPRK1	37888263	JICJBGPOMZQUBB-OAQYLSRUSA-N	Launched	selective serotonin reuptake enhancer (SSRE)	neurology/psychiatry|pulmonary|gastroenterology	depression|asthma|irritable bowel syndrome
tianeptine	OPRM1	37888263	JICJBGPOMZQUBB-OAQYLSRUSA-N	Launched	selective serotonin reuptake enhancer (SSRE)	neurology/psychiatry|pulmonary|gastroenterology	depression|asthma|irritable bowel syndrome
tiapride	DRD2	5467	JTVPZMFULRWINT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	dyskinesia|abstinence from alcohol|psychosis
tiapride	DRD3	5467	JTVPZMFULRWINT-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	dyskinesia|abstinence from alcohol|psychosis
tiaprofenic-acid	PTGS2	181380	GUHPRPJDBZHYCJ-SECBINFHSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis
tibolone	ESR1	124484332	WZDGZWOAQTVYBX-TZTUDTKPSA-N	Launched	androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist	obstetrics/gynecology	endometriosis
ticagrelor	P2RY12	9871419	OEKWJQXRCDYSHL-FNOIDJSQSA-N	Launched	purinergic receptor antagonist	cardiology	acute coronary syndrome (ACS)|myocardial infarction
ticlopidine	P2RY12	5472	PHWBOXQYWZNQIN-UHFFFAOYSA-N	Launched	purinergic receptor antagonist	hematology|neurology/psychiatry	thrombosis|stroke
TIC10	AKT1	336423	RSAQARAFWMUYLL-UHFFFAOYSA-N	Phase 2	AKT inhibitor|TRAIL modulator	NA	NA
TIC10	MAPK1	336423	RSAQARAFWMUYLL-UHFFFAOYSA-N	Phase 2	AKT inhibitor|TRAIL modulator	NA	NA
tideglusib	GSK3B	11313622	PMJIHLSCWIDGMD-UHFFFAOYSA-N	Phase 2	glycogen synthase kinase inhibitor	NA	NA
tienilic-acid	CYP2C9	38409	AGHANLSBXUWXTB-UHFFFAOYSA-N	Withdrawn	cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor	NA	NA
tienilic-acid	SLC12A1	38409	AGHANLSBXUWXTB-UHFFFAOYSA-N	Withdrawn	cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor	NA	NA
tie2-kinase-inhibitor	KDR	92852530	SINQIEAULQKUPD-JGCGQSQUSA-N	Preclinical	TIE tyrosine kinase inhibitor	NA	NA
tie2-kinase-inhibitor	MAPK14	92852530	SINQIEAULQKUPD-JGCGQSQUSA-N	Preclinical	TIE tyrosine kinase inhibitor	NA	NA
tifenazoxide	ABCC8	135410911	KYSFUHHFTIGRJN-UHFFFAOYSA-N	Phase 1	ATP-sensitive potassium channel agonist	NA	NA
tifenazoxide	KCNJ11	135410911	KYSFUHHFTIGRJN-UHFFFAOYSA-N	Phase 1	ATP-sensitive potassium channel agonist	NA	NA
tiludronate	ATP6V1A	60937	DKJJVAGXPKPDRL-UHFFFAOYSA-N	Launched	bone resorption inhibitor|osteoclast inhibitor	orthopedics	navicular syndrome
tiludronate	MMP2	60937	DKJJVAGXPKPDRL-UHFFFAOYSA-N	Launched	bone resorption inhibitor|osteoclast inhibitor	orthopedics	navicular syndrome
tiludronate	PTPN1	60937	DKJJVAGXPKPDRL-UHFFFAOYSA-N	Launched	bone resorption inhibitor|osteoclast inhibitor	orthopedics	navicular syndrome
timofibrate	LPL	51371472	QSNOWCXXECLALL-LLVKDONJSA-N	Phase 2	cholesterol inhibitor|lipase clearing factor inhibitor	NA	NA
timolol	ADRB1	33624	BLJRIMJGRPQVNF-JTQLQIEISA-N	Launched	adrenergic receptor antagonist	ophthalmology	ocular hypertension|glaucoma
timolol	ADRB2	33624	BLJRIMJGRPQVNF-JTQLQIEISA-N	Launched	adrenergic receptor antagonist	ophthalmology	ocular hypertension|glaucoma
tiotidine	HRH2	50287	YDDXVAXDYKBWDX-UHFFFAOYSA-N	Phase 2	histamine receptor antagonist	NA	NA
tiotropium	CHRM1	NA	LERNTVKEWCAPOY-DZZGSBJMSA-N	Launched	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
tiotropium	CHRM2	NA	LERNTVKEWCAPOY-DZZGSBJMSA-N	Launched	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
tiotropium	CHRM3	NA	LERNTVKEWCAPOY-DZZGSBJMSA-N	Launched	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
tioxolone	CA2	72139	SLYPOVJCSQHITR-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
tipifarnib	FNTA	159324	"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1"	Phase 3	farnesyltransferase inhibitor	NA	NA
tipifarnib	FNTB	159324	"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1"	Phase 3	farnesyltransferase inhibitor	NA	NA
tiplaxtinin	SERPINE1	6450819	ODXQFEWQSHNQNI-UHFFFAOYSA-N	Phase 1	plasminogen activator inhibitor	NA	NA
tiprenolol	ADRB1	76966339	CSUNLSYSEQIDMO-NSHDSACASA-N	Phase 2	adrenergic receptor antagonist	NA	NA
tiprenolol	ADRB2	76966339	CSUNLSYSEQIDMO-NSHDSACASA-N	Phase 2	adrenergic receptor antagonist	NA	NA
tiprenolol	ADRB3	76966339	CSUNLSYSEQIDMO-NSHDSACASA-N	Phase 2	adrenergic receptor antagonist	NA	NA
tiracizine	SCN5A	71264	KJAMZCVTJDTESW-UHFFFAOYSA-N	Withdrawn	sodium channel blocker	NA	NA
tiratricol	THRA	5803	UOWZUVNAGUAEQC-UHFFFAOYSA-N	Launched	thyroid hormone stimulant	endocrinology	Refetoff syndrome
tiratricol	THRB	5803	UOWZUVNAGUAEQC-UHFFFAOYSA-N	Launched	thyroid hormone stimulant	endocrinology	Refetoff syndrome
tirofiban	ITGA2B	60947	COKMIXFXJJXBQG-NRFANRHFSA-N	Launched	platelet aggregation inhibitor|structural glycoprotein antagonist	cardiology	myocardial infarction|refactory angina
tirofiban	ITGB3	60947	COKMIXFXJJXBQG-NRFANRHFSA-N	Launched	platelet aggregation inhibitor|structural glycoprotein antagonist	cardiology	myocardial infarction|refactory angina
tivantinib	MET	11494412	UCEQXRCJXIVODC-PMACEKPBSA-N	Phase 3	tyrosine kinase inhibitor	NA	NA
tivozanib	FLT1	9911830	SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched	VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
tivozanib	FLT4	9911830	SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched	VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
tivozanib	KDR	9911830	SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched	VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
tivozanib	KIT	9911830	SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched	VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
tivozanib	PDGFRA	9911830	SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched	VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
tivozanib	PDGFRB	9911830	SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched	VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
tizanidine	ADRA2A	5487	XFYDIVBRZNQMJC-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	spasms
tizanidine	ADRA2B	5487	XFYDIVBRZNQMJC-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	spasms
tizanidine	ADRA2C	5487	XFYDIVBRZNQMJC-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	spasms
tizanidine	NISCH	5487	XFYDIVBRZNQMJC-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	spasms
TMN-355	PPIA	44249042	SFNLLCUAISZNRV-UHFFFAOYSA-N	Preclinical	cyclophilin inhibitor	NA	NA
TNP-470	METAP2	369976	MSHZHSPISPJWHW-PVDLLORBSA-N	Phase 2	methionine aminopeptidase inhibitor	NA	NA
tocainide	SCN5A	3080825	BUJAGSGYPOAWEI-SECBINFHSA-N	Launched	sodium channel blocker	cardiology	cardiac arrythmia
toceranib	FLT1	5329106	SRSGVKWWVXWSJT-ATVHPVEESA-N	Launched	protein tyrosine kinase inhibitor	oncology	cutaneous mast cell tumors
toceranib	FLT3	5329106	SRSGVKWWVXWSJT-ATVHPVEESA-N	Launched	protein tyrosine kinase inhibitor	oncology	cutaneous mast cell tumors
toceranib	KDR	5329106	SRSGVKWWVXWSJT-ATVHPVEESA-N	Launched	protein tyrosine kinase inhibitor	oncology	cutaneous mast cell tumors
toceranib	PDGFRA	5329106	SRSGVKWWVXWSJT-ATVHPVEESA-N	Launched	protein tyrosine kinase inhibitor	oncology	cutaneous mast cell tumors
toceranib	PDGFRB	5329106	SRSGVKWWVXWSJT-ATVHPVEESA-N	Launched	protein tyrosine kinase inhibitor	oncology	cutaneous mast cell tumors
tofacitinib	JAK1	9926791	UJLAWZDWDVHWOW-YPMHNXCESA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
tofacitinib	JAK2	9926791	UJLAWZDWDVHWOW-YPMHNXCESA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
tofacitinib	JAK3	9926791	UJLAWZDWDVHWOW-YPMHNXCESA-N	Launched	JAK inhibitor	rheumatology	rheumatoid arthritis
tofisopam	CYP3A4	129009868	LOUZDJSQOFXLAP-UHFFFAOYSA-N	Launched	cytochrome P450 inhibitor|phosphodiesterase inhibitor	neurology/psychiatry	anxiety|abstinence from alcohol
tofogliflozin	GCK	46908929	VWVKUNOPTJGDOB-BDHVOXNPSA-N	Launched	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
tolamolol	ADRB1	66743765	SKQDKFOTIPJUSV-INIZCTEOSA-N	Phase 3	adrenergic receptor antagonist	NA	NA
tolamolol	ADRB2	66743765	SKQDKFOTIPJUSV-INIZCTEOSA-N	Phase 3	adrenergic receptor antagonist	NA	NA
tolamolol	ADRB3	66743765	SKQDKFOTIPJUSV-INIZCTEOSA-N	Phase 3	adrenergic receptor antagonist	NA	NA
tolazamide	ABCC8	5503	OUDSBRTVNLOZBN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolazamide	KCNJ1	5503	OUDSBRTVNLOZBN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolazamide	KCNJ10	5503	OUDSBRTVNLOZBN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolazamide	KCNJ11	5503	OUDSBRTVNLOZBN-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolazoline	ADRA1A	5504	JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
tolazoline	ADRA2A	5504	JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
tolazoline	ADRA2B	5504	JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
tolazoline	ADRA2C	5504	JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
tolazoline	HRH1	5504	JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
tolazoline	HRH2	5504	JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
tolbutamide	ABCC8	5505	JLRGJRBPOGGCBT-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolbutamide	KCNJ1	5505	JLRGJRBPOGGCBT-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolbutamide	KCNJ11	5505	JLRGJRBPOGGCBT-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolbutamide	KCNJ8	5505	JLRGJRBPOGGCBT-UHFFFAOYSA-N	Launched	ATP channel blocker	endocrinology	diabetes mellitus
tolcapone	COMT	4659569	MIQPIUSUKVNLNT-UHFFFAOYSA-N	Withdrawn	catechol O methyltransferase inhibitor	NA	NA
tolimidone	LYN	39065	HJQILFPVRNHTIG-UHFFFAOYSA-N	Phase 2	SRC activator	NA	NA
tolimidone	SRC	39065	HJQILFPVRNHTIG-UHFFFAOYSA-N	Phase 2	SRC activator	NA	NA
tolmetin	PTGS1	5509	UPSPUYADGBWSHF-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
tolmetin	PTGS2	5509	UPSPUYADGBWSHF-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis|osteoarthritis
tolonidine	ADRA2A	72138	KWBTZIFLQYYPTH-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	NA	NA
toloxatone	MAOA	13753599	MXUNKHLAEDCYJL-JTQLQIEISA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
toloxatone	MAOB	13753599	MXUNKHLAEDCYJL-JTQLQIEISA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
tolperisone	CYP2C19	688589	FSKFPVLPFLJRQB-AWEZNQCLSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry|infectious disease|rheumatology|cardiology	muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease
tolperisone	CYP2D6	688589	FSKFPVLPFLJRQB-AWEZNQCLSA-N	Launched	voltage-gated sodium channel blocker	neurology/psychiatry|infectious disease|rheumatology|cardiology	muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease
tolrestat	AKR1A1	53359	LUBHDINQXIHVLS-UHFFFAOYSA-N	Withdrawn	aldose reductase inhibitor	NA	NA
tolrestat	AKR1B1	53359	LUBHDINQXIHVLS-UHFFFAOYSA-N	Withdrawn	aldose reductase inhibitor	NA	NA
tolrestat	AKR1B10	53359	LUBHDINQXIHVLS-UHFFFAOYSA-N	Withdrawn	aldose reductase inhibitor	NA	NA
tolterodine	CHRM1	443879	OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
tolterodine	CHRM2	443879	OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
tolterodine	CHRM3	443879	OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
tolterodine	CHRM4	443879	OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
tolterodine	CHRM5	443879	OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
tolvaptan	AVPR1A	443894	GYHCTFXIZSNGJT-XMMPIXPASA-N	Launched	vasopressin receptor antagonist	endocrinology|cardiology|gastroenterology	hyponatremia|congestive heart failure|hepatic cirrhosis
tolvaptan	AVPR2	443894	GYHCTFXIZSNGJT-XMMPIXPASA-N	Launched	vasopressin receptor antagonist	endocrinology|cardiology|gastroenterology	hyponatremia|congestive heart failure|hepatic cirrhosis
tomelukast	CYSLTR1	3969	MWYHLEQJTQJHSS-UHFFFAOYSA-N	Phase 3	leukotriene receptor antagonist	NA	NA
topiramate	CA1	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	CA12	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	CA2	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	CA4	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	CA7	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRA1	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRA2	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRA3	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRA4	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRA5	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRA6	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRB1	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRB2	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRB3	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRD	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRE	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRG1	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRG2	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRG3	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRP	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GABRQ	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIA1	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIA2	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIA3	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIA4	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIK1	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIK2	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIK3	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIK4	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	GRIK5	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN10A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN11A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN1A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN2A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN3A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN4A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN5A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN7A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN8A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiramate	SCN9A	5284627	KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry	epilepsy|migraine headache
topiroxostat	XDH	5288320	UBVZQGOVTLIHLH-UHFFFAOYSA-N	Launched	xanthine oxidase inhibitor	rheumatology|nephrology	gout|hyperuricemia
topotecan	TOP1	60700	UCFGDBYHRUNTLO-QHCPKHFHSA-N	Launched	topoisomerase inhibitor	oncology	small cell lung cancer|cervical cancer
topotecan	TOP1MT	60700	UCFGDBYHRUNTLO-QHCPKHFHSA-N	Launched	topoisomerase inhibitor	oncology	small cell lung cancer|cervical cancer
torasemide	SLC12A1	51371498	NGBFQHCMQULJNZ-UHFFFAOYSA-N	Launched	electrolyte reabsorption inhibitor|thromboxane receptor antagonist	cardiology	edema|congestive heart failure|hypertension
torcetrapib	CETP	159325	CMSGWTNRGKRWGS-NQIIRXRSSA-N	Phase 3	cholesteryl ester transfer protein inhibitor	NA	NA
torcitabine	DCK	13711	CKTSBUTUHBMZGZ-SHYZEUOFSA-N	Phase 2	DNA polymerase inhibitor	NA	NA
torcitabine	TK2	13711	CKTSBUTUHBMZGZ-SHYZEUOFSA-N	Phase 2	DNA polymerase inhibitor	NA	NA
toremifene	ESR1	3005573	XFCLJVABOIYOMF-QPLCGJKRSA-N	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer
torin-1	MTOR	49836027	AKCRNFFTGXBONI-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
torin-2	MTOR	51358113	GUXXEUUYCAYESJ-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
tosedostat	ANPEP	15547703	FWFGIHPGRQZWIW-SQNIBIBYSA-N	Phase 2	peptidase inhibitor	NA	NA
tosedostat	LAP3	15547703	FWFGIHPGRQZWIW-SQNIBIBYSA-N	Phase 2	peptidase inhibitor	NA	NA
tosedostat	NPEPPS	15547703	FWFGIHPGRQZWIW-SQNIBIBYSA-N	Phase 2	peptidase inhibitor	NA	NA
toyocamycin	ERN1	11824	XOKJUSAYZUAMGJ-WOUKDFQISA-N	Phase 1	serine/threonine kinase inhibitor	NA	NA
tozadenant	ADORA2A	11618368	XNBRWUQWSKXMPW-UHFFFAOYSA-N	Phase 3	adenosine receptor antagonist	NA	NA
tozasertib	AURKA	5494449	GCIKSSRWRFVXBI-UHFFFAOYSA-N	Phase 2	Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
tozasertib	AURKB	5494449	GCIKSSRWRFVXBI-UHFFFAOYSA-N	Phase 2	Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
tozasertib	AURKC	5494449	GCIKSSRWRFVXBI-UHFFFAOYSA-N	Phase 2	Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
tozasertib	LCK	5494449	GCIKSSRWRFVXBI-UHFFFAOYSA-N	Phase 2	Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor	NA	NA
TP-003	GABRA1	10001434	SJMMDWXJSSJHOQ-UHFFFAOYSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
TP-003	GABRA2	10001434	SJMMDWXJSSJHOQ-UHFFFAOYSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
TP-003	GABRA3	10001434	SJMMDWXJSSJHOQ-UHFFFAOYSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
TP-003	GABRA5	10001434	SJMMDWXJSSJHOQ-UHFFFAOYSA-N	Preclinical	GABA receptor inverse agonist	NA	NA
TP-0903	AXL	56839178	YUAALFPUEOYPNX-UHFFFAOYSA-N	Phase 1/Phase 2	AXL kinase inhibitor	NA	NA
TPCA-1	IKBKB	9903786	SAYGKHKXGCPTLX-UHFFFAOYSA-N	Preclinical	IKK inhibitor	NA	NA
tracazolate	GABRA1	5522	PCTRYMLLRKWXGF-UHFFFAOYSA-N	Phase 2	GABA receptor modulator	NA	NA
TRAM-34	KCNN4	656734	KBFUQFVFYYBHBT-UHFFFAOYSA-N	Preclinical	potassium channel antagonist	NA	NA
TRAM-39	KCNN4	9861261	JHNRTPKGSCVKKC-UHFFFAOYSA-N	Preclinical	calcium-activated potassium channel activator	NA	NA
trametinib	MAP2K1	11707110	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	Launched	MEK inhibitor	oncology	melanoma
trametinib	MAP2K2	11707110	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	Launched	MEK inhibitor	oncology	melanoma
tramiprosate	APP	6991996	SNKZJIOFVMKAOJ-UHFFFAOYSA-N	Phase 3	beta amyloid protein neurotoxicity inhibitor	NA	NA
trandolapril	ACE	5484727	VXFJYXUZANRPDJ-WTNASJBWSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension|myocardial infarction
tranexamic-acid	PLG		GYDJEQRTZSCIOI-LJGSYFOKSA-N	Launched	antifibrinolytic|plasminogen activator inhibitor	hematology	hemophilia
tranilast	HPGDS	5282230	NZHGWWWHIYHZNX-CSKARUKUSA-N	Launched	angiogenesis inhibitor	pulmonary	asthma
tranilast	HRH1	5282230	NZHGWWWHIYHZNX-CSKARUKUSA-N	Launched	angiogenesis inhibitor	pulmonary	asthma
tranylcypromine	KDM1A	26070	AELCINSCMGFISI-BDAKNGLRSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
tranylcypromine	MAOA	26070	AELCINSCMGFISI-BDAKNGLRSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
tranylcypromine	MAOB	26070	AELCINSCMGFISI-BDAKNGLRSA-N	Launched	monoamine oxidase inhibitor	neurology/psychiatry	depression
trap-101	OPRL1	11494970	DCRGHMJXEBSRQG-UHFFFAOYSA-N	Preclinical	nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist	NA	NA
trapidil	PDGFRA	5531	GSNOZLZNQMLSKJ-UHFFFAOYSA-N	Launched	PDGFR tyrosine kinase receptor inhibitor	cardiology	coronary artery disease (CAD)
travoprost	PTGFR	5282226	MKPLKVHSHYCHOC-AHTXBMBWSA-N	Launched	prostanoid receptor agonist	ophthalmology	ocular hypertension|glaucoma
traxoprodil	GRIN2B	219101	QEMSVZNTSXPFJA-HNAYVOBHSA-N	Phase 2	glutamate receptor antagonist	NA	NA
trazodone	ADRA1A	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trazodone	ADRA2A	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trazodone	HRH1	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trazodone	HTR1A	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trazodone	HTR2A	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trazodone	HTR2B	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trazodone	HTR2C	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trazodone	SLC6A4	5533	PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression
trelagliptin	DPP4	15983988	IWYJYHUNXVAVAA-OAHLLOKOSA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
trepibutone	CHRM1	5536	YPTFHLJNWSJXKG-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	gastroenterology	irritable bowel syndrome
trepibutone	CHRM2	5536	YPTFHLJNWSJXKG-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	gastroenterology	irritable bowel syndrome
trepibutone	CHRM3	5536	YPTFHLJNWSJXKG-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	gastroenterology	irritable bowel syndrome
trepibutone	CHRM4	5536	YPTFHLJNWSJXKG-UHFFFAOYSA-N	Launched	cholinergic receptor antagonist	gastroenterology	irritable bowel syndrome
treprostinil	P2RY12	6918140	PAJMKGZZBBTTOY-ZFORQUDYSA-N	Launched	prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
treprostinil	PPARD	6918140	PAJMKGZZBBTTOY-ZFORQUDYSA-N	Launched	prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
treprostinil	PTGIR	6918140	PAJMKGZZBBTTOY-ZFORQUDYSA-N	Launched	prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
trequinsin	PDE5A	NA	MCMSJVMUSBZUCN-YYDJUVGSSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
tretazicar	NQO2	89105	WOCXQMCIOTUMJV-UHFFFAOYSA-N	Phase 2	DNA replication inhibitor	NA	NA
tretinoin	ALDH1A1	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	ALDH1A2	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	GPRC5A	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	NR0B1	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	NR2C2	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	PPARD	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RARA	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RARB	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RARG	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RARRES1	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RORB	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RORC	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RXRB	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
tretinoin	RXRG	444795	SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
triamcinolone	NR3C1	31307	GFNANZIMVAIWHM-OBYCQNJPSA-N	Launched	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
triamcinolone-acetonide	NR3C1	6436	YNDXUCZADRHECN-JNQJZLCISA-N	Launched	glucocorticoid receptor agonist|immunosuppressant	dermatology	corticosteroid-responsive dermatoses
triamcinolone-acetonide	SERPINA6	6436	YNDXUCZADRHECN-JNQJZLCISA-N	Launched	glucocorticoid receptor agonist|immunosuppressant	dermatology	corticosteroid-responsive dermatoses
triamterene	SCNN1A	5546	FNYLWPVRPXGIIP-UHFFFAOYSA-N	Launched	sodium channel blocker	endocrinology|cardiology	hypokalemia|hypertension|edema
triamterene	SCNN1B	5546	FNYLWPVRPXGIIP-UHFFFAOYSA-N	Launched	sodium channel blocker	endocrinology|cardiology	hypokalemia|hypertension|edema
triamterene	SCNN1D	5546	FNYLWPVRPXGIIP-UHFFFAOYSA-N	Launched	sodium channel blocker	endocrinology|cardiology	hypokalemia|hypertension|edema
triamterene	SCNN1G	5546	FNYLWPVRPXGIIP-UHFFFAOYSA-N	Launched	sodium channel blocker	endocrinology|cardiology	hypokalemia|hypertension|edema
triapine	RRM1	9571836	XMYKNCNAZKMVQN-NYYWCZLTSA-N	Phase 2	ribonucleotide reductase inhibitor	NA	NA
triapine	RRM2	9571836	XMYKNCNAZKMVQN-NYYWCZLTSA-N	Phase 2	ribonucleotide reductase inhibitor	NA	NA
trichlormethiazide	PTGS1	12444480	LMJSLTNSBFUCMU-QMMMGPOBSA-N	Launched	chloride channel blocker	cardiology	hypertension|edema
trichlormethiazide	PTGS2	12444480	LMJSLTNSBFUCMU-QMMMGPOBSA-N	Launched	chloride channel blocker	cardiology	hypertension|edema
trichlormethiazide	SLC12A1	12444480	LMJSLTNSBFUCMU-QMMMGPOBSA-N	Launched	chloride channel blocker	cardiology	hypertension|edema
trichostatin-a	HDAC1	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC10	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC2	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC3	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC4	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC5	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC6	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC7	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC8	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
trichostatin-a	HDAC9	444732	RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	HDAC inhibitor	NA	NA
triciribine	AKT1	65399	HOGVTUZUJGHKPL-HTVVRFAVSA-N	Phase 1/Phase 2	AKT inhibitor	NA	NA
triciribine	AKT2	65399	HOGVTUZUJGHKPL-HTVVRFAVSA-N	Phase 1/Phase 2	AKT inhibitor	NA	NA
triciribine	AKT3	65399	HOGVTUZUJGHKPL-HTVVRFAVSA-N	Phase 1/Phase 2	AKT inhibitor	NA	NA
triclabendazole	DNMT1	50248	NQPDXQQQCQDHHW-UHFFFAOYSA-N	Launched	microtubule inhibitor	infectious disease	tapeworm
triclosan	DNMT1	5564	XEFQLINVKFYRCS-UHFFFAOYSA-N	Launched	antibacterial agent	infectious disease	first-aid antiseptic
trientine	CA14	5565	VILCJCGEZXAXTO-UHFFFAOYSA-N	Launched	chelating agent	metabolism	Wilson's disease
trifluoperazine	ADRA1A	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	CALM1	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	CALY	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	DRD2	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	DRD4	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	HRH1	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	HTR2A	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	HTR2C	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	S100A4	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
trifluoperazine	TNNC1	5566	ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
triflupromazine	CHRM1	5568	XSCGXQMFQXDFCW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting
triflupromazine	CHRM2	5568	XSCGXQMFQXDFCW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting
triflupromazine	DRD1	5568	XSCGXQMFQXDFCW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting
triflupromazine	DRD2	5568	XSCGXQMFQXDFCW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting
triflupromazine	HTR2B	5568	XSCGXQMFQXDFCW-UHFFFAOYSA-N	Launched	dopamine receptor antagonist	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting
trifluridine	TYMS	6256	VSQQQLOSPVPRAZ-RRKCRQDMSA-N	Launched	DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor	infectious disease	virus herpes simplex (HSV)
triflusal	NFKB1	9458	RMWVZGDJPAKBDE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)
triflusal	NOS2	9458	RMWVZGDJPAKBDE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)
triflusal	PDE10A	9458	RMWVZGDJPAKBDE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)
triflusal	PTGS1	9458	RMWVZGDJPAKBDE-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)
trihexyphenidyl	CHRM1	207845	HWHLPVGTWGOCJO-HXUWFJFHSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	parkinsonism
trimebutine	OPRD1	13248159	LORDFXWUHHSAQU-JOCHJYFZSA-N	Launched	opioid receptor agonist	gastroenterology	irritable bowel syndrome
trimebutine	OPRK1	13248159	LORDFXWUHHSAQU-JOCHJYFZSA-N	Launched	opioid receptor agonist	gastroenterology	irritable bowel syndrome
trimebutine	OPRM1	13248159	LORDFXWUHHSAQU-JOCHJYFZSA-N	Launched	opioid receptor agonist	gastroenterology	irritable bowel syndrome
trimetazidine	ACAA2	21109	UHWVSEOVJBQKBE-UHFFFAOYSA-N	Launched	3-ketoacyl CoA thiolase inhibitor	cardiology	angina pectoris
trimethadione	CACNA1G	5576	IRYJRGCIQBGHIV-UHFFFAOYSA-N	Launched	oxazolidine antiepileptic	neurology/psychiatry	seizures
trimethadione	CACNA1H	5576	IRYJRGCIQBGHIV-UHFFFAOYSA-N	Launched	oxazolidine antiepileptic	neurology/psychiatry	seizures
trimethadione	CACNA1I	5576	IRYJRGCIQBGHIV-UHFFFAOYSA-N	Launched	oxazolidine antiepileptic	neurology/psychiatry	seizures
trimethobenzamide	DRD2	5577	FEZBIKUBAYAZIU-UHFFFAOYSA-N	Launched	histamine receptor antagonist	gastroenterology	vomiting|nausea|gastroenteritis
trimethoprim	DHFR	5578	IEDVJHCEMCRBQM-UHFFFAOYSA-N	Launched	dihydrofolate reductase inhibitor	infectious disease|gastroenterology	urinary tract infections|ear infections|diarrhea
trimethoprim	TYMS	5578	IEDVJHCEMCRBQM-UHFFFAOYSA-N	Launched	dihydrofolate reductase inhibitor	infectious disease|gastroenterology	urinary tract infections|ear infections|diarrhea
trimethoquinol	ADRB2	12224034	RGVPOXRFEPSFGH-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	pulmonary	asthma
trimethoquinol	ADRB3	12224034	RGVPOXRFEPSFGH-CQSZACIVSA-N	Launched	adrenergic receptor antagonist	pulmonary	asthma
trimetrexate	DHFR	5583	NOYPYLRCIDNJJB-UHFFFAOYSA-N	Phase 3	dihydrofolate reductase inhibitor	NA	NA
trimipramine	SLC6A2	6604024	ZSCDBOWYZJWBIY-INIZCTEOSA-N	Launched	norepinephrine reputake inhibitor|tricyclic antidepressant	neurology/psychiatry	depression
trimipramine	SLC6A3	6604024	ZSCDBOWYZJWBIY-INIZCTEOSA-N	Launched	norepinephrine reputake inhibitor|tricyclic antidepressant	neurology/psychiatry	depression
trimipramine	SLC6A4	6604024	ZSCDBOWYZJWBIY-INIZCTEOSA-N	Launched	norepinephrine reputake inhibitor|tricyclic antidepressant	neurology/psychiatry	depression
tripelennamine	HRH1	5587	UFLGIAIHIAPJJC-UHFFFAOYSA-N	Launched	histamine receptor antagonist	pulmonary|allergy	asthma|allergic rhinitis|urticaria
triprolidine	HRH1	5282443	CBEQULMOCCWAQT-WOJGMQOQSA-N	Launched	histamine receptor antagonist	allergy	allergic rhinitis
triptan	HTR1B	10044	ZISSAWUMDACLOM-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
triptan	HTR1D	10044	ZISSAWUMDACLOM-UHFFFAOYSA-N	Phase 1	serotonin receptor agonist	NA	NA
triptolide	RELA	107985	"InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1"	Phase 3	RNA polymerase inhibitor	NA	NA
triptorelin	GNRHR	25074470	VXKHXGOKWPXYNA-PGBVPBMZSA-N	Launched	gonadotropin releasing factor hormone receptor agonist	oncology|endocrinology|obstetrics/gynecology	prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria
trofinetide	IFNG	3080768	JJGBXTYGTKWGAT-YUMQZZPRSA-N	Phase 2	cytokine production inhibitor	NA	NA
trofinetide	IL6	3080768	JJGBXTYGTKWGAT-YUMQZZPRSA-N	Phase 2	cytokine production inhibitor	NA	NA
trofinetide	TNF	3080768	JJGBXTYGTKWGAT-YUMQZZPRSA-N	Phase 2	cytokine production inhibitor	NA	NA
troglitazone	CYP2C8	9824580	GXPHKUHSUJUWKP-NTKDMRAZSA-N	Withdrawn	insulin sensitizer|PPAR receptor agonist	NA	NA
troglitazone	PPARG	9824580	GXPHKUHSUJUWKP-NTKDMRAZSA-N	Withdrawn	insulin sensitizer|PPAR receptor agonist	NA	NA
troglitazone	TRPM3	9824580	GXPHKUHSUJUWKP-NTKDMRAZSA-N	Withdrawn	insulin sensitizer|PPAR receptor agonist	NA	NA
trometamol	AMD1	6503	LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched		NA	NA
trometamol	CANT1	6503	LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched		NA	NA
trometamol	DCN	6503	LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched		NA	NA
trometamol	NEIL1	6503	LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched		NA	NA
trometamol	VEGFA	6503	LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched		NA	NA
"tropanyl-3,5-dimethylbenzoate"	HTR3A	NA	HDDNYFLPWFSBLN-ZSHCYNCHSA-N	Preclinical	serotonin receptor antagonist	NA	NA
"tropanyl-3,5-dimethylbenzoate"	HTR3B	NA	HDDNYFLPWFSBLN-ZSHCYNCHSA-N	Preclinical	serotonin receptor antagonist	NA	NA
tropesin	PTGS1	12606305	UCCJWNPWWPJKGL-XMMPIXPASA-N	Launched	cyclooxygenase inhibitor	NA	NA
tropesin	PTGS2	12606305	UCCJWNPWWPJKGL-XMMPIXPASA-N	Launched	cyclooxygenase inhibitor	NA	NA
tropicamide	CHRM3	688595	BGDKAVGWHJFAGW-INIZCTEOSA-N	Launched	acetylcholine receptor antagonist	ophthalmology	mydriasis diagnostic|cycloplegia diagnostic
tropicamide	CHRM4	688595	BGDKAVGWHJFAGW-INIZCTEOSA-N	Launched	acetylcholine receptor antagonist	ophthalmology	mydriasis diagnostic|cycloplegia diagnostic
tropisetron	GLRA1		ZNRGQMMCGHDTEI-ITGUQSILSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
tropisetron	GLRA2		ZNRGQMMCGHDTEI-ITGUQSILSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
tropisetron	GLRB		ZNRGQMMCGHDTEI-ITGUQSILSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
tropisetron	HTR3A		ZNRGQMMCGHDTEI-ITGUQSILSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
tropisetron	HTR4		ZNRGQMMCGHDTEI-ITGUQSILSA-N	Launched	serotonin receptor antagonist	gastroenterology	nausea|vomiting
trospium	CHRM1	NA	OYYDSUSKLWTMMQ-JKHIJQBDSA-N	Launched	acetylcholine receptor antagonist	urology	urinary incontinence|urinary frequency
trovafloxacin	TOP2A	NA	WVPSKSLAZQPAKQ-CDMJZVDBSA-N	Withdrawn	bacterial DNA gyrase inhibitor	NA	NA
TRV130	OPRM1	66553195	DMNOVGJWPASQDL-OAQYLSRUSA-N	Phase 3	opioid receptor agonist	NA	NA
tryptanthrin	IDO1	73549	VQQVWGVXDIPORV-UHFFFAOYSA-N	Preclinical	cyclooxygenase inhibitor	NA	NA
tryptophan	CASR	6923516	QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched	serotonin receptor partial agonist	neurology/psychiatry|gastroenterology	anxiety|bloating|constipation|fatigue|sleeplessness
tryptophan	IDO1	6923516	QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched	serotonin receptor partial agonist	neurology/psychiatry|gastroenterology	anxiety|bloating|constipation|fatigue|sleeplessness
tryptophan	SLC36A1	6923516	QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched	serotonin receptor partial agonist	neurology/psychiatry|gastroenterology	anxiety|bloating|constipation|fatigue|sleeplessness
tryptophan	WARS	6923516	QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched	serotonin receptor partial agonist	neurology/psychiatry|gastroenterology	anxiety|bloating|constipation|fatigue|sleeplessness
tryptophan	WARS2	6923516	QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched	serotonin receptor partial agonist	neurology/psychiatry|gastroenterology	anxiety|bloating|constipation|fatigue|sleeplessness
TTNPB	RARA	5289501	FOIVPCKZDPCJJY-JQIJEIRASA-N	Phase 1	retinoid receptor agonist	NA	NA
TTNPB	RARB	5289501	FOIVPCKZDPCJJY-JQIJEIRASA-N	Phase 1	retinoid receptor agonist	NA	NA
TTNPB	RARG	5289501	FOIVPCKZDPCJJY-JQIJEIRASA-N	Phase 1	retinoid receptor agonist	NA	NA
TTP-22	CSNK2A1	1536915	RAOULLCLLOGTDA-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
tubastatin-A	HDAC6	49850262	GOVYBPLHWIEHEJ-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
tubocurarine	ACHE	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tubocurarine	CHRNA2	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tubocurarine	HTR3A	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tubocurarine	HTR3B	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tubocurarine	KCNN1	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tubocurarine	KCNN2	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tubocurarine	KCNN3	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tubocurarine	ZACN	6000	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tucatinib	ERBB2	51039094	SDEAXTCZPQIFQM-UHFFFAOYSA-N	Phase 3	EGFR inhibitor	NA	NA
TUG-770	FFAR1	66553168	KIZUBVPJNPVIIN-UHFFFAOYSA-N	Preclinical	free fatty acid receptor agonist	NA	NA
TUG-891	FFAR4	57522038	LPGBXHWIQNZEJB-UHFFFAOYSA-N	Preclinical	free fatty acid receptor agonist	NA	NA
tulobuterol	ADRB2	688591	YREYLAVBNPACJM-NSHDSACASA-N	Launched	adrenergic receptor agonist	pulmonary	asthma
TW-37	BCL2	11455910	PQAPVTKIEGUPRN-UHFFFAOYSA-N	Preclinical	BCL inhibitor	NA	NA
TW-37	BCL2L1	11455910	PQAPVTKIEGUPRN-UHFFFAOYSA-N	Preclinical	BCL inhibitor	NA	NA
TW-37	MCL1	11455910	PQAPVTKIEGUPRN-UHFFFAOYSA-N	Preclinical	BCL inhibitor	NA	NA
TWS-119	GSK3B	9549289	VPVLEBIVXZSOMQ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
TWS-119	JUN	9549289	VPVLEBIVXZSOMQ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
TWS-119	MYC	9549289	VPVLEBIVXZSOMQ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
TY-52156	S1PR3	16046248	XONRRGIRSGNWFP-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor antagonist	NA	NA
tyrphostin-AG-1296	FLT3	2049	QNOXYUNHIGOWNY-UHFFFAOYSA-N	Preclinical	FLT3 inhibitor	NA	NA
tyrphostin-AG-1478	EGFR	2051	GFNNBHLJANVSQV-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
tyrphostin-AG-1478	MAPK14	2051	GFNNBHLJANVSQV-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
tyrphostin-AG-18	EGFR	2052	VTJXFTPMFYAJJU-UHFFFAOYSA-N	Preclinical	EGFR inhibitor|tyrosine kinase inhibitor	NA	NA
tyrphostin-AG-494	EGFR	5328771	HKHOVJYOELRGMV-XYOKQWHBSA-N	Preclinical	EGFR inhibitor	NA	NA
tyrphostin-AG-825	ERBB2	6091659	KXDONFLNGBQLTN-WUXMJOGZSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
tyrphostin-AG-835	EGFR	5328769	UMGQVUWXNOJOSJ-DGGAMASNSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
tyrphostin-AG-879	ERBB2	135419190	XRZYELWZLNAXGE-KPKJPENVSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
tyrphostin-AG-879	KDR	135419190	XRZYELWZLNAXGE-KPKJPENVSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
tyrphostin-AG-879	NTRK1	135419190	XRZYELWZLNAXGE-KPKJPENVSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
tyrphostin-AG-99	EGFR	5328768	USOXQZNJFMKTKJ-XVNBXDOJSA-N	Preclinical	tyrosine kinase inhibitor	NA	NA
U-0126	AKT1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	CHEK1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	GSK3B	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	LCK	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAP2K1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAP2K2	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAP2K7	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAPK1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAPK11	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAPK12	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAPK14	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	MAPK8	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	PRKCA	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	RAF1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	ROCK1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	RPS6KB1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0126	SGK1	54539763	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	MEK inhibitor	NA	NA
U-0521	COMT	21632	VDQLKIBLTMPAHI-UHFFFAOYSA-N	Preclinical	catechol O methyltransferase inhibitor	NA	NA
U-104	CA1	310360	YJQZNWPYLCNRLP-UHFFFAOYSA-N	Phase 1/Phase 2	carbonic anhydrase inhibitor	NA	NA
U-104	CA12	310360	YJQZNWPYLCNRLP-UHFFFAOYSA-N	Phase 1/Phase 2	carbonic anhydrase inhibitor	NA	NA
U-104	CA2	310360	YJQZNWPYLCNRLP-UHFFFAOYSA-N	Phase 1/Phase 2	carbonic anhydrase inhibitor	NA	NA
U-104	CA9	310360	YJQZNWPYLCNRLP-UHFFFAOYSA-N	Phase 1/Phase 2	carbonic anhydrase inhibitor	NA	NA
U-50488-(-)	OPRK1	6604724	VQLPLYSROCPWFF-ROUUACIJSA-N	Preclinical	opioid receptor agonist	NA	NA
U-54494A	OPRK1	183470	JUBNVWGVNWIXMB-SJORKVTESA-N	Preclinical	opioid receptor agonist	NA	NA
U-75799E	GHSR	9919153	WZHKXNSOCOQYQX-FUAFALNISA-N	Phase 1	growth hormone releasing factor agonist	NA	NA
U-99194	DRD3	5626	UOLJKAPABHXFRE-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
UAMC-00039	DPP4	11232124	DNVZYSMOLXCOLY-HNNXBMFYSA-N	Preclinical	dipeptidyl peptidase inhibitor	NA	NA
UAMC-00039	DPP7	11232124	DNVZYSMOLXCOLY-HNNXBMFYSA-N	Preclinical	dipeptidyl peptidase inhibitor	NA	NA
UB-165	CHRNA3	6604855	TVSNVPGPFGAKPT-JQWIXIFHSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
UB-165	CHRNA4	6604855	TVSNVPGPFGAKPT-JQWIXIFHSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
UB-165	CHRNB2	6604855	TVSNVPGPFGAKPT-JQWIXIFHSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
ubenimex	LTA4H	72172	VGGGPCQERPFHOB-RDBSUJKOSA-N	Launched	leukotriene synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
ubenimex	RNPEP	72172	VGGGPCQERPFHOB-RDBSUJKOSA-N	Launched	leukotriene synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
UBP-296	GRIK1	6420161	UUIYULWYHDSXHL-NSHDSACASA-N	Preclinical	glutamate receptor antagonist	NA	NA
UBP-302	GRIK1	6420161	UUIYULWYHDSXHL-NSHDSACASA-N	Preclinical	glutamate receptor antagonist	NA	NA
UBP-310	GRIK1	6420160	ZTAZUCRXCRXNSU-VIFPVBQESA-N	Preclinical	glutamate receptor antagonist	NA	NA
UBP-310	GRIK5	6420160	ZTAZUCRXCRXNSU-VIFPVBQESA-N	Preclinical	glutamate receptor antagonist	NA	NA
UC-112	XIAP	3426979	LTGLGIQQZXSLLF-UHFFFAOYSA-N	Preclinical	XIAP inhibitor	NA	NA
UF-010	HDAC1	4596836	BVQCFCYPFJOOAV-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
UF-010	HDAC2	4596836	BVQCFCYPFJOOAV-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
UF-010	HDAC3	4596836	BVQCFCYPFJOOAV-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
UF-010	HDAC8	4596836	BVQCFCYPFJOOAV-UHFFFAOYSA-N	Preclinical	HDAC inhibitor	NA	NA
ufenamate	PTGS1	5632	JDLSRXWHEBFHNC-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	dermatology	eczema|dermatitis
ufenamate	PTGS2	5632	JDLSRXWHEBFHNC-UHFFFAOYSA-N	Launched	cyclooxygenase inhibitor	dermatology	eczema|dermatitis
UH-232-(+)	DRD2	6604756	BTOJYCTUJJHANF-WMLDXEAASA-N	Preclinical	dopamine receptor antagonist	NA	NA
UH-232-(+)	DRD3	6604756	BTOJYCTUJJHANF-WMLDXEAASA-N	Preclinical	dopamine receptor antagonist	NA	NA
UH-232-(+)	DRD4	6604756	BTOJYCTUJJHANF-WMLDXEAASA-N	Preclinical	dopamine receptor antagonist	NA	NA
UH-232-(+)	HTR1A	6604756	BTOJYCTUJJHANF-WMLDXEAASA-N	Preclinical	dopamine receptor antagonist	NA	NA
UK-356618	MMP13	10370504	"InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1"	Preclinical	metalloproteinase inhibitor	NA	NA
UK-356618	MMP14	10370504	"InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1"	Preclinical	metalloproteinase inhibitor	NA	NA
UK-356618	MMP2	10370504	"InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1"	Preclinical	metalloproteinase inhibitor	NA	NA
UK-356618	MMP3	10370504	"InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1"	Preclinical	metalloproteinase inhibitor	NA	NA
UK-356618	MMP9	10370504	"InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1"	Preclinical	metalloproteinase inhibitor	NA	NA
UK-383367	BMP1	9818682	ARJCBSRIPGJMAD-LLVKDONJSA-N	Phase 1	procollagen C-endopeptidase inhibitor	NA	NA
UK-5099	SLC16A1	6438504	BIZNHCWFGNKBBZ-JLHYYAGUSA-N	Preclinical	monocarboxylate transporter inhibitor	NA	NA
ulipristal	PGR	130904	OOLLAFOLCSJHRE-ZHAKMVSLSA-N	Launched	progesterone receptor antagonist	endocrinology	contraceptive
umeclidinium	CHRM1	11519070	FVTWTVQXNAJTQP-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
umeclidinium	CHRM2	11519070	FVTWTVQXNAJTQP-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
umeclidinium	CHRM3	11519070	FVTWTVQXNAJTQP-UHFFFAOYSA-N	Launched	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
UNC0224	EHMT1	44251522	XIVUGRBSBIXXJE-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0224	EHMT2	44251522	XIVUGRBSBIXXJE-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0321	EHMT2	46901937	AULLUGALUBVBDD-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0631	EHMT2	53315868	XFAXSWXKPQWHDW-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0638	EHMT1	46224516	QOECJCJVIMVJGX-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0638	EHMT2	46224516	QOECJCJVIMVJGX-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0642	EHMT1	53315878	RNAMYOYQYRYFQY-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0642	EHMT2	53315878	RNAMYOYQYRYFQY-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0646	EHMT2	53315882	OUKWLRHRXOPODD-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0737	EHMT1	52953431	ATORKVYCKKBNTF-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC0737	EHMT2	52953431	ATORKVYCKKBNTF-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC1215	L3MBTL3	57339144	PQOOIERVZAXHBP-UHFFFAOYSA-N	Preclinical	L3MBTL antagonist	NA	NA
UNC1999	EZH2	72551585	DPJNKUOXBZSZAI-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
UNC2025	FLT3	NA	MJSHVHLADKXCML-RQNOJGIXSA-N	Preclinical	FLT3 inhibitor|MER tyrosine kinase inhibitor	NA	NA
UNC2025	MERTK	NA	MJSHVHLADKXCML-RQNOJGIXSA-N	Preclinical	FLT3 inhibitor|MER tyrosine kinase inhibitor	NA	NA
UNC2250	MERTK	NA	HSYSSKFCQHXOBP-MXVIHJGJSA-N	Preclinical	MER tyrosine kinase inhibitor	NA	NA
UNC2327	PRMT3	71583615	MYTRGTBDVGKKRO-UHFFFAOYSA-N	Preclinical	protein arginine N-methyltransferase inhibitor	NA	NA
UNC3230	PIP5K1C	46355372	RZCNASHHHSKTGP-UHFFFAOYSA-N	Preclinical	phosphatidyl-inositol activator	NA	NA
UNC669	L3MBTL1	46931242	CQERVFFAOOUFEQ-UHFFFAOYSA-N	Preclinical	L3MBTL antagonist	NA	NA
UNC926	L3MBTL1	61041645	OWGLFIKZKQOYHZ-UHFFFAOYSA-N	Preclinical	MBT inhibitor	NA	NA
UPF-1069	PARP2	25015515	JJWMRRNGWSITSQ-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
uprosertib	AKT1	51042438	AXTAPYRUEKNRBA-JTQLQIEISA-N	Phase 2	AKT inhibitor	NA	NA
uprosertib	AKT2	51042438	AXTAPYRUEKNRBA-JTQLQIEISA-N	Phase 2	AKT inhibitor	NA	NA
uprosertib	AKT3	51042438	AXTAPYRUEKNRBA-JTQLQIEISA-N	Phase 2	AKT inhibitor	NA	NA
uracil	DPYD	1174	ISAKRJDGNUQOIC-UHFFFAOYSA-N	Launched		NA	NA
uracil	UCKL1	1174	ISAKRJDGNUQOIC-UHFFFAOYSA-N	Launched		NA	NA
urapidil	HTR1A	5639	ICMGLRUYEQNHPF-UHFFFAOYSA-N	Launched	adrenergic receptor antagonist	cardiology	hypertension
URB597	FAAH	1383884	ROFVXGGUISEHAM-UHFFFAOYSA-N	Phase 1	FAAH inhibitor	NA	NA
URB597	FAAH2	1383884	ROFVXGGUISEHAM-UHFFFAOYSA-N	Phase 1	FAAH inhibitor	NA	NA
URB597	TRPA1	1383884	ROFVXGGUISEHAM-UHFFFAOYSA-N	Phase 1	FAAH inhibitor	NA	NA
urea	ARG1	1176	XSQUKJJJFZCRTK-UHFFFAOYSA-N	Launched	hydroxy radical formation stimulant	dermatology	psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis
urea	CA2	1176	XSQUKJJJFZCRTK-UHFFFAOYSA-N	Launched	hydroxy radical formation stimulant	dermatology	psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis
urea	CTNNB1	1176	XSQUKJJJFZCRTK-UHFFFAOYSA-N	Launched	hydroxy radical formation stimulant	dermatology	psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis
uric-acid	PYGL	1175	LEHOTFFKMJEONL-UHFFFAOYSA-N	Phase 3		NA	NA
uridine	LSM6	6029	DRTQHJPVMGBUCF-XVFCMESISA-N	Phase 2	dopamine receptor agonist	NA	NA
uridine	TYMP	6029	DRTQHJPVMGBUCF-XVFCMESISA-N	Phase 2	dopamine receptor agonist	NA	NA
uridine-5'-triphosphate	P2RY11	6133	PGAVKCOVUIYSFO-XVFCMESISA-N	Launched	purinergic receptor activator	NA	NA
uridine-5'-triphosphate	P2RY2	6133	PGAVKCOVUIYSFO-XVFCMESISA-N	Launched	purinergic receptor activator	NA	NA
uridine-5'-triphosphate	P2RY4	6133	PGAVKCOVUIYSFO-XVFCMESISA-N	Launched	purinergic receptor activator	NA	NA
uridine-5'-triphosphate	P2RY6	6133	PGAVKCOVUIYSFO-XVFCMESISA-N	Launched	purinergic receptor activator	NA	NA
uridine-5'-triphosphate	UCK2	6133	PGAVKCOVUIYSFO-XVFCMESISA-N	Launched	purinergic receptor activator	NA	NA
URMC-099	CDKL2	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	DAPK3	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	FLT3	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	LRRK2	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	MAP3K10	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	MAP3K11	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	MAP3K2	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	MAP3K9	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
URMC-099	SRPK2	54764565	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	mixed lineage kinase inhibitor	NA	NA
ursodiol	AKR1C2	31401	RUDATBOHQWOJDD-UZVSRGJWSA-N	Launched	nuclear factor erythroid derived|like (NRF2) activator	gastroenterology	gallstones
ursodiol	NR1H4	31401	RUDATBOHQWOJDD-UZVSRGJWSA-N	Launched	nuclear factor erythroid derived|like (NRF2) activator	gastroenterology	gallstones
ursolic-acid	HSD11B1	64945	WCGUUGGRBIKTOS-GPOJBZKASA-N	Phase 2/Phase 3	ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor	NA	NA
ursolic-acid	PLA2G1B	64945	WCGUUGGRBIKTOS-GPOJBZKASA-N	Phase 2/Phase 3	ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor	NA	NA
ursolic-acid	PTPN1	64945	WCGUUGGRBIKTOS-GPOJBZKASA-N	Phase 2/Phase 3	ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor	NA	NA
ursolic-acid	PYGM	64945	WCGUUGGRBIKTOS-GPOJBZKASA-N	Phase 2/Phase 3	ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor	NA	NA
usniacin-(+)	PTPN1		ZQHDVMCIDXEICF-SFHVURJKSA-N	Preclinical	MAP kinase activator	NA	NA
valdecoxib	CA12	119607	LNPDTQAFDNKSHK-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
valdecoxib	PTGS2	119607	LNPDTQAFDNKSHK-UHFFFAOYSA-N	Withdrawn	cyclooxygenase inhibitor	NA	NA
valethamate	CHRM1	38989053	UPPMZCXMQRVMME-SJLPKXTDSA-N	Launched	acetylcholine receptor antagonist	obstetrics/gynecology	labor induction
valethamate	CHRM4	38989053	UPPMZCXMQRVMME-SJLPKXTDSA-N	Launched	acetylcholine receptor antagonist	obstetrics/gynecology	labor induction
valethamate	CHRM5	38989053	UPPMZCXMQRVMME-SJLPKXTDSA-N	Launched	acetylcholine receptor antagonist	obstetrics/gynecology	labor induction
valproic-acid	ABAT	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	ACADSB	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	ALDH5A1	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	HDAC1	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	HDAC2	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	HDAC9	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	OGDH	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN10A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN11A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN1A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN1B	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN2A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN2B	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN3A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN3B	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN4A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN4B	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN5A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN7A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN8A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valproic-acid	SCN9A	3121	NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	benzodiazepine receptor agonist|HDAC inhibitor	neurology/psychiatry	epilepsy|seizures|seizures
valrubicin	TOP2A	454216	ZOCKGBMQLCSHFP-KQRAQHLDSA-N	Launched	DNA inhibitor|topoisomerase inhibitor	oncology	bladder cancer
valsartan	AGTR1	60846	ACWBQPMHZXGDFX-QFIPXVFZSA-N	Launched	angiotensin receptor antagonist	cardiology	hypertension|congestive heart failure|congestive heart failure
valspodar	ABCB1	5281884	YJDYDFNKCBANTM-QCWCSKBGSA-N	Phase 3	P glycoprotein inhibitor	NA	NA
vandetanib	EGFR	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA1	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA10	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA2	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA3	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA4	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA5	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA6	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA7	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHA8	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHB1	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHB2	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHB3	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHB4	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	EPHB6	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	ERBB2	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	ERBB3	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	ERBB4	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	FLT1	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	FLT4	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	KDR	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	PTK6	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	RET	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	SRC	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	TEK	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vandetanib	VEGFA	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vanillin	ABAT	1183	MWOOGOJBHIARFG-UHFFFAOYSA-N	Preclinical		NA	NA
vanillin	ALDH5A1	1183	MWOOGOJBHIARFG-UHFFFAOYSA-N	Preclinical		NA	NA
vanoxerine	SLC6A3	3455	NAUWTFJOPJWYOT-UHFFFAOYSA-N	Phase 3	dopamine reuptake inhibitor	NA	NA
vardenafil	PDE5A	135400189	SECKRCOLJRRGGV-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
vardenafil	PDE6G	135400189	SECKRCOLJRRGGV-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
vardenafil	PDE6H	135400189	SECKRCOLJRRGGV-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	urology	erectile dysfunction
varenicline	CHRNA3	5310966	JQSHBVHOMNKWFT-DTORHVGOSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
varenicline	CHRNA4	5310966	JQSHBVHOMNKWFT-DTORHVGOSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
varenicline	CHRNA6	5310966	JQSHBVHOMNKWFT-DTORHVGOSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
varenicline	CHRNA7	5310966	JQSHBVHOMNKWFT-DTORHVGOSA-N	Launched	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
varespladib	PLA2G2A	155815	BHLXTPHDSZUFHR-UHFFFAOYSA-N	Phase 3	secretory phospholipase inhibitor	NA	NA
vasopressin	AVPR1A	133698096	KBZOIRJILGZLEJ-PLCMWKKKSA-N	Launched	vasopressin receptor agonist	gastroenterology	abdominal distension
vasopressin	AVPR1B	133698096	KBZOIRJILGZLEJ-PLCMWKKKSA-N	Launched	vasopressin receptor agonist	gastroenterology	abdominal distension
vasopressin	AVPR2	133698096	KBZOIRJILGZLEJ-PLCMWKKKSA-N	Launched	vasopressin receptor agonist	gastroenterology	abdominal distension
vasopressin	OXTR	133698096	KBZOIRJILGZLEJ-PLCMWKKKSA-N	Launched	vasopressin receptor agonist	gastroenterology	abdominal distension
vatalanib	EGFR	151194	YCOYDOIWSSHVCK-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
vatalanib	FLT1	151194	YCOYDOIWSSHVCK-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
vatalanib	FLT4	151194	YCOYDOIWSSHVCK-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
vatalanib	KDR	151194	YCOYDOIWSSHVCK-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
vatalanib	PDGFRB	151194	YCOYDOIWSSHVCK-UHFFFAOYSA-N	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	NA	NA
VBY-825	CTSB	70945511	PPUXXDKQNAHHON-BJLQDIEVSA-N	Preclinical	cathepsin inhibitor	NA	NA
VBY-825	CTSL	70945511	PPUXXDKQNAHHON-BJLQDIEVSA-N	Preclinical	cathepsin inhibitor	NA	NA
VBY-825	CTSS	70945511	PPUXXDKQNAHHON-BJLQDIEVSA-N	Preclinical	cathepsin inhibitor	NA	NA
VE-821	ATR	51000408	DUIHHZKTCSNTGM-UHFFFAOYSA-N	Preclinical	ATR kinase inhibitor	NA	NA
VE-822	ATM	59472121	JZCWLJDSIRUGIN-UHFFFAOYSA-N	Phase 2	ATR kinase inhibitor	NA	NA
VE-822	ATR	59472121	JZCWLJDSIRUGIN-UHFFFAOYSA-N	Phase 2	ATR kinase inhibitor	NA	NA
VE-822	MTOR	59472121	JZCWLJDSIRUGIN-UHFFFAOYSA-N	Phase 2	ATR kinase inhibitor	NA	NA
VE-822	PIK3CG	59472121	JZCWLJDSIRUGIN-UHFFFAOYSA-N	Phase 2	ATR kinase inhibitor	NA	NA
vecuronium	CHRNA2	39765	BGSZAXLLHYERSY-XQIGCQGXSA-N	Launched	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
vedaprofen	PTGS2	25271747	VZUGVMQFWFVFBX-ZDUSSCGKSA-N	Launched	anti-inflammatory agent	neurology/psychiatry|endocrinology	pain relief|fever
veliflapon	ALOX5AP	123723	ZEYYDOLCHFETHQ-JOCHJYFZSA-N	Phase 3	leukotriene synthesis inhibitor	NA	NA
veliparib	PARP1	11960529	JNAHVYVRKWKWKQ-CYBMUJFWSA-N	Phase 3	PARP inhibitor	NA	NA
veliparib	PARP2	11960529	JNAHVYVRKWKWKQ-CYBMUJFWSA-N	Phase 3	PARP inhibitor	NA	NA
velneperit	NPY5R	NA	WGEWUYACXPEFPO-AULYBMBSSA-N	Phase 2	neuropeptide receptor antagonist	NA	NA
vemurafenib	BRAF	42611257	GPXBXXGIAQBQNI-UHFFFAOYSA-N	Launched	RAF inhibitor	oncology	melanoma
vemurafenib	RAF1	42611257	GPXBXXGIAQBQNI-UHFFFAOYSA-N	Launched	RAF inhibitor	oncology	melanoma
venetoclax	BCL2	49846579	LQBVNQSMGBZMKD-UHFFFAOYSA-N	Launched	BCL inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
venlafaxine	SLC6A2	11846746	PNVNVHUZROJLTJ-MRXNPFEDSA-N	Launched	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder
venlafaxine	SLC6A4	11846746	PNVNVHUZROJLTJ-MRXNPFEDSA-N	Launched	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder
VER-155008	HSPA1A	25195348	ZXGGCBQORXDVTE-UMCMBGNQSA-N	Preclinical	HSP inhibitor	NA	NA
VER-49009	HSP90AA1	4369536	HUNAOTXNHVALTN-UHFFFAOYSA-N	Preclinical	HSP inhibitor	NA	NA
verapamil	CACNA1A	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNA1B	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNA1C	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNA1D	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNA1F	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNA1G	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNA1I	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNA1S	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNB1	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNB2	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNB3	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CACNB4	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	CYP3A4	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	KCNA10	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	KCNA7	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	KCNH2	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	KCNJ11	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	NALCN	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	SCN5A	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	SLC29A4	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
verapamil	SLC6A4	2520	SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	calcium channel blocker	cardiology	hypertension
vercirnon	CCR9	10343454	JRWROCIMSDXGOZ-UHFFFAOYSA-N	Phase 3	CC chemokine receptor antagonist	NA	NA
verinurad	SLC22A12	54767229	YYBOLPLTQDKXPM-UHFFFAOYSA-N	Phase 2	urate transporter inhibitor	NA	NA
vernakalant	KCNA5	9930049	VBHQKCBVWWUUKN-KZNAEPCWSA-N	Launched	potassium channel blocker	cardiology	atrial fibrillation (AF)
verubulin	TUBB	11414799	SNHCRNMVYDHVDT-UHFFFAOYSA-N	Phase 2	tubulin polymerization inhibitor	NA	NA
vesamicol	SLC18A3	659840	YSSBJODGIYRAMI-IAGOWNOFSA-N	Preclinical	acetylcholinesterase inhibitor	NA	NA
vesnarinone	KCNH2	5663	ZVNYJIZDIRKMBF-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
vesnarinone	PDE3A	5663	ZVNYJIZDIRKMBF-UHFFFAOYSA-N	Launched	phosphodiesterase inhibitor	cardiology	congestive heart failure
VGX-1027	TLR4	92981775	MUFJHYRCIHHATF-SECBINFHSA-N	Phase 1	tumor necrosis factor receptor antagonist	NA	NA
vicriviroc	CCR5	3009355	CNPVJJQCETWNEU-CYFREDJKSA-N	Phase 3	CC chemokine receptor antagonist	NA	NA
vidarabine	ADA	21704	OIRDTQYFTABQOQ-UHTZMRCNSA-N	Launched	antiviral	infectious disease	virus herpes simplex (HSV)|varicella-zoster virus (VZV)
vigabatrin	ABAT	40466946	PJDFLNIOAUIZSL-RXMQYKEDSA-N	Launched	GABA aminotransferase inhibitor	neurology/psychiatry	seizures|spasms
vigabatrin	SLC32A1	40466946	PJDFLNIOAUIZSL-RXMQYKEDSA-N	Launched	GABA aminotransferase inhibitor	neurology/psychiatry	seizures|spasms
vilanterol	ADRB2	44482554	KLOLZALDXGTNQE-JIDHJSLPSA-N	Launched	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)
vilazodone	DRD2	6918314	SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched	serotonin reuptake inhibitor	neurology/psychiatry	depression
vilazodone	DRD3	6918314	SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched	serotonin reuptake inhibitor	neurology/psychiatry	depression
vilazodone	HRH1	6918314	SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched	serotonin reuptake inhibitor	neurology/psychiatry	depression
vilazodone	HTR1A	6918314	SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched	serotonin reuptake inhibitor	neurology/psychiatry	depression
vilazodone	HTR4	6918314	SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched	serotonin reuptake inhibitor	neurology/psychiatry	depression
vilazodone	SLC6A4	6918314	SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched	serotonin reuptake inhibitor	neurology/psychiatry	depression
vildagliptin	DPP4	NA	SYOKIDBDQMKNDQ-NHMCJKAESA-N	Launched	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
viloxazine	SLC6A2	12226596	YWPHCCPCQOJSGZ-LLVKDONJSA-N	Launched	norepinephrine reuptake inhibitor	neurology/psychiatry	depression
vinblastine	JUN	13342	JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
vinblastine	TUBA1A	13342	JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
vinblastine	TUBB	13342	JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
vinblastine	TUBD1	13342	JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
vinblastine	TUBE1	13342	JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
vinblastine	TUBG1	13342	JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched	microtubule inhibitor|tubulin polymerization inhibitor	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
vinburnine	CHRM1	71203	WYJAPUKIYAZSEM-MOPGFXCFSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	stroke
vinburnine	CHRM2	71203	WYJAPUKIYAZSEM-MOPGFXCFSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	stroke
vinburnine	CHRM3	71203	WYJAPUKIYAZSEM-MOPGFXCFSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	stroke
vinburnine	CHRM4	71203	WYJAPUKIYAZSEM-MOPGFXCFSA-N	Launched	adrenergic receptor antagonist	neurology/psychiatry	stroke
vincamine	CHRM1	15376	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	Withdrawn	adrenergic receptor antagonist	NA	NA
vincamine	CHRM2	15376	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	Withdrawn	adrenergic receptor antagonist	NA	NA
vincamine	CHRM3	15376	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	Withdrawn	adrenergic receptor antagonist	NA	NA
vincamine	CHRM4	15376	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	Withdrawn	adrenergic receptor antagonist	NA	NA
vincristine	TUBA4A	5388993	OGWKCGZFUXNPDA-CFWMRBGOSA-N	Launched	tubulin polymerization inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
vincristine	TUBB	5388993	OGWKCGZFUXNPDA-CFWMRBGOSA-N	Launched	tubulin polymerization inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
vindesine	TUBB	40839	HHJUWIANJFBDHT-KOTLKJBCSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|melanoma
vindesine	TUBB1	40839	HHJUWIANJFBDHT-KOTLKJBCSA-N	Launched	tubulin polymerization inhibitor	oncology	breast cancer|non-small cell lung cancer (NSCLC)|melanoma
vinorelbine	TUBA1A	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBA1B	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBA1C	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBA3C	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBA3D	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBA3E	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBA4A	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB1	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB2A	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB2B	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB3	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB4A	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB4B	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB6	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinorelbine	TUBB8	5311497	GBABOYUKABKIAF-IELIFDKJSA-N	Launched	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinpocetine	PDE1A	443955	DDNCQMVWWZOMLN-IRLDBZIGSA-N	Launched	phosphodiesterase inhibitor|sodium channel blocker	neurology/psychiatry	stroke|senile dementia
vinpocetine	PDE1C	443955	DDNCQMVWWZOMLN-IRLDBZIGSA-N	Launched	phosphodiesterase inhibitor|sodium channel blocker	neurology/psychiatry	stroke|senile dementia
vipadenant	ADORA1	21874557	HQSBCDPYXDGTCL-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
vipadenant	ADORA2A	21874557	HQSBCDPYXDGTCL-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
vipadenant	ADORA2B	21874557	HQSBCDPYXDGTCL-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
vipadenant	ADORA3	21874557	HQSBCDPYXDGTCL-UHFFFAOYSA-N	Phase 1	adenosine receptor antagonist	NA	NA
vismodegib	SMO	24776445	"InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)"	Launched	hedgehog pathway inhibitor|smoothened receptor antagonist	oncology	basal cell carcinoma (BCC)
vitamin-E	ALOX5	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	DGKA	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	NR1I2	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	PPP2CA	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	PPP2CB	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	PRKCA	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	PRKCB	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	SEC14L2	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	SEC14L3	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
vitamin-E	SEC14L4	14985	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	LDL oxidation inhibitor|PKC inhibitor	NA	NA
VLX600	TP53	6413301	"InChI=1S/C17H15N7/c1-10-6-5-7-12-14(10)19-16-15(12)22-24-17(20-16)23-21-11(2)13-8-3-4-9-18-13/h3-9H,1-2H3,(H2,19,20,23,24)/b21-11-"	Phase 1	antitumor agent|ubiquitin C-terminal hydrolase inhibitor	NA	NA
VLX600	USP14	6413301	"InChI=1S/C17H15N7/c1-10-6-5-7-12-14(10)19-16-15(12)22-24-17(20-16)23-21-11(2)13-8-3-4-9-18-13/h3-9H,1-2H3,(H2,19,20,23,24)/b21-11-"	Phase 1	antitumor agent|ubiquitin C-terminal hydrolase inhibitor	NA	NA
voglibose	MGAM	444020	FZNCGRZWXLXZSZ-CIQUZCHMSA-N	Launched	glucosidase inhibitor	endocrinology	diabetes mellitus|hyperglycemia
volasertib	PLK1	NA	"InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1"	Phase 3	PLK inhibitor	NA	NA
volinanserin	HTR2A	5311271	HXTGXYRHXAGCFP-OAQYLSRUSA-N	Phase 3	serotonin receptor antagonist	NA	NA
volinanserin	HTR2B	5311271	HXTGXYRHXAGCFP-OAQYLSRUSA-N	Phase 3	serotonin receptor antagonist	NA	NA
volinanserin	HTR2C	5311271	HXTGXYRHXAGCFP-OAQYLSRUSA-N	Phase 3	serotonin receptor antagonist	NA	NA
volinanserin	KCNH2	5311271	HXTGXYRHXAGCFP-OAQYLSRUSA-N	Phase 3	serotonin receptor antagonist	NA	NA
vonoprazan	ATP4A	15981397	BFDBKMOZYNOTPK-UHFFFAOYSA-N	Launched	potassium-competitive acid antagonist	gastroenterology	peptic ulcer disease (PUD)
vorapaxar	F2R	10077130	ZBGXUVOIWDMMJE-QHNZEKIYSA-N	Launched	thrombin inhibitor	cardiology	myocardial infarction|peripheral artery disease (PAD)
voreloxin	TOP2A	9952884	XZAFZXJXZHRNAQ-STQMWFEESA-N	Phase 3	topoisomerase inhibitor	NA	NA
voriconazole	CYP2C19	71616	BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched	cytochrome P450 inhibitor	infectious disease	esophageal candidiasis|aspergillosis|skin infections
voriconazole	CYP2C9	71616	BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched	cytochrome P450 inhibitor	infectious disease	esophageal candidiasis|aspergillosis|skin infections
voriconazole	CYP3A4	71616	BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched	cytochrome P450 inhibitor	infectious disease	esophageal candidiasis|aspergillosis|skin infections
voriconazole	CYP3A5	71616	BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched	cytochrome P450 inhibitor	infectious disease	esophageal candidiasis|aspergillosis|skin infections
voriconazole	PTGS1	71616	BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched	cytochrome P450 inhibitor	infectious disease	esophageal candidiasis|aspergillosis|skin infections
vorinostat	HDAC1	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC10	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC11	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC2	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC3	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC5	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC6	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC8	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vorinostat	HDAC9	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vortioxetine	HTR1A	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	HTR1B	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	HTR2A	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	HTR2C	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	HTR3A	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	HTR5A	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	HTR6	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	HTR7	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
vortioxetine	SLC6A4	9966051	YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression
voxtalisib	MTOR	16123056	RGHYDLZMTYDBDT-UHFFFAOYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
voxtalisib	PIK3CA	16123056	RGHYDLZMTYDBDT-UHFFFAOYSA-N	Phase 2	mTOR inhibitor|PI3K inhibitor	NA	NA
VP-20629	PLA2G2E	3744	GOLXRNDWAUTYKT-UHFFFAOYSA-N	Phase 1	beta amyloid antagonist	NA	NA
VP-20629	SLC36A1	3744	GOLXRNDWAUTYKT-UHFFFAOYSA-N	Phase 1	beta amyloid antagonist	NA	NA
VT-464	CYP17A1	78357816	ZBRAJOQFSNYJMF-SFHVURJKSA-N	Phase 2	cytochrome P450 inhibitor	NA	NA
VTP-27999	REN	16126898	NXWASIVXQMMPLM-ZXMXYHOLSA-N	Phase 1	renin inhibitor	NA	NA
VUF10166	HTR3A	24278976	FFXVTQDGTKEXHF-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
VUF10166	HTR3B	24278976	FFXVTQDGTKEXHF-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
VUF10460	HRH4	25129523	NIJGWJIOMPHDBP-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
VUF11207	ACKR3	97018453	JVRRRKAXHMGUHZ-JIKIWWBOSA-N	Preclinical	CC chemokine receptor agonist	NA	NA
VU0155069	PLD1	25105713	DRIMIUYGTDAQOX-KRWDZBQOSA-N	Preclinical	phospholipase inhibitor	NA	NA
VU0238429	CHRM5	42633508	CKLGZXFOLMHCMC-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
VU0240551	SLC12A5	7211972	WJRWSLORVIHRNX-UHFFFAOYSA-N	Preclinical	potassium/chloride cotransporter inhibitor	NA	NA
VU0357121	GRM5	2296132	AHCYOTLTLQTPSU-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
VU0360172	GRM5	53318624	NEMHWVUKNWAKTM-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
VU0361737	GRM4	44191096	ARYUXFNGXHNNDM-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
VU0364439	GRM4	46934289	IXHCGJXBIHHIEF-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
VU0364739	PLD2	46937439	MSTXJJGAXXJCBY-UHFFFAOYSA-N	Preclinical	phospholipase inhibitor	NA	NA
VU0364770	GRM4	836002	SUYUTNCKIOLMAJ-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
VU0422288	GRM3	73058507	MZRLPXFGQKQHST-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
VU10010	CHRM4	714286	FPRULFHDSFKYBV-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
VU152100	CHRM4	864492	MDNWGCQSCGNTKH-UHFFFAOYSA-N	Preclinical	acetylcholine receptor allosteric modulator	NA	NA
VU1545	GRM5	11625520	BRAZLURTFMCAHU-UHFFFAOYSA-N	Preclinical	glutamate receptor positive allosteric modulator	NA	NA
VU29	GRM5	11610682	KIALCSMRIHRFPL-UHFFFAOYSA-N	Preclinical	glutamate receptor potentiator	NA	NA
VU591	KCNJ1	44123657	ZQPXNYLXYNRFNP-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
VX-11e	MAPK1	11634725	WUTVMXLIGHTZJC-OAQYLSRUSA-N	Preclinical	MAP kinase inhibitor	NA	NA
VX-702	IL1B	10341154	FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-702	IL6	10341154	FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-702	MAPK11	10341154	FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-702	MAPK12	10341154	FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-702	MAPK14	10341154	FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-702	TNF	10341154	FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-745	MAPK11	3038525	VEPKQEUBKLEPRA-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-745	MAPK12	3038525	VEPKQEUBKLEPRA-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-745	MAPK14	3038525	VEPKQEUBKLEPRA-UHFFFAOYSA-N	Phase 2	p38 MAPK inhibitor	NA	NA
VX-765	CASP1	11398092	SJDDOCKBXFJEJB-MOKWFATOSA-N	Phase 2	caspase inhibitor	NA	NA
W-54011	C5AR1	59597209	DVYASSBBADJRAS-MUUNZHRXSA-N	Preclinical	anaphylatoxin chemotactic receptor antagonist	NA	NA
warfarin	VKORC1	54688261	PJVWKTKQMONHTI-HNNXBMFYSA-N	Launched	vitamin K antagonist	hematology|cardiology	deep vein thrombosis (DVT)|pulmonary embolism (PE)|atrial fibrillation (AF)|myocardial infarction
WAY-100635	HTR1A	5684	SBPRIAGPYFYCRT-UHFFFAOYSA-N	Phase 1	serotonin receptor antagonist	NA	NA
WAY-161503	HTR2C	6604916	PHGWDAICBXUJDU-SNVBAGLBSA-N	Preclinical	serotonin receptor agonist	NA	NA
WAY-170523	MMP13	9830392	FARMEEAGJWMFSZ-UHFFFAOYSA-N	Preclinical	metalloproteinase inhibitor	NA	NA
WAY-200070	ERBB2	135418373	BAAILVWEAXFTSF-UHFFFAOYSA-N	Preclinical	estrogen receptor agonist	NA	NA
WAY-200070	ERBB3	135418373	BAAILVWEAXFTSF-UHFFFAOYSA-N	Preclinical	estrogen receptor agonist	NA	NA
WAY-200070	ERBB4	135418373	BAAILVWEAXFTSF-UHFFFAOYSA-N	Preclinical	estrogen receptor agonist	NA	NA
WAY-200070	ESR2	135418373	BAAILVWEAXFTSF-UHFFFAOYSA-N	Preclinical	estrogen receptor agonist	NA	NA
WAY-207024	GNRHR	11496610	AVEVJMZJJJDOCI-UHFFFAOYSA-N	Preclinical	gonadotropin releasing factor hormone receptor antagonist	NA	NA
WAY-207024	HRH2	11496610	AVEVJMZJJJDOCI-UHFFFAOYSA-N	Preclinical	gonadotropin releasing factor hormone receptor antagonist	NA	NA
WAY-207024	TACR2	11496610	AVEVJMZJJJDOCI-UHFFFAOYSA-N	Preclinical	gonadotropin releasing factor hormone receptor antagonist	NA	NA
WAY-208466	DRD2	10337743	SFSFIDVAEMDPIP-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
WAY-208466	HTR2A	10337743	SFSFIDVAEMDPIP-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
WAY-208466	HTR2C	10337743	SFSFIDVAEMDPIP-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
WAY-208466	HTR6	10337743	SFSFIDVAEMDPIP-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
WAY-208466	HTR7	10337743	SFSFIDVAEMDPIP-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
WAY-213613	SLC1A2	11531745	BNYDDAAZMBUFRG-ZDUSSCGKSA-N	Preclinical	glutamate inhibitor	NA	NA
WAY-316606	SFRP1	16727102	ITBGJNVZJBVPLJ-UHFFFAOYSA-N	Preclinical	secreted frizzled related protein inhibitor	NA	NA
WAY-362450	NR1H4	10026128	INASOKQDNHHMRE-UHFFFAOYSA-N	Phase 1	FXR agonist	NA	NA
WAY-600	MTOR	25229526	FPEIJQLXFHKLJV-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
WAY-629	HTR2C	6604933	OIGHTPDWPMLMGT-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
WB-4101	ADRA1A	13305910	GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
WB-4101	ADRA1B	13305910	GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
WB-4101	ADRA1D	13305910	GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
WB-4101	ADRA2A	13305910	GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
WB-4101	ADRA2B	13305910	GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
WB-4101	ADRA2C	13305910	GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
WB-4101	HTR1A	13305910	GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
WDR5-0103	WDR5	6457069	ZPLBXOVTSNRBFB-UHFFFAOYSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
WH-4-023	LCK	11844351	NBTNHSGBRGTFJS-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
WH-4-023	SRC	11844351	NBTNHSGBRGTFJS-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
WHI-P154	EGFR	3795	CBIAKDAYHRWZCU-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
WHI-P154	JAK1	3795	CBIAKDAYHRWZCU-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
WHI-P154	JAK2	3795	CBIAKDAYHRWZCU-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
WHI-P154	JAK3	3795	CBIAKDAYHRWZCU-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
WIKI4	TNKS2	2984337	RNUXIZKXJOGYQP-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor|WNT pathway inhibitor	NA	NA
WIN-18446	ALDH1A2	15134	FAOMZVDZARKPFJ-UHFFFAOYSA-N	Preclinical	aldehyde dehydrogenase inhibitor	NA	NA
WIN-64338	BDKRB2	132928	UKMJWGFHXMGRNG-QLKFWGTOSA-O	Preclinical	bradykinin receptor antagonist	NA	NA
wiskostatin	WASL	981326	XUBJEDZHBUPBKL-CYBMUJFWSA-N	Preclinical	actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor	NA	NA
wnt-c59	PORCN	57519544	KHZOJCQBHJUJFY-UHFFFAOYSA-N	Preclinical	porcupine inhibitor	NA	NA
wortmannin	PI4KA	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
wortmannin	PI4KB	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
wortmannin	PIK3CA	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
wortmannin	PIK3CD	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
wortmannin	PIK3CG	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
wortmannin	PIK3R1	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
wortmannin	PLK1	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
wortmannin	PRKDC	312145	QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	PI3K inhibitor	NA	NA
WP1066	STAT3	11210478	VFUAJMPDXIRPKO-LQELWAHVSA-N	Phase 1	STAT inhibitor	NA	NA
WP1130	JAK2	11222830	LIDOPKHSVQTSJY-VMEIHUARSA-N	Preclinical	deubiquitinase inhibitor	NA	NA
WP1130	UCHL5	11222830	LIDOPKHSVQTSJY-VMEIHUARSA-N	Preclinical	deubiquitinase inhibitor	NA	NA
WP1130	USP14	11222830	LIDOPKHSVQTSJY-VMEIHUARSA-N	Preclinical	deubiquitinase inhibitor	NA	NA
WP1130	USP9X	11222830	LIDOPKHSVQTSJY-VMEIHUARSA-N	Preclinical	deubiquitinase inhibitor	NA	NA
WR99210	TYMS	121750	MJZJYWCQPMNPRM-UHFFFAOYSA-N	Preclinical	dihydrofolate reductase inhibitor	infectious disease	malaria
WWL-113	CES3	17759482	AKIIPHDGVCFVCC-UHFFFAOYSA-N	Preclinical	carboxylesterase inhibitor	NA	NA
WWL-123	ABHD6	90209976	UUJGYRHAOHORFC-UHFFFAOYSA-N	Preclinical	monoacylglycerol lipase inhibitor	NA	NA
WYE-125132	MTOR	25227469	QLHHRYZMBGPBJG-OYRHEFFESA-N	Preclinical	mTOR inhibitor	NA	NA
WYE-354	MTOR	44219749	IMXHGCRIEAKIBU-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
WYE-687	MTOR	25229450	VDOCQQKGPJENHJ-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
WZ-3146	EGFR	44607360	APHGZZPEOCCYNO-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
WZ-4002	EGFR	44607530	ITTRLTNMFYIYPA-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
WZ-4002	ERBB2	44607530	ITTRLTNMFYIYPA-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
WZ4003	NUAK1	72200024	SDGJBAUIGHSMRI-UHFFFAOYSA-N	Preclinical	AMPK inhibitor	NA	NA
WZ4003	NUAK2	72200024	SDGJBAUIGHSMRI-UHFFFAOYSA-N	Preclinical	AMPK inhibitor	NA	NA
WZ8040	EGFR	44607531	KIISCIGBPUVZBF-UHFFFAOYSA-N	Preclinical	EGFR inhibitor	NA	NA
WZ811	CXCR4	11565518	KBVFRXIGQQRMEF-UHFFFAOYSA-N	Preclinical	CC chemokine receptor antagonist	NA	NA
xaliproden	HTR1A	128919	WJJYZXPHLSLMGE-UHFFFAOYSA-N	Phase 3	serotonin receptor agonist	NA	NA
xamoterol	ADRB1	6917710	DXPOSRCHIDYWHW-UHFFFAOYSA-N	Phase 3	adrenergic receptor agonist	NA	NA
xanomeline	CHRM1	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	CHRM2	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	CHRM3	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	CHRM4	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	CHRM5	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR1A	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR1B	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR1D	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR1E	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR1F	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR2A	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR2B	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR2C	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR6	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
xanomeline	HTR7	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	acetylcholine receptor agonist	NA	NA
XAV-939	TNKS	135418940	KLGQSVMIPOVQAX-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor	NA	NA
XAV-939	TNKS2	135418940	KLGQSVMIPOVQAX-UHFFFAOYSA-N	Preclinical	tankyrase inhibitor	NA	NA
XBD173	TSPO	6433109	NBMBIEOUVBHEBM-UHFFFAOYSA-N	Phase 2	benzodiazepine receptor ligand	NA	NA
XD-14	BRD2	52670832	DPBKLIVPNYGQQG-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
XD-14	BRD3	52670832	DPBKLIVPNYGQQG-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
XD-14	BRD4	52670832	DPBKLIVPNYGQQG-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
XD-14	BRDT	52670832	DPBKLIVPNYGQQG-UHFFFAOYSA-N	Preclinical	bromodomain inhibitor	NA	NA
XE-991	KCNQ1	656732	KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
XE-991	KCNQ2	656732	KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
XE-991	KCNQ3	656732	KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
XE-991	KCNQ4	656732	KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
XE-991	KCNQ5	656732	KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical	potassium channel blocker	NA	NA
xipamide	SLC12A3	26618	MTZBBNMLMNBNJL-UHFFFAOYSA-N	Launched	carbonic anhydrase inhibitor	cardiology	edema|hypertension
XL019	JAK1	57990869	ISOCDPQFIXDIMS-QHCPKHFHSA-N	Phase 1	JAK inhibitor	NA	NA
XL019	JAK2	57990869	ISOCDPQFIXDIMS-QHCPKHFHSA-N	Phase 1	JAK inhibitor	NA	NA
XL019	JAK3	57990869	ISOCDPQFIXDIMS-QHCPKHFHSA-N	Phase 1	JAK inhibitor	NA	NA
XL147	PIK3CA	1893730	MQMKRQLTIWPEDM-UHFFFAOYSA-N	Phase 2	PI3K inhibitor	NA	NA
XL147	PIK3CD	1893730	MQMKRQLTIWPEDM-UHFFFAOYSA-N	Phase 2	PI3K inhibitor	NA	NA
XL147	PIK3CG	1893730	MQMKRQLTIWPEDM-UHFFFAOYSA-N	Phase 2	PI3K inhibitor	NA	NA
XL228	IGF1R	59757974	ALKJNCZNEOTEMP-UHFFFAOYSA-N	Phase 1	Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor	NA	NA
XL228	SRC	59757974	ALKJNCZNEOTEMP-UHFFFAOYSA-N	Phase 1	Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor	NA	NA
XL388	MTOR	59604787	LNFBAYSBVQBKFR-UHFFFAOYSA-N	Preclinical	mTOR inhibitor	NA	NA
XL647	EGFR	NA	HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3	EGFR inhibitor|VEGFR inhibitor	NA	NA
XL647	EPHB4	NA	HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3	EGFR inhibitor|VEGFR inhibitor	NA	NA
XL647	ERBB2	NA	HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3	EGFR inhibitor|VEGFR inhibitor	NA	NA
XL647	FLT4	NA	HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3	EGFR inhibitor|VEGFR inhibitor	NA	NA
XL647	KDR	NA	HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3	EGFR inhibitor|VEGFR inhibitor	NA	NA
XMD17-109	MAPK7	71604307	XVBGRTMNFNMINE-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
XMD8-92	DCLK2	46843772	QAPAJIZPZGWAND-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
XMD8-92	MAPK7	46843772	QAPAJIZPZGWAND-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
XMD8-92	PLK4	46843772	QAPAJIZPZGWAND-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
XMD8-92	TNK1	46843772	QAPAJIZPZGWAND-UHFFFAOYSA-N	Preclinical	MAP kinase inhibitor	NA	NA
xylazine	ADRA2A	5707	BPICBUSOMSTKRF-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	anesthetic
xylazine	ADRA2B	5707	BPICBUSOMSTKRF-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	anesthetic
xylazine	ADRA2C	5707	BPICBUSOMSTKRF-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	neurology/psychiatry	anesthetic
xylometazoline	ADRA1A	5709	HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology|allergy	nasal congestion|allergic rhinitis
xylometazoline	ADRA1B	5709	HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology|allergy	nasal congestion|allergic rhinitis
xylometazoline	ADRA1D	5709	HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology|allergy	nasal congestion|allergic rhinitis
xylometazoline	ADRA2A	5709	HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology|allergy	nasal congestion|allergic rhinitis
xylometazoline	ADRA2B	5709	HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology|allergy	nasal congestion|allergic rhinitis
xylometazoline	ADRA2C	5709	HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched	adrenergic receptor agonist	otolaryngology|allergy	nasal congestion|allergic rhinitis
Y-11	PTK2	427018	SQWGHMPVSMSPNY-UHFFFAOYSA-N	Preclinical	focal adhesion kinase inhibitor	NA	NA
Y-134	ESR1	11784736	LQEOPHGPHCWOAC-UHFFFAOYSA-N	Preclinical	estrogen receptor antagonist	NA	NA
Y-134	ESR2	11784736	LQEOPHGPHCWOAC-UHFFFAOYSA-N	Preclinical	estrogen receptor antagonist	NA	NA
Y-26763	KCNJ8	121878	IWTCFIIOUXJOOV-OLZOCXBDSA-N	Phase 1	potassium channel activator	NA	NA
Y-27152	KCNJ8	6918184	RHFUXPCCELGMFC-UXHICEINSA-N	Phase 1	potassium channel activator	NA	NA
Y-27632	PKIA	NA	IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
Y-27632	PKN2	NA	IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
Y-27632	PRKACA	NA	IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
Y-27632	PRKCE	NA	IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
Y-27632	ROCK1	NA	IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
Y-27632	ROCK2	NA	IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
Y-29794	PREP	195609	HAGHKJDWBDSFKC-UHFFFAOYSA-N	Preclinical	prolyl endopeptidase inhibitor	NA	NA
Y-320	IL17A	22227931	BWZNJVZTAWBIFG-UHFFFAOYSA-N	Preclinical	interleukin inhibitor	NA	NA
Y-39983	ROCK1	9810884	JTVBXQAYBIJXRP-SNVBAGLBSA-N	Phase 2	rho associated kinase inhibitor	NA	NA
Y-39983	ROCK2	9810884	JTVBXQAYBIJXRP-SNVBAGLBSA-N	Phase 2	rho associated kinase inhibitor	NA	NA
YC-1	GUCY1A2	5712	OQQVFCKUDYMWGV-UHFFFAOYSA-N	Preclinical	guanylyl cyclase activator	NA	NA
YC-1	GUCY1A3	5712	OQQVFCKUDYMWGV-UHFFFAOYSA-N	Preclinical	guanylyl cyclase activator	NA	NA
YC-1	GUCY1B3	5712	OQQVFCKUDYMWGV-UHFFFAOYSA-N	Preclinical	guanylyl cyclase activator	NA	NA
YC-1	HIF1A	5712	OQQVFCKUDYMWGV-UHFFFAOYSA-N	Preclinical	guanylyl cyclase activator	NA	NA
YIL-781	GHSR	23631116	FRKXOBMDEXCHHD-SFHVURJKSA-N	Preclinical	ghrelin receptor antagonist	NA	NA
YK-4-279	EWSR1	93948843	HLXSCTYHLQHQDJ-KRWDZBQOSA-N	Preclinical	apoptosis inhibitor	NA	NA
YK-4-279	FLI1	93948843	HLXSCTYHLQHQDJ-KRWDZBQOSA-N	Preclinical	apoptosis inhibitor	NA	NA
YM-022	CCKBR	122130	YCXFHPUBGMMWJQ-PMERELPUSA-N	Phase 2	CCK receptor antagonist	NA	NA
YM-155	BIRC5	10126189	OTSOOHRUMBRSHZ-UHFFFAOYSA-N	Phase 2	survivin inhibitor	NA	NA
YM-298198	GRM1	9819432	KCBXOMYXOBVLED-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
YM-298198-desmethyl	GRM1	11716890	VWOMTTIMBHBPBI-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
YM-511	CYP19A1	177865	GGPPBTSXFROGAE-UHFFFAOYSA-N	Phase 2	aromatase inhibitor	NA	NA
YM-58483	TRPC3	2455	XPRZIORDEVHURQ-UHFFFAOYSA-N	Preclinical	calcium channel blocker	NA	NA
YM-58483	TRPC5	2455	XPRZIORDEVHURQ-UHFFFAOYSA-N	Preclinical	calcium channel blocker	NA	NA
YM-58483	TRPM4	2455	XPRZIORDEVHURQ-UHFFFAOYSA-N	Preclinical	calcium channel blocker	NA	NA
YM-750	SOAT1	9911716	FMLJREWZCZHGGW-UHFFFAOYSA-N	Phase 1	ACAT inhibitor	NA	NA
YM-90709	CSF2RB	1103147	HIXSPVQXXDULHS-UHFFFAOYSA-N	Preclinical	IL5 inhibitor	NA	NA
YM-90709	IL5RA	1103147	HIXSPVQXXDULHS-UHFFFAOYSA-N	Preclinical	IL5 inhibitor	NA	NA
YM-976	PDE4A	6604918	MNHXYNNKDDXKNP-UHFFFAOYSA-N	Phase 1	phosphodiesterase inhibitor	NA	NA
yoda-1	PIEZO1	2746822	BQNXBSYSQXSXPT-UHFFFAOYSA-N	Preclinical	piezo channel activator	NA	NA
yohimbine	ADRA2A	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	ADRA2B	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	ADRA2C	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	DRD2	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	DRD3	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR1A	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR1B	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR1D	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR1E	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR1F	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR2A	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR2B	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR2C	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR5A	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	HTR7	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	KCNJ1	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	KCNJ10	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	KCNJ11	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	KCNJ12	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	KCNJ14	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	KCNJ15	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
yohimbine	KCNJ8	8969	BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	adrenergic receptor antagonist	cardiology	cardiac arrythmia|bradycardia
YZ9	MIF	5289613	IETDBZQIWIJQJG-UHFFFAOYSA-N	Preclinical	phosphofructokinase inhibitor	NA	NA
YZ9	PFKFB3	5289613	IETDBZQIWIJQJG-UHFFFAOYSA-N	Preclinical	phosphofructokinase inhibitor	NA	NA
Y16	RHOA	989521	ITMLWGWTDWJSRZ-PXLXIMEGSA-N	Preclinical	rho associated kinase inhibitor	NA	NA
zacopride	HTR3A	9819593	FEROPKNOYKURCJ-ZDUSSCGKSA-N	Phase 2	serotonin receptor antagonist	NA	NA
zacopride	HTR3B	9819593	FEROPKNOYKURCJ-ZDUSSCGKSA-N	Phase 2	serotonin receptor antagonist	NA	NA
zacopride	HTR4	9819593	FEROPKNOYKURCJ-ZDUSSCGKSA-N	Phase 2	serotonin receptor antagonist	NA	NA
zacopride	HTR5A	9819593	FEROPKNOYKURCJ-ZDUSSCGKSA-N	Phase 2	serotonin receptor antagonist	NA	NA
zafirlukast	CYSLTR1	5717	YEEZWCHGZNKEEK-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	asthma
zafirlukast	CYSLTR2	5717	YEEZWCHGZNKEEK-UHFFFAOYSA-N	Launched	leukotriene receptor antagonist	pulmonary	asthma
zaldaride	CALM1	92460626	HTGCJAAPDHZCHL-SANMLTNESA-N	Phase 3	calmodulin antagonist	NA	NA
zaltidine	HRH2	56051	GIMNAEMRNXUAQP-UHFFFAOYSA-N	Phase 3	histamine receptor antagonist	NA	NA
zamifenacin	CHRM3	3086618	BDNFQGRSKSQXRI-XMMPIXPASA-N	Phase 3	acetylcholine receptor antagonist	NA	NA
zanamivir	NEU2	60855	ARAIBEBZBOPLMB-UFGQHTETSA-N	Launched	neuraminidase inhibitor	infectious disease	influenza A virus infection
zaprinast	GPR35	135399235	REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
zaprinast	PDE1A	135399235	REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
zaprinast	PDE4D	135399235	REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
zaprinast	PDE5A	135399235	REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
zaprinast	PDE9A	135399235	REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
zardaverine	PDE4D	5723	HJMQDJPMQIHLPB-UHFFFAOYSA-N	Phase 2	phosphodiesterase inhibitor	NA	NA
zatebradine	HCN1	65637	KEDQCFRVSHYKLR-UHFFFAOYSA-N	Phase 3	HCN channel blocker	NA	NA
zatebradine	HCN2	65637	KEDQCFRVSHYKLR-UHFFFAOYSA-N	Phase 3	HCN channel blocker	NA	NA
zatebradine	HCN3	65637	KEDQCFRVSHYKLR-UHFFFAOYSA-N	Phase 3	HCN channel blocker	NA	NA
zatebradine	HCN4	65637	KEDQCFRVSHYKLR-UHFFFAOYSA-N	Phase 3	HCN channel blocker	NA	NA
ZCL-278	CDC42	1791111	XKZDWYDHEBCGCG-UHFFFAOYSA-N	Preclinical	CDC inhibitor	NA	NA
ZD-2079	ADRB3	158794	SRBPKVWITYPHQR-KRWDZBQOSA-N	Phase 2	adrenergic receptor agonist	NA	NA
ZD-7114	ADRB3	121877	RVMBDLSFFNKKLG-SFHVURJKSA-N	Phase 1	adrenergic receptor agonist	NA	NA
ZD-7155	AGTR1	4673492	BFVNEYDCFJNLGN-UHFFFAOYSA-N	Preclinical	angiotensin receptor antagonist	NA	NA
ZD-7288	HCN1	123984	JABSKGQQWUDVRU-UHFFFAOYSA-N	Phase 2	HCN channel blocker	NA	NA
ZD-7288	HCN2	123984	JABSKGQQWUDVRU-UHFFFAOYSA-N	Phase 2	HCN channel blocker	NA	NA
ZD-7288	HCN3	123984	JABSKGQQWUDVRU-UHFFFAOYSA-N	Phase 2	HCN channel blocker	NA	NA
ZD-7288	HCN4	123984	JABSKGQQWUDVRU-UHFFFAOYSA-N	Phase 2	HCN channel blocker	NA	NA
zebularine	CDA	100016	RPQZTTQVRYEKCR-WCTZXXKLSA-N	Preclinical	DNA methyltransferase inhibitor	NA	NA
zebularine	DNMT1	100016	RPQZTTQVRYEKCR-WCTZXXKLSA-N	Preclinical	DNA methyltransferase inhibitor	NA	NA
zibotentan	EDNRA	9910224	FJHHZXWJVIEFGJ-UHFFFAOYSA-N	Phase 3	endothelin receptor antagonist	NA	NA
zidovudine	TERT	35370	HBOMLICNUCNMMY-XLPZGREQSA-N	Launched	nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)
zileuton	ALOX5	10681296	MWLSOWXNZPKENC-SSDOTTSWSA-N	Launched	leukotriene synthesis inhibitor|lipoxygenase inhibitor	pulmonary	asthma
zilpaterol	ADRB2	25218684	ZSTCZWJCLIRCOJ-AAEUAGOBSA-N	Launched	adrenergic receptor agonist	endocrinology	weight-gain aid
zimelidine	MAOA	5365247	OYPPVKRFBIWMSX-SXGWCWSVSA-N	Withdrawn	selective serotonin reuptake inhibitor (SSRI)	NA	NA
zimelidine	MAOB	5365247	OYPPVKRFBIWMSX-SXGWCWSVSA-N	Withdrawn	selective serotonin reuptake inhibitor (SSRI)	NA	NA
zimelidine	SLC6A4	5365247	OYPPVKRFBIWMSX-SXGWCWSVSA-N	Withdrawn	selective serotonin reuptake inhibitor (SSRI)	NA	NA
ziprasidone	ADRA1A	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	ADRA1B	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	ADRA2A	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	ADRA2B	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	ADRA2C	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	CHRM1	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	CHRM2	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	CHRM3	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	CHRM4	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	CHRM5	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	DRD1	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	DRD2	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	DRD3	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	DRD4	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	DRD5	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HRH1	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR1A	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR1B	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR1D	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR1E	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR2A	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR2C	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR3A	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR6	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	HTR7	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ziprasidone	SLC6A4	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
ZK-164015	ESR1	9806489	LYJSJVYJLZOMCD-UHFFFAOYSA-N	Preclinical	estrogen receptor antagonist	NA	NA
ZK-164015	ESR2	9806489	LYJSJVYJLZOMCD-UHFFFAOYSA-N	Preclinical	estrogen receptor antagonist	NA	NA
ZK-811752	CCR1	512282	XQYASZNUFDVMFH-CQSZACIVSA-N	Phase 2	CC chemokine receptor antagonist	NA	NA
ZK-93423	GABRA1	121926	ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
ZK-93423	GABRA2	121926	ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
ZK-93423	GABRA3	121926	ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
ZK-93423	GABRA5	121926	ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
ZK-93423	GABRB2	121926	ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
ZK-93423	GABRG2	121926	ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3	benzodiazepine receptor agonist	NA	NA
ZK-93426	GABRA1	115210	VMDUABMKBUKKPG-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor antagonist	NA	NA
ZK-93426	GABRA2	115210	VMDUABMKBUKKPG-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor antagonist	NA	NA
ZK-93426	GABRA3	115210	VMDUABMKBUKKPG-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor antagonist	NA	NA
ZK-93426	GABRA5	115210	VMDUABMKBUKKPG-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor antagonist	NA	NA
ZLN024	PRKAA1	1825716	KWJRSHZSULRJHE-UHFFFAOYSA-N	Preclinical	AMPK activator	NA	NA
ZLN024	PRKAB1	1825716	KWJRSHZSULRJHE-UHFFFAOYSA-N	Preclinical	AMPK activator	NA	NA
ZLN024	PRKAG1	1825716	KWJRSHZSULRJHE-UHFFFAOYSA-N	Preclinical	AMPK activator	NA	NA
ZM-241385	ADORA1	176407	PWTBZOIUWZOPFT-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
ZM-241385	ADORA2A	176407	PWTBZOIUWZOPFT-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
ZM-241385	ADORA2B	176407	PWTBZOIUWZOPFT-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
ZM-241385	ADORA3	176407	PWTBZOIUWZOPFT-UHFFFAOYSA-N	Preclinical	adenosine receptor antagonist	NA	NA
ZM-306416	EGFR	5329006	YHUIUSRCUKUUQA-UHFFFAOYSA-N	Preclinical	Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor	NA	NA
ZM-306416	FLT1	5329006	YHUIUSRCUKUUQA-UHFFFAOYSA-N	Preclinical	Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor	NA	NA
ZM-306416	FLT4	5329006	YHUIUSRCUKUUQA-UHFFFAOYSA-N	Preclinical	Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor	NA	NA
ZM-306416	KDR	5329006	YHUIUSRCUKUUQA-UHFFFAOYSA-N	Preclinical	Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor	NA	NA
ZM-323881	KDR	16759369	NVBNDZZLJRYRPD-UHFFFAOYSA-N	Preclinical	VEGFR inhibitor	NA	NA
ZM-336372	BRAF	5730	PYEFPDQFAZNXLI-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
ZM-336372	LCK	5730	PYEFPDQFAZNXLI-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
ZM-336372	MAPK14	5730	PYEFPDQFAZNXLI-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
ZM-336372	RAF1	5730	PYEFPDQFAZNXLI-UHFFFAOYSA-N	Preclinical	RAF inhibitor	NA	NA
ZM-39923	JAK1	3797	JSASWRWALCMOQP-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
ZM-39923	JAK3	3797	JSASWRWALCMOQP-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
ZM-447439	AURKA	9914412	OGNYUTNQZVRGMN-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
ZM-447439	AURKB	9914412	OGNYUTNQZVRGMN-UHFFFAOYSA-N	Preclinical	Aurora kinase inhibitor	NA	NA
zofenopril-calcium	ACE	92400	IAIDUHCBNLFXEF-MNEFBYGVSA-N	Launched	angiotensin converting enzyme inhibitor	cardiology	hypertension
zoledronic-acid	FDPS	68740	XRASPMIURGNCCH-UHFFFAOYSA-N	Launched	bone resorption inhibitor	endocrinology	Paget's disease
zoledronic-acid	GGPS1	68740	XRASPMIURGNCCH-UHFFFAOYSA-N	Launched	bone resorption inhibitor	endocrinology	Paget's disease
zolmitriptan	HTR1A	60857	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
zolmitriptan	HTR1B	60857	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
zolmitriptan	HTR1D	60857	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
zolmitriptan	HTR1E	60857	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
zolmitriptan	HTR1F	60857	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	Launched	serotonin receptor agonist	neurology/psychiatry	migraine headache
zomepirac	PTGDR2	5733	ZXVNMYWKKDOREA-UHFFFAOYSA-N	Withdrawn	prostaglandin synthesis inhibitor	NA	NA
zoniporide	SLC9A1	6433110	GDXBRVCQGGKXJY-UHFFFAOYSA-N	Phase 3	sodium/hydrogen exchanger inhibitor	NA	NA
zonisamide	CA1	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA10	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA11	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA12	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA13	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA14	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA2	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA3	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA4	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA5A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA5B	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA6	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA7	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA8	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CA9	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CACNA1G	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CACNA1H	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	CACNA1I	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	MAOA	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	MAOB	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN10A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN11A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN1A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN1B	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN2A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN2B	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN3A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN3B	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN4A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN4B	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN5A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN7A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN8A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zonisamide	SCN9A	5734	UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry	seizures|epilepsy
zopolrestat	AKR1B1	1613	BCSVCWVQNOXFGL-UHFFFAOYSA-N	Phase 2		NA	NA
zopolrestat	AKR1B10	1613	BCSVCWVQNOXFGL-UHFFFAOYSA-N	Phase 2		NA	NA
zosuquidar	ABCB1	NA	IHOVFYSQUDPMCN-DBEBIPAYSA-N	Phase 3	P glycoprotein inhibitor	NA	NA
zosuquidar	ABCB4	NA	IHOVFYSQUDPMCN-DBEBIPAYSA-N	Phase 3	P glycoprotein inhibitor	NA	NA
zotarolimus	FKBP1A	NA	CGTADGCBEXYWNE-GYKXXMIGSA-N	Launched	mTOR inhibitor	cardiology	coronary artery restenosis
zotepine	ADRA2B	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	DRD2	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	DRD3	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	DRD4	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HRH1	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR1A	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR1B	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR1D	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR1E	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR2A	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR2C	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR6	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	HTR7	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	SLC6A2	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zotepine	SLC6A4	5736	HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia
ZSTK-474	PIK3CB	11647372	HGVNLRPZOWWDKD-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
ZSTK-474	PIK3CD	11647372	HGVNLRPZOWWDKD-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
ZSTK-474	PIK3CG	11647372	HGVNLRPZOWWDKD-UHFFFAOYSA-N	Phase 1/Phase 2	PI3K inhibitor	NA	NA
zuclopenthixol	ADRA1A	5311507	WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
zuclopenthixol	ADRA2A	5311507	WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
zuclopenthixol	DRD1	5311507	WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
zuclopenthixol	DRD2	5311507	WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
zuclopenthixol	DRD5	5311507	WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
zuclopenthixol	HRH1	5311507	WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
zuclopenthixol	HTR2A	5311507	WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	dopamine receptor antagonist	neurology/psychiatry	schizophrenia|bipolar disorder
Z160	CACNA2D1	4988454	VCPMZDWBEWTGNW-UHFFFAOYSA-N	Phase 2	N-type calcium channel blocker	NA	NA
"1,2,3,4,5,6-hexabromocyclohexane"	JAK2	74603	QFQZKISCBJKVHI-UHFFFAOYSA-N	Preclinical	JAK inhibitor	NA	NA
"1,4-butanediol"	MAN1B1	8064	WERYXYBDKMZEQL-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist	NA	NA
"1,4-butanediol"	PLA2G2A	8064	WERYXYBDKMZEQL-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist	NA	NA
"1,4-butanediol"	PLA2G2E	8064	WERYXYBDKMZEQL-UHFFFAOYSA-N	Phase 1	benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist	NA	NA
1-azakenpaullone	CCNB1	6538897	NTSBZVCEIVPKBJ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
1-azakenpaullone	CDK1	6538897	NTSBZVCEIVPKBJ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
1-azakenpaullone	CDK5	6538897	NTSBZVCEIVPKBJ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
1-azakenpaullone	GSK3B	6538897	NTSBZVCEIVPKBJ-UHFFFAOYSA-N	Preclinical	glycogen synthase kinase inhibitor	NA	NA
1-deoxymannojirimycin	MAN2A1	72258	LXBIFEVIBLOUGU-KVTDHHQDSA-N	Preclinical	alpha mannosidase inhibitor	NA	NA
1-EBIO	KCNN1	82320	CXUCKELNYMZTRT-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
1-EBIO	KCNN2	82320	CXUCKELNYMZTRT-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
1-EBIO	KCNN3	82320	CXUCKELNYMZTRT-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
1-EBIO	KCNN4	82320	CXUCKELNYMZTRT-UHFFFAOYSA-N	Preclinical	potassium channel activator	NA	NA
1-hexadecanal	DBI	984	NIOYUNMRJMEDGI-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor substrate	NA	NA
1-hexadecanal	RHO	984	NIOYUNMRJMEDGI-UHFFFAOYSA-N	Preclinical	sphingosine 1-phosphate receptor substrate	NA	NA
1-naphthyl-PP1	SRC	4877	XSHQBIXMLULFEV-UHFFFAOYSA-N	Preclinical	SRC inhibitor	NA	NA
1-octanol	GJA1	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJA10	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJA3	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJA4	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJA5	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJA8	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJA9	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJB1	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJB2	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJB3	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJB4	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJB5	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJB6	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJB7	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJC1	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJC2	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJC3	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJD2	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJD3	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJD4	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-octanol	GJE1	957	KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2		NA	NA
1-phenylbiguanide	HTR3A	4780	CUQCMXFWIMOWRP-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
1-phenylbiguanide	HTR3B	4780	CUQCMXFWIMOWRP-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
10-DEBC	PIM1	10521421	GYBXAGDWMCJZJK-UHFFFAOYSA-N	Preclinical	AKT inhibitor	NA	NA
10-hydroxycamptothecin	TOP1	97226	HAWSQZCWOQZXHI-FQEVSTJZSA-N	Preclinical	topoisomerase inhibitor	NA	NA
12-O-tetradecanoylphorbol-13-acetate	KCNT2	27924	PHEDXBVPIONUQT-RGYGYFBISA-N	Phase 2	PKC activator	NA	NA
12-O-tetradecanoylphorbol-13-acetate	TRPV4	27924	PHEDXBVPIONUQT-RGYGYFBISA-N	Phase 2	PKC activator	NA	NA
1400W	NOS1	1433	RODUKNYOEVZQPR-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
1400W	NOS2	1433	RODUKNYOEVZQPR-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
1400W	NOS3	1433	RODUKNYOEVZQPR-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
"16,16-dimethylprostaglandin-e2"	HPGD	5283066	QAOBBBBDJSWHMU-WMBBNPMCSA-N	Phase 2	prostanoid receptor agonist	NA	NA
17-hydroxyprogesterone-caproate	AR	169870	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
17-hydroxyprogesterone-caproate	ESR1	169870	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
17-hydroxyprogesterone-caproate	ESR2	169870	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
17-hydroxyprogesterone-caproate	NR1H4	169870	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
17-hydroxyprogesterone-caproate	NR1I2	169870	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
17-hydroxyprogesterone-caproate	NR3C1	169870	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
17-hydroxyprogesterone-caproate	PGR	169870	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
2'-MeCCPA	ADORA1	10475082	MMPAUXMIDJWGFO-ROMFRFKVSA-N	Preclinical	adenosine receptor agonist	NA	NA
"2,3-DCPE"	BCL2L1	2250975	QVEIRCZEBQRCTR-UHFFFAOYSA-N	Preclinical	BCL-XL downregulator	NA	NA
"2,4-dinitrochlorobenzene"	TXN	6	VYZAHLCBVHPDDF-UHFFFAOYSA-N	Phase 2	thioredoxin inhibitor	NA	NA
"2,4-dinitrophenol"	APP	1493	UFBJCMHMOXMLKC-UHFFFAOYSA-N	Preclinical	ATP synthase inhibitor	NA	NA
"2,5-furandimethanol"	HBB	74663	DSLRVRBSNLHVBH-UHFFFAOYSA-N	Phase 2	hemoglobin modulator	NA	NA
2-(3-mercaptopropyl)pentanedioic-acid	FOLH1	11735892	FNLNSQHJKVQCBP-ZCFIWIBFSA-N	Phase 1	glutamate carboxypeptidase inhibitor	NA	NA
2-[1-(4-piperonyl)piperazinyl]benzothiazole	HTR4	127902	BYHKGNWKJMGHGE-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-aminobenzenesulfonamide	CA12	72894	YAZSBRQTAHVVGE-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
2-aminobenzenesulfonamide	CA14	72894	YAZSBRQTAHVVGE-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
2-aminobenzenesulfonamide	CA2	72894	YAZSBRQTAHVVGE-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
2-aminobenzenesulfonamide	CA6	72894	YAZSBRQTAHVVGE-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
2-aminobenzenesulfonamide	CA9	72894	YAZSBRQTAHVVGE-UHFFFAOYSA-N	Preclinical	carbonic anhydrase inhibitor	NA	NA
2-APB	TRPC1	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPC3	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPC4	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPC5	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPC6	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPC7	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPM2	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPM3	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPM6	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPV1	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-APB	TRPV6	1598	BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	"1,4,5-trisphosphate inhibitor"	NA	NA
2-BFI	ADRA2A	3080926	YTJOHEUHUVBKSB-UHFFFAOYSA-N	Preclinical	imidazoline receptor ligand	NA	NA
2-BFI	ADRA2B	3080926	YTJOHEUHUVBKSB-UHFFFAOYSA-N	Preclinical	imidazoline receptor ligand	NA	NA
2-BFI	ADRA2C	3080926	YTJOHEUHUVBKSB-UHFFFAOYSA-N	Preclinical	imidazoline receptor ligand	NA	NA
2-BFI	MAOA	3080926	YTJOHEUHUVBKSB-UHFFFAOYSA-N	Preclinical	imidazoline receptor ligand	NA	NA
2-BFI	MAOB	3080926	YTJOHEUHUVBKSB-UHFFFAOYSA-N	Preclinical	imidazoline receptor ligand	NA	NA
2-chloro-N6-cyclopentyladenosine	ADORA1	123807	XSMYYYQVWPZWIZ-IDTAVKCVSA-N	Preclinical	adenosine receptor agonist	NA	NA
2-chloro-N6-cyclopentyladenosine	ADORA2A	123807	XSMYYYQVWPZWIZ-IDTAVKCVSA-N	Preclinical	adenosine receptor agonist	NA	NA
2-chloro-N6-cyclopentyladenosine	ADORA2B	123807	XSMYYYQVWPZWIZ-IDTAVKCVSA-N	Preclinical	adenosine receptor agonist	NA	NA
2-chloro-N6-cyclopentyladenosine	ADORA3	123807	XSMYYYQVWPZWIZ-IDTAVKCVSA-N	Preclinical	adenosine receptor agonist	NA	NA
2-chloroadenosine	ADORA1	8974	BIXYYZIIJIXVFW-UUOKFMHZSA-N	Preclinical	adenosine receptor agonist	NA	NA
2-chloroadenosine	ADORA2A	8974	BIXYYZIIJIXVFW-UUOKFMHZSA-N	Preclinical	adenosine receptor agonist	NA	NA
2-chloroadenosine	ADORA2B	8974	BIXYYZIIJIXVFW-UUOKFMHZSA-N	Preclinical	adenosine receptor agonist	NA	NA
2-CMDO	DRD2	32224	OTKUTGIVEREJLL-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
2-CMDO	DRD4	32224	OTKUTGIVEREJLL-UHFFFAOYSA-N	Preclinical	dopamine receptor antagonist	NA	NA
2-deoxyglucose	SLC2A1	9062	PMMURAAUARKVCB-ZXXMMSQZSA-N	Phase 2	glycolysis inhibitor	NA	NA
2-deoxyglucose	SLC2A2	9062	PMMURAAUARKVCB-ZXXMMSQZSA-N	Phase 2	glycolysis inhibitor	NA	NA
2-deoxyglucose	SLC2A3	9062	PMMURAAUARKVCB-ZXXMMSQZSA-N	Phase 2	glycolysis inhibitor	NA	NA
2-deoxyglucose	SLC2A4	9062	PMMURAAUARKVCB-ZXXMMSQZSA-N	Phase 2	glycolysis inhibitor	NA	NA
2-fluoro-2-deoxy-D-galactose	LCT	445913	ZCXUVYAZINUVJD-AIECOIEWSA-N	Phase 1		NA	NA
2-hydroxyflutamide	AR	91649	YPQLFJODEKMJEF-UHFFFAOYSA-N	Phase 2	androgen receptor antagonist	NA	NA
2-hydroxysaclofen	GABBR1	7005135	WBSMZVIMANOCNX-SECBINFHSA-N	Preclinical	GABA receptor antagonist	NA	NA
2-hydroxysaclofen	GABBR2	7005135	WBSMZVIMANOCNX-SECBINFHSA-N	Preclinical	GABA receptor antagonist	NA	NA
2-iminobiotin	NOS1	135678104	WWVANQJRLPIHNS-ZKWXMUAHSA-N	Phase 2	nitric oxide synthase inhibitor	NA	NA
2-iminobiotin	NOS2	135678104	WWVANQJRLPIHNS-ZKWXMUAHSA-N	Phase 2	nitric oxide synthase inhibitor	NA	NA
2-iodomelatonin	MTNR1A	115348	FJDDSMSDZHURBJ-UHFFFAOYSA-N	Preclinical	melatonin receptor agonist	NA	NA
2-iodomelatonin	MTNR1B	115348	FJDDSMSDZHURBJ-UHFFFAOYSA-N	Preclinical	melatonin receptor agonist	NA	NA
2-iodomelatonin	NQO2	115348	FJDDSMSDZHURBJ-UHFFFAOYSA-N	Preclinical	melatonin receptor agonist	NA	NA
2-methoxyestradiol	COMT	66414	CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2	hypoxia inducible factor inhibitor	NA	NA
2-methoxyestradiol	CYP19A1	66414	CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2	hypoxia inducible factor inhibitor	NA	NA
2-methoxyestradiol	CYP1A1	66414	CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2	hypoxia inducible factor inhibitor	NA	NA
2-methoxyestradiol	CYP1B1	66414	CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2	hypoxia inducible factor inhibitor	NA	NA
2-methoxyestradiol	HIF1A	66414	CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2	hypoxia inducible factor inhibitor	NA	NA
2-methoxyestradiol	TUBB	66414	CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2	hypoxia inducible factor inhibitor	NA	NA
2-methyl-5-hydroxytryptamine	HTR1B	1574	WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-methyl-5-hydroxytryptamine	HTR1D	1574	WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-methyl-5-hydroxytryptamine	HTR1E	1574	WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-methyl-5-hydroxytryptamine	HTR1F	1574	WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-methyl-5-hydroxytryptamine	HTR3A	1574	WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-methyl-5-hydroxytryptamine	HTR3B	1574	WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-methyl-5-hydroxytryptamine	HTR6	1574	WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
2-oleoylglycerol	GPR119	5319879	UPWGQKDVAURUGE-KTKRTIGZSA-N	Phase 1	glucose dependent insulinotropic receptor ligand	NA	NA
2-oxoglutaric-acid	OXGR1	51	KPGXRSRHYNQIFN-UHFFFAOYSA-N	Preclinical		NA	NA
2-oxopropanoate	ABAT	37873	FEWFXBUNENSNBQ-UHFFFAOYSA-N	Preclinical	pyruvate dehydrogenase kinase inhibitor	NA	NA
2-phenylmelatonin	MTNR1A	4018512	OFCLARYYBGKCHN-UHFFFAOYSA-N	Preclinical	melatonin receptor agonist	NA	NA
2-phenylmelatonin	MTNR1B	4018512	OFCLARYYBGKCHN-UHFFFAOYSA-N	Preclinical	melatonin receptor agonist	NA	NA
2-PMDQ	ADRA1A	NA	ONSOQRPYFKDOEB-INIZCTEOSA-N	Preclinical	adrenergic receptor antagonist	NA	NA
2-pyridylethylamine	HRH1	75919	XPQIPUZPSLAZDV-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
2-TEDC	ALOX12	6069552	KCGLTUBCAGZLHP-XYOKQWHBSA-N	Preclinical	lipoxygenase inhibitor	NA	NA
3'-fluorobenzylspiperone	DRD2	3248000	DXZKTRNEOISOCA-UHFFFAOYSA-N	Preclinical	dopamine receptor ligand	NA	NA
"3,3'-dichlorobenzaldazine"	GRM5	6861557	XMOVWXSCYLINBJ-BEQMOXJMSA-N	Preclinical	glutamate receptor modulator	NA	NA
"3,3'-diindolylmethane"	AR	3071	VFTRKSBEFQDZKX-UHFFFAOYSA-N	Phase 3	"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor"	NA	NA
"3,3'-diindolylmethane"	HIF1A	3071	VFTRKSBEFQDZKX-UHFFFAOYSA-N	Phase 3	"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor"	NA	NA
"3,3'-diindolylmethane"	IFNG	3071	VFTRKSBEFQDZKX-UHFFFAOYSA-N	Phase 3	"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor"	NA	NA
"3,3'-diindolylmethane"	PI3	3071	VFTRKSBEFQDZKX-UHFFFAOYSA-N	Phase 3	"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor"	NA	NA
"3,4-DCPG-(+/-)"	GRM8	6604849	IJVMOGKBEVRBPP-SSDOTTSWSA-N	Preclinical	glutamate receptor agonist	NA	NA
"3,4-DCPG-(S)"	GRM8	16062593	IJVMOGKBEVRBPP-ZETCQYMHSA-N	Preclinical	glutamate receptor agonist	NA	NA
"3,4-methylenedioxy-beta-nitrostyrene"	SRC	672296	KFLWBZPSJQPRDD-ONEGZZNKSA-N	Preclinical	SRC inhibitor|SYK inhibitor	NA	NA
"3,4-methylenedioxy-beta-nitrostyrene"	SYK	672296	KFLWBZPSJQPRDD-ONEGZZNKSA-N	Preclinical	SRC inhibitor|SYK inhibitor	NA	NA
"3,5-DHPG-(S)"	GRM1	71668376	HOOWCUZPEFNHDT-ZETCQYMHSA-N	Preclinical	glutamate receptor agonist	NA	NA
3-alpha-bis-(4-fluorophenyl)-methoxytropane	CHRM1	NA	MHNSOBBJZCWUGS-PMOLBWCYSA-N	Preclinical	dopamine uptake inhibitor	NA	NA
3-alpha-bis-(4-fluorophenyl)-methoxytropane	SLC6A2	NA	MHNSOBBJZCWUGS-PMOLBWCYSA-N	Preclinical	dopamine uptake inhibitor	NA	NA
3-alpha-bis-(4-fluorophenyl)-methoxytropane	SLC6A3	NA	MHNSOBBJZCWUGS-PMOLBWCYSA-N	Preclinical	dopamine uptake inhibitor	NA	NA
3-alpha-bis-(4-fluorophenyl)-methoxytropane	SLC6A4	NA	MHNSOBBJZCWUGS-PMOLBWCYSA-N	Preclinical	dopamine uptake inhibitor	NA	NA
3-alpha-hydroxy-5-beta-androstan-17-one	HSD17B11	5880	QGXBDMJGAMFCBF-BNSUEQOYSA-N	Preclinical		NA	NA
3-alpha-hydroxy-5-beta-androstan-17-one	IGHG2	5880	QGXBDMJGAMFCBF-BNSUEQOYSA-N	Preclinical		NA	NA
3-alpha-hydroxy-5-beta-androstan-17-one	SULT2A1	5880	QGXBDMJGAMFCBF-BNSUEQOYSA-N	Preclinical		NA	NA
3-amino-benzamide	PARP1	1645	GSCPDZHWVNUUFI-UHFFFAOYSA-N	Phase 2	PARP inhibitor	NA	NA
3-AQC	HTR3A	3073499	IDOXKFDPDOIUMG-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
3-bromo-7-nitroindazole	NOS1	1649	NFSTZPMYAZRZPC-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
3-bromo-7-nitroindazole	NOS2	1649	NFSTZPMYAZRZPC-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
3-bromo-7-nitroindazole	NOS3	1649	NFSTZPMYAZRZPC-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
3-bromopyruvate	HK2	129924149	CHNJCELMWMIDSC-UHFFFAOYSA-N	Preclinical	hexokinase inhibitor	NA	NA
3-carboxy-4-hydroxyphenylglycine-(R)	GRIN1	6604713	CHZBCZTXSTWCIG-SSDOTTSWSA-N	Preclinical	glutamate receptor antagonist	NA	NA
3-carboxy-4-hydroxyphenylglycine-(R)	GRIN2A	6604713	CHZBCZTXSTWCIG-SSDOTTSWSA-N	Preclinical	glutamate receptor antagonist	NA	NA
3-carboxy-4-hydroxyphenylglycine-(R)	GRIN2B	6604713	CHZBCZTXSTWCIG-SSDOTTSWSA-N	Preclinical	glutamate receptor antagonist	NA	NA
3-carboxy-4-hydroxyphenylglycine-(R)	GRIN2C	6604713	CHZBCZTXSTWCIG-SSDOTTSWSA-N	Preclinical	glutamate receptor antagonist	NA	NA
3-carboxy-4-hydroxyphenylglycine-(S)	GRM1	5311460	CHZBCZTXSTWCIG-ZETCQYMHSA-N	Preclinical	glutamate receptor antagonist	NA	NA
3-carboxy-4-hydroxyphenylglycine-(S)	GRM5	5311460	CHZBCZTXSTWCIG-ZETCQYMHSA-N	Preclinical	glutamate receptor antagonist	NA	NA
3-deazaadenosine	AHCY	12769724	DBZQFUNLCALWDY-GPUHXXMPSA-N	Phase 2	adenosylhomocysteinase inhibitor	NA	NA
3-deazaneplanocin-A	EZH2	73087	OMKHWTRUYNAGFG-IEBDPFPHSA-N	Preclinical	histone lysine methyltransferase inhibitor	NA	NA
3-indolebutyric-acid	B2M	8617	JTEDVYBZBROSJT-UHFFFAOYSA-N	Preclinical		NA	NA
3-indolebutyric-acid	HLA-A	8617	JTEDVYBZBROSJT-UHFFFAOYSA-N	Preclinical		NA	NA
3-indolebutyric-acid	TRAC	8617	JTEDVYBZBROSJT-UHFFFAOYSA-N	Preclinical		NA	NA
3-indolebutyric-acid	TRBC1	8617	JTEDVYBZBROSJT-UHFFFAOYSA-N	Preclinical		NA	NA
3-MATIDA	GRM1	92327883	KOMWRBFEDDEWEP-RXMQYKEDSA-N	Preclinical	glutamate receptor antagonist	NA	NA
3-methyl-GABA	ABAT	6604938	CZGLBWZXGIAIBU-SCSAIBSYSA-N	Preclinical	GABA aminotransferase activator	NA	NA
3-methyladenine	PI3	135398661	ZPBYVFQJHWLTFB-UHFFFAOYSA-N	Preclinical	PI3K inhibitor	NA	NA
3-MPPI	ADRA1A	4013695	AQASGOHUMGAWJJ-UHFFFAOYSA-N	Preclinical	adrenergic receptor ligand	NA	NA
3PO	PFKFB3	5720233	UOWGYMNWMDNSTL-ONEGZZNKSA-N	Preclinical	phosphofructokinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	AKT1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	CHEK1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	CSNK2A1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	GSK3B	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	LCK	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	MAP2K1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	MAPK1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	MAPK11	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	MAPK12	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	MAPK14	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	MAPK8	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	PRKCA	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	ROCK1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	RPS6KB1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
"4,5,6,7-tetrabromobenzotriazole"	SGK1	1694	OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	casein kinase inhibitor	NA	NA
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	HTR2A	5234410	FTJXZACAQRDRNT-UHFFFAOYSA-N	Preclinical	serotonin receptor antagonist	NA	NA
4-aminohippuric-acid	SLC22A6	2148	HSMNQINEKMPTIC-UHFFFAOYSA-N	Launched		nephrology	renal diagnostic agent
4-carboxy-3-hydroxyphenylglycine-(RS)	GRM1	6604709	GXZSAQLJWLCLOX-SSDOTTSWSA-N	Preclinical	glutamate receptor agonist|glutamate receptor antagonist	NA	NA
4-carboxy-3-hydroxyphenylglycine-(S)	GRM1	5311455	GXZSAQLJWLCLOX-ZETCQYMHSA-N	Preclinical	glutamate receptor agonist|glutamate receptor antagonist	NA	NA
4-carboxy-3-hydroxyphenylglycine-(S)	GRM2	5311455	GXZSAQLJWLCLOX-ZETCQYMHSA-N	Preclinical	glutamate receptor agonist|glutamate receptor antagonist	NA	NA
4-chlorophenylguanidine	PLAUR	2757788	ZSJNJAJDBNFVCA-UHFFFAOYSA-N	Preclinical	urokinase inhibitor	NA	NA
4-CMTB	FFAR2	854190	AZYDQCGCBQYFSE-GFCCVEGCSA-N	Preclinical	free fatty acid receptor agonist	NA	NA
4-DAMP	CHRM1	1734	HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
4-DAMP	CHRM2	1734	HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
4-DAMP	CHRM3	1734	HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
4-DAMP	CHRM4	1734	HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
4-DAMP	CHRM5	1734	HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical	cholinergic receptor antagonist	NA	NA
4-HQN	PARP1	135408753	QMNUDYFKZYBWQX-UHFFFAOYSA-N	Preclinical	PARP inhibitor	NA	NA
4-IBP	SIGMAR1	132995	HELCSESNNDZLFM-UHFFFAOYSA-N	Preclinical	sigma receptor agonist	NA	NA
4-iodo-L-phenylalanine	DPP4	7047041	PZNQZSRPDOEBMS-MRVPVSSYSA-N	Preclinical		NA	NA
4-iodo-6-phenylpyrimidine	MIF	817368	ZTCJXHNJVLUUMR-UHFFFAOYSA-N	Preclinical	macrophage migration inhibiting factor inhibitor	NA	NA
4-methylgenistein	CYP19A1	5280373	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
4-methylgenistein	ESRRA	5280373	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
4-methylgenistein	ESRRB	5280373	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
4-methylgenistein	ESRRG	5280373	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
4-methylgenistein	FASN	5280373	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical	protein tyrosine kinase inhibitor	NA	NA
4-methylhistamine	HRH4	37463	UGYXPZQILZRKJJ-UHFFFAOYSA-N	Preclinical	histamine receptor agonist	NA	NA
4-mu-8C	ERN1	12934390	RTHHSXOVIJWFQP-UHFFFAOYSA-N	Preclinical	IRE1 inhibitor	NA	NA
4-P-PDOT	MTNR1A	24750357	RCYLUNPFECYGDW-AEFFLSMTSA-N	Preclinical	melatonin receptor antagonist	NA	NA
4-P-PDOT	MTNR1B	24750357	RCYLUNPFECYGDW-AEFFLSMTSA-N	Preclinical	melatonin receptor antagonist	NA	NA
4-PPBP	SIGMAR1	3035672	HQGDPZPNAXRCSA-UHFFFAOYSA-N	Preclinical	sigma receptor ligand	NA	NA
4BP-TQS	CHRNA7	6979017	YNCXHXYZTLIZTO-RLFYNMQTSA-N	Preclinical	nicotinic receptor agonist	NA	NA
4EGI-1	EIF4E	2831024	KFRKRECSIYXARE-UHFFFAOYSA-N	Preclinical	protein synthesis inhibitor	NA	NA
4E1RCat	EIF4E	16195554	BBQRBOIMSKMFFO-LTGZKZEYSA-N	Preclinical	protein synthesis inhibitor	NA	NA
4E1RCat	EIF4G1	16195554	BBQRBOIMSKMFFO-LTGZKZEYSA-N	Preclinical	protein synthesis inhibitor	NA	NA
4SC-202	HDAC1	15985904	PRXXYMVLYKJITB-IZZDOVSWSA-N	Phase 1	HDAC inhibitor	NA	NA
5'-chloro-5'-deoxy-ENBA-(+/-)	ADORA1	NA	PVJGDYDNVNCGBT-CYDCOVMPSA-N	Preclinical	adenosine receptor agonist	NA	NA
"5,7-dichlorokynurenic-acid"	GLRA2	1779	BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
"5,7-dichlorokynurenic-acid"	GRIN1	1779	BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
"5,7-dichlorokynurenic-acid"	GRIN2A	1779	BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
"5,7-dichlorokynurenic-acid"	GRIN2B	1779	BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
"5,7-dichlorokynurenic-acid"	GRIN2C	1779	BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
"5,7-dichlorokynurenic-acid"	GRIN2D	1779	BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione"	TLR7	135409474	TZYVRXZQAWPIAB-FCLHUMLKSA-N	Preclinical		NA	NA
5-aminolevulinic-acid	ALAD	7048523	ZGXJTSGNIOSYLO-UHFFFAOYSA-N	Launched	oxidizing agent	oncology|dermatology	glioma|actinic keratosis (AK)
5-BDBD	P2RX4	9841560	NKYMVQPXXTZHSF-UHFFFAOYSA-N	Preclinical	purinergic receptor antagonist	NA	NA
5-carboxamidotryptamine	HTR1A	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR1B	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR1D	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR1E	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR1F	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR2A	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR2B	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR2C	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR5A	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR6	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-carboxamidotryptamine	HTR7	1809	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	serotonin receptor agonist	NA	NA
5-fluorouracil	DPYD	3385	GHASVSINZRGABV-UHFFFAOYSA-N	Launched	thymidylate synthase inhibitor	oncology	colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma
5-fluorouracil	TYMS	3385	GHASVSINZRGABV-UHFFFAOYSA-N	Launched	thymidylate synthase inhibitor	oncology	colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma
5-FP	TYMS	101498	HPABFFGQPLJKBP-UHFFFAOYSA-N	Phase 1	thymidylate synthase inhibitor	NA	NA
5-hydroxymethyl-tolterodine	CHRM3	9819382	DUXZAXCGJSBGDW-HXUWFJFHSA-N	Phase 1	acetylcholine receptor antagonist	NA	NA
5-hydroxytryptophan	SLC36A1	6971044	LDCYZAJDBXYCGN-VIFPVBQESA-N	Launched	neurotransmitter	neurology/psychiatry	insomnia
5-hydroxytryptophan	SLC36A2	6971044	LDCYZAJDBXYCGN-VIFPVBQESA-N	Launched	neurotransmitter	neurology/psychiatry	insomnia
5-methylfurmethiodide	CHRM1	4141	KOWVJDFMEZKDDT-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
5-methylfurmethiodide	CHRM2	4141	KOWVJDFMEZKDDT-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
5-methylfurmethiodide	CHRM3	4141	KOWVJDFMEZKDDT-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
5-methylfurmethiodide	CHRM4	4141	KOWVJDFMEZKDDT-UHFFFAOYSA-N	Preclinical	acetylcholine receptor agonist	NA	NA
6-chloromelatonin	MTNR1A	1858	LUINDDOUWHRIPW-UHFFFAOYSA-N	Preclinical	melatonin receptor agonist	NA	NA
6-chloromelatonin	MTNR1B	1858	LUINDDOUWHRIPW-UHFFFAOYSA-N	Preclinical	melatonin receptor agonist	NA	NA
6-iodo-nordihydrocapsaicin	TRPV1	5149140	AAORACFZMYMFCG-UHFFFAOYSA-N	Preclinical	TRPV antagonist	NA	NA
7-chlorokynurenic-acid	GRIN1	1884	UAWVRVFHMOSAPU-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
7-chlorokynurenic-acid	GRIN2A	1884	UAWVRVFHMOSAPU-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
7-chlorokynurenic-acid	GRIN2B	1884	UAWVRVFHMOSAPU-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
7-chlorokynurenic-acid	GRIN2C	1884	UAWVRVFHMOSAPU-UHFFFAOYSA-N	Preclinical	glutamate receptor antagonist	NA	NA
7-hydroxy-DPAT	DRD2	23928184	BLYMJBIZMIGWFK-HNNXBMFYSA-N	Preclinical	dopamine receptor agonist	NA	NA
7-hydroxy-DPAT	DRD3	23928184	BLYMJBIZMIGWFK-HNNXBMFYSA-N	Preclinical	dopamine receptor agonist	NA	NA
7-hydroxy-PIPAT	DRD3	10317104	RTMIJLQPWFKAFE-GZTQLTBSSA-N	Preclinical	dopamine receptor ligand	NA	NA
7-hydroxystaurosporine	CDK1	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	CHEK1	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	CHEK2	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	GSK3B	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	LCK	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	MAPK14	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	MARK1	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	MARK3	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	PDPK1	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	PRKCA	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	PRKCB	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	PRKCD	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	PRKCE	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-hydroxystaurosporine	PRKCG	3078519	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	NA	NA
7-methoxytacrine	ACHE	119053	APQPVVOYBLOJDY-UHFFFAOYSA-N	Phase 2	acetylcholinesterase inhibitor	NA	NA
7-nitroindazole	NOS1	1893	PQCAUHUKTBHUSA-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
7-nitroindazole	NOS2	1893	PQCAUHUKTBHUSA-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
7-nitroindazole	NOS3	1893	PQCAUHUKTBHUSA-UHFFFAOYSA-N	Preclinical	nitric oxide synthase inhibitor	NA	NA
8-bromo-cGMP	PRKG1	135419186	YUFCOOWNNHGGOD-UMMCILCDSA-N	Preclinical	PKA activator	NA	NA
8-hydroxy-DPAT	HTR5A	10125797	ASXGJMSKWNBENU-AWEZNQCLSA-N	Preclinical	serotonin receptor agonist	NA	NA
8-hydroxy-DPAT	HTR7	10125797	ASXGJMSKWNBENU-AWEZNQCLSA-N	Preclinical	serotonin receptor agonist	NA	NA
8-hydroxy-PIPAT	DRD2	15288637	QBXHUZJZYDSLRH-MDDUGHTDSA-N	Preclinical	dopamine receptor ligand	NA	NA
8-hydroxy-PIPAT	DRD3	15288637	QBXHUZJZYDSLRH-MDDUGHTDSA-N	Preclinical	dopamine receptor ligand	NA	NA
8-M-PDOT	MTNR1A	92211535	RVIGBTUDFAGRTQ-NSHDSACASA-N	Preclinical	melatonin receptor agonist	NA	NA
8-M-PDOT	MTNR1B	92211535	RVIGBTUDFAGRTQ-NSHDSACASA-N	Preclinical	melatonin receptor agonist	NA	NA
9-aminocamptothecin	TOP1	72402	FUXVKZWTXQUGMW-FQEVSTJZSA-N	Phase 2	topoisomerase inhibitor	NA	NA
9-anthracenecarboxylic-acid	ANO1	2201	XGWFJBFNAQHLEF-UHFFFAOYSA-N	Preclinical		NA	NA
9-anthracenecarboxylic-acid	CLCN1	2201	XGWFJBFNAQHLEF-UHFFFAOYSA-N	Preclinical		NA	NA
